Petrelli F, Cabiddu M, Barni S. 5-Fluorouracil or capecitabine in the treatment of advanced colorectal cancer: a pooled-analysis of randomized trials. Medical oncology (Northwood, London, England). 2011;29(2):1020-9.	10.1007/s12032-011-9958-0	21516482	systematic-review	2f6c4f550f330ecc46181ee5380e2e90a8939898	-	{'publication_type': {'year': 2011, 'cited_medium': None, 'issue': '2', 'issn': '1357-0560', 'volume': '29', 'title': 'Medical Oncology', 'pagination': '1020-1029'}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.8833333333333333, 'authors': 0.9333333333333332}, 'authors': [{'given': 'Fausto', 'family': 'Petrelli'}, {'given': 'Mary', 'family': 'Cabiddu'}, {'given': 'Sandro', 'family': 'Barni'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '21516482', 'scopus': None, 'doi': '10.1007/s12032-011-9958-0'}, 'title': '5-Fluorouracil or capecitabine in the treatment of advanced colorectal cancer: a pooled-analysis of randomized trials', 'source': 'CrossRef'}
Petrelli F, Cabiddu M, Barni S. 5-Fluorouracil or capecitabine in the treatment of advanced colorectal cancer: a pooled-analysis of randomized trials. Medical oncology (Northwood, London, England). 2011;29(2):1020-9.	10.1007/s12032-011-9958-0	21516482	systematic-review	2f6c4f550f330ecc46181ee5380e2e90a8939898	-	{'publication_type': {'year': 2008, 'cited_medium': None, 'issue': None, 'issn': '1357-0560 (Print)', 'volume': None, 'title': 'Medical oncology (Northwood, London, England)', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 0.38095238095238093, 'total': 0.3476190476190476, 'authors': 0.0}, 'authors': [{'given': 'I P', 'family': 'Popov'}, {'given': 'S B', 'family': 'Jelic'}, {'given': 'Z V', 'family': 'Krivokapic'}, {'given': 'S D', 'family': 'Jezdic'}, {'given': 'P M', 'family': 'Pesko'}, {'given': 'M T', 'family': 'Micev'}, {'given': 'D R', 'family': 'Babic'}], 'abstract': 'BACKGROUND: To investigate the activity and toxicity of high dose (HD) infusional 5-FU in comparison to EAP regimen as first-line chemotherapy in patients with advanced gastric cancer. PATIENTS AND METHODS: Histologically confirmed measurable advanced gastric cancer, age < 72 yr, ECOG performance status 0-2, no prior chemo- and radiotherapy, adequate organ functions. TREATMENT: EAP arm: doxorubicin (40 mg/m(2)), etoposide (360 mg/m(2)), and cisplatin (80 mg/m(2)) every 28 d; HD 5-FU arm: 5-FU 2.6 g/m(2) 24 h infusion, biweekly. RESULTS: Sixty patients were randomized. Patient characteristics (arms EAP/HD 5-FU): Median age 57/55 yr, median PS 1/1, LAD (patients) 3/8, M1 (patients) 27/22. Median number of cycles (range): EAP arm 4 (2-8), HD 5-FU arm 2 (1-8). Worst toxicity per cycle (grade 3 and 4 in%): Neutropenia 20/3, thrombocytopenia 9/0, anemia 9/13, diarrhea 3/10, nausea 17/7, vomiting 10/0 for EAP and HD 5-FU arms, respectively. All patients were eligible for response in both arms. Confirmed response rate (95%CI): EAP arm 34% [16-50%]/HD 5-FU arm 10% (0-21%), no change: 46/40%, progression of disease: 20/50, respectively. Overall survival (range): EAP arm A 7 mo [3-27], HD 5-FU arm 6 mo (4-25). CONCLUSIONS: Infusional HD 5-FU showed a low incidence of severe toxicity. But given the low efficacy of 5-FU in the dosage we applied in the study, it cannot be recommended as a single treatment for further studies. Assessment of higher dose intensity and/or dose density of 5-FU, with introduction of other active drugs in combination, could be an option for further studies.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '17972024', 'scopus': None, 'doi': '10.1007/s12032-007-0042-8'}, 'title': 'Bimonthly 24 h infusion of high-dose 5-fluorouracil vs EAP regimen in patients with advanced gastric cancer. A randomized phase II study.', 'source': 'Mendeley'}
Rowe AK, Rowe SY, Holloway KA, Ivanovska V, Muhe L, Lambrechts T. Does shortening the training on Integrated Management of Childhood Illness guidelines reduce its effectiveness? A systematic review. Health policy and planning. 2011;27(3):179-93.	10.1093/heapol/czr033	21515912	systematic-review	057d47b73f2344e03939e049d9f7d7710d0ac56c	-	{'publication_type': {'year': 2011, 'cited_medium': None, 'issue': '3', 'issn': '0268-1080', 'volume': '27', 'title': 'Health Policy and Planning', 'pagination': '179-193'}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.8791666666666667, 'authors': 0.9166666666666666}, 'authors': [{'given': 'A. K.', 'family': 'Rowe'}, {'given': 'S. Y.', 'family': 'Rowe'}, {'given': 'K. A.', 'family': 'Holloway'}, {'given': 'V.', 'family': 'Ivanovska'}, {'given': 'L.', 'family': 'Muhe'}, {'given': 'T.', 'family': 'Lambrechts'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '21515912', 'scopus': None, 'doi': '10.1093/heapol/czr033'}, 'title': 'Does shortening the training on Integrated Management of Childhood Illness guidelines reduce its effectiveness? A systematic review', 'source': 'CrossRef'}
Rowe AK, Rowe SY, Holloway KA, Ivanovska V, Muhe L, Lambrechts T. Does shortening the training on Integrated Management of Childhood Illness guidelines reduce its effectiveness? A systematic review. Health policy and planning. 2011;27(3):179-93.	10.1093/heapol/czr033	21515912	systematic-review	057d47b73f2344e03939e049d9f7d7710d0ac56c	-	{'publication_type': {'year': 2012, 'cited_medium': None, 'issue': None, 'issn': '02681080', 'volume': None, 'title': 'Health Policy and Planning', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.8791666666666667, 'authors': 0.9166666666666666}, 'authors': [{'given': 'Alexander K.', 'family': 'Rowe'}, {'given': 'Samantha Y.', 'family': 'Rowe'}, {'given': 'Kathleen A.', 'family': 'Holloway'}, {'given': 'Verica', 'family': 'Ivanovska'}, {'given': 'Lulu', 'family': 'Muhe'}, {'given': 'Thierry', 'family': 'Lambrechts'}], 'abstract': 'Implementation of the Integrated Management of Childhood Illness (IMCI) strategy with an 11-day training course for health workers improves care for ill children in outpatient settings in developing countries. The 11-day course duration is recommended by the World Health Organization, which developed IMCI. Our aim was to determine if shortening the training (to reduce cost) reduces its effectiveness.', 'type': 'generic', 'ids': {'embase': None, 'pubmed': '21515912', 'scopus': '2-s2.0-84860139001', 'doi': '10.1093/heapol/czr033'}, 'title': 'Does shortening the training on Integrated Management of Childhood Illness guidelines reduce its effectiveness? A systematic review', 'source': 'Mendeley'}
Rathmony, H and Ministry of Health of Cambodia. Cambodia Health Facility Survey, PowerPoint presentation. 2006.	-	-	reference	057d47b73f2344e03939e049d9f7d7710d0ac56c	6a84896375606b0dc06b7918442b513304da49a9_	{'publication_type': {'year': None, 'cited_medium': None, 'issue': None, 'issn': None, 'volume': None, 'title': 'Foreign Law Guide', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.6666666666666666, 'total': 0.43333333333333335, 'authors': 0}, 'authors': [], 'abstract': None, 'type': 'dataset', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1163/2213-2996_flg_com_045083'}, 'title': 'Cambodia - Health', 'source': 'CrossRef'}
Rathmony, H and Ministry of Health of Cambodia. Cambodia Health Facility Survey, PowerPoint presentation. 2006.	-	-	reference	057d47b73f2344e03939e049d9f7d7710d0ac56c	6a84896375606b0dc06b7918442b513304da49a9_	{'publication_type': {'year': 2005, 'cited_medium': None, 'issue': None, 'issn': None, 'volume': None, 'title': 'Kingdom of Cambodia Ministry of Health', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.3333333333333333, 'total': 0.21666666666666667, 'authors': 0.0}, 'authors': [{'given': 'Nation Religion', 'family': 'King'}], 'abstract': 'The National TB Program of the National Center for Tuberculosis and Leprosy Control (CENAT), Cambodia, successfully conducted the 1st National TB Prevalence Survey in 2002. 97% of the population was covered by the survey except for four remote and population scattered provinces due to logistical difficulties. A high participation rate of 96.7% was achieved: 30,032 out of 31,050 eligible subjects in 42 clusters across the country participated in the study. An interview by a physician or a medical assistant and an X-ray examination were given to each study subject aged 10 or more to identify TB suspects for sputum examination. Out of 22,160 study participants aged 10 or more, 3,301 were examined for sputum. 81 smear positive and 191 smear negative / culture positive pulmonary TB cases were detected. Weighed prevalence rates of the popullation aged 10 or more were 362 (95% C.I.: 284-461) for smear positive and 846 (675-1059) for smear negative/culture positive per 100,000 respectively. If we assume that we can neglect smear positive cases among children aged less than 10, a prevalence rate of smear positive TB becomes 269 per 100,000 populations. Around 34,000 smear positive TB patients, more than 110,000 bacteriologically positive TB patients, lived in Cambodia at the survey time in 2002. While the prevalence rate of smear positive TB was lower than expected, the prevalence rate of smear negative/culture positive TB was much higher than expected. However, no-MDR TB strain was isolated from the survey subjects. Although 60% of smear positive cases belonged to adults aged between 15 and 54, the older age groups occupied a significant portion of the prevalence. The older the age group is, the higher the prevalence rate is. A smear positive prevalence rate in the age group 65 or more was as high as 1,512 per 100,000. The prevalence rate in male was 2.5 times higher than that in female. Areas with better access to DOTS facilities such as Phnom Penh, provincial capital towns and villages within 5 km from the DOTS centers tended to have lower prevalence rates of smear positive TB. According to the interview, 6.8% of the study participants aged 10 or more experienced cough for 3 weeks or more in the past one month. The prevalence rate of chronic cough increased as age increased. When we define TB suspects as those who had “cough for 3 weeks or more” and/or “blood contained sputum”, 7.3% fell in the category of TB suspects by symptom screening. However, out of 81 smear positive TB cases, only 50 or 62%, belonged to the category of TB suspects. For bacteriological positive cases including smear negative/culture positive, only 39.1% were screened by the interview. The X-ray examination could detect all bacteriologically positive cases except for a few smear negative culture positive subjects. Children less than 15 year old received a BCG scar check and a tuberculin test. A BCG scar was observed in 50.2% of children aged between 1 and 14. The BCG scar rate among children aged 1-4 was as low as 64.6% with no sex and geographical differences. This figure was consistent with the government estimation of the vaccination coverage. When we applied the cut-off point of 10 mm as tuberculin reaction, 2.7% of children were infected with TB by age 2.8, 13.7% by age 7.2, and 32.7% by age 12.. The annual risk of TB infection in the age group between 5 and 9 was estimated at 2.06%. Despite the fact that the numbers of case notifications in male and female have been almost at the same level in Cambodia, the survey saw a considerable difference in the prevalence between male and female. The Prevalence/Notification ratios were relatively constant across all age groups in both sexes. However, male always showed higher ratios than female in every age group. Since there was no difference in delays of diagnosis between male and female, the case detection rate in male might be much lower than that in female. As the TB prevalence rate increases along the age, it was suggested that, at present, a significant portion of TB diseases in Cambodia are developed from latent infection and reactivation, not from new infections. Using other available information and some additional studies on TB and HIV in Cambodia, the incidence of TB was estimated. The point estimate of incidence of new smear positive TB was 229/100,000, which was very close to the WHO’s recent estimation. The incidence of all forms of TB was estimated approximately at 600/100,000. HIV/AIDS attributed around 13% of incidence of smear positive. However, since the prevalence of smear negative and culture positive TB was much higher than expected, and since we might have more TB cases than expected among children, the total TB burden, or an incidence rate of all TB, could be as high as 700/100,000. Compared with the past studies from the 1980s and 1990s, the observed prevalence rate of smear positive was much lower in this study, especially in the younger adult population. The better access to DOTS shortened a delay of diagnosis and cut the infection chain. The exerted efforts of expanding DOTS in the past 8 years seemed to have made a significant impact on the TB burden. However, a large pool of latent infection in the middle and elder generations and the impact of HIV/AIDS account for the high TB incidence in Cambodia. As a result, the country still remains a high TB burden country.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '15769', 'scopus': None, 'doi': None}, 'title': 'National TB Prevalence Survey 2002 Cambodia', 'source': 'Mendeley'}
Rehlis N. Health Facility Survey in Cambodia. Principal Indicators. June 2007. Unpublished report.	-	-	reference	057d47b73f2344e03939e049d9f7d7710d0ac56c	3ba121a4cba609e9ae76268954dfc9d213f96d13_	{'publication_type': {'year': 2007, 'cited_medium': None, 'issue': None, 'issn': None, 'volume': None, 'title': None, 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.25, 'total': 0.1625, 'authors': 0.0}, 'authors': [{'given': 'D. L.', 'family': 'Sisterson'}], 'abstract': None, 'type': 'report', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.2172/966778'}, 'title': 'Atmospheric Radiation Measurement program climate research facility operations quarterly report April 1 - June 30, 2007.', 'source': 'CrossRef'}
Rehlis N. Health Facility Survey in Cambodia. Principal Indicators. June 2007. Unpublished report.	-	-	reference	057d47b73f2344e03939e049d9f7d7710d0ac56c	3ba121a4cba609e9ae76268954dfc9d213f96d13_	{'publication_type': {'year': 2003, 'cited_medium': None, 'issue': None, 'issn': None, 'volume': None, 'title': 'Health Facility Survey', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 0.4, 'total': 0.36, 'authors': 0.0}, 'authors': [{'given': None, 'family': 'Who'}], 'abstract': 'Gives details on how to conduct a health facility survey. There is a checklist for supervisors prior to starting the survey', 'type': 'book_section', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': None}, 'title': 'Conducting and supervising the survey', 'source': 'Mendeley'}
Anonymous. Implementación de la estrategia de Atención Integrada a las Enfermedades Prevalentes de la Infancia, Reporte Final, Linea Base, Provincia de Imbabura, Republica del Ecuador. 1997. Unpublished report.	-	-	reference	057d47b73f2344e03939e049d9f7d7710d0ac56c	5eeef2021dcc990071c9369ab7e73a3a1886a797_	{'publication_type': {'year': 2005, 'cited_medium': None, 'issue': '4', 'issn': '1020-4989', 'volume': '17', 'title': 'Revista Panamericana de Salud Pública', 'pagination': '280-281'}, 'language': None, 'rating': {'year': 0, 'title': 0.9333333333333333, 'total': 0.6066666666666667, 'authors': 0}, 'authors': [], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1590/s1020-49892005000400010'}, 'title': 'La estrategia de atención integrada a las enfermedades prevalentes de la infancia en el Perú', 'source': 'CrossRef'}
Anonymous. Implementación de la estrategia de Atención Integrada a las Enfermedades Prevalentes de la Infancia, Reporte Final, Linea Base, Provincia de Imbabura, Republica del Ecuador. 1997. Unpublished report.	-	-	reference	057d47b73f2344e03939e049d9f7d7710d0ac56c	5eeef2021dcc990071c9369ab7e73a3a1886a797_	{'publication_type': {'year': 2011, 'cited_medium': None, 'issue': None, 'issn': '0124-0064', 'volume': None, 'title': 'Revista de Salud Pública', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.7692307692307693, 'total': 0.5, 'authors': 0.0}, 'authors': [{'given': 'Diana F', 'family': 'López'}, {'given': 'María V', 'family': 'Benjumea'}], 'abstract': "RESUMEN Objetivo Evaluar la aplicación de la estrategia AIEPI en la prevención, detección y el tratamiento de la ferropenia en menores de 5 años atendidos en la Clínica La Asunción-ASSBASALUD de Manizales durante 2007. Métodos Estudio descriptivo de corte transversal en 310 niños entre 6 y 71 meses de la clínica La Asunción en el primer nivel de Manizales. Se evaluó la prevalencia de ferropenia en los niños y la aplicación de AIEPI para su prevención, diagnóstico y tratamiento por los profesionales de la salud responsables de la atención en ese centro. Resultados La mayoría de los niños tenía menos de 24 meses, era de SISBEN 2, fue atendida en Crecimiento y Desarrollo y por personal de enfermería. Entre la población afectada por ferropenia, el déficit de hierro sin anemia fue el que prevaleció. En la mitad de la población que tenía anemia, ésta se debió a déficit de hierro; la prevalencia de anemia de otro tipo fue superior a la de la anemia asociada con infección. Por cada niño con anemia ferropénica se presentaron casi tres con déficit de hierro. Sólo seis acompañantes de los niños estudiados refirieron haber recibido indicaciones dietarias para la prevención de la anemia y en la mitad de los casos, ésta fue errada. Conclusión Se evidenció que durante la atención de los menores de cinco años los procesos dirigidos a la prevención, diagnóstico y tratamiento de la anemia ferropénica no siguen los lineamientos estipulados por la estrategia AIEPI. Palabras Clave: Anemia ferropénica, deficiencia de hierro, niños, crecimiento y desarrollo, dieta (source: DeCS, BIREME). ABSTRACT Objective Evaluating implementing the integrated management of childhood illness (IMCI) strategy in the prevention, detection and treatment of iron deficiency in children aged less than 5 who were treated at ASSBASALUD's Clinica La Asunción in", 'type': 'journal', 'ids': {'embase': None, 'pubmed': None, 'scopus': '2-s2.0-80155132824', 'doi': '10.1590/S0124-00642011000100009'}, 'title': 'Atención Integrada a las Enfermedades Prevalentes de la Infancia-AIEPI, para ferropenia en niños', 'source': 'Mendeley'}
Salgado R, Baruda G, Choi M, Weinstock A. Health Facility Survey of Child Health Services, Southern Nations, Nationalities and Peoples Region (SNNPR) Ethiopia, March 2002. John Snow International, Inc., 2002. Unpublished report.	-	-	reference	057d47b73f2344e03939e049d9f7d7710d0ac56c	4435d30c647265b60b26ce52455d800091528852_	{'publication_type': {'year': 2015, 'cited_medium': None, 'issue': '1', 'issn': '2049-3258', 'volume': '73', 'title': 'Archives of Public Health', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.3225806451612903, 'total': 0.20967741935483872, 'authors': 0.0}, 'authors': [{'given': 'Asrat', 'family': 'Sonko'}, {'given': 'Amare', 'family': 'Worku'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '26629339', 'scopus': None, 'doi': '10.1186/s13690-015-0098-4'}, 'title': 'Prevalence and predictors of exclusive breastfeeding for the first six months of life among women in Halaba special woreda, Southern Nations, Nationalities and Peoples’ Region/SNNPR/, Ethiopia: a community based cross-sectional study', 'source': 'CrossRef'}
Salgado R, Baruda G, Choi M, Weinstock A. Health Facility Survey of Child Health Services, Southern Nations, Nationalities and Peoples Region (SNNPR) Ethiopia, March 2002. John Snow International, Inc., 2002. Unpublished report.	-	-	reference	057d47b73f2344e03939e049d9f7d7710d0ac56c	4435d30c647265b60b26ce52455d800091528852_	{'publication_type': {'year': 1999, 'cited_medium': None, 'issue': None, 'issn': '1021-6790', 'volume': None, 'title': 'Ethiopian Journal of Health Development', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.47058823529411764, 'total': 0.3058823529411765, 'authors': 0.0}, 'authors': [{'given': 'D. D.', 'family': 'Dilbato'}, {'given': 'T. M.', 'family': 'Tito'}], 'abstract': 'A study on traditional medicinal use of garlic was carried out among rural and semi urban resident traditional health practitioners in the Southern Nations Nationalities and Peoples Regional State (SNNPR) in 1996. A total of 125 traditional healers took part in the study in 8 zones and 3 Special Woredas in the Region. Their responses indicated that garlic is used for the treatment of common cold (88 %), malaria (85 %), cough and lung TB (66 %), hypertension (57 %), wounds (25 %), sexually transmitted diseases (22 %), mental illnesses (22 %), kidney (19 %), and liver diseases (16 %). The responses also suggest that the medicinal content lies in the broad-bulb which must be taken raw. 96 (77 %) respondents stated that the bulb should be crushed before use while', 'type': 'journal', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': None}, 'title': '*8Medicinal preparation and use of garlic by traditional healers in Southern Nations Nationalities and Peoples State, Ethiopia.', 'source': 'Mendeley'}
Naimoli JF. Theoretical and empirical advances in research on the implementation of an integrated approach to managing childhood illness in outpatient facilities in developing countries [ScD Dissertation]. [Cambridge (MA)]: Harvard University; 2001. 347 p.	-	-	reference	057d47b73f2344e03939e049d9f7d7710d0ac56c	c1321756887ee6e8a2173bfd5305ca358ca4f34b_	{'publication_type': {'year': 1976, 'cited_medium': None, 'issue': None, 'issn': None, 'volume': None, 'title': None, 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.4444444444444444, 'total': 0.28888888888888886, 'authors': 0}, 'authors': [], 'abstract': None, 'type': 'report', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.2172/7215065'}, 'title': 'Progress report. [Summaries of research activities at Harvard University]', 'source': 'CrossRef'}
Naimoli JF. Theoretical and empirical advances in research on the implementation of an integrated approach to managing childhood illness in outpatient facilities in developing countries [ScD Dissertation]. [Cambridge (MA)]: Harvard University; 2001. 347 p.	-	-	reference	057d47b73f2344e03939e049d9f7d7710d0ac56c	c1321756887ee6e8a2173bfd5305ca358ca4f34b_	{'publication_type': {'year': 2008, 'cited_medium': None, 'issue': None, 'issn': None, 'volume': None, 'title': 'Missouri Botanical Garden, St. Louis, MO & Harvard University Herbaria, Cambridge, MA.', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.0, 'total': 0.0, 'authors': 0.0}, 'authors': [{'given': None, 'family': 'Missouri Botanical Garden'}, {'given': None, 'family': 'Harvard University Herbaria'}], 'abstract': "'eFloras (2008). Published on the Internet http://www.efloras.org [accessed 22 February 2008]*' Missouri Botanical Garden, St. Louis, MO & Harvard University Herbaria, Cambridge, MA.", 'type': 'web_page', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': None}, 'title': 'eFloras', 'source': 'Mendeley'}
Kelley, E., et al., Compliance, workload, and the cost of using the Integrated Management of Childhood Illness algorithm in Niger. Operations Research Results 2002;2(11): p. 15.	-	-	reference	057d47b73f2344e03939e049d9f7d7710d0ac56c	6962b67a2ba2ecf7c5feb49389df377cddc6e332_	{'publication_type': {'year': 2001, 'cited_medium': None, 'issue': '3', 'issn': '0749-6753', 'volume': '16', 'title': 'The International Journal of Health Planning and Management', 'pagination': '195-205'}, 'language': None, 'rating': {'year': 0, 'title': 0.5217391304347826, 'total': 0.5891304347826087, 'authors': 1.0}, 'authors': [{'given': 'Edward', 'family': 'Kelley'}, {'given': 'Colette', 'family': 'Geslin'}, {'given': 'Sabou', 'family': 'Djibrina'}, {'given': 'Maina', 'family': 'Boucar'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '11596557', 'scopus': None, 'doi': '10.1002/hpm.632'}, 'title': 'Improving performance with clinical standards: the impact of feedback on compliance with the Integrated Management of Childhood Illness algorithm in Niger, West Africa', 'source': 'CrossRef'}
Kelley, E., et al., Compliance, workload, and the cost of using the Integrated Management of Childhood Illness algorithm in Niger. Operations Research Results 2002;2(11): p. 15.	-	-	reference	057d47b73f2344e03939e049d9f7d7710d0ac56c	6962b67a2ba2ecf7c5feb49389df377cddc6e332_	{'publication_type': {'year': 1979, 'cited_medium': None, 'issue': None, 'issn': None, 'volume': None, 'title': 'TRAINING METHODES IN THE USA (UNITED STATES OF AMERICA) (FROM INTERNATIONAL POLICE ASSOCIATION - STUDY TOUR P 15-46, 1979, BY KENNETH H ROBINSON - SEE NCJ-65549)', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.23076923076923078, 'total': 0.275, 'authors': 0.5}, 'authors': [{'given': 'M', 'family': 'WOOSEY'}, {'given': 'International Police', 'family': 'Assoc'}], 'abstract': 'THE FEDERAL BUREAU OF INVESTIGATION (FBI) MAINTAINS HIGH STANDARDS FOR ITS OFFICERS. IN 1972, A NEW FBI TRAINING ACADEMY WAS OPENED IN QUANTICO, VIRGINIA, AND WAS EQUIPPED WITH MODERN CLASSROOMS, LIBRARY, DORMITORIES, FIREARMS RANGES, AND A PHYSICAL TRAINING CENTER. NEW FBI AGENTS ARE INTENSIVELY TRAINED AT QUANTICO OVER A 16-WEEK PERIOD IN FEDERAL CRIMINAL PROCEDURE, EVIDENCE, INVESTIGATION TECHNIQUES, DEFENSIVE TECHNIQUES, AND MANY OTHER SUBJECTS AND PRACTICES; LAW, ACCOUNTING, AND PHYSICAL SCIENCE ARE AMONG THE PROFESSIONAL BACKGROUNDS REQUIRED OF ALL CANDIDATES. THE NATIONAL ACADEMY AT THE FBI TRAINING ACADEMY, AN 11-WEEK COURSE, TRAINS PROMISING CAREER POLICE OFFICERS FROM ALL PARTS OF THE COUNTRY TO BE POLICE INSTRUCTORS AND ADMINISTRATORS. STUDENTS MUST BE NOMINATED BY THE HEADS OF THEIR AGENCIES AND COURSEWORK COVERS MANAGEMENT, BEHAVIORAL SCIENCE, LAW, EDUCATION, COMMUNICATIONS, FORENSIC SCIENCE, AND LAW ENFORCEMENT. THE FBI NATIONAL INSTITUTE PROVIDES SOPHISTICATED MANAGEMENT TRAINING FOR TOP POLICE MANAGERS. SCHEDULING IS FLEXIBLE AND STUDY TOPICS COVER SOCIAL, ECONOMIC, AND POLITICAL TRENDS; PUBLIC AND LABOR RELATIONS; AND BUDGETING. THE NORTHERN VIRGINIA CRIMINAL JUSTICE ACADEMY PROVIDES ALL POLICE TRAINING FOR SEVERAL NORTHERN VIRGINIA COUNTIES. NEW RECRUITS UNDERGO 16 WEEKS OF TRAINING AND A COURSE LIST IS PROVIDED. FINALLY, THE METROPOLITAN POLICE ACADEMY OF WASHINGTON, D.C. TRAINS ALL OF ITS RECRUITS FROM START TO FINISH, BUT CAN DEAL WITH THE GREAT FLUCTUATIONS OF RECRUIT CLASS SIZE COMMON IN ACADEMIES SERVING ONLY ONE CITY. DISCUSSION OF ITS TRAINING PROGRAM IS INCLUDED. FINAL TOPICS INCLUDE A COMPARISON OF POLICE TRAINING IN THE U.S. AND UNITED KINGDOM AND DISCUSSION OF THE IMPORTANCE OF POLICE PHYSICAL FITNESS TRAINING. TABLES, CHARTS, AND A BIBLIOGRAPHY ARE INCLUDED. (PAP)', 'type': 'generic', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': None}, 'title': 'TRAINING METHODES IN THE USA (UNITED STATES OF AMERICA) (FROM INTERNATIONAL POLICE ASSOCIATION - STUDY TOUR P 15-46, 1979, BY KENNETH H ROBINSON - SEE NCJ-65549)', 'source': 'Mendeley'}
Tavrow P, Kekitiinwa Rukyalekere A, Maganda A, et al. A comparison of computer-based and standard training in the Integrated Management of Childhood Illness in Uganda. Quality Assurance Project, 2002.	-	-	reference	057d47b73f2344e03939e049d9f7d7710d0ac56c	82311f56b0f32d5e575ac686ec620429a72d5889_	{'publication_type': {'year': 1985, 'cited_medium': None, 'issue': '1', 'issn': '0736-5845', 'volume': '2', 'title': 'Robotics and Computer-Integrated Manufacturing', 'pagination': '87'}, 'language': None, 'rating': {'year': 0, 'title': 0.2647058823529412, 'total': 0.17205882352941176, 'authors': 0}, 'authors': [], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1016/0736-5845(85)90039-0'}, 'title': '1084852 AD-A144 891/9 ICAM (Integrated Computer-Aided Manufacturing) Conceptual Design for Computer-Integrated Manufacturing. Volume 4, part 6. Task D. quality assurance/quality control/technical requirement/task, quality assurance modeling and analysis, quality assurance program management standard recommendations (ISP)', 'source': 'CrossRef'}
Tavrow P, Kekitiinwa Rukyalekere A, Maganda A, et al. A comparison of computer-based and standard training in the Integrated Management of Childhood Illness in Uganda. Quality Assurance Project, 2002.	-	-	reference	057d47b73f2344e03939e049d9f7d7710d0ac56c	82311f56b0f32d5e575ac686ec620429a72d5889_	{'publication_type': {'year': 2002, 'cited_medium': None, 'issue': None, 'issn': None, 'volume': None, 'title': 'Report', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 1.0, 'total': 0.65, 'authors': 0}, 'authors': [{'given': None, 'family': 'Center for Human Services'}], 'abstract': 'The Quality Assurance (QA) Project is funded by the U.S. Agency for International Develop-ment (USAID), under Contract Number HRN-C-00-96-90013. The QA Project serves coun-tries eligible for USAID assistance, USAID Missions and Bureaus, and other agencies and nongovernmental organizations that cooperate with USAID. The QA Project team consists of prime contractor Center for Human Services; Joint Commission Resources, Inc.; and Johns Hopkins University (including the School of Hygiene and Public Health [JHSPH], the Center for Communication Programs [CCP], and the Johns Hopkins Program for International Education in Reproductive Health [JHPIEGO]). The QA Project provides comprehensive, leading-edge technical expertise in the design, management, and implementation of quality assurance programs in developing countries. Center for Human Services, the nonprofit affiliate of University Research Co., LLC, provides technical assistance and research for the design, management, improvement, and monitoring of health systems and service delivery in over 30 countries.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': None}, 'title': 'A Comparison of Computer-Based and Standard Training in the Integrated Management of Childhood Illness in Uganda', 'source': 'Mendeley'}
Mwinga K, Siziya S, Kasungami D, et al. Research Study Report: Comparative study of Integrated Management of Childhood Illness (IMCI) case management skills of primary health care workers trained in eleven-day standard course and six-day abridged course for physicians. Unpublished report from the Zambia Ministry of Health, 2006	-	-	reference	057d47b73f2344e03939e049d9f7d7710d0ac56c	cf143b4352a3489a8ff9eded441ab313499d58c0_	{'publication_type': {'year': 2009, 'cited_medium': None, 'issue': '2', 'issn': '0268-1080', 'volume': '24', 'title': 'Health Policy and Planning', 'pagination': '94-100'}, 'language': None, 'rating': {'year': 0, 'title': 0.6666666666666666, 'total': 0.43333333333333335, 'authors': 0}, 'authors': [{'given': 'D.', 'family': 'Kumar'}, {'given': 'A. K', 'family': 'Aggarwal'}, {'given': 'R.', 'family': 'Kumar'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '19181673', 'scopus': None, 'doi': '10.1093/heapol/czn051'}, 'title': 'The effect of interrupted 5-day training on Integrated Management of Neonatal and Childhood Illness on the knowledge and skills of primary health care workers', 'source': 'CrossRef'}
Mwinga K, Siziya S, Kasungami D, et al. Research Study Report: Comparative study of Integrated Management of Childhood Illness (IMCI) case management skills of primary health care workers trained in eleven-day standard course and six-day abridged course for physicians. Unpublished report from the Zambia Ministry of Health, 2006	-	-	reference	057d47b73f2344e03939e049d9f7d7710d0ac56c	cf143b4352a3489a8ff9eded441ab313499d58c0_	{'publication_type': {'year': 2007, 'cited_medium': None, 'issue': None, 'issn': None, 'volume': None, 'title': 'World Health Organisation Technical Consultation of IMCI inservice and preservice training approaches and methods', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.75, 'total': 0.7075, 'authors': 0.8800000000000001}, 'authors': [{'given': 'K', 'family': 'Mwinga'}, {'given': 'S', 'family': 'Siziya'}, {'given': 'D', 'family': 'Kasungami'}, {'given': 'P', 'family': 'Kalesha'}, {'given': 'Tambatamba', 'family': 'B'}], 'abstract': ': Com- parative study of two types of IMCI Case Management courses in Zambia. Presented at', 'type': 'conference_proceedings', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': None}, 'title': 'Comparative study of two types of IMCI Case Management courses in Zambia', 'source': 'Mendeley'}
Syla, S. A comparison of standard training (11-days) with adapted 8 days in the Integrated Management of Childhood Illness (IMCI) in Kosova [Masters Thesis]. [Copenhagen]: Institute of Public Health, University of Copenhagen; 2003. (and personal communication from S. Syla, Kosovo WHO Country Office, Prishtina, November 14 and 15, 2007)	-	-	reference	057d47b73f2344e03939e049d9f7d7710d0ac56c	58fde6172a3509cca8914c1643da11943af4bfd9_	{'publication_type': {'year': 2015, 'cited_medium': None, 'issue': None, 'issn': '1857-9655', 'volume': None, 'title': 'Open Access Macedonian Journal of Medical Sciences', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.25, 'total': 0.1625, 'authors': 0.0}, 'authors': [{'given': 'Lul', 'family': 'Raka'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '27275217', 'scopus': None, 'doi': '10.3889/oamjms.2015.013'}, 'title': 'Ebola in West Africa', 'source': 'CrossRef'}
Syla, S. A comparison of standard training (11-days) with adapted 8 days in the Integrated Management of Childhood Illness (IMCI) in Kosova [Masters Thesis]. [Copenhagen]: Institute of Public Health, University of Copenhagen; 2003. (and personal communication from S. Syla, Kosovo WHO Country Office, Prishtina, November 14 and 15, 2007)	-	-	reference	057d47b73f2344e03939e049d9f7d7710d0ac56c	58fde6172a3509cca8914c1643da11943af4bfd9_	{'publication_type': {'year': 2006, 'cited_medium': None, 'issue': None, 'issn': '2078-6204', 'volume': None, 'title': 'South African Family Practice', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.8888888888888888, 'total': 0.7027777777777777, 'authors': 0.5}, 'authors': [{'given': 'T', 'family': 'Kerry'}], 'abstract': 'The Integrated Management of Childhood Illness (IMCI) strategy is the primary child-care approach of choice for South Africa. 1 , 2  IMCI training was introduced into South Africa in 1996 by WHO and UNICEF. Since then 8695 health workers have been trained in IMCI – mainly primary health care nurse practitioners, but also primary care doctors and paediatricians. The basic 11-day course comprises classroom activities, assessing children both in an outpatient setting and paediatric ward. 3  A compact 4- day course has been developed for doctors and is being taught in some medical schools. IMCI has been very well received by nurse practitioner and doctor alike in empowering them to make easy, evidence-based decisions in the management of sick children at first contact level. However many doctors continue to work with children without knowledge of IMCI.  Keywords: IMCI; case management; sick children; pneumonia; diarrhoea; fever;    For full text, click here: SA Fam Pract 2005;47(8):32-38', 'type': 'generic', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': None}, 'title': 'A review of Integrated Management of Childhood Illness (IMCI)', 'source': 'Mendeley'}
Anonymous. Evaluación del proceso de implementacion de la estrategia de Atención Integrada a las Enfermedades Prevalentes en la Infancia - AIEPI - en ambitos de las Direcciones de Salud Callao y Lima Norte (Ventanilla y Puente Piedra), 2004. Unpublished report.	-	-	reference	057d47b73f2344e03939e049d9f7d7710d0ac56c	674d790a9e4081aeecb259d3d9e01500666a5175_	{'publication_type': {'year': 2002, 'cited_medium': None, 'issue': '2', 'issn': '0370-4106', 'volume': '73', 'title': 'Revista chilena de pediatría', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.65, 'total': 0.42250000000000004, 'authors': 0.0}, 'authors': [{'given': 'Adalid D.', 'family': 'Zamora G'}, {'given': 'Dilberth', 'family': 'Cordero V.'}, {'given': 'Martha', 'family': 'Mejia S.'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.4067/s0370-41062002000200014'}, 'title': 'Evaluación de la estrategia "Atención integrada a las enfermedades prevalentes de la infancia" (AIEPI) en Servicios de Salud, Bolivia 1999', 'source': 'CrossRef'}
Anonymous. Evaluación del proceso de implementacion de la estrategia de Atención Integrada a las Enfermedades Prevalentes en la Infancia - AIEPI - en ambitos de las Direcciones de Salud Callao y Lima Norte (Ventanilla y Puente Piedra), 2004. Unpublished report.	-	-	reference	057d47b73f2344e03939e049d9f7d7710d0ac56c	674d790a9e4081aeecb259d3d9e01500666a5175_	{'publication_type': {'year': 2002, 'cited_medium': None, 'issue': None, 'issn': '03704106', 'volume': None, 'title': 'Revista Chilena de Pediatria', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.6, 'total': 0.39, 'authors': 0.0}, 'authors': [{'given': 'Adalid D.', 'family': 'Zamora G'}, {'given': 'Dilberth', 'family': 'Cordero V'}, {'given': 'Martha', 'family': 'Mejia S'}], 'abstract': 'La implementación de la estrategia AIEPI en Bolivia, se inicio a fines del año 1996; en este proceso se capacitó y realizó visitas de seguimiento a personal de salud de tres distritos considerados como iniciales. El presente artículo presenta los resultados de la aplicación de una metodología de evaluación del impacto de la capacitación y seguimiento de AIEPI, recomendada por la Organización Mundial de la Salud (OMS), la cual se constituye en la primera prueba mundial. Los objetivos de la primera prueba mundial de la evaluación AIEPI fueron: conocer la calidad de atención al niño menor de cinco años, disponibilidad de medicamentos y equipamiento para la atención integral en servicios de salud de primer nivel de tres distritos; identificar las barreras que impiden la integridad de la atención; validar la metodología propuesta por la OMS. La evaluación fue realizada en abril de 1999 en los distritos rurales Altiplano Valle Sur en La Paz, Valles Cruceños y Chuquitania Centro en Santa Cruz. Consistió en la visita de equipos de evaluadores para observar el manejo de casos, realizar una entrevista de salida a la madre, re-examinar al niño y revisar el equipamiento y provisión de medicamentos. Se incluyeron 36 servicios de salud seleccionados aleatoriamente, se observó a 54 trabajadores de salud que atendieron 102 niños. Los resultados mostraron que las habilidades clínicas han mejorado ostensiblemente, en comparación con la línea de base del año 1997. Hubo una reducción en el uso innecesario de antibióticos. Las debilidades estuvieron relacionadas con la identificación y conducta hacia la clasificación de anemia y con aspectos de consejería a la madre. Se identificaron problemas con la disponibilidad de medicamentos y la vacunación en servicios. Luego del análisis de la información recolectada se efectuaron talleres de devolución de la información a los niveles operativos, los cuales consiguieron que el personal de salud plantee recomendaciones orientadas a mejorar la aplicación de AIEPI en sus servicios. Finalmente se realizaron recomendaciones sobre la metodología de evaluación (AU)', 'type': 'journal', 'ids': {'embase': None, 'pubmed': None, 'scopus': '2-s2.0-0036285895', 'doi': None}, 'title': 'Evaluaci??n de la estrategia "Atenci??n integrada a las enfermedades prevalentes de la infancia" (AIEPI) en Servicios de Salud, Bolivia 1999', 'source': 'Mendeley'}
Ortiz JL, Chumacero LL, Dávila M. Impacto de la aplicación de la estrategia AIEPI en el Uso de Antibióticos para el tratamiento de las Infecciones Respiratorias Agudas y Enfermedades Diarreicas, en Centros de Salud de Lambayeque – Perú. 1998. Unpublished report.	-	-	reference	057d47b73f2344e03939e049d9f7d7710d0ac56c	58abe4035febb2527cdb370db1704a8bb2e0d2bb_	{'publication_type': {'year': 2006, 'cited_medium': None, 'issue': '5', 'issn': '1696-2818', 'volume': '4', 'title': 'Anales de Pediatría Continuada', 'pagination': '311-315'}, 'language': None, 'rating': {'year': 0, 'title': 0.64, 'total': 0.41600000000000004, 'authors': 0}, 'authors': [], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1016/s1696-2818(06)73630-7'}, 'title': '¿Cuál es la eficacia de los medicamentos para el tratamiento de la tos en las infecciones respiratorias agudas de las vías altas en los niños?', 'source': 'CrossRef'}
Ortiz JL, Chumacero LL, Dávila M. Impacto de la aplicación de la estrategia AIEPI en el Uso de Antibióticos para el tratamiento de las Infecciones Respiratorias Agudas y Enfermedades Diarreicas, en Centros de Salud de Lambayeque – Perú. 1998. Unpublished report.	-	-	reference	057d47b73f2344e03939e049d9f7d7710d0ac56c	58abe4035febb2527cdb370db1704a8bb2e0d2bb_	{'publication_type': {'year': 2005, 'cited_medium': None, 'issue': None, 'issn': None, 'volume': None, 'title': 'El diseño instruccional de un programa para la enseñanza de la estadística y la metodología apoyado en el uso de las Tecnologías de la Información y la Comunicación', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.6428571428571429, 'total': 0.5428571428571429, 'authors': 0.5}, 'authors': [{'given': 'M.', 'family': 'García, Benilde; Márquez, L.; Lajoie, S. y Villaseñor'}], 'abstract': 'El trabajo presenta resultados de la evaluacion al programa "Estadistica Autentica para las Ciencias Sociales" (ESACS), desarrollado como diseño instruccional para estudiantes de licenciatura, inspirado en el programa computarizado ASP (Authentic Statistics Project), con el fin de "facilitar el proceso de aprendizaje y evaluación de la Estadística". Ponencia presentada en el Primer Coloquio- Taller de Educación Estadística. Xalapa, Veracruz, 24 al 28 de octubre de 2005.', 'type': 'report', 'ids': {'embase': None, 'pubmed': '17155760', 'scopus': None, 'doi': '10.1103/PhysRevLett.97.216601'}, 'title': 'El diseño instruccional de un programa para la enseñanza de la Estadística y la Metodología apoyado en el uso de las Tecnologías de la Información y la Comunicación', 'source': 'Mendeley'}
Anonymous. Informe Preliminar: Evaluación AIEPI a Servicios de Salud, Primera Prueba Mundial, Bolivia, 12–30 de Abril 1999. Unpublished report.	-	-	reference	057d47b73f2344e03939e049d9f7d7710d0ac56c	65afbeee68347a2e28a39a2c81f6371c4e2f27c7_	{'publication_type': {'year': 2002, 'cited_medium': None, 'issue': '2', 'issn': '0370-4106', 'volume': '73', 'title': 'Revista chilena de pediatría', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.6, 'total': 0.39, 'authors': 0.0}, 'authors': [{'given': 'Adalid D.', 'family': 'Zamora G'}, {'given': 'Dilberth', 'family': 'Cordero V.'}, {'given': 'Martha', 'family': 'Mejia S.'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.4067/s0370-41062002000200014'}, 'title': 'Evaluación de la estrategia "Atención integrada a las enfermedades prevalentes de la infancia" (AIEPI) en Servicios de Salud, Bolivia 1999', 'source': 'CrossRef'}
Anonymous. Informe Preliminar: Evaluación AIEPI a Servicios de Salud, Primera Prueba Mundial, Bolivia, 12–30 de Abril 1999. Unpublished report.	-	-	reference	057d47b73f2344e03939e049d9f7d7710d0ac56c	65afbeee68347a2e28a39a2c81f6371c4e2f27c7_	{'publication_type': {'year': 2002, 'cited_medium': None, 'issue': None, 'issn': '03704106', 'volume': None, 'title': 'Revista Chilena de Pediatria', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.55, 'total': 0.35750000000000004, 'authors': 0.0}, 'authors': [{'given': 'Adalid D.', 'family': 'Zamora G'}, {'given': 'Dilberth', 'family': 'Cordero V'}, {'given': 'Martha', 'family': 'Mejia S'}], 'abstract': 'La implementación de la estrategia AIEPI en Bolivia, se inicio a fines del año 1996; en este proceso se capacitó y realizó visitas de seguimiento a personal de salud de tres distritos considerados como iniciales. El presente artículo presenta los resultados de la aplicación de una metodología de evaluación del impacto de la capacitación y seguimiento de AIEPI, recomendada por la Organización Mundial de la Salud (OMS), la cual se constituye en la primera prueba mundial. Los objetivos de la primera prueba mundial de la evaluación AIEPI fueron: conocer la calidad de atención al niño menor de cinco años, disponibilidad de medicamentos y equipamiento para la atención integral en servicios de salud de primer nivel de tres distritos; identificar las barreras que impiden la integridad de la atención; validar la metodología propuesta por la OMS. La evaluación fue realizada en abril de 1999 en los distritos rurales Altiplano Valle Sur en La Paz, Valles Cruceños y Chuquitania Centro en Santa Cruz. Consistió en la visita de equipos de evaluadores para observar el manejo de casos, realizar una entrevista de salida a la madre, re-examinar al niño y revisar el equipamiento y provisión de medicamentos. Se incluyeron 36 servicios de salud seleccionados aleatoriamente, se observó a 54 trabajadores de salud que atendieron 102 niños. Los resultados mostraron que las habilidades clínicas han mejorado ostensiblemente, en comparación con la línea de base del año 1997. Hubo una reducción en el uso innecesario de antibióticos. Las debilidades estuvieron relacionadas con la identificación y conducta hacia la clasificación de anemia y con aspectos de consejería a la madre. Se identificaron problemas con la disponibilidad de medicamentos y la vacunación en servicios. Luego del análisis de la información recolectada se efectuaron talleres de devolución de la información a los niveles operativos, los cuales consiguieron que el personal de salud plantee recomendaciones orientadas a mejorar la aplicación de AIEPI en sus servicios. Finalmente se realizaron recomendaciones sobre la metodología de evaluación (AU)', 'type': 'journal', 'ids': {'embase': None, 'pubmed': None, 'scopus': '2-s2.0-0036285895', 'doi': None}, 'title': 'Evaluaci??n de la estrategia "Atenci??n integrada a las enfermedades prevalentes de la infancia" (AIEPI) en Servicios de Salud, Bolivia 1999', 'source': 'Mendeley'}
Cordero D, Salgado R, Drasbeck C. An analysis of the IMCI implementation process in four countries of Latin America. Edited by Tina G. Sanghvi and Mireille Mather. Arlington, Virginia: BASICS II for the United States Agency for International Development and the Pan American Health Organization. 2004.	-	-	reference	057d47b73f2344e03939e049d9f7d7710d0ac56c	27cbbd4828693b4d4c71331ff608991f65a7d538_	{'publication_type': {'year': 2016, 'cited_medium': None, 'issue': '1', 'issn': '1471-2458', 'volume': '16', 'title': 'BMC Public Health', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.45714285714285713, 'total': 0.29714285714285715, 'authors': 0.0}, 'authors': [{'given': 'Lauren', 'family': 'Arnesen'}, {'given': 'Thomas', 'family': 'O’Connell'}, {'given': 'Luisa', 'family': 'Brumana'}, {'given': 'Pablo', 'family': 'Durán'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '27443628', 'scopus': None, 'doi': '10.1186/s12889-016-3238-z'}, 'title': 'An analysis of three levels of scaled-up coverage for 28 interventions to avert stillbirths and maternal, newborn and child mortality in 27 countries in Latin America and the Caribbean with the Lives Saved Tool (LiST)', 'source': 'CrossRef'}
Cordero D, Salgado R, Drasbeck C. An analysis of the IMCI implementation process in four countries of Latin America. Edited by Tina G. Sanghvi and Mireille Mather. Arlington, Virginia: BASICS II for the United States Agency for International Development and the Pan American Health Organization. 2004.	-	-	reference	057d47b73f2344e03939e049d9f7d7710d0ac56c	27cbbd4828693b4d4c71331ff608991f65a7d538_	{'publication_type': {'year': 2004, 'cited_medium': None, 'issue': None, 'issn': None, 'volume': None, 'title': 'Health (San Francisco)', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 1.0, 'total': 0.8833333333333333, 'authors': 0.9333333333333332}, 'authors': [{'given': 'Dilberth', 'family': 'Cordero'}, {'given': 'Rene', 'family': 'Salgado'}, {'given': 'Christopher', 'family': 'Drasbeck'}], 'abstract': 'This report is a synthesis of lessons learned about the early implementation phase of Integrated Management of Childhood Illness in four countries (Bolivia, El Salvador, Honduras, and Nicaragua). It is not an evaluation of the impact of the strategy on child health indicators, but rather a documentation of the processes and feedback from front-line staff in health facilities about their experiences. The specific objectives of this review were to identify the main achievements and difficulties and to summarize the lessons learned from the process of implementing IMCI in order to facilitate future implementation.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': None}, 'title': 'An Analysis of the IMCI Implementation Process in Four Countries of Latin America', 'source': 'Mendeley'}
Zamora ADG, Cordero DV, Mejia MS. Evaluación de la estrategia “Atención integrada a las enfermedades prevalentes de la infancia” (AIEPI) en Servicios de Salud, Bolivia 1999. Revista Chilena de Pediatría, 2002;73(2):184–191.	-	-	reference	057d47b73f2344e03939e049d9f7d7710d0ac56c	fe70bce64eb536e7fba706b81fbc1642a985f8e1_	{'publication_type': {'year': 2002, 'cited_medium': None, 'issue': '2', 'issn': '0370-4106', 'volume': '73', 'title': 'Revista chilena de pediatría', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.9, 'total': 0.5850000000000001, 'authors': 0.0}, 'authors': [{'given': 'Adalid D.', 'family': 'Zamora G'}, {'given': 'Dilberth', 'family': 'Cordero V.'}, {'given': 'Martha', 'family': 'Mejia S.'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.4067/s0370-41062002000200014'}, 'title': 'Evaluación de la estrategia "Atención integrada a las enfermedades prevalentes de la infancia" (AIEPI) en Servicios de Salud, Bolivia 1999', 'source': 'CrossRef'}
Zamora ADG, Cordero DV, Mejia MS. Evaluación de la estrategia “Atención integrada a las enfermedades prevalentes de la infancia” (AIEPI) en Servicios de Salud, Bolivia 1999. Revista Chilena de Pediatría, 2002;73(2):184–191.	-	-	reference	057d47b73f2344e03939e049d9f7d7710d0ac56c	fe70bce64eb536e7fba706b81fbc1642a985f8e1_	{'publication_type': {'year': 2002, 'cited_medium': None, 'issue': None, 'issn': '03704106', 'volume': None, 'title': 'Revista Chilena de Pediatria', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.85, 'total': 0.5525, 'authors': 0.0}, 'authors': [{'given': 'Adalid D.', 'family': 'Zamora G'}, {'given': 'Dilberth', 'family': 'Cordero V'}, {'given': 'Martha', 'family': 'Mejia S'}], 'abstract': 'La implementación de la estrategia AIEPI en Bolivia, se inicio a fines del año 1996; en este proceso se capacitó y realizó visitas de seguimiento a personal de salud de tres distritos considerados como iniciales. El presente artículo presenta los resultados de la aplicación de una metodología de evaluación del impacto de la capacitación y seguimiento de AIEPI, recomendada por la Organización Mundial de la Salud (OMS), la cual se constituye en la primera prueba mundial. Los objetivos de la primera prueba mundial de la evaluación AIEPI fueron: conocer la calidad de atención al niño menor de cinco años, disponibilidad de medicamentos y equipamiento para la atención integral en servicios de salud de primer nivel de tres distritos; identificar las barreras que impiden la integridad de la atención; validar la metodología propuesta por la OMS. La evaluación fue realizada en abril de 1999 en los distritos rurales Altiplano Valle Sur en La Paz, Valles Cruceños y Chuquitania Centro en Santa Cruz. Consistió en la visita de equipos de evaluadores para observar el manejo de casos, realizar una entrevista de salida a la madre, re-examinar al niño y revisar el equipamiento y provisión de medicamentos. Se incluyeron 36 servicios de salud seleccionados aleatoriamente, se observó a 54 trabajadores de salud que atendieron 102 niños. Los resultados mostraron que las habilidades clínicas han mejorado ostensiblemente, en comparación con la línea de base del año 1997. Hubo una reducción en el uso innecesario de antibióticos. Las debilidades estuvieron relacionadas con la identificación y conducta hacia la clasificación de anemia y con aspectos de consejería a la madre. Se identificaron problemas con la disponibilidad de medicamentos y la vacunación en servicios. Luego del análisis de la información recolectada se efectuaron talleres de devolución de la información a los niveles operativos, los cuales consiguieron que el personal de salud plantee recomendaciones orientadas a mejorar la aplicación de AIEPI en sus servicios. Finalmente se realizaron recomendaciones sobre la metodología de evaluación (AU)', 'type': 'journal', 'ids': {'embase': None, 'pubmed': None, 'scopus': '2-s2.0-0036285895', 'doi': None}, 'title': 'Evaluaci??n de la estrategia "Atenci??n integrada a las enfermedades prevalentes de la infancia" (AIEPI) en Servicios de Salud, Bolivia 1999', 'source': 'Mendeley'}
World Health Organization. Regional Office for the Eastern Mediterranean. Implementation of IMCI in Sudan. Systematic approach to IMCI implementation at district level: key steps and tools. Available at: http://www.emro.who.int/cah/IMCI-implementation-sud.htm#Section2.4, accessed October 6, 2008.	-	-	reference	057d47b73f2344e03939e049d9f7d7710d0ac56c	e969d402911baf902c0f9c161684e6072f945b5f_	{'publication_type': {'year': 2010, 'cited_medium': None, 'issue': '1', 'issn': '1471-2431', 'volume': '10', 'title': 'BMC Pediatrics', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.5555555555555556, 'total': 0.36111111111111116, 'authors': 0.0}, 'authors': [{'given': 'Nantalile', 'family': 'Mugala'}, {'given': 'Wilbroad', 'family': 'Mutale'}, {'given': 'Penny', 'family': 'Kalesha'}, {'given': 'Elijah', 'family': 'Sinyinza'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '21167016', 'scopus': None, 'doi': '10.1186/1471-2431-10-93'}, 'title': 'Barriers to implementation of the HIV guidelines in the IMCI algorithm among IMCI trained health workers in Zambia', 'source': 'CrossRef'}
World Health Organization. Regional Office for the Eastern Mediterranean. Implementation of IMCI in Sudan. Systematic approach to IMCI implementation at district level: key steps and tools. Available at: http://www.emro.who.int/cah/IMCI-implementation-sud.htm#Section2.4, accessed October 6, 2008.	-	-	reference	057d47b73f2344e03939e049d9f7d7710d0ac56c	e969d402911baf902c0f9c161684e6072f945b5f_	{'publication_type': {'year': 2006, 'cited_medium': None, 'issue': None, 'issn': '0023-7213', 'volume': None, 'title': 'Læknablađiđ', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.5384615384615384, 'total': 0.35, 'authors': 0.0}, 'authors': [{'given': 'Sigurdur', 'family': 'Ragnarsson'}, {'given': 'Lovísa', 'family': 'Leifsdóttir'}, {'given': 'Fredrick', 'family': 'Kapinga'}, {'given': 'Geir', 'family': 'Gunnlaugsson'}], 'abstract': 'OBJECTIVES Examine primary health care services for ill children in a sub-Saharan African country, assess the appropriateness of the Integrated Management of Childhood Illness (IMCI) in such a setting and evaluate its implementation. MATERIAL AND METHODS The study was carried out in March, 2005 in the Monkey Bay area, Malawi, in two state-run health facilities that provide services free of charge and in three privately run facilities that charge user fees. Data was collected from each facility regarding all out-patient visits but in particular of children under five years of age (U5s). Interviews were conducted with health workers and drug inventories were carried out in the facilities. RESULTS Eight out of 10 health workers were trained in IMCI. It was 1.22 times more likely (RR, 95% CI 1.18-1.26) that U5s were brought to a state-run facility than a private one. Around 4/5 of all disease classifications during the research period are dealt with in the IMCI. About half of U5s were classified with malaria, 28% with other respiratory infections, 6% with pneumonia, and 5% with diarrhoea. Most IMCI-recommended drugs were in stock at the time of inspection but all facilities lacked at least one recommended drug. CONCLUSION Results show that IMCI reaches the periphery of the health care system in a low-income country such as Malawi. They confirm that IMCI deals with the majority of diseases affecting U5s in such a setting. User fees seem to influence health care seeking behaviour. It is important to support and strengthen health services for ill children in the area, support continuous education of staff and ensure availability of drugs and equipment.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '16582455', 'scopus': None, 'doi': None}, 'title': '[Health services for children and the implementation of IMCI in Monkey Bay, Malawi].', 'source': 'Mendeley'}
Goga A. IMCI health facility survey: Eastern Cape and North West Provinces, 2003. Final draft. September 20, 2003. South Africa National Department of Health (plus personal communication from A. Goga, Medical Research Council of South Africa, on July 13, 2009, which included supplementary tables).	-	-	reference	057d47b73f2344e03939e049d9f7d7710d0ac56c	f6345cd87c1a8e7214e1e7f0869b78bb47bbaeab_	{'publication_type': {'year': 2016, 'cited_medium': None, 'issue': 'Number 9/10', 'issn': '0038-2353', 'volume': 'Volume 112', 'title': 'South African Journal of Science', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.35294117647058826, 'total': 0.22941176470588237, 'authors': 0.0}, 'authors': [{'given': 'Petal', 'family': 'Petersen Williams'}, {'given': 'Tara', 'family': 'Carney'}, {'given': 'Charles D.H.', 'family': 'Parry'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.17159/sajs.2016/20150425'}, 'title': 'Reducing substance use and sexual risk behaviour among men who have sex with men in South Africa', 'source': 'CrossRef'}
Goga A. IMCI health facility survey: Eastern Cape and North West Provinces, 2003. Final draft. September 20, 2003. South Africa National Department of Health (plus personal communication from A. Goga, Medical Research Council of South Africa, on July 13, 2009, which included supplementary tables).	-	-	reference	057d47b73f2344e03939e049d9f7d7710d0ac56c	f6345cd87c1a8e7214e1e7f0869b78bb47bbaeab_	{'message': 'Internal Server Error'}
South Africa National Department of Health. Report of IMCI health facility survey in South Africa. March 18, 2005. South Africa.	-	-	reference	057d47b73f2344e03939e049d9f7d7710d0ac56c	c7e8a2627f33a824dcabd3eb1bc60013e5e7a20f_	{'publication_type': {'year': None, 'cited_medium': None, 'issue': None, 'issn': None, 'volume': None, 'title': None, 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.65, 'authors': 0}, 'authors': [], 'abstract': None, 'type': 'component', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1787/888933152401'}, 'title': 'South Africa', 'source': 'CrossRef'}
South Africa National Department of Health. Report of IMCI health facility survey in South Africa. March 18, 2005. South Africa.	-	-	reference	057d47b73f2344e03939e049d9f7d7710d0ac56c	c7e8a2627f33a824dcabd3eb1bc60013e5e7a20f_	{'publication_type': {'year': 2008, 'cited_medium': None, 'issue': None, 'issn': None, 'volume': None, 'title': 'Africa', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.3, 'total': 0.32, 'authors': 0.5}, 'authors': [{'given': 'South Africa', 'family': 'National Department of Health'}], 'abstract': 'The 2007 antenatal survey was conducted, in all nine provinces using the standard unlinked anonymous methodology (WHO & UNAIDS), to estimate the prevalence of HIV infection in the South African population. To enhance the sensitivity of the estimates and to provide greater robustness, the HIV sample size was expanded in 2006 to provide prevalence estimates for each district in the country in addition to the national and provincial rates. A total of 36 000 pregnant women were targeted. The women were recruited from 1 415 sentinel sites compared to the previous cohort of 861 sentinel sites in 1990 to 2005.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': None}, 'title': 'The National HIV and Syphilis Prevalence Survey, South Africa 2007', 'source': 'Mendeley'}
Ministry of Health of Vietnam, National Institute of Hygiene and Epidemiology of Vietnam. Official Travel Report, Annex 1: IMCI health facility survey in Vietnam; Planning Workshop, Hanoi, June 17–21, 2002. World Health Organization, Western Pacific Regional Office, Reference number MR/2002/0289 (plus personal communication from T. Lambrechts, WHO, on July 1, 2009 and December 9, 2009, which included data summary tables).	-	-	reference	057d47b73f2344e03939e049d9f7d7710d0ac56c	ebcae8a1209aecaa6491308b2ee7adcffe0e4f63_	{'publication_type': {'year': 2002, 'cited_medium': None, 'issue': '4', 'issn': '1460-2245', 'volume': '17', 'title': 'Health Promotion International', 'pagination': '373-381'}, 'language': None, 'rating': {'year': 0, 'title': 0.4444444444444444, 'total': 0.28888888888888886, 'authors': 0.0}, 'authors': [{'given': 'B.', 'family': 'Powis'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1093/heapro/17.4.373'}, 'title': 'National environmental health planning in Vietnam: flying some kites', 'source': 'CrossRef'}
Ministry of Health of Vietnam, National Institute of Hygiene and Epidemiology of Vietnam. Official Travel Report, Annex 1: IMCI health facility survey in Vietnam; Planning Workshop, Hanoi, June 17–21, 2002. World Health Organization, Western Pacific Regional Office, Reference number MR/2002/0289 (plus personal communication from T. Lambrechts, WHO, on July 1, 2009 and December 9, 2009, which included data summary tables).	-	-	reference	057d47b73f2344e03939e049d9f7d7710d0ac56c	ebcae8a1209aecaa6491308b2ee7adcffe0e4f63_	{'publication_type': {'year': 1987, 'cited_medium': None, 'issue': None, 'issn': '08135444', 'volume': None, 'title': 'Virus Information Exchange Newsletter for South-East Asia & the Western Pacific', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.45454545454545453, 'total': 0.5329545454545455, 'authors': 0.95}, 'authors': [{'given': 'W H O', 'family': 'World Health Organization'}, {'given': 'Office', 'family': 'Western Pacific Regional'}], 'abstract': 'The World Health Organization will be publishing this AIDS (Acquired Immune Deficiency Syndrome) Information Update for the Western Pacific Region on a quarterly basis and will include the most recent information on the prevalence of AIDS and HIV infections. Depending upon space availability, detailed analysis of the AIDS and HIV infections in addition to pertinent developments in AIDS control in each country will be included in subsequent issues. The 1st case of AIDS in the Region was reported in Australia in 1982. In September 1985, the attention of the WHO Regional Committee for the Western Pacific was drawn to the occurrence of 132 cases of AIDS in 5 countries in the Region -- Australia, 110 cases; New Zealand, 11 cases; Japan, 7 cases; Hong Kong, 3 cases; and China, 1 case. As of November 18, 1987, a cumulative total of 748 cases of AIDS had been reported by 11 countries in the Region, representing a 5-fold increase over the September 1985 figures. In Australia, infection with HIV other than AIDS is a notifiable condition in some states and territories only. A table also indicates the variation in category and in the total surveyed under each category in each country. Another table rearranges this data according to certain risk factors. Results of HIV antibody tests performed on a limited number of homosexuals/bisexuals in Papua New Guinea, the Philippines, and Singapore ranged from around 1/1000 in the Philippines to 20% in Papua New Guinea. Hiv antibody tests performed on a limited number of intravenous drug users in Hong Kong, Macao, and Singapore yielded negative results. It appears that even among prostitutes the proportion of HIV antibody positive reactors continues to be low, ranging from 1-8/10,000 in the Philippines and the Republic of Korea. The proportion of HIV positive reactors among blood donors in 7 countries was quite low indicating that HIV infection has not spread in the general population. The figures indicate that HIV infection rate is low in many countries of the region, indicating it is a relatively new infection, but the danger that it will eventually become widespread is evident.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '12159119', 'scopus': '2-s2.0-0023459690', 'doi': None}, 'title': 'AIDS information update from WHO Western Pacific Regional Office. November 1987.', 'source': 'Mendeley'}
Chauffier K, Salliot C, Berenbaum F, Sellam J. Effect of biotherapies on fatigue in rheumatoid arthritis: a systematic review of the literature and meta-analysis. Rheumatology (Oxford, England). 2012;51(1):60-8.	10.1093/rheumatology/ker162	21515629	systematic-review	6add5761c517ccb6096d79ad3832faaed79379c7	-	{'publication_type': {'year': 2011, 'cited_medium': None, 'issue': '1', 'issn': '1462-0324', 'volume': '51', 'title': 'Rheumatology', 'pagination': '60-68'}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 0.9812500000000001, 'authors': 0.925}, 'authors': [{'given': 'K.', 'family': 'Chauffier'}, {'given': 'C.', 'family': 'Salliot'}, {'given': 'F.', 'family': 'Berenbaum'}, {'given': 'J.', 'family': 'Sellam'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '21515629', 'scopus': None, 'doi': '10.1093/rheumatology/ker162'}, 'title': 'Effect of biotherapies on fatigue in rheumatoid arthritis: a systematic review of the literature and meta-analysis', 'source': 'CrossRef'}
Chauffier K, Salliot C, Berenbaum F, Sellam J. Effect of biotherapies on fatigue in rheumatoid arthritis: a systematic review of the literature and meta-analysis. Rheumatology (Oxford, England). 2012;51(1):60-8.	10.1093/rheumatology/ker162	21515629	systematic-review	6add5761c517ccb6096d79ad3832faaed79379c7	-	{'publication_type': {'year': 1990, 'cited_medium': None, 'issue': None, 'issn': None, 'volume': None, 'title': 'Journal of Mammalogy', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.5454545454545454, 'total': 0.39621212121212124, 'authors': 0.16666666666666666}, 'authors': [{'given': 'C P', 'family': 'Doncaster'}, {'given': 'C R', 'family': 'Dickman'}, {'given': 'D W', 'family': 'Macdonald'}], 'abstract': 'The diet of red foxes (Vulpes vulpes) in inhabiting the city of Oxford, England, was analyzed from 2,939 feces collected October 1980-February 1984. The dry weight of undigested remains comprised scavenged food (37%), earthworms (Lumbricus terrestris, 27%), mammals (16%), frueits (9%), birds (8%), other invertebrates (2%), and domestic stock (1%). No single category of food occurred in more than 50% of the samples. Eighty-one types of food were identified, including five orders of birds, 14 species of small mammals, and 14 species of fruits. The composition of the diet varied monthly and seasonally. Small mammals peaked in late winter, lagomorphs in April, and birds in June; fruits constituted a large proportion of the diet in autumn. Occurrence in feces of fruits, Passeriformes, Coleoptera, and invertebrate larvae correlated strongly with seasonal variations in indices of the abundance of these prey, suggesting that they were taken in proportion to their availability. Columbiformes, lagomorphs, and rodents showed no such direct relationship, indicating that foxes selected for or against these foods in some way not directly related to their abundances as censused.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': None}, 'title': 'Feeding ecology of red foxes in the city of Oxford, England', 'source': 'Mendeley'}
Kay J, Doyle MK, Smolen J, et al. Golimumab significantly improves physical function and fatigue in RA patients previously treated with anti-TNFa agents: results from the GO-AFTER study. EULAR Meeting 2009;Abstract AB0206.	-	-	reference	6add5761c517ccb6096d79ad3832faaed79379c7	0384c84387458240b40327b098fa65f3f44ceead_	{'publication_type': {'year': 2011, 'cited_medium': None, 'issue': 'Supplement 2', 'issn': '1462-0324', 'volume': '50', 'title': 'Rheumatology', 'pagination': 'ii3-ii4'}, 'language': None, 'rating': {'year': 0, 'title': 0.5909090909090909, 'total': 0.5840909090909092, 'authors': 0.8}, 'authors': [{'given': 'J. S.', 'family': 'Smolen'}, {'given': 'J.', 'family': 'Kay'}, {'given': 'M. K.', 'family': 'Doyle'}, {'given': 'R.', 'family': 'Landewe'}, {'given': 'E.', 'family': 'Matteson'}, {'given': 'J.', 'family': 'Wollenhaupt'}, {'given': 'N.', 'family': 'Gaylis'}, {'given': 'F. T.', 'family': 'Murphy'}, {'given': 'Y.', 'family': 'Zhou'}, {'given': 'S.', 'family': 'Visvanathan'}, {'given': 'E. C.', 'family': 'Hsia'}, {'given': 'M. U.', 'family': 'Rahman'}, {'given': 'P.', 'family': 'Nash'}, {'given': 'F. C.', 'family': 'Breedveld'}, {'given': 'D.', 'family': 'Robertson'}, {'given': 'J.', 'family': 'Foehl'}, {'given': 'T.', 'family': 'Ferdousi'}, {'given': 'B.', 'family': 'Freundlich'}, {'given': 'A.', 'family': 'Koenig'}, {'given': 'A. E.', 'family': 'Ozdemirel'}, {'given': 'H. R.', 'family': 'Erdem'}, {'given': 'B.', 'family': 'Nacir'}, {'given': 'A.', 'family': 'Karagoz'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1093/rheumatology/ker094'}, 'title': 'Thematic stream: inflammatory arthritis: BPP1. Golimumab in Rheumatoid Arthritis Patients Previously Treated with Anti-Tnf Alpha Agents: 2 Year Results from go-after Study', 'source': 'CrossRef'}
Kay J, Doyle MK, Smolen J, et al. Golimumab significantly improves physical function and fatigue in RA patients previously treated with anti-TNFa agents: results from the GO-AFTER study. EULAR Meeting 2009;Abstract AB0206.	-	-	reference	6add5761c517ccb6096d79ad3832faaed79379c7	0384c84387458240b40327b098fa65f3f44ceead_	{'publication_type': {'year': 2009, 'cited_medium': None, 'issue': None, 'issn': '1462-0324', 'volume': None, 'title': 'Rheumatology', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.4117647058823529, 'total': 0.41764705882352937, 'authors': 0.6}, 'authors': [{'given': 'Wordsworth', 'family': 'P.'}, {'given': 'Smolen', 'family': 'J.'}, {'given': 'Kay', 'family': 'J.'}, {'given': 'Doyle', 'family': 'M.K.'}, {'given': 'Landewe', 'family': 'R.'}, {'given': 'Matteson', 'family': 'E.L.'}, {'given': 'Zhou', 'family': 'Y.'}, {'given': 'Hsia', 'family': 'E.C.'}, {'given': 'Rahman', 'family': 'M.U.'}], 'abstract': 'Background: To assess golimumab (GLM) efficacy/safety in active rheumatoid arthritis (RA) patients previously treated with anti-TNF(alpha) agent(s). Methods: In the multicenter, randomized, double-blind, PBO-controlled study, active RA ((gamma) 4 tender and swollen joints) pts were randomized to sc injections of PBO, GLM 50mg or 100mg q4wks. Pts continued to receive stable doses of methotrexate, sulfasalazine, hydroxychloroquine, corticosteroids, and NSAIDs if receiving them at baseline. Pts could have received (greater-than or equal to)1 anti-TNF(alpha) agent(s) and discontined for any reason(s). The primary endpoint was the proportion of pts achieving ACR20 at wk14. Wk 24 HAQ improvement was also assessed. Results: 461 pts were randomized. All pts received (greater-than or equal to)1 anti-TNF(alpha) agent, 24.9% received 2, 9.3% received 3. Prior anti-TNF(alpha) therapy had been discontinued for lack of efficacy (58%) or non-efficacy (53%) reasons. Among pts discontinuing previous anti-TNF(alpha) therapy due to lack of efficacy, 36% (p=0.006) and 43% (p<0.001) of GLM 50 & 100mg pts had ACR20 response at wk14 vs. 18% of PBO pts. Through wk24, 72%, 66% & 78%, in PBO, GLM 50 mg, 100mg grps had (greater-than or equal to)1 AE, resp. Respective rates were 10%, 7% & 5% for SAEs & 3%, 3% & 0.7% for serious infections. Injection-site reactions through wk16 were reported in 3%, 4% & 11% of pts, resp (mainly erythema); no severe reactions were reported. Conclusions: GLM significantly reduced RA signs and symptoms and improved physical function in pts previously receiving anti-TNF(alpha) therapy. GLM was generally well-tolerated.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': None}, 'title': 'Golimumab, a human TNF-alpha (mu)onoclonal antibody, in rheumatoid arthritis patients previously treated with anti-TNF-alpha agents (go-after study)', 'source': 'Mendeley'}
Sobotta BA, Reiber T, Nitschke I. Oral health of seafarers - a review. International maritime health. 2011;62(1):8-16.	-	21534220	systematic-review	f962a0e4a749416d72e8837927397f507e3b6c6d	-	{'publication_type': {'year': 2011, 'cited_medium': None, 'issue': '2', 'issn': '1873-9598', 'volume': '5', 'title': 'International Journal of Gerontology', 'pagination': '98-102'}, 'language': None, 'rating': {'year': 0, 'title': 0.2, 'total': 0.305, 'authors': 0.7}, 'authors': [{'given': 'Ina', 'family': 'Schumann'}, {'given': 'Bernhard Albert Johannes', 'family': 'Sobotta'}, {'given': 'Thomas', 'family': 'Reiber'}, {'given': 'Ina', 'family': 'Nitschke'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1016/j.ijge.2011.04.014'}, 'title': 'Oral Health Services in Long-term Care Facilities Between 1989 and 2003—Has Germany Seen any Progress?', 'source': 'CrossRef'}
Sobotta BA, Reiber T, Nitschke I. Oral health of seafarers - a review. International maritime health. 2011;62(1):8-16.	-	21534220	systematic-review	f962a0e4a749416d72e8837927397f507e3b6c6d	-	{'publication_type': {'year': 1965, 'cited_medium': None, 'issue': None, 'issn': None, 'volume': None, 'title': 'XIIth International Congress of Entomology, London, 8-16 July, 1964. Proceedings.', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.3, 'total': 0.195, 'authors': 0.0}, 'authors': [{'given': None, 'family': 'Freeman'}], 'abstract': "The bulk of this volume comprises summaries of 650 scientific papers presented at the International Congress of Entomology held in London in 1964. Some of the papers have been or are to be published in full elsewhere [cf. R.A.E., A 53 526]. They are classified in 12 main sections, of which those containing material of specifically economic interest with respect to arthropods of importance as pests of crops, forest trees, timber or stored pro-ducts are: SECTION 1, SYSTEMATICS, INCLUDING PHYLOGENY (63-125); SECTION 3, PHYSIOLOGY AND BIOCHEMISTRY (172-230); SECTION 4, GENETICS AND CYTOLOGY (231-277); SECTION 5, BEHAVIOUR (278-350); SECTION 6, ECOLOGY (351-439); SECTION 7, GEOGRAPHICAL DISTRIBUTION (440-477); SECTION 8, INSECTICIDES AND TOXICOLOGY (478-517); SECTION 9A, AGRICULTURAL ENTOMOLOGY (518-619); SECTION 9B, INDUSTRIAL AND STORED PRODUCTS ENTOMOLOGY (620-665); SECTION 10, FOREST ENTOMOLOGY AND PESTS OF TIMBER (666-711); and SECTION 11, INSECT PATHOLOGY AND RELATIONSHIPS BETWEEN INSECTS AND MICRO-ORGANISMS (712-752). The summaries include the following: SECTION 1, Effect of temperature with and without hosts on 4 field biotypes of corn leaf aphid, Rhopalosiphum maidis (105-106), by S. R. SINGH & R. H. PAINTER [cf. 52 409]; SECTION 3, The effects of X-rays on the meal worm, Tenebrio molitor, embryo (180), by D. S. POCHEDLEY, Some endocrinological aspects of the larval diapause in rice stem borer, Chilo suppressalis (212), by M. FUKAYA, Effect of age on humidity relations in adults of Tribolium confusum (221), by P. W. WINSTON & V. E. NELSON, and Comparative studies on oxygen consumption in the albino and normal strains of Schistocerca gregaria bred under crowded and isolated conditions (222-223), by M. P. PENER; SECTION 4, The sterility principle of insect population control (251-252), by E. F. KNIPLING, Some remarks on the biology of Tribolium [five species] (271-272), by R. W. HOWE, A re-evaluation of Reynolds' study of the inheritance of food effects in Tribolium destructor (272-273), by L. P. LEFKOVITCH, Studies of natural selection in Tribolium castaneum in two different media (273-274), by A. SOKOLOFF, and Components of selection in Tribolium [castaneum] and house-flies [Musca domestica] (274-275), by R. R. SOKAL & F. J. SONLEITNER; SECTION 5, Light responses of the two-spotted spider mite Tetranychus urticae [telarius] (Acarina: Tetranychidae) (284-285), by Z. W. SUSKI, Hormonal influences in locust [Schistocerca gregaria and Locusta migratoria migratorioides] marching behaviour (290-291), by P. T. HASKELL, D. B. CARLISLE, P. E. ELLIS & J. E. MOORHOUSE, In-flight dispersal and orientation of two Scolytus species [S. multistriatus and S. quadrispinosus] to their host plants for ovipositional purposes (293), by D. M. NORRIS, Control of the orientation and feeding behaviour of red cotton bug, Dysdercus koenigii by chemical constituents of plants (294), by K. N. SAXENA, L'attractivite des crucifera a l'egard des larves de Psylliodes chrysocephala [Attractiveness of crucifers to larvae of P. chrysocephalus] (295-296), by Y. QUEINNEC, Observations on Zonocerus variegatus in Sierra Leone (306), by J. PHIPPS, Dispersion behaviour of adult beetles in grain (307), by G. SURTEES [cf. 53 265, etc.], Etude de la repartition des larves neonates d'Acanthoscelides obtectus [A study on the distribution of newly hatched larvae of A. obtectus] (310-311), by V. LABEYRIE, Flight behaviour in some Anobiid beetles [Xestobium rufovillosum, Anobium punctatum and Ernobius mottis] (319-320), by J. M. BAKER, Individual variation and the dispersive capacity of Neodiprion sertifer (Hymenoptera) (326), by W. R. HENSON, The dispersal flight of Meligethes beetles and spring migration of Delphacids [Javesella pellucida] with special reference to the application of the tracer method (328), by J. DLABOLA & L. TAIMR, Movements of some insects to and inside rape fields [in Sweden] (329), by E. SYLVEN, Factors influencing dispersal of insects is rain forest areas converted to cacao lands [in New Guinea and New Britain] (330), by J. J. H. SZENT-IVANY, Hibernation und Gregarisation von Heuschreckenschwarmen in Argentinien [Hibernation and gregarisation of locust swarms in Argentina] (330-331), by P. KOHLER, Biology of a slug-killing fly, Tetanocera elata (Sciomyzidae) (343), by L. V. KNUTSON, J. W. STEPHENSON & C. O. BERG, Laboratory experiments on the spontaneous take-off activity of Blastophagus [Myelophilus] piniperda (Scolytidae) in relation to temperature and light intensity at different seasons of the year (344-345), by V. PERTTUNEN & T. BOMAN, Population studies on the Citrus purple scale, Lepidosaphes beckii in Egypt (346-347), by M. HAFEZ & H. S. A. R. SALAMA, Neuere Erkenntnisse uber Plug und Eiablage der Brachfliege (Phorbia coarctata) [Recent findings on the flight and oviposition of Hylemya coarctata] (347-348), by R. SOL [cf. 53 415, etc.], Beobachtungen zum Frassverhalten der Larven und Imagines von Apion virens (Col. : Curculionidae) [Observations on the feeding behaviour of the larvae and adults of A. virens] (349), by W. STEIN, and Circadian rhythms in the leafcutter bee, Megachile rotundata (350), by W. P. STEPHEN; SECTION 6, The economic significance of parasitic Cynipoidea associated with apple in the Netherlands (359), by H. H. EVENHUIS, Beitrag zur Kenntnis einiger Tachinen von Kief ern-Schadlepidopteren [Contribution to knowledge of Tachinid parasites of Lepidopterous pests of pine (in western Germany)] (360-361), by R. GAUSS, Massenvermehrungen forstschadlicher Insekten Osterreichs in ihrer Abhangigkeit von Umweltfaktoren [Outbreaks of forest insects in Austria in relation to environmental factors] (362-363), by E. JAHN, The pink bollworm (Pectinophora gossypiella) [on cotton] in Yugoslavia (363-364), by M. D. TADIC & B. BINCEV [cf. 53 257], Mite populations in Florida Citrus groves before and after severe freezes (364-366), by W. A. SIMANTON, Natural control of the black-headed budworm [Acleris variarna in New Brunswick] (367), by C. A. MILLER & R. M. BELYEA, The analysis of factors affecting reproduction and mortality in a natural population of the pine looper, Bupalus piniarius [in Holland] (369-372), by H. KLOMP & P. GRUYS, Modification of the natural regulation of aphids [on lucerne] by local climates in California (372-374), by R. F. SMITH & K. S. HAGEN, Factors of population dynamics of Eurygaster integriceps in different parts of its range [in the Soviet Union] (374), by G. A. VIKTOROV, The natural regulation of the population of the southern green stink bug, Nezara viridula [in Japan] (375), by K. KIRITANI, Dynamisme de la population Prospaltiella perniciosi How., eleve sur le pon de San-Jose (Quadraspidiotus perniciosus), dans la chambre acclinatisee [Population dynamics of Prospaltella perniciosi reared on Q. perniciosus in constant conditions] (376-377), by M. TADIC, Interpreting winter moth [Operophtera brumata (L.)] population changes [in Britain] (377-378), by G. C. VARLEY & G. R. GRADWELL, Contribution to the biology and population dynamics of the pine sawfly Acantholyda serbica (Hymenoptera) [in Yugoslavia] (382), by M. MAKSIMOVIC, Population density regulation of Sminthurus viridis in pastures [in Australia] with special reference to density-induced changes in numbers (383), by M. M. H. WALLACE, Factors influencing egg survival in Scolypopa australis (Homoptera, Ricaniidae) in New Zealand (383-384), by R. A. CUMBER, Predicting qualitative changes in insect populations (384-386), by D. CHITTY, Individual variation in ovary development and in reproductive behaviour of Oscinella frit (Diptera) (390), by R. J. HILLYER, The biology of Oscinella frit (Chloropidae) in N.E. England (390-391), by A. IBBOTSON, La resistance an jefine des imagos isoles et groupes chez Locusta migratoria migratorioides [Resistance to fasting in isolated and crowded adults of L. migratoria migratorioides] (391-392), by F. O. ALBRECHT, Individual differences in Malacosoma neustria [in Germany] (393-394), by J. M. FRANZ & W. LAUX, Capacity for increase of the garden chafer, Phyllopertha [Anomala] horticola (Coleoptera) [in Britain] (394), by R. LAUGHLIN, Sex attractant traps with female odour of the gypsy moth [Lymantria dispar] used for forecasting the increase of population of gypsy moth [in Yugoslavia] (398), by M. MAKSIMOVIE, The influence of micro-climate on the distribution of stored products insects (403), by R. W. HOWE, The effect of environmental temperature on the ecology of Heliothis zea [on maize in the United States] (406-407), by V. J. VALLI, Economy of growth in Hylotrupes [bajulus] (Coleoptera) at different ecological conditions [in Denmark] (408), by S. RASMUSSEN, Importance de la photoperiode pendant la ponte de 3 races du criquet migrateur [The importance of photoperiod during the oviposition of three races of the migratory locust (Locusta migratoria)] (409), by M. VERDIER, Effets des couleurs sur le comportement de diverses races du puceron du pois, Acyrthosiphon pisum, en elevage sur un regime nutritif de composition chimique connue [The effects of colours on the behaviour of several races of the pea aphid, Macrosiphum pisum, feeding on a diet of known chemical composition] (414), by J. I. CARTIER & J. L. AUCLAIR, Long range dispersal of insects in relation to synoptic meteorology (419), by R. A. FRENCH, Some factors affecting distribution and survival of African migratory and desert locusts [Locusta migratoria migratorioides and Schtsiocerca gregaria] (419-420), by Z. WALOFF, D. E, DAVIES & A, BATTEN, Migration and population change in Oscinella Jrit (Diptera) on the oat crop [in Britain] (420-421), by T. R. E. SOUTHWOOD, Factors determining the distribution of the two related stink bugs, Nezara viridula and N. antennata [in Japan] (423), by K. KIRITANI, The interaction of two spreading populations [of mushroom Cecidomyiids in Britain] (423-425), by I. J. WYATT, Factors affecting the diapause and number of g", 'type': 'journal', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': None}, 'title': 'XIIth International Congress of Entomology, London, 8-16 July, 1964. Proceedings', 'source': 'Mendeley'}
Sinert R, Newman DH, Brandler E, Paladino L. Immediate beta-blockade in patients with myocardial infarctions: is there evidence of benefit?. Database of Abstracts of Reviews of Effects (DARE). 2011;	-	-	structured-summary-of-systematic-review	5d0cc1c95e30eb95aed407dd2c56921706802fc7	-	{'publication_type': {'year': 2010, 'cited_medium': None, 'issue': '5', 'issn': '0196-0644', 'volume': '56', 'title': 'Annals of Emergency Medicine', 'pagination': '571-577.e1'}, 'language': None, 'rating': {'year': 0, 'title': 0.9166666666666666, 'total': 0.8270833333333334, 'authors': 0.925}, 'authors': [{'given': 'Richard', 'family': 'Sinert'}, {'given': 'David H.', 'family': 'Newman'}, {'given': 'Ethan', 'family': 'Brandler'}, {'given': 'Lorenzo', 'family': 'Paladino'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '20493586', 'scopus': None, 'doi': '10.1016/j.annemergmed.2010.03.036'}, 'title': 'Immediate β-Blockade in Patients With Myocardial Infarctions: Is There Evidence of Benefit?', 'source': 'CrossRef'}
Sinert R, Newman DH, Brandler E, Paladino L. Immediate beta-blockade in patients with myocardial infarctions: is there evidence of benefit?. Database of Abstracts of Reviews of Effects (DARE). 2011;	-	-	structured-summary-of-systematic-review	5d0cc1c95e30eb95aed407dd2c56921706802fc7	-	{'publication_type': {'year': 2008, 'cited_medium': None, 'issue': None, 'issn': '0027-9684', 'volume': None, 'title': 'Centre for Reviews and Dissemination. National Instuitute for Health Research. University of York.', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.3125, 'total': 0.428125, 'authors': 0.9}, 'authors': [{'given': None, 'family': 'Database of Abstracts of Reviews of Effects (DARE)'}], 'abstract': 'To examine effectiveness of depression treatment in racial and ethnic minority women.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '17393951', 'scopus': None, 'doi': None}, 'title': 'Examining differential treatment effects for depression in racial and ethnic minority women: a qualitative systematic review', 'source': 'Mendeley'}
Takagi H, Kawai N, Umemoto T. Stenting versus coronary artery bypass grafting for unprotected left main coronary artery disease: a meta-analysis of comparative studies. Database of Abstracts of Reviews of Effects (DARE). 2011;	-	-	structured-summary-of-systematic-review	a9bdcb7259b912548d66f3e2121b7c60b7aa8076	-	{'publication_type': {'year': 2009, 'cited_medium': None, 'issue': '1', 'issn': '0022-5223', 'volume': '137', 'title': 'The Journal of Thoracic and Cardiovascular Surgery', 'pagination': 'e54-e57'}, 'language': None, 'rating': {'year': 0, 'title': 1.0, 'total': 0.8833333333333333, 'authors': 0.9333333333333332}, 'authors': [{'given': 'Hisato', 'family': 'Takagi'}, {'given': 'Norikazu', 'family': 'Kawai'}, {'given': 'Takuya', 'family': 'Umemoto'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '19154888', 'scopus': None, 'doi': '10.1016/j.jtcvs.2008.06.006'}, 'title': 'Stenting versus coronary artery bypass grafting for unprotected left main coronary artery disease: A meta-analysis of comparative studies', 'source': 'CrossRef'}
Takagi H, Kawai N, Umemoto T. Stenting versus coronary artery bypass grafting for unprotected left main coronary artery disease: a meta-analysis of comparative studies. Database of Abstracts of Reviews of Effects (DARE). 2011;	-	-	structured-summary-of-systematic-review	a9bdcb7259b912548d66f3e2121b7c60b7aa8076	-	{'publication_type': {'year': 2008, 'cited_medium': None, 'issue': None, 'issn': '0027-9684', 'volume': None, 'title': 'Centre for Reviews and Dissemination. National Instuitute for Health Research. University of York.', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.3125, 'total': 0.428125, 'authors': 0.9}, 'authors': [{'given': None, 'family': 'Database of Abstracts of Reviews of Effects (DARE)'}], 'abstract': 'To examine effectiveness of depression treatment in racial and ethnic minority women.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '17393951', 'scopus': None, 'doi': None}, 'title': 'Examining differential treatment effects for depression in racial and ethnic minority women: a qualitative systematic review', 'source': 'Mendeley'}
Madhi SA, Cunliffe NA, Steele D, Witte D, Kirsten M, Louw C, Ngwira B, Victor JC, Gillard PH, Cheuvart BB, Han HH, Neuzil KM. Effect of human rotavirus vaccine on severe diarrhea in African infants. The New England journal of medicine. 2010;362(4):289-98.	10.1056/NEJMoa0904797	20107214	primary-study	5a57cda7954f4d89ad625953e42affe36808e7e9	-	{'publication_type': {'year': 2010, 'cited_medium': None, 'issue': '4', 'issn': '0028-4793', 'volume': '362', 'title': 'New England Journal of Medicine', 'pagination': '289-298'}, 'language': None, 'rating': {'year': 0, 'title': 1.0, 'total': 0.8750000000000001, 'authors': 0.9000000000000002}, 'authors': [{'given': 'Shabir A.', 'family': 'Madhi'}, {'given': 'Nigel A.', 'family': 'Cunliffe'}, {'given': 'Duncan', 'family': 'Steele'}, {'given': 'Desirée', 'family': 'Witte'}, {'given': 'Mari', 'family': 'Kirsten'}, {'given': 'Cheryl', 'family': 'Louw'}, {'given': 'Bagrey', 'family': 'Ngwira'}, {'given': 'John C.', 'family': 'Victor'}, {'given': 'Paul H.', 'family': 'Gillard'}, {'given': 'Brigitte B.', 'family': 'Cheuvart'}, {'given': 'Htay H.', 'family': 'Han'}, {'given': 'Kathleen M.', 'family': 'Neuzil'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1056/nejmoa0904797'}, 'title': 'Effect of Human Rotavirus Vaccine on Severe Diarrhea in African Infants', 'source': 'CrossRef'}
Madhi SA, Cunliffe NA, Steele D, Witte D, Kirsten M, Louw C, Ngwira B, Victor JC, Gillard PH, Cheuvart BB, Han HH, Neuzil KM. Effect of human rotavirus vaccine on severe diarrhea in African infants. The New England journal of medicine. 2010;362(4):289-98.	10.1056/NEJMoa0904797	20107214	primary-study	5a57cda7954f4d89ad625953e42affe36808e7e9	-	{'publication_type': {'year': 2010, 'cited_medium': None, 'issue': None, 'issn': '1533-4406', 'volume': None, 'title': 'The New England journal of medicine', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 0.75, 'authors': 0.0}, 'authors': [{'given': 'Neuzil K M', 'family': 'Madhi S A, Cunliffe N A, Steele D, Witte D, Kirsten M, Louw C, Ngwira B, Victor J C, Gillard P H, Cheuvart B B, Han H H'}], 'abstract': 'BACKGROUND Rotavirus is the most common cause of severe gastroenteritis among young children worldwide. Data are needed to assess the efficacy of the rotavirus vaccine in African children. METHODS We conducted a randomized, placebo-controlled, multicenter trial in South Africa (3166 infants; 64.1% of the total) and Malawi (1773 infants; 35.9% of the total) to evaluate the efficacy of a live, oral rotavirus vaccine in preventing severe rotavirus gastroenteritis. Healthy infants were randomly assigned in a 1:1:1 ratio to receive two doses of vaccine (in addition to one dose of placebo) or three doses of vaccine--the pooled vaccine group--or three doses of placebo at 6, 10, and 14 weeks of age. Episodes of gastroenteritis caused by wild-type rotavirus during the first year of life were assessed through active follow-up surveillance and were graded with the use of the Vesikari scale. RESULTS A total of 4939 infants were enrolled and randomly assigned to one of the three groups; 1647 infants received two doses of the vaccine, 1651 infants received three doses of the vaccine, and 1641 received placebo. Of the 4417 infants included in the per-protocol efficacy analysis, severe rotavirus gastroenteritis occurred in 4.9% of the infants in the placebo group and in 1.9% of those in the pooled vaccine group (vaccine efficacy, 61.2%; 95% confidence interval, 44.0 to 73.2). Vaccine efficacy was lower in Malawi than in South Africa (49.4% vs. 76.9%); however, the number of episodes of severe rotavirus gastroenteritis that were prevented was greater in Malawi than in South Africa (6.7 vs. 4.2 cases prevented per 100 infants vaccinated per year). Efficacy against all-cause severe gastroenteritis was 30.2%. At least one serious adverse event was reported in 9.7% of the infants in the pooled vaccine group and in 11.5% of the infants in the placebo group. CONCLUSIONS Human rotavirus vaccine significantly reduced the incidence of severe rotavirus gastroenteritis among African infants during the first year of life. (ClinicalTrials.gov number, NCT00241644.)', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '20107214', 'scopus': '2-s2.0-75449098835', 'doi': '10.1056/NEJMoa1304048'}, 'title': 'Effect of human rotavirus vaccine on severe diarrhea in African infants', 'source': 'Mendeley'}
Phua KB, Lim FS, Lau YL, Nelson EA, Huang LM, Quak SH, Lee BW, Teoh YL, Tang H, Boudville I, Oostvogels LC, Suryakiran PV, Smolenov IV, Han HH, Bock HL. Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: randomised, double-blind, controlled study. Vaccine. 2009;27(43):5936-41.	10.1016/j.vaccine.2009.07.098	19679216	primary-study	30b50b2d046f2ba98c3a6fe227131614637a7de5	-	{'publication_type': {'year': 2009, 'cited_medium': None, 'issue': '43', 'issn': '0264-410X', 'volume': '27', 'title': 'Vaccine', 'pagination': '5936-5941'}, 'language': None, 'rating': {'year': 1, 'title': 1.0, 'total': 0.9750000000000001, 'authors': 0.9000000000000002}, 'authors': [{'given': 'K.B.', 'family': 'Phua'}, {'given': 'F.S.', 'family': 'Lim'}, {'given': 'Y.L.', 'family': 'Lau'}, {'given': 'E.A.S.', 'family': 'Nelson'}, {'given': 'L.M.', 'family': 'Huang'}, {'given': 'S.H.', 'family': 'Quak'}, {'given': 'B.W.', 'family': 'Lee'}, {'given': 'Y.L.', 'family': 'Teoh'}, {'given': 'H.', 'family': 'Tang'}, {'given': 'I.', 'family': 'Boudville'}, {'given': 'L.C.', 'family': 'Oostvogels'}, {'given': 'P.V.', 'family': 'Suryakiran'}, {'given': 'I.V.', 'family': 'Smolenov'}, {'given': 'H.H.', 'family': 'Han'}, {'given': 'H.L.', 'family': 'Bock'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '19679216', 'scopus': None, 'doi': '10.1016/j.vaccine.2009.07.098'}, 'title': 'Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: Randomised, double-blind, controlled study', 'source': 'CrossRef'}
Phua KB, Lim FS, Lau YL, Nelson EA, Huang LM, Quak SH, Lee BW, Teoh YL, Tang H, Boudville I, Oostvogels LC, Suryakiran PV, Smolenov IV, Han HH, Bock HL. Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: randomised, double-blind, controlled study. Vaccine. 2009;27(43):5936-41.	10.1016/j.vaccine.2009.07.098	19679216	primary-study	30b50b2d046f2ba98c3a6fe227131614637a7de5	-	{'publication_type': {'year': 2009, 'cited_medium': None, 'issue': None, 'issn': '0264410X', 'volume': None, 'title': 'Vaccine', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 1.0, 'total': 0.9750000000000001, 'authors': 0.9000000000000002}, 'authors': [{'given': 'K.B.', 'family': 'Phua'}, {'given': 'F.S.', 'family': 'Lim'}, {'given': 'Y.L.', 'family': 'Lau'}, {'given': 'E.A.S.', 'family': 'Nelson'}, {'given': 'L.M.', 'family': 'Huang'}, {'given': 'S.H.', 'family': 'Quak'}, {'given': 'B.W.', 'family': 'Lee'}, {'given': 'Y.L.', 'family': 'Teoh'}, {'given': 'H.', 'family': 'Tang'}, {'given': 'I.', 'family': 'Boudville'}, {'given': 'L.C.', 'family': 'Oostvogels'}, {'given': 'P.V.', 'family': 'Suryakiran'}, {'given': 'I.V.', 'family': 'Smolenov'}, {'given': 'H.H.', 'family': 'Han'}, {'given': 'H.L.', 'family': 'Bock'}], 'abstract': 'This study evaluates the safety and efficacy against severe rotavirus gastroenteritis of the oral live attenuated human rotavirus vaccine RIX4414 (Rotarix™) during the first 2 years of life in Asian infants from high-income countries. Healthy infants were enrolled to receive 2 doses of RIX4414 (N = 5359) or placebo (N = 5349). From 2 weeks post-dose 2 to 2 years of age, vaccine efficacy was 96.1% (95%CI:85.1%; 99.5%) against severe rotavirus gastroenteritis, 100% (95%CI:80.8%; 100%) against wild-type G1P[8] and 93.6% (95%CI:74.7%; 99.3%) against circulating non-G1 rotavirus types. No intussusception cases were reported within 31 days post-vaccination. RIX4414 shows a good safety profile and offers high protection during the first 2 years of life with potentially significant public health impact in this population. © 2009 Elsevier Ltd. All rights reserved.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '19679216', 'scopus': None, 'doi': '10.1016/j.vaccine.2009.07.098'}, 'title': 'Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: Randomised, double-blind, controlled study', 'source': 'Mendeley'}
Narang A, Bose A, Pandit AN, Dutta P, Kang G, Bhattacharya SK, Datta SK, Suryakiran PV, Delem A, Han HH, Bock HL. Immunogenicity, reactogenicity and safety of human rotavirus vaccine (RIX4414) in Indian infants. Human vaccines. 2009;5(6):414-9.	-	19276664	primary-study	8a258e450fbfae4b1a794e516b7fc4232fcb1196	-	{'publication_type': {'year': 2009, 'cited_medium': None, 'issue': '6', 'issn': '1554-8600', 'volume': '5', 'title': 'Human Vaccines', 'pagination': '414-419'}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.865909090909091, 'authors': 0.8636363636363638}, 'authors': [{'given': 'Anil', 'family': 'Narang'}, {'given': 'Anuradha', 'family': 'Bose'}, {'given': 'Anand Nilkanth', 'family': 'Pandit'}, {'given': 'Phalguni', 'family': 'Dutta'}, {'given': 'Gagandeep', 'family': 'Kang'}, {'given': 'Sujit Kumar', 'family': 'Bhattacharya'}, {'given': 'Sanjoy', 'family': 'Datta'}, {'given': 'Suryakiran', 'family': 'P.V.'}, {'given': 'Andrée', 'family': 'Delem'}, {'given': 'Htay Htay', 'family': 'Han'}, {'given': 'Hans Ludwig', 'family': 'Bock'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.4161/hv.5.6.8176'}, 'title': 'Immunogenicity, reactogenicity and safety of human rotavirus vaccine (RIX4414) in Indian infants', 'source': 'CrossRef'}
Narang A, Bose A, Pandit AN, Dutta P, Kang G, Bhattacharya SK, Datta SK, Suryakiran PV, Delem A, Han HH, Bock HL. Immunogenicity, reactogenicity and safety of human rotavirus vaccine (RIX4414) in Indian infants. Human vaccines. 2009;5(6):414-9.	-	19276664	primary-study	8a258e450fbfae4b1a794e516b7fc4232fcb1196	-	{'publication_type': {'year': 2009, 'cited_medium': None, 'issue': None, 'issn': '1554-8619', 'volume': None, 'title': 'Human vaccines', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 0.9750000000000001, 'authors': 0.9000000000000002}, 'authors': [{'given': 'Anil', 'family': 'Narang'}, {'given': 'Anuradha', 'family': 'Bose'}, {'given': 'Anand Nilkanth', 'family': 'Pandit'}, {'given': 'Phalguni', 'family': 'Dutta'}, {'given': 'Gagandeep', 'family': 'Kang'}, {'given': 'Sujit Kumar', 'family': 'Bhattacharya'}, {'given': 'Sanjoy Kumar', 'family': 'Datta'}, {'given': 'P V', 'family': 'Suryakiran'}, {'given': 'Andrée', 'family': 'Delem'}, {'given': 'Htay Htay', 'family': 'Han'}, {'given': 'Hans Ludwig', 'family': 'Bock'}], 'abstract': 'AIM: This study was undertaken to assess the immunogenicity, reactogenicity and safety of two doses of an oral live-attenuated human rotavirus vaccine, strain RIX4414 (Rotarix()) in an Indian setting.\\n\\nRESULTS: The seroconversion rate observed one month post-dose 2 in the RIX4414 group 58.3% [95% CI: 48.7; 67.4] was significantly higher when compared to the placebo group 6.3%; [95% CI: 2.5; 12.5]. The reactogenicity and safety profile was similar for both groups.\\n\\nPATIENTS AND METHODS: Healthy infants (N = 363), approximately eight weeks of age were enrolled to receive two doses of RIX4414 vaccine (n = 182) or placebo (n = 181) separated by one month. To assess the immune response, blood samples were taken before vaccination and one month post-dose 2 of RIX4414/placebo. Solicited symptoms were collected for eight-days post each dose and safety data was collected throughout the study.\\n\\nCONCLUSIONS: Two doses of RIX4414 (Rotarix()) were immunogenic, had a good safety profile and were well-tolerated when administered to healthy Indian infants.\\n\\nCLINICAL TRIALS REGISTRATION: ClinicalTrials.gov; NCT00289172; eTrack 103792.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '19276664', 'scopus': '2-s2.0-70249090946', 'doi': '8176 [pii]'}, 'title': 'Immunogenicity, reactogenicity and safety of human rotavirus vaccine (RIX4414) in Indian infants.', 'source': 'Mendeley'}
Ciarlet M, He S, Lai S, Petrecz M, Yuan G, Liu GF, Mikviman E, Heaton PM, Panzer F, Rose T, Koller DY, Van Damme P, Schödel F. Concomitant use of the 3-dose oral pentavalent rotavirus vaccine with a 3-dose primary vaccination course of a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine: immunogenicity and reactogenicity. The Pediatric infectious disease journal. 2009;28(3):177-81.	10.1097/INF.0b013e31818c0161	19209092	primary-study	d934a4951ea2520d898ae665ca960b609286032b	-	{'publication_type': {'year': 2009, 'cited_medium': None, 'issue': '3', 'issn': '0891-3668', 'volume': '28', 'title': 'The Pediatric Infectious Disease Journal', 'pagination': '177-181'}, 'language': None, 'rating': {'year': 0, 'title': 1.0, 'total': 0.876923076923077, 'authors': 0.9076923076923079}, 'authors': [{'given': 'Max', 'family': 'Ciarlet'}, {'given': 'Su', 'family': 'He'}, {'given': 'Sherry', 'family': 'Lai'}, {'given': 'Maria', 'family': 'Petrecz'}, {'given': 'Guojun', 'family': 'Yuan'}, {'given': 'Guanghan F.', 'family': 'Liu'}, {'given': 'Elena', 'family': 'Mikviman'}, {'given': 'Penny M.', 'family': 'Heaton'}, {'given': 'Falko', 'family': 'Panzer'}, {'given': 'Thomas', 'family': 'Rose'}, {'given': 'Dieter Y.', 'family': 'Koller'}, {'given': 'Pierre', 'family': 'Van Damme'}, {'given': 'Florian', 'family': 'Schödel'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1097/inf.0b013e31818c0161'}, 'title': 'Concomitant Use of the 3-Dose Oral Pentavalent Rotavirus Vaccine With a 3-Dose Primary Vaccination Course of a Diphtheria-Tetanus-Acellular Pertussis-Hepatitis B-Inactivated Polio-Haemophilus influenzae Type b Vaccine', 'source': 'CrossRef'}
Ciarlet M, He S, Lai S, Petrecz M, Yuan G, Liu GF, Mikviman E, Heaton PM, Panzer F, Rose T, Koller DY, Van Damme P, Schödel F. Concomitant use of the 3-dose oral pentavalent rotavirus vaccine with a 3-dose primary vaccination course of a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine: immunogenicity and reactogenicity. The Pediatric infectious disease journal. 2009;28(3):177-81.	10.1097/INF.0b013e31818c0161	19209092	primary-study	d934a4951ea2520d898ae665ca960b609286032b	-	{'publication_type': {'year': 2009, 'cited_medium': None, 'issue': None, 'issn': '0891-3668', 'volume': None, 'title': 'The Pediatric infectious disease journal', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 0.976923076923077, 'authors': 0.9076923076923079}, 'authors': [{'given': 'Max', 'family': 'Ciarlet'}, {'given': 'Su', 'family': 'He'}, {'given': 'Sherry', 'family': 'Lai'}, {'given': 'Maria', 'family': 'Petrecz'}, {'given': 'Guojun', 'family': 'Yuan'}, {'given': 'Guanghan F', 'family': 'Liu'}, {'given': 'Elena', 'family': 'Mikviman'}, {'given': 'Penny M', 'family': 'Heaton'}, {'given': 'Falko', 'family': 'Panzer'}, {'given': 'Thomas', 'family': 'Rose'}, {'given': 'Dieter Y', 'family': 'Koller'}, {'given': 'Pierre', 'family': 'Van Damme'}, {'given': 'Florian', 'family': 'Schödel'}], 'abstract': 'The pentavalent rotavirus vaccine (PRV), RotaTeq, can be concomitantly administered with most routine childhood vaccines. This study evaluated the immunogenicity and reactogenicity of PRV when used concomitantly with a hexavalent vaccine containing diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus, and Haemophilus influenzae type b.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '19209092', 'scopus': '2-s2.0-63449098234', 'doi': '10.1097/INF.0b013e31818c0161'}, 'title': 'Concomitant use of the 3-dose oral pentavalent rotavirus vaccine with a 3-dose primary vaccination course of a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine: immunogenicity and reactogenicity.', 'source': 'Mendeley'}
Zaman K, Sack DA, Yunus M, Arifeen SE, Podder G, Azim T, Luby S, Breiman RF, Neuzil K, Datta SK, Delem A, Suryakiran PV, Bock HL. Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age. Vaccine. 2009;27(9):1333-9.	10.1016/j.vaccine.2008.12.059	19162114	primary-study	c2d8323beb81691a3da84f2d814c698d64b4e8c6	-	{'publication_type': {'year': 2009, 'cited_medium': None, 'issue': '9', 'issn': '0264-410X', 'volume': '27', 'title': 'Vaccine', 'pagination': '1333-1339'}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 0.9750000000000001, 'authors': 0.9000000000000002}, 'authors': [{'given': 'K.', 'family': 'Zaman'}, {'given': 'D.A.', 'family': 'Sack'}, {'given': 'M.', 'family': 'Yunus'}, {'given': 'S.E.', 'family': 'Arifeen'}, {'given': 'G.', 'family': 'Podder'}, {'given': 'T.', 'family': 'Azim'}, {'given': 'S.', 'family': 'Luby'}, {'given': 'R.F.', 'family': 'Breiman'}, {'given': 'K.', 'family': 'Neuzil'}, {'given': 'S.K.', 'family': 'Datta'}, {'given': 'A.', 'family': 'Delem'}, {'given': 'P.V.', 'family': 'Suryakiran'}, {'given': 'H.L.', 'family': 'Bock'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '19162114', 'scopus': None, 'doi': '10.1016/j.vaccine.2008.12.059'}, 'title': 'Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age', 'source': 'CrossRef'}
Zaman K, Sack DA, Yunus M, Arifeen SE, Podder G, Azim T, Luby S, Breiman RF, Neuzil K, Datta SK, Delem A, Suryakiran PV, Bock HL. Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age. Vaccine. 2009;27(9):1333-9.	10.1016/j.vaccine.2008.12.059	19162114	primary-study	c2d8323beb81691a3da84f2d814c698d64b4e8c6	-	{'publication_type': {'year': 2008, 'cited_medium': None, 'issue': None, 'issn': '0002-8223', 'volume': None, 'title': 'Fao, 9', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.0, 'total': 0.125, 'authors': 0.5}, 'authors': [{'given': '9', 'family': 'FAO'}], 'abstract': 'Vitamin A deficiency, which is especially widespread among children younger than age 5 years, is a major barrier to reducing child mortality rates in French-speaking West Africa. A large amount of an indigenous plant source of provitamin A carotenoids are lost to postharvest waste. For example, the postharvest loss of mangoes in the region exceeds an annual total of 100,000 metric tons. In our study, 3.75 metric tons of fresh mangoes were dried using a solar dryer to a final moisture content of 10% to 12%, yielding a total of 360 kg dried mango. The product analysis revealed 4,000+/-500 microg beta carotene/100 g and 3,680+/-150 microg beta carotene/100 g after 2 and 6 months of storage, respectively. Thus, one greenhouse solar dryer is capable of reducing postharvest mango waste by 3.75 tons providing up to 1.15 million retinol activity equivalents of dietary vitamin A. The use of this technology that requires solar energy and manpower has the potential of increasing dietary vitamin A supply by up to 27,000-fold, compared to the currently available vitamin A in the region. Moreover, mango is a fruit that is well-liked by the population in this geographic area increasing the likelihood of its ready acceptance. Reducing postharvest loss of mangoes by using greenhouse model solar dryers is a promising strategy to help combat vitamin A deficiency in French-speaking West Africa.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '18502231', 'scopus': None, 'doi': '10.1016/j.jada.2008.03.013'}, 'title': 'MEAT PROCESSING TECHONOLOGY Solar drying', 'source': 'Mendeley'}
Steele AD, De Vos B, Tumbo J, Reynders J, Scholtz F, Bos P, de Beer MC, Van der Merwe CF, Delem A. Co-administration study in South African infants of a live-attenuated oral human rotavirus vaccine (RIX4414) and poliovirus vaccines. Vaccine. 2010;28(39):6542-8.	10.1016/j.vaccine.2008.08.034	18786585	primary-study	446d9067c44b91c50625062b9911bf588a07b1aa	-	{'publication_type': {'year': 2010, 'cited_medium': None, 'issue': '39', 'issn': '0264-410X', 'volume': '28', 'title': 'Vaccine', 'pagination': '6542-6548'}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 0.9777777777777777, 'authors': 0.9111111111111112}, 'authors': [{'given': 'A.D.', 'family': 'Steele'}, {'given': 'B.', 'family': 'De Vos'}, {'given': 'J.', 'family': 'Tumbo'}, {'given': 'J.', 'family': 'Reynders'}, {'given': 'F.', 'family': 'Scholtz'}, {'given': 'P.', 'family': 'Bos'}, {'given': 'M.C.', 'family': 'de Beer'}, {'given': 'C.F.', 'family': 'Van der Merwe'}, {'given': 'A.', 'family': 'Delem'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '18786585', 'scopus': None, 'doi': '10.1016/j.vaccine.2008.08.034'}, 'title': 'Co-administration study in South African infants of a live-attenuated oral human rotavirus vaccine (RIX4414) and poliovirus vaccines', 'source': 'CrossRef'}
Steele AD, De Vos B, Tumbo J, Reynders J, Scholtz F, Bos P, de Beer MC, Van der Merwe CF, Delem A. Co-administration study in South African infants of a live-attenuated oral human rotavirus vaccine (RIX4414) and poliovirus vaccines. Vaccine. 2010;28(39):6542-8.	10.1016/j.vaccine.2008.08.034	18786585	primary-study	446d9067c44b91c50625062b9911bf588a07b1aa	-	{'publication_type': {'year': 2010, 'cited_medium': None, 'issue': None, 'issn': '0264410X', 'volume': None, 'title': 'Vaccine', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 0.9777777777777777, 'authors': 0.9111111111111112}, 'authors': [{'given': 'A. D.', 'family': 'Steele'}, {'given': 'B.', 'family': 'De Vos'}, {'given': 'J.', 'family': 'Tumbo'}, {'given': 'J.', 'family': 'Reynders'}, {'given': 'F.', 'family': 'Scholtz'}, {'given': 'P.', 'family': 'Bos'}, {'given': 'M. C.', 'family': 'de Beer'}, {'given': 'C. F.', 'family': 'Van der Merwe'}, {'given': 'A.', 'family': 'Delem'}], 'abstract': 'A double-blind, placebo-controlled phase II trial (e-Track 444563-014/. NCT00346892) was conducted in South Africa to evaluate the co-administration of RIX4414 (live-attenuated human G1P[8] rotavirus vaccine) and oral poliovirus vaccine (OPV) administered simultaneously. Healthy infants (n=450) were randomized into three groups (RIX4414 + OPV, RIX4414 + IPV or Placebo + OPV) to receive two oral doses of RIX4414/placebo with OPV or IPV using two vaccination schedules (6-10 weeks and 10-14 weeks). Serum anti-rotavirus IgA antibodies (ELISA) and neutralizing antibodies (micro-neutralization assay) to poliovirus serotypes 1, 2 and 3 were measured. Co-administration of RIX4414 with OPV did not result in a decrease in the high sero-protection rates against poliovirus serotypes 1, 2 and 3 detected after the third OPV dose (98-100%). The anti-rotavirus IgA antibody sero-conversion rates were higher for the 10-14 weeks schedule (55-61%) compared to the 6-10 weeks schedule (36-43%). Solicited symptoms were reported at similar rates between RIX4414 and placebo groups and no serious adverse events related to RIX4414 were reported. This study provided evidence that RIX4414 can be co-administered with routine EPI immunizations including OPV and that two doses of RIX4414 were well tolerated and immunogenic in South African infants. ?? 2010.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '18786585', 'scopus': '2-s2.0-77956413830', 'doi': '10.1016/j.vaccine.2008.08.034'}, 'title': 'Co-administration study in South African infants of a live-attenuated oral human rotavirus vaccine (RIX4414) and poliovirus vaccines', 'source': 'Mendeley'}
Phua KB, Quak SH, Lim FS, Goh P, Teoh YL, Datta SK, Han HH, Bock HL. Immunogenicity, reactogenicity and safety of a diphtheria-tetanus-acellular pertussis-inactivated polio and Haemophilus influenzae type b vaccine in a placebo-controlled rotavirus vaccine study. Annals of the Academy of Medicine, Singapore. 2008;37(7):546-53.	-	18695765	primary-study	cf93dfe5c2e8264e65b791d6d7a9297e88f36ae4	-	{'publication_type': {'year': 2009, 'cited_medium': None, 'issue': '3', 'issn': '0891-3668', 'volume': '28', 'title': 'The Pediatric Infectious Disease Journal', 'pagination': '177-181'}, 'language': None, 'rating': {'year': 0, 'title': 0.48, 'total': 0.3293076923076923, 'authors': 0.06923076923076923}, 'authors': [{'given': 'Max', 'family': 'Ciarlet'}, {'given': 'Su', 'family': 'He'}, {'given': 'Sherry', 'family': 'Lai'}, {'given': 'Maria', 'family': 'Petrecz'}, {'given': 'Guojun', 'family': 'Yuan'}, {'given': 'Guanghan F.', 'family': 'Liu'}, {'given': 'Elena', 'family': 'Mikviman'}, {'given': 'Penny M.', 'family': 'Heaton'}, {'given': 'Falko', 'family': 'Panzer'}, {'given': 'Thomas', 'family': 'Rose'}, {'given': 'Dieter Y.', 'family': 'Koller'}, {'given': 'Pierre', 'family': 'Van Damme'}, {'given': 'Florian', 'family': 'Schödel'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1097/inf.0b013e31818c0161'}, 'title': 'Concomitant Use of the 3-Dose Oral Pentavalent Rotavirus Vaccine With a 3-Dose Primary Vaccination Course of a Diphtheria-Tetanus-Acellular Pertussis-Hepatitis B-Inactivated Polio-Haemophilus influenzae Type b Vaccine', 'source': 'CrossRef'}
Phua KB, Quak SH, Lim FS, Goh P, Teoh YL, Datta SK, Han HH, Bock HL. Immunogenicity, reactogenicity and safety of a diphtheria-tetanus-acellular pertussis-inactivated polio and Haemophilus influenzae type b vaccine in a placebo-controlled rotavirus vaccine study. Annals of the Academy of Medicine, Singapore. 2008;37(7):546-53.	-	18695765	primary-study	cf93dfe5c2e8264e65b791d6d7a9297e88f36ae4	-	{'publication_type': {'year': 2008, 'cited_medium': None, 'issue': None, 'issn': '03044602', 'volume': None, 'title': 'Annals of the Academy of Medicine Singapore', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.9545454545454546, 'total': 0.7329545454545455, 'authors': 0.45}, 'authors': [{'given': 'Boo Phua', 'family': 'Kong'}, {'given': 'Hock Quak', 'family': 'Seng'}, {'given': 'Seng Lim', 'family': 'Fong'}, {'given': 'Paul', 'family': 'Goh'}, {'given': 'Leong Teoh', 'family': 'Yee'}, {'given': 'Sanjoy Kumar', 'family': 'Datta'}, {'given': 'Htay Htay', 'family': 'Han'}, {'given': 'Hans Ludwig', 'family': 'Bock'}], 'abstract': 'INTRODUCTION: In recent years, acellular pertussis combination vaccines have facilitated compliance with and coverage of the national immunisation programme in Singapore. This phase-II study (Rota-007) evaluated the immunogenicity, reactogenicity and safety of a DTPa-IPV/Hib combined vaccine when co-administered with a rotavirus vaccine. MATERIALS AND METHODS: A total of 2464 children aged 3 months were vaccinated with DTPa-IPV/Hib together with a randomised 1:3 ratio of either placebo (n=653) or 1 of 3 different formulations of a rotavirus vaccine. Blood samples were collected for immunogenicity analysis 1 month after the third DTPa-IPV/Hib vaccine dose in a subset of subjects (n = 640). Local and general reactogenicity and unsolicited adverse events were recorded during the follow-up after each vaccination. RESULTS: Serological analysis showed >95% response for all antigens in the co-administered DTPa-IPV/Hib vaccine, with no difference between the rotavirus vaccine and placebo groups. No differences in adverse events and reactogenicity were reported in the rotavirus vaccine and placebo groups. Only 0.2% of the subjects reported Grade 3 adverse events. Three subjects (from the vaccine groups) died during the study, which were assessed by the investigators as unrelated to vaccination. No deaths were reported in the placebo group. CONCLUSION: The combined DTPa- IPV/Hib vaccine is safe, well tolerated and highly immunogenic when given alone or coadministered with the rotavirus vaccine for infants in Singapore.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '18695765', 'scopus': '2-s2.0-49449099387', 'doi': None}, 'title': 'Immunogenicity, reactogenicity and safety of a diphtheria-tetanus-acellular pertussis-inactivated polio and Haemophilus Influenzae type b combination vaccine in a placebo-controlled rotavirus vaccine study', 'source': 'Mendeley'}
Linhares AC, Velázquez FR, Pérez-Schael I, Sáez-Llorens X, Abate H, Espinoza F, López P, Macías-Parra M, Ortega-Barría E, Rivera-Medina DM, Rivera L, Pavía-Ruz N, Nuñez E, Damaso S, Ruiz-Palacios GM, De Vos B, O'Ryan M, Gillard P, Bouckenooghe A. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet. 2008;371(9619):1181-9.	10.1016/S0140-6736(08)60524-3	18395579	primary-study	db9cc8247bfda6b52cfda3164b6924c964d99687	-	{'publication_type': {'year': 2008, 'cited_medium': None, 'issue': '9619', 'issn': '0140-6736', 'volume': '371', 'title': 'The Lancet', 'pagination': '1181-1189'}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.8763157894736843, 'authors': 0.905263157894737}, 'authors': [{'given': 'Alexandre C', 'family': 'Linhares'}, {'given': 'F Raúl', 'family': 'Velázquez'}, {'given': 'Irene', 'family': 'Pérez-Schael'}, {'given': 'Xavier', 'family': 'Sáez-Llorens'}, {'given': 'Hector', 'family': 'Abate'}, {'given': 'Felix', 'family': 'Espinoza'}, {'given': 'Pío', 'family': 'López'}, {'given': 'Mercedes', 'family': 'Macías-Parra'}, {'given': 'Eduardo', 'family': 'Ortega-Barría'}, {'given': 'Doris Maribel', 'family': 'Rivera-Medina'}, {'given': 'Luis', 'family': 'Rivera'}, {'given': 'Noris', 'family': 'Pavía-Ruz'}, {'given': 'Ernesto', 'family': 'Nuñez'}, {'given': 'Silvia', 'family': 'Damaso'}, {'given': 'Guillermo M', 'family': 'Ruiz-Palacios'}, {'given': 'Béatrice', 'family': 'De Vos'}, {'given': 'Miguel', 'family': "O'Ryan"}, {'given': 'Paul', 'family': 'Gillard'}, {'given': 'Alain', 'family': 'Bouckenooghe'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1016/s0140-6736(08)60524-3'}, 'title': 'Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study', 'source': 'CrossRef'}
Linhares AC, Velázquez FR, Pérez-Schael I, Sáez-Llorens X, Abate H, Espinoza F, López P, Macías-Parra M, Ortega-Barría E, Rivera-Medina DM, Rivera L, Pavía-Ruz N, Nuñez E, Damaso S, Ruiz-Palacios GM, De Vos B, O'Ryan M, Gillard P, Bouckenooghe A. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet. 2008;371(9619):1181-9.	10.1016/S0140-6736(08)60524-3	18395579	primary-study	db9cc8247bfda6b52cfda3164b6924c964d99687	-	{'message': 'Remote API error.'}
Vesikari T, Karvonen A, Prymula R, Schuster V, Tejedor JC, Cohen R, Meurice F, Han HH, Damaso S, Bouckenooghe A. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet. 2007;370(9601):1757-63.	10.1016/S0140-6736(07)61744-9	18037080	primary-study	a78b024d2d47fef05a170a5bcde143f2b6ebd61d	-	{'publication_type': {'year': 2007, 'cited_medium': None, 'issue': '9601', 'issn': '0140-6736', 'volume': '370', 'title': 'The Lancet', 'pagination': '1757-1763'}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.9, 'authors': 1.0}, 'authors': [{'given': 'T', 'family': 'Vesikari'}, {'given': 'A', 'family': 'Karvonen'}, {'given': 'R', 'family': 'Prymula'}, {'given': 'V', 'family': 'Schuster'}, {'given': 'JC', 'family': 'Tejedor'}, {'given': 'R', 'family': 'Cohen'}, {'given': 'F', 'family': 'Meurice'}, {'given': 'HH', 'family': 'Han'}, {'given': 'S', 'family': 'Damaso'}, {'given': 'A', 'family': 'Bouckenooghe'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1016/s0140-6736(07)61744-9'}, 'title': 'Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study', 'source': 'CrossRef'}
Vesikari T, Karvonen A, Prymula R, Schuster V, Tejedor JC, Cohen R, Meurice F, Han HH, Damaso S, Bouckenooghe A. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet. 2007;370(9601):1757-63.	10.1016/S0140-6736(07)61744-9	18037080	primary-study	a78b024d2d47fef05a170a5bcde143f2b6ebd61d	-	{'publication_type': {'year': 2007, 'cited_medium': None, 'issue': None, 'issn': '01406736', 'volume': None, 'title': 'The Lancet', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.8900000000000001, 'authors': 0.9600000000000002}, 'authors': [{'given': 'T', 'family': 'Vesikari'}, {'given': 'A', 'family': 'Karvonen'}, {'given': 'R', 'family': 'Prymula'}, {'given': 'V.', 'family': 'Schuster'}, {'given': 'Jc', 'family': 'Tejedor'}, {'given': 'R.', 'family': 'Cohen'}, {'given': 'F.', 'family': 'Meurice'}, {'given': 'Hh', 'family': 'Han'}, {'given': 'S.', 'family': 'Damaso'}, {'given': 'A.', 'family': 'Bouckenooghe'}], 'abstract': 'Background: We aimed to assess the efficacy of the oral live attenuated human rotavirus vaccine Rotarix (RIX4414) for prevention of rotavirus gastroenteritis in European infants during their first 2 years of life. Methods: 3994 study participants were enrolled from six countries and were randomly assigned two oral doses of either RIX4414 (n=2646) or placebo (n=1348), which were coadministered with the first two doses of specific childhood vaccinations. Follow-up for gastroenteritis episodes was undertaken from 2 weeks post-dose two through the two consecutive rotavirus seasons following vaccinations (combined efficacy follow-up period; mean duration 17 months [SD 1·6]). Our primary endpoint was vaccine efficacy against rotavirus gastroenteritis of any severity during the first efficacy follow-up period (2 weeks post-dose two to the end of the first rotavirus season). Stool specimens obtained during gastroenteritis episodes were tested for rotavirus by ELISA and typed by RT-PCR. Episodes scoring 11 or greater on the 20-point Vesikari scale were classified as severe. Analysis was according to protocol. This study is registered with ClinicalTrials.gov, number NCT00140686 (eTrack102247). Findings: 120 infants were excluded from the according-to-protocol analysis. During the first efficacy follow-up period (mean duration 5·7 months [SD 1·2]), 24 of 2572 infants allocated RIX4414 versus 94 of 1302 given placebo had rotavirus gastroenteritis episodes of any severity, resulting in a vaccine efficacy of 87·1% (95% CI 79·6-92·1; p<0·0001). For the combined efficacy follow-up period, vaccine efficacy against severe rotavirus gastroenteritis was 90·4% (85·1-94·1; p<0·0001), for admission owing to rotavirus gastroenteritis 96·0% (83·8-99·5; p<0·0001), and for rotavirus-related medical attention 83·8% (76·8-88·9; p<0.0001), and significant protection against severe rotavirus gastroenteritis by circulating G1, G2, G3, G4, and G9 rotavirus types was shown. Interpretation: In a European setting, two doses of RIX4414 coadministered with childhood vaccines provided high protection against any and severe rotavirus gastroenteritis, with an overall reduction of admissions for gastroenteritis over two consecutive rotavirus epidemic seasons. © 2007 Elsevier Ltd. All rights reserved.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '18037080', 'scopus': None, 'doi': '10.1016/S0140-6736(07)61744-9'}, 'title': 'Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study', 'source': 'Mendeley'}
Perez-Schael I, Salinas B, Tomat M, Linhares AC, Guerrero ML, Ruiz-Palacios GM, Bouckenooghe A, Yarzabal JP. Efficacy of the human rotavirus vaccine RIX4414 in malnourished children. The Journal of infectious diseases. 2007;196(4):537-40.	10.1086/519687	17624838	primary-study	9db203506e44748515246d0a3a2be19c4c6487f4	-	{'publication_type': {'year': 2007, 'cited_medium': None, 'issue': '4', 'issn': '0022-1899', 'volume': '196', 'title': 'The Journal of Infectious Diseases', 'pagination': '537-540'}, 'language': None, 'rating': {'year': 0, 'title': 1.0, 'total': 0.875, 'authors': 0.9000000000000001}, 'authors': [{'given': 'Irene', 'family': 'Perez‐Schael'}, {'given': 'Belén', 'family': 'Salinas'}, {'given': 'Maria', 'family': 'Tomat'}, {'given': 'Alexandre\xa0C.', 'family': 'Linhares'}, {'given': 'M.\xa0Lourdes', 'family': 'Guerrero'}, {'given': 'Guillermo\xa0M.', 'family': 'Ruiz‐Palacios'}, {'given': 'Alain', 'family': 'Bouckenooghe'}, {'given': 'Juan\xa0Pablo', 'family': 'Yarzábal'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '17624838', 'scopus': None, 'doi': '10.1086/519687'}, 'title': 'Efficacy of the Human Rotavirus Vaccine RIX4414 in Malnourished Children', 'source': 'CrossRef'}
Perez-Schael I, Salinas B, Tomat M, Linhares AC, Guerrero ML, Ruiz-Palacios GM, Bouckenooghe A, Yarzabal JP. Efficacy of the human rotavirus vaccine RIX4414 in malnourished children. The Journal of infectious diseases. 2007;196(4):537-40.	10.1086/519687	17624838	primary-study	9db203506e44748515246d0a3a2be19c4c6487f4	-	{'publication_type': {'year': 2007, 'cited_medium': None, 'issue': None, 'issn': None, 'volume': None, 'title': 'The Journal of Infectious Diseases', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.8875000000000001, 'authors': 0.9500000000000001}, 'authors': [{'given': 'I', 'family': 'Perez-Schael'}, {'given': 'B', 'family': 'Salinas'}, {'given': 'M', 'family': 'Tomat'}, {'given': 'A C', 'family': 'Linhares'}, {'given': 'M L', 'family': 'Guerrero'}, {'given': 'G M', 'family': 'Ruiz-Palacios'}, {'given': 'A', 'family': 'Bouckenooghe'}, {'given': 'J P', 'family': 'Yarzabal'}], 'abstract': 'The effect of nutritional status on protective efficacy of a live attenuated human rotavirus vaccine (RIX4414) was studied. Vaccine protection was evaluated through a secondary analysis of data from an efficacy study conducted in Brazil, Mexico, and Venezuela. Vaccine efficacy against rotavirus gastroenteritis (RVGE) was similar in well-nourished and malnourished infants: 74.1% (95% confidence interval [CI], 52.2%-86.2%) and 73% (95% CI, 11.2%-92.3%) for severe RVGE and 60.9% (95% CI, 37.4%-75.4%) and 61.2% (95% CI, 10.4%-83.1%) for RVGE of any severity, respectively. RIX4414 significantly decreased the rate of RVGE regardless of nutritional status, which suggests that this patient group can also benefit from rotavirus vaccination. CLINICAL TRIALS REGISTRY: e-Track 444563-006, NCT00385320 (http://www.clinicaltrials.gov).', 'type': 'generic', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': None}, 'title': 'Efficacy of the human rotavirus vaccine RIX4414 in malnourished children', 'source': 'Mendeley'}
Ruiz-Palacios GM, Guerrero ML, Bautista-Márquez A, Ortega-Gallegos H, Tuz-Dzib F, Reyes-González L, Rosales-Pedraza G, Martínez-López J, Castañón-Acosta E, Cervantes Y, Costa-Clemens S, DeVos B. Dose response and efficacy of a live, attenuated human rotavirus vaccine in Mexican infants. Pediatrics. 2007;120(2):e253-61.	10.1542/peds.2006-2630	17606534	primary-study	28b43d5f2ed6c9d3592142593a4a09d95450d039	-	{'publication_type': {'year': 2007, 'cited_medium': None, 'issue': '2', 'issn': '0031-4005', 'volume': '120', 'title': 'PEDIATRICS', 'pagination': 'e253-e261'}, 'language': None, 'rating': {'year': 0, 'title': 1.0, 'total': 0.86875, 'authors': 0.8750000000000001}, 'authors': [{'given': 'G. M.', 'family': 'Ruiz-Palacios'}, {'given': 'M. L.', 'family': 'Guerrero'}, {'given': 'A.', 'family': 'Bautista-Marquez'}, {'given': 'H.', 'family': 'Ortega-Gallegos'}, {'given': 'F.', 'family': 'Tuz-Dzib'}, {'given': 'L.', 'family': 'Reyes-Gonzalez'}, {'given': 'G.', 'family': 'Rosales-Pedraza'}, {'given': 'J.', 'family': 'Martinez-Lopez'}, {'given': 'E.', 'family': 'Castanon-Acosta'}, {'given': 'Y.', 'family': 'Cervantes'}, {'given': 'S.', 'family': 'Costa-Clemens'}, {'given': 'B.', 'family': 'DeVos'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '17606534', 'scopus': None, 'doi': '10.1542/peds.2006-2630'}, 'title': 'Dose Response and Efficacy of a Live, Attenuated Human Rotavirus Vaccine in Mexican Infants', 'source': 'CrossRef'}
Ruiz-Palacios GM, Guerrero ML, Bautista-Márquez A, Ortega-Gallegos H, Tuz-Dzib F, Reyes-González L, Rosales-Pedraza G, Martínez-López J, Castañón-Acosta E, Cervantes Y, Costa-Clemens S, DeVos B. Dose response and efficacy of a live, attenuated human rotavirus vaccine in Mexican infants. Pediatrics. 2007;120(2):e253-61.	10.1542/peds.2006-2630	17606534	primary-study	28b43d5f2ed6c9d3592142593a4a09d95450d039	-	{'publication_type': {'year': 2007, 'cited_medium': None, 'issue': None, 'issn': '0031-4005', 'volume': None, 'title': 'Pediatrics', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 0.9770833333333334, 'authors': 0.9083333333333335}, 'authors': [{'given': 'Guillermo M', 'family': 'Ruiz-Palacios'}, {'given': 'M Lourdes', 'family': 'Guerrero'}, {'given': 'Aurora', 'family': 'Bautista-Márquez'}, {'given': 'Hilda', 'family': 'Ortega-Gallegos'}, {'given': 'Fernando', 'family': 'Tuz-Dzib'}, {'given': 'Leticia', 'family': 'Reyes-González'}, {'given': 'Gustavo', 'family': 'Rosales-Pedraza'}, {'given': 'Julia', 'family': 'Martínez-López'}, {'given': 'Erika', 'family': 'Castañón-Acosta'}, {'given': 'Yolanda', 'family': 'Cervantes'}, {'given': 'SueAnn', 'family': 'Costa-Clemens'}, {'given': 'Beatrice', 'family': 'DeVos'}], 'abstract': 'OBJECTIVE: Immunization against rotavirus has been proposed as the most cost-effective intervention to reduce the disease burden associated with this infection worldwide. The objective of this study was to determine the dose response, immunogenicity, and efficacy of 2 doses of an oral, attenuated monovalent G1[P8] human rotavirus vaccine in children from the same setting in Mexico, where the natural protection against rotavirus infection was studied. METHODS: From June 2001 through May 2003, 405 healthy infants were randomly assigned to 1 of 3 vaccine groups (virus concentrations 10(4.7), 10(5.2), and 10(5.8) infectious units) and to a placebo group and were monitored to the age of 2 years. The vaccine/placebo was administered concurrently with diphtheria-tetanus toxoid-pertussis/hepatitis B/Haemophilus influenzae type b vaccine at 2 and 4 months of age. After the administration of the first vaccine/placebo dose, weekly home visits to collect information regarding infant health were conducted. Stool samples were collected during each gastroenteritis episode and tested for rotavirus antigen and serotype. RESULTS: The vaccine was well tolerated and induced a greater rate of seroconversion than observed in infants who received placebo. For the pooled vaccine groups, efficacy after 2 oral doses was 80% and 95% against any and severe rotavirus gastroenteritis, respectively. Efficacy was 100% against severe rotavirus gastroenteritis and 70% against severe gastroenteritis of any cause with the vaccine at the highest virus concentration (10(5.8) infectious units). The predominant infecting rotavirus serotype in this cohort was wild-type G1 (85%). Adverse events, including fever, irritability, loss of appetite, cough, diarrhea, and vomiting, were similar among vaccinees and placebo recipients. CONCLUSION: This new oral, live, attenuated human rotavirus vaccine was safe, immunogenic, and highly efficacious in preventing any and, more importantly, severe rotavirus gastroenteritis in healthy infants. This vaccine produced comparable protection to natural infection.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '17606534', 'scopus': '2-s2.0-34547670923', 'doi': '10.1542/peds.2006-2630'}, 'title': 'Dose response and efficacy of a live, attenuated human rotavirus vaccine in Mexican infants.', 'source': 'Mendeley'}
Block SL, Vesikari T, Goveia MG, Rivers SB, Adeyi BA, Dallas MJ, Bauder J, Boslego JW, Heaton PM. Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life. Pediatrics. 2007;119(1):11-8.	10.1542/peds.2006-2058	17200266	primary-study	81ecb1689ccc1af86e56e428addda214b510db31	-	{'publication_type': {'year': 2007, 'cited_medium': None, 'issue': '1', 'issn': '0031-4005', 'volume': '119', 'title': 'PEDIATRICS', 'pagination': '11-18'}, 'language': None, 'rating': {'year': 0, 'title': 1.0, 'total': 0.875, 'authors': 0.9000000000000001}, 'authors': [{'given': 'S. L.', 'family': 'Block'}, {'given': 'T.', 'family': 'Vesikari'}, {'given': 'M. G.', 'family': 'Goveia'}, {'given': 'S. B.', 'family': 'Rivers'}, {'given': 'B. A.', 'family': 'Adeyi'}, {'given': 'M. J.', 'family': 'Dallas'}, {'given': 'J.', 'family': 'Bauder'}, {'given': 'J. W.', 'family': 'Boslego'}, {'given': 'P. M.', 'family': 'Heaton'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '17200266', 'scopus': None, 'doi': '10.1542/peds.2006-2058'}, 'title': 'Efficacy, Immunogenicity, and Safety of a Pentavalent Human-Bovine (WC3) Reassortant Rotavirus Vaccine at the End of Shelf Life', 'source': 'CrossRef'}
Block SL, Vesikari T, Goveia MG, Rivers SB, Adeyi BA, Dallas MJ, Bauder J, Boslego JW, Heaton PM. Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life. Pediatrics. 2007;119(1):11-8.	10.1542/peds.2006-2058	17200266	primary-study	81ecb1689ccc1af86e56e428addda214b510db31	-	{'publication_type': {'year': 2007, 'cited_medium': None, 'issue': None, 'issn': '1098-4275', 'volume': None, 'title': 'Pediatrics', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 0.975, 'authors': 0.9000000000000001}, 'authors': [{'given': 'Stan L', 'family': 'Block'}, {'given': 'Timo', 'family': 'Vesikari'}, {'given': 'Michelle G', 'family': 'Goveia'}, {'given': 'Stephen B', 'family': 'Rivers'}, {'given': 'Ben a', 'family': 'Adeyi'}, {'given': 'Michael J', 'family': 'Dallas'}, {'given': 'Jeffrey', 'family': 'Bauder'}, {'given': 'John W', 'family': 'Boslego'}, {'given': 'Penny M', 'family': 'Heaton'}], 'abstract': 'Rotavirus is the leading cause of dehydrating acute gastroenteritis in infants worldwide. Previous studies of a live pentavalent human-bovine reassortant rotavirus vaccine have shown it to be efficacious across a range of potencies.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '17200266', 'scopus': '2-s2.0-33846907238', 'doi': '10.1542/peds.2006-2058'}, 'title': 'Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life.', 'source': 'Mendeley'}
Ward RL, Kirkwood CD, Sander DS, Smith VE, Shao M, Bean JA, Sack DA, Bernstein DI. Reductions in cross-neutralizing antibody responses in infants after attenuation of the human rotavirus vaccine candidate 89-12. The Journal of infectious diseases. 2006;194(12):1729-36.	10.1086/509623	17109346	primary-study	68ecbb51f033c692c1d38a3522574575658e2360	-	{'publication_type': {'year': 2006, 'cited_medium': None, 'issue': '12', 'issn': '0022-1899', 'volume': '194', 'title': 'The Journal of Infectious Diseases', 'pagination': '1729-1736'}, 'language': None, 'rating': {'year': 0, 'title': 0.875, 'total': 0.79375, 'authors': 0.9000000000000001}, 'authors': [{'given': 'Richard\xa0L.', 'family': 'Ward'}, {'given': 'Carl\xa0D.', 'family': 'Kirkwood'}, {'given': 'Donna\xa0S.', 'family': 'Sander'}, {'given': 'Vicki\xa0E.', 'family': 'Smith'}, {'given': 'Mingyuan', 'family': 'Shao'}, {'given': 'Judy\xa0A.', 'family': 'Bean'}, {'given': 'David\xa0A.', 'family': 'Sack'}, {'given': 'and\xa0David\xa0I.', 'family': 'Bernstein'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '17109346', 'scopus': None, 'doi': '10.1086/509623'}, 'title': 'Reductions in Cross‐Neutralizing Antibody Responses in Infants after Attenuation of the Human Rotavirus Vaccine Candidate 89‐12', 'source': 'CrossRef'}
Ward RL, Kirkwood CD, Sander DS, Smith VE, Shao M, Bean JA, Sack DA, Bernstein DI. Reductions in cross-neutralizing antibody responses in infants after attenuation of the human rotavirus vaccine candidate 89-12. The Journal of infectious diseases. 2006;194(12):1729-36.	10.1086/509623	17109346	primary-study	68ecbb51f033c692c1d38a3522574575658e2360	-	{'publication_type': {'year': 2006, 'cited_medium': None, 'issue': None, 'issn': '0022-1899', 'volume': None, 'title': 'The Journal of infectious diseases', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 0.975, 'authors': 0.9000000000000001}, 'authors': [{'given': 'Richard L', 'family': 'Ward'}, {'given': 'Carl D', 'family': 'Kirkwood'}, {'given': 'Donna S', 'family': 'Sander'}, {'given': 'Vicki E', 'family': 'Smith'}, {'given': 'Mingyuan', 'family': 'Shao'}, {'given': 'Judy a', 'family': 'Bean'}, {'given': 'David a', 'family': 'Sack'}, {'given': 'David I', 'family': 'Bernstein'}], 'abstract': 'The G1P1A[8] rotavirus vaccine candidate 89-12, the precursor to Rotarix, stimulated high titers of neutralizing antibodies to non-G1/P1A[8] serotypes of human rotavirus in naturally infected subjects before attenuation by cell-culture passages. These responses were greatly diminished in young infants (median age, 11 weeks) administered the attenuated vaccine. Because of the possibility of improved responses in older infants, the immunogenicity of the 89-12 vaccine candidate was evaluated after administration of 2 doses beginning at either 4 or 6 months of age. As was found in young infants, neutralizing antibody responses to non-G1/P1A[8] rotaviruses were considerably lower than those observed after natural infection. The reasons identified were overall (P<.0001) lower neutralizing antibody responses stimulated by the attenuated 89-12 strain, compared with those stimulated by its virulent precursor, and 5 mutations selected in the gene encoding the immunodominant VP4 (P) neutralization protein. Even so, the Rotarix vaccine developed from attenuated 89-12 was found to elicit excellent protection against non-G1 rotaviruses.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '17109346', 'scopus': '2-s2.0-33845462577', 'doi': '10.1086/509623'}, 'title': 'Reductions in cross-neutralizing antibody responses in infants after attenuation of the human rotavirus vaccine candidate 89-12.', 'source': 'Mendeley'}
Linhares AC, Verstraeten T, Wolleswinkel-van den Bosch J, Clemens R, Breuer T. Rotavirus serotype G9 is associated with more-severe disease in Latin America. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2006;43(3):312-4.	10.1086/505493	16804845	primary-study	66522404b8b8baa86222bd8064e579188aa3a43e	-	{'publication_type': {'year': 2006, 'cited_medium': None, 'issue': '3', 'issn': '1058-4838', 'volume': '43', 'title': 'Clinical Infectious Diseases', 'pagination': '312-314'}, 'language': None, 'rating': {'year': 0, 'title': 0.9090909090909091, 'total': 0.8209090909090909, 'authors': 0.9199999999999999}, 'authors': [{'given': 'A. C.', 'family': 'Linhares'}, {'given': 'Thomas', 'family': 'Verstraeten'}, {'given': 'Judith', 'family': 'Wolleswinkel‐van den Bosch'}, {'given': 'Ralf', 'family': 'Clemens'}, {'given': 'Thomas', 'family': 'Breuer'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '16804845', 'scopus': None, 'doi': '10.1086/505493'}, 'title': 'Rotavirus Serotype G9 Is Associated with More‐Severe Disease in Latin America', 'source': 'CrossRef'}
Linhares AC, Verstraeten T, Wolleswinkel-van den Bosch J, Clemens R, Breuer T. Rotavirus serotype G9 is associated with more-severe disease in Latin America. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2006;43(3):312-4.	10.1086/505493	16804845	primary-study	66522404b8b8baa86222bd8064e579188aa3a43e	-	{'publication_type': {'year': 2006, 'cited_medium': None, 'issue': None, 'issn': '1537-6591', 'volume': None, 'title': 'Clinical infectious diseases : an official publication of the Infectious Diseases Society of America', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 0.6, 'total': 0.49, 'authors': 0.0}, 'authors': [{'given': 'Theerapong', 'family': 'Krajaejun'}, {'given': 'Boonmee', 'family': 'Sathapatayavongs'}, {'given': 'Roongnapa', 'family': 'Pracharktam'}, {'given': 'Prawat', 'family': 'Nitiyanant'}, {'given': 'Paisan', 'family': 'Leelachaikul'}, {'given': 'Wanchai', 'family': 'Wanachiwanawin'}, {'given': 'Angkana', 'family': 'Chaiprasert'}, {'given': 'Paraya', 'family': 'Assanasen'}, {'given': 'Marisa', 'family': 'Saipetch'}, {'given': 'Piroon', 'family': 'Mootsikapun'}, {'given': 'Ploenchan', 'family': 'Chetchotisakd'}, {'given': 'Arnuparp', 'family': 'Lekhakula'}, {'given': 'Winyou', 'family': 'Mitarnun'}, {'given': 'Sineenart', 'family': 'Kalnauwakul'}, {'given': 'Khuanchai', 'family': 'Supparatpinyo'}, {'given': 'Romanee', 'family': 'Chaiwarith'}, {'given': 'Siri', 'family': 'Chiewchanvit'}, {'given': 'Napaporn', 'family': 'Tananuvat'}, {'given': 'Sawet', 'family': 'Srisiri'}, {'given': 'Chusana', 'family': 'Suankratay'}, {'given': 'Wanla', 'family': 'Kulwichit'}, {'given': 'Mawin', 'family': 'Wongsaisuwan'}, {'given': 'Shawarash', 'family': 'Somkaew'}], 'abstract': 'BACKGROUND: Pythiosis is an emerging and life-threatening infectious disease in humans and animals that is caused by the pathogenic oomycete Pythium insidiosum. Human pythiosis is found mostly in Thailand, although disease in animals has been increasingly reported worldwide. Clinical information on human pythiosis is limited, and health care professionals are unfamiliar with the disease, leading to underdiagnosis, delayed treatment, and poor prognosis. METHODS: To retrospectively study the clinical and epidemiological features of human pythiosis, we analyzed clinical data from patients with pythiosis diagnosed during the period of January 1985 through June 2003 at 9 tertiary care hospitals throughout Thailand. RESULTS: A total of 102 cases of human pythiosis were documented nationwide. A substantial proportion (40%) of cases occurred in the last 4 years of the 18-year study interval. Clinical presentations fell into 4 groups: cutaneous/subcutaneous cases (5% of cases), vascular cases (59%), ocular cases (33%), and disseminated cases (3%). Almost all patients with cutaneous/subcutaneous, vascular, and disseminated pythiosis (85%) had underlying thalassemia-hemoglobinopathy syndrome. Most ocular cases (84%) were associated with no underlying disease. A majority of the patients were male (71%), were aged 20-60 years (86%), and reported an agricultural occupation (75%). Regarding treatment outcomes, all patients with disseminated infection died; 78% of patients with vascular disease required limb amputation, and 40% of these patients died; and 79% of patients with ocular pythiosis required enucleation/evisceration. CONCLUSIONS: Here, we report, to our knowledge, the largest case study of human pythiosis. The disease has high rates of morbidity and mortality. Early diagnosis and effective treatment are urgently needed to improve clinical outcomes. Because P. insidiosum is distributed worldwide and can infect healthy individuals, an awareness of human pythiosis should be promoted in Thailand and in other countries.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '16886148', 'scopus': None, 'doi': '10.1086/506353'}, 'title': 'and epidemiological analyses of human pythiosis in Thailand. Clinical Infectious Diseases : An Official Publication', 'source': 'Mendeley'}
Phua KB, Quak SH, Emmanuel S, Goh PS, Han HH, Hardt K, Bock HL, De Vos B. A short report on highlights of worldwide development of RIX4414: a Singaporean experience. Vaccine. 2006;24(18):3782-3.	10.1016/j.vaccine.2006.03.040	16600443	primary-study	0db9e60cdc476e9cdf3022f6e9feb5b530d38b06	-	{'publication_type': {'year': 2006, 'cited_medium': None, 'issue': '18', 'issn': '0264-410X', 'volume': '24', 'title': 'Vaccine', 'pagination': '3782-3783'}, 'language': None, 'rating': {'year': 1, 'title': 1.0, 'total': 0.978125, 'authors': 0.9125000000000001}, 'authors': [{'given': 'K.B.', 'family': 'Phua'}, {'given': 'S.H.', 'family': 'Quak'}, {'given': 'S.', 'family': 'Emmanuel'}, {'given': 'P.S.C.', 'family': 'Goh'}, {'given': 'H.H.', 'family': 'Han'}, {'given': 'K.', 'family': 'Hardt'}, {'given': 'H.L.', 'family': 'Bock'}, {'given': 'B.', 'family': 'De Vos'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '16600443', 'scopus': None, 'doi': '10.1016/j.vaccine.2006.03.040'}, 'title': 'A short report on highlights of worldwide development of RIX4414: A Singaporean experience', 'source': 'CrossRef'}
Phua KB, Quak SH, Emmanuel S, Goh PS, Han HH, Hardt K, Bock HL, De Vos B. A short report on highlights of worldwide development of RIX4414: a Singaporean experience. Vaccine. 2006;24(18):3782-3.	10.1016/j.vaccine.2006.03.040	16600443	primary-study	0db9e60cdc476e9cdf3022f6e9feb5b530d38b06	-	{'publication_type': {'year': 1972, 'cited_medium': None, 'issue': None, 'issn': None, 'volume': None, 'title': '18', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 0.2, 'total': 0.23, 'authors': 0.0}, 'authors': [{'given': 'B O', 'family': 'Bawagan'}, {'given': 'E M', 'family': 'Midrano'}, {'given': 'E P', 'family': 'Villanueva'}], 'abstract': 'An unbleached-grade of high alpha pulp could be developed from abaca fiber. The unbleached prehydrolyzed sulfate pulp yield 0.52 percent ash, 0.75 percent lignin, 2.25 percent pentonsans, and 95.05 percent alpha cellulose. Purified by a 3 stage C-E-H bleaching sequence, with a cold extraction stage, prehydrolyzed sulfate pulp of abaca fiber yielded 96.9 percent bleached  pulp, analyzed as 0.06 percent ash, 0 percent lignin, 1.46 percent pentosans and 93.04 percent alpha cellulose. Bleaching developed a viscosity of 6.44 years and a brightness of 86.0 percent. The quality of the purified abaca pulp surpassed the specifications for commercial dissolving pulp.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': None}, 'title': 'High alpha pulp from abaca  (musa Textiles Nee) fibers.', 'source': 'Mendeley'}
Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, Abate H, Breuer T, Clemens SC, Cheuvart B, Espinoza F, Gillard P, Innis BL, Cervantes Y, Linhares AC, López P, Macías-Parra M, Ortega-Barría E, Richardson V, Rivera-Medina DM, Rivera L, Salinas B, Pavía-Ruz N, Salmerón J, Rüttimann R, Tinoco JC, Rubio P, Nuñez E, Guerrero ML, Yarzábal JP, Damaso S, Tornieporth N, Sáez-Llorens X, Vergara RF, Vesikari T, Bouckenooghe A, Clemens R, De Vos B, O'Ryan M. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. The New England journal of medicine. 2006;354(1):11-22.	10.1056/NEJMoa052434	16394298	primary-study	de3ab989254e3ab22d72b28cb6f02a1c56026a8a	-	{'publication_type': {'year': 2006, 'cited_medium': None, 'issue': '1', 'issn': '0028-4793', 'volume': '354', 'title': 'New England Journal of Medicine', 'pagination': '11-22'}, 'language': None, 'rating': {'year': 0, 'title': 1.0, 'total': 0.8756944444444443, 'authors': 0.9027777777777772}, 'authors': [{'given': 'Guillermo M.', 'family': 'Ruiz-Palacios'}, {'given': 'Irene', 'family': 'Pérez-Schael'}, {'given': 'F. Raúl', 'family': 'Velázquez'}, {'given': 'Hector', 'family': 'Abate'}, {'given': 'Thomas', 'family': 'Breuer'}, {'given': 'SueAnn Costa', 'family': 'Clemens'}, {'given': 'Brigitte', 'family': 'Cheuvart'}, {'given': 'Felix', 'family': 'Espinoza'}, {'given': 'Paul', 'family': 'Gillard'}, {'given': 'Bruce L.', 'family': 'Innis'}, {'given': 'Yolanda', 'family': 'Cervantes'}, {'given': 'Alexandre C.', 'family': 'Linhares'}, {'given': 'Pío', 'family': 'López'}, {'given': 'Mercedes', 'family': 'Macías-Parra'}, {'given': 'Eduardo', 'family': 'Ortega-Barría'}, {'given': 'Vesta', 'family': 'Richardson'}, {'given': 'Doris Maribel', 'family': 'Rivera-Medina'}, {'given': 'Luis', 'family': 'Rivera'}, {'given': 'Belén', 'family': 'Salinas'}, {'given': 'Noris', 'family': 'Pavía-Ruz'}, {'given': 'Jorge', 'family': 'Salmerón'}, {'given': 'Ricardo', 'family': 'Rüttimann'}, {'given': 'Juan Carlos', 'family': 'Tinoco'}, {'given': 'Pilar', 'family': 'Rubio'}, {'given': 'Ernesto', 'family': 'Nuñez'}, {'given': 'M. Lourdes', 'family': 'Guerrero'}, {'given': 'Juan Pablo', 'family': 'Yarzábal'}, {'given': 'Silvia', 'family': 'Damaso'}, {'given': 'Nadia', 'family': 'Tornieporth'}, {'given': 'Xavier', 'family': 'Sáez-Llorens'}, {'given': 'Rodrigo F.', 'family': 'Vergara'}, {'given': 'Timo', 'family': 'Vesikari'}, {'given': 'Alain', 'family': 'Bouckenooghe'}, {'given': 'Ralf', 'family': 'Clemens'}, {'given': 'Béatrice', 'family': 'De Vos'}, {'given': 'Miguel', 'family': "O'Ryan"}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1056/nejmoa052434'}, 'title': 'Safety and Efficacy of an Attenuated Vaccine against Severe Rotavirus Gastroenteritis', 'source': 'CrossRef'}
Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, Abate H, Breuer T, Clemens SC, Cheuvart B, Espinoza F, Gillard P, Innis BL, Cervantes Y, Linhares AC, López P, Macías-Parra M, Ortega-Barría E, Richardson V, Rivera-Medina DM, Rivera L, Salinas B, Pavía-Ruz N, Salmerón J, Rüttimann R, Tinoco JC, Rubio P, Nuñez E, Guerrero ML, Yarzábal JP, Damaso S, Tornieporth N, Sáez-Llorens X, Vergara RF, Vesikari T, Bouckenooghe A, Clemens R, De Vos B, O'Ryan M. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. The New England journal of medicine. 2006;354(1):11-22.	10.1056/NEJMoa052434	16394298	primary-study	de3ab989254e3ab22d72b28cb6f02a1c56026a8a	-	{'publication_type': {'year': 2006, 'cited_medium': None, 'issue': None, 'issn': '1533-4406', 'volume': None, 'title': 'N Engl J Med', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.8864864864864864, 'authors': 0.9459459459459457}, 'authors': [{'given': 'G M', 'family': 'Ruiz-Palacios'}, {'given': 'I', 'family': 'Perez-Schael'}, {'given': 'F R', 'family': 'Velazquez'}, {'given': 'H', 'family': 'Abate'}, {'given': 'T', 'family': 'Breuer'}, {'given': 'S C', 'family': 'Clemens'}, {'given': 'B', 'family': 'Cheuvart'}, {'given': 'F', 'family': 'Espinoza'}, {'given': 'P', 'family': 'Gillard'}, {'given': 'B L', 'family': 'Innis'}, {'given': 'Y', 'family': 'Cervantes'}, {'given': 'A C', 'family': 'Linhares'}, {'given': 'P', 'family': 'Lopez'}, {'given': 'M', 'family': 'Macias-Parra'}, {'given': 'E', 'family': 'Ortega-Barria'}, {'given': 'V', 'family': 'Richardson'}, {'given': 'D M', 'family': 'Rivera-Medina'}, {'given': 'L', 'family': 'Rivera'}, {'given': 'B', 'family': 'Salinas'}, {'given': 'N', 'family': 'Pavia-Ruz'}, {'given': 'J', 'family': 'Salmeron'}, {'given': 'R', 'family': 'Ruttimann'}, {'given': 'J C', 'family': 'Tinoco'}, {'given': 'P', 'family': 'Rubio'}, {'given': 'E', 'family': 'Nunez'}, {'given': 'M L', 'family': 'Guerrero'}, {'given': 'J P', 'family': 'Yarzabal'}, {'given': 'S', 'family': 'Damaso'}, {'given': 'N', 'family': 'Tornieporth'}, {'given': 'X', 'family': 'Saez-Llorens'}, {'given': 'R F', 'family': 'Vergara'}, {'given': 'T', 'family': 'Vesikari'}, {'given': 'A', 'family': 'Bouckenooghe'}, {'given': 'R', 'family': 'Clemens'}, {'given': 'B', 'family': 'De Vos'}, {'given': 'M', 'family': "O'Ryan"}, {'given': 'Group', 'family': 'Human Rotavirus Vaccine Study'}], 'abstract': 'BACKGROUND: The safety and efficacy of an attenuated G1P[8] human rotavirus (HRV) vaccine were tested in a randomized, double-blind, phase 3 trial. METHODS: We studied 63,225 healthy infants from 11 Latin American countries and Finland who received two oral doses of either the HRV vaccine (31,673 infants) or placebo (31,552 infants) at approximately two months and four months of age. Severe gastroenteritis episodes were identified by active surveillance. The severity of disease was graded with the use of the 20-point Vesikari scale. Vaccine efficacy was evaluated in a subgroup of 20,169 infants (10,159 vaccinees and 10,010 placebo recipients). RESULTS: The efficacy of the vaccine against severe rotavirus gastroenteritis and against rotavirus-associated hospitalization was 85 percent (P<0.001 for the comparison with placebo) and reached 100 percent against more severe rotavirus gastroenteritis. Hospitalization for diarrhea of any cause was reduced by 42 percent (95 percent confidence interval, 29 to 53 percent; P<0.001). During the 31-day window after each dose, six vaccine recipients and seven placebo recipients had definite intussusception (difference in risk, -0.32 per 10,000 infants; 95 percent confidence interval, -2.91 to 2.18; P=0.78). CONCLUSIONS: Two oral doses of the live attenuated G1P[8] HRV vaccine were highly efficacious in protecting infants against severe rotavirus gastroenteritis, significantly reduced the rate of severe gastroenteritis from any cause, and were not associated with an increased risk of intussusception. (ClinicalTrials.gov numbers, NCT00139347 and NCT00263666.)', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '16394298', 'scopus': '2-s2.0-30044438810', 'doi': '10.1056/NEJMoa052434'}, 'title': 'Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis', 'source': 'Mendeley'}
Salinas B, Pérez Schael I, Linhares AC, Ruiz Palacios GM, Guerrero ML, Yarzábal JP, Cervantes Y, Costa Clemens S, Damaso S, Hardt K, De Vos B. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: A randomized, placebo-controlled trial in Latin American infants. The Pediatric infectious disease journal. 2005;24(9):807-16.	-	16148848	primary-study	ee95ff456fe34290138f4e210b2abd721086b800	-	{'publication_type': {'year': 2005, 'cited_medium': None, 'issue': '9', 'issn': '0891-3668', 'volume': '24', 'title': 'The Pediatric Infectious Disease Journal', 'pagination': '807-816'}, 'language': None, 'rating': {'year': 0, 'title': 1.0, 'total': 0.8568181818181819, 'authors': 0.8272727272727274}, 'authors': [{'given': 'B??len', 'family': 'Salinas'}, {'given': 'Irene P??rez', 'family': 'Schael'}, {'given': 'Alexandre C.', 'family': 'Linhares'}, {'given': 'Guillermo M.', 'family': 'Ruiz Palacios'}, {'given': 'M Lourdes', 'family': 'Guerrero'}, {'given': 'Juan Pablo', 'family': 'Yarz??bal'}, {'given': 'Yolanda', 'family': 'Cervantes'}, {'given': 'SueAnn Costa', 'family': 'Clemens'}, {'given': 'Silvia', 'family': 'Damaso'}, {'given': 'Karin', 'family': 'Hardt'}, {'given': 'B??atrice', 'family': 'De Vos'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1097/01.inf.0000178294.13954.a1'}, 'title': 'Evaluation of Safety, Immunogenicity and Efficacy of an Attenuated Rotavirus Vaccine, RIX4414', 'source': 'CrossRef'}
Salinas B, Pérez Schael I, Linhares AC, Ruiz Palacios GM, Guerrero ML, Yarzábal JP, Cervantes Y, Costa Clemens S, Damaso S, Hardt K, De Vos B. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: A randomized, placebo-controlled trial in Latin American infants. The Pediatric infectious disease journal. 2005;24(9):807-16.	-	16148848	primary-study	ee95ff456fe34290138f4e210b2abd721086b800	-	{'publication_type': {'year': 2005, 'cited_medium': None, 'issue': None, 'issn': '0891-3668', 'volume': None, 'title': 'The Pediatric infectious disease journal', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 0.9772727272727273, 'authors': 0.9090909090909093}, 'authors': [{'given': 'Bélen', 'family': 'Salinas'}, {'given': 'Irene', 'family': 'Pérez Schael'}, {'given': 'Alexandre C', 'family': 'Linhares'}, {'given': 'Guillermo M', 'family': 'Ruiz Palacios'}, {'given': 'M Lourdes', 'family': 'Guerrero'}, {'given': 'Juan Pablo', 'family': 'Yarzábal'}, {'given': 'Yolanda', 'family': 'Cervantes'}, {'given': 'SueAnn', 'family': 'Costa Clemens'}, {'given': 'Silvia', 'family': 'Damaso'}, {'given': 'Karin', 'family': 'Hardt'}, {'given': 'Béatrice', 'family': 'De Vos'}], 'abstract': "BACKGROUND: A live attenuated monovalent rotavirus vaccine RIX4414 was developed with a human strain of G1P1A P[8] specificity to reduce the rotavirus burden in children. METHODS: A double blind, randomized, placebo-controlled study evaluated the efficacy, immunogenicity, safety and reactogenicity of 2 oral doses of RIX4414 (10(4.7), 10(5.2) or 10(5.8) focus-forming units) at 2 and 4 months coadministered with routine vaccinations and oral poliovirus vaccine given for study purposes at least 14 days apart. The 2155 infants (1618 vaccine/537 placebo) enrolled in Brazil, Mexico and Venezuela were followed until 1 year of age. RESULTS: Antirotavirus IgA seroconversion rates 2 months after dose 2 ranged between 61% (10(4.7) ffu group) and 65% (10(5.8) ffu group), and most of the infants had seroprotective levels of antibodies to coadministered routine vaccinations. The reactogenicity profile of RIX4414 was similar to that of the placebo, and no vaccination-related serious adverse events were reported. Protective efficacy against severe and any rotavirus gastroenteritis from 15 days post-dose 2 was highest in the 10(5.8) ffu group [86%; 95% confidence interval (95% CI), 63-96% and 70% (95% CI 46-84%), P < 0.001, 2-sided Fisher's exact test]. The efficacy against hospitalization was 79% (95% CI 48-92%) for pooled vaccine groups. Multiple rotavirus serotypes [G1 (50%), G9 (40%), G2, G3 and G4] were identified from gastroenteritis stools (enzyme-linked immunosorbent assay and reverse transcription-polymerase chain reaction) during the study period. For severe gastroenteritis caused by G9 serotypes, the protection reached 77% (95% CI 18-96%) in the 10(5.8) ffu group, providing proof of concept that the monovalent G1P1A P[8] human rotavirus vaccine elicits cross-protection against the G9 strain. A reduction in any and severe rotavirus gastroenteritis was already observed at post-dose 1 (period: day of dose 1 to 14 days post-dose 2) in vaccinees compared with placebo recipients. CONCLUSIONS: Two doses of RIX4414 are highly efficacious, providing cross-protection (G1 and G9 strains, prevalent during this study) and early protection against any and severe rotavirus gastroenteritis and hospitalization to infants in Latin America.", 'type': 'journal', 'ids': {'embase': None, 'pubmed': '16148848', 'scopus': '2-s2.0-24944583986', 'doi': '10.1097/01.inf.0000178294.13954.a1'}, 'title': 'Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: A randomized, placebo-controlled trial in Latin American infants.', 'source': 'Mendeley'}
Dennehy PH. A short report on the highlights of world-wide development of RIX4414: a North American experience comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccine (RIX4414) in infants in the United States and Canada. Vaccine. 2006;24(18):3780-1.	10.1016/j.vaccine.2005.07.030	16111790	primary-study	0a0ba8fd7847d9ebfdb395d1307eb0b125572ab8	-	{'publication_type': {'year': 2006, 'cited_medium': None, 'issue': '18', 'issn': '0264-410X', 'volume': '24', 'title': 'Vaccine', 'pagination': '3780-3781'}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 0.975, 'authors': 0.9}, 'authors': [{'given': 'Penelope H.', 'family': 'Dennehy'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '16111790', 'scopus': None, 'doi': '10.1016/j.vaccine.2005.07.030'}, 'title': 'A short report on the highlights of world-wide development of RIX4414: a North American experience', 'source': 'CrossRef'}
Dennehy PH. A short report on the highlights of world-wide development of RIX4414: a North American experience comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccine (RIX4414) in infants in the United States and Canada. Vaccine. 2006;24(18):3780-1.	10.1016/j.vaccine.2005.07.030	16111790	primary-study	0a0ba8fd7847d9ebfdb395d1307eb0b125572ab8	-	{'publication_type': {'year': 2006, 'cited_medium': None, 'issue': None, 'issn': '0264410X', 'volume': None, 'title': 'Vaccine', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 0.9285714285714286, 'total': 0.7035714285714286, 'authors': 0.0}, 'authors': [{'given': 'A. C.', 'family': 'Linhares'}, {'given': 'G. M.', 'family': 'Ruiz-Palacios'}, {'given': 'M. L.', 'family': 'Guerrero'}, {'given': 'B.', 'family': 'Salinas'}, {'given': 'I.', 'family': 'Perez-Schael'}, {'given': 'S. A Costa', 'family': 'Clemens'}, {'given': 'B.', 'family': 'Innis'}, {'given': 'J. P.', 'family': 'Yarzabal'}, {'given': 'G.', 'family': 'Vespa'}, {'given': 'Y.', 'family': 'Cervantes'}, {'given': 'K.', 'family': 'Hardt'}, {'given': 'B. De', 'family': 'Vos'}], 'abstract': 'An oral, human-derived monovalent (G1P1A) rotavirus vaccine, strain RIX4414, has been developed by GlaxoSmithKline, Rixensart, Belgium. The safety, immunogenicity and efficacy of this vaccine were evaluated in a randomized, double-blind, placebo-controlled, phase IIb trial conducted in Brazil, Mexico and Venezuela. Healthy infants were given two doses of vaccine (104.7, 105.2 or 105.8 ffu) or placebo at age 2 and 4 months, with routine DTPw-HBV and Hib vaccines. OPV was given separately, at least 2 weeks before or after administration of the study vaccine. A total of 2155 infants were enrolled, of whom 1618 received one of the three vaccine viral concentrations and 537 were given placebo. Analysis of efficacy included diarrheal episodes occurring from 2 weeks after second dose until one year of age. Efficacy rates against any rotavirus gastroenteritis, severe rotavirus gastroenteritis and hospitalizations for rotavirus disease were as high as 70% (46-84%; 95%CI), 86% (63-96%; 95%CI), and 93% (54-100%; 95%CI), respectively. For non-G1 (mainly G9) serotypes, RIX4414 vaccine conferred protection as high as 83% (40-97%; 95%CI) against severe gastroenteritis. A decrease was noted in the incidence of severe rotavirus-related gastroenteritis after first dose. It is demonstrated that two doses of RIX4414 are highly efficacious against severe rotavirus gastroenteritis and hospitalization, including disease caused by non-G1 strains, namely G9 serotypes. ?? 2005.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '16600443', 'scopus': '2-s2.0-33646471531', 'doi': '10.1016/j.vaccine.2005.07.027'}, 'title': 'A short report on highlights of world-wide development of RIX4414: A Latin American experience', 'source': 'Mendeley'}
Linhares AC, Ruiz-Palacios GM, Guerrero ML, Salinas B, Perez-Schael I, Clemens SA, Innis B, Yarzabal JP, Vespa G, Cervantes Y, Hardt K, De Vos B. A short report on highlights of world-wide development of RIX4414: a Latin American experience. Vaccine. 2006;24(18):3784-5.	10.1016/j.vaccine.2005.07.027	16098636	primary-study	f50627a99ef3e52829a82cf605ac77827e96548d	-	{'publication_type': {'year': 2006, 'cited_medium': None, 'issue': '18', 'issn': '0264-410X', 'volume': '24', 'title': 'Vaccine', 'pagination': '3784-3785'}, 'language': None, 'rating': {'year': 1, 'title': 1.0, 'total': 0.9604166666666667, 'authors': 0.8416666666666668}, 'authors': [{'given': 'A.C.', 'family': 'Linhares'}, {'given': 'G.M.', 'family': 'Ruiz-Palacios'}, {'given': 'M.L.', 'family': 'Guerrero'}, {'given': 'B.', 'family': 'Salinas'}, {'given': 'I.', 'family': 'Perez-Schael'}, {'given': 'S.A. Costa', 'family': 'Clemens'}, {'given': 'B.', 'family': 'Innis'}, {'given': 'J.P.', 'family': 'Yarzabal'}, {'given': 'G.', 'family': 'Vespa'}, {'given': 'Y.', 'family': 'Cervantes'}, {'given': 'K.', 'family': 'Hardt'}, {'given': 'B. De', 'family': 'Vos'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '16098636', 'scopus': None, 'doi': '10.1016/j.vaccine.2005.07.027'}, 'title': 'A short report on highlights of world-wide development of RIX4414: A Latin American experience', 'source': 'CrossRef'}
Linhares AC, Ruiz-Palacios GM, Guerrero ML, Salinas B, Perez-Schael I, Clemens SA, Innis B, Yarzabal JP, Vespa G, Cervantes Y, Hardt K, De Vos B. A short report on highlights of world-wide development of RIX4414: a Latin American experience. Vaccine. 2006;24(18):3784-5.	10.1016/j.vaccine.2005.07.027	16098636	primary-study	f50627a99ef3e52829a82cf605ac77827e96548d	-	{'publication_type': {'year': 2006, 'cited_medium': None, 'issue': None, 'issn': '0264410X', 'volume': None, 'title': 'Vaccine', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 1.0, 'total': 0.9604166666666667, 'authors': 0.8416666666666668}, 'authors': [{'given': 'A. C.', 'family': 'Linhares'}, {'given': 'G. M.', 'family': 'Ruiz-Palacios'}, {'given': 'M. L.', 'family': 'Guerrero'}, {'given': 'B.', 'family': 'Salinas'}, {'given': 'I.', 'family': 'Perez-Schael'}, {'given': 'S. A Costa', 'family': 'Clemens'}, {'given': 'B.', 'family': 'Innis'}, {'given': 'J. P.', 'family': 'Yarzabal'}, {'given': 'G.', 'family': 'Vespa'}, {'given': 'Y.', 'family': 'Cervantes'}, {'given': 'K.', 'family': 'Hardt'}, {'given': 'B. De', 'family': 'Vos'}], 'abstract': 'An oral, human-derived monovalent (G1P1A) rotavirus vaccine, strain RIX4414, has been developed by GlaxoSmithKline, Rixensart, Belgium. The safety, immunogenicity and efficacy of this vaccine were evaluated in a randomized, double-blind, placebo-controlled, phase IIb trial conducted in Brazil, Mexico and Venezuela. Healthy infants were given two doses of vaccine (104.7, 105.2 or 105.8 ffu) or placebo at age 2 and 4 months, with routine DTPw-HBV and Hib vaccines. OPV was given separately, at least 2 weeks before or after administration of the study vaccine. A total of 2155 infants were enrolled, of whom 1618 received one of the three vaccine viral concentrations and 537 were given placebo. Analysis of efficacy included diarrheal episodes occurring from 2 weeks after second dose until one year of age. Efficacy rates against any rotavirus gastroenteritis, severe rotavirus gastroenteritis and hospitalizations for rotavirus disease were as high as 70% (46-84%; 95%CI), 86% (63-96%; 95%CI), and 93% (54-100%; 95%CI), respectively. For non-G1 (mainly G9) serotypes, RIX4414 vaccine conferred protection as high as 83% (40-97%; 95%CI) against severe gastroenteritis. A decrease was noted in the incidence of severe rotavirus-related gastroenteritis after first dose. It is demonstrated that two doses of RIX4414 are highly efficacious against severe rotavirus gastroenteritis and hospitalization, including disease caused by non-G1 strains, namely G9 serotypes. ?? 2005.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '16600443', 'scopus': '2-s2.0-33646471531', 'doi': '10.1016/j.vaccine.2005.07.027'}, 'title': 'A short report on highlights of world-wide development of RIX4414: A Latin American experience', 'source': 'Mendeley'}
Phua KB, Quak SH, Lee BW, Emmanuel SC, Goh P, Han HH, De Vos B, Bock HL. Evaluation of RIX4414, a live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean infants. The Journal of infectious diseases. 2005;192 Suppl 1:S6-S16.	10.1086/431511	16088807	primary-study	b8ddc13aa481dee8c9a1275cf69d53b61bdf0473	-	{'publication_type': {'year': 2005, 'cited_medium': None, 'issue': 's1', 'issn': '0022-1899', 'volume': '192', 'title': 'The Journal of Infectious Diseases', 'pagination': 'S6-S16'}, 'language': None, 'rating': {'year': 0, 'title': 0.9, 'total': 0.81, 'authors': 0.9000000000000001}, 'authors': [{'given': 'Kong\xa0Boo', 'family': 'Phua'}, {'given': 'Seng\xa0Hock', 'family': 'Quak'}, {'given': 'Bee\xa0Wah', 'family': 'Lee'}, {'given': 'Shanta\xa0Christina', 'family': 'Emmanuel'}, {'given': 'Paul', 'family': 'Goh'}, {'given': 'Htay\xa0Htay', 'family': 'Han'}, {'given': 'Beatrice', 'family': 'De\xa0Vos'}, {'given': 'Hans\xa0Ludwig', 'family': 'Bock'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '16088807', 'scopus': None, 'doi': '10.1086/431511'}, 'title': 'Evaluation of RIX4414, A Live, Attenuated Rotavirus Vaccine, in a Randomized, Double‐Blind, Placebo‐Controlled Phase 2 Trial Involving 2464 Singaporean Infants', 'source': 'CrossRef'}
Phua KB, Quak SH, Lee BW, Emmanuel SC, Goh P, Han HH, De Vos B, Bock HL. Evaluation of RIX4414, a live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean infants. The Journal of infectious diseases. 2005;192 Suppl 1:S6-S16.	10.1086/431511	16088807	primary-study	b8ddc13aa481dee8c9a1275cf69d53b61bdf0473	-	{'publication_type': {'year': 2005, 'cited_medium': None, 'issue': None, 'issn': '0022-1899', 'volume': None, 'title': 'The Journal of infectious diseases', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 0.975, 'authors': 0.9000000000000001}, 'authors': [{'given': 'Kong Boo', 'family': 'Phua'}, {'given': 'Seng Hock', 'family': 'Quak'}, {'given': 'Bee Wah', 'family': 'Lee'}, {'given': 'Shanta Christina', 'family': 'Emmanuel'}, {'given': 'Paul', 'family': 'Goh'}, {'given': 'Htay Htay', 'family': 'Han'}, {'given': 'Beatrice', 'family': 'De Vos'}, {'given': 'Hans Ludwig', 'family': 'Bock'}], 'abstract': 'BACKGROUND: At present, no rotavirus vaccine is commercially available for use worldwide. Hence, a live, attenuated monovalent vaccine was developed with human strain RIX4414 (G1P1A P[8] specificity). Vaccination trials involving infants are ongoing in developed and developing countries. METHODS: This study was a randomized, double-blind, placebo-controlled trial conducted at pediatric hospitals and polyclinics in Singapore for the evaluation of the immunogenicity, reactogenicity, and efficacy of 2 oral doses of RIX4414. In total, 2464 healthy infants (who were 11-17 weeks old when the first dose was administered, which is in accordance with the local immunization schedule) were enrolled to receive RIX4414 at 3 concentrations of virus (10(4.7), 10(5.2), or 10(6.1) focus-forming units) or placebo at 1-month intervals, concomitantly with routinely administered infant vaccines. RESULTS: The RIX4414 vaccine was highly immunogenic, and virtually all vaccine recipients (98%-100%) experienced "vaccine take" (i.e., a combined immunogenicity end point based on seroconversion and/or shedding of RIX4414 in postvaccination stool samples) after receipt of 2 doses at all 3 dosage levels. Depending on the virus concentration, the anti-rotavirus IgA seroconversion rate varied from 76% (95% confidence interval [CI], 68%-83%) to 91% (95% CI, 85%-95%). Two doses of RIX4414 were well tolerated, with no increase in high fever, severe diarrhea, or vomiting after either dose or with increased viral concentration, compared with placebo. There was no observed interference with routine vaccinations of infants when RIX4414 was coadministered. The calculated efficacy of RIX4414 against rotavirus gastroenteritis was 82% (P = .046); however, this result was considered to be of limited conclusive value because of the low number of rotavirus gastroenteritis episodes identified during the follow-up period. CONCLUSIONS: The live, attenuated rotavirus vaccine (RIX4414) was well tolerated and highly immunogenic in Singaporean infants. The immunogenicity of routinely administered infant vaccines was not impaired by concomitant administration of RIX4414 vaccine.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '16088807', 'scopus': '2-s2.0-23944484057', 'doi': '10.1086/431511'}, 'title': 'Evaluation of RIX4414, a live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean infants.', 'source': 'Mendeley'}
Dennehy PH, Brady RC, Halperin SA, Ward RL, Alvey JC, Fischer FH, Innis BL, Rathfon H, Schuind A, De Vos B. Comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccine. The Pediatric infectious disease journal. 2005;24(6):481-8.	-	15933555	primary-study	3fce385b9bf8c239d6f06418ddf47d834c6a4850	-	{'publication_type': {'year': 2005, 'cited_medium': None, 'issue': '6', 'issn': '0891-3668', 'volume': '24', 'title': 'The Pediatric Infectious Disease Journal', 'pagination': '481-488'}, 'language': None, 'rating': {'year': 0, 'title': 1.0, 'total': 0.8675, 'authors': 0.8700000000000001}, 'authors': [{'given': 'Penelope H.', 'family': 'Dennehy'}, {'given': 'Rebecca C.', 'family': 'Brady'}, {'given': 'Scott A.', 'family': 'Halperin'}, {'given': 'Richard L.', 'family': 'Ward'}, {'given': 'Justin C.', 'family': 'Alvey'}, {'given': 'Francis H.', 'family': 'Fischer'}, {'given': 'Bruce L.', 'family': 'Innis'}, {'given': 'Hal', 'family': 'Rathfon'}, {'given': 'Anne', 'family': 'Schuind'}, {'given': 'Beatrice', 'family': 'De Vos'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1097/01.inf.0000164763.55558.71'}, 'title': 'Comparative Evaluation of Safety and Immunogenicity of Two Dosages of an Oral Live Attenuated Human Rotavirus Vaccine', 'source': 'CrossRef'}
Dennehy PH, Brady RC, Halperin SA, Ward RL, Alvey JC, Fischer FH, Innis BL, Rathfon H, Schuind A, De Vos B. Comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccine. The Pediatric infectious disease journal. 2005;24(6):481-8.	-	15933555	primary-study	3fce385b9bf8c239d6f06418ddf47d834c6a4850	-	{'publication_type': {'year': 1996, 'cited_medium': None, 'issue': None, 'issn': '0891-3668 (Print)', 'volume': None, 'title': 'The Pediatric infectious disease journal', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 0.7142857142857143, 'total': 0.6601190476190476, 'authors': 0.3833333333333333}, 'authors': [{'given': 'P H', 'family': 'Dennehy'}, {'given': 'G C Jr', 'family': 'Rodgers'}, {'given': 'R L', 'family': 'Ward'}, {'given': 'A J', 'family': 'Markwick'}, {'given': 'M', 'family': 'Mack'}, {'given': 'E T', 'family': 'Zito'}], 'abstract': 'OBJECTIVE: To compare the safety and immunogenicity of two dosages of tetravalent rhesus rotavirus vaccine (RRV-TV) and the effect of age at dosing. METHODS: A total of 195 infants were stratified by age into 2 groups, 6 to 12 weeks and 16 to 24 weeks, and randomly assigned to receive a single dose of placebo or RRV-TV containing either 4 x 10(5) or 4 x 10(6) plaque-forming units (pfu). Symptoms were recorded for 5 days after vaccination. Anti-rotavirus IgA and neutralizing antibody to human rotavirus serotypes G1 to G4 and RRV were measured in serum obtained pre- and postvaccination. RESULTS: Rates of fever > 38 degrees C (9%), diarrhea (6%) and vomiting (8%) were similar in all groups. IgA (69% vs. 49%, P = 0.02) and RRV (85% vs. 66%, P = 0.004) seroconversion rates were significantly higher in the 4 x 10(6) pfu vaccine group as were antibody titers to RRV (440.2 vs. 263.7, P = 0.04). Older infants demonstrated significantly higher seroconversion rates and antibody titers for IgA (71% vs. 52%, P = 0.03; and 110.6 vs. 54.8, P = 0.004) and RRV (92% vs. 66%, P = 0.05 and 498.3 vs. 205.6, P = 0.01) at either dose level than did the younger infants. There were no significant differences in seroconversion rates or antibody titers to human rotavirus types G1 to G4 between the two vaccination groups. CONCLUSIONS: RRV-TV at a dose of 4 x 10(6) pfu can be safely administered to infants 6 to 24 weeks of age. A single dose of 4 x 10(6) pfu of RRV-TV was significantly more immunogenic than a single dose of 4 x 10(5) pfu but did not improve responses to the human serotypes. Older vaccine recipients demonstrated significantly higher IgA and neutralizing antibody seroconversion rates and antibody titers than younger infants independent of dosage.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '8933551', 'scopus': '2-s2.0-10544227758', 'doi': '10.1097/00006454-199611000-00016'}, 'title': 'Comparative evaluation of reactogenicity and immunogenicity of two dosages of oral tetravalent rhesus rotavirus vaccine. US Rhesus Rotavirus Vaccine Study Group.', 'source': 'Mendeley'}
Vesikari T, Karvonen A, Puustinen L, Zeng SQ, Szakal ED, Delem A, De Vos B. Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants. The Pediatric infectious disease journal. 2004;23(10):937-43.	-	15602194	primary-study	34504dc40b8b277624a227784f6c5a39d57bb35d	-	{'publication_type': {'year': 2004, 'cited_medium': None, 'issue': '10', 'issn': '0891-3668', 'volume': '23', 'title': 'The Pediatric Infectious Disease Journal', 'pagination': '937-943'}, 'language': None, 'rating': {'year': 0, 'title': 1.0, 'total': 0.8785714285714286, 'authors': 0.9142857142857144}, 'authors': [{'given': 'Timo', 'family': 'Vesikari'}, {'given': 'Aino', 'family': 'Karvonen'}, {'given': 'Leena', 'family': 'Puustinen'}, {'given': 'Shang-Qin', 'family': 'Zeng'}, {'given': 'Evelyn Dora', 'family': 'Szakal'}, {'given': 'Andrée', 'family': 'Delem'}, {'given': 'Beatrice', 'family': 'De Vos'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1097/01.inf.0000141722.10130.50'}, 'title': 'Efficacy of RIX4414 Live Attenuated Human Rotavirus Vaccine in Finnish Infants', 'source': 'CrossRef'}
Vesikari T, Karvonen A, Puustinen L, Zeng SQ, Szakal ED, Delem A, De Vos B. Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants. The Pediatric infectious disease journal. 2004;23(10):937-43.	-	15602194	primary-study	34504dc40b8b277624a227784f6c5a39d57bb35d	-	{'publication_type': {'year': 2004, 'cited_medium': None, 'issue': None, 'issn': '0891-3668', 'volume': None, 'title': 'The Pediatric infectious disease journal', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 0.9785714285714285, 'authors': 0.9142857142857144}, 'authors': [{'given': 'Timo', 'family': 'Vesikari'}, {'given': 'Aino', 'family': 'Karvonen'}, {'given': 'Leena', 'family': 'Puustinen'}, {'given': 'Shang-Qin', 'family': 'Zeng'}, {'given': 'Evelyn Dora', 'family': 'Szakal'}, {'given': 'Andrée', 'family': 'Delem'}, {'given': 'Beatrice', 'family': 'De Vos'}], 'abstract': 'BACKGROUND: Rotavirus gastroenteritis, a major cause of mortality and morbidity worldwide, is a vaccine-preventable disease. New safe and effective candidate rotavirus vaccines are needed to replace the withdrawn rhesus rotavirus-based oral vaccine. METHODS: We evaluated a monovalent human rotavirus vaccine, serotype G1, strain RIX4414, for efficacy, immunogenicity and safety in a randomized, double blind, placebo-controlled trial in Finland. We randomly allocated 405 healthy infants to receive 2 doses of vaccine or placebo (ratio 2:1) at approximately 2 and 4 months of age. The infants were followed during 2 rotavirus epidemic seasons (2000-2002) for acute gastroenteritis. Rotaviruses in diarrheal stool samples were primarily detected by enzyme-linked immunosorbent assay and confirmed and G-typed by reverse transciption-polymerase chain reaction. RESULTS: The vaccine was well-tolerated. No vaccine-related serious adverse events were observed during the study period. Rotavirus IgA (enzyme-linked immunosorbent assay) seroconversion rate was 80% after 2 doses. Thirty-eight cases of rotavirus gastroenteritis were detected during the entire follow-up period; 35 of these were of the G1 type. RIX4414 vaccine significantly decreased the occurrence of any rotavirus compared with placebo. Efficacy during the first rotavirus epidemic season was 73% [95% confidence interval (95% CI), 27-91%] and 90% (95% CI 10-100%) against any and severe rotavirus gastroenteritis, respectively, and during the entire follow-up period 72% (95% CI 42-87%) against any and 85% (95% CI 42-97%) against severe rotavirus gastroenteritis (P < 0.05 for all comparisons). CONCLUSIONS: RIX4414 strain of G1 human rotavirus vaccine was well-tolerated, immunogenic and efficacious in infants against rotavirus gastroenteritis during a 2-year period. To further increase vaccine "take" and efficacy, a higher dose of this vaccine may be considered for future efficacy trials.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '15602194', 'scopus': '2-s2.0-16544366154', 'doi': '10.1097/01.inf.0000141722.10130.50'}, 'title': 'Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants.', 'source': 'Mendeley'}
De Vos B, Vesikari T, Linhares AC, Salinas B, Pérez-Schael I, Ruiz-Palacios GM, Guerrero Mde L, Phua KB, Delem A, Hardt K. A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis. The Pediatric infectious disease journal. 2004;23(10 Suppl):S179-82.	-	15502699	primary-study	35f4b6e79e4398884922ec6960180c0b6f928edc	-	{'publication_type': {'year': 2004, 'cited_medium': None, 'issue': 'Supplement', 'issn': '0891-3668', 'volume': '23', 'title': 'The Pediatric Infectious Disease Journal', 'pagination': 'S179-S182'}, 'language': None, 'rating': {'year': 0, 'title': 1.0, 'total': 0.855, 'authors': 0.8200000000000001}, 'authors': [{'given': 'Beatrice', 'family': 'De Vos'}, {'given': 'Timo', 'family': 'Vesikari'}, {'given': 'Alexandre C.', 'family': 'Linhares'}, {'given': 'Bel??n', 'family': 'Salinas'}, {'given': 'Irene', 'family': 'P??rez-Schael'}, {'given': 'Guillermo M.', 'family': 'Ruiz-Palacios'}, {'given': 'Maria de Lourdes', 'family': 'Guerrero'}, {'given': 'Kong Boo', 'family': 'Phua'}, {'given': 'Andr??e', 'family': 'Delem'}, {'given': 'Karin', 'family': 'Hardt'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1097/01.inf.0000142370.16514.4a'}, 'title': 'A Rotavirus Vaccine for Prophylaxis of Infants Against Rotavirus Gastroenteritis', 'source': 'CrossRef'}
De Vos B, Vesikari T, Linhares AC, Salinas B, Pérez-Schael I, Ruiz-Palacios GM, Guerrero Mde L, Phua KB, Delem A, Hardt K. A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis. The Pediatric infectious disease journal. 2004;23(10 Suppl):S179-82.	-	15502699	primary-study	35f4b6e79e4398884922ec6960180c0b6f928edc	-	{'publication_type': {'year': 2004, 'cited_medium': None, 'issue': None, 'issn': '0891-3668', 'volume': None, 'title': 'The Pediatric infectious disease journal', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 0.9775, 'authors': 0.9100000000000001}, 'authors': [{'given': 'Beatrice', 'family': 'De Vos'}, {'given': 'Timo', 'family': 'Vesikari'}, {'given': 'Alexandre C', 'family': 'Linhares'}, {'given': 'Belén', 'family': 'Salinas'}, {'given': 'Irene', 'family': 'Pérez-Schael'}, {'given': 'Guillermo M', 'family': 'Ruiz-Palacios'}, {'given': 'Maria De Lourdes', 'family': 'Guerrero'}, {'given': 'Kong Boo', 'family': 'Phua'}, {'given': 'Andrée', 'family': 'Delem'}, {'given': 'Karin', 'family': 'Hardt'}], 'abstract': 'The need for safe and effective vaccines to reduce morbidity and mortality caused by rotavirus gastroenteritis in children is well-known. A live attenuated monovalent rotavirus vaccine (Rotarix) containing human rotavirus strain RIX4414 of G1P1A P[8] specificity is being developed to meet the global need. An overview of RIX4414 trials in developed and developing settings is presented for 3 selected trials conducted in Finland (pilot study), Latin America (Brazil, Mexico and Venezuela) and Singapore involving 5024 infants. The vaccine was well-tolerated, with no increase in any solicited symptoms as compared with the placebo. After 2 doses, 61-91% of vaccinated infants developed rotavirus-specific IgA antibodies. There was no interference with immunogenicity of coadministered routine pediatric vaccines. Rotarix significantly reduced rotavirus gastroenteritis episodes and rotavirus-related hospitalizations in vaccinated infants compared with placebo recipients (P < 0.05). Vaccine efficacy was observed against severe rotavirus gastroenteritis caused by G1 and non-G1 types including the emerging G9 type (P < 0.05) in Latin America. These results show prospects for widespread use of Rotarix to reduce rotavirus disease burden and warrant continued worldwide evaluation.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '15502699', 'scopus': '2-s2.0-16544377711', 'doi': '10.1097/01.inf.0000142370.16514.4a'}, 'title': 'A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis.', 'source': 'Mendeley'}
Vesikari T, Karvonen A, Korhonen T, Espo M, Lebacq E, Forster J, Zepp F, Delem A, De Vos B. Safety and immunogenicity of RIX4414 live attenuated human rotavirus vaccine in adults, toddlers and previously uninfected infants. Vaccine. 2004;22(21-22):2836-42.	10.1016/j.vaccine.2004.01.044	15246619	primary-study	51f08d496f505a0685d2002b11c189c559a620f6	-	{'publication_type': {'year': 2004, 'cited_medium': None, 'issue': '21-22', 'issn': '0264-410X', 'volume': '22', 'title': 'Vaccine', 'pagination': '2836-2842'}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 1.0, 'authors': 1.0}, 'authors': [{'given': 'T', 'family': 'Vesikari'}, {'given': 'A', 'family': 'Karvonen'}, {'given': 'T', 'family': 'Korhonen'}, {'given': 'M', 'family': 'Espo'}, {'given': 'E', 'family': 'Lebacq'}, {'given': 'J', 'family': 'Forster'}, {'given': 'F', 'family': 'Zepp'}, {'given': 'A', 'family': 'Delem'}, {'given': 'B', 'family': 'De Vos'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '15246619', 'scopus': None, 'doi': '10.1016/j.vaccine.2004.01.044'}, 'title': 'Safety and immunogenicity of RIX4414 live attenuated human rotavirus vaccine in adults, toddlers and previously uninfected infants', 'source': 'CrossRef'}
Vesikari T, Karvonen A, Korhonen T, Espo M, Lebacq E, Forster J, Zepp F, Delem A, De Vos B. Safety and immunogenicity of RIX4414 live attenuated human rotavirus vaccine in adults, toddlers and previously uninfected infants. Vaccine. 2004;22(21-22):2836-42.	10.1016/j.vaccine.2004.01.044	15246619	primary-study	51f08d496f505a0685d2002b11c189c559a620f6	-	{'publication_type': {'year': 2004, 'cited_medium': None, 'issue': None, 'issn': '0264410X', 'volume': None, 'title': 'Vaccine', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 0.9666666666666667, 'authors': 0.8666666666666667}, 'authors': [{'given': 'T.', 'family': 'Vesikari'}, {'given': 'A.', 'family': 'Karvonen'}, {'given': 'T.', 'family': 'Korhonen'}, {'given': 'M.', 'family': 'Espo'}, {'given': 'E.', 'family': 'Lebacq'}, {'given': 'J.', 'family': 'Forster'}, {'given': 'F.', 'family': 'Zepp'}, {'given': 'A.', 'family': 'Delem'}, {'given': 'B.', 'family': 'De Vos'}], 'abstract': 'A live attenuated human rotavirus (HRV) vaccine, strain RIX4414, was tested sequentially in adults, previously infected toddlers, and previously uninfected infants. A single dose was given to adults and toddlers and found well tolerated. Next, a dose ranging (three different viral concentrations) safety and immunogenicity study was conducted in rotavirus IgA antibody negative infants (N=192), who received two doses of RIX4414 vaccine or placebo at 2 and 4 months of age. No side effects were seen after vaccination. Specifically, administration of RIX4414 vaccine was not temporally associated with fever, diarrhea, or increase in liver transaminases. Rotavirus IgA seroconversion ranged from 50 to 88% after one dose and from 73 to 96% after two doses, depending on vaccine titer. After the first dose, on days 7-9 post vaccination, between 38 and 60% of the infants shed the vaccine virus, whereas after the second dose only 0 to 13% of the vaccinees shed the vaccine virus. It is concluded that RIX4414 strain HRV vaccine is virtually non-reactogenic and, at high titer, highly immunogenic in susceptible infants. © 2004 Elsevier Ltd. All rights reserved.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '15246619', 'scopus': '2-s2.0-3142570744', 'doi': '10.1016/j.vaccine.2004.01.044'}, 'title': 'Safety and immunogenicity of RIX4414 live attenuated human rotavirus vaccine in adults, toddlers and previously uninfected infants', 'source': 'Mendeley'}
Clark HF, Bernstein DI, Dennehy PH, Offit P, Pichichero M, Treanor J, Ward RL, Krah DL, Shaw A, Dallas MJ, Laura D, Eiden JJ, Ivanoff N, Kaplan KM, Heaton P. Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants. The Journal of pediatrics. 2004;144(2):184-90.	10.1016/j.jpeds.2003.10.054	14760258	primary-study	ac7b2a7cd46be1d336de969cbf23e9c58d9f0b0a	-	{'publication_type': {'year': 2004, 'cited_medium': None, 'issue': '2', 'issn': '0022-3476', 'volume': '144', 'title': 'The Journal of Pediatrics', 'pagination': '184-190'}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.8766666666666667, 'authors': 0.9066666666666668}, 'authors': [{'given': 'H.Fred', 'family': 'Clark'}, {'given': 'David I', 'family': 'Bernstein'}, {'given': 'Penelope H', 'family': 'Dennehy'}, {'given': 'Paul', 'family': 'Offit'}, {'given': 'Michael', 'family': 'Pichichero'}, {'given': 'John', 'family': 'Treanor'}, {'given': 'Richard L', 'family': 'Ward'}, {'given': 'David L', 'family': 'Krah'}, {'given': 'Alan', 'family': 'Shaw'}, {'given': 'Michael J', 'family': 'Dallas'}, {'given': 'Digilio', 'family': 'Laura'}, {'given': 'Joseph J', 'family': 'Eiden'}, {'given': 'Nathalie', 'family': 'Ivanoff'}, {'given': 'Karen M', 'family': 'Kaplan'}, {'given': 'Penny', 'family': 'Heaton'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '14760258', 'scopus': None, 'doi': '10.1016/j.jpeds.2003.10.054'}, 'title': 'Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants', 'source': 'CrossRef'}
Clark HF, Bernstein DI, Dennehy PH, Offit P, Pichichero M, Treanor J, Ward RL, Krah DL, Shaw A, Dallas MJ, Laura D, Eiden JJ, Ivanoff N, Kaplan KM, Heaton P. Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants. The Journal of pediatrics. 2004;144(2):184-90.	10.1016/j.jpeds.2003.10.054	14760258	primary-study	ac7b2a7cd46be1d336de969cbf23e9c58d9f0b0a	-	{'publication_type': {'year': 2004, 'cited_medium': None, 'issue': None, 'issn': '00223476', 'volume': None, 'title': 'Journal of Pediatrics', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.8766666666666667, 'authors': 0.9066666666666668}, 'authors': [{'given': 'H. Fred', 'family': 'Clark'}, {'given': 'David I.', 'family': 'Bernstein'}, {'given': 'Penelope H.', 'family': 'Dennehy'}, {'given': 'Paul', 'family': 'Offit'}, {'given': 'Michael', 'family': 'Pichichero'}, {'given': 'John', 'family': 'Treanor'}, {'given': 'Richard L.', 'family': 'Ward'}, {'given': 'David L.', 'family': 'Krah'}, {'given': 'Alan', 'family': 'Shaw'}, {'given': 'Michael J.', 'family': 'Dallas'}, {'given': 'Digilio', 'family': 'Laura'}, {'given': 'Joseph J.', 'family': 'Eiden'}, {'given': 'Nathalie', 'family': 'Ivanoff'}, {'given': 'Karen M.', 'family': 'Kaplan'}, {'given': 'Penny', 'family': 'Heaton'}], 'abstract': 'Objectives To investigate safety, efficacy, and immunogenicity of live quadrivalent rotavirus vaccine (QRV) containing human-bovine (WC3) reassortant rotavirus serotypes G1, G2, G3, and P1a. Study design This was a randomized, double-blinded, placebo-controlled trial. During 1993 to 1994, at 10 US study sites, 439 healthy infants ???2 to 6 months of age, were enrolled to receive 3 doses of oral QRV or placebo at approximately 8-week intervals. Results The vaccine was generally well tolerated; no serious vaccine-related adverse experiences were reported. Risk differences and 95% confidence intervals suggested no differences between vaccine and placebo recipients in the incidences of fever, irritability, vomiting, or diarrhea during the 14 days after any dose. QRV was 74.6% efficacious (95% CI: 49.5%, 88.3%) in preventing rotavirus acute gastroenteritis (AGE), regardless of severity and 100% efficacious (95% CI: 43.5%, 100%) in preventing severe rotavirus AGE through one rotavirus season. Serotype G1 was identified in most infants with rotavirus AGE. A ???3-fold rise in serum neutralizing antibody to G1 was observed in 57% (45/79) of vaccinees. A ???3-fold rise in serum anti-rotavirus IgA and fecal anti-rotavirus IgA was observed in 88% (162/185) and 65% (104/159) of vaccinees, respectively. Conclusions QRV was generally well tolerated, immungenic, and highly effective against rotavirus gastroenteritis.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '14760258', 'scopus': '2-s2.0-1542287426', 'doi': '10.1016/j.jpeds.2003.10.054'}, 'title': 'Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants', 'source': 'Mendeley'}
Clark HF, Burke CJ, Volkin DB, Offit P, Ward RL, Bresee JS, Dennehy P, Gooch WM, Malacaman E, Matson D, Walter E, Watson B, Krah DL, Dallas MJ, Schödel F, Kaplan M, Heaton P. Safety, immunogenicity and efficacy in healthy infants of G1 and G2 human reassortant rotavirus vaccine in a new stabilizer/buffer liquid formulation. The Pediatric infectious disease journal. 2003;22(10):914-20.	10.1097/01.inf.0000091887.48999.77	14551493	primary-study	0601f37b2b034e02fffae48bb1faf40b21a558da	-	{'publication_type': {'year': 2003, 'cited_medium': None, 'issue': '10', 'issn': '0891-3668', 'volume': '22', 'title': 'The Pediatric Infectious Disease Journal', 'pagination': '914-920'}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.8632352941176471, 'authors': 0.8529411764705884}, 'authors': [{'given': 'H. FRED', 'family': 'CLARK'}, {'given': 'CARL J.', 'family': 'BURKE'}, {'given': 'DAVID B.', 'family': 'VOLKIN'}, {'given': 'PAUL', 'family': 'OFFIT'}, {'given': 'RICHARD L.', 'family': 'WARD'}, {'given': 'JOSEPH S.', 'family': 'BRESEE'}, {'given': 'PENELOPE', 'family': 'DENNEHY'}, {'given': 'W. MANFRED', 'family': 'GOOCH'}, {'given': 'EDGARDO', 'family': 'MALACAMAN'}, {'given': 'DAVID', 'family': 'MATSON'}, {'given': 'EMMANUEL', 'family': 'WALTER'}, {'given': 'BARBARA', 'family': 'WATSON'}, {'given': 'DAVID L.', 'family': 'KRAH'}, {'given': 'MICHAEL J.', 'family': 'DALLAS'}, {'given': 'FLORIAN', 'family': 'SCH??DEL'}, {'given': 'KAREN M.', 'family': 'KAPLAN'}, {'given': 'PENNY', 'family': 'HEATON'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '14551493', 'scopus': None, 'doi': '10.1097/01.inf.0000091887.48999.77'}, 'title': 'Safety, immunogenicity and efficacy in healthy infants of G1 and G2 human reassortant rotavirus vaccine in a new stabilizer/buffer liquid formulation', 'source': 'CrossRef'}
Clark HF, Burke CJ, Volkin DB, Offit P, Ward RL, Bresee JS, Dennehy P, Gooch WM, Malacaman E, Matson D, Walter E, Watson B, Krah DL, Dallas MJ, Schödel F, Kaplan M, Heaton P. Safety, immunogenicity and efficacy in healthy infants of G1 and G2 human reassortant rotavirus vaccine in a new stabilizer/buffer liquid formulation. The Pediatric infectious disease journal. 2003;22(10):914-20.	10.1097/01.inf.0000091887.48999.77	14551493	primary-study	0601f37b2b034e02fffae48bb1faf40b21a558da	-	{'publication_type': {'year': 2003, 'cited_medium': None, 'issue': None, 'issn': '0891-3668', 'volume': None, 'title': 'The Pediatric infectious disease journal', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 0.9764705882352942, 'authors': 0.9058823529411767}, 'authors': [{'given': 'H Fred', 'family': 'Clark'}, {'given': 'Carl J', 'family': 'Burke'}, {'given': 'David B', 'family': 'Volkin'}, {'given': 'Paul', 'family': 'Offit'}, {'given': 'Richard L', 'family': 'Ward'}, {'given': 'Joseph S', 'family': 'Bresee'}, {'given': 'Penelope', 'family': 'Dennehy'}, {'given': 'W Manfred', 'family': 'Gooch'}, {'given': 'Edgardo', 'family': 'Malacaman'}, {'given': 'David', 'family': 'Matson'}, {'given': 'Emmanuel', 'family': 'Walter'}, {'given': 'Barbara', 'family': 'Watson'}, {'given': 'David L', 'family': 'Krah'}, {'given': 'Michael J', 'family': 'Dallas'}, {'given': 'Florian', 'family': 'Schödel'}, {'given': 'Karen M', 'family': 'Kaplan'}, {'given': 'Penny', 'family': 'Heaton'}], 'abstract': 'BACKGROUND: A refrigerator-stable rotavirus (RV) vaccine that withstands gastric acid is anticipated to permit more widespread use of RV vaccine.\\n\\nOBJECTIVE: We investigated for the first time in infants an oral, liquid formulation of G1 and G2 human bovine reassortant rotavirus vaccine (HRRV) with a new stabilizer/buffer (S/B) containing sucrose, sodium phosphate and sodium citrate.\\n\\nMETHODS: During 1997 through 1998, 731 healthy infants approximately 2 to 4 months of age were enrolled at 19 US sites to receive 3 HRRV or placebo doses approximately 6 to 8 weeks apart in a partially double blinded study. Infants were randomized to: (1) HRRV with no S/B but with prefeeding; (2) HRRV plus 1 of 3 different concentrations/volumes of S/B; or (3) placebo.\\n\\nRESULTS: No serious vaccine-related adverse experiences or intussusception cases were reported. No statistically significant differences were observed between vaccine and placebo recipients for fever (> or =38.1 degrees C) 0 to 7 days after any dose, irritability, vomiting or diarrhea incidence 0 to 42 days after any dose. Vaccine virus shedding among vaccine recipients was uncommon. Among S/B vaccine groups, proportions of infants with a > or =3-fold titer rise from baseline to Postdose 3 for G1 serum-neutralizing antibody (SNA), G2 SNA, WC3 SNA, serum anti-RV IgA, serum anti-RV IgG and stool anti-RV IgA were generally similar to those of the prefed non-S/B group.\\n\\nCONCLUSIONS: HRRV with a new S/B was generally well-tolerated; immunogenicity was generally similar to the prefed non-S/B group. No intussusception cases were reported, but the small sample size precluded a definitive conclusion. A large international clinical study is under way to address safety and efficacy of an S/B formulation of a pentavalent version of HRRV.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '14551493', 'scopus': '2-s2.0-0142120677', 'doi': '10.1097/01.inf.0000091887.48999.77'}, 'title': 'Safety, immunogenicity and efficacy in healthy infants of G1 and G2 human reassortant rotavirus vaccine in a new stabilizer/buffer liquid formulation.', 'source': 'Mendeley'}
Bernstein DI, Sack DA, Reisinger K, Rothstein E, Ward RL. Second-year follow-up evaluation of live, attenuated human rotavirus vaccine 89-12 in healthy infants. The Journal of infectious diseases. 2002;186(10):1487-9.	10.1086/344732	12404166	primary-study	14028c5fc6dc9dc9a6f2fb892cc4133c255e027c	-	{'publication_type': {'year': 2002, 'cited_medium': None, 'issue': '10', 'issn': '0022-1899', 'volume': '186', 'title': 'The Journal of Infectious Diseases', 'pagination': '1487-1489'}, 'language': None, 'rating': {'year': 0, 'title': 0.7692307692307693, 'total': 0.725, 'authors': 0.9}, 'authors': [{'given': 'David\xa0I.', 'family': 'Bernstein'}, {'given': 'David\xa0A.', 'family': 'Sack'}, {'given': 'Keith', 'family': 'Reisinger'}, {'given': 'Edward', 'family': 'Rothstein'}, {'given': 'Richard\xa0L.', 'family': 'Ward'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '12404166', 'scopus': None, 'doi': '10.1086/344732'}, 'title': 'Second‐Year Follow‐up Evaluation of Live, Attenuated Human Rotavirus Vaccine 89‐12 in Healthy Infants', 'source': 'CrossRef'}
Bernstein DI, Sack DA, Reisinger K, Rothstein E, Ward RL. Second-year follow-up evaluation of live, attenuated human rotavirus vaccine 89-12 in healthy infants. The Journal of infectious diseases. 2002;186(10):1487-9.	10.1086/344732	12404166	primary-study	14028c5fc6dc9dc9a6f2fb892cc4133c255e027c	-	{'publication_type': {'year': 2002, 'cited_medium': None, 'issue': None, 'issn': '0022-1899', 'volume': None, 'title': 'The Journal of Infectious Diseases', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.875, 'authors': 0.9}, 'authors': [{'given': 'David I.', 'family': 'Bernstein'}, {'given': 'David A.', 'family': 'Sack'}, {'given': 'Keith', 'family': 'Reisinger'}, {'given': 'Edward', 'family': 'Rothstein'}, {'given': 'Richard L.', 'family': 'Ward'}], 'abstract': 'Rotavirus vaccine development is a high priority. The association between the tetravalent rhesus-human reassortant rotavirus vaccine and intussusception has increased the need to develop new vaccines. In a small efficacy trial, the human rotavirus vaccine 89-12 recently has been shown to be safe and effective; 184 of the 215 healthy infants initially enrolled in this trial were followed for a second year. Vaccine efficacy during the second year was 59% (P=.047). For the 2 years of observation, vaccine efficacy was 76% against rotavirus gastroenteritis, 83% against severe rotavirus gastroenteritis, and 100% against rotavirus illnesses requiring medical intervention (P<.001 for each). These encouraging results have led to continued evaluation, in several countries, of a vaccine candidate derived from strain 89-12.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '12404166', 'scopus': '2-s2.0-0037111031', 'doi': '10.1086/344732'}, 'title': 'Second-year follow-up evaluation of live, attenuated human rotavirus vaccine 89-12 in healthy infants.', 'source': 'Mendeley'}
Bernstein DI, Sack DA, Rothstein E, Reisinger K, Smith VE, O'Sullivan D, Spriggs DR, Ward RL. Efficacy of live, attenuated, human rotavirus vaccine 89-12 in infants: a randomised placebo-controlled trial. Lancet. 1999;354(9175):287-90.	10.1016/S0140-6736(98)12106-2	10440305	primary-study	5de06dcec458ec65a702c178812d54a420e2f7f5	-	{'publication_type': {'year': 1999, 'cited_medium': None, 'issue': '9175', 'issn': '0140-6736', 'volume': '354', 'title': 'The Lancet', 'pagination': '287-290'}, 'language': None, 'rating': {'year': 0, 'title': 0.9285714285714286, 'total': 0.8285714285714287, 'authors': 0.9000000000000001}, 'authors': [{'given': 'David I', 'family': 'Bernstein'}, {'given': 'David A', 'family': 'Sack'}, {'given': 'Edward', 'family': 'Rothstein'}, {'given': 'Keith', 'family': 'Reisinger'}, {'given': 'Vicki E', 'family': 'Smith'}, {'given': 'Donna', 'family': "O'Sullivan"}, {'given': 'Dale R', 'family': 'Spriggs'}, {'given': 'Richard L', 'family': 'Ward'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1016/s0140-6736(98)12106-2'}, 'title': 'Efficacy of live, attenuated, human rotavirus vaccine 89–12 in infants: a randomised placebo-controlled trial', 'source': 'CrossRef'}
Bernstein DI, Sack DA, Rothstein E, Reisinger K, Smith VE, O'Sullivan D, Spriggs DR, Ward RL. Efficacy of live, attenuated, human rotavirus vaccine 89-12 in infants: a randomised placebo-controlled trial. Lancet. 1999;354(9175):287-90.	10.1016/S0140-6736(98)12106-2	10440305	primary-study	5de06dcec458ec65a702c178812d54a420e2f7f5	-	{'publication_type': {'year': 1999, 'cited_medium': None, 'issue': None, 'issn': '01406736', 'volume': None, 'title': 'Lancet', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 1.0, 'total': 0.975, 'authors': 0.9000000000000001}, 'authors': [{'given': 'David I.', 'family': 'Bernstein'}, {'given': 'David A.', 'family': 'Sack'}, {'given': 'Edward', 'family': 'Rothstein'}, {'given': 'Keith', 'family': 'Reisinger'}, {'given': 'Vicki E.', 'family': 'Smith'}, {'given': 'Donna', 'family': "O'Sullivan"}, {'given': 'Dale R.', 'family': 'Spriggs'}, {'given': 'Richard L.', 'family': 'Ward'}], 'abstract': 'Background. Rotavirus is the most common cause of severe, dehydrating diarrhoea in infants worldwide. We assessed the safety, immunogenicity, and efficacy of a live, oral human rotavirus vaccine, 89-12, in US children in a randomised, placebo-controlled, double-blind multicentre trial. Methods. 215 healthy infants were enrolled, of whom 213 were given two doses of 89-12 (containing 1 x 105 plaque-forming units) or placebo, and 213 were followed up through one rotavirus season. The frequency of side-effects was compared for 7 days after each dose of vaccine. Immune responses to rotavirus were assessed by serum and stool IgA, and by serum 89-12 neutralising titres. The primary outcome variable (protection from rotavirus disease) was evaluated by comparing the frequencies of rotavirus gastroenteritis in an intention-to-treat analysis. Findings. Adverse reactions were mild. Low-grade fever (??? 38.1??C) after the first dose was the only side-effect significantly more common in the vaccine group than in the placebo group (21 [19%] vs 5 [5%], p = 0.001). An immune response to vaccine was detected in 94.4% of vaccinees. Rotavirus disease occurred in 18 of 107 placebo recipients and two of 108 vaccine recipients (vaccine efficacy 89.0% [95% CI 65.4-94.5]). Ten infants in the placebo group but none in the vaccine group were presented for medical care. Interpretation. The 89-12 rotavirus vaccine was safe and immunogenic and provided a high degree of protection against rotavirus disease. Further investigations of this vaccine are needed to confirm these findings in other settings.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '10440305', 'scopus': '2-s2.0-0033600431', 'doi': '10.1016/S0140-6736(98)12106-2'}, 'title': 'Efficacy of live, attenuated, human rotavirus vaccine 89-12 in infants: A randomised placebo-controlled trial', 'source': 'Mendeley'}
Bernstein DI, Smith VE, Sherwood JR, Schiff GM, Sander DS, DeFeudis D, Spriggs DR, Ward RL. Safety and immunogenicity of live, attenuated human rotavirus vaccine 89-12. Vaccine. 1998;16(4):381-7.	-	9607059	primary-study	fbde5f3bd46a7babdce44b8f29327d1d18e594d1	-	{'publication_type': {'year': 1998, 'cited_medium': None, 'issue': '4', 'issn': '0264-410X', 'volume': '16', 'title': 'Vaccine', 'pagination': '381-387'}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 1.0, 'authors': 1.0}, 'authors': [{'given': 'D', 'family': 'BERNSTEIN'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1016/s0264-410x(97)00210-7'}, 'title': 'Safety and immunogenicity of live, attenuated human rotavirus vaccine 89-12', 'source': 'CrossRef'}
Bernstein DI, Smith VE, Sherwood JR, Schiff GM, Sander DS, DeFeudis D, Spriggs DR, Ward RL. Safety and immunogenicity of live, attenuated human rotavirus vaccine 89-12. Vaccine. 1998;16(4):381-7.	-	9607059	primary-study	fbde5f3bd46a7babdce44b8f29327d1d18e594d1	-	{'publication_type': {'year': 1998, 'cited_medium': None, 'issue': None, 'issn': '0264-410X', 'volume': None, 'title': 'Vaccine', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 0.953125, 'authors': 0.8125}, 'authors': [{'given': 'D I', 'family': 'Bernstein'}, {'given': 'V E', 'family': 'Smith'}, {'given': 'J R', 'family': 'Sherwood'}, {'given': 'G M', 'family': 'Schiff'}, {'given': 'D S', 'family': 'Sander'}, {'given': 'D', 'family': 'DeFeudis'}, {'given': 'D R', 'family': 'Spriggs'}, {'given': 'R L', 'family': 'Ward'}], 'abstract': 'The safety and immunogenicity of an orally administered live human rotavirus vaccine candidate (89-12), attenuated by 33 passages in monkey kidney cells, were evaluated in placebo-controlled trials in adults, children and infants. This strain was selected because natural infections with 89-12-like rotaviruses provided 100% protection over two years. The initial evaluations in adults, seropositive children and nine infants indicated that the vaccine was safe. Two doses of vaccine (10(5) p.f.u. dose-1) or placebo were then given to 42 infants, aged from 6 to 26 weeks. No significant difference in side effects was seen. Seroconversion was demonstrated in 19 of 20 previously uninfected vaccine recipients, but > or = 4-fold rises in 89-12 neutralizing antibody titers were detected in only seven subjects. Intestinal IgA responses were detected in 15 subjects. This attenuated human rotavirus was safe and immunogenic and should be further evaluated as a vaccine candidate.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '9607059', 'scopus': None, 'doi': 'S0264-410X(97)00210-7 [pii]'}, 'title': 'Safety and immunogenicity of live, attenuated human rotavirus vaccine 89-12.', 'source': 'Mendeley'}
Childs E, de Wit H. Enhanced mood and psychomotor performance by a caffeine-containing energy capsule in fatigued individuals. Experimental and clinical psychopharmacology. 2008;16(1):13-21.	10.1037/1064-1297.16.1.13	18266548	primary-study	90661e2a1bd9a899009a37f721140229f17e59c4	-	{'publication_type': {'year': 2008, 'cited_medium': None, 'issue': '1', 'issn': '1936-2293', 'volume': '16', 'title': 'Experimental and Clinical Psychopharmacology', 'pagination': '13-21'}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.8875, 'authors': 0.95}, 'authors': [{'given': 'Emma', 'family': 'Childs'}, {'given': 'Harriet', 'family': 'de Wit'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '18266548', 'scopus': None, 'doi': '10.1037/1064-1297.16.1.13'}, 'title': 'Enhanced mood and psychomotor performance by a caffeine-containing energy capsule in fatigued individuals.', 'source': 'CrossRef'}
Childs E, de Wit H. Enhanced mood and psychomotor performance by a caffeine-containing energy capsule in fatigued individuals. Experimental and clinical psychopharmacology. 2008;16(1):13-21.	10.1037/1064-1297.16.1.13	18266548	primary-study	90661e2a1bd9a899009a37f721140229f17e59c4	-	{'publication_type': {'year': 2008, 'cited_medium': None, 'issue': None, 'issn': '1064-1297', 'volume': None, 'title': 'Experimental and clinical psychopharmacology', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 0.9874999999999999, 'authors': 0.95}, 'authors': [{'given': 'Emma', 'family': 'Childs'}, {'given': 'Harriet', 'family': 'de Wit'}], 'abstract': 'Caffeine produces mild psychostimulant effects that may be particularly evident in individuals whose mood or performance is impaired by sleep restriction or caffeine withdrawal. Caffeinated energy drinks have been shown to improve energy and cognition but expectancy effects cannot be ruled out in these studies. Very few studies have examined the effects of caffeine-containing energy capsules upon behavioral and subjective measures. This study compared the effects of a caffeine-containing (200 mg) supplement (CAF) or placebo in capsule form after prolonged wakefulness, in participants who varied in their level of habitual caffeine use. Thirty-five healthy volunteers (16 male, 19 female) participated in two experimental sessions in which they remained awake between 5 p.m. and 5 a.m. At 3:30 a.m. they consumed CAF or placebo in random order under double-blind conditions. Participants completed subjective effects questionnaires and performed computerized attention tasks before and after consuming capsules. Heart rate and blood pressure were monitored at regular intervals. Compared to measures at 5 p.m., participants reported more tiredness and mood disturbance at 3 a.m., and exhibited longer reaction times and more attentional lapses. Heavier caffeine consumers exhibited the greatest decreases in Profile of Mood States (POMS) Vigor. CAF produced stimulant-like effects and significantly improved mood and reaction times upon the tasks. These effects did not vary with level of habitual caffeine consumption. These findings indicate that consumption of a caffeine-containing food supplement improves subjective state and cognitive performance in fatigued individuals that is likely a result of its caffeine content.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '18266548', 'scopus': '2-s2.0-39749179628', 'doi': '10.1037/1064-1297.16.1.13'}, 'title': 'Enhanced mood and psychomotor performance by a caffeine-containing energy capsule in fatigued individuals.', 'source': 'Mendeley'}
Kohler M, Pavy A, van den Heuvel C. The effects of chewing versus caffeine on alertness, cognitive performance and cardiac autonomic activity during sleep deprivation. Journal of sleep research. 2006;15(4):358-68.	10.1111/j.1365-2869.2006.00547.x	17118092	primary-study	d8ad3e46f7e3371997b568f813309709150b8088	-	{'publication_type': {'year': 2006, 'cited_medium': None, 'issue': '4', 'issn': '0962-1105', 'volume': '15', 'title': 'Journal of Sleep Research', 'pagination': '358-368'}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.8833333333333333, 'authors': 0.9333333333333332}, 'authors': [{'given': 'MARK', 'family': 'KOHLER'}, {'given': 'ALAN', 'family': 'PAVY'}, {'given': 'CAMERON', 'family': 'VAN DEN HEUVEL'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '17118092', 'scopus': None, 'doi': '10.1111/j.1365-2869.2006.00547.x'}, 'title': 'The effects of chewing versus caffeine on alertness, cognitive performance and cardiac autonomic activity during sleep deprivation', 'source': 'CrossRef'}
Kohler M, Pavy A, van den Heuvel C. The effects of chewing versus caffeine on alertness, cognitive performance and cardiac autonomic activity during sleep deprivation. Journal of sleep research. 2006;15(4):358-68.	10.1111/j.1365-2869.2006.00547.x	17118092	primary-study	d8ad3e46f7e3371997b568f813309709150b8088	-	{'publication_type': {'year': 2006, 'cited_medium': None, 'issue': None, 'issn': '09621105', 'volume': None, 'title': 'Journal of Sleep Research', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.8833333333333333, 'authors': 0.9333333333333332}, 'authors': [{'given': 'Mark', 'family': 'Kohler'}, {'given': 'Alan', 'family': 'Pavy'}, {'given': 'Cameron', 'family': 'Van Den Heuvel'}], 'abstract': 'Chewing has been shown to alleviate feelings of sleepiness and improve cognitive performance during the day. This study investigated the effect of chewing on alertness and cognitive performance across one night without sleep as well as the possible mediating role of cardiac autonomic activity. Fourteen adults participated in a randomized, counterbalanced protocol employing a chewing, placebo and caffeine condition. Participants completed tasks assessing psychomotor vigilance, tracking, grammatical reasoning, alertness and sleepiness each hour across the night. All participants received either placebo or caffeine (200 mg), while the chewing condition also chewed on a tasteless and odorless substance for 15 min each hour. Heart rate (HR), root mean square of the successive differences in R-R intervals on the ECG (RMSSD), and preejection period (PEP) were simultaneously recorded. Alertness and cognitive performance amongst the chewing condition did not differ or were in fact worse when compared with placebo. Similarly, measures of HR and RMSSD remained the same between these two conditions; however, PEP was reduced in the later part of the night in the chewing condition compared with a relative increase for placebo. Caffeine led to improved speed and accuracy on cognitive tasks and increased alertness when compared with chewing. Relative increases in RMSSD and reductions in HR were demonstrated following caffeine; however, no change in PEP was seen. Strong associations between cardiac parasympathetic activity and complex cognitive tasks, as well as between subjective alertness and simpler cognitive tasks, suggest a differential process mediating complex versus simple cognitive performance during sleep deprivation.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '17118092', 'scopus': '2-s2.0-33751176220', 'doi': '10.1111/j.1365-2869.2006.00547.x'}, 'title': 'The effects of chewing versus caffeine on alertness, cognitive performance and cardiac autonomic activity during sleep deprivation', 'source': 'Mendeley'}
Dagan Y, Doljansky JT. Cognitive performance during sustained wakefulness: A low dose of caffeine is equally effective as modafinil in alleviating the nocturnal decline. Chronobiology international. 2006;23(5):973-83.	10.1080/07420520600920734	17050212	primary-study	9ed583bee490c8d08ae9e2b915a21f793a76b5bf	-	{'publication_type': {'year': 2006, 'cited_medium': None, 'issue': '5', 'issn': '0742-0528', 'volume': '23', 'title': 'Chronobiology International', 'pagination': '973-983'}, 'language': None, 'rating': {'year': 0, 'title': 1.0, 'total': 0.875, 'authors': 0.9}, 'authors': [{'given': 'Yaron', 'family': 'Dagan'}, {'given': 'Julia T.', 'family': 'Doljansky'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '17050212', 'scopus': None, 'doi': '10.1080/07420520600920734'}, 'title': 'Cognitive Performance during Sustained Wakefulness: A Low Dose of Caffeine Is Equally Effective as Modafinil in Alleviating the Nocturnal Decline', 'source': 'CrossRef'}
Dagan Y, Doljansky JT. Cognitive performance during sustained wakefulness: A low dose of caffeine is equally effective as modafinil in alleviating the nocturnal decline. Chronobiology international. 2006;23(5):973-83.	10.1080/07420520600920734	17050212	primary-study	9ed583bee490c8d08ae9e2b915a21f793a76b5bf	-	{'publication_type': {'year': 2006, 'cited_medium': None, 'issue': None, 'issn': '0742-0528', 'volume': None, 'title': 'Chronobiology international', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 1.0, 'total': 1.0, 'authors': 1.0}, 'authors': [{'given': 'Y', 'family': 'Dagan'}, {'given': 'Jt', 'family': 'Doljansky'}], 'abstract': 'Cognitive performance at night exhibits a substantial drop, typically before dawn. One of the means of dealing with this phenomenon, as well as with the accompanying sleepiness during sustained wakefulness, is the administration of stimulants. The most widely used and well-documented stimulants are caffeine, amphetamines, and modafinil. Of these, amphetamines are the least recommended, as they may severely affect behavior. Caffeine and modafinil seem to produce relatively milder side effects and usually only at high doses. Previous comparison studies have revealed equal efficacy of both the stimulants in maintaining alertness and performance during sustained wakefulness. However, these studies used relatively high, and thus not completely safe, doses of these drugs (600 mg caffeine and 400 mg modafinil). Therefore, the aim of the present study was to assess the efficacy of a low and medically safe dose of caffeine (200 mg) and modafinil (200 mg) in maintaining cognitive performance during sustained wakefulness. A flight simulation task was chosen for the assessment of the stimulants in a counter-balanced, within-subject design under four different conditions: baseline (no drugs), placebo, caffeine (200 mg), and modafinil (200 mg). The equal effectiveness of both drugs in abolishing the nocturnal drop in cognitive performance, as well as of oral temperature and blood pressure, supported the use of low doses of caffeine and modafinil for the maintenance of alertness in healthy subjects during sustained wakefulness.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '17050212', 'scopus': '2-s2.0-33750134851', 'doi': '10.1080/07420520600920734'}, 'title': 'Cognitive performance during sustained wakefulness: a low dose of caffeine is equally effective as modafinil in alleviating the nocturnal decline', 'source': 'Mendeley'}
Doan BK, Hickey PA, Lieberman HR, Fischer JR. Caffeinated tube food effect on pilot performance during a 9-hour, simulated nighttime U-2 mission. Aviation, space, and environmental medicine. 2006;77(10):1034-40.	-	17042248	primary-study	c9dd409de987b252c099522c4b8633b42ba07b48	-	{'publication_type': {'year': None, 'cited_medium': None, 'issue': None, 'issn': None, 'volume': None, 'title': 'PsycEXTRA Dataset', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.5833333333333334, 'total': 0.5077380952380953, 'authors': 0.5142857142857143}, 'authors': [{'given': 'Brandon K.', 'family': 'Doan'}, {'given': 'Patrick', 'family': 'Hickey'}, {'given': 'Joseph R.', 'family': 'Fischer'}, {'given': 'James C.', 'family': 'Miller'}, {'given': 'Harris', 'family': 'Lieberman'}, {'given': 'Daniel', 'family': 'Nattress'}, {'given': 'Lisa', 'family': 'Smith'}], 'abstract': None, 'type': 'dataset', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1037/e423682005-001'}, 'title': 'The Effect of Caffeinated Tube Food on Cognitive Performance During Fatigue/Circadian Desynchronosis', 'source': 'CrossRef'}
Doan BK, Hickey PA, Lieberman HR, Fischer JR. Caffeinated tube food effect on pilot performance during a 9-hour, simulated nighttime U-2 mission. Aviation, space, and environmental medicine. 2006;77(10):1034-40.	-	17042248	primary-study	c9dd409de987b252c099522c4b8633b42ba07b48	-	{'publication_type': {'year': 2006, 'cited_medium': None, 'issue': None, 'issn': '00956562', 'volume': None, 'title': 'Aviation Space and Environmental Medicine', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.875, 'authors': 0.9}, 'authors': [{'given': 'Brandon K.', 'family': 'Doan'}, {'given': 'Patrick A.', 'family': 'Hickey'}, {'given': 'Harris R.', 'family': 'Lieberman'}, {'given': 'Joseph R.', 'family': 'Fischer'}], 'abstract': 'INTRODUCTION: Interventions to maintain performance are necessary to meet demanding mission requirements during sustained and surge aviation operations. Tube foods are the only foods that can be consumed during a U-2 mission due to the confining and encapsulating nature of required support equipment. Caffeine is a safe and effective strategy to enhance cognitive performance and is an ingredient in some tube foods. The objective of this study was to determine whether moderate doses of caffeinated tube foods would enhance performance in a simulated U-2 mission. METHODS: Volunteers were 12 healthy USAF male pilots. The study used a double blind, placebo-controlled, two-factor, repeated-measures (five iterations per night) design. Caffeinated (200 mg each) or placebo tube food was consumed at 00:00 and 04:00. Dependent measures assessed included standardized tests of cognitive performance, vigilance, and mood designed to simulate the demands of a nighttime U-2 mission. RESULTS: Statistically significant (p < 0.05) improvements in performance due to caffeine administration compared with placebo were present in all five cognitive tasks either as main effects, interactions, or absence of significant degradation in the caffeine treatment condition compared with the placebo condition. A majority of sleep deprivation-induced performance decrements were attenuated by 200 mg of caffeine in tube food consumed every 4 h, and in some cases, performance was improved beyond baseline levels. CONCLUSIONS: Caffeinated tube food maintained cognitive performance representative of U-2 long-duration mission tasks at or near baseline levels for a 9-h overnight period in qualified USAF pilots. Side effects were minor and did not differ between placebo and caffeine conditions.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '17042248', 'scopus': '2-s2.0-33750065758', 'doi': None}, 'title': 'Caffeinated tube food effect on pilot performance during a 9-hour, simulated nighttime U-2 mission', 'source': 'Mendeley'}
Philip P, Taillard J, Moore N, Delord S, Valtat C, Sagaspe P, Bioulac B. The effects of coffee and napping on nighttime highway driving: a randomized trial. Annals of internal medicine. 2006;144(11):785-91.	-	16754920	primary-study	2aacb7212a550ab5aa212af6b034785879a3fbdb	-	{'publication_type': {'year': 2006, 'cited_medium': None, 'issue': '11', 'issn': '0003-4819', 'volume': '144', 'title': 'Annals of Internal Medicine', 'pagination': '785'}, 'language': None, 'rating': {'year': 0, 'title': 1.0, 'total': 0.875, 'authors': 0.9}, 'authors': [{'given': 'Pierre', 'family': 'Philip'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.7326/0003-4819-144-11-200606060-00004'}, 'title': 'The Effects of Coffee and Napping on Nighttime Highway Driving', 'source': 'CrossRef'}
Philip P, Taillard J, Moore N, Delord S, Valtat C, Sagaspe P, Bioulac B. The effects of coffee and napping on nighttime highway driving: a randomized trial. Annals of internal medicine. 2006;144(11):785-91.	-	16754920	primary-study	2aacb7212a550ab5aa212af6b034785879a3fbdb	-	{'publication_type': {'year': 2006, 'cited_medium': None, 'issue': None, 'issn': '00034819', 'volume': None, 'title': 'Annals of Internal Medicine', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 1.0, 'total': 0.8785714285714286, 'authors': 0.9142857142857144}, 'authors': [{'given': 'Pierre', 'family': 'Philip'}, {'given': 'Jacques', 'family': 'Taillard'}, {'given': 'Nicholas', 'family': 'Moore'}, {'given': 'Sandrine', 'family': 'Delord'}, {'given': 'C??dric', 'family': 'Valtat'}, {'given': 'Patricia', 'family': 'Sagaspe'}, {'given': 'Bernard', 'family': 'Bioulac'}], 'abstract': 'BACKGROUND: Sleep-related accidents often involve healthy young persons who are driving at night. Coffee and napping restore alertness, but no study has compared their effects on real nighttime driving performances. OBJECTIVE: To test the effects of 125 mL of coffee (half a cup) containing 200 mg of caffeine, placebo (decaffeinated coffee containing 15 mg of caffeine), or a 30-minute nap (at 1:00 a.m.) in a car on nighttime driving performance. DESIGN: Double-blind, randomized, crossover study. SETTING: Sleep laboratory and open highway. PARTICIPANTS: 12 young men (mean age, 21.3 years [SD, 1.8]). MEASUREMENTS: Self-rated fatigue and sleepiness, inappropriate line crossings from video recordings during highway driving, and polysomnographic recordings during the nap and subsequent sleep. INTERVENTION: Participants drove 200 km (125 miles) between 6:00 p.m. and 7:30 p.m. (daytime reference condition) or between 2:00 a.m. and 3:30 a.m. (coffee, decaffeinated coffee, or nap condition). After intervention, participants returned to the laboratory to sleep. RESULTS: Nighttime driving performance was similar to daytime performance (0 to 1 line crossing) for 75% of participants after coffee (0 or 1 line crossing), for 66% after the nap (P = 0.66 vs. coffee), and for only 13% after placebo (P = 0.041 vs. nap; P = 0.014 vs. coffee). The incidence rate ratios for having a line crossing after placebo were 3.7 (95% CI, 1.2 to 11.0; P = 0.001) compared with coffee and 2.9 (CI, 1.7 to 5.1; P = 0.021) compared with nap. A statistically significant interindividual variability was observed in response to sleep deprivation and countermeasures. Sleep latencies and efficiency during sleep after nighttime driving were similar in the 3 conditions. LIMITATIONS: Only 1 dose of coffee and 1 nap duration were tested. Effects may differ in other patient or age groups. CONCLUSIONS: Drinking coffee or napping at night statistically significantly reduces driving impairment without altering subsequent sleep.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '16754920', 'scopus': '2-s2.0-33745001821', 'doi': '144/11/785 [pii]'}, 'title': 'The effects of coffee and napping on nighttime highway driving: A randomized trial', 'source': 'Mendeley'}
Jay SM, Petrilli RM, Ferguson SA, Dawson D, Lamond N. The suitability of a caffeinated energy drink for night-shift workers. Physiology & behavior. 2006;87(5):925-31.	10.1016/j.physbeh.2006.02.012	16574171	primary-study	620f3def540f381ca860ebc3e3db0228fa3b9027	-	{'publication_type': {'year': 2006, 'cited_medium': None, 'issue': '5', 'issn': '0031-9384', 'volume': '87', 'title': 'Physiology & Behavior', 'pagination': '925-931'}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.88, 'authors': 0.9199999999999999}, 'authors': [{'given': 'Sarah M.', 'family': 'Jay'}, {'given': 'Renée M.', 'family': 'Petrilli'}, {'given': 'Sally A.', 'family': 'Ferguson'}, {'given': 'Drew', 'family': 'Dawson'}, {'given': 'Nicole', 'family': 'Lamond'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '16574171', 'scopus': None, 'doi': '10.1016/j.physbeh.2006.02.012'}, 'title': 'The suitability of a caffeinated energy drink for night-shift workers', 'source': 'CrossRef'}
Jay SM, Petrilli RM, Ferguson SA, Dawson D, Lamond N. The suitability of a caffeinated energy drink for night-shift workers. Physiology & behavior. 2006;87(5):925-31.	10.1016/j.physbeh.2006.02.012	16574171	primary-study	620f3def540f381ca860ebc3e3db0228fa3b9027	-	{'publication_type': {'year': 2006, 'cited_medium': None, 'issue': None, 'issn': '00319384', 'volume': None, 'title': 'Physiology and Behavior', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.88, 'authors': 0.9199999999999999}, 'authors': [{'given': 'Sarah M.', 'family': 'Jay'}, {'given': 'Renée M.', 'family': 'Petrilli'}, {'given': 'Sally A.', 'family': 'Ferguson'}, {'given': 'Drew', 'family': 'Dawson'}, {'given': 'Nicole', 'family': 'Lamond'}], 'abstract': "Past research has indicated that caffeinated 'functional energy drinks' (FEDs) are effective in counteracting sleepiness. It is not known however, what impact FEDs have on sleep itself. FEDs contain several active ingredients, including caffeine. They may therefore impact negatively on sleep and hence subsequent performance, deeming their use counterproductive. In a randomised cross-over design, 15 young adults participated in a simulated first night-shift protocol with 2 conditions, Functional Energy Drink (FED) and Non Functional Energy Drink (NonFED). Both involved a period of extended wakefulness (0700-0730 h-24.5 h) followed by an 8-h daytime 'recovery' sleep (0730-1530 h). During the FED condition, a commercially available FED was administered twice during the night. Sleepiness was assessed during the period of extended wakefulness and for a further 6 h after waking. Sleep periods were recorded using a standard 5 channel polysomnogram. Comparison of the sleep periods showed that sleep onset latency remained unchanged as did stage 2 and slow wave sleep. Total sleep time however, was 29.1 min shorter (p < .05) in the FED condition. Sleep efficiency was also significantly reduced from 91.8 ?? .9% to 84.7 ?? 2.7% (p < .05). It is evident that the residual effects of the FED's active ingredients impact on some aspects of daytime sleep following a simulated night-shift. Subsequent performance however was unaffected. The results deem FEDs to be effective for a single night-shift and warrant investigation into their use over successive night-shifts. ?? 2006 Elsevier Inc. All rights reserved.", 'type': 'journal', 'ids': {'embase': None, 'pubmed': '16574171', 'scopus': '2-s2.0-33746313649', 'doi': '10.1016/j.physbeh.2006.02.012'}, 'title': 'The suitability of a caffeinated energy drink for night-shift workers', 'source': 'Mendeley'}
Schweitzer PK, Randazzo AC, Stone K, Erman M, Walsh JK. Laboratory and field studies of naps and caffeine as practical countermeasures for sleep-wake problems associated with night work. Sleep. 2006;29(1):39-50.	-	16453980	primary-study	12b0b77d6f94b87b12b0867e8af3d730fd8a7ecc	-	{'publication_type': {'year': 1992, 'cited_medium': None, 'issue': '4', 'issn': '0267-8373', 'volume': '6', 'title': 'Work & Stress', 'pagination': '355-365'}, 'language': None, 'rating': {'year': 0, 'title': 0.5882352941176471, 'total': 0.5323529411764706, 'authors': 0.6}, 'authors': [{'given': 'Paula K.', 'family': 'Schweitzer'}, {'given': 'Mark J.', 'family': 'Muehlbach'}, {'given': 'James K.', 'family': 'Walsh'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1080/02678379208259966'}, 'title': 'Countermeasures for night work performance deficits: The effect of napping or caffeine on continuous performance at night', 'source': 'CrossRef'}
Schweitzer PK, Randazzo AC, Stone K, Erman M, Walsh JK. Laboratory and field studies of naps and caffeine as practical countermeasures for sleep-wake problems associated with night work. Sleep. 2006;29(1):39-50.	-	16453980	primary-study	12b0b77d6f94b87b12b0867e8af3d730fd8a7ecc	-	{'publication_type': {'year': 2006, 'cited_medium': None, 'issue': None, 'issn': '0161-8105', 'volume': None, 'title': 'Sleep', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 0.975, 'authors': 0.9}, 'authors': [{'given': 'Paula K', 'family': 'Schweitzer'}, {'given': 'Angela C', 'family': 'Randazzo'}, {'given': 'Kara', 'family': 'Stone'}, {'given': 'Milton', 'family': 'Erman'}, {'given': 'James K', 'family': 'Walsh'}], 'abstract': 'STUDY OBJECTIVES: To evaluate the effects of napping, caffeine, and napping plus caffeine on performance and alertness in both laboratory and field settings.\\n\\nDESIGN: (1) Laboratory Study: parallel-groups design with random assignment to 1 of 4 experimental conditions. (2) Field Study: crossover design.\\n\\nSETTING: Sleep laboratory and field settings.\\n\\nPARTICIPANTS: (1) Laboratory Study: 68 healthy individuals; (2) Field Study: 53 shiftworkers who worked nights or rotating shifts.\\n\\nINTERVENTIONS: (1) Laboratory Study: an evening nap opportunity before the first 2 of 4 consecutive simulated night shifts plus placebo taken all 4 nights, caffeine taken nightly, the combination of the nap and caffeine conditions, or placebo. (2) Field Study: an evening nap on the first 2 of 4 consecutive night shifts plus caffeine taken nightly versus placebo taken nightly without naps.\\n\\nMEASUREMENTS AND RESULTS: (1) Laboratory Study: Napping, caffeine, and their combination all improved alertness and performance as measured by Maintenance of Wakefulness Test and Psychomotor Vigilance Task, but the combination of napping and caffeine was best in improving alertness. (2) Field Study: Napping plus caffeine improved performance as measured by Psychomotor Vigilance Test and decreased subjective sleepiness in individuals working the night shift.\\n\\nCONCLUSIONS: Napping plus caffeine helps improve performance and alertness of night-shift workers.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '16453980', 'scopus': '2-s2.0-33645743988', 'doi': None}, 'title': 'Laboratory and field studies of naps and caffeine as practical countermeasures for sleep-wake problems associated with night work.', 'source': 'Mendeley'}
Wyatt JK, Cajochen C, Ritz-De Cecco A, Czeisler CA, Dijk DJ. Low-dose repeated caffeine administration for circadian-phase-dependent performance degradation during extended wakefulness. Sleep. 2004;27(3):374-81.	-	15164887	primary-study	80cd2acb91e8de656e5dfe2ae3290065b11f7519	-	{'publication_type': {'year': 2002, 'cited_medium': None, 'issue': '4', 'issn': '0306-4522', 'volume': '114', 'title': 'Neuroscience', 'pagination': '1047-1060'}, 'language': None, 'rating': {'year': 0, 'title': 0.4166666666666667, 'total': 0.5020833333333333, 'authors': 0.9249999999999999}, 'authors': [{'given': 'C', 'family': 'Cajochen'}, {'given': 'J.K', 'family': 'Wyatt'}, {'given': 'C.A', 'family': 'Czeisler'}, {'given': 'D.J', 'family': 'Dijk'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1016/s0306-4522(02)00209-9'}, 'title': 'Separation of circadian and wake duration-dependent modulation of EEG activation during wakefulness', 'source': 'CrossRef'}
Wyatt JK, Cajochen C, Ritz-De Cecco A, Czeisler CA, Dijk DJ. Low-dose repeated caffeine administration for circadian-phase-dependent performance degradation during extended wakefulness. Sleep. 2004;27(3):374-81.	-	15164887	primary-study	80cd2acb91e8de656e5dfe2ae3290065b11f7519	-	{'publication_type': {'year': 2004, 'cited_medium': None, 'issue': None, 'issn': '0161-8105', 'volume': None, 'title': 'Sleep', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 0.975, 'authors': 0.9}, 'authors': [{'given': 'James K', 'family': 'Wyatt'}, {'given': 'Christian', 'family': 'Cajochen'}, {'given': 'Angela', 'family': 'Ritz-De Cecco'}, {'given': 'Charles a', 'family': 'Czeisler'}, {'given': 'Derk-Jan', 'family': 'Dijk'}], 'abstract': 'OBJECTIVE: To investigate whether the effectiveness of a novel high-frequency low-dose caffeine regimen in counteracting the deterioration of performance during extended wakefulness is related to its interaction with homeostatic or circadian signals modulating performance and sleep propensity. DESIGN: Double-blind, placebo-controlled, parallel-group design in a 29-day forced desynchrony paradigm in which the period of the sleep-wake cycle was scheduled to be 42.85 hours, i.e., far removed from the circadian range. This design allowed for separate estimation of the sleep homeostatic, circadian, and caffeine contributions to performance deficits or improvements. SETTING: Private suite of a general clinical research center, in the absence of time of day information. PARTICIPANTS: Sixteen healthy normal-sleeping men (aged 18-30 years) INTERVENTIONS: Caffeine (0.3 mg per kg per hour) or placebo was administered hourly during the 28.57-hour wake episodes. RESULTS: Plasma caffeine concentrations rose in an exponential saturating manner during wakefulness. Rising caffeine levels markedly attenuated wake-dependent deterioration of a number of measures of cognitive performance, particularly at the circadian performance nadir. Moreover, caffeine enhanced the ability of subjects to remain consistently awake for extended periods, holding subjects back from completing the full transition to sleep, but at the expense of increasing subjective sleepiness. CONCLUSIONS: High-frequency low-dose caffeine administration is effective in countering the detrimental performance effects of extended wakefulness. These data are in accordance with the hypothesis that adenosine is a mediator of performance decrements associated with extended wakefulness and may lead to new strategies to use caffeine in situations in which neurobehavioral functioning is affected by sleep loss.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '15164887', 'scopus': '2-s2.0-3542995692', 'doi': 'Cn-00559899 Pubmed 15164887'}, 'title': 'Low-dose repeated caffeine administration for circadian-phase-dependent performance degradation during extended wakefulness.', 'source': 'Mendeley'}
Beaumont M, Batéjat D, Piérard C, Van Beers P, Denis JB, Coste O, Doireau P, Chauffard F, French J, Lagarde D. Caffeine or melatonin effects on sleep and sleepiness after rapid eastward transmeridian travel. Journal of applied physiology (Bethesda, Md. : 1985). 2004;96(1):50-8.	10.1152/japplphysiol.00940.2002	12959951	primary-study	cc1ef56f49655a2d678b4bd00e95bc544c4e7509	-	{'publication_type': {'year': 2003, 'cited_medium': None, 'issue': '1', 'issn': '8750-7587', 'volume': '96', 'title': 'Journal of Applied Physiology', 'pagination': '50-58'}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.875, 'authors': 0.9}, 'authors': [{'given': 'M.', 'family': 'Beaumont'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '12959951', 'scopus': None, 'doi': '10.1152/japplphysiol.00940.2002'}, 'title': 'Caffeine or melatonin effects on sleep and sleepiness after rapid eastward transmeridian travel', 'source': 'CrossRef'}
Beaumont M, Batéjat D, Piérard C, Van Beers P, Denis JB, Coste O, Doireau P, Chauffard F, French J, Lagarde D. Caffeine or melatonin effects on sleep and sleepiness after rapid eastward transmeridian travel. Journal of applied physiology (Bethesda, Md. : 1985). 2004;96(1):50-8.	10.1152/japplphysiol.00940.2002	12959951	primary-study	cc1ef56f49655a2d678b4bd00e95bc544c4e7509	-	{'publication_type': {'year': 2004, 'cited_medium': None, 'issue': None, 'issn': '8750-7587', 'volume': None, 'title': 'Journal of applied physiology (Bethesda, Md. : 1985)', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 0.9974999999999999, 'authors': 0.99}, 'authors': [{'given': 'M', 'family': 'Beaumont'}, {'given': 'D', 'family': 'Batéjat'}, {'given': 'C', 'family': 'Piérard'}, {'given': 'P', 'family': 'Van Beers'}, {'given': 'J B', 'family': 'Denis'}, {'given': 'O', 'family': 'Coste'}, {'given': 'P', 'family': 'Doireau'}, {'given': 'F', 'family': 'Chauffard'}, {'given': 'J', 'family': 'French'}, {'given': 'D', 'family': 'Lagarde'}], 'abstract': 'We measured the effects of slow-release caffeine (SRC) and melatonin (Mlt) on sleep and daytime sleepiness after a seven-time zone eastbound flight. In a double-blind, randomized, placebo-controlled study, each of three groups of nine subjects was given either 300 mg SRC on recovery day 1 (D1) to D5 (0800) or 5 mg Mlt on preflight D-1 (1700), flight day D0 (1600), and from D1 to D3 (2300), or placebo (Pbo) at the same times. Nighttime sleep was evaluated by polysomnography and daytime sleepiness from measurements of sleep latencies and continuous wrist actigraphy. Compared with baseline, we found a significant rebound of slow-wave sleep on night 1 (N1) to N2 under Pbo and Mlt and a significant decrease in rapid eye movement sleep on N1 (Pbo) and N1-N3 (Mlt). Sleepiness was objectively increased under Pbo (D1-D6) and Mlt (D1-D3). SRC reduced sleepiness but also tended to affect sleep quality until the last drug day. In conclusion, both drugs have positive effects on some jet lag symptoms after an eastbound flight: SRC on daytime sleepiness, and Mlt on sleep.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '12959951', 'scopus': '2-s2.0-0347363489', 'doi': '10.1152/japplphysiol.00940.2002'}, 'title': 'Caffeine or melatonin effects on sleep and sleepiness after rapid eastward transmeridian travel.', 'source': 'Mendeley'}
Babkoff H, French J, Whitmore J, Sutherlin R. Single-dose bright light and/or caffeine effect on nocturnal performance. Aviation, space, and environmental medicine. 2002;73(4):341-50.	-	11952054	primary-study	621c41977f3292d320af6af252514ec3f46a96b3	-	{'publication_type': {'year': 2006, 'cited_medium': None, 'issue': '12', 'issn': '0095-6562', 'volume': '77', 'title': 'Aviation, Space, and Environmental Medicine', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.4444444444444444, 'total': 0.28888888888888886, 'authors': 0.0}, 'authors': [{'given': None, 'family': 'Rosekind'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.3357/asem.1879.2006'}, 'title': "'Alertness Management in Aviation Operations: Enhancing Performance and Sleep'", 'source': 'CrossRef'}
Babkoff H, French J, Whitmore J, Sutherlin R. Single-dose bright light and/or caffeine effect on nocturnal performance. Aviation, space, and environmental medicine. 2002;73(4):341-50.	-	11952054	primary-study	621c41977f3292d320af6af252514ec3f46a96b3	-	{'publication_type': {'year': 2002, 'cited_medium': None, 'issue': None, 'issn': '00956562', 'volume': None, 'title': 'Aviation Space and Environmental Medicine', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.8812500000000001, 'authors': 0.925}, 'authors': [{'given': 'Harvey', 'family': 'Babkoff'}, {'given': 'Jon', 'family': 'French'}, {'given': 'Jeff', 'family': 'Whitmore'}, {'given': 'Ralph', 'family': 'Sutherlin'}], 'abstract': 'Background. The impact of the separate and combined effects of a 1-h\\nexposure to bright light (similar to3000 lx) and a 200-mg dose of\\ncaffeine on nocturnal performance was studied during a simulated\\nshift-work schedule beginning 1730 in the evening and ending 1000 the\\nnext morning. Hypothesis. Light and caffeine exposure were expected to\\nimprove nocturnal fatigue degradation. Methods: There were 11 subjects\\ntested under 4 treatment conditions: 1) 1 h Dim Light-Placebo; 2) 1 h\\nBright Light-Placebo; 3) 1 h Dim Light-Caffeine; 4) 1 h Bright\\nLight-Caffeine. Exposure to the light occurred between 0130 and 0230\\nhours. Caffeine or placebo was administered at 0140 hours. Results:\\nChoice Reaction Time (RT) recorded during the four post-treatment\\nsessions were shorter for the Bright Light-Caffeine, Bright\\nLight-Placebo, and Dim Light-Caffeine conditions than for the Dim\\nLight-Placebo condition. During the sessions beginning 0430 and 0830\\nhours, the shortest RT was recorded for the Bright Light-Caffeine\\ntreatment. The largest number of trials without false alarms per session\\nfor the working memory task (letter cancellation) was found for the\\nBright Light-Caffeine condition. Exposure for 1 h to 3000 lx reduced\\nmelatonin concentration between 42-47% from 0230 to 0410 hours. A\\n200-mg dose of caffeine also reduced melatonin levels, although to a\\nlesser degree than 1 h exposure to 3000 lx. Conclusion: Although 1 h\\nexposure to bright light at 0130 hours combined with a 200-mg dose of\\ncaffeine maintains performance throughout the remainder of the\\nnight/early morning, a 1-h exposure to bright light without the caffeine\\nmay actually degrade performance.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '11952054', 'scopus': '2-s2.0-0036207536', 'doi': None}, 'title': 'Single-dose bright light and/or caffeine effect on nocturnal performance', 'source': 'Mendeley'}
Piérard C, Beaumont M, Enslen M, Chauffard F, Tan DX, Reiter RJ, Fontan A, French J, Coste O, Lagarde D. Resynchronization of hormonal rhythms after an eastbound flight in humans: effects of slow-release caffeine and melatonin. European journal of applied physiology. 2001;85(1-2):144-50.	-	11513308	primary-study	9e0ecd47f5e6152977e7ad2fe6b80786f77b6a04	-	{'publication_type': {'year': 2001, 'cited_medium': None, 'issue': '1-2', 'issn': '1439-6319', 'volume': '85', 'title': 'European Journal of Applied Physiology', 'pagination': '144-150'}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.8775000000000001, 'authors': 0.9100000000000001}, 'authors': [{'given': 'Christophe', 'family': 'Piérard'}, {'given': 'Maurice', 'family': 'Beaumont'}, {'given': 'Marc', 'family': 'Enslen'}, {'given': 'Françoise', 'family': 'Chauffard'}, {'given': 'Dux-Xian', 'family': 'Tan'}, {'given': 'Russel J.', 'family': 'Reiter'}, {'given': 'Annick', 'family': 'Fontan'}, {'given': 'Jonathan', 'family': 'French'}, {'given': 'Olivier', 'family': 'Coste'}, {'given': 'Didier', 'family': 'Lagarde'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '11513308', 'scopus': None, 'doi': '10.1007/s004210100418'}, 'title': 'Resynchronization of hormonal rhythms after an eastbound flight in humans: effects of slow-release caffeine and melatonin', 'source': 'CrossRef'}
Piérard C, Beaumont M, Enslen M, Chauffard F, Tan DX, Reiter RJ, Fontan A, French J, Coste O, Lagarde D. Resynchronization of hormonal rhythms after an eastbound flight in humans: effects of slow-release caffeine and melatonin. European journal of applied physiology. 2001;85(1-2):144-50.	-	11513308	primary-study	9e0ecd47f5e6152977e7ad2fe6b80786f77b6a04	-	{'publication_type': {'year': 2001, 'cited_medium': None, 'issue': None, 'issn': '14396319', 'volume': None, 'title': 'European Journal of Applied Physiology', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 1.0, 'total': 0.8775000000000001, 'authors': 0.9100000000000001}, 'authors': [{'given': 'C.', 'family': 'Piérard'}, {'given': 'M.', 'family': 'Beaumont'}, {'given': 'M.', 'family': 'Enslen'}, {'given': 'F.', 'family': 'Chauffard'}, {'given': 'D. X.', 'family': 'Tan'}, {'given': 'R. J.', 'family': 'Reiter'}, {'given': 'A.', 'family': 'Fontan'}, {'given': 'J.', 'family': 'French'}, {'given': 'O.', 'family': 'Coste'}, {'given': 'D.', 'family': 'Lagarde'}], 'abstract': 'The aim of this work was to investigate the potential chronobiotic properties of slow-release caffeine, in comparison with melatonin, on resynchronization of endogenous melatonin and cortisol secretions after an eastbound flight by jet incurring a time loss of 7 h. A group of 27 reservists of the US Air Force received either slow-release caffeine (300 mg), melatonin (5 mg) or placebo before, during and/or after the transmeridian flight. Saliva and urine were sampled before the flight in the United States (from day -2 to day 0) and after the flight in France (from day 1 to day 10). Saliva was collected once a day on waking to determine saliva melatonin and cortisol concentrations. In addition, concentrations of caffeine in saliva were determined three times a day and of 6-sulphatoxymelatonin in urine collected overnight to check that the treatment regimes had been complied with. From day 3 to day 5, post-flight saliva melatonin concentrations were significantly different from control values in the placebo group only. During treatment with melatonin, the mean urinary 6-sulphatoxymelatonin concentration in the melatonin group was more than twice as high as in the two other groups. In the slow-release caffeine group and the melatonin group, mean saliva cortisol concentrations were significantly lower than control from day 2 to day 5, whereas the placebo group had a mean saliva cortisol concentration significantly lower than the control value from day 2 to day 9. In conclusion, these results indicate that administration of slow-release caffeine, as well as of melatonin, allows a faster resynchronization of hormone rhythms during the 4 days following an eastbound flight incurring the loss of 7 h.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '11513308', 'scopus': '2-s2.0-0034928409', 'doi': '10.1007/s004210100418'}, 'title': 'Resynchronization of hormonal rhythms after an eastbound flight in humans: Effects of slow-release caffeine and melatonin', 'source': 'Mendeley'}
Lagarde D, Chappuis B, Billaud PF, Ramont L, Chauffard F, French J. Evaluation of pharmacological aids on physical performance after a transmeridian flight. Medicine and science in sports and exercise. 2001;33(4):628-34.	-	11283440	primary-study	bc327edc848950a9dd218895bb165a365da4aa26	-	{'publication_type': {'year': 2001, 'cited_medium': None, 'issue': None, 'issn': '0195-9131', 'volume': None, 'title': 'Medicine and Science in Sports and Exercise', 'pagination': '628-634'}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.8791666666666667, 'authors': 0.9166666666666666}, 'authors': [{'given': 'DIDIER', 'family': 'LAGARDE'}, {'given': 'BRUNO', 'family': 'CHAPPUIS'}, {'given': 'PHILIPPE F.', 'family': 'BILLAUD'}, {'given': 'LAURENT', 'family': 'RAMONT'}, {'given': 'FRAN??OISE', 'family': 'CHAUFFARD'}, {'given': 'JONATHAN', 'family': 'FRENCH'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1097/00005768-200104000-00018'}, 'title': 'Evaluation of pharmacological aids on physical performance after a transmeridian flight', 'source': 'CrossRef'}
Lagarde D, Chappuis B, Billaud PF, Ramont L, Chauffard F, French J. Evaluation of pharmacological aids on physical performance after a transmeridian flight. Medicine and science in sports and exercise. 2001;33(4):628-34.	-	11283440	primary-study	bc327edc848950a9dd218895bb165a365da4aa26	-	{'publication_type': {'year': 2001, 'cited_medium': None, 'issue': None, 'issn': '0195-9131 (Print)', 'volume': None, 'title': 'Medicine and science in sports and exercise', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 1.0, 'total': 0.9958333333333333, 'authors': 0.9833333333333334}, 'authors': [{'given': 'D', 'family': 'Lagarde'}, {'given': 'B', 'family': 'Chappuis'}, {'given': 'P F', 'family': 'Billaud'}, {'given': 'L', 'family': 'Ramont'}, {'given': 'F', 'family': 'Chauffard'}, {'given': 'J', 'family': 'French'}], 'abstract': "PURPOSE: The purpose of this study was to evaluate physical performance (static and dynamic) of U.S. Air Force reservists after an eastbound air travel across seven time zones and to estimate the pharmacological aids slow-release caffeine and melatonin versus placebo in attempt to overcome the decline in performance. METHODS: 27 American volunteers were randomly divided into three groups: caffeine 300 mg, melatonin 5 mg, and placebo (lactose capsules). Two days before the flight and 10 d after, three tests were performed: hand grip strength test (static performance), squat jump test (maximal height), and multiple jump test (power and endurance). All measures were repeated twice a day: morning and afternoon. RESULTS: In placebo conditions, the static performance of the dominant hand decreased significantly during the first three mornings and tended to decrease the fourth morning. Simultaneously, the caffeine group's static performance increased significantly, whereas the melatonin group maintained its levels. No significant differences were observed the afternoons. No statistical differences appeared for the nondominant hand in the mornings or afternoons. Dynamic capacities presented no significant degradation after the travel. In the placebo group, for the squat jump test, performance increased from the fourth day. No real explanation can be given about this result. CONCLUSIONS: We demonstrated that slow-release caffeine and melatonin might be used to compensate for jet-lag troubles and particularly for the static physical performance decrease. The slow-release caffeine seems to be the best treatment, but its effects are only demonstrated on previously damaged performance. These preliminary results need further investigation, but we are the first to report a beneficial effect of slow-release caffeine and melatonin on physical performances after jet-lag.", 'type': 'journal', 'ids': {'embase': None, 'pubmed': '11283440', 'scopus': '2-s2.0-0035064417', 'doi': None}, 'title': 'Evaluation of pharmacological aids on physical performance after a transmeridian  flight.', 'source': 'Mendeley'}
Muehlbach MJ, Walsh JK. The effects of caffeine on simulated night-shift work and subsequent daytime sleep. Sleep. 1995;18(1):22-9.	-	7761739	primary-study	2cb923a617d4b5e1f93f8e99157bd65d01ba62e9	-	{'publication_type': {'year': 2001, 'cited_medium': None, 'issue': '3', 'issn': '0962-1105', 'volume': '10', 'title': 'Journal of Sleep Research', 'pagination': '181-192'}, 'language': None, 'rating': {'year': 0, 'title': 0.75, 'total': 0.48750000000000004, 'authors': 0.0}, 'authors': [{'given': 'Katherine M.', 'family': 'Sharkey'}, {'given': 'Louis F.', 'family': 'Fogg'}, {'given': 'Charmane I.', 'family': 'Eastman'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1046/j.1365-2869.2001.00256.x'}, 'title': 'Effects of melatonin administration on daytime sleep after simulated night shift work', 'source': 'CrossRef'}
Muehlbach MJ, Walsh JK. The effects of caffeine on simulated night-shift work and subsequent daytime sleep. Sleep. 1995;18(1):22-9.	-	7761739	primary-study	2cb923a617d4b5e1f93f8e99157bd65d01ba62e9	-	{'publication_type': {'year': 1995, 'cited_medium': None, 'issue': None, 'issn': '0161-8105', 'volume': None, 'title': 'Sleep', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 0.975, 'authors': 0.9}, 'authors': [{'given': 'M J', 'family': 'Muehlbach'}, {'given': 'J K', 'family': 'Walsh'}], 'abstract': 'Thirty healthy volunteers were randomly assigned to either a caffeine or a placebo group to investigate the alerting effects of caffeine at night. Subjects adhered to a simulated night-shift schedule for 5 consecutive nights. On the first 3 nights, 2 mg/kg caffeine was added to decaffeinated coffee at 2220 and 0120 hours for the caffeine group. On nights 4 and 5 both groups received placebo. Each night, subjects completed five 60-minute sessions of a computerized simulated assembly line performance task (SALT), a multiple sleep latency test (MSLT) and questionnaires. Daytime sleep was recorded in the laboratory between 0900 and 1700 hours each day following nighttime testing. Caffeine decreased physiological sleep tendency on the night shift compared with placebo; however, the two groups performed at equivalent levels on the SALT. On nights 4 and 5, when both groups received placebo, there were no differences between the groups on the MSLT, suggesting the absence of a discontinuation effect. There were no differences on daytime polysomnograms between the groups', 'type': 'journal', 'ids': {'embase': None, 'pubmed': None, 'scopus': '2-s2.0-0028957582', 'doi': None}, 'title': 'The effects of caffeine on simulated night-shift work and subsequent daytime sleep', 'source': 'Mendeley'}
Rogers AS, Spencer MB, Stone BM, Nicholson AN. The influence of a 1 h nap on performance overnight. Ergonomics. 1990;32(10):1193-205.	10.1080/00140138908966890	2598905	primary-study	ba5cbc2dde24963036280eca7820d082362dc611	-	{'publication_type': {'year': 1989, 'cited_medium': None, 'issue': '10', 'issn': '0014-0139', 'volume': '32', 'title': 'Ergonomics', 'pagination': '1193-1205'}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 0.975, 'authors': 0.9}, 'authors': [{'given': 'A. S.', 'family': 'ROGERS'}, {'given': 'M. B.', 'family': 'SPENCER'}, {'given': 'B. M.', 'family': 'STONE'}, {'given': 'A. N.', 'family': 'NICHOLSON'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '2598905', 'scopus': None, 'doi': '10.1080/00140138908966890'}, 'title': 'The influence of a 1 h nap on performance overnight', 'source': 'CrossRef'}
Rogers AS, Spencer MB, Stone BM, Nicholson AN. The influence of a 1 h nap on performance overnight. Ergonomics. 1990;32(10):1193-205.	10.1080/00140138908966890	2598905	primary-study	ba5cbc2dde24963036280eca7820d082362dc611	-	{'publication_type': {'year': 1989, 'cited_medium': None, 'issue': None, 'issn': '0014-0139', 'volume': None, 'title': 'Ergonomics', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 0.975, 'authors': 0.9}, 'authors': [{'given': 'a S', 'family': 'Rogers'}, {'given': 'M B', 'family': 'Spencer'}, {'given': 'B M', 'family': 'Stone'}, {'given': 'a N', 'family': 'Nicholson'}], 'abstract': 'The effect on performance overnight of a 1 h nap taken at 0200 h was studied in six young female subjects. The subjects completed three schedules, including one with a nap and two without a nap, during which either a placebo or 300 mg caffeine was ingested at 2315 h. Performance was measured from 1700 h in the evening until 1030 h the next morning. Caffeine improved performance overnight on almost all tasks compared with placebo. The nap had some limited beneficial effect compared with placebo, but most tasks remained impaired.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '2598905', 'scopus': '2-s2.0-0024852945', 'doi': '10.1080/00140138908966890'}, 'title': 'The influence of a 1 h nap on performance overnight.', 'source': 'Mendeley'}
Daoud AS, Batieha A, al-Sheyyab M, Abuekteish F, Hijazi S. Effectiveness of iron therapy on breath-holding spells. The Journal of pediatrics. 1997;130(4):547-50.	-	9108851	primary-study	494f5c93991d9227356e25b5166c4392c35a65c5	-	{'publication_type': {'year': 1997, 'cited_medium': None, 'issue': '4', 'issn': '0022-3476', 'volume': '130', 'title': 'The Journal of Pediatrics', 'pagination': '547-550'}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.88, 'authors': 0.9199999999999999}, 'authors': [{'given': 'Azhar S.', 'family': 'Daoud'}, {'given': 'Anwar', 'family': 'Batieha'}, {'given': 'Mahmoud', 'family': 'Al-Sheyyab'}, {'given': 'Faisal', 'family': 'Abuekteish'}, {'given': "Sa'ad", 'family': 'Hijazi'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1016/s0022-3476(97)70237-3'}, 'title': 'Effectiveness of iron therapy on breath-holding spells', 'source': 'CrossRef'}
Daoud AS, Batieha A, al-Sheyyab M, Abuekteish F, Hijazi S. Effectiveness of iron therapy on breath-holding spells. The Journal of pediatrics. 1997;130(4):547-50.	-	9108851	primary-study	494f5c93991d9227356e25b5166c4392c35a65c5	-	{'publication_type': {'year': 1997, 'cited_medium': None, 'issue': None, 'issn': '0022-3476 (Print)', 'volume': None, 'title': 'J Pediatr', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.15384615384615385, 'total': 0.1, 'authors': 0.0}, 'authors': [{'given': 'D W', 'family': 'Hannon'}], 'abstract': 'Breath-holding spells can be dramatic and recurrent. Most pediatricians have offered parents the reassurance that these alarming episodes are not life-threatening and are likely to resolve spontaneously with time. In this month\'s issue of The Journal, Daoud et al. [1] report on the efficacy of iron therapy for breath-holding spells. Tam and Rash [2] also report a case of anemia-associated severe pallid breath-holding spells that apparently responded to iron treatment despite evidence of transient erythroblastopenia of childhood rather than iron deficiency. In a third article in this issue of The Journal, DiMario and Sarfarazi [3] report on their family pedigree analysis of breath-holding children. Thirty years ago Lombroso and Lerman [4] wrote their classic article, which remains required reading for physicians interested in breath-holding spells. Their description bears repeating as illustrative of many important points that must be accounted for in any pathophysiologic hypothesis: "The child may be frightened, hurt, or angered; cry vigorously for one or a few breaths; then "hold his breath." After a few seconds, he becomes more or less cyanotic, loses consciousness, and falls limp. Limpness may be followed by a few jerks of the limbs or, instead of limpness, there may be a short period of increased tonus. . . . Anxiety and diagnostic uncertainty are compounded when the apnea and loss of consciousness supervene early in the crying or after only a gasp or a negligible amount of crying and are followed by convulsions or severe opisthotonus rather than limpness or mild stiffness. Pallor may be present rather than cyanosis. [4]" Lombroso and Lerman [4] were able to demonstrate that many cases of breath-holding spells involved an immediate fall in heart rate after relatively minor noxious stimuli. In one case, electrocardiographic monitoring showed 24 seconds of asystole when the child angrily refused a sedative. The onset of asystole preceded loss of consciousness by 10 seconds. This pattern could be duplicated in numerous breath-holding patients when ocular compression was performed. "Abnormal vagotonia" was suggested as an important mechanism, at least in those patients with a rapid loss of consciousness without prolonged prior apnea. The term pallid infantile syncope was coined to deemphasize the primary role of actual holding of the breath. In 1963 Holowach and Thurston [5] demonstrated a statistically occurrence rate of clinically important low hemoglobin values in 102 breath-holding patients at the St. Louis Children\'s Hospital. Because of the striking bradycardia they observed, Lombroso and Lerman recommended atropine treatment for severe and pallid attacks. Nevertheless, they did note that "anemic breath holders show a remarkable improvement after treatment of their anemia." In the 1970s, Stephenson [6] reemphasized that an abnormal degree of bradycardia occurred during ocular massage in these patients, but the role of anemia in addition to (or as a possible cause of) the abnormal autonomic function was not noted. It has since remained a somewhat obscure and often forgotten observation, and no study of the effect of treatment of anemia in breath-holding children has ever been done. In the current issue, Daoud et al [1] show that iron was greatly more effective in diminishing the frequency of attacks in 33 iron-treated children than in 34 placebo-treated children, all of whom had frequent breath-holding spells. No significant pretreatment differences in patient or laboratory variables existed between the two groups. In the iron-treated group, a successful decrease in spells was associated with a lower pretreatment hemoglobin concentration (8.6 gm/dl) than in those few patients who responded poorly to iron (hemoglobin concentration: 10.6 gm/dl), supporting the hypothesis that iron deficiency or anemia has a role in the pathophysiology of breath-holding spells. Daoud et al. [1] are to be congratulated for having performed a study that any large pediatric practice could have performed during the past three decades. They not only revive an old concept, but their study itself is reminiscent of good clinical studies from the era in which their hypothesis originated: patient-oriented research done with simple resources and answering a clinical question of concern to general practitioners. The laboratory tests performed were inexpensive and clinically indicated, given the existing if somewhat obscure literature. The study was prospective and double-blinded. However, patients were not randomly selected; alternating assignment to placebo and iron groups was made, instead of true randomization. The authors\' conclusion that iron therapy was beneficial in these patients seems satisfactorily demonstrated. The case report by Tam and Rash, [2] in which the patient was anemic but not necessarily iron deficient, adds an interesting postscript to the study by Daoud et al. [1] One could argue that the breath-holding spells would have spontaneously resolved in this one patient with or without iron. However, Daoud et al. also found a favorable response to treatment in some children not meeting clinical criteria for iron deficiency. The possible reasons offered in both of these articles for the benefit of iron therapy are plausible: namely, that iron deficiency with or without anemia per se may adversely affect autonomic nervous function. DiMario and Sarfarazi [3] demonstrate an underlying genetic predisposition in many children with breath-holding spells; this appears to be an autosomal dominant condition with incomplete penetrance or expression. Fifty-seven probands with severe breath-holding spells had 38 first-degree relatives with a history of childhood breath holding. In 31 nuclear families, parent-to-child transmission was observed, with approximately a 50:50 risk of inheritance from an affected parent within those families. Families without such histories could indicate that some breath-holding spells are not inherited, or could reflect reduced penetrance or expression of a genetic condition. Because hematologic data were not recorded in this study, it is uncertain whether iron deficiency or anemia was a factor in any of the familial or apparently nonfamilial cases of breath-holding spells. In my own practice I have often found that parents are less concerned about severe breath-holding spells than are day care personnel or physicians. Usually the reason is that one of the parents or another close relative had identical symptoms in early childhood that resolved without problems. DiMario and Sarfarazi [3] also noted that some parents and siblings of proband breath holders had fainting spells, rather than breath-holding spells, and that some family members with a history of breath holding later had typical fainting spells. Interestingly, when Holowach and Thurston [5] described the association of breath-holding spells with anemia, they commented that "we are impressed with the similarity between breath-holding spells and other types of fainting-. . . . Several of the children with classic breath-holding spells in infancy later exhibited . . . syncope." Others have noted a familial predilection for common vasovagal faints in adults, adolescents, and older children. [7] Can these clinical observations be explained by any unifying hypothesis for the pathophysiology of breath-holding spells? I believe that many breath holders have a self-resolving infantile variant of vasovagal or neurocardiogenic syncope that is often familial and that may recur as classic "medical faints" or simple vasovagal syncope in later life. This explains the profound and early bradycardia noted in many recordings during breath-holding spells, recordings that are similar to those obtained during vasovagal syncopal attacks in which asystole can be abrupt and severe. This also explains the apparent "evolution" into vasovagal syncope noted by DiMario and Sarfarazi [3] and by others, as well as the variable manifestations within family histories. As with "medical fainters" (patients whose vasovagal syncopes are triggered by venipuncture or other medical procedures), emotional/situational factors probably interact with a genetically determined autonomic abnormality to produce breath-holding spells. Iron deficiency may aggravate this tendency or possibly cause it in cases where there is not an underlying genetic substrate. Lombroso and Lerman [4] made a clinical distinction between pallid and cyanotic breath holders, but it has never been clear whether these are pathophysiologically distinct. In the current articles in this Journal, this remains true. In the studies by Daoud et al. [1] and by DiMario and Sarfarazi, [3] patients were categorized as having one form or the other but were combined for analyses. Cases of both types of spells in the same families and in the same patient support this. In the case report by Tam and Rash, [2] the infant is described as having cyanotic breath-holding spells but was noted to have pallor with loss of consciousness. In breath holders, various combinations of sudden apnea, bradycardia, asystole, and cerebral ischemia may produce various "types" of breath-holding spells. In both pallid and cyanotic breath-holding spells, physicians should look for anemia and iron deficiency. Physicians should also inquire regarding family members with either breath-holding spells or syncope. A family history of syncope or breath-holding spells may be helpful in securing the clinical diagnosis. An additional simple but important recommendation from the 1943 review by Bridge et al. [8] has been neglected in recent literature and texts: "The child should be placed in a horizontal position to prevent an accident and to improve cerebral circulation." When full syncope occurs, a parent often holds the child upright against the chest. If lessons learned during tilt-table testing for neurocardiogenic syncope apply, it is likely that the duration', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '9108843', 'scopus': '2-s2.0-0030830268', 'doi': None}, 'title': 'Breath-holding spells: waiting to inhale, waiting for systole, or waiting for iron therapy?', 'source': 'Mendeley'}
Paul R, Manchanda SS. Breath-holding attacks. The role of psychological factors and iron therapy. Indian journal of pediatrics. 1969;36(259):271-7.	-	5823631	primary-study	46bf8a395afd3fe5fe9280466d8ad1db2a0a4427	-	{'publication_type': {'year': 1969, 'cited_medium': None, 'issue': '8', 'issn': '0019-5456', 'volume': '36', 'title': 'The Indian Journal of Pediatrics', 'pagination': '271-277'}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.875, 'authors': 0.9}, 'authors': [{'given': 'Ravi', 'family': 'Paul'}, {'given': 'S. S.', 'family': 'Manchanda'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1007/bf02756332'}, 'title': 'Breath-holding attacks', 'source': 'CrossRef'}
Paul R, Manchanda SS. Breath-holding attacks. The role of psychological factors and iron therapy. Indian journal of pediatrics. 1969;36(259):271-7.	-	5823631	primary-study	46bf8a395afd3fe5fe9280466d8ad1db2a0a4427	-	{'publication_type': {'year': 2007, 'cited_medium': None, 'issue': None, 'issn': '0195-7910', 'volume': None, 'title': 'American Journal of Forensic Medicine & Pathology.28(3):271-7,', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.25, 'total': 0.24583333333333335, 'authors': 0.3333333333333333}, 'authors': [{'given': 'T S', 'family': 'Corey'}, {'given': 'R', 'family': 'Hanzlick'}, {'given': 'J', 'family': 'Howard'}, {'given': 'C', 'family': 'Nelson'}, {'given': 'H', 'family': 'Krous'}, {'given': 'NAME Ad Hoc Committee on Sudden Unexplained Infant', 'family': 'Death'}], 'abstract': 'There is a great deal of variation in the methods and wording used by medical examiners in the medicolegal investigation and certification of infant deaths. This paper was created by the NAME Ad Hoc Committee on Sudden Unexplained Infant Death to address several specific issues, namely: * To establish a functional approach to the investigation of sudden unexplained infant deaths; * To outline a "bare minimum" set of recommendations to define the scope of investigation required; * To recommend methods and wording to be used when certifying infant deaths; * To develop a list of potential stressors or possible external causes of death that should be identified and reported on the death certificate and/or within a medical examiner/coroner office database. This paper was electronically posted for NAME member review and comment for a period of 30 days. The paper was further revised based on member comments and then submitted to the NAME board of directors in the fall of 2005 prior to the annual meeting. This text of this paper was officially approved and endorsed by the NAME board of directors on October 14, 2005, at the annual meeting in Los Angeles, CA', 'type': 'journal', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': None}, 'title': 'A functional approach to sudden unexplained infant deaths', 'source': 'Mendeley'}
Chughtai T, Chen LQ, Salasidis G, Nguyen D, Tchervenkov C, Morin JF. Clips versus suture technique: is there a difference?. The Canadian journal of cardiology. 2000;16(11):1403-7.	-	11109037	primary-study	4c3b7b163a835604ac5f5baabb53dcad6c3a8b05	-	{'publication_type': {'year': 1997, 'cited_medium': None, 'issue': '5', 'issn': '0022-5223', 'volume': '114', 'title': 'The Journal of Thoracic and Cardiovascular Surgery', 'pagination': '727-737'}, 'language': None, 'rating': {'year': 0, 'title': 0.13636363636363635, 'total': 0.15292207792207793, 'authors': 0.2571428571428572}, 'authors': [{'given': 'Christo I.', 'family': 'Tchervenkov'}, {'given': 'Gary', 'family': 'Salasidis'}, {'given': 'Renzo', 'family': 'Cecere'}, {'given': 'Marie J.', 'family': 'Béland'}, {'given': 'Luc', 'family': 'Jutras'}, {'given': 'Marc', 'family': 'Paquet'}, {'given': 'Anthony R.C.', 'family': 'Dobell'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1016/s0022-5223(97)70076-x'}, 'title': 'One-stage midline unifocalization and complete repair in infancy versus multiple-stage unifocalization followed by repair for complex heart disease with major aortopulmonary collaterals', 'source': 'CrossRef'}
Chughtai T, Chen LQ, Salasidis G, Nguyen D, Tchervenkov C, Morin JF. Clips versus suture technique: is there a difference?. The Canadian journal of cardiology. 2000;16(11):1403-7.	-	11109037	primary-study	4c3b7b163a835604ac5f5baabb53dcad6c3a8b05	-	{'publication_type': {'year': 2015, 'cited_medium': None, 'issue': None, 'issn': '2213-8595', 'volume': None, 'title': 'The lancet. Diabetes & endocrinology', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.3076923076923077, 'total': 0.42500000000000004, 'authors': 0.9}, 'authors': [{'given': None, 'family': '11'}], 'abstract': 'BACKGROUND: Comwpared with normal weight, obesity might be associated with worse clinical outcomes, including chronic kidney disease. Whether this association is modified by age is not known. We investigated the association of BMI with progressive loss of kidney function and all-cause mortality in US veterans. METHODS: In a national cohort of 3 376 187 US veterans with an estimated glomerular filtration rate (eGFR) of more than 60 mL/min per 1·73 m(2), we assessed the association of BMI in patients of different ages (<40 years, 40 years to <50 years, 50 years to <60 years, 60 years to <70 years, 70 years to <80 years, and ≥80 years) with loss of kidney function and with all-cause mortality in logistic regression models and Cox proportional hazards models adjusted for ethnic origin, sex, comorbidities, medications, and baseline eGFR. FINDINGS: 274 764 (8·1%) of 3 376 187 veterans had a rapid decline in kidney function (decrease in slope of >5 mL/min per 1·73 m(2)). The lowest risk for loss of kidney function was noted in patients with BMI of at least 25 kg/m(2) but less than 30 kg/m(2). A generally consistent U-shaped association was noted between BMI and rapid loss of kidney function that was more prominent with increasing age, except in the patients younger than 40 years, in whom BMI did not seem to be predictive of renal function impairment. 672 341 veterans died (28·7 per 1000 patient-years, 95% CI 28·6-28·7) over a median follow-up of 6·8 years (IQR 6·5-7·7). BMI also showed a U-shaped association with mortality, which was similar in all age groups. INTERPRETATION: A BMI of 30 kg/m(2) or more is associated with rapid loss of kidney function in patients with eGFR of at least 60 mL/min per 1·73 m(2), and this association is accentuated in older patients. A BMI of 35 kg/m(2) or more is also associated with high mortality. A BMI of at least 25 kg/m(2) but less than 30 kg/m(2) is associated with the best clinical outcomes. FUNDING: National Institute of Health, Memphis VA Medical Center, Long Beach VA Healthcare System, Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development, and VA Information Resource Center.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '26235959', 'scopus': None, 'doi': '10.1016/S2213-8587(15)00128-X'}, 'title': 'Association of age and BMI with kidney function and mortality: a cohort study.', 'source': 'Mendeley'}
Mullen JC, Bentley MJ, Mong K, Karmy-Jones R, Lemermeyer G, Gelfand ET, Koshal A, Modry DL, Penkoske PA. Reduction of leg wound infections following coronary artery bypass surgery. The Canadian journal of cardiology. 1999;15(1):65-8.	-	10024861	primary-study	eeff9e7cb5d240bf884f61f60d18ba4327ab5404	-	{'publication_type': {'year': None, 'cited_medium': None, 'issue': None, 'issn': None, 'volume': None, 'title': 'http://isrctn.org/>', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.8, 'total': 0.645, 'authors': 0.5}, 'authors': [{'given': 'M', 'family': 'Zafar'}], 'abstract': None, 'type': 'dataset', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1186/isrctn47246088'}, 'title': 'Reduction of leg wound complications following coronary artery bypass grafting', 'source': 'CrossRef'}
Mullen JC, Bentley MJ, Mong K, Karmy-Jones R, Lemermeyer G, Gelfand ET, Koshal A, Modry DL, Penkoske PA. Reduction of leg wound infections following coronary artery bypass surgery. The Canadian journal of cardiology. 1999;15(1):65-8.	-	10024861	primary-study	eeff9e7cb5d240bf884f61f60d18ba4327ab5404	-	{'publication_type': {'year': 2004, 'cited_medium': None, 'issue': None, 'issn': '0160-6689', 'volume': None, 'title': 'Journal of Clinical Psychiatry. Vol 65(8)', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.3333333333333333, 'total': 0.21666666666666667, 'authors': 0.0}, 'authors': [{'given': 'M. Waqar (Ed)', 'family': 'Mohamand'}, {'given': 'Richard M. (Ed)', 'family': 'Sarles'}, {'given': 'Michael H. (Ed)', 'family': 'Ebert'}], 'abstract': 'Reviews the book, "Bipolar Disorder in Childhood and Early Adolescence," edited by edited by Barbara Geller and Melissa P. DelBello (see record 2003-04754-000). This volume is divided relatively equally into 3 major sections. The first section addresses the diagnosis, natural history, and longitudinal course of bipolar disorder and presents material on comorbid disorders, including pervasive developmental disorder and offspring studies. Overall, this book does an excellent job of offering something for everyone, clinicians and researchers alike. As with many publications dealing with psychiatric disorders that are in the early stages of being studied and understood, many chapters raise more questions than provide answers. Also, some readers may have trouble with some unevenness of content and style, ranging from technical research methodology to internet support groups. However, this seeming unevenness is actually a strength in that it broadly addresses our burgeoning understanding of the child with bipolar disorder and offers a good balance of research, clinical findings, and treatment options. Each chapter provides a comprehensive bibliography, and the chapter authors openly discuss the shortcomings of the available research and treatment studies. On balance, this is an excellent, up-to-date, edited volume dealing with the complex problems of juvenile-onset bipolar disorder. It should be the single source that clinicians and researchers reach for to guide them in their struggle to help not only the child with bipolar disorder but also the family. (PsycINFO Database Record (c) 2010 APA, all rights reserved)', 'type': 'journal', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': None}, 'title': 'Review of Bipolar Disorder in Childhood and Early Adolescence.', 'source': 'Mendeley'}
Johnson RG, Cohn WE, Thurer RL, McCarthy JR, Sirois CA, Weintraub RM. Cutaneous closure after cardiac operations: a controlled, randomized, prospective comparison of intradermal versus staple closures. Annals of surgery. 1997;226(5):606-12.	-	9389394	primary-study	e29e3d89d4228cd41ecd37c1b07b44e2233d3654	-	{'publication_type': {'year': 1997, 'cited_medium': None, 'issue': '5', 'issn': '0003-4932', 'volume': '226', 'title': 'Annals of Surgery', 'pagination': '606-612'}, 'language': None, 'rating': {'year': 0, 'title': 1.0, 'total': 0.875, 'authors': 0.9}, 'authors': [{'given': 'Robert G.', 'family': 'Johnson'}, {'given': 'William E.', 'family': 'Cohn'}, {'given': 'Robert L.', 'family': 'Thurer'}, {'given': 'James R.', 'family': 'McCarthy'}, {'given': 'Cheryl A.', 'family': 'Sirois'}, {'given': 'Ronald M.', 'family': 'Weintraub'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1097/00000658-199711000-00005'}, 'title': 'Cutaneous Closure After Cardiac Operations', 'source': 'CrossRef'}
Johnson RG, Cohn WE, Thurer RL, McCarthy JR, Sirois CA, Weintraub RM. Cutaneous closure after cardiac operations: a controlled, randomized, prospective comparison of intradermal versus staple closures. Annals of surgery. 1997;226(5):606-12.	-	9389394	primary-study	e29e3d89d4228cd41ecd37c1b07b44e2233d3654	-	{'publication_type': {'year': 1997, 'cited_medium': None, 'issue': None, 'issn': '0003-4932', 'volume': None, 'title': 'Annals of surgery', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 0.975, 'authors': 0.9}, 'authors': [{'given': 'R G', 'family': 'Johnson'}, {'given': 'W E', 'family': 'Cohn'}, {'given': 'R L', 'family': 'Thurer'}, {'given': 'J R', 'family': 'McCarthy'}, {'given': 'C A', 'family': 'Sirois'}, {'given': 'R M', 'family': 'Weintraub'}], 'abstract': 'To determine the difference in wound complication and infection rates between suture and staple closure techniques applied to clean incisions in coronary bypass patients.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '9389394', 'scopus': '2-s2.0-0031459543', 'doi': '10.1097/00000658-199711000-00005'}, 'title': 'Cutaneous closure after cardiac operations: a controlled, randomized, prospective comparison of intradermal versus staple closures.', 'source': 'Mendeley'}
Angelini GD, Butchart EG, Armistead SH, Breckenridge IM. Comparative study of leg wound skin closure in coronary artery bypass graft operations. Thorax. 1985;39(12):942-5.	-	6096982	primary-study	2f3a7f6c3fe13125badd2cf7aa07932bb3ff1d5d	-	{'publication_type': {'year': 1984, 'cited_medium': None, 'issue': '12', 'issn': '0040-6376', 'volume': '39', 'title': 'Thorax', 'pagination': '942-945'}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 0.975, 'authors': 0.9}, 'authors': [{'given': 'G D', 'family': 'Angelini'}, {'given': 'E G', 'family': 'Butchart'}, {'given': 'S H', 'family': 'Armistead'}, {'given': 'I M', 'family': 'Breckenridge'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1136/thx.39.12.942'}, 'title': 'Comparative study of leg wound skin closure in coronary artery bypass graft operations.', 'source': 'CrossRef'}
Angelini GD, Butchart EG, Armistead SH, Breckenridge IM. Comparative study of leg wound skin closure in coronary artery bypass graft operations. Thorax. 1985;39(12):942-5.	-	6096982	primary-study	2f3a7f6c3fe13125badd2cf7aa07932bb3ff1d5d	-	{'publication_type': {'year': 1984, 'cited_medium': None, 'issue': None, 'issn': '00406376', 'volume': None, 'title': 'Thorax', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 0.975, 'authors': 0.9}, 'authors': [{'given': 'G D', 'family': 'Angelini'}, {'given': 'E G', 'family': 'Butchart'}, {'given': 'S H', 'family': 'Armistead'}, {'given': 'I M', 'family': 'Breckenridge'}], 'abstract': 'A prospective randomised study of four different methods of leg wound skin closure after removal of the long saphenous vein was carried out in 113 patients undergoing coronary artery bypass grafting. These methods were: (1) continuous nylon vertical mattress suture (27 patients); (2) continuous subcuticular absorbable (Dexon) suture (29 patients); (3) metal skin staples (Autosuture) (27 patients); and (4) adhesive sutureless skin closure ("Op-site") (30 patients). All wounds were examined by two independent observers at five, 10, and 45 days after operation. At five days, inflammation, extent of oedema, discharge, and infection were assessed. At 10 days attention was paid to the state of wound healing and at 45 days to the final cosmetic appearance. The use of continuous subcuticular suture resulted in significantly less discharge than did the use of metal staples, nylon vertical mattress suture, or Op-site. The incidence of established wound infection was 4.5% overall, with no infection in the wounds closed with Dexon. Assessment of the healing process showed subcuticular Dexon to be more effective than metal staples or vertical mattress nylon suture. The final cosmetic result showed continuous subcuticular suture to be superior to nylon vertical mattress suture and skin staples but as effective as Op-site sutureless skin closure.', 'type': 'generic', 'ids': {'embase': None, 'pubmed': '6096982', 'scopus': '2-s2.0-0021688588', 'doi': '10.1136/thx.39.12.942'}, 'title': 'Comparative study of leg wound skin closure in coronary artery bypass graft operations', 'source': 'Mendeley'}
Tjandra JJ, Chan MK, Yeh HC. Injectable silicone biomaterial (PTQ) is more effective than carbon-coated beads (Durasphere) in treating passive faecal incontinence--a randomized trial. Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland. 2008;11(4):382-9.	10.1111/j.1463-1318.2008.01634.x	18637935	primary-study	247db25309a529af5d5afd34816125520dfefc6b	-	{'publication_type': {'year': 2009, 'cited_medium': None, 'issue': '4', 'issn': '1462-8910', 'volume': '11', 'title': 'Colorectal Disease', 'pagination': '382-389'}, 'language': None, 'rating': {'year': 0, 'title': 0.9, 'total': 0.81, 'authors': 0.9}, 'authors': [{'given': 'J. J.', 'family': 'Tjandra'}, {'given': 'M. K. Y.', 'family': 'Chan'}, {'given': 'H. C. H.', 'family': 'Yeh'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '18637935', 'scopus': None, 'doi': '10.1111/j.1463-1318.2008.01634.x'}, 'title': 'Injectable silicone biomaterial (PTQTM) is more effective than carbon-coated beads (Durasphere®) in treating passive faecal incontinence - a randomized trial', 'source': 'CrossRef'}
Tjandra JJ, Chan MK, Yeh HC. Injectable silicone biomaterial (PTQ) is more effective than carbon-coated beads (Durasphere) in treating passive faecal incontinence--a randomized trial. Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland. 2008;11(4):382-9.	10.1111/j.1463-1318.2008.01634.x	18637935	primary-study	247db25309a529af5d5afd34816125520dfefc6b	-	{'publication_type': {'year': 2009, 'cited_medium': None, 'issue': None, 'issn': '14628910', 'volume': None, 'title': 'Colorectal Disease', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.9, 'total': 0.81, 'authors': 0.9}, 'authors': [{'given': 'J. J.', 'family': 'Tjandra'}, {'given': 'M. K Y', 'family': 'Chan'}, {'given': 'H. C H', 'family': 'Yeh'}], 'abstract': "OBJECTIVE: Both injectable silicone biomaterial (PTQ) and pyrolytic carbon-coated beads (Durasphere) have been shown to be effective in treating passive faecal incontinence due to internal sphincter dysfunction. This is a randomized study to evaluate their relative safety and efficacy.\\n\\nMETHOD: Forty patients (mean age 59.5 years vs 58.9 years) were randomized to have inter-sphincteric injection of PTQ or submucosal injection of Durasphere. Patients were assessed with anorectal physiology, endoanal ultrasound, a validated incontinence score and quality of life questionnaires.\\n\\nRESULTS: In the Durasphere group, complications included rectal pain (5%), erosion through rectal mucosa (10%), and type III hypersensitivity reaction (5%). No complications occurred in the PTQ group. Compared with PTQ, Durasphere group has a more rapid action, with improved continence at 2 weeks after injection. In both groups, faecal continence significantly improved 6 weeks after injection, and continued to improve significantly up to 6 months in both groups (P < 0.0001). At 6 weeks, 6 and 12 months after injection, significantly more PTQ patients achieved greater than 50% improvement in Wexner's continence score than Durasphere patients (respectively, P = 0.01; P < 0.0001; P = 0.001). There was a significant improvement in faecal incontinence quality of life scale and the 12-month physical health scale of Short Form-12 health survey in the PTQ group but not in the Durasphere group.\\n\\nCONCLUSION: In patients with internal sphincter dysfunction, injectable silicone biomaterial was safer and more effective than Durasphere.", 'type': 'journal', 'ids': {'embase': None, 'pubmed': '18637935', 'scopus': '2-s2.0-65249123523', 'doi': '10.1111/j.1463-1318.2008.01634.x'}, 'title': 'Injectable silicone biomaterial (PTQ™) is more effective than carbon-coated beads (Durasphere®) in treating passive faecal incontinence - A randomized trial', 'source': 'Mendeley'}
Maeda Y, Vaizey CJ, Kamm MA. Pilot study of two new injectable bulking agents for the treatment of faecal incontinence. Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland. 2008;10(3):268-72.	10.1111/j.1463-1318.2007.01318.x	17655723	primary-study	7ced6382163c6bde3dce473bab779086b0c78c63	-	{'publication_type': {'year': 2008, 'cited_medium': None, 'issue': '3', 'issn': '1462-8910', 'volume': '10', 'title': 'Colorectal Disease', 'pagination': '268-272'}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.875, 'authors': 0.9}, 'authors': [{'given': 'Y.', 'family': 'Maeda'}, {'given': 'C. J.', 'family': 'Vaizey'}, {'given': 'M. A.', 'family': 'Kamm'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '17655723', 'scopus': None, 'doi': '10.1111/j.1463-1318.2007.01318.x'}, 'title': 'Pilot study of two new injectable bulking agents for the treatment of faecal incontinence', 'source': 'CrossRef'}
Maeda Y, Vaizey CJ, Kamm MA. Pilot study of two new injectable bulking agents for the treatment of faecal incontinence. Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland. 2008;10(3):268-72.	10.1111/j.1463-1318.2007.01318.x	17655723	primary-study	7ced6382163c6bde3dce473bab779086b0c78c63	-	{'publication_type': {'year': 2014, 'cited_medium': None, 'issue': None, 'issn': '1463-1318', 'volume': None, 'title': 'Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 0.65, 'total': 0.6475000000000001, 'authors': 0.5}, 'authors': [{'given': 'J', 'family': 'Tiernan'}, {'given': 'a', 'family': 'Cook'}, {'given': 'I', 'family': 'Geh'}, {'given': 'B', 'family': 'George'}, {'given': 'L', 'family': 'Magill'}, {'given': 'J', 'family': 'Northover'}, {'given': 'a', 'family': 'Verjee'}, {'given': 'J', 'family': 'Wheeler'}, {'given': 'N', 'family': 'Fearnhead'}], 'abstract': 'AIM: The modified Delphi approach is an established method for reaching a consensus opinion among a group of experts in a particular field. We have used this technique to survey the entire membership of the Association of Coloproctology of Great Britain and Ireland (ACPGBI) to reach a consensus on prioritizing clinical research questions in colorectal disease.\\n\\nMETHOD: Three rounds of surveys were conducted using a web-based tool. In the first, the ACPGBI membership was invited to submit research questions. In Rounds 2 and 3 they were asked to score questions on priority. A steering group analysed the results of each round to identify those questions ranked as being of highest priority.\\n\\nRESULTS: Five hundred and two questions were submitted in Round 1. Following two rounds of voting and analysis, a list of 25 priority questions was produced, including 15 cancer-related and 10 noncancer-related questions.\\n\\nCONCLUSION: It is anticipated that these results will: (i) set the research agenda over the next few years for the study of colorectal disease in the United Kingdom, (ii) promote development and (iii) define funding of new research and prioritize areas of unmet clinical need where the potential clinical impact is greatest.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '25284641', 'scopus': None, 'doi': '10.1111/codi.12790'}, 'title': 'Use of a modified Delphi approach to develop research priorities for the association of coloproctology of Great Britain and Ireland.', 'source': 'Mendeley'}
Siproudhis L, Morcet J, Lainé F. Elastomer implants in faecal incontinence: a blind, randomized placebo-controlled study. Alimentary pharmacology & therapeutics. 2007;25(9):1125-32.	10.1111/j.1365-2036.2007.03293.x	17439514	primary-study	057e89da7e18e7b6f1295ae789044e234bf41d46	-	{'publication_type': {'year': 2007, 'cited_medium': None, 'issue': '9', 'issn': '0269-2813', 'volume': '25', 'title': 'Alimentary Pharmacology & Therapeutics', 'pagination': '1125-1132'}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.8833333333333333, 'authors': 0.9333333333333332}, 'authors': [{'given': 'L.', 'family': 'SIPROUDHIS'}, {'given': 'J.', 'family': 'MORCET'}, {'given': 'F.', 'family': 'LAINÉ'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '17439514', 'scopus': None, 'doi': '10.1111/j.1365-2036.2007.03293.x'}, 'title': 'Elastomer implants in faecal incontinence: a blind, randomized placebo-controlled study', 'source': 'CrossRef'}
Siproudhis L, Morcet J, Lainé F. Elastomer implants in faecal incontinence: a blind, randomized placebo-controlled study. Alimentary pharmacology & therapeutics. 2007;25(9):1125-32.	10.1111/j.1365-2036.2007.03293.x	17439514	primary-study	057e89da7e18e7b6f1295ae789044e234bf41d46	-	{'publication_type': {'year': 2007, 'cited_medium': None, 'issue': None, 'issn': '0269-2813', 'volume': None, 'title': 'Alimentary Pharmacology and Therapeutics', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 1.0, 'total': 0.775, 'authors': 0.5}, 'authors': [{'given': 'Siproudhis', 'family': 'L.'}, {'given': 'Morcet', 'family': 'J.'}, {'given': 'Lainé', 'family': 'F.'}], 'abstract': "Aim: To test efficacy and safety of polydimethylsiloxane elastomer implants, a silicone biomaterial, in patients with severe faecal incontinence related to an impaired internal anal sphincter. Methods: Subjects were randomized to receive three injections of 2.5 mL of either physiological saline or polydimethylsiloxane elastomer. After local anaesthesia, an 18 gauge, 2.5-in needle was inserted through the perianal skin and laid down into the intersphincteric space. Treatment (saline or polydimethylsiloxane elastomer) was administered by means of a ratchet gun. Three injections of 2.5 mL each were performed in the area of the internal anal sphincter at 3, 7 and 11 o'clock positions. Main end point was the percentage of subjects in each treatment arm experiencing a successful treatment, defined as a Cleveland Clinic Florida-Faecal Incontinence score <8, 3 months after treatment. Secondary end points were quality of life scores, weekly number of faecal incontinence episodes, subject acceptance and adverse events rate. Both patients and end point assessments were blinded to treatment. Results: 44 women (64.3 ± 9 years) with a baseline Cleveland Clinic Florida-Faecal Incontinence score ≥8 were enrolled prospectively; 22 received polydimethylsiloxane elastomer and 22 saline treatment. Treatment was well tolerated. At 3 months, the percentage of subjects experiencing a successful treatment was not different between polydimethylsiloxane elastomer and saline groups (23% vs. 27%, respectively, P = 0.73). Moreover, Cleveland Clinic Florida-Faecal Incontinence score was not significantly different between polydimethylsiloxane elastomer and saline groups (11.7 ± 4.7 vs. 11.4 ± 4.5, respectively, P = 0.79). Conclusions: Polydimethylsiloxane elastomer implants cannot be recommended for treatment of severe faecal incontinence related to impaired internal anal sphincter. © 2007 The Authors.", 'type': 'journal', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': None}, 'title': 'Elastomer implants in faecal incontinence: A blind, randomized placebo-controlled study', 'source': 'Mendeley'}
Tjandra JJ, Lim JF, Hiscock R, Rajendra P. Injectable silicone biomaterial for fecal incontinence caused by internal anal sphincter dysfunction is effective. Diseases of the colon and rectum. 2004;47(12):2138-46.	10.1007/s10350-004-0760-3	15657666	primary-study	9286058fdced4f6f3d4b40dd57a84aec9d8c5892	-	{'publication_type': {'year': 2004, 'cited_medium': None, 'issue': '12', 'issn': '0012-3706', 'volume': '47', 'title': 'Diseases of the Colon & Rectum', 'pagination': '2138-2146'}, 'language': None, 'rating': {'year': 0, 'title': 1.0, 'total': 0.8812500000000001, 'authors': 0.925}, 'authors': [{'given': 'J. J.', 'family': 'Tjandra'}, {'given': 'J. F.', 'family': 'Lim'}, {'given': 'R.', 'family': 'Hiscock'}, {'given': 'P.', 'family': 'Rajendra'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '15657666', 'scopus': None, 'doi': '10.1007/s10350-004-0760-3'}, 'title': 'Injectable Silicone Biomaterial for Fecal Incontinence Caused by Internal Anal Sphincter Dysfunction Is Effective', 'source': 'CrossRef'}
Tjandra JJ, Lim JF, Hiscock R, Rajendra P. Injectable silicone biomaterial for fecal incontinence caused by internal anal sphincter dysfunction is effective. Diseases of the colon and rectum. 2004;47(12):2138-46.	10.1007/s10350-004-0760-3	15657666	primary-study	9286058fdced4f6f3d4b40dd57a84aec9d8c5892	-	{'publication_type': {'year': 2004, 'cited_medium': None, 'issue': None, 'issn': '00123706', 'volume': None, 'title': 'Diseases of the Colon and Rectum', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.8812500000000001, 'authors': 0.925}, 'authors': [{'given': 'J. J.', 'family': 'Tjandra'}, {'given': 'J. F.', 'family': 'Lim'}, {'given': 'R.', 'family': 'Hiscock'}, {'given': 'P.', 'family': 'Rajendra'}], 'abstract': "PURPOSE: Fecal incontinence caused by a weak or disrupted internal anal sphincter is common but there has been no effective treatment. This prospective study evaluates the medium-term clinical effects of an injectable silicone biomaterial, PTP (Bioplastique), used to augment the internal anal sphincter. METHOD: Eighty-two patients (64 females; median age, 66 years) with severe fecal incontinence and a low anal resting pressure caused by internal anal sphincter dysfunction (defect, n = 11; intact, n = 71) were randomized to PTP injection into intersphincteric space and internal anal sphincter with (Group A, n = 42) or without (Group B, n = 40) guidance by endoanal ultrasound. Both groups were similar in terms of age, gender, past anorectal surgery, duration of follow-up (median, 6 months; range, 1-12 months), and baseline continence score. Sixty-two percent of Group A and 55 percent of Group B had prolonged pudendal nerve terminal motor latency. RESULTS: There was no significant complication. Two patients in Group A and four patients in Group B noted minor discomfort at injection sites. At one month postprocedure, endoanal ultrasound confirmed retention of silicone biomaterial without migration. In both groups, fecal continence was significantly improved by PTP implants 1 month after injection, but continued to improve significantly for up to 12 months in Group A and 6 months in Group B (P < 0.001). Improvement in fecal continence and maximum anal resting pressure was significantly greater in Group A, in whom injection was guided by endoanal ultrasound, than in Group B. At three months after injection, significantly more Group A patients than Group B patients achieved >50 percent improvement in Wexner's continence score (69 percent vs. 40 percent; P = 0.014). Ninety-three percent of Group A and 92 percent of Group B had >50 percent improvement in global quality of life scores (visual analog scale). At a median follow-up of 6 months, all domains of the fecal incontinence quality of life scale improved significantly in both groups; however, the physical function and mental health scores of Short Form-12 only improved in Group A. A prolonged pudendal nerve terminal motor latency had no effect on functional outcome in either group. CONCLUSION: Injection of silicone biomaterial provided a marked improvement in fecal continence and quality of life in patients with internal sphincter dysfunction, despite the presence of pudendal neuropathy.", 'type': 'journal', 'ids': {'embase': None, 'pubmed': '15657666', 'scopus': '2-s2.0-13144256734', 'doi': '10.1007/s10350-004-0760-3'}, 'title': 'Injectable silicone biomaterial for fecal incontinence caused by internal anal sphincter dysfunction is effective', 'source': 'Mendeley'}
Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. American journal of respiratory and critical care medicine. 2008;177(1):19-26.	10.1164/rccm.200707-973OC	17916806	primary-study	64ff4cecd194ade9b5ed072735bc5f8487f43f5f	-	{'publication_type': {'year': 2008, 'cited_medium': None, 'issue': '1', 'issn': '1073-449X', 'volume': '177', 'title': 'American Journal of Respiratory and Critical Care Medicine', 'pagination': '19-26'}, 'language': None, 'rating': {'year': 0, 'title': 1.0, 'total': 0.875, 'authors': 0.9}, 'authors': [{'given': 'Jadwiga A.', 'family': 'Wedzicha'}, {'given': 'Peter M. A.', 'family': 'Calverley'}, {'given': 'Terence A.', 'family': 'Seemungal'}, {'given': 'Gerry', 'family': 'Hagan'}, {'given': 'Zainab', 'family': 'Ansari'}, {'given': 'Robert A.', 'family': 'Stockley'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1164/rccm.200707-973oc'}, 'title': 'The Prevention of Chronic Obstructive Pulmonary Disease Exacerbations by Salmeterol/Fluticasone Propionate or Tiotropium Bromide', 'source': 'CrossRef'}
Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. American journal of respiratory and critical care medicine. 2008;177(1):19-26.	10.1164/rccm.200707-973OC	17916806	primary-study	64ff4cecd194ade9b5ed072735bc5f8487f43f5f	-	{'publication_type': {'year': 2004, 'cited_medium': None, 'issue': None, 'issn': None, 'volume': None, 'title': 'Metallurgia Italiana, 103, 1 (2011) 19-26��', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.3, 'total': 0.195, 'authors': 0.0}, 'authors': [{'given': 'Gramegna N.; Corte E.D.; Quaglia G.; Lorente F.G.; Loizaga I.; Berrocal', 'family': 'S.'}], 'abstract': 'The absorbed energy during impact test and the velocity reduction of the body are the reference diagram to evaluate the performance of the Al-alloy component under impact test. Tests and laboratory tools are sophisticated, expensive and the clamping system is specific for each component, but today the destructive tests represent the ideal and final approach to validate the casting, unless the CAE tools are enable to replace (even though partially) the real lab test. A new virtual design chain tool is an ambitious target because it needs a deeply research and understanding of factors to define the elasto-plastic behavior of the Al-alloy material. The objective is more challenging in case of high pressure die casting process where the local mechanical properties depend strongly on foundry defects rather than microstructure. The European research NADIA project (New Automotive components Designed for and manufactured by Intelligent processing of light Alloys, Thematic priorities 3 - NMP, Contract N�: 026563-2) has been awarded as reference FP6 project in automotive sector to integrate the manufacturing process with mechanical response of light alloys. The basic research activity was related to secondary light alloys, trace element and foundry process parameters effects with the successive application of material models in the engineering application. With particular reference to one demonstrator component, the high pressure die casting ""Rack&Pinion"", an innovative correlation of defects (e.g. air inclusion, shrinkage porosity etc.) and mechanical properties has been implemented inMAGMASOFT simulation tool in order to transfer the realistic local ultimate tensile strength to LS-Dyna FEMcode. The final impact simulation, taking into account the local mechanical properties and residual stress, has been compared with test results to validate the full integrated virtual approach.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': None}, 'title': 'Die casting process optimisation to improve the component impact performance', 'source': 'Mendeley'}
Seemungal T, Stockley R, Calverley P, Hagan G, Wedzicha JA. Investigating new standards for prophylaxis in reduction of exacerbations--the INSPIRE study methodology. COPD. 2007;4(3):177-83.	10.1080/15412550701407862	17729060	primary-study	91114b56222b2f87d71bfc50f17e64972c993f55	-	{'publication_type': {'year': 2007, 'cited_medium': None, 'issue': '3', 'issn': '1541-2555', 'volume': '4', 'title': 'COPD: Journal of Chronic Obstructive Pulmonary Disease', 'pagination': '177-183'}, 'language': None, 'rating': {'year': 0, 'title': 0.9166666666666666, 'total': 0.8208333333333333, 'authors': 0.9}, 'authors': [{'given': 'Terence', 'family': 'Seemungal'}, {'given': 'Robert', 'family': 'Stockley'}, {'given': 'Peter', 'family': 'Calverley'}, {'given': 'Gerry', 'family': 'Hagan'}, {'given': 'Jadwiga A.', 'family': 'Wedzicha'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '17729060', 'scopus': None, 'doi': '10.1080/15412550701407862'}, 'title': 'Investigating New Standards for Prophylaxis in Reduction of Exacerbations—The INSPIRE Study Methodology', 'source': 'CrossRef'}
Seemungal T, Stockley R, Calverley P, Hagan G, Wedzicha JA. Investigating new standards for prophylaxis in reduction of exacerbations--the INSPIRE study methodology. COPD. 2007;4(3):177-83.	10.1080/15412550701407862	17729060	primary-study	91114b56222b2f87d71bfc50f17e64972c993f55	-	{'publication_type': {'year': 2002, 'cited_medium': None, 'issue': None, 'issn': None, 'volume': None, 'title': 'Pathobiology : journal of immunopathology, molecular and cellular biology, 2002-2003, 70(3):177-83', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.3, 'total': 0.2991666666666667, 'authors': 0.4166666666666667}, 'authors': [{'given': 'C', 'family': 'Schmidt'}, {'given': 'T', 'family': 'Marth'}, {'given': 'B M', 'family': 'Wittig'}, {'given': 'A', 'family': 'Hombach'}, {'given': 'H', 'family': 'Abken'}, {'given': 'A', 'family': 'Stallmach'}], 'abstract': "Inflammatory bowel diseases (IBDs; Crohn's disease (CD) and ulcerative colitis) are chronic inflammatory diseases leading to destruction of gastrointestinal tissue. They are characterized by an exaggerated immune response. In CD, an increased expression of T-helper-1 (Th1) cytokines was observed in which interleukin-12 (IL-12) seems to play a pivotal role. Different immunosuppressive agents have been used to treat patients suffering from IBD, nevertheless remarkable side effects or treatment failure are limiting factors in this regard. Therefore, studies on more specific treatment of CD have recently been published, using recombinant anti-inflammatory cytokines or inhibitors of proinflammatory cytokines and their receptors. Beyond these principles anti-IL-12 strategies seem to play a promising role because of the central position of this Th1-inducing cytokine in the inflammatory cascade. Up to now anti-IL-12 antibodies, complement receptor-3 antibodies and IL-12p40 homodimers have been evaluated in their potential to suppress the mucosal inflammation. Based on our understanding of the pathogenesis of CD, the available data and experiences concerning these principles are presented in this review. (Copyright 2003 S. Karger AG, Basel)", 'type': 'journal', 'ids': {'embase': None, 'pubmed': '12571423', 'scopus': None, 'doi': None}, 'title': 'Interleukin-12 antagonists as new therapeutic agents in inflammatory bowel disease', 'source': 'Mendeley'}
Schallhorn S, Tanzer D, Sanders DR, Sanders ML. Randomized prospective comparison of visian toric implantable collamer lens and conventional photorefractive keratectomy for moderate to high myopic astigmatism. Journal of refractive surgery (Thorofare, N.J. : 1995). 2007;23(9):853-67.	-	18041238	primary-study	525df37374e1bdfaaca50a549a613d365c205874	-	{'publication_type': {'year': 2010, 'cited_medium': None, 'issue': '5', 'issn': '1081-597X', 'volume': '26', 'title': 'Journal of Refractive Surgery', 'pagination': '321-326'}, 'language': None, 'rating': {'year': 0, 'title': 0.8260869565217391, 'total': 0.6869565217391305, 'authors': 0.6}, 'authors': [{'given': 'Steven', 'family': 'Schallhorn'}, {'given': 'David', 'family': 'Tanzer'}, {'given': 'Donald R.', 'family': 'Sanders'}, {'given': 'Monica', 'family': 'Sanders'}, {'given': 'Mitch', 'family': 'Brown'}, {'given': 'Sandor E.', 'family': 'Kaupp'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.3928/1081597x-20090617-09'}, 'title': 'Night Driving Simulation in a Randomized Prospective Comparison of Visian Toric Implantable Collamer Lens and Conventional PRK for Moderate to High Myopic Astigmatism', 'source': 'CrossRef'}
Schallhorn S, Tanzer D, Sanders DR, Sanders ML. Randomized prospective comparison of visian toric implantable collamer lens and conventional photorefractive keratectomy for moderate to high myopic astigmatism. Journal of refractive surgery (Thorofare, N.J. : 1995). 2007;23(9):853-67.	-	18041238	primary-study	525df37374e1bdfaaca50a549a613d365c205874	-	{'publication_type': {'year': 2007, 'cited_medium': None, 'issue': None, 'issn': '1081597X', 'volume': None, 'title': 'Journal of Refractive Surgery', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 1.0, 'total': 0.65, 'authors': 0.0}, 'authors': [{'given': 'Steven', 'family': 'Schallhorn MD'}, {'given': 'David', 'family': 'Tanzer MD'}, {'given': 'Donald R', 'family': 'Sanders MD, PhD'}, {'given': 'Monica L', 'family': 'Sanders BS'}], 'abstract': 'To compare the Visian Toric Implantable Collamer Lens (TICL), a toric phakic intraocular lens (IOL), and photorefractive keratectomy (PRK) in the correction of moderate to high myopic astigmatism. This prospective, randomized study consisted of 43 eyes implanted with the TICL (20 bilateral cases) and 45 eyes receiving PRK with mitomycin C (22 bilateral cases) with moderate to high myopia (-6.00 to -20.00 diopters [D] sphere) measured at the spectacle plane and 1.00 to 4.00 D of astigmatism. All patient treatment and follow-up occurred at the Naval Medical Center San Diego. Study follow-up was 1 day, 1 week, 1, 3, 6, and 12 months postoperative. Mean best spectacle-corrected visual acuity (BSCVA), change in BSCVA, proportion of cases with improvement of 1 or more lines of BSCVA, proportion of cases with BSCVA and uncorrected visual acuity (UCVA) 20/12.5 or better, proportion of cases with BSCVA and UCVA 20/16 or better (6 months, 88% vs 54%, P=.002), and predictability +/-1.00 D (6 months, 100% vs 67%, P<.001) were all significantly better in the TICL group than the PRK group at all time periods studied postoperatively. Similarly, contrast sensitivity, tested at both the 5% photopic level and the 25% mesopic level, was significantly better at all postoperative time points in the TICL group. Mean spherical equivalent refraction was closer to emmetropia (0.28+/-0.41 vs 0.76+/-0.86, P=.005), and predictability +/-0.50 D and stability of manifest refraction (+/-0.50 D and +/-1.00 D) were significantly better in the TICL group at all postoperative visits through 6 months. Mean astigmatism correction at 6 months was not significantly different between the two groups (0.52+/-0.33 vs 0.46+/-0.35, P=.450). The TICL performed better than PRK in all measures of safety (BSCVA), efficacy (UCVA), predictability, and stability in this comparison, supporting the TICL as a viable alternative to existing refractive surgical treatments.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '20506988', 'scopus': '2-s2.0-77953039299', 'doi': '10.3928/1081597X-20090617-09'}, 'title': 'Randomized Prospective Comparison of Visian Toric Implantable Collamer Lens and Conventional Photorefractive Keratectomy for Moderate to High Myopic Astigmatism', 'source': 'Mendeley'}
Malecaze FJ, Hulin H, Bierer P, Fournié P, Grandjean H, Thalamas C, Guell JL. A randomized paired eye comparison of two techniques for treating moderately high myopia: LASIK and artisan phakic lens. Ophthalmology. 2002;109(9):1622-30.	-	12208708	primary-study	400f20b2b8d3ed9b9fdd44c6496be098ee99cd3f	-	{'publication_type': {'year': 2002, 'cited_medium': None, 'issue': '9', 'issn': '0161-6420', 'volume': '109', 'title': 'Ophthalmology', 'pagination': '1622-1630'}, 'language': None, 'rating': {'year': 1, 'title': 1.0, 'total': 1.0, 'authors': 1.0}, 'authors': [{'given': 'F', 'family': 'Malecaze'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1016/s0161-6420(02)01164-8'}, 'title': 'A randomized paired eye comparison of two techniques for treating moderately high myopia LASIK and artisan phakic lens', 'source': 'CrossRef'}
Malecaze FJ, Hulin H, Bierer P, Fournié P, Grandjean H, Thalamas C, Guell JL. A randomized paired eye comparison of two techniques for treating moderately high myopia: LASIK and artisan phakic lens. Ophthalmology. 2002;109(9):1622-30.	-	12208708	primary-study	400f20b2b8d3ed9b9fdd44c6496be098ee99cd3f	-	{'publication_type': {'year': 2002, 'cited_medium': None, 'issue': None, 'issn': '01616420', 'volume': None, 'title': 'Ophthalmology', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 0.975, 'authors': 0.9000000000000001}, 'authors': [{'given': 'François J.', 'family': 'Malecaze'}, {'given': 'Hervé', 'family': 'Hulin'}, {'given': 'Pascal', 'family': 'Bierer'}, {'given': 'Pierre', 'family': 'Fournié'}, {'given': 'Hélène', 'family': 'Grandjean'}, {'given': 'Claire', 'family': 'Thalamas'}, {'given': 'José L.', 'family': 'Guell'}], 'abstract': 'Objective: To compare refractive performance and safety of laser in situ keratomileusis (LASIK) and Artisan phakic intraocular lens (PIOL) for moderately high myopia. Design: A prospective, randomized trial with paired eye control. Participants: Twenty-five patients with myopia ranging from -8.00 to -12.00 diopters (D). Intervention: For each patient, one eye received LASIK and the other one was implanted with an Artisan phakic intraocular lens. The treated eye and the surgical technique were randomized. Main Outcome Measures: Primary outcome measure was spherical equivalent refraction. Main secondary outcome measures were the change of two or more lines and safety index (ratio postoperative to preoperative best-corrected visual acuity). Results: One year after surgery, the mean spherical equivalent refraction was -0.74 ± 0.67 D for LASIK-treated eyes and -0.95 ± 0.45 D for Artisan-treated eyes, and the majority of LASIK-treated eyes (64%) and Artisan-treated eyes (60%) were within ± 1.00 D of the intended result. At 1 month, the mean spherical equivalent refraction was -0.28 ± 0.71 D for LASIK and -1.07 ± 0.59 D for Artisan (P < 0.01). The changes of two or more lines were in favor of Artisan (P < 0.05). The safety index was significantly better for Artisan (1.12 ± 0.21) than for LASIK (0.99 ± 0.17) at 1 year (P < 0.02). Conclusions: In cases of moderately high myopia, LASIK and Artisan phakic intraocular lenses seemed to produce a similar predictability. The best-corrected visual acuity and subjective evaluation of quality of vision were better for Artisan. © 2002 by the American Academy of Ophthalmology.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '12208708', 'scopus': '2-s2.0-0036713599', 'doi': '10.1016/S0161-6420(02)01164-8'}, 'title': 'A randomized paired eye comparison of two techniques for treating moderately high myopia: LASIK and artisan phakic lens', 'source': 'Mendeley'}
El Danasoury MA, El Maghraby A, Gamali TO. Comparison of iris-fixed Artisan lens implantation with excimer laser in situ keratomileusis in correcting myopia between -9.00 and -19.50 diopters: a randomized study. Ophthalmology. 2002;109(5):955-64.	-	11986104	primary-study	d228fd1df010657332846ff478e3b6560a489dfa	-	{'publication_type': {'year': 2002, 'cited_medium': None, 'issue': '5', 'issn': '0161-6420', 'volume': '109', 'title': 'Ophthalmology', 'pagination': '955-964'}, 'language': None, 'rating': {'year': 1, 'title': 0.9, 'total': 0.91, 'authors': 0.9}, 'authors': [{'given': 'M.Alaa', 'family': 'El Danasoury'}, {'given': 'Akef', 'family': 'El Maghraby'}, {'given': 'Tamer O.', 'family': 'Gamali'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1016/s0161-6420(02)00964-8'}, 'title': 'Comparison of iris-fixed Artisan lens implantation with excimer laser in situ keratomileusis in correcting myopia between −9.00 and −19.50 diopters', 'source': 'CrossRef'}
El Danasoury MA, El Maghraby A, Gamali TO. Comparison of iris-fixed Artisan lens implantation with excimer laser in situ keratomileusis in correcting myopia between -9.00 and -19.50 diopters: a randomized study. Ophthalmology. 2002;109(5):955-64.	-	11986104	primary-study	d228fd1df010657332846ff478e3b6560a489dfa	-	{'publication_type': {'year': 2002, 'cited_medium': None, 'issue': None, 'issn': '01616420', 'volume': None, 'title': 'Ophthalmology', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 1.0, 'total': 0.975, 'authors': 0.9}, 'authors': [{'given': 'M. Alaa', 'family': 'El Danasoury'}, {'given': 'Akef', 'family': 'El Maghraby'}, {'given': 'Tamer O.', 'family': 'Gamali'}], 'abstract': 'Objective: To compare Artisan lens implantation with laser in situ keratomileusis (LASIK) for the correction of myopia between -9.00 and -19.50 diopters. Design: Prospective randomized clinical trial. Participants: Ninety eyes of 61 consecutive patients were enrolled in the study. Intervention: Forty-five eyes (50%) received Artisan lens, and 45 eyes (50%) received LASIK; the procedure assigned to each eye was randomized. Eighteen patients (29.5%) received Artisan lens in one eye and LASIK in the other. Main Outcome Measures: Slit-lamp microscopy, manifest refraction, uncorrected and spectacle-corrected visual acuity, contrast sensitivity, and specular microscopy were performed before surgery, and 1, 3, 6, and 12 months after surgery. Patient satisfaction and preference were assessed by a subjective questionnaire. Results: At 1 year, 43 eyes (95.6%) from the Artisan group and 41 eyes (91.1 %) from the LASIK group were examined, the mean spherical equivalent refraction was -0.64 ?? 0.8 diopter in the Artisan eyes and -0.87 ?? 0.8 in the LASIK eyes. The uncorrected visual acuity was 20/20 or better in 9 Artisan eyes (20.9%) and 5 LASIK eyes (12.2%) and 20/40 or better in 38 Artisan eyes (88.4%) and 24 LASIK eyes (58.5%); no Artisan eyes and 5 LASIK eyes (12.2%) lost 2 or more Snellen lines of spectacle-corrected visual acuity. One Artisan eye (2.3%) and six LASIK eyes (14.6%) reported severe night glare; the Artisan lens was exchanged with a larger optic diameter lens. Mean endothelial cell loss at 1 year was 0.7 ?? 1.1 cells/mm2 in the Artisan eyes and 0.3 ?? 0.9 cells/mm2 in the LASIK eyes. Contrast sensitivity curve decreased by 2 or more lines in two Artisan (4.7%) and six LASIK eyes (14.6%). Of the 18 patients who received both surgeries, one in each eye, 13 patients (72.2%) preferred the Artisan procedure because of the better quality of vision. Conclusions: In this study, Artisan lens implantation and LASIK were found to be similarly effective, stable, and reasonably safe for the correction of myopia between -9.00 and -19.50 diopters. Better uncorrected and spectacle-corrected visual acuity and contrast sensitivity, a lower enhancement rate, and exchangeability are the main advantages of Artisan lens implantation. Thirteen (72.2%) of the 18 patients who received the Artisan lens in one eye and LASIK in the other preferred the Artisan lens to the LASIK, mainly because of the better quality of vision. ?? 2002 by the American Academy of Ophthalmology.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '11986104', 'scopus': '2-s2.0-0036242615', 'doi': '10.1016/S0161-6420(02)00964-8'}, 'title': 'Comparison of iris-fixed Artisan lens implantation with excimer laser in situ keratomileusis in correcting myopia between -9.00 and -19.50 diopters: A randomized study', 'source': 'Mendeley'}
Qureshi NS, Edi-Osagie EC, Ogbo V, Ray S, Hopkins RE. First trimester threatened miscarriage treatment with human chorionic gonadotrophins: a randomised controlled trial. BJOG : an international journal of obstetrics and gynaecology. 2005;112(11):1536-41.	10.1111/j.1471-0528.2005.00750.x	16225575	primary-study	68d292745bf6b6290e664fa87472631ce32a580d	-	{'publication_type': {'year': 2005, 'cited_medium': None, 'issue': '11', 'issn': '1470-0328', 'volume': '112', 'title': 'BJOG: An International Journal of Obstetrics and Gynaecology', 'pagination': '1536-1541'}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.875, 'authors': 0.9}, 'authors': [{'given': 'N.S.', 'family': 'Qureshi'}, {'given': 'E.C.', 'family': 'Edi-Osagie'}, {'given': 'V.', 'family': 'Ogbo'}, {'given': 'S.', 'family': 'Ray'}, {'given': 'R.E.', 'family': 'Hopkins'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '16225575', 'scopus': None, 'doi': '10.1111/j.1471-0528.2005.00750.x'}, 'title': 'First trimester threatened miscarriage treatment with human chorionic gonadotrophins: a randomised controlled trial', 'source': 'CrossRef'}
Qureshi NS, Edi-Osagie EC, Ogbo V, Ray S, Hopkins RE. First trimester threatened miscarriage treatment with human chorionic gonadotrophins: a randomised controlled trial. BJOG : an international journal of obstetrics and gynaecology. 2005;112(11):1536-41.	10.1111/j.1471-0528.2005.00750.x	16225575	primary-study	68d292745bf6b6290e664fa87472631ce32a580d	-	{'publication_type': {'year': 2005, 'cited_medium': None, 'issue': None, 'issn': '14700328', 'volume': None, 'title': 'BJOG: An International Journal of Obstetrics and Gynaecology', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 1.0, 'total': 0.875, 'authors': 0.9}, 'authors': [{'given': 'N. S.', 'family': 'Qureshi'}, {'given': 'E. C.', 'family': 'Edi-Osagie'}, {'given': 'V.', 'family': 'Ogbo'}, {'given': 'S.', 'family': 'Ray'}, {'given': 'R. E.', 'family': 'Hopkins'}], 'abstract': 'To determine whether administration of exogenous human chorionic gonadotrophin (hCG) treatment improve the pregnancy outcome in first trimester threatened miscarriages.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '16225575', 'scopus': '2-s2.0-33644613607', 'doi': '10.1111/j.1471-0528.2005.00750.x'}, 'title': 'First trimester threatened miscarriage treatment with human chorionic gonadotrophins: A randomised controlled trial', 'source': 'Mendeley'}
Suvonnakote T. Treatment of threatened abortion with human chorionic gonadotropin. Journal of the Medical Association of Thailand = Chotmaihet thangphaet. 1987;69(12):654-8.	-	3572279	primary-study	1e169082957d06935cc0e2d9bbc40fb728e71e03	-	{'publication_type': {'year': 2008, 'cited_medium': None, 'issue': '1', 'issn': '2391-5463', 'volume': '3', 'title': 'Open Medicine', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.5294117647058824, 'total': 0.34411764705882353, 'authors': 0.0}, 'authors': [{'given': 'Andrew', 'family': 'Czeizel'}, {'given': 'István', 'family': 'Dudás'}, {'given': 'János', 'family': 'Gidai'}, {'given': 'Erzsébet', 'family': 'Horváth-Puhó'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.2478/s11536-007-0056-9'}, 'title': 'No effect of human chorionic gonadotropin treatment due to threatened abortion in early pregnancy for birth outcomes', 'source': 'CrossRef'}
Suvonnakote T. Treatment of threatened abortion with human chorionic gonadotropin. Journal of the Medical Association of Thailand = Chotmaihet thangphaet. 1987;69(12):654-8.	-	3572279	primary-study	1e169082957d06935cc0e2d9bbc40fb728e71e03	-	{'publication_type': {'year': 2005, 'cited_medium': None, 'issue': None, 'issn': '01252208', 'volume': None, 'title': 'Journal of the Medical Association of Thailand = Chotmaihet thangphaet.', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 0.4375, 'total': 0.384375, 'authors': 0.0}, 'authors': [{'given': 'Somwang', 'family': 'Danchaivijitr'}, {'given': 'Somsak', 'family': 'Chakpaiwong'}, {'given': 'Uapong', 'family': 'Jaturatramrong'}, {'given': 'Arunee', 'family': 'Wachiraporntip'}, {'given': 'Rachada', 'family': 'Cherdrungsi'}, {'given': 'Siriporn', 'family': 'Sripalakij'}], 'abstract': 'OBJECTIVES: To identify defects in the program on NI in curricula of medical, dental, medical technology and nursing schools. Impacts of the results of the study on the changes of the program were also evaluated MATERIAL AND METHOD: Questionnaires study of all 12, 8, 9 medical, dental, medical technology and 20 of 62 nursing schools. Data were collected and analyzed. Defects in the program of NI were identified and recommendation for improving was drafted in a workshop participated by curriculum directors and researchers. Results of the study were fedback to the schools enrolled. Changes of the program were later followed.. RESULTS: Program on NI was present in the curricula of 11 of 12 medical, some dental and medical technology but in none of the nursing schools. Education program varied in methods of teaching, hours and years of students. A few schools modified the program in their curricula by the results of the study and recommendation of a workshop participated in by researchers and program directors. CONCLUSION: Program on NI in the curricula of medical, dental, medical technology and nursing schools in Thailand varied in education methods, teaching hours and in student years. The present study results had little impact on changing the program. An evidence-based program on NI in medical, dentistry, medical technology and nursing is urgently needed.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '16850661', 'scopus': '2-s2.0-33749051665', 'doi': None}, 'title': 'Program on nosocomial infection in the curricula of medicine, dentistry, nursing and medical technology in Thailand.', 'source': 'Mendeley'}
Schaafsma F, Hulshof C, de Boer A, van Dijk F. Effectiveness and efficiency of a literature search strategy to answer questions on the etiology of occupational diseases: a controlled trial. International archives of occupational and environmental health. 2007;80(3):239-47.	10.1007/s00420-006-0126-3	16944192	primary-study	a0a236c3b087b359eef2e557e1be559a2d99abf6	-	{'publication_type': {'year': 2006, 'cited_medium': None, 'issue': '3', 'issn': '0340-0131', 'volume': '80', 'title': 'Int Arch Occup Environ Health', 'pagination': '239-247'}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.8812500000000001, 'authors': 0.925}, 'authors': [{'given': 'Frederieke', 'family': 'Schaafsma'}, {'given': 'Carel', 'family': 'Hulshof'}, {'given': 'Angela', 'family': 'de Boer'}, {'given': 'Frank', 'family': 'van Dijk'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '16944192', 'scopus': None, 'doi': '10.1007/s00420-006-0126-3'}, 'title': 'Effectiveness and efficiency of a literature search strategy to answer questions on the etiology of occupational diseases: a controlled trial', 'source': 'CrossRef'}
Schaafsma F, Hulshof C, de Boer A, van Dijk F. Effectiveness and efficiency of a literature search strategy to answer questions on the etiology of occupational diseases: a controlled trial. International archives of occupational and environmental health. 2007;80(3):239-47.	10.1007/s00420-006-0126-3	16944192	primary-study	a0a236c3b087b359eef2e557e1be559a2d99abf6	-	{'publication_type': {'year': 2007, 'cited_medium': None, 'issue': None, 'issn': None, 'volume': None, 'title': 'International Archives of Occupational & Environmental Health', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.9, 'authors': 1.0}, 'authors': [{'given': 'F', 'family': 'Schaafsma'}, {'given': 'C', 'family': 'Hulshof'}, {'given': 'Boer A', 'family': 'de'}, {'given': 'Dijk F', 'family': 'van'}], 'abstract': "OBJECTIVES: To evaluate the effectiveness and efficiency of a search strategy to find evidence-based answers to questions related to the possible occupational etiology of diseases. METHODS: A controlled trial of 70 occupational health physicians and 55 insurance physicians who were asked to answer one out of four 'occupational disease case-vignettes' following the steps of evidence-based medicine (EBM). The intervention group were given the search strategy as a tool. RESULTS: The intervention group scored significantly better than the control group in answering the main question of the case-vignette correctly (57% versus 37%) using more adequate search terms. The intervention group scored significantly better regarding satisfaction with the applied search strategy (28% very satisfied versus 8%). We found no differences in time spent in solving the case or in the intention of future practice of EBM. CONCLUSIONS: The introduction and application of specific search strategies can have a positive effect on the effectiveness of searching literature. Future initiatives for developing and testing specific search strategies in the field of occupational health should be encouraged", 'type': 'journal', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': None}, 'title': 'Effectiveness and efficiency of a literature search strategy to answer questions on the etiology of occupational diseases: a controlled trial', 'source': 'Mendeley'}
Cheng GY. A study of clinical questions posed by hospital clinicians. Journal of the Medical Library Association : JMLA. 2004;92(4):445-58.	-	15494760	primary-study	66416773bb8787a7b191c0d7265b923053d1188e	-	{'publication_type': {'year': 2016, 'cited_medium': None, 'issue': '1', 'issn': '1536-5050', 'volume': '104', 'title': 'J Med Libr Assoc', 'pagination': '91-92'}, 'language': None, 'rating': {'year': 0, 'title': 0.0, 'total': 0.0, 'authors': 0.0}, 'authors': [{'given': 'Rachel', 'family': 'Pinotti'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.3163/1536-5050.104.1.022'}, 'title': 'PROQOLID', 'source': 'CrossRef'}
Cheng GY. A study of clinical questions posed by hospital clinicians. Journal of the Medical Library Association : JMLA. 2004;92(4):445-58.	-	15494760	primary-study	66416773bb8787a7b191c0d7265b923053d1188e	-	{'publication_type': {'year': 2011, 'cited_medium': None, 'issue': None, 'issn': '1536-5050', 'volume': None, 'title': 'Journal of the Medical Library Association : JMLA', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 0.3076923076923077, 'total': 0.30000000000000004, 'authors': 0.0}, 'authors': [{'given': 'Stephanie J', 'family': 'SchuSchulte, S. J. (2011). Eliminating traditional reference services in an academic health sciences library: a case study. Journal of the Medical Library Association : JMLA, 99(4), 273–279. http://doi.org/10.3163/1536-5050.99.4.004lte'}], 'abstract': 'How were traditional librarian reference desk services successfully eliminated at one health sciences library?', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '22022221', 'scopus': None, 'doi': '10.3163/1536-5050.99.4.004'}, 'title': 'Eliminating traditional reference services in an academic health sciences library: a case study', 'source': 'Mendeley'}
Cheng GY. Educational workshop improved information-seeking skills, knowledge, attitudes and the search outcome of hospital clinicians: a randomised controlled trial. Health information and libraries journal. 2003;20 Suppl 1:22-33.	-	12757433	primary-study	ff40b70ae53d6ae3df6b5382dbd7e633c4e146b6	-	{'publication_type': {'year': 2003, 'cited_medium': None, 'issue': 's1', 'issn': '1471-1834', 'volume': '20', 'title': 'Health Information and Libraries Journal', 'pagination': '22-33'}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.875, 'authors': 0.9}, 'authors': [{'given': 'Grace Y. T.', 'family': 'Cheng'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1046/j.1365-2532.20.s1.5.x'}, 'title': 'Educational workshop improved information-seeking skills, knowledge, attitudes and the search outcome of hospital clinicians: a randomised controlled trial', 'source': 'CrossRef'}
Cheng GY. Educational workshop improved information-seeking skills, knowledge, attitudes and the search outcome of hospital clinicians: a randomised controlled trial. Health information and libraries journal. 2003;20 Suppl 1:22-33.	-	12757433	primary-study	ff40b70ae53d6ae3df6b5382dbd7e633c4e146b6	-	{'publication_type': {'year': 2003, 'cited_medium': None, 'issue': None, 'issn': '1471-1834', 'volume': None, 'title': 'Health information and libraries journal', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 0.975, 'authors': 0.9}, 'authors': [{'given': 'Grace Y T', 'family': 'Cheng'}], 'abstract': 'A double-blind randomised controlled trial was conducted on a group of Hong Kong hospital clinicians. The objective was to test if a three-hour educational workshop (with supervised hands-on practice) is more effective (than no training) to improve clinical question formulation, information-seeking skills, knowledge, attitudes, and search outcomes. The design was a post-test-only control group; recruitment by stratified randomization (by profession), blocked at 800. End-user training was more effective than no training in improving clinical question formulation, in raising awareness, knowledge, confidence and use of databases, but had made no impact on preference for secondary databases. It changed the attitude of clinicians to become more positive towards the use of electronic information services (EIS). Participants had higher search performance and outcomes (satisfaction with information obtained (NNT = 3), EIS satisfaction (NNT = 3) and success in problem solving (NNT = 4)). The workshop improved knowledge and skills in evidence-based searching, but this effect gradually eroded with time. Search logs confirmed that follow-up is required if effects are to be sustained. Longer effects on search behaviours appear to be positive. A randomised controlled trial is valuable in identifying cause-and-effect relations and to quantify the magnitude of the effects for management decision-making.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '12757433', 'scopus': '2-s2.0-0037659458', 'doi': '436 [pii]'}, 'title': 'Educational workshop improved information-seeking skills, knowledge, attitudes and the search outcome of hospital clinicians: a randomised controlled trial.', 'source': 'Mendeley'}
Bradley DR, Rana GK, Martin PW, Schumacher RE. Real-time, evidence-based medicine instruction: a randomized controlled trial in a neonatal intensive care unit. Journal of the Medical Library Association : JMLA. 2002;90(2):194-201.	-	11999177	primary-study	e6a1484ba995b3dd21876582b0305ca6e8f2c707	-	{'publication_type': {'year': 2012, 'cited_medium': None, 'issue': '3', 'issn': '1536-5050', 'volume': '100', 'title': 'Journal of the Medical Library Association : JMLA', 'pagination': '190-196'}, 'language': None, 'rating': {'year': 1, 'title': 0.5294117647058824, 'total': 0.4441176470588235, 'authors': 0.0}, 'authors': [{'given': 'Dragan', 'family': 'Ilic'}, {'given': 'Katrina', 'family': 'Tepper'}, {'given': 'Marie', 'family': 'Misso'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '22879808', 'scopus': None, 'doi': '10.3163/1536-5050.100.3.009'}, 'title': 'Teaching evidence-based medicine literature searching skills to medical students during the clinical years: a randomized controlled trial', 'source': 'CrossRef'}
Bradley DR, Rana GK, Martin PW, Schumacher RE. Real-time, evidence-based medicine instruction: a randomized controlled trial in a neonatal intensive care unit. Journal of the Medical Library Association : JMLA. 2002;90(2):194-201.	-	11999177	primary-study	e6a1484ba995b3dd21876582b0305ca6e8f2c707	-	{'publication_type': {'year': 1994, 'cited_medium': None, 'issue': None, 'issn': None, 'volume': None, 'title': 'International Journal of STD & AIDS.5(3):194-201,', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.26666666666666666, 'total': 0.20458333333333334, 'authors': 0.125}, 'authors': [{'given': 'R P', 'family': 'Brettle'}, {'given': 'L', 'family': 'Willcocks'}, {'given': 'F M', 'family': 'Cowan'}, {'given': 'A M', 'family': 'Richardson'}], 'abstract': 'A retrospective analysis of HIV-positive patients admitted to the City Hospital, Edinburgh by 31st December 1992, 7 years after the inception of the HIV clinic, revealed that 373 patients, 72% of them injection drug users (IDUs), had required 2069 admissions (5.5/admitted patient, 3.3/clinic patient or 0.5/clinic patient/year) and had utilized 21,934 bed days (59 bed days/admitted patient, 35 days/clinic patient or 5 bed days/clinic patient/year). The average length of stay (ALOS) was significantly longer for AIDS than HIV (non-AIDS) admissions (14.0 vs 9.5, P < 0.0001) as it was for admissions with a CD200 diagnosis (a CD4 count below 200 cells per mm3 on two consecutive occasions) compared to those without (12.1 vs 10.0 days, P = 0.004). There was no gender effect on ALOS but there was a significant effect of risk activity; homo/bisexuals had a significantly longer ALOS than drug users (P < 0.0001). Homo/bisexual patients with AIDS or a CD200 diagnosis had longer ALOS than drug users (15.7 vs 13 days and 15.8 vs 10.8). By 1992 each member of the clinic was on average utilizing one admission per year and 11.6 bed days per year. The number of admissions in that year for patients without a CD200 or AIDS diagnosis was however low (0.5 and 0.75 admissions/patient/year) compared to patients with an AIDS or CD200 diagnosis (2.6 and 1.6 admissions/patient/year). The annual number of occupied bed days/living patient was greatest for those with AIDS (60 vs 5 days) or with a CD200 diagnosis (23.5 vs 4.1 days).(ABSTRACT TRUNCATED AT 250 WORDS)', 'type': 'journal', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': None}, 'title': 'Inpatient health care utilization for patients with HIV and AIDS in the Edinburgh City Hospital', 'source': 'Mendeley'}
Villanueva EV, Burrows EA, Fennessy PA, Rajendran M, Anderson JN. Improving question formulation for use in evidence appraisal in a tertiary care setting: a randomised controlled trial. BMC medical informatics and decision making. 2001;1:4.	-	11716797	primary-study	46028ff000f67f40e444e93b5c0f17d87c170229	-	{'publication_type': {'year': 2001, 'cited_medium': None, 'issue': '1', 'issn': '1472-6947', 'volume': '1', 'title': 'BMC Med Inform Decis Mak', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.9444444444444444, 'total': 0.8388888888888889, 'authors': 0.9}, 'authors': [{'given': 'Elmer V', 'family': 'Villanueva'}, {'given': 'Elizabeth A', 'family': 'Burrows'}, {'given': 'Paul A', 'family': 'Fennessy'}, {'given': 'Meera', 'family': 'Rajendran'}, {'given': 'Jeremy N', 'family': 'Anderson'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1186/1472-6947-1-4'}, 'title': 'Improving question formulation for use in evidence appraisal in a tertiary care setting: a randomised controlled trial [ISRCTN66375463]', 'source': 'CrossRef'}
Villanueva EV, Burrows EA, Fennessy PA, Rajendran M, Anderson JN. Improving question formulation for use in evidence appraisal in a tertiary care setting: a randomised controlled trial. BMC medical informatics and decision making. 2001;1:4.	-	11716797	primary-study	46028ff000f67f40e444e93b5c0f17d87c170229	-	{'publication_type': {'year': 2001, 'cited_medium': None, 'issue': None, 'issn': '1472-6947', 'volume': None, 'title': 'BMC medical informatics and decision making', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 0.9444444444444444, 'total': 0.9238888888888889, 'authors': 0.8400000000000001}, 'authors': [{'given': 'E V', 'family': 'Villanueva'}, {'given': 'E A', 'family': 'Burrows'}, {'given': 'P A', 'family': 'Fennessy'}, {'given': 'M', 'family': 'Rajendran'}, {'given': 'J N', 'family': 'Anderson'}], 'abstract': 'BACKGROUND: The specificity of clinical questions is gauged by explicit descriptions of four dimensions: subjects, interventions, comparators and outcomes of interest. This study determined whether adding simple instructions and examples on clinical question formulation would increase the specificity of the submitted question compared to using a standard form without instructions and examples.\\n\\nMETHODS: A randomised controlled trial was conducted in an evidence-search and appraisal service. New participants were invited to reformulate clinical queries. The Control Group was given no instructions. The Intervention Group was given a brief explanation of proper formulation, written instructions, and diagrammatic examples. The primary outcome was the change in the proportion of reformulated questions that described each the dimensions of specificity.\\n\\nRESULTS: Fifty-two subjects agreed to participate in the trial of which 13 were lost to follow-up. The remaining 17 Intervention Group and 22 Control Group participants were analysed. Baseline characteristics were comparable. Overall, 20% of initially submitted questions from both groups were properly specified (defined as an explicit statement describing all dimensions of specificity). On follow-up, 7/14 questions previously rated as mis-specified in the Intervention Group had all dimensions described at follow-up (p = 0.008) while the Control Group did not show any changes from baseline. Participants in the Intervention Group were also more likely to explicitly describe patients (p = 0.028), comparisons (p = 0.014), and outcomes (p = 0.008).\\n\\nCONCLUSIONS: This trial demonstrated the positive impact of specific instructions on the proportion of properly-specified clinical queries. The evaluation of the long-term impact of such changes is an area of continued research.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '11716797', 'scopus': '2-s2.0-3142544186', 'doi': '10.1186/1472-6947-1-4'}, 'title': 'Improving question formulation for use in evidence appraisal in a tertiary care setting: a randomised controlled trial [ISRCTN66375463].', 'source': 'Mendeley'}
Moseley JB, O'Malley K, Petersen NJ, Menke TJ, Brody BA, Kuykendall DH, Hollingsworth JC, Ashton CM, Wray NP. A controlled trial of arthroscopic surgery for osteoarthritis of the knee. The New England journal of medicine. 2002;347(2):81-8.	10.1056/NEJMoa013259	12110735	primary-study	2c0b050558174ee1af535e3af7eb2ab61c85f9fe	-	{'publication_type': {'year': 2002, 'cited_medium': None, 'issue': '2', 'issn': '0028-4793', 'volume': '347', 'title': 'New England Journal of Medicine', 'pagination': '81-88'}, 'language': None, 'rating': {'year': 0, 'title': 1.0, 'total': 0.875, 'authors': 0.9000000000000001}, 'authors': [{'given': 'J. Bruce', 'family': 'Moseley'}, {'given': 'Kimberly', 'family': "O'Malley"}, {'given': 'Nancy J.', 'family': 'Petersen'}, {'given': 'Terri J.', 'family': 'Menke'}, {'given': 'Baruch A.', 'family': 'Brody'}, {'given': 'David H.', 'family': 'Kuykendall'}, {'given': 'John C.', 'family': 'Hollingsworth'}, {'given': 'Carol M.', 'family': 'Ashton'}, {'given': 'Nelda P.', 'family': 'Wray'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1056/nejmoa013259'}, 'title': 'A Controlled Trial of Arthroscopic Surgery for Osteoarthritis of the Knee', 'source': 'CrossRef'}
Moseley JB, O'Malley K, Petersen NJ, Menke TJ, Brody BA, Kuykendall DH, Hollingsworth JC, Ashton CM, Wray NP. A controlled trial of arthroscopic surgery for osteoarthritis of the knee. The New England journal of medicine. 2002;347(2):81-8.	10.1056/NEJMoa013259	12110735	primary-study	2c0b050558174ee1af535e3af7eb2ab61c85f9fe	-	{'publication_type': {'year': 2011, 'cited_medium': None, 'issue': None, 'issn': '1746-1561', 'volume': None, 'title': 'Journal of School Health.81(8):477-84,', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.2777777777777778, 'total': 0.2698412698412699, 'authors': 0.35714285714285715}, 'authors': [{'given': 'S L', 'family': 'Escobar-Chaves'}, {'given': 'R', 'family': 'Shegog'}, {'given': 'M R', 'family': 'Moscoso-Alvarez'}, {'given': 'C', 'family': 'Markham'}, {'given': 'G', 'family': 'Tortolero-Luna'}, {'given': 'M', 'family': 'Peskin'}, {'given': 'S', 'family': 'Tortolero'}], 'abstract': 'BACKGROUND: To assess the need for cultural tailoring of an effective sexual health middle school curriculum, "It\'s Your Game: Keep It Real" (IYG), prior to implementation in Puerto Rican (PR) middle schools. METHODS: Seventy-three seventh-grade bilingual students participated in IYG curriculum activities (both group-based and computer-based) in two 2-hour testing sessions in spring 2008. Rating scales of acceptability, understandability, credibility, ease of use, and motivational appeal and qualitative feedback via open-ended responses and group process provided insight into needed surface and deep structure cultural tailoring. RESULTS: Students rated IYG highly on cultural tailoring and motivational parameters and were highly engaged by the lesson content. School personnel rated IYG as a feasible strategy for use in PR middle schools. While surface cultural elements (eg, characters, attire, body language) were identified as important foci for adaptation, content related to deeper cultural elements such as core behaviors, risky situations, attitudes, and specific skills were considered as relevant to PR youth as to their US counterparts. CONCLUSION: Effective human immunodeficiency virus, sexually transmitted disease, and pregnancy skills training prevention programs such as IYG that are developed for minority US youth may offer a feasible option for international implementation when extensive cultural adaptation is not a viable option. 2011, American School Health Association', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '21740433', 'scopus': None, 'doi': '10.1111/j.1746-1561.2011.00617.x'}, 'title': 'Cultural tailoring and feasibility assessment of a sexual health middle school curriculum: a pilot test in Puerto Rico', 'source': 'Mendeley'}
Bradley JD, Heilman DK, Katz BP, Gsell P, Wallick JE, Brandt KD. Tidal irrigation as treatment for knee osteoarthritis: a sham-controlled, randomized, double-blinded evaluation. Arthritis and rheumatism. 2002;46(1):100-8.	-	11817581	primary-study	0f2cf34e44a7ffeb2d802b14fb3718a54acc6b9c	-	{'publication_type': {'year': 2002, 'cited_medium': None, 'issue': '1', 'issn': '0004-3591', 'volume': '46', 'title': 'Arthritis & Rheumatism', 'pagination': '100-108'}, 'language': None, 'rating': {'year': 0, 'title': 1.0, 'total': 0.8375, 'authors': 0.75}, 'authors': [{'given': 'John D.', 'family': 'Bradley'}, {'given': 'Douglas K.', 'family': 'Heilman'}, {'given': 'Barry P.', 'family': 'Katz'}, {'given': 'Patricia', 'family': "G'Sell"}, {'given': 'Janine E.', 'family': 'Wallick'}, {'given': 'Kenneth D.', 'family': 'Brandt'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1002/1529-0131(200201)46:1<100::aid-art10037>3.0.co;2-v'}, 'title': 'Tidal irrigation as treatment for knee osteoarthritis: A sham-controlled, randomized, double-blinded evaluation', 'source': 'CrossRef'}
Bradley JD, Heilman DK, Katz BP, Gsell P, Wallick JE, Brandt KD. Tidal irrigation as treatment for knee osteoarthritis: a sham-controlled, randomized, double-blinded evaluation. Arthritis and rheumatism. 2002;46(1):100-8.	-	11817581	primary-study	0f2cf34e44a7ffeb2d802b14fb3718a54acc6b9c	-	{'publication_type': {'year': 2002, 'cited_medium': None, 'issue': None, 'issn': '00043591', 'volume': None, 'title': 'Arthritis and Rheumatism', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 1.0, 'total': 0.8375, 'authors': 0.75}, 'authors': [{'given': 'John D.', 'family': 'Bradley'}, {'given': 'Douglas K.', 'family': 'Heilman'}, {'given': 'Barry P.', 'family': 'Katz'}, {'given': 'Patricia', 'family': "G'Sell"}, {'given': 'Janine E.', 'family': 'Wallick'}, {'given': 'Kenneth D.', 'family': 'Brandt'}], 'abstract': 'OBJECTIVE: To evaluate the effectiveness of tidal irrigation (TI) in comparison with a well-matched sham irrigation (SI) procedure as a treatment for knee osteoarthritis (OA). METHODS: One hundred eighty subjects with knee OA were randomized to receive TI or SI, with clinical followup over the ensuing 12 months. The primary outcomes of interest were change in pain and function, as measured by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Subjects and the nurse assessor were blinded, and success of blinding was assessed. RESULTS: Although the study groups were otherwise comparable, the baseline WOMAC pain and physical functioning scores were higher (worse) in the SI group. After adjustment for baseline, there were no differences between the effects of', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '11817581', 'scopus': '2-s2.0-0036159118', 'doi': '10.1002/1529-0131(200201)46:1<100::AID-ART10037>3.0.CO;2-V'}, 'title': 'Tidal irrigation as treatment for knee osteoarthritis: A sham-controlled, randomized, double-blinded evaluation', 'source': 'Mendeley'}
Kalunian KC, Moreland LW, Klashman DJ, Brion PH, Concoff AL, Myers S, Singh R, Ike RW, Seeger LL, Rich E, Skovron ML. Visually-guided irrigation in patients with early knee osteoarthritis: a multicenter randomized, controlled trial. Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society. 2000;8(6):412-8.	10.1053/joca.1999.0316	11069725	primary-study	c5cd96385fdb75bac06f73ffd0945479db1bfd78	-	{'publication_type': {'year': 2000, 'cited_medium': None, 'issue': '6', 'issn': '1063-4584', 'volume': '8', 'title': 'Osteoarthritis and Cartilage', 'pagination': '412-418'}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.8613636363636364, 'authors': 0.8454545454545456}, 'authors': [{'given': 'K.C', 'family': 'Kalunian'}, {'given': 'L.W', 'family': 'Moreland'}, {'given': 'D.J', 'family': 'Klashman'}, {'given': 'P.H', 'family': 'Brion'}, {'given': 'A.L', 'family': 'Concoff'}, {'given': 'S', 'family': 'Myers'}, {'given': 'R', 'family': 'Singh'}, {'given': 'R.W', 'family': 'Ike§'}, {'given': 'L.L', 'family': 'Seeger'}, {'given': 'E', 'family': 'Rich'}, {'given': 'M.L', 'family': 'Skovron'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '11069725', 'scopus': None, 'doi': '10.1053/joca.1999.0316'}, 'title': 'Visually-guided irrigation in patients with early knee osteoarthritis: a multicenter randomized, controlled trial', 'source': 'CrossRef'}
Kalunian KC, Moreland LW, Klashman DJ, Brion PH, Concoff AL, Myers S, Singh R, Ike RW, Seeger LL, Rich E, Skovron ML. Visually-guided irrigation in patients with early knee osteoarthritis: a multicenter randomized, controlled trial. Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society. 2000;8(6):412-8.	10.1053/joca.1999.0316	11069725	primary-study	c5cd96385fdb75bac06f73ffd0945479db1bfd78	-	{'publication_type': {'year': 2000, 'cited_medium': None, 'issue': None, 'issn': '1063-4584 (Print)', 'volume': None, 'title': 'Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 0.9818181818181818, 'authors': 0.9272727272727274}, 'authors': [{'given': 'K C', 'family': 'Kalunian'}, {'given': 'L W', 'family': 'Moreland'}, {'given': 'D J', 'family': 'Klashman'}, {'given': 'P H', 'family': 'Brion'}, {'given': 'a L', 'family': 'Concoff'}, {'given': 'S', 'family': 'Myers'}, {'given': 'R', 'family': 'Singh'}, {'given': 'R W', 'family': 'Ike'}, {'given': 'L L', 'family': 'Seeger'}, {'given': 'E', 'family': 'Rich'}, {'given': 'M L', 'family': 'Skovron'}], 'abstract': "OBJECTIVE: To determine if visually-guided arthroscopic irrigation is an effective therapeutic intervention in patients with early knee osteoarthritis. DESIGN: Ninety patients with knee osteoarthritis were randomized in a double-blind fashion to receive either arthroscopic irrigation with 3000 ml of saline (treatment group) or the minimal amount of irrigation (250 ml) required to perform arthroscopy (placebo group). The primary outcome variable was aggregate WOMAC score. RESULTS: The study did not demonstrate an effect of irrigation on arthritis severity as measured by aggregate WOMAC scores, the primary outcome variable; the mean change in aggregate WOMAC score at 12 months was 15.5 (95% CI 7.7, 23.4) for the full irrigation group compared to 8.9 (95% CI 4.9, 13.0) for the minimal irrigation group (P=0.10). Full irrigation did have a statistically significant effect on patients' self-reported pain as measured by the WOMAC pain subscale and by a visual analog scale (VAS) (the secondary outcome variables). Mean change in WOMAC pain scores decreased by 4.2 (95% CI -0.9, 9.4) for the full irrigation group compared with a mean decrease of 2.3 (95% CI -0.1, 4.7) in the minimal irrigation group (P=0.04). Mean VAS pain scores decreased by 1.47 (95% CI -1.2, 4.1) in the full irrigation group compared to a mean decrease of 0.12 (95% CI 0.0, 0.3) in the minimal irrigation group (P=0.02). A hypothesis-generating post-hoc analysis of the effect of positively birefrigent intraarticular crystals showed that patients with and without intraarticular crystals had statistically significant improvements in pain assessments and aggregate WOMAC scores at 12 months; patients with crystals had statistically greater improvements in pain. CONCLUSIONS: Visually-guided arthroscopic irrigation may be a useful therapeutic option for relief of pain in a subset of patients with knee OA, particularly in those who have occult intraarticular crystals.", 'type': 'journal', 'ids': {'embase': None, 'pubmed': '11069725', 'scopus': None, 'doi': '10.1053/joca.2000.0316'}, 'title': 'Visually-guided irrigation in patients with early knee osteoarthritis: a multicenter randomized, controlled trial.', 'source': 'Mendeley'}
Ravaud P, Moulinier L, Giraudeau B, Ayral X, Guerin C, Noel E, Thomas P, Fautrel B, Mazieres B, Dougados M. Effects of joint lavage and steroid injection in patients with osteoarthritis of the knee: results of a multicenter, randomized, controlled trial. Arthritis and rheumatism. 1999;42(3):475-82.	10.1002/1529-0131(199904)42:3<475::AID-ANR12>3.0.CO;2-S	10088770	primary-study	6cd400537d210e444cc3879159d8cdb7b0b021b0	-	{'publication_type': {'year': 1999, 'cited_medium': None, 'issue': '3', 'issn': '0004-3591', 'volume': '42', 'title': 'Arthritis & Rheumatism', 'pagination': '475-482'}, 'language': None, 'rating': {'year': 0, 'title': 1.0, 'total': 0.8775000000000001, 'authors': 0.9100000000000001}, 'authors': [{'given': 'Philippe', 'family': 'Ravaud'}, {'given': 'Laurence', 'family': 'Moulinier'}, {'given': 'Bruno', 'family': 'Giraudeau'}, {'given': 'Xavier', 'family': 'Ayral'}, {'given': 'Corinne', 'family': 'Guerin'}, {'given': 'Eric', 'family': 'Noel'}, {'given': 'Philippe', 'family': 'Thomas'}, {'given': 'Bruno', 'family': 'Fautrel'}, {'given': 'Bernard', 'family': 'Mazieres'}, {'given': 'Maxime', 'family': 'Dougados'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1002/1529-0131(199904)42:3<475::aid-anr12>3.0.co;2-s'}, 'title': 'Effects of joint lavage and steroid injection in patients with osteoarthritis of the knee: Results of a multicenter, randomized, controlled trial', 'source': 'CrossRef'}
Ravaud P, Moulinier L, Giraudeau B, Ayral X, Guerin C, Noel E, Thomas P, Fautrel B, Mazieres B, Dougados M. Effects of joint lavage and steroid injection in patients with osteoarthritis of the knee: results of a multicenter, randomized, controlled trial. Arthritis and rheumatism. 1999;42(3):475-82.	10.1002/1529-0131(199904)42:3<475::AID-ANR12>3.0.CO;2-S	10088770	primary-study	6cd400537d210e444cc3879159d8cdb7b0b021b0	-	{'publication_type': {'year': 1999, 'cited_medium': None, 'issue': None, 'issn': '0004-3591', 'volume': None, 'title': 'Arthritis and rheumatism', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 1.0, 'authors': 1.0}, 'authors': [{'given': 'P', 'family': 'Ravaud'}, {'given': 'L', 'family': 'Moulinier'}, {'given': 'B', 'family': 'Giraudeau'}, {'given': 'X', 'family': 'Ayral'}, {'given': 'C', 'family': 'Guerin'}, {'given': 'E', 'family': 'Noel'}, {'given': 'P', 'family': 'Thomas'}, {'given': 'B', 'family': 'Fautrel'}, {'given': 'B', 'family': 'Mazieres'}, {'given': 'M', 'family': 'Dougados'}], 'abstract': "OBJECTIVE: To evaluate the efficacy of joint lavage and intraarticular steroid injection, alone and in combination, in the treatment of patients with symptomatic knee osteoarthritis (OA). METHODS: Ninety-eight patients with painful tibiofemoral OA were enrolled in a prospective, randomized, controlled, 2 x 2 factorial-design trial of 6 months' duration. The 4 treatment groups consisted of 1) intraarticular placebo (1.5 ml of 0.9% normal saline), 2) intraarticular corticosteroids (3.75 mg of cortivazol in 1.5 ml), 3) joint lavage and intraarticular placebo, and 4) joint lavage and intraarticular corticosteroid. Outcome measures evaluated at baseline, week 1, week 4, week 12, and week 24 included severity of pain (100-mm visual analog scale [VAS]), global status (100-mm VAS), and Lequesne's functional index. RESULTS: No interaction between steroid injection and joint lavage was demonstrated. Patients who had undergone joint lavage had significantly improved pain VAS scores at week 24 (P = 0.020). In contrast, corticosteroid injection had no long-term effect (P = 0.313); corticosteroid injection was associated with a decrease in pain only at week 1 (P = 0.003) and week 4 (P = 0.020). After week 4, Lequesne's functional index was not significantly improved regardless of the assigned treatment. CONCLUSION: Compared with placebo, both treatments significantly relieved pain but did not improve functional impairment. The effects of the 2 treatments were additive. Cortivazol provided short-term relief of pain (up to week 4). The effects of joint lavage persisted up to week 24.", 'type': 'journal', 'ids': {'embase': None, 'pubmed': '10088770', 'scopus': '2-s2.0-0032976634', 'doi': '10.1002/1529-0131(199904)42:3<475::AID-ANR12>3.0.CO;2-S'}, 'title': 'Effects of joint lavage and steroid injection in patients with osteoarthritis of the knee: results of a multicenter, randomized, controlled trial.', 'source': 'Mendeley'}
Moseley JB, Wray NP, Kuykendall D, Willis K, Landon G. Arthroscopic treatment of osteoarthritis of the knee: a prospective, randomized, placebo-controlled trial. Results of a pilot study. The American journal of sports medicine. 1996;24(1):28-34.	-	8638750	primary-study	2756af33a7c8f7672a006ce26620319ca2812a70	-	{'publication_type': {'year': 1996, 'cited_medium': None, 'issue': '1', 'issn': '0363-5465', 'volume': '24', 'title': 'The American Journal of Sports Medicine', 'pagination': '28-34'}, 'language': None, 'rating': {'year': 0, 'title': 0.9411764705882353, 'total': 0.841764705882353, 'authors': 0.9199999999999999}, 'authors': [{'given': 'J. B.', 'family': 'Moseley'}, {'given': 'N. P.', 'family': 'Wray'}, {'given': 'D.', 'family': 'Kuykendall'}, {'given': 'K.', 'family': 'Willis'}, {'given': 'G.', 'family': 'Landon'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1177/036354659602400106'}, 'title': 'Arthroscopic Treatment of Osteoarthritis of the Knee: A Prospective, Randomized, Placebo-Controlled Trial: Results of a Pilot Study', 'source': 'CrossRef'}
Moseley JB, Wray NP, Kuykendall D, Willis K, Landon G. Arthroscopic treatment of osteoarthritis of the knee: a prospective, randomized, placebo-controlled trial. Results of a pilot study. The American journal of sports medicine. 1996;24(1):28-34.	-	8638750	primary-study	2756af33a7c8f7672a006ce26620319ca2812a70	-	{'publication_type': {'year': 1999, 'cited_medium': None, 'issue': None, 'issn': None, 'volume': None, 'title': 'VETERINARY PATHOLOGY 36(1):28-34. 1999.', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.25, 'total': 0.1625, 'authors': 0.0}, 'authors': [{'given': 'B S and D F COWAN.', 'family': 'TURNBULL'}], 'abstract': 'A new disease, angiomatosis, was recognized in 25 of 54 (46.3%) Atlantic bottlenose dolphins (Tursiops truncatus) necropsied after being stranded along the Texas Gulf coast during 1991-1996. Angiomatosis was first recognized by the authors in 1992 and has increased in incidence and severity, affecting 100% of juveniles and adults. This disease is characterized by proliferation of small, thick-walled blood vessels diffusely throughout the lungs, without inflammation, exudation, or alveolar hemorrhage. The vascular proliferation also occurs in lung-associated and other visceral lymph nodes. Hemangiomas frequently occur in affected lymph nodes and occasionally in the lungs. The vascular proliferation reduces airspace and may occlude small airways. Angiomatosis appears to be a broad-field defect of vascular endothelium. Although this process appears to be an increasingly important factor in the morbidity of T. truncatus, its etiology has not been determined.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': None}, 'title': 'Angiomatosis, a newly recognized disease in Atlantic bottlenose dolphins (Tursiops truncatus) from the Gulf of Mexico.', 'source': 'Mendeley'}
Ike RW, Arnold WJ, Rothschild EW, Shaw HL. Tidal irrigation versus conservative medical management in patients with osteoarthritis of the knee: a prospective randomized study. Tidal Irrigation Cooperating Group. The Journal of rheumatology. 1992;19(5):772-9.	-	1613709	primary-study	6e05d9fa789644e098c3601654340a16d947ccdd	-	{'publication_type': {'year': 2000, 'cited_medium': None, 'issue': '6', 'issn': '1063-4584', 'volume': '8', 'title': 'Osteoarthritis and Cartilage', 'pagination': '412-418'}, 'language': None, 'rating': {'year': 0, 'title': 0.46153846153846156, 'total': 0.3340909090909091, 'authors': 0.13636363636363635}, 'authors': [{'given': 'K.C', 'family': 'Kalunian'}, {'given': 'L.W', 'family': 'Moreland'}, {'given': 'D.J', 'family': 'Klashman'}, {'given': 'P.H', 'family': 'Brion'}, {'given': 'A.L', 'family': 'Concoff'}, {'given': 'S', 'family': 'Myers'}, {'given': 'R', 'family': 'Singh'}, {'given': 'R.W', 'family': 'Ike§'}, {'given': 'L.L', 'family': 'Seeger'}, {'given': 'E', 'family': 'Rich'}, {'given': 'M.L', 'family': 'Skovron'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '11069725', 'scopus': None, 'doi': '10.1053/joca.1999.0316'}, 'title': 'Visually-guided irrigation in patients with early knee osteoarthritis: a multicenter randomized, controlled trial', 'source': 'CrossRef'}
Ike RW, Arnold WJ, Rothschild EW, Shaw HL. Tidal irrigation versus conservative medical management in patients with osteoarthritis of the knee: a prospective randomized study. Tidal Irrigation Cooperating Group. The Journal of rheumatology. 1992;19(5):772-9.	-	1613709	primary-study	6e05d9fa789644e098c3601654340a16d947ccdd	-	{'publication_type': {'year': 1992, 'cited_medium': None, 'issue': None, 'issn': '0315-162X (Print)', 'volume': None, 'title': 'J Rheumatol', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.875, 'authors': 0.9}, 'authors': [{'given': 'R W', 'family': 'Ike'}, {'given': 'W J', 'family': 'Arnold'}, {'given': 'E W', 'family': 'Rothschild'}, {'given': 'H L', 'family': 'Shaw'}], 'abstract': "To determine the efficacy of tidal knee irrigation for knee pain due to osteoarthritis (OA), we conducted a randomized, single blind, 14-week prospective trial comparing medical management with tidal knee irrigation in 77 patients with non-end stage OA of the knee and unilateral pain refractory to standard medical treatment. Fifty-seven patients completed the study. Statistically significant differences (p less than 0.05) favoring tidal knee irrigation over medical management were pain after 50' walk, pain after 4-stair climb, most intense pain in previous day, frequency of knee stiffness with inactivity, days of morning knee stiffness in previous week, physician assessment of knee tenderness and overall assessments of therapy effectiveness by both patient and physician. Tidal knee irrigation results in more favorable improvement of pain due to OA than can be accomplished with traditional medical management.", 'type': 'journal', 'ids': {'embase': None, 'pubmed': '1613709', 'scopus': None, 'doi': None}, 'title': 'Tidal irrigation versus conservative medical management in patients with osteoarthritis of the knee: a prospective randomized study. Tidal Irrigation Cooperating Group', 'source': 'Mendeley'}
Dawes PT, Kirlew C, Haslock I. Saline washout for knee osteoarthritis: results of a controlled study. Clinical rheumatology. 1987;6(1):61-3.	-	3581699	primary-study	a5b34b231fb4bc9d80e6bbb1bc2f11a8cc3217a6	-	{'publication_type': {'year': 1987, 'cited_medium': None, 'issue': '1', 'issn': '0770-3198', 'volume': '6', 'title': 'Clinical Rheumatology', 'pagination': '61-63'}, 'language': None, 'rating': {'year': 0, 'title': 1.0, 'total': 0.8833333333333333, 'authors': 0.9333333333333332}, 'authors': [{'given': 'P. T.', 'family': 'Dawes'}, {'given': 'C.', 'family': 'Kirlew'}, {'given': 'I.', 'family': 'Haslock'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1007/bf02201002'}, 'title': 'Saline washout for knee osteoarthritis: Results of a controlled study', 'source': 'CrossRef'}
Dawes PT, Kirlew C, Haslock I. Saline washout for knee osteoarthritis: results of a controlled study. Clinical rheumatology. 1987;6(1):61-3.	-	3581699	primary-study	a5b34b231fb4bc9d80e6bbb1bc2f11a8cc3217a6	-	{'publication_type': {'year': 2010, 'cited_medium': None, 'issue': None, 'issn': None, 'volume': None, 'title': 'Sodobna pedagogogika 61 (3)', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.0, 'total': 0.0, 'authors': 0.0}, 'authors': [{'given': 'Darko', 'family': 'Zupanc'}, {'given': 'Matevž', 'family': 'Bren'}], 'abstract': "Abstract: Grade inflation is defined as an upward shift of average school grades over an extended period of time without a corresponding increase in student achievement. This issue was pointed out years ago when experts in the U.S. became aware of the year–to-year rise of the grade point average (GPA) and also when similar situation occurred with the internal grading of various subjects of general Matura in Slovenia. The article shows differences (academic years 87/88 and 05/06) in the distribution of overall achievement in primary schools in Slovenia and high graded internal parts of the general Matura exams over time (1995 to 2008). The study confirms the prognosis given nine years ago predicting that internal grades in the school-based parts of the Matura exams (i.e. oral exam, laboratory work, coursework, etc.) will increase each year; these are now approaching a 90% average, and in some subjects even exceed that percentage. The study analyzes the internal grades of subject groups with the same proportion (20%, 25%, 30% and 40%) of the internal part of the exam. Internal grades are higher in groups with a higher proportion of the internal exam; the fastest growing internal grade average is in the group with 30% of internal proportion. The second highest slope of increase is in the groups with 40% and 25% of the internal part, where the group with the 40% proportion of school-based part starts much higher in the beginning year (2000). The minimum annual growth has been recorded in the group with the lowest, i.e. 20%, internal part. All upward trends are statistically significant. Grade inflation, meaning that higher grades do not derive from a corresponding increase in student achievement, is confirmed by a correlation research between the internal and the external part of the Matura exams (correlations are relatively low), and by the Matura Subject Commission's trial where teachers' and external examiners' grades regarding the same objectives were compared.", 'type': 'journal', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': None}, 'title': 'Inflacija pri internem ocenjevanju v Sloveniji', 'source': 'Mendeley'}
Spiro SG, Rudd RM, Souhami RL, Brown J, Fairlamb DJ, Gower NH, Maslove L, Milroy R, Napp V, Parmar MK, Peake MD, Stephens RJ, Thorpe H, Waller DA, West P. Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life. Thorax. 2004;59(10):828-36.	10.1136/thx.2003.020164	15454647	primary-study	ad2d8eb82bbf304548db1b78c1c89377a6d7ff63	-	{'publication_type': {'year': 2004, 'cited_medium': None, 'issue': '10', 'issn': '0040-6376', 'volume': '59', 'title': 'Thorax', 'pagination': '828-836'}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 0.975, 'authors': 0.9}, 'authors': [{'given': 'S G', 'family': 'Spiro'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '15454647', 'scopus': None, 'doi': '10.1136/thx.2003.020164'}, 'title': 'Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life', 'source': 'CrossRef'}
Spiro SG, Rudd RM, Souhami RL, Brown J, Fairlamb DJ, Gower NH, Maslove L, Milroy R, Napp V, Parmar MK, Peake MD, Stephens RJ, Thorpe H, Waller DA, West P. Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life. Thorax. 2004;59(10):828-36.	10.1136/thx.2003.020164	15454647	primary-study	ad2d8eb82bbf304548db1b78c1c89377a6d7ff63	-	{'publication_type': {'year': 2004, 'cited_medium': None, 'issue': None, 'issn': None, 'volume': None, 'title': 'Thorax', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 1.0, 'total': 0.875, 'authors': 0.5}, 'authors': [{'given': 'Spiro', 'family': 'S.G.'}, {'given': 'Rudd', 'family': 'R.M.'}, {'given': 'Souhami', 'family': 'R.L.'}, {'given': 'Brown', 'family': 'J.'}, {'given': 'Fairlamb', 'family': 'D.J.'}, {'given': 'Gower', 'family': 'N.H.'}, {'given': 'Maslove', 'family': 'L.'}, {'given': 'Milroy', 'family': 'R.'}, {'given': 'Napp', 'family': 'V.'}, {'given': 'Parmar', 'family': 'M.K.B.'}, {'given': 'Peake', 'family': 'M.D.'}, {'given': 'Stephens', 'family': 'R.J.'}, {'given': 'Thorpe', 'family': 'H.'}, {'given': 'Waller', 'family': 'D.A.'}, {'given': 'West', 'family': 'P.'}], 'abstract': 'Background: In 1995 a meta-analysis of randomised trials investigating the value of adding chemotherapy to primary treatment for non-small cell lung cancer (NSCLC) suggested a small survival benefit for cisplatin-based chemotherapy in each of the primary treatment settings. However, the meta-analysis included many small trials and trials with differing eligibility criteria and chemotherapy regimens. Methods: The aim of the Big Lung Trial was to confirm the survival benefits seen in the meta-analysis and to assess quality of life and cost in the supportive care setting. A total of 725 patients were randomised to receive supportive care alone (n = 361) or supportive care plus cisplatin-based chemotherapy (n = 364). Results: 65% of patients allocated chemotherapy (C) received all three cycles of treatment and a further 27% received one or two cycles. 74% of patients allocated no chemotherapy (NoC) received thoracic radiotherapy compared with 47% of the C group. Patients allocated C had a significantly better survival than those allocated NoC: HR 0.77 (95% CI 0.66 to 0.89, p = 0.0006), median survival 8.0 months for the C group v 5.7 months for the NoC group, a difference of 9 weeks. There were 19 (5%) treatment related deaths in the C group. There was no evidence that any subgroup benefited more or less from chemotherapy. No significant differences were observed between the two groups in terms of the pre-defined primary and secondary quality of life end points, although large negative effects of chemotherapy were ruled out. The regimens used proved to be cost effective, the extra cost of chemotherapy being offset by longer survival. Conclusions: The survival benefit seen in this trial was entirely consistent with the NSCLC meta-analysis and subsequent similarly designed large trials. The information on quality of life and cost should enable patients and their clinicians to make more informed treatment choices.', 'type': 'generic', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': None}, 'title': 'Chemotherapy versus supportive care in advanced non-small cell lung cancer: Improved survival without detriment to quality of life', 'source': 'Mendeley'}
Anderson H, Hopwood P, Stephens RJ, Thatcher N, Cottier B, Nicholson M, Milroy R, Maughan TS, Falk SJ, Bond MG, Burt PA, Connolly CK, McIllmurray MB, Carmichael J. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer. British journal of cancer. 2000;83(4):447-53.	10.1054/bjoc.2000.1307	10945489	primary-study	71d5d5ba63e7d0816172cc4ef0864c9f933549d7	-	{'publication_type': {'year': 1997, 'cited_medium': None, 'issue': None, 'issn': '0169-5002', 'volume': '18', 'title': 'Lung Cancer', 'pagination': '9'}, 'language': None, 'rating': {'year': 1, 'title': 0.631578947368421, 'total': 0.6955263157894737, 'authors': 0.74}, 'authors': [{'given': 'H.', 'family': 'Anderson'}, {'given': 'B.', 'family': 'Cottier'}, {'given': 'M.', 'family': 'Nicolson'}, {'given': 'R.', 'family': 'Milroy'}, {'given': 'T.', 'family': 'Maughan'}, {'given': 'M.', 'family': 'Bond'}, {'given': 'S.', 'family': 'Falk'}, {'given': 'P.', 'family': 'Burt'}, {'given': 'J.', 'family': 'Carmichael'}, {'given': 'N.', 'family': 'Thatcher'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1016/s0169-5002(97)89303-8'}, 'title': '24 Phase III study of gemcitabine (Gemzar®) versus best supportive care (BSC) in advanced non-small cell lung cancer (NSCLC)', 'source': 'CrossRef'}
Anderson H, Hopwood P, Stephens RJ, Thatcher N, Cottier B, Nicholson M, Milroy R, Maughan TS, Falk SJ, Bond MG, Burt PA, Connolly CK, McIllmurray MB, Carmichael J. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer. British journal of cancer. 2000;83(4):447-53.	10.1054/bjoc.2000.1307	10945489	primary-study	71d5d5ba63e7d0816172cc4ef0864c9f933549d7	-	{'publication_type': {'year': 2000, 'cited_medium': None, 'issue': None, 'issn': '00070920', 'volume': None, 'title': 'British Journal of Cancer', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 1.0, 'total': 0.65, 'authors': 0.0}, 'authors': [{'given': 'P.b Stephens R.J.c Thatcher N.d Cottier B.e Nicholson M.f Milroy R.g Maughan T.S.h Falk S.J.i Bond M.G.j Burt P.A.k Connolly C.K.l McIllmurray M.B.m Carmichael J.n', 'family': 'Anderson H.a Hopwood'}], 'abstract': "Three hundred patients with symptomatic, locally advanced or metastatic NSCLC not requiring immediate radiotherapy were enrolled into this randomized multicentre trial comparing gemcitabine + BSC vs BSC alone. Patients allocated gemcitabine received 1000 mg/m2 on days 1, 8 and 15 of a 28-day cycle, for a maximum of six cycles. The main aim of this trial was to compare patient assessment of a predefined subset of commonly reported symptoms (SS14) from the EORTC QLQ-C30 and LC13 scales. The primary end-points were defined as (1) the percentage change in mean SS14 score between baseline and 2 months and (2) the proportion of patients with a marked (≥ 25%) improvement in SS14 score between baseline and 2 months sustained for ≥ 4 weeks. The secondary objectives were to compare treatments with respect to overall survival, and multidimensional QL parameters. The treatment groups were balanced with regard to age, gender, Karnofsky performance status (KPS) and disease stage (40% had metastatic disease). The percentage change in mean SS14 score from baseline to 2 months was a 10% decrease (i.e. improvement) for gemcitabine plus BSC and a 1% increase (i.e. deterioration) for BSC alone (P = 0.113, two-sample t-test). A sustained (≥ 4 weeks) improvement (≥ 25%) on SS14 was recorded in a significantly higher proportion of gemcitabine + BSC patients (22%) than in BSC alone patients (9%) (P = 0.0014, Pearson's chi-squared test). The QLQ-C30 and L13 subscales showed greater improvement in the gemcitabine plus BSC arm (in 11 domains) than in the BSC arm tone symptom item). There was greater deterioration in the BSC alone arm (six domains/items) than in the gemcitabine + BSC arm (three QL domains). Tumour response occurred in 19% (95% CI 13-27) of gemcitabine patients. There was no difference in overall survival: median 5.7 months (95% CI 4.6-7.6) for gemcitabine + BSC patients and 5.9 months (95% CI 5.0-7.9) (log-rank, P = 0.84) for BSC patients, and 1-year survival was 25% for gemcitabine + BSC and 22% for BSC. Overall, 74 (49%) gemcitabine + BSC patients and 119 (79%) BSC patients received palliative radiotherapy. The median time to radiotherapy was 29 weeks for gemcitabine + BSC patients and 3.8 weeks for BSC. Patients treated with gemcitabine + BSC reported better QL and reduced disease-related symptoms compared with those receiving BSC alone. These improvements in patient-assessed QL were significant in magnitude and were sustained. (C) 2000 Cancer Research Campaign.", 'type': 'journal', 'ids': {'embase': None, 'pubmed': None, 'scopus': '2-s2.0-0033913982', 'doi': None}, 'title': 'Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer - A randomized trial with quality of life as the primary outcome', 'source': 'Mendeley'}
Ranson M, Davidson N, Nicolson M, Falk S, Carmichael J, Lopez P, Anderson H, Gustafson N, Jeynes A, Gallant G, Washington T, Thatcher N. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. Journal of the National Cancer Institute. 2000;92(13):1074-80.	-	10880550	primary-study	0131346fce659301c5559e1766f43749f2b31b23	-	{'publication_type': {'year': 2000, 'cited_medium': None, 'issue': '13', 'issn': '1460-2105', 'volume': '92', 'title': 'Journal of the National Cancer Institute', 'pagination': '1074-1080'}, 'language': None, 'rating': {'year': 1, 'title': 1.0, 'total': 0.975, 'authors': 0.9}, 'authors': [{'given': 'M.', 'family': 'Ranson'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1093/jnci/92.13.1074'}, 'title': 'Randomized Trial of Paclitaxel Plus Supportive Care Versus Supportive Care for Patients With Advanced Non-Small-Cell Lung Cancer', 'source': 'CrossRef'}
Ranson M, Davidson N, Nicolson M, Falk S, Carmichael J, Lopez P, Anderson H, Gustafson N, Jeynes A, Gallant G, Washington T, Thatcher N. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. Journal of the National Cancer Institute. 2000;92(13):1074-80.	-	10880550	primary-study	0131346fce659301c5559e1766f43749f2b31b23	-	{'publication_type': {'year': 2000, 'cited_medium': None, 'issue': None, 'issn': None, 'volume': None, 'title': 'Journal of the National Cancer Institute', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 0.875, 'authors': 0.5}, 'authors': [{'given': 'Ranson', 'family': 'M.'}, {'given': 'Davidson', 'family': 'N.'}, {'given': 'Nicolson', 'family': 'M.'}, {'given': 'Falk', 'family': 'S.'}, {'given': 'Carmichael', 'family': 'J.'}, {'given': 'Lopez', 'family': 'P.'}, {'given': 'Anderson', 'family': 'H.'}, {'given': 'Gustafson', 'family': 'N.'}, {'given': 'Jeynes', 'family': 'A.'}, {'given': 'Gallant', 'family': 'G.'}, {'given': 'Washington', 'family': 'T.'}, {'given': 'Thatcher', 'family': 'N.'}], 'abstract': 'Background: In phase II trials, paclitaxel has been shown to have antitumor activity in patients with advanced non-small-cell lung cancer (NSCLC). However, the survival and quality-of-life (QOL) benefits of paclitaxel used as a single agent compared with supportive care alone have not been assessed in a randomized clinical trial. Methods: A total of 157 patients with stage IIIB or IV NSCLC who had received no prior chemotherapy were randomly assigned to receive either best supportive care alone (78 patients) or paclitaxel plus supportive care (79 patients). Paclitaxel was administered as a 3-hour intravenous infusion every 3 weeks. Sup-portive care included palliative radiotherapy and supportive therapy with corticosteroids, antibiotics, analgesics, anti-emetics, transfusions, and other symptomatic therapy as required. The primary end point of the study was survival. Time to disease progression, response rate, adverse events, and QOL were secondary end points. Results: Pretreatment characteristics were evenly distributed between the two arms. Survival was statistically significantly better in the paclitaxel plus supportive care arm than in the supportive care alone arm (two-sided P = .037) (median survival = 6.8 months versus 4.8 months). Cox multivariate analysis showed paclitaxel plus supportive care to be statistically sig-nificantly associated with improved survival (two-sided P = .048). QOL was similar for both treatment arms, except for the functional activity score of the Rotterdam Symptom Checklist, where QOL data statistically significantly favored the paclitaxel plus supportive care arm (two-sided P = .043). Conclusion: The addition of paclitaxel to best supportive care significantly improved survival and time to disease progression compared with best supportive care in patients with advanced NSCLC and may improve some aspects of QOL.', 'type': 'generic', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': None}, 'title': 'Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer', 'source': 'Mendeley'}
Cullen MH, Billingham LJ, Woodroffe CM, Chetiyawardana AD, Gower NH, Joshi R, Ferry DR, Rudd RM, Spiro SG, Cook JE, Trask C, Bessell E, Connolly CK, Tobias J, Souhami RL. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1999;17(10):3188-94.	-	10506617	primary-study	d0c0ee8fec657229890af05d3f3c865e6951c374	-	{'publication_type': {'year': 1997, 'cited_medium': None, 'issue': None, 'issn': '0169-5002', 'volume': '18', 'title': 'Lung Cancer', 'pagination': '5'}, 'language': None, 'rating': {'year': 0, 'title': 0.5416666666666666, 'total': 0.5770833333333334, 'authors': 0.9000000000000001}, 'authors': [{'given': 'M.H.', 'family': 'Cullen'}, {'given': 'L.J.', 'family': 'Billingham'}, {'given': 'C.M.', 'family': 'Woodroffe'}, {'given': 'N.', 'family': 'Gower'}, {'given': 'R.L.', 'family': 'Souhami'}, {'given': 'A.D.', 'family': 'Chetiyawardana'}, {'given': 'R.', 'family': 'Joshi'}, {'given': 'R.', 'family': 'Rudd'}, {'given': 'C.', 'family': 'Trask'}, {'given': 'S.', 'family': 'Spiro'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1016/s0169-5002(97)89289-6'}, 'title': '10 Mitomycin, ifosfamide and cisplatin (MIC) in non-small cell lung cancer (NSCLC): 1. Results of a randomised trial in patients with localised, inoperable disease', 'source': 'CrossRef'}
Cullen MH, Billingham LJ, Woodroffe CM, Chetiyawardana AD, Gower NH, Joshi R, Ferry DR, Rudd RM, Spiro SG, Cook JE, Trask C, Bessell E, Connolly CK, Tobias J, Souhami RL. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1999;17(10):3188-94.	-	10506617	primary-study	d0c0ee8fec657229890af05d3f3c865e6951c374	-	{'publication_type': {'year': 1999, 'cited_medium': None, 'issue': None, 'issn': '0732-183X', 'volume': None, 'title': 'Journal of clinical oncology : official journal of the American Society of Clinical Oncology', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 0.9683333333333334, 'authors': 0.8733333333333334}, 'authors': [{'given': 'M H', 'family': 'Cullen'}, {'given': 'L J', 'family': 'Billingham'}, {'given': 'C M', 'family': 'Woodroffe'}, {'given': 'a D', 'family': 'Chetiyawardana'}, {'given': 'N H', 'family': 'Gower'}, {'given': 'R', 'family': 'Joshi'}, {'given': 'D R', 'family': 'Ferry'}, {'given': 'R M', 'family': 'Rudd'}, {'given': 'S G', 'family': 'Spiro'}, {'given': 'J E', 'family': 'Cook'}, {'given': 'C', 'family': 'Trask'}, {'given': 'E', 'family': 'Bessell'}, {'given': 'C K', 'family': 'Connolly'}, {'given': 'J', 'family': 'Tobias'}, {'given': 'R L', 'family': 'Souhami'}], 'abstract': 'Chemotherapy for non-small-cell lung cancer (NSCLC) remains controversial. We describe the two largest reported, randomized, parallel trials designed to determine whether the addition of chemotherapy influences duration and quality of life in localized, unresectable (mitomycin, ifosfamide, cisplatin [MIC]1 trial) and extensive (MIC2 trial) disease.', 'type': 'generic', 'ids': {'embase': None, 'pubmed': '10506617', 'scopus': None, 'doi': None}, 'title': 'Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life.', 'source': 'Mendeley'}
 Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. Journal of the National Cancer Institute. 1999;91(1):66-72.	-	9890172	primary-study	6bbd676c0754c2cdb5cd572246d7dc2de0e96f5c	-	{'publication_type': {'year': 1999, 'cited_medium': None, 'issue': '1', 'issn': '0027-8874', 'volume': '91', 'title': 'JNCI Journal of the National Cancer Institute', 'pagination': '66-72'}, 'language': None, 'rating': {'year': 0, 'title': 1.0, 'total': 0.65, 'authors': 0}, 'authors': [], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1093/jnci/91.1.66'}, 'title': 'Effects of Vinorelbine on Quality of Life and Survival of Elderly Patients With Advanced Non-Small-Cell Lung Cancer', 'source': 'CrossRef'}
 Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. Journal of the National Cancer Institute. 1999;91(1):66-72.	-	9890172	primary-study	6bbd676c0754c2cdb5cd572246d7dc2de0e96f5c	-	{'publication_type': {'year': 1999, 'cited_medium': None, 'issue': None, 'issn': '0027-8874', 'volume': None, 'title': 'Journal of the National Cancer Institute', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 0.875, 'authors': 0.5}, 'authors': [{'given': 'The Elderly Lung Cancer Vinorelbine Italian Study', 'family': 'Group'}], 'abstract': 'BACKGROUND: Vinorelbine, a semisynthetic vinca alkaloid, represents a well-tolerated treatment for elderly patients with advanced non-small-cell lung cancer (NSCLC). We explored the quality of life (QoL) of such patients in a multicenter randomized trial that compared vinorelbine treatment with supportive care alone. METHODS: Eligible patients were 70 years of age or older, had stage IV or IIIB NSCLC that was ineligible for radiotherapy, and had a performance status of 0-2 (a status of fully active to a status of capable of all self-care but unable to work). Vinorelbine was given intravenously on days 1 and 8 of a 21-day treatment cycle, for a total of six cycles. QoL was evaluated with European Organization for Research and Treatment of Cancer questionnaires QLQ-C30 and QLQ-LC13, and the QoL data were analyzed by fitting a linear mixed model for each QoL scale. Survival curves were plotted and were compared with the Mantel-Haenszel test. Relative hazards of death and 95% confidence intervals (CIs) were estimated by the Cox model. RESULTS: Investigators, blinded to the results, stopped the trial early because of a low enrollment rate. (From April 1996 to November 1997, 191 of the 350 targeted patients were randomly assigned.) Data from 161 patients have been analyzed. Vinorelbine-treated patients scored better than control patients on QoL functioning scales, and they reported fewer lung cancer-related symptoms but reported worse toxicity-related symptoms. There was a statistically significant (two-sided P = .03) survival advantage for patients receiving vinorelbine; median survival increased from 21 to 28 weeks in the vinorelbine-treated group. The relative hazard of death for vinorelbine-treated patients was 0.65 (95% CI = 0.45-0.93). CONCLUSION: Vinorelbine improves survival of elderly patients with advanced NSCLC and possibly improves overall QoL.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '9890172', 'scopus': None, 'doi': None}, 'title': 'Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group.', 'source': 'Mendeley'}
Helsing M, Bergman B, Thaning L, Hero U. Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre randomised phase III trial. Joint Lung Cancer Study Group. European journal of cancer (Oxford, England : 1990). 1998;34(7):1036-44.	-	9849452	primary-study	12629b4c6a58d4809149cb4779a1693856f27632	-	{'publication_type': {'year': 1998, 'cited_medium': None, 'issue': '7', 'issn': '0959-8049', 'volume': '34', 'title': 'European Journal of Cancer', 'pagination': '1036-1044'}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.9, 'authors': 1.0}, 'authors': [{'given': 'M', 'family': 'Helsing'}, {'given': 'B', 'family': 'Bergman'}, {'given': 'L', 'family': 'Thaning'}, {'given': 'U', 'family': 'Hero'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1016/s0959-8049(97)10122-8'}, 'title': 'Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre randomised phase III trial', 'source': 'CrossRef'}
Helsing M, Bergman B, Thaning L, Hero U. Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre randomised phase III trial. Joint Lung Cancer Study Group. European journal of cancer (Oxford, England : 1990). 1998;34(7):1036-44.	-	9849452	primary-study	12629b4c6a58d4809149cb4779a1693856f27632	-	{'publication_type': {'year': 1998, 'cited_medium': None, 'issue': None, 'issn': None, 'volume': None, 'title': 'European journal of cancer (Oxford, England : 1990)', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 1.0, 'total': 1.0, 'authors': 1.0}, 'authors': [{'given': 'M', 'family': 'Helsing'}, {'given': 'B', 'family': 'Bergman'}, {'given': 'L', 'family': 'Thaning'}, {'given': 'U', 'family': 'Hero'}], 'abstract': 'The aim of the present trial was to evaluate the effects of chemotherapy o\\nn the quality of life and survival of patients with advanced non-small cell lung\\n cancer (NSCLC) (stage IIIB or IV). In a controlled multicentre trial, patients \\nwere randomised to receive supportive care only or supportive care plus chemothe\\nrapy. Chemotherapy consisted of intravenous (i.v.) carboplatin 300 mg/m2 on day \\n1 and etoposide 120 mg/m2 orally on days 1-5 every 4 weeks for a maximum of eigh\\nt courses. Quality of life was measured at randomisation and prior to each treat\\nment course and at corresponding 4-week intervals in the control arm, using the \\nEORTC QLQ-C30 + LC13 questionnaire. 48 patients were randomised (supportive care\\n 26, chemotherapy 22), being eligible for comparative analyses. Another 102 pati\\nents, 97 of which received chemotherapy, were subsequently included in the study\\n on an individual treatment preference basis. Data from these patients were used\\n for confirmative purposes. Patients in the chemotherapy group reported better o\\nverall physical functioning and symptom control compared with the supportive car\\ne group. Group differences were smaller within the psychosocial domain, although\\n trends were seen in favour of the chemotherapy group. No significant difference\\ns were seen in favour of the supportive care group, except for hair loss. Median\\n survival times were 29 weeks in the chemotherapy group versus 11 weeks in the s\\nupportive care group, and 1-year survival rates were 28% versus 8%. Quality of l\\nife and survival outcomes were similar in the randomised and non-randomised pati\\nents receiving chemotherapy. No treatment-related deaths occurred. In conclusion\\n, treatment with carboplatin and etoposide can improve both the quality of life \\nand the survival of patients with advanced NSCLC.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': None}, 'title': 'Quality of life and survival in patients with advanced non-small cell lung  cancer receiving supportive care plus chemotherapy with carboplatin and etoposi', 'source': 'Mendeley'}
Cartei G, Cartei F, Cantone A, Causarano D, Genco G, Tobaldin A, Interlandi G, Giraldi T. Cisplatin-cyclophosphamide-mitomycin combination chemotherapy with supportive care versus supportive care alone for treatment of metastatic non-small-cell lung cancer. Journal of the National Cancer Institute. 1993;85(10):794-800.	-	8387607	primary-study	92fa62e838c59d2a85fad528303b23c5f9f82822	-	{'publication_type': {'year': 1993, 'cited_medium': None, 'issue': '10', 'issn': '0027-8874', 'volume': '85', 'title': 'JNCI Journal of the National Cancer Institute', 'pagination': '794-800'}, 'language': None, 'rating': {'year': 0, 'title': 1.0, 'total': 0.878125, 'authors': 0.9125000000000001}, 'authors': [{'given': 'G.', 'family': 'Cartei'}, {'given': 'F.', 'family': 'Cartei'}, {'given': 'A.', 'family': 'Cantone'}, {'given': 'D.', 'family': 'Causarano'}, {'given': 'G.', 'family': 'Genco'}, {'given': 'A.', 'family': 'Tobaldin'}, {'given': 'G.', 'family': 'Interlandi'}, {'given': 'T.', 'family': 'Giraldi'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1093/jnci/85.10.794'}, 'title': 'Cisplatin-Cyclophosphamide-Mitomycin Combination Chemotherapy With Supportive Care Versus Supportive Care Alone for Treatment of Metastatic Non-Small-Cell Lung Cancer', 'source': 'CrossRef'}
Cartei G, Cartei F, Cantone A, Causarano D, Genco G, Tobaldin A, Interlandi G, Giraldi T. Cisplatin-cyclophosphamide-mitomycin combination chemotherapy with supportive care versus supportive care alone for treatment of metastatic non-small-cell lung cancer. Journal of the National Cancer Institute. 1993;85(10):794-800.	-	8387607	primary-study	92fa62e838c59d2a85fad528303b23c5f9f82822	-	{'publication_type': {'year': 1993, 'cited_medium': None, 'issue': None, 'issn': '0027-8874', 'volume': None, 'title': 'Journal of the National Cancer Institute', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 1.0, 'authors': 1.0}, 'authors': [{'given': 'G', 'family': 'Cartei'}, {'given': 'F', 'family': 'Cartei'}, {'given': 'a', 'family': 'Cantone'}, {'given': 'D', 'family': 'Causarano'}, {'given': 'G', 'family': 'Genco'}, {'given': 'a', 'family': 'Tobaldin'}, {'given': 'G', 'family': 'Interlandi'}, {'given': 'T', 'family': 'Giraldi'}], 'abstract': 'Patients with TNM stage IV non-small-cell lung cancer have short survival times. Previous controlled studies comparing chemotherapy and supportive care for the treatment of this type of cancer have not given consistent results, have included patients with different disease stages, and have rarely reported drug dose intensity.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '8387607', 'scopus': None, 'doi': None}, 'title': 'Cisplatin-cyclophosphamide-mitomycin combination chemotherapy with supportive care versus supportive care alone for treatment of metastatic non-small-cell lung cancer.', 'source': 'Mendeley'}
Cellerino R, Tummarello D, Guidi F, Isidori P, Raspugli M, Biscottini B, Fatati G. A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1991;9(8):1453-61.	-	1649267	primary-study	198806bc8d8433414730cf9eb26e9f00fa423feb	-	{'publication_type': {'year': 1988, 'cited_medium': None, 'issue': '12', 'issn': '0277-5379', 'volume': '24', 'title': 'European Journal of Cancer and Clinical Oncology', 'pagination': '1839-1843'}, 'language': None, 'rating': {'year': 0, 'title': 0.7058823529411765, 'total': 0.6588235294117648, 'authors': 0.8}, 'authors': [{'given': 'Riccardo', 'family': 'Cellerino'}, {'given': 'Diego', 'family': 'Tummarello'}, {'given': 'Emilio', 'family': 'Porfiri'}, {'given': 'Francesco', 'family': 'Guidi'}, {'given': 'Pierpaolo', 'family': 'Isidori'}, {'given': 'Marzio', 'family': 'Raspugli'}, {'given': 'Bruno', 'family': 'Biscottini'}, {'given': 'Giuseppe', 'family': 'Fatati'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1016/0277-5379(88)90095-8'}, 'title': "Non small cell lung cancer (NSCLC). A prospective randomized trial with alternating chemotherapy CEP/MEC' versus no treatment", 'source': 'CrossRef'}
Cellerino R, Tummarello D, Guidi F, Isidori P, Raspugli M, Biscottini B, Fatati G. A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1991;9(8):1453-61.	-	1649267	primary-study	198806bc8d8433414730cf9eb26e9f00fa423feb	-	{'publication_type': {'year': 1991, 'cited_medium': None, 'issue': None, 'issn': '0732-183X', 'volume': None, 'title': 'Journal of clinical oncology : official journal of the American Society of Clinical Oncology', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 1.0, 'authors': 1.0}, 'authors': [{'given': 'R', 'family': 'Cellerino'}, {'given': 'D', 'family': 'Tummarello'}, {'given': 'F', 'family': 'Guidi'}, {'given': 'P', 'family': 'Isidori'}, {'given': 'M', 'family': 'Raspugli'}, {'given': 'B', 'family': 'Biscottini'}, {'given': 'G', 'family': 'Fatati'}], 'abstract': "From April 1985 to September 1988, 128 patients with advanced non-small-cell lung cancer (NSCLC) were enrolled in a prospective randomized trial evaluating chemotherapy (arm A) versus best supportive care (arm B). Chemotherapy consisted of cyclophosphamide 500 mg/m2 intravenously (IV) day 1, epirubicin 50 mg/m2 IV day 1, and cisplatin 80 mg/m2 IV day 1 (CE'P regimen) alternating every 4 weeks with methotrexate 30 mg/m2 IV day 1, etoposide 200 mg/m2 IV day 1, and lomustine (CCNU) 70 mg/m2 orally day 1 (MEC' regimen) until progression. Of the 123 patients (62 treated and 61 controls) eligible for survival, 115 were fully evaluable for response (58 treated and 57 controls). Response rates were 21% partial response, 53% stable disease, and 26% progressive disease in arm A, and 47% stable disease and 53% progressive disease in arm B. Median survival was 34.3 weeks (range, 4.3 to 218.6+ weeks) in arm A versus 21.1 weeks (range, 4.3 to 188.6 weeks) in arm B; the difference was not significant at P = .153 (Mantel-Cox). Subgroups of patients retrospectively analyzed by age, performance status, stage M0/M1, and weight loss or not showed no significant difference in survival. Poor-risk patients (at least two of the following: poor performance status, stage M1, weight loss) of arm A survived significantly longer than poor-risk patients of arm B (23.6 weeks v 12.4 weeks, Mantel-Cox P = .008); a significant difference in survival was also observed between nonsquamous cell patients of arm A and those of arm B (median survival, 38.6 weeks v 16.7 weeks; Mantel-Cox P = .041). Toxicity on the chemotherapy arm was hematologic (World Health Organization [WHO] grade greater than 3) in 12% of CE'P and in 13% of MEC' courses and gastroenteric (WHO grade greater than 3) in 24% of CE'P courses and in 8% of MEC' courses. Our alternating treatment was not significantly superior to supportive care. It is likely that certain subgroups of the NSCLC category may have an advantage with chemotherapy.", 'type': 'journal', 'ids': {'embase': None, 'pubmed': '1649267', 'scopus': None, 'doi': None}, 'title': 'A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small-cell lung cancer.', 'source': 'Mendeley'}
Kaasa S, Lund E, Thorud E, Hatlevoll R, Høst H. Symptomatic treatment versus combination chemotherapy for patients with extensive non-small cell lung cancer. Cancer. 1991;67(10):2443-7.	-	1849786	primary-study	c3a330d366062def73864aee57b92328f05a789d	-	{'publication_type': {'year': 1991, 'cited_medium': None, 'issue': '10', 'issn': '0008-543X', 'volume': '67', 'title': 'Cancer', 'pagination': '2443-2447'}, 'language': None, 'rating': {'year': 1, 'title': 0.9166666666666666, 'total': 0.9258333333333333, 'authors': 0.9199999999999999}, 'authors': [{'given': 'Stein', 'family': 'Kaasa'}, {'given': 'Eiliv', 'family': 'Lund'}, {'given': 'Erik', 'family': 'Thorud'}, {'given': 'Reidulv', 'family': 'Hatlevoll'}, {'given': 'Herman', 'family': 'Høst'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1002/1097-0142(19910515)67:10<2443::aid-cncr2820671008>3.0.co;2-k'}, 'title': 'Symptomatic treatmentversus combination chemotherapy for patients with extensive non-small cell lung cancer', 'source': 'CrossRef'}
Kaasa S, Lund E, Thorud E, Hatlevoll R, Høst H. Symptomatic treatment versus combination chemotherapy for patients with extensive non-small cell lung cancer. Cancer. 1991;67(10):2443-7.	-	1849786	primary-study	c3a330d366062def73864aee57b92328f05a789d	-	{'publication_type': {'year': 1991, 'cited_medium': None, 'issue': None, 'issn': '0008-543X', 'volume': None, 'title': 'Cancer', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 1.0, 'authors': 1.0}, 'authors': [{'given': 'S', 'family': 'Kaasa'}, {'given': 'E', 'family': 'Lund'}, {'given': 'E', 'family': 'Thorud'}, {'given': 'R', 'family': 'Hatlevoll'}, {'given': 'H', 'family': 'Høst'}], 'abstract': 'In a randomized clinical trial, 87 patients with inoperable, extensive non-small cell lung cancer (NSCLC) were randomized to receive either combination chemotherapy (cisplatin at 70 mg/m2 intravenously [i.v.] on day 1 and etoposide at 100 mg/m2 i.v. on day 1 and 200 mg/m2 orally on days 2 and 3) or symptomatic treatment. No statistically significant differences in survival time were found between the two treatment techniques. A major problem in the interpretation of the results was the use of semicurative radiation therapy (3000 to 4200 cGy) to the primary tumor and mediastinum, which was given with symptomatic intent. Three long-term survivors were seen in the latter group.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '1849786', 'scopus': '2-s2.0-0025827357', 'doi': None}, 'title': 'Symptomatic treatment versus combination chemotherapy for patients with extensive non-small cell lung cancer.', 'source': 'Mendeley'}
Quoix E, Dietemann A, Charbonneau J, Boutin C, Meurice JC, Orlando JP, Ducolone A, Pauli G, Roegel E. [Is chemotherapy with cisplatin useful in non small cell bronchial cancer at staging IV? Results of a randomized study]. Bulletin du cancer. 1991;78(4):341-6.	-	1650266	primary-study	17f01cd9a993064c221ee75a106f2ba533c66c2f	-	{'publication_type': {'year': 2005, 'cited_medium': None, 'issue': '3', 'issn': '0169-5002', 'volume': '47', 'title': 'Lung Cancer', 'pagination': '405-412'}, 'language': None, 'rating': {'year': 0, 'title': 0.43478260869565216, 'total': 0.3326086956521739, 'authors': 0.2}, 'authors': [{'given': 'Elisabeth', 'family': 'Quoix'}, {'given': 'Jean-Luc', 'family': 'Breton'}, {'given': 'Alain', 'family': 'Ducoloné'}, {'given': 'Bertrand', 'family': 'Mennecier'}, {'given': 'Alain', 'family': 'Depierre'}, {'given': 'Etienne', 'family': 'Lemarié'}, {'given': 'Denis', 'family': 'Moro-Sibilot'}, {'given': 'Caroline', 'family': 'Germa'}, {'given': 'Anne-Catherine', 'family': 'Neidhardt'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '15713524', 'scopus': None, 'doi': '10.1016/j.lungcan.2004.08.012'}, 'title': 'First line chemotherapy with gemcitabine in advanced non-small cell lung cancer elderly patients: a randomized phase II study of 3-week versus 4-week schedule', 'source': 'CrossRef'}
Quoix E, Dietemann A, Charbonneau J, Boutin C, Meurice JC, Orlando JP, Ducolone A, Pauli G, Roegel E. [Is chemotherapy with cisplatin useful in non small cell bronchial cancer at staging IV? Results of a randomized study]. Bulletin du cancer. 1991;78(4):341-6.	-	1650266	primary-study	17f01cd9a993064c221ee75a106f2ba533c66c2f	-	{'publication_type': {'year': 1991, 'cited_medium': None, 'issue': None, 'issn': '0007-4551 (Print)', 'volume': None, 'title': 'Bulletin du cancer', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 0.9944444444444445, 'authors': 0.9777777777777779}, 'authors': [{'given': 'E', 'family': 'Quoix'}, {'given': 'A', 'family': 'Dietemann'}, {'given': 'J', 'family': 'Charbonneau'}, {'given': 'C', 'family': 'Boutin'}, {'given': 'J C', 'family': 'Meurice'}, {'given': 'J P', 'family': 'Orlando'}, {'given': 'A', 'family': 'Ducolone'}, {'given': 'G', 'family': 'Pauli'}, {'given': 'E', 'family': 'Roegel'}], 'abstract': 'The benefit of chemotherapy for patients with disseminated non small cell lung cancer (NSCLC) is controversial. The introduction of cisplatinum in the combination chemotherapy for NSCLC gave rise to higher response rates. To study the question of the usefulness of cisplatinum-based chemotherapy in disseminated NSCLC we conducted a prospective randomized trial comparing best supportive care to vindesine + cisplatin. Between December 1985 and March 1988, 49 patients with stage IV NSCLC were enrolled. Of the 46 eligible patients 24 were in the chemotherapy group and 22 in the best supportive care group. The treatment groups were not significantly different in terms of age, performance status, histology. Toxicity on the chemotherapy arm grade 3 or more was observed in 17.5% for neutropenia, in 8.75% for vomiting. There was one death related to treatment. The overall response rate in the chemotherapy group was 41.7%. Patients of the chemotherapy group had a median survival time of 199 days and the patients of the best supportive care group had a median survival time of 73 days. The difference in survival is highly significant (p less than 0.001).', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '1650266', 'scopus': None, 'doi': None}, 'title': '[Is chemotherapy with cisplatin useful in non small cell bronchial cancer at staging IV? Results of a randomized study].', 'source': 'Mendeley'}
Woods RL, Williams CJ, Levi J, Page J, Bell D, Byrne M, Kerestes ZL. A randomised trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer. British journal of cancer. 1990;61(4):608-11.	-	1691921	primary-study	99da09cf48b9ee7dc0ccb85c110c93ffe30d5b04	-	{'publication_type': {'year': 1990, 'cited_medium': None, 'issue': '4', 'issn': '0007-0920', 'volume': '61', 'title': 'British Journal of Cancer', 'pagination': '608-611'}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.9, 'authors': 1.0}, 'authors': [{'given': 'RL', 'family': 'Woods'}, {'given': 'CJ', 'family': 'Williams'}, {'given': 'J', 'family': 'Levi'}, {'given': 'J', 'family': 'Page'}, {'given': 'D', 'family': 'Bell'}, {'given': 'M', 'family': 'Byrne'}, {'given': 'ZL', 'family': 'Kerestes'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1038/bjc.1990.135'}, 'title': 'A randomised trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer', 'source': 'CrossRef'}
Woods RL, Williams CJ, Levi J, Page J, Bell D, Byrne M, Kerestes ZL. A randomised trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer. British journal of cancer. 1990;61(4):608-11.	-	1691921	primary-study	99da09cf48b9ee7dc0ccb85c110c93ffe30d5b04	-	{'publication_type': {'year': 1990, 'cited_medium': None, 'issue': None, 'issn': '0007-0920', 'volume': None, 'title': 'British journal of cancer', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 0.9892857142857143, 'authors': 0.9571428571428572}, 'authors': [{'given': 'R L', 'family': 'Woods'}, {'given': 'C J', 'family': 'Williams'}, {'given': 'J', 'family': 'Levi'}, {'given': 'J', 'family': 'Page'}, {'given': 'D', 'family': 'Bell'}, {'given': 'M', 'family': 'Byrne'}, {'given': 'Z L', 'family': 'Kerestes'}], 'abstract': 'The value of chemotherapy in advanced non-small cell lung cancer (NSCLC) remains contentious. Because of this two separate but very similar trials were set up in Australia and Southampton (UK). Two hundred and one patients with stage IIIb or IV NSCLC were randomly assigned to cisplatin 120 mg m-2 on days 1 and 29 and vindesine 3 mg m-2 weekly x 6 or to no chemotherapy. Both groups were eligible to receive radiotherapy or other palliative treatment as required. Of 188 evaluable patients, 97 received chemotherapy and 91 were in the control arm. Response was assessed between days 42 and 49. Responders continued chemotherapy at the same doses though cisplatin being given 6 weekly x 4 and the vindesine 2 weekly x 12. The overall response rate to chemotherapy was 28%; there were no significant differences according to major prognostic criteria. Although the overall survival of the chemotherapy group (median 27 weeks) was longer than that of the no chemotherapy group (median 17 weeks) this was not statistically significant (log rank P = 0.33). For patients without dissemination (IIIb), median survival was 45 weeks in the chemotherapy arm and 26 weeks in the non-chemotherapy (log rank P = 0.075). Toxicity was universal and frequently severe: of 17 patients discontinuing chemotherapy after one cycle, 13 did so because of unacceptable toxicity. This chemotherapy cannot be recommended as routine treatment. Further phase III studies of chemotherapy in advanced NSCLC should continue to use a no chemotherapy control and should also attempt to measure quality of life, an issue not addressed effectively in this or other recent trials.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '1691921', 'scopus': '2-s2.0-0025232673', 'doi': '10.1038/bjc.1990.135'}, 'title': 'A randomised trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer.', 'source': 'Mendeley'}
Ganz PA, Figlin RA, Haskell CM, La Soto N, Siau J. Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer. Does chemotherapy make a difference?. Cancer. 1989;63(7):1271-8.	-	2465815	primary-study	d71b62b0ed07f5b966ba3fc761d8d5a1c0b68947	-	{'publication_type': {'year': 1989, 'cited_medium': None, 'issue': '7', 'issn': '0008-543X', 'volume': '63', 'title': 'Cancer', 'pagination': '1271-1278'}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 0.98, 'authors': 0.9199999999999999}, 'authors': [{'given': 'Patricia A.', 'family': 'Ganz'}, {'given': 'Robert A.', 'family': 'Figlin'}, {'given': 'Charles M.', 'family': 'Haskell'}, {'given': 'Nancy', 'family': 'la Soto'}, {'given': 'Jessie', 'family': 'Siau'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1002/1097-0142(19890401)63:7<1271::aid-cncr2820630707>3.0.co;2-6'}, 'title': 'Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer. Does chemotherapy make a difference?', 'source': 'CrossRef'}
Ganz PA, Figlin RA, Haskell CM, La Soto N, Siau J. Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer. Does chemotherapy make a difference?. Cancer. 1989;63(7):1271-8.	-	2465815	primary-study	d71b62b0ed07f5b966ba3fc761d8d5a1c0b68947	-	{'publication_type': {'year': 1989, 'cited_medium': None, 'issue': None, 'issn': '0008-543X', 'volume': None, 'title': 'Cancer', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 0.985, 'authors': 0.9400000000000001}, 'authors': [{'given': 'P A', 'family': 'Ganz'}, {'given': 'R A', 'family': 'Figlin'}, {'given': 'C M', 'family': 'Haskell'}, {'given': 'N', 'family': 'La Soto'}, {'given': 'J', 'family': 'Siau'}], 'abstract': 'Current chemotherapy treatment of metastatic non-small cell lung cancer has demonstrated some objective responses, but is still largely palliative. This report reviews the results of a randomized trial in patients with advanced metastatic non-small cell lung cancer which compared treatment with supportive care (treatment with palliative radiation, psychosocial support, analgesics, nutritional support) to supportive care plus combination chemotherapy with cisplatin and vinblastine. Although the patients receiving combination chemotherapy had a slightly longer median survival (20.43 weeks versus 13.57 weeks), it was not statistically significant (P = 0.09). In addition, the patients receiving chemotherapy experienced serious toxicity, and showed no significant benefit in terms of quality of life as measured by Karnofsky performance status score. The authors conclude that contemporary combination chemotherapy provides only modest survival benefit to patients with advanced metastatic non-small cell lung cancer and should not be considered standard therapy. Future investigations of chemotherapy in patients with unresectable non-small cell lung cancer should continue to utilize control arms which provide high-quality supportive care.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '2465815', 'scopus': '2-s2.0-0024562637', 'doi': None}, 'title': 'Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer. Does chemotherapy make a difference?', 'source': 'Mendeley'}
Rapp E, Pater JL, Willan A, Cormier Y, Murray N, Evans WK, Hodson DI, Clark DA, Feld R, Arnold AM. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1988;6(4):633-41.	-	2833577	primary-study	b50beb455abece9f18433d6cd5aed159cb569774	-	{'publication_type': {'year': 1986, 'cited_medium': None, 'issue': None, 'issn': '0360-3016', 'volume': '12', 'title': 'International Journal of Radiation Oncology*Biology*Physics', 'pagination': '157'}, 'language': None, 'rating': {'year': 0, 'title': 0.5416666666666666, 'total': 0.4645833333333333, 'authors': 0.45}, 'authors': [{'given': 'P.', 'family': 'Coy'}, {'given': 'W.K.', 'family': 'Evans'}, {'given': 'R.', 'family': 'Feld'}, {'given': 'I.', 'family': 'Hodson'}, {'given': 'A.S.', 'family': 'MacDonald'}, {'given': 'D.', 'family': 'Osoba'}, {'given': 'D.G.', 'family': 'Payne'}, {'given': 'J.L.', 'family': 'Pater'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1016/0360-3016(86)90629-2'}, 'title': 'Canadian multicentre randomized trial comparing two dose levels of thoracic radiation given in combination with chemotherapy to patients with limited small cell lung cancer', 'source': 'CrossRef'}
Rapp E, Pater JL, Willan A, Cormier Y, Murray N, Evans WK, Hodson DI, Clark DA, Feld R, Arnold AM. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1988;6(4):633-41.	-	2833577	primary-study	b50beb455abece9f18433d6cd5aed159cb569774	-	{'publication_type': {'year': 2003, 'cited_medium': None, 'issue': None, 'issn': '0732-183X', 'volume': None, 'title': 'Journal of clinical oncology : official journal of the American Society of Clinical Oncology', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 0.6363636363636364, 'total': 0.6386363636363636, 'authors': 0.5}, 'authors': [{'given': 'American Society of Clinical', 'family': 'Oncology'}], 'abstract': "UNLABELLED: Well-publicized lapses in the review or implementation of clinical research studies have raised public questions about the integrity of the clinical research process. Public trust in the integrity of research is critical not only for funding and participation in clinical trials but also for confidence in the treatments that result from the trials. The questions raised by these unfortunate cases pose an important opportunity to reassess the clinical trials oversight system to ensure the integrity of clinical research and the safety of those who enroll in clinical trials. Since its inception, the American Society of Clinical Oncology (ASCO) has worked for the advancement of cancer treatments through clinical research and to help patients gain prompt access to scientifically excellent and ethically unimpeachable clinical trials. As an extension of its mission, ASCO is affirming with this policy statement the critical importance of a robust review and oversight system to ensure that clinical trials participants give fully informed consent and that their safety is a top priority. Ensuring the integrity of research cannot be stressed enough because of its seminal connection to the advancement of clinical cancer treatment. The overall goal of this policy is to enhance public trust in the cancer clinical trials process. To achieve this, the following elements are essential: 1. Ensure safety precautions for clinical trial participants and their fully informed consent. 2. Ensure the validity and integrity of scientific research. 3. Enhance the educational training of clinical scientists and research staff to ensure the highest standards of research conduct. 4. Promote accountability and responsibility among all those involved in clinical research (not just those serving on institutional review boards [IRBs], but also institutional officials, researchers, sponsors, and participants) and ensure support for an effective oversight process. 5. Enhance the professional and public understanding of clinical research oversight. 6. Enhance the efficiency and cost-effectiveness of the clinical research oversight system. This policy statement makes recommendations in several areas that serve as principles to support an improved system of oversight for clinical research. ASCO will work with all parties involved in the clinical research system to develop the steps necessary to implement these recommendations. Centralized Trial Review: A large percentage of oncology clinical trials are coordinated through the National Cancer Institute's (NCI) system of cooperative groups, which already incorporates centralized scientific review. As such, there is a tremendous opportunity to employ a centralized mechanism to provide ethical review by highly trained IRB members, allowing local IRBs to take advantage of the financial and time efficiencies that central review provides. Centralized review boards (CRBs) would also contribute consistency and efficiency to the process. Once successfully completed, the review would represent an approval to open the protocol at all of the institutions that have subscribed to the centralized review system. Local IRBs would be able to devote time usually spent on initial review to ongoing monitoring of the trial taking place at their institution. Considering the enormous size and complexity of the clinical research enterprise, ASCO envisions multiple CRBs, which could be distributed as regional review boards. Central review will use a single protocol and consent form, and monitor and evaluate adverse events (AEs) on a global basis, eliminating many of the time-consuming steps for the local IRB. Global monitoring and assessment of AEs has real potential to enhance trial participants' safety by giving local institutions more information on the overall trial and enabling them to devote more time to ongoing review of the trial onsite. Use of a CRB also has real potential to reduce the costs of clinical trial oversight by allowing local IRBs to eliminate the costs of initial review. These efficiencies will likely lead to institutions redirecting funds toward monitoring ongoing trials. Although a CRB has potential to improve the efficiency of the process, a CRB could also have tremendous ability to delay valuable trials. Checks and balances must be included in the newly devised system to ensure timely review and appeals of CRB actions. ASCO proposes the advent of a new pilot program for centralizing review of clinical trials. It requires clear engagement of all stakeholders in planning the experiment, clear articulation of the goals, and assurance of federal regulatory protection for institutions choosing to participate. If successful, this CRB pilot project could be expanded to include multi-institutional industry-sponsored research. Education and Training:Education and training are critical to the ultimate success of an improved oversight system. All members of the research team should receive comprehensive education on conducting scientifically and ethically valid clinical research. The curriculum should also include information on the prevailing local and federal regulations that pertain to the clinical trials process. IRB members should also receive ongoing education and training in the review of clinical research protocols. IRB training should pay particular attention to nonscientific members to give them the tools necessary to speak on behalf of research participants. ASCO should develop a curriculum that focuses on the proper conduct of human research and emphasize ethically sound clinical research in the context of its Annual Meeting. Informed Consent: Investigators and review boards have specific roles to play in ensuring the education of trial participants through the informed consent process, both when they are considering trial enrollment and as they participate in the trial. Review boards and investigators should focus primarily on the informed consent process, rather than the informed consent documents. Federal Oversight: The federal government has an important role to play in the oversight of clinical research. This role should be expanded to cover all research, not just that which is funded by the federal government or conducted with the oversight of the Food and Drug Administration (FDA). The Department of Health and Human Services (HHS) Office for Human Research Protections (OHRP) and the FDA should provide clear regulatory support and guidance for local institutions that choose to employ a CRB. In the case of the pilot CRB discussed in this policy statement, it should serve as the preferred option for the cancer cooperative group clinical trials. Ideally, the federal government should unify and streamline its regulations for the oversight of clinical research. Resources Supporting Clinical Research Infrastructure:An effective oversight process demands the highest quality scientific and ethical review and onsite monitoring of the safety of trial participants. This can only be accomplished by the involvement of an experienced IRB that receives funding, resources, and institutional support enabling it to fulfill its mandate., CONFLICT OF INTEREST: Critical to the integrity of research is the absence of bias in the process. ASCO strongly recommends the adoption of standards for the identification, management, and, where appropriate, elimination of conflicts of interests, whether they are actual, potential, or apparent.", 'type': 'journal', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': None}, 'title': 'American Society of Clinical Oncology policy statement: oversight of clinical research.', 'source': 'Mendeley'}
Anderson G, Payne H. Response rate and toxicity of etoposide (VP-16) in squamous carcinoma of the lung: report from the Lung Cancer Treatment Study Group. Seminars in oncology. 1985;12(1 Suppl 2):21-2.	-	3883504	primary-study	ec97cac8a8a6ca6972a15695885ac1400d4e3ef5	-	{'publication_type': {'year': 1987, 'cited_medium': None, 'issue': '2', 'issn': '0169-5002', 'volume': '3', 'title': 'Lung Cancer', 'pagination': '102'}, 'language': None, 'rating': {'year': 1, 'title': 0.5172413793103449, 'total': 0.4362068965517242, 'authors': 0}, 'authors': [], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1016/s0169-5002(87)80108-3'}, 'title': 'Cisplatin and etoposide before definitive radiation therapy for inoperable squamous carcinoma, adenocarcinoma, and large cell carcinoma of the lung: A phase I-II study of the radiation therapy oncology group', 'source': 'CrossRef'}
Anderson G, Payne H. Response rate and toxicity of etoposide (VP-16) in squamous carcinoma of the lung: report from the Lung Cancer Treatment Study Group. Seminars in oncology. 1985;12(1 Suppl 2):21-2.	-	3883504	primary-study	ec97cac8a8a6ca6972a15695885ac1400d4e3ef5	-	{'publication_type': {'year': 1985, 'cited_medium': None, 'issue': None, 'issn': '0093-7754', 'volume': None, 'title': 'Seminars in oncology', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 1.0, 'authors': 1.0}, 'authors': [{'given': 'G', 'family': 'Anderson'}, {'given': 'H', 'family': 'Payne'}], 'abstract': 'In two multicenter studies, 325 patients with advanced squamous lung cancer were randomized to receive either no treatment v oral etoposide (VePe-sid) 300 mg/m2 on days 1 and 2 for 6 cycles, or the same dose of oral etoposide v the same dose of oral etoposide plus cyclophosphamide 300 mg/m2 IV on days 1 and 2, each given for 6 cycles. A total of 175 patients in both trials received oral etoposide alone. All patients assigned to treatment were included in the results. Remissions occurred in 20 (11%) patients (CR in 1; PR in 19). Leukopenia occurred in 2% of patients and other toxicity was acceptable.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '3883504', 'scopus': '2-s2.0-0022415902', 'doi': None}, 'title': 'Response rate and toxicity of etoposide (VP-16) in squamous carcinoma of the lung: report from the Lung Cancer Treatment Study Group.', 'source': 'Mendeley'}
Hughes DA, Elliott PM, Shah J, Zuckerman J, Coghlan G, Brookes J, Mehta AB. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart (British Cardiac Society). 2008;94(2):153-8.	10.1136/hrt.2006.104026	17483124	primary-study	815839a16591f4cc4fb67db0d6a48f7903f45a7c	-	{'publication_type': {'year': 2008, 'cited_medium': None, 'issue': '2', 'issn': '1355-6037', 'volume': '94', 'title': 'Heart', 'pagination': '153-158'}, 'language': None, 'rating': {'year': 1, 'title': 1.0, 'total': 0.9892857142857143, 'authors': 0.9571428571428572}, 'authors': [{'given': 'D A', 'family': 'Hughes'}, {'given': 'P M', 'family': 'Elliott'}, {'given': 'J', 'family': 'Shah'}, {'given': 'J', 'family': 'Zuckerman'}, {'given': 'G', 'family': 'Coghlan'}, {'given': 'J', 'family': 'Brookes'}, {'given': 'A B', 'family': 'Mehta'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '17483124', 'scopus': None, 'doi': '10.1136/hrt.2006.104026'}, 'title': 'Effects of enzyme replacement therapy on the cardiomyopathy of Anderson Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa', 'source': 'CrossRef'}
Hughes DA, Elliott PM, Shah J, Zuckerman J, Coghlan G, Brookes J, Mehta AB. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart (British Cardiac Society). 2008;94(2):153-8.	10.1136/hrt.2006.104026	17483124	primary-study	815839a16591f4cc4fb67db0d6a48f7903f45a7c	-	{'publication_type': {'year': 2008, 'cited_medium': None, 'issue': None, 'issn': '1468-201X', 'volume': None, 'title': 'Heart (British Cardiac Society)', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 0.9892857142857143, 'authors': 0.9571428571428572}, 'authors': [{'given': 'D a', 'family': 'Hughes'}, {'given': 'P M', 'family': 'Elliott'}, {'given': 'J', 'family': 'Shah'}, {'given': 'J', 'family': 'Zuckerman'}, {'given': 'G', 'family': 'Coghlan'}, {'given': 'J', 'family': 'Brookes'}, {'given': 'a B', 'family': 'Mehta'}], 'abstract': 'BACKGROUND: Anderson-Fabry disease is an X-linked glycosphingolipid storage disorder caused by deficient activity of the lysosomal enzyme alpha-galactosidase A. This leads to a progressive accumulation of globotriaosylceramide (Gb(3)) in the lysosomes of cells throughout the body that ultimately results in premature death from renal, cardiac or cerebrovascular complications. Until recently, there was no effective therapy available for this disease. The present study was designed to assess the safety and efficacy of enzyme replacement therapy with agalsidase alfa on the cardiac manifestations of Anderson-Fabry disease.\\n\\nMETHOD: The effects of therapy with agalsidase alfa on cardiac structure and function were assessed in a randomised, double-blind, placebo-controlled study of 15 adult male patients with Anderson-Fabry disease. The following parameters were measured at baseline and 6 months: left ventricular mass, QRS duration and levels of Gb(3) in cardiac tissue, urine sediment and plasma. After 6 months of the randomised trial patients were enrolled in a 2-year open-label extension study.\\n\\nRESULTS: Left ventricular mass, as measured by MRI, was significantly reduced following 6 months of treatment with agalsidase alfa compared with placebo (p = 0.041). A mean 20% reduction in myocardial Gb(3) content as assessed by serial transvenous endomyocardial biopsies was demonstrated over the 6 months of enzyme replacement compared to a mean 10% increase in patients receiving placebo (p = 0.42)\\n\\nCONCLUSION: Enzyme replacement therapy with agalsidase alfa resulted in regression of the hypertrophic cardiomyopathy associated with Anderson-Fabry disease.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '17483124', 'scopus': None, 'doi': '10.1136/hrt.2006.104026'}, 'title': 'Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa.', 'source': 'Mendeley'}
Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M, Finkel R, Packman S, Bichet DG, Warnock DG, Desnick RJ. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Annals of internal medicine. 2007;146(2):77-86.	-	17179052	primary-study	6e43253dc43b51464f8910611015177044b13f4d	-	{'publication_type': {'year': 2007, 'cited_medium': None, 'issue': None, 'issn': '0149-2918', 'volume': '29', 'title': 'Clinical Therapeutics', 'pagination': 'S29-S29'}, 'language': None, 'rating': {'year': 0, 'title': 0.4, 'total': 0.47500000000000003, 'authors': 0.8600000000000001}, 'authors': [{'given': 'S.', 'family': 'Waldek'}, {'given': 'M.', 'family': 'Banikazemi'}, {'given': 'J.', 'family': 'Bultas'}, {'given': 'W.', 'family': 'Wilcox'}, {'given': 'C.', 'family': 'Whitley'}, {'given': 'M.', 'family': 'McDonald'}, {'given': 'R.', 'family': 'Finke'}, {'given': 'S.', 'family': 'Packman'}, {'given': 'D.', 'family': 'Bichet'}, {'given': 'D.', 'family': 'Warnock'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1016/s0149-2918(07)80149-4'}, 'title': 'Clinical benefits of early treatment with Fabrazyme in Fabry disease', 'source': 'CrossRef'}
Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M, Finkel R, Packman S, Bichet DG, Warnock DG, Desnick RJ. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Annals of internal medicine. 2007;146(2):77-86.	-	17179052	primary-study	6e43253dc43b51464f8910611015177044b13f4d	-	{'publication_type': {'year': 2007, 'cited_medium': None, 'issue': None, 'issn': '1539-3704', 'volume': None, 'title': 'Annals of internal Medicine', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 1.0, 'total': 0.875, 'authors': 0.9}, 'authors': [{'given': 'Desnick RJ; Fabry Disease Clinical Trial Study Group.', 'family': 'Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M, Finkel R, Packman S, Bichet DG, Warnock DG'}], 'abstract': 'BACKGROUND: Fabry disease (alpha-galactosidase A deficiency) is a rare, X-linked lysosomal storage disorder that can cause early death from renal, cardiac, and cerebrovascular involvement. OBJECTIVE: To see whether agalsidase beta delays the onset of a composite clinical outcome of renal, cardiovascular, and cerebrovascular events and death in patients with advanced Fabry disease. DESIGN: Randomized (2:1 treatment-to-placebo randomization), double-blind, placebo-controlled trial. SETTING: 41 referral centers in 9 countries. PATIENTS: 82 adults with mild to moderate kidney disease; 74 of whom were protocol-adherent. INTERVENTION: Intravenous infusion of agalsidase beta (1 mg per kg of body weight) or placebo every 2 weeks for up to 35 months (median, 18.5 months). MEASUREMENTS: The primary end point was the time to first clinical event (renal, cardiac, or cerebrovascular event or death). Six patients withdrew before reaching an end point: 3 to receive commercial therapy and 3 due to positive or inconclusive serum IgE or skin test results. Three patients assigned to agalsidase beta elected to transition to open-label treatment before reaching an end point. RESULTS: Thirteen (42%) of the 31 patients in the placebo group and 14 (27%) of the 51 patients in the agalsidase-beta group experienced clinical events. Primary intention-to-treat analysis that adjusted for an imbalance in baseline proteinuria showed that, compared with placebo, agalsidase beta delayed the time to first clinical event (hazard ratio, 0.47 [95% CI, 0.21 to 1.03]; P = 0.06). Secondary analyses of protocol-adherent patients showed similar results (hazard ratio, 0.39 [CI, 0.16 to 0.93]; P = 0.034). Ancillary subgroup analyses found larger treatment effects in patients with baseline estimated glomerular filtration rates greater than 55 mL/min per 1.73 m2 (hazard ratio, 0.19 [CI, 0.05 to 0.82]; P = 0.025) compared with 55 mL/min per 1.73 m2 or less (hazard ratio, 0.85 [CI, 0.32 to 2.3]; P = 0.75) (formal test for interaction, P = 0.09). Most treatment-related adverse events were mild or moderate infusion-associated reactions, reported by 55% of patients in the agalsidase-beta group and 23% of patients in the placebo group. LIMITATIONS: The study sample was small. Only one third of the patients experienced clinical events, and some patients withdrew before experiencing any event. CONCLUSIONS: Agalsidase-beta therapy slowed progression to the composite clinical outcome of renal, cardiac, and cerebrovascular complications and death compared with placebo in patients with advanced Fabry disease. Therapeutic intervention before irreversible organ damage may provide greater clinical benefit. TRIAL REGISTRATION: ClinicalTrials.gov NCT00074984.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '17179052', 'scopus': None, 'doi': None}, 'title': 'Agalsidase-beta therapy for advanced Fabry disease a randomized trial', 'source': 'Mendeley'}
Bierer G, Balfe D, Wilcox WR, Mosenifar Z. Improvement in serial cardiopulmonary exercise testing following enzyme replacement therapy in Fabry disease. Journal of inherited metabolic disease. 2006;29(4):572-9.	10.1007/s10545-006-0361-5	16817011	primary-study	5e91bb9228ecfa638ba325d9836dfd4d53dcd411	-	{'publication_type': {'year': 2006, 'cited_medium': None, 'issue': '4', 'issn': '0141-8955', 'volume': '29', 'title': 'Journal of Inherited Metabolic Disease', 'pagination': '572-579'}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.8812500000000001, 'authors': 0.925}, 'authors': [{'given': 'Gregory', 'family': 'Bierer'}, {'given': 'David', 'family': 'Balfe'}, {'given': 'William R.', 'family': 'Wilcox'}, {'given': 'Zab', 'family': 'Mosenifar'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '16817011', 'scopus': None, 'doi': '10.1007/s10545-006-0361-5'}, 'title': 'Improvement in serial cardiopulmonary exercise testing following enzyme replacement therapy in Fabry disease', 'source': 'CrossRef'}
Bierer G, Balfe D, Wilcox WR, Mosenifar Z. Improvement in serial cardiopulmonary exercise testing following enzyme replacement therapy in Fabry disease. Journal of inherited metabolic disease. 2006;29(4):572-9.	10.1007/s10545-006-0361-5	16817011	primary-study	5e91bb9228ecfa638ba325d9836dfd4d53dcd411	-	{'publication_type': {'year': 2006, 'cited_medium': None, 'issue': None, 'issn': '01418955', 'volume': None, 'title': 'Journal of Inherited Metabolic Disease', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.8812500000000001, 'authors': 0.925}, 'authors': [{'given': 'Gregory', 'family': 'Bierer'}, {'given': 'David', 'family': 'Balfe'}, {'given': 'William R.', 'family': 'Wilcox'}, {'given': 'Zab', 'family': 'Mosenifar'}], 'abstract': 'BACKGROUND: Fabry disease is an X-linked genetic disorder resulting in the accumulation of glycosphingolipids in various organs, leading to exercise intolerance and early mortality. Enzyme replacement therapy (ERT) has recently been approved for use in Fabry patients. GOALS OF STUDY: To assess baseline cardiopulmonary exercise characteristics in both invasive and noninvasive tests and to study the impact of ERT on exercise.\\n\\nMETHODS: A total of 15 patients with Fabry disease underwent baseline cardiopulmonary exercise tests. Six patients were randomized 2:1 to receive either ERT or placebo. We performed serial cardiopulmonary exercise tests at baseline and every 3 months over a period of at least 18 months. The baseline test was compared to the last two exercise tests for each patient.\\n\\nRESULTS: Mean age was 32 years. Mean VO2max was 1.680 +/- 0.67 L/min and increased by 0.459 +/- 0.64 L/min in the patients receiving ERT. Mean VO2max was 1.462 +/- 0.25 L/min and decreased by 0.116 +/- 0.44 L/min in patients on placebo. Mean oxygen pulse (VO2/HR) increased by 1.71 with enzyme, but increased only 0.025 in patients taking placebo. Estimated stroke volume (SV) increased by 10 ml in patients on ERT.\\n\\nCONCLUSIONS: In this small cohort, exercise tolerance increased in patients receiving enzyme replacement therapy. Cardiopulmonary exercise testing is a useful test in measuring the response to therapy in Fabry disease patients.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '16817011', 'scopus': '2-s2.0-33746882747', 'doi': '10.1007/s10545-006-0361-5'}, 'title': 'Improvement in serial cardiopulmonary exercise testing following enzyme replacement therapy in Fabry disease', 'source': 'Mendeley'}
Schiffmann R, Hauer P, Freeman B, Ries M, Scott LJ, Polydefkis M, Brady RO, McArthur JC, Wagner K. Enzyme replacement therapy and intraepidermal innervation density in Fabry disease. Muscle & nerve. 2006;34(1):53-6.	10.1002/mus.20550	16583374	primary-study	2372d58ad9b2b3d29978f2de44c6a363a01a5668	-	{'publication_type': {'year': 2006, 'cited_medium': None, 'issue': '1', 'issn': '0148-639X', 'volume': '34', 'title': 'Muscle & Nerve', 'pagination': '53-56'}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.8777777777777778, 'authors': 0.9111111111111112}, 'authors': [{'given': 'Raphael', 'family': 'Schiffmann'}, {'given': 'Peter', 'family': 'Hauer'}, {'given': 'Barbara', 'family': 'Freeman'}, {'given': 'Markus', 'family': 'Ries'}, {'given': 'Leland J. C.', 'family': 'Scott'}, {'given': 'Michael', 'family': 'Polydefkis'}, {'given': 'Roscoe O.', 'family': 'Brady'}, {'given': 'Justin C.', 'family': 'McArthur'}, {'given': 'Kathryn', 'family': 'Wagner'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '16583374', 'scopus': None, 'doi': '10.1002/mus.20550'}, 'title': 'Enzyme replacement therapy and intraepidermal innervation density in Fabry disease', 'source': 'CrossRef'}
Schiffmann R, Hauer P, Freeman B, Ries M, Scott LJ, Polydefkis M, Brady RO, McArthur JC, Wagner K. Enzyme replacement therapy and intraepidermal innervation density in Fabry disease. Muscle & nerve. 2006;34(1):53-6.	10.1002/mus.20550	16583374	primary-study	2372d58ad9b2b3d29978f2de44c6a363a01a5668	-	{'publication_type': {'year': 2006, 'cited_medium': None, 'issue': None, 'issn': '0148639X', 'volume': None, 'title': 'Muscle and Nerve', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.8777777777777778, 'authors': 0.9111111111111112}, 'authors': [{'given': 'Raphael', 'family': 'Schiffmann'}, {'given': 'Peter', 'family': 'Hauer'}, {'given': 'Barbara', 'family': 'Freeman'}, {'given': 'Markus', 'family': 'Ries'}, {'given': 'Leland J C', 'family': 'Scott'}, {'given': 'Michael', 'family': 'Polydefkis'}, {'given': 'Roscoe O.', 'family': 'Brady'}, {'given': 'Justin C.', 'family': 'McArthur'}, {'given': 'Kathryn', 'family': 'Wagner'}], 'abstract': 'We prospectively evaluated the effect of enzyme replacement therapy (ERT) on the intraepidermal nerve fiber density (IENFD) and thermal threshold in patients with Fabry disease, an X-linked disorder associated with a painful small-fiber neuropathy and decreased linear IENFD in a length-dependent pattern. Twenty-five hemizygous male patients with Fabry disease were enrolled in a 6-month, randomized, placebo-controlled ERT trial of 0.2 mg/kg of alpha-galactosidase A (agalsidase-alfa) every 2 weeks followed by an additional 12 months of open-label ERT for both populations. IENFD and thermal threshold were measured in the distal thigh at baseline, 6 months, and 18 months from initiation of the trial. We found no significant difference in IENFD between the treatment groups at 6 months. After an additional year of ERT, there was a significant reduction in IENFD in the patient group as a whole, attributable to the declining glomerular filtration rate. Thermal thresholds remained unchanged. We conclude that epidermal nerve fiber regeneration, as measured in the distal thigh, does not occur in this patient population after 12-18 months of ERT.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '16583374', 'scopus': '2-s2.0-33745686659', 'doi': '10.1002/mus.20550'}, 'title': 'Enzyme replacement therapy and intraepidermal innervation density in Fabry disease', 'source': 'Mendeley'}
Wilcox WR, Banikazemi M, Guffon N, Waldek S, Lee P, Linthorst GE, Desnick RJ, Germain DP. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. American journal of human genetics. 2004;75(1):65-74.	10.1086/422366	15154115	primary-study	6c7332447cc52b91c514ab4c0935045740d1b9ec	-	{'publication_type': {'year': 2004, 'cited_medium': None, 'issue': '1', 'issn': '0002-9297', 'volume': '75', 'title': 'The American Journal of Human Genetics', 'pagination': '65-74'}, 'language': None, 'rating': {'year': 0, 'title': 0.9, 'total': 0.81, 'authors': 0.9000000000000001}, 'authors': [{'given': 'William R.', 'family': 'Wilcox'}, {'given': 'Maryam', 'family': 'Banikazemi'}, {'given': 'Nathalie', 'family': 'Guffon'}, {'given': 'Stephen', 'family': 'Waldek'}, {'given': 'Philip', 'family': 'Lee'}, {'given': 'Gabor E.', 'family': 'Linthorst'}, {'given': 'Robert J.', 'family': 'Desnick'}, {'given': 'Dominique P.', 'family': 'Germain'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '15154115', 'scopus': None, 'doi': '10.1086/422366'}, 'title': 'Long-Term Safety and Efficacy of Enzyme Replacement Therapyfor Fabry Disease', 'source': 'CrossRef'}
Wilcox WR, Banikazemi M, Guffon N, Waldek S, Lee P, Linthorst GE, Desnick RJ, Germain DP. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. American journal of human genetics. 2004;75(1):65-74.	10.1086/422366	15154115	primary-study	6c7332447cc52b91c514ab4c0935045740d1b9ec	-	{'publication_type': {'year': 1998, 'cited_medium': None, 'issue': None, 'issn': '00301299', 'volume': None, 'title': 'Oikos. 83(1):65-74, 1998 Oct.', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.26666666666666666, 'total': 0.17333333333333334, 'authors': 0.0}, 'authors': [{'given': 'D G', 'family': 'Milchunas'}, {'given': 'W K', 'family': 'Lauenroth'}, {'given': 'I C', 'family': 'Burke'}], 'abstract': "We synthesized published and unpublished data from long-term grazing treatments in North American shortgrass steppe on diversity and abundance of plants, lagomorphs, rodents, birds, aboveground and belowground macroarthropods, microarthropods, and nematodes. The relatively small response of the plant community to grazing provides an opportunity to address some broad questions concerning relationships among responses of structural and functional aspects of systems in general. Are there consistencies in diversity and abundance responses to prating among groups of organisms? Are some groups more sensitive than others, or do responses mirror that of vegetation? Are the responses in terms of biodiversity related to ecosystem-level functional responses? Diversity, abundance, dominance, and dissimilarity responses to long-term grazing were highly variable across classes of organisms. Some groups of consumers displayed large differences among treatments even though differences in plant community attributes were relatively minor. Some responses were large even when comparing ungrazed to lightly or lightly to moderately grazed treatments. Birds appear to be particularly responsive to grazing. Differences among treatments in richness within groups other than plants and birds were relatively minor, especially when compared to large declines in abundance of some groups with increasing grazing intensity. For the well-studied groups (plants and birds), shifts in species in terms of 'quality' factors, such as exotic, endemic, and rare, generally suggest that livestock grazing may be more similar to conditions in recent evolutionary time in this particular system than would conditions resulting from the removal of the exotic, domestic grazers that appear to functionally serve as a surrogate to bison. Trophic structure composition did not vary greatly across grazing treatments. Further, large effects of grazing on some consumer groups did not translate into similarly large effects on ecosystem processes such as primary production or soil nutrient pools and cycling rates. [References: 48] Number of References 48", 'type': 'journal', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.2307/3546547'}, 'title': 'Livestock grazing: animal and plant biodiversity of shortgrass steppe and the relationship to ecosystem function', 'source': 'Mendeley'}
Thurberg BL, Randolph Byers H, Granter SR, Phelps RG, Gordon RE, O'Callaghan M. Monitoring the 3-year efficacy of enzyme replacement therapy in fabry disease by repeated skin biopsies. The Journal of investigative dermatology. 2004;122(4):900-8.	10.1111/j.0022-202X.2004.22425.x	15102080	primary-study	f3707e8ca5401bc1c0b780bb67471b62ca57aaa1	-	{'publication_type': {'year': 2004, 'cited_medium': None, 'issue': '4', 'issn': '0022-202X', 'volume': '122', 'title': 'Journal of Investigative Dermatology', 'pagination': '900-908'}, 'language': None, 'rating': {'year': 0, 'title': 1.0, 'total': 0.8791666666666667, 'authors': 0.9166666666666666}, 'authors': [{'given': 'Beth L.', 'family': 'Thurberg'}, {'given': 'H.', 'family': 'Randolph Byers'}, {'given': 'Scott R.', 'family': 'Granter'}, {'given': 'Robert G.', 'family': 'Phelps'}, {'given': 'Ronald E.', 'family': 'Gordon'}, {'given': 'Michael', 'family': "O'Callaghan"}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1111/j.0022-202x.2004.22425.x'}, 'title': 'Monitoring the 3-Year Efficacy of Enzyme Replacement Therapy in Fabry Disease by Repeated Skin Biopsies', 'source': 'CrossRef'}
Thurberg BL, Randolph Byers H, Granter SR, Phelps RG, Gordon RE, O'Callaghan M. Monitoring the 3-year efficacy of enzyme replacement therapy in fabry disease by repeated skin biopsies. The Journal of investigative dermatology. 2004;122(4):900-8.	10.1111/j.0022-202X.2004.22425.x	15102080	primary-study	f3707e8ca5401bc1c0b780bb67471b62ca57aaa1	-	{'publication_type': {'year': 2004, 'cited_medium': None, 'issue': None, 'issn': '0022202X', 'volume': None, 'title': 'Journal of Investigative Dermatology', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.8791666666666667, 'authors': 0.9166666666666666}, 'authors': [{'given': 'Beth L.', 'family': 'Thurberg'}, {'given': 'H. Randolph', 'family': 'Byers'}, {'given': 'Scott R.', 'family': 'Granter'}, {'given': 'Robert G.', 'family': 'Phelps'}, {'given': 'Ronald E.', 'family': 'Gordon'}, {'given': 'Michael', 'family': "O'Callaghan"}], 'abstract': 'The earliest clinical signs of Fabry disease often manifest as dermatologic disturbances such as angiokeratomata, hypohidrosis, acroparesthesias, and impaired thermal and vibration detection. These disturbances are caused by cellular globotriaosylceramide accumulation in the skin due to deficient lysosomal alpha-galactosidase A activity. In this histologic study, we analyzed pre- and post-treatment dermatologic biopsies from 58 Fabry patients enrolled in a 5 mo, Phase 3 double-blind, randomized, placebo-controlled trial followed by a 30 mo open label extension study of recombinant human alpha-galactosidase A (r-halphaGalA), administered i.v. at 1 mg per kg every 2 wk. Baseline evaluations revealed globotriaosylceramide in multiple dermal cell types (vascular endothelial cells, vascular smooth muscle cells, perineurium). Five months of r-halphaGalA treatment in the Phase 3 trial resulted in complete clearance of globotriaosylceramide from the superficial capillary endothelium in all treatment patients and in only 1 (3%) placebo patient (p<0.001). The placebo group achieved similar results after 6 mo of r-halphaGalA in the open label trial. The capillary endothelium remained free of globotriaosylceramide for up to 30 mo into the extension study among 39 of 40 (98%) patients who underwent biopsies. Globotriaosylceramide clearance from deep vascular endothelial cells was similarly robust. Vascular smooth muscle cells and perineurium demonstrated moderate clearance. These findings suggest that long-term treatment with r-halphaGalA may halt the progression of pathology and prevent the dermatologic disturbances in Fabry patients, and that periodic dermal biopsies can serve as a reliable monitor of sustained efficacy.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '15102080', 'scopus': '2-s2.0-2342544939', 'doi': '10.1111/j.0022-202X.2004.22425.x'}, 'title': 'Monitoring the 3-year efficacy of enzyme replacement therapy in fabry disease by repeated skin biopsies', 'source': 'Mendeley'}
Hajioff D, Goodwin S, Quiney R, Zuckerman J, MacDermot KD, Mehta A. Hearing improvement in patients with Fabry disease treated with agalsidase alfa. Acta paediatrica (Oslo, Norway : 1992). Supplement. 2003;92(443):28-30; discussion 27.	-	14989462	primary-study	7a01cc5597d71ead7c942ff27a05e8d07be69a25	-	{'publication_type': {'year': 2003, 'cited_medium': None, 'issue': '0', 'issn': '0803-5253', 'volume': '92', 'title': 'Acta Paediatrica', 'pagination': '28-30'}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.775, 'authors': 0.5}, 'authors': [{'given': 'Hajioff', 'family': 'D'}, {'given': 'Goodwin', 'family': 'S'}, {'given': 'Quiney', 'family': 'R'}, {'given': 'Zuckerman', 'family': 'J'}, {'given': 'MacDermot', 'family': 'KD'}, {'given': 'Mehta', 'family': 'A'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1080/08035320310000429'}, 'title': 'Hearing improvement in patients with Fabry disease treated with agalsidase alfa', 'source': 'CrossRef'}
Hajioff D, Goodwin S, Quiney R, Zuckerman J, MacDermot KD, Mehta A. Hearing improvement in patients with Fabry disease treated with agalsidase alfa. Acta paediatrica (Oslo, Norway : 1992). Supplement. 2003;92(443):28-30; discussion 27.	-	14989462	primary-study	7a01cc5597d71ead7c942ff27a05e8d07be69a25	-	{'publication_type': {'year': 2003, 'cited_medium': None, 'issue': None, 'issn': '0803-5326', 'volume': None, 'title': 'Acta Paediatrica', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.775, 'authors': 0.5}, 'authors': [{'given': 'Hajioff', 'family': 'D'}, {'given': 'Goodwin', 'family': 'S'}, {'given': 'Quiney', 'family': 'R'}, {'given': 'Zuckerman', 'family': 'J'}, {'given': 'MacDermot', 'family': 'KD'}, {'given': 'Mehta', 'family': 'A'}], 'abstract': 'AIM: To describe the nature and prevalence of hearing loss in Fabry disease, and its response to enzyme replacement therapy (ERT) with agalsidase alfa. METHODS: Fifteen male patients with Fabry disease were enrolled in a randomized, double-blind study and received placebo (n = 8) or ERT (n = 7) with agalsidase alfa for 6 months. This was followed by an open-label extension of 36 months thus far. Alongside this trial, an additional eight men and two women have so far received open-label ERT for between 6 and 30 months. Pure-tone audiometry, impedance audiometry and otoacoustic emission testing were performed at 0 (baseline), 6, 18, 30 and 42 months. RESULTS: Nine patients (36%) had bilateral and ten (40%) had unilateral high-frequency sensorineural hearing loss (SNHL). Three (12%) had unilateral middle ear effusions with conductive losses persisting beyond 6 months. Only five patients (20%) had normal hearing. The high-frequency SNHL deteriorated over the first 6 months in both placebo and active treatment groups by a median 6.3 dB (p < 0.0001, Wilcoxon matched-pairs). This hearing loss subsequently improved above baseline by 1.5 dB at 18 months (p = 0.07), by 5.0 dB at 30 months (p = 0.006) and by 4.0 dB at 42 months (p = 0.01). CONCLUSION: Significant hearing loss, usually high-frequency SNHL, is a common manifestation of Fabry disease in adults. Alpha-galactosidase A replacement therapy with agalsidase alfa appears to reverse the hearing deterioration in these patients. This improvement, however, is gradual, suggesting the need for long-term ERT.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '14989462', 'scopus': '2-s2.0-1642496923', 'doi': '10.1080/08035320310000429'}, 'title': 'Hearing improvement in patients with Fabry disease treated with agalsidase alfa', 'source': 'Mendeley'}
Hajioff D, Enever Y, Quiney R, Zuckerman J, Mackermot K, Mehta A. Hearing loss in Fabry disease: the effect of agalsidase alfa replacement therapy. Journal of inherited metabolic disease. 2003;26(8):787-94.	10.1023/B:BOLI.0000009948.86528.72	14739683	primary-study	45e0b5ad24de1c1d5e7da582a7d9a889baad12ff	-	{'publication_type': {'year': 2003, 'cited_medium': None, 'issue': '8', 'issn': '0141-8955', 'volume': '26', 'title': 'Journal of Inherited Metabolic Disease', 'pagination': '787-794'}, 'language': None, 'rating': {'year': 0, 'title': 1.0, 'total': 0.8625, 'authors': 0.85}, 'authors': [{'given': 'D.', 'family': 'Hajioff'}, {'given': 'Y.', 'family': 'Enever'}, {'given': 'R.', 'family': 'Quiney'}, {'given': 'J.', 'family': 'Zuckerman'}, {'given': 'K.', 'family': 'Mackermot'}, {'given': 'A.', 'family': 'Mehta'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1023/b:boli.0000009948.86528.72'}, 'title': 'Hearing loss in Fabry disease: The effect of agalsidase alfa replacement therapy', 'source': 'CrossRef'}
Hajioff D, Enever Y, Quiney R, Zuckerman J, Mackermot K, Mehta A. Hearing loss in Fabry disease: the effect of agalsidase alfa replacement therapy. Journal of inherited metabolic disease. 2003;26(8):787-94.	10.1023/B:BOLI.0000009948.86528.72	14739683	primary-study	45e0b5ad24de1c1d5e7da582a7d9a889baad12ff	-	{'publication_type': {'year': 2003, 'cited_medium': None, 'issue': None, 'issn': '0803-5326', 'volume': None, 'title': 'Acta Paediatrica', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.5454545454545454, 'total': 0.4753787878787879, 'authors': 0.48333333333333334}, 'authors': [{'given': 'Hajioff', 'family': 'D'}, {'given': 'Goodwin', 'family': 'S'}, {'given': 'Quiney', 'family': 'R'}, {'given': 'Zuckerman', 'family': 'J'}, {'given': 'MacDermot', 'family': 'KD'}, {'given': 'Mehta', 'family': 'A'}], 'abstract': 'AIM: To describe the nature and prevalence of hearing loss in Fabry disease, and its response to enzyme replacement therapy (ERT) with agalsidase alfa. METHODS: Fifteen male patients with Fabry disease were enrolled in a randomized, double-blind study and received placebo (n = 8) or ERT (n = 7) with agalsidase alfa for 6 months. This was followed by an open-label extension of 36 months thus far. Alongside this trial, an additional eight men and two women have so far received open-label ERT for between 6 and 30 months. Pure-tone audiometry, impedance audiometry and otoacoustic emission testing were performed at 0 (baseline), 6, 18, 30 and 42 months. RESULTS: Nine patients (36%) had bilateral and ten (40%) had unilateral high-frequency sensorineural hearing loss (SNHL). Three (12%) had unilateral middle ear effusions with conductive losses persisting beyond 6 months. Only five patients (20%) had normal hearing. The high-frequency SNHL deteriorated over the first 6 months in both placebo and active treatment groups by a median 6.3 dB (p < 0.0001, Wilcoxon matched-pairs). This hearing loss subsequently improved above baseline by 1.5 dB at 18 months (p = 0.07), by 5.0 dB at 30 months (p = 0.006) and by 4.0 dB at 42 months (p = 0.01). CONCLUSION: Significant hearing loss, usually high-frequency SNHL, is a common manifestation of Fabry disease in adults. Alpha-galactosidase A replacement therapy with agalsidase alfa appears to reverse the hearing deterioration in these patients. This improvement, however, is gradual, suggesting the need for long-term ERT.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '14989462', 'scopus': '2-s2.0-1642496923', 'doi': '10.1080/08035320310000429'}, 'title': 'Hearing improvement in patients with Fabry disease treated with agalsidase alfa', 'source': 'Mendeley'}
Thurberg BL, Rennke H, Colvin RB, Dikman S, Gordon RE, Collins AB, Desnick RJ, O'Callaghan M. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney international. 2002;62(6):1933-46.	10.1046/j.1523-1755.2002.00675.x	12427118	primary-study	36d6bfbdc861c1646faf11c4c7911d2a9edb5627	-	{'publication_type': {'year': 2002, 'cited_medium': None, 'issue': '6', 'issn': '0085-2538', 'volume': '62', 'title': 'Kidney International', 'pagination': '1933-1946'}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.878125, 'authors': 0.9125000000000001}, 'authors': [{'given': 'Beth L.', 'family': 'Thurberg'}, {'given': 'Helmut', 'family': 'Rennke'}, {'given': 'Robert B.', 'family': 'Colvin'}, {'given': 'Steven', 'family': 'Dikman'}, {'given': 'Ronald E.', 'family': 'Gordon'}, {'given': 'A. Bernard', 'family': 'Collins'}, {'given': 'Robert J.', 'family': 'Desnick'}, {'given': 'Michael', 'family': "O'Callaghan"}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '12427118', 'scopus': None, 'doi': '10.1046/j.1523-1755.2002.00675.x'}, 'title': 'Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy', 'source': 'CrossRef'}
Thurberg BL, Rennke H, Colvin RB, Dikman S, Gordon RE, Collins AB, Desnick RJ, O'Callaghan M. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney international. 2002;62(6):1933-46.	10.1046/j.1523-1755.2002.00675.x	12427118	primary-study	36d6bfbdc861c1646faf11c4c7911d2a9edb5627	-	{'publication_type': {'year': 2002, 'cited_medium': None, 'issue': None, 'issn': '00852538', 'volume': None, 'title': 'Kidney International', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 1.0, 'total': 0.878125, 'authors': 0.9125000000000001}, 'authors': [{'given': 'Beth L.', 'family': 'Thurberg'}, {'given': 'Helmut', 'family': 'Rennke'}, {'given': 'Robert B.', 'family': 'Colvin'}, {'given': 'Steven', 'family': 'Dikman'}, {'given': 'Ronald E.', 'family': 'Gordon'}, {'given': 'A. Bernard', 'family': 'Collins'}, {'given': 'Robert J.', 'family': 'Desnick'}, {'given': 'Michael', 'family': "O'Callaghan"}], 'abstract': 'BACKGROUND: Fabry disease, a lysosomal storage disease caused by deficient lysosomal alpha-galactosidase A activity, is characterized by globotriaosylceramide (GL-3) accumulation in multiple cell types, particularly the vasculature, leading to end organ failure. Accumulation in the kidney is responsible for progressive decline in renal function in male patients with the classical phenotype, resulting in renal failure in their third to fifth decades of life. With the advent of recombinant protein synthesis technology, enzyme replacement therapy has become a viable alternative to dialysis or renal transplantation, previously the only available treatment options for end-stage renal disease. METHODS: The pre- and post-treatment renal biopsies were analyzed from fifty-eight Fabry patients enrolled in a Phase 3 double-blind, randomized, placebo-controlled trial followed by a six-month open label extension study of the recombinant human enzyme, alpha-galactosidase A (r-halphaGalA), administered IV at 1 mg/kg biweekly. The purpose of this investigation was to detail the pathologic changes in glycosphingolipid distribution and the pattern of post-treatment clearance in the kidney. RESULTS: Baseline evaluations revealed GL-3 accumulations in nearly all renal cell types including vascular endothelial cells, vascular smooth muscle cells, mesangial cells and interstitial cells, with particularly dense accumulations in podocytes and distal tubular epithelial cells. After 11 months of r-halphaGalA treatment there was complete clearance of glycolipid from the endothelium of all vasculature as well as from the mesangial cells of the glomerulus and interstitial cells of the cortex. Moderate clearance was noted from the smooth muscle cells of arterioles and small arteries. Podocytes and distal tubular epithelium also demonstrated evidence for decreased GL-3, although this clearance was more limited than that observed in other cell types. No evidence of immune complex disease was found by immunofluorescence despite circulating anti-r-halphaGalA IgG antibodies. CONCLUSIONS: These findings indicate a striking reversal of renal glycosphingolipid accumulation in the vasculature and in other renal cell types, and suggest that long-term treatment with r-halphaGalA may halt the progression of pathology and prevent renal failure in patients with Fabry disease.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '12427118', 'scopus': '2-s2.0-0036436320', 'doi': '10.1046/j.1523-1755.2002.00675.x'}, 'title': 'Globotriaosylceramide accumulation in the fabry kidney is cleared from multiple cell types after enzyme replacement therapy', 'source': 'Mendeley'}
Moore DF, Altarescu G, Herscovitch P, Schiffmann R. Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease. BMC neurology. 2002;2:4.	-	12079501	primary-study	5c45bf0d403e6dc50a4f6398ed483b8565ae0ea5	-	{'publication_type': {'year': 2002, 'cited_medium': None, 'issue': '1', 'issn': '1471-2377', 'volume': '2', 'title': 'BMC Neurology', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.8812500000000001, 'authors': 0.925}, 'authors': [{'given': 'David F', 'family': 'Moore'}, {'given': 'Gheona', 'family': 'Altarescu'}, {'given': 'Peter', 'family': 'Herscovitch'}, {'given': 'Raphael', 'family': 'Schiffmann'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1186/1471-2377-2-4'}, 'title': 'Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease', 'source': 'CrossRef'}
Moore DF, Altarescu G, Herscovitch P, Schiffmann R. Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease. BMC neurology. 2002;2:4.	-	12079501	primary-study	5c45bf0d403e6dc50a4f6398ed483b8565ae0ea5	-	{'publication_type': {'year': 2002, 'cited_medium': None, 'issue': None, 'issn': '1471-2377 (Electronic)', 'volume': None, 'title': 'BMC neurology', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 0.9812500000000001, 'authors': 0.925}, 'authors': [{'given': 'David F', 'family': 'Moore'}, {'given': 'Gheona', 'family': 'Altarescu'}, {'given': 'Peter', 'family': 'Herscovitch'}, {'given': 'Raphael', 'family': 'Schiffmann'}], 'abstract': 'BACKGROUND: Fabry disease is a lysosomal X-linked enzyme deficiency of alpha-galactosidase A associated with an increased mortality and morbidity due to renal failure, cardiac disease and early onset stroke. METHODS: We examined the functional blood flow response of the brain after visual stimulation (reversing checkerboard pattern), and cerebral vasoreactivity following acetazolamide (15 mg/kg) with [15O]H2O and positron emission tomography (PET) in Fabry disease. Twenty-six hemizygous patients (age range 19-47 years) were enrolled in a randomized double-blind placebo-controlled 6-month trial of enzyme replacement therapy administered by intravenous infusion every two weeks. Regional cerebral blood flow (rCBF) was measured with PET at the beginning and end of the trial. RESULTS: Fabry patients had a significantly greater increase in rCBF following visual stimulation and acetazolamide challenge compared to controls. Visual reactivity was normal. The time for recovery of the cerebral vasculature following acetazolamide was prolonged in Fabry patients compared to controls. The abnormal rCBF response induced by visual stimulation and acetazolamide decreased significantly following enzyme replacement therapy, as did the prolonged recovery of the cerebral vasculature. CONCLUSIONS: Enzyme replacement therapy reverses the exaggerated cerebrovascular response in Fabry disease.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '12079501', 'scopus': '2-s2.0-0013155111', 'doi': '10.1186/1471-2377-2-4'}, 'title': 'Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease.', 'source': 'Mendeley'}
Moore DF, Altarescu G, Ling GS, Jeffries N, Frei KP, Weibel T, Charria-Ortiz G, Ferri R, Arai AE, Brady RO, Schiffmann R. Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement. Stroke; a journal of cerebral circulation. 2002;33(2):525-31.	-	11823664	primary-study	092d017b13edf3603ec421f3e006e82ab947e041	-	{'publication_type': {'year': 2002, 'cited_medium': None, 'issue': '2', 'issn': '0039-2499', 'volume': '33', 'title': 'Stroke', 'pagination': '525-531'}, 'language': None, 'rating': {'year': 1, 'title': 1.0, 'total': 0.9500000000000001, 'authors': 0.8}, 'authors': [{'given': 'D. F.', 'family': 'Moore'}, {'given': 'G.', 'family': 'Altarescu'}, {'given': 'G. S.F.', 'family': 'Ling'}, {'given': 'N.', 'family': 'Jeffries'}, {'given': 'K. P.', 'family': 'Frei'}, {'given': 'T.', 'family': 'Weibel'}, {'given': 'G.', 'family': 'Charria-Ortiz'}, {'given': 'R.', 'family': 'Ferri'}, {'given': 'A. E.', 'family': 'Arai'}, {'given': 'R. O.', 'family': 'Brady'}, {'given': 'R.', 'family': 'Schiffmann'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1161/hs0202.102601'}, 'title': 'Elevated Cerebral Blood Flow Velocities in Fabry Disease With Reversal After Enzyme Replacement', 'source': 'CrossRef'}
Moore DF, Altarescu G, Ling GS, Jeffries N, Frei KP, Weibel T, Charria-Ortiz G, Ferri R, Arai AE, Brady RO, Schiffmann R. Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement. Stroke; a journal of cerebral circulation. 2002;33(2):525-31.	-	11823664	primary-study	092d017b13edf3603ec421f3e006e82ab947e041	-	{'publication_type': {'year': 2002, 'cited_medium': None, 'issue': None, 'issn': None, 'volume': None, 'title': 'Stroke', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 0.9795454545454545, 'authors': 0.9181818181818181}, 'authors': [{'given': 'D F', 'family': 'Moore'}, {'given': 'G', 'family': 'Altarescu'}, {'given': 'G S', 'family': 'Ling'}, {'given': 'N', 'family': 'Jeffries'}, {'given': 'K P', 'family': 'Frei'}, {'given': 'T', 'family': 'Weibel'}, {'given': 'G', 'family': 'Charria-Ortiz'}, {'given': 'R', 'family': 'Ferri'}, {'given': 'A E', 'family': 'Arai'}, {'given': 'R O', 'family': 'Brady'}, {'given': 'R', 'family': 'Schiffmann'}], 'abstract': 'BACKGROUND AND PURPOSE: Fabry disease is an X-linked inherited disorder resulting from a deficiency of alpha-galactosidase A. Cerebrovascular disease in Fabry disease includes small-vessel disease and larger-vessel ectasia in a predominantly posterior distribution. We assessed transcranial Doppler (TCD) blood flow velocities in naive and enzyme-treated Fabry patients. METHODS: TCD was used to noninvasively examine patients with Fabry disease for abnormal cerebral blood flow velocities. TCD measurements were also made during CO2 retention by breathholding to examine cerebrovascular vessel reactivity. Twenty-six patients were enrolled in a 6-month, double-blind, placebo-controlled trial of enzyme replacement therapy consisting of biweekly intravenous alpha-galactosidase A infusions, with a subsequent 18-month follow-up in an open-label trial. Statistical analysis consisted of applying a mixed-effects ANOVA model for correlated outcomes. RESULTS: Peak velocity, mean velocity, pulsatility index, and resistance index were found to be significantly higher in patients compared with control subjects. When the individual vessels were considered, elevated flow velocities were found in the middle cerebral M1 branch and the posterior cerebral artery. Enzyme replacement therapy significantly decreased peak, mean, and end-diastolic velocities and flow acceleration at the 18-month follow-up time point. CONCLUSIONS: Patients with Fabry disease have elevated cerebral blood flow velocities. These velocities significantly improved with enzyme replacement therapy.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '11823664', 'scopus': None, 'doi': None}, 'title': 'Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement', 'source': 'Mendeley'}
Moore DF, Scott LT, Gladwin MT, Altarescu G, Kaneski C, Suzuki K, Pease-Fye M, Ferri R, Brady RO, Herscovitch P, Schiffmann R. Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy. Circulation. 2001;104(13):1506-12.	-	11571244	primary-study	d8506316f9a519e6e0fd2e8566f93627ddc7c7bd	-	{'publication_type': {'year': 2001, 'cited_medium': None, 'issue': '13', 'issn': '0009-7322', 'volume': '104', 'title': 'Circulation', 'pagination': '1506-1512'}, 'language': None, 'rating': {'year': 1, 'title': 1.0, 'total': 0.9681818181818183, 'authors': 0.8727272727272729}, 'authors': [{'given': 'D. F.', 'family': 'Moore'}, {'given': 'L. T.C.', 'family': 'Scott'}, {'given': 'M. T.', 'family': 'Gladwin'}, {'given': 'G.', 'family': 'Altarescu'}, {'given': 'C.', 'family': 'Kaneski'}, {'given': 'K.', 'family': 'Suzuki'}, {'given': 'M.', 'family': 'Pease-Fye'}, {'given': 'R.', 'family': 'Ferri'}, {'given': 'R. O.', 'family': 'Brady'}, {'given': 'P.', 'family': 'Herscovitch'}, {'given': 'R.', 'family': 'Schiffmann'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1161/hc3801.096352'}, 'title': 'Regional Cerebral Hyperperfusion and Nitric Oxide Pathway Dysregulation in Fabry Disease: Reversal by Enzyme Replacement Therapy', 'source': 'CrossRef'}
Moore DF, Scott LT, Gladwin MT, Altarescu G, Kaneski C, Suzuki K, Pease-Fye M, Ferri R, Brady RO, Herscovitch P, Schiffmann R. Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy. Circulation. 2001;104(13):1506-12.	-	11571244	primary-study	d8506316f9a519e6e0fd2e8566f93627ddc7c7bd	-	{'publication_type': {'year': 2001, 'cited_medium': None, 'issue': None, 'issn': '1524-4539 (Electronic)', 'volume': None, 'title': 'Circulation', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 0.9909090909090909, 'authors': 0.9636363636363636}, 'authors': [{'given': 'D F', 'family': 'Moore'}, {'given': 'L T', 'family': 'Scott'}, {'given': 'M T', 'family': 'Gladwin'}, {'given': 'G', 'family': 'Altarescu'}, {'given': 'C', 'family': 'Kaneski'}, {'given': 'K', 'family': 'Suzuki'}, {'given': 'M', 'family': 'Pease-Fye'}, {'given': 'R', 'family': 'Ferri'}, {'given': 'R O', 'family': 'Brady'}, {'given': 'P', 'family': 'Herscovitch'}, {'given': 'R', 'family': 'Schiffmann'}], 'abstract': 'BACKGROUND: Fabry disease is an X-linked lysosomal deficiency of alpha-galactosidase A that results in cellular accumulation of galacto-conjugates such as globotriosylceramide, particularly in blood vessels. It is associated with early-onset stroke and kidney and heart failure. METHODS AND RESULTS: Using [(15)O] H(2)O and PET, we found increased resting regional cerebral blood flow in Fabry disease without evidence of occlusive vasculopathy or cerebral hypoperfusion. Because nitric oxide is known to play an important role in vascular tone and reactivity, we studied plasma nitrate, nitrite, and low-molecular-weight S-nitrosothiol levels by chemiluminescence. Skin biopsy specimens and archived brain tissue were also examined immunohistochemically for nitrotyrosine. Plasma nitrate, nitrite, and low-molecular-weight S-nitrosothiol were in the normal range; however, enhanced nitrotyrosine staining was observed in dermal and cerebral blood vessels. After a double-blind, placebo-controlled trial of alpha-galactosidase A therapy, the resting regional cerebral blood flow in the treated group was significantly reduced, with a notable decrease of nitrotyrosine staining in dermal blood vessels. CONCLUSIONS: These findings suggest a chronic alteration of the nitric oxide pathway in Fabry disease, with critical protein nitration that is reversible with enzyme replacement therapy.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '11571244', 'scopus': '2-s2.0-0035949721', 'doi': '10.1161/hc3801.096352'}, 'title': 'Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy.', 'source': 'Mendeley'}
Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, Caplan L, Linthorst GE, Desnick RJ. Safety and efficacy of recombinant human alpha-galactosidase A--replacement therapy in Fabry's disease. The New England journal of medicine. 2001;345(1):9-16.	10.1056/NEJM200107053450102	11439963	primary-study	5276de5ceb5b5f5b3424b37dc25cd5d0abe06b5f	-	{'publication_type': {'year': 2001, 'cited_medium': None, 'issue': '1', 'issn': '0028-4793', 'volume': '345', 'title': 'New England Journal of Medicine', 'pagination': '9-16'}, 'language': None, 'rating': {'year': 0, 'title': 0.9230769230769231, 'total': 0.8250000000000002, 'authors': 0.9000000000000001}, 'authors': [{'given': 'Christine M.', 'family': 'Eng'}, {'given': 'Nathalie', 'family': 'Guffon'}, {'given': 'William R.', 'family': 'Wilcox'}, {'given': 'Dominique P.', 'family': 'Germain'}, {'given': 'Philip', 'family': 'Lee'}, {'given': 'Steve', 'family': 'Waldek'}, {'given': 'Louis', 'family': 'Caplan'}, {'given': 'Gabor E.', 'family': 'Linthorst'}, {'given': 'Robert J.', 'family': 'Desnick'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1056/nejm200107053450102'}, 'title': "Safety and Efficacy of Recombinant Human α-Galactosidase A Replacement Therapy in Fabry's Disease", 'source': 'CrossRef'}
Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, Caplan L, Linthorst GE, Desnick RJ. Safety and efficacy of recombinant human alpha-galactosidase A--replacement therapy in Fabry's disease. The New England journal of medicine. 2001;345(1):9-16.	10.1056/NEJM200107053450102	11439963	primary-study	5276de5ceb5b5f5b3424b37dc25cd5d0abe06b5f	-	{'publication_type': {'year': 1999, 'cited_medium': None, 'issue': None, 'issn': '0020-9643', 'volume': None, 'title': 'Interpretation', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.0, 'total': 0.0, 'authors': 0.0}, 'authors': [{'given': 'Samuel E.', 'family': 'Balentine'}], 'abstract': "Job proclaimed two unharmonious affirmations in his speech found in the Book of Job chapters 23-24. His first statement stressing God's absence is the basis of questions about the abandonment of human beings and the world by God. Job considered God a failure in giving justice in his second affirmation which calls for justice. Job's speech manifested his hope to find a God that could be with the people more when needed.", 'type': 'journal', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': None}, 'title': 'Job 23:1-9, 16-17', 'source': 'Mendeley'}
Schiffmann R, Kopp JB, Austin HA, Sabnis S, Moore DF, Weibel T, Balow JE, Brady RO. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA : the journal of the American Medical Association. 2001;285(21):2743-9.	-	11386930	primary-study	2e371a8a41b6c8b5798e94459a08b733135daea3	-	{'publication_type': {'year': 2001, 'cited_medium': None, 'issue': '21', 'issn': '0098-7484', 'volume': '285', 'title': 'JAMA', 'pagination': '2743'}, 'language': None, 'rating': {'year': 1, 'title': 1.0, 'total': 0.946875, 'authors': 0.7875000000000001}, 'authors': [{'given': 'Raphael', 'family': 'Schiffmann'}, {'given': 'Jeffrey B.', 'family': 'Kopp'}, {'given': 'Howard A.', 'family': 'Austin III'}, {'given': 'Sharda', 'family': 'Sabnis'}, {'given': 'David F.', 'family': 'Moore'}, {'given': 'Thais', 'family': 'Weibel'}, {'given': 'James E.', 'family': 'Balow'}, {'given': 'Roscoe O.', 'family': 'Brady'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1001/jama.285.21.2743'}, 'title': 'Enzyme Replacement Therapy in Fabry Disease', 'source': 'CrossRef'}
Schiffmann R, Kopp JB, Austin HA, Sabnis S, Moore DF, Weibel T, Balow JE, Brady RO. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA : the journal of the American Medical Association. 2001;285(21):2743-9.	-	11386930	primary-study	2e371a8a41b6c8b5798e94459a08b733135daea3	-	{'publication_type': {'year': 2001, 'cited_medium': None, 'issue': None, 'issn': None, 'volume': None, 'title': 'JAMA', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 0.875, 'authors': 0.5}, 'authors': [{'given': 'Brady RO', 'family': 'Schiffmann R, Kopp JB, Austin HA, Sabnis S, Moore DF, Weibel T, Balow JE'}], 'abstract': 'CONTEXT: Fabry disease is a metabolic disorder without a specific treatment, caused by a deficiency of the lysosomal enzyme alpha-galactosidase A (alpha-gal A). Most patients experience debilitating neuropathic pain and premature mortality because of renal failure, cardiovascular disease, or cerebrovascular disease. OBJECTIVE: To evaluate the safety and efficacy of intravenous alpha-gal A for Fabry disease. DESIGN AND SETTING: Double-blind placebo-controlled trial conducted from December 1998 to August 1999 at the Clinical Research Center of the National Institutes of Health. PATIENTS: Twenty-six hemizygous male patients, aged 18 years or older, with Fabry disease that was confirmed by alpha-gal A assay. INTERVENTION: A dosage of 0.2 mg/kg of alpha-gal A, administered intravenously every other week (12 doses total). MAIN OUTCOME MEASURE: Effect of therapy on neuropathic pain while without neuropathic pain medications measured by question 3 of the Brief Pain Inventory (BPI). RESULTS: Mean (SE) BPI neuropathic pain severity score declined from 6.2 (0.46) to 4.3 (0.73) in patients treated with alpha-gal A vs no significant change in the placebo group (P =.02). Pain-related quality of life declined from 3.2 (0.55) to 2.1 (0.56) for patients receiving alpha-gal A vs 4.8 (0.59) to 4.2 (0.74) for placebo (P =.05). In the kidney, glomeruli with mesangial widening decreased by a mean of 12.5% for patients receiving alpha-gal vs a 16.5% increase for placebo (P =.01). Mean inulin clearance decreased by 6.2 mL/min for patients receiving alpha-gal A vs 19.5 mL/min for placebo (P =.19). Mean creatinine clearance increased by 2.1 mL/min (0.4 mL/s) for patients receiving alpha-gal A vs a decrease of 16.1 mL/min (0.3 mL/s) for placebo (P =.02). In patients treated with alpha-gal A, there was an approximately 50% reduction in plasma glycosphingolipid levels, a significant improvement in cardiac conduction, and a significant increase in body weight. CONCLUSION: Intravenous infusions of alpha-gal A are safe and have widespread therapeutic efficacy in Fabry disease.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': None}, 'title': 'Enzyme replacement therapy in Fabry disease: a randomized controlled trial.', 'source': 'Mendeley'}
Valery PC, Masters IB, Taylor B, Laifoo Y, O'Rourke PK, Chang AB. An education intervention for childhood asthma by Aboriginal and Torres Strait Islander health workers: a randomised controlled trial. The Medical journal of Australia. 2010;192(10):574-9.	-	20477733	primary-study	ec233c770d2bb2fe427dd7dc8e3e223c20e6086e	-	{'publication_type': {'year': 2013, 'cited_medium': None, 'issue': '1', 'issn': '0025-729X', 'volume': '198', 'title': 'The Medical Journal of Australia', 'pagination': '23'}, 'language': None, 'rating': {'year': 0, 'title': 0.75, 'total': 0.48750000000000004, 'authors': 0.0}, 'authors': [{'given': 'Gillian S', 'family': 'Gould'}, {'given': 'Andy', 'family': 'McEwen'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.5694/mja12.11221'}, 'title': 'An intensive smoking intervention for pregnant Aboriginal and Torres Strait Islander women: a randomised controlled trial', 'source': 'CrossRef'}
Valery PC, Masters IB, Taylor B, Laifoo Y, O'Rourke PK, Chang AB. An education intervention for childhood asthma by Aboriginal and Torres Strait Islander health workers: a randomised controlled trial. The Medical journal of Australia. 2010;192(10):574-9.	-	20477733	primary-study	ec233c770d2bb2fe427dd7dc8e3e223c20e6086e	-	{'publication_type': {'year': 2010, 'cited_medium': None, 'issue': None, 'issn': None, 'volume': None, 'title': 'The Medical journal of Australia', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 0.75, 'authors': 0.0}, 'authors': [{'given': 'Masters I B', 'family': "Valery PC  Taylor B, Laifoo Y, O'Rourke PK, Chang AB"}], 'abstract': 'OBJECTIVE: To assess the outcomes of an education intervention for childhood asthma conducted by Australian Indigenous health care workers (IHCWs).,  DESIGN AND SETTING: Randomised controlled trial in a primary health care setting on Thursday Island and Horn Island, and in Bamaga, Torres Strait region of northern Australia, April 2005 to March 2007.,  PARTICIPANTS: 88 children, aged 1-17 years, with asthma diagnosed by a respiratory physician (intervention group, 35; control group, 53; 98% Indigenous children).,  INTERVENTIONS: Children were randomly allocated to: (i) three additional asthma education sessions with a trained IHCW, or (ii) no additional asthma education. Both groups were re-assessed at 12 months.,  MAIN OUTCOME MEASURES: Primary endpoint: number of unscheduled visits to hospital or a doctor caused by asthma exacerbation. Secondary outcomes: measures of quality of life (QoL) and functional severity index; asthma knowledge and understanding of asthma action plans (AAPs); and school days missed because of wheezing.,  RESULTS: The groups were comparable at baseline (except for asthma severity, which was adjusted for in the analysis). There were no significant differences in the primary outcome (number of unscheduled medical visits for asthma). School children in the intervention group missed fewer school days because of wheezing (100% < 7 days v 21% of those in the control group missed 7-14 days). Significantly more carers in the intervention group could answer questions about asthma medication, knew where their AAP was kept (84% v 56%), and were able to describe the plan (67% v 40%). In both the intervention and control groups (before-and-after comparison), there was a significantly reduced frequency of asthma exacerbations, as well as an improved QoL score and functional severity index, with no significant differences between the groups.,  CONCLUSIONS: A community-based asthma education program conducted by trained IHCWs improves some important asthma outcomes in Indigenous children with asthma.,  TRIAL REGISTRATION: Australian Clinical Trials Registry ACTRN012605000718640.', 'type': 'generic', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': None}, 'title': 'An education intervention for childhood asthma by Aboriginal and Torres Strait Islander health workers: a randomised controlled trial.', 'source': 'Mendeley'}
Ellis CN, Clark S. Fibrin glue as an adjunct to flap repair of anal fistulas: a randomized, controlled study. Diseases of the colon and rectum. 2006;49(11):1736-40.	10.1007/s10350-006-0718-8	17053867	primary-study	f876e879fb5d7505d5d9543baab47af6c560d994	-	{'publication_type': {'year': 2006, 'cited_medium': None, 'issue': '11', 'issn': '0012-3706', 'volume': '49', 'title': 'Diseases of the Colon & Rectum', 'pagination': '1736-1740'}, 'language': None, 'rating': {'year': 0, 'title': 1.0, 'total': 0.8875, 'authors': 0.95}, 'authors': [{'given': 'C. Neal', 'family': 'Ellis'}, {'given': 'Stephen', 'family': 'Clark'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '17053867', 'scopus': None, 'doi': '10.1007/s10350-006-0718-8'}, 'title': 'Fibrin Glue as an Adjunct to Flap Repair of Anal Fistulas: A Randomized, Controlled Study', 'source': 'CrossRef'}
Ellis CN, Clark S. Fibrin glue as an adjunct to flap repair of anal fistulas: a randomized, controlled study. Diseases of the colon and rectum. 2006;49(11):1736-40.	10.1007/s10350-006-0718-8	17053867	primary-study	f876e879fb5d7505d5d9543baab47af6c560d994	-	{'publication_type': {'year': 2006, 'cited_medium': None, 'issue': None, 'issn': '00123706', 'volume': None, 'title': 'Diseases of the Colon and Rectum', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 1.0, 'total': 0.8875, 'authors': 0.95}, 'authors': [{'given': 'C. Neal', 'family': 'Ellis'}, {'given': 'Stephen', 'family': 'Clark'}], 'abstract': "PURPOSE: Both flap repair and fibrin glue are accepted sphincter-preserving techniques for managing anal fistulas. Additionally, the two techniques are not mutually exclusive and can be combined. This trial was undertaken to determine whether the combination of flap repair and fibrin glue resulted in better outcomes than flap repair alone.\\n\\nMETHODS: Between July 2000 and March 2004, patients with trans-sphincteric anal fistulas were randomly assigned to advancement flap repair alone or flap repair combined with fibrin glue obliteration of the fistula tract. Data regarding age, gender, fistula anatomy, race, and previous repairs were collected. Fistulas managed by fistulotomy or caused by Crohn's disease, acute obstetric trauma, or radiation were excluded from this study.\\n\\nRESULTS: There were 58 patients randomized to flap repair alone or flap repair with fibrin glue (47 males; median age, 47 (range, 29-68) years). Mucosal advancement flap was performed in 36 patients and anodermal advancement flap was performed in 22. The median follow-up was 22 (range, 12-36) months. Total fistula recurrence rate for all patients was 32.6 percent. The recurrence rate for fistulas repaired by advancement flap alone was 20 percent, whereas the recurrence rate for fistulas repaired by advancement flap with fibrin glue was 46.4 percent (P < 0.05).\\n\\nCONCLUSIONS: The data fail to show improved outcomes when fibrin sealant is used in combination with an advancement flap compared with advancement flap alone for the management of complex anal fistulas.", 'type': 'journal', 'ids': {'embase': None, 'pubmed': '17053867', 'scopus': '2-s2.0-33751288112', 'doi': '10.1007/s10350-006-0718-8'}, 'title': 'Fibrin glue as an adjunct to flap repair of anal fistulas: A randomized, controlled study', 'source': 'Mendeley'}
Pescatori M, Ayabaca SM, Cafaro D, Iannello A, Magrini S. Marsupialization of fistulotomy and fistulectomy wounds improves healing and decreases bleeding: a randomized controlled trial. Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland. 2006;8(1):11-4.	10.1111/j.1463-1318.2005.00835.x	16519632	primary-study	f159c1a3a7c3ea8d55de2c00552c9778c1f651b6	-	{'publication_type': {'year': 2006, 'cited_medium': None, 'issue': '1', 'issn': '1462-8910', 'volume': '8', 'title': 'Colorect Dis', 'pagination': '11-14'}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.86, 'authors': 0.8399999999999999}, 'authors': [{'given': 'M.', 'family': 'Pescatori'}, {'given': 'S. M.', 'family': 'Ayabaca'}, {'given': 'D.', 'family': 'Cafaro'}, {'given': 'A.', 'family': 'Iannello'}, {'given': 'S.', 'family': 'Magrini'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '16519632', 'scopus': None, 'doi': '10.1111/j.1463-1318.2005.00835.x'}, 'title': 'Marsupialization of fistulotomy and fistulectomy wounds improves healing and decreases bleeding: a randomized controlled trial', 'source': 'CrossRef'}
Pescatori M, Ayabaca SM, Cafaro D, Iannello A, Magrini S. Marsupialization of fistulotomy and fistulectomy wounds improves healing and decreases bleeding: a randomized controlled trial. Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland. 2006;8(1):11-4.	10.1111/j.1463-1318.2005.00835.x	16519632	primary-study	f159c1a3a7c3ea8d55de2c00552c9778c1f651b6	-	{'publication_type': {'year': 2006, 'cited_medium': None, 'issue': None, 'issn': '14628910', 'volume': None, 'title': 'Colorectal Disease', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 1.0, 'total': 0.86, 'authors': 0.8399999999999999}, 'authors': [{'given': 'M.', 'family': 'Pescatori'}, {'given': 'S. M.', 'family': 'Ayabaca'}, {'given': 'D.', 'family': 'Cafaro'}, {'given': 'A.', 'family': 'Iannello'}, {'given': 'S.', 'family': 'Magrini'}], 'abstract': 'BACKGROUND: Marsupialization of anal fistulotomy/fistulectomy wound leaves less raw unepithelialized tissue. The suture results in a more rapid healing and is likely to reduce the risk of bleeding but at the cost of an increased pain and infection. The aim of this prospective study was to compare the outcomes of marsupialization and open wound. METHODS: Forty-six consecutive patients with anal fistulae were recruited in a randomized controlled trial. Fistula tracks were treated by fistulotomy and/or fistulectomy. The resulting wounds were marsupialized to the skin edges with locking continuous absorbable sutures (M group) or left open (O group). The clinical outcome was then evaluated. The intra-operative effect of the suture on wound size was recorded as well as the postoperative pain using a 0-10 visual analogue scale (VAS) and the occurrence of both wound bleeding and infection. RESULTS: Twenty-two patients were randomized to the M group and 24 to the O group. There were no differences in the age, sex and fistula type between the groups. Mean follow-up times were 10.5 and 13.8 months, respectively. No significant difference was observed in postoperative pain, the VAS being 3.5 +/- 1.5 in the M group and 3.4 +/- 1.6 in the O group at 12 h (mean +/- s.e.m.; n.s). The marsupialization nearly halved the size of the wound intra-operatively from an area of 1749 +/- 66 mm2 to 819 +/- 38 mm2 (P < 0.001), which subsequently decreased to 217 +/- 15 mm2 after 4 weeks (P < 0.01). No significant reduction of wound size was observed in the O group (from 1171 +/- 31 mm2 to 543 +/- 19; n.s). Bleeding occurred less frequently in M group than in O group (36%vs 46%, P < 0.05), whereas the difference in the postoperative sepsis rate was not significant, being 14% in M vs 21% in the O group. Three reinterventions were needed in both groups due to wound sepsis. CONCLUSION: Marsupialization after fistulotomy/fistulectomy significantly reduces the size of the wound and the risk of bleeding, without increasing postoperative pain and sepsis.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '16519632', 'scopus': '2-s2.0-33644856300', 'doi': '10.1007/88-470-0367-9_2'}, 'title': 'Marsupialization of fistulotomy and fistulectomy wounds improves healing and decreases bleeding: A randomized controlled trial', 'source': 'Mendeley'}
Ho KS, Ho YH. Controlled, randomized trial of island flap anoplasty for treatment of trans-sphincteric fistula-in-ano: early results. Techniques in coloproctology. 2005;9(2):166-8.	10.1007/s10151-005-0220-7	16007352	primary-study	38ffe5d7eca63fbaeb2b1cefe552d6c85f2ff2dc	-	{'publication_type': {'year': 2005, 'cited_medium': None, 'issue': '2', 'issn': '1123-6337', 'volume': '9', 'title': 'Techniques in Coloproctology', 'pagination': '166-168'}, 'language': None, 'rating': {'year': 0, 'title': 0.8571428571428571, 'total': 0.7821428571428571, 'authors': 0.9}, 'authors': [{'given': 'K. S.', 'family': 'Ho'}, {'given': 'Y. H.', 'family': 'Ho'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '16007352', 'scopus': None, 'doi': '10.1007/s10151-005-0220-7'}, 'title': 'Controlled, randomized trial of island flap anoplasty for treatment of trans–sphincteric fistula–in-ano: early results', 'source': 'CrossRef'}
Ho KS, Ho YH. Controlled, randomized trial of island flap anoplasty for treatment of trans-sphincteric fistula-in-ano: early results. Techniques in coloproctology. 2005;9(2):166-8.	10.1007/s10151-005-0220-7	16007352	primary-study	38ffe5d7eca63fbaeb2b1cefe552d6c85f2ff2dc	-	{'publication_type': {'year': 2005, 'cited_medium': None, 'issue': None, 'issn': '11236337', 'volume': None, 'title': 'Techniques in Coloproctology', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 1.0, 'total': 0.875, 'authors': 0.9}, 'authors': [{'given': 'K. S.', 'family': 'Ho'}, {'given': 'Y. H.', 'family': 'Ho'}], 'abstract': 'Treatment of trans-sphincteric fistula is usually a compromise between recurrence and incontinence. Dermal island flap anoplasty has been found to be useful in the treatment of these fistulas. We performed a randomized trial to compare dermal island flap anoplasty with conventional treatment for trans-sphincteric fistula-in-ano. Seventy nine patients with fistula-in-ano were recruited; twenty patients with trans-sphincteric fistula confirmed by endoanal ultrasound were prospectively randomized to receive either dermal island flap anoplasty (IFA) or conventional treatment (CVN) for trans-sphincteric fistula-inano. Conventional treatment consisted of lay open fistulotomy or seton insertion if deemed unsuitable for fistulotomy. Dermal island flap anoplasty involved a cutaneous advancement flap into the rectum. Pain scores, fecal incontinence scores, operative complications, wound healing and recurrence rates were charted. Two patients in the CVN group required seton insertions, which were still intact at the 9-month follow-up. Two patients with similar high trans-sphincteric fistula in the IFA group avoided having a long-term seton. There were no differences in the postoperative pain score, incontinence score, complications, wound healing and recurrence rates between the two groups. IFA is a safe and useful method for treating transsphincteric fistula. It can be considered when a suprasphincteric extension is suspected, thus avoiding risk of incontinence or the discomfort of a long-term seton.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '16007352', 'scopus': '2-s2.0-27744435760', 'doi': '10.1007/s10151-005-0220-7'}, 'title': 'Controlled, randomized trial of island flap anoplasty for treatment of trans-sphincteric fistula-in-ano: Early results', 'source': 'Mendeley'}
Gupta PJ. Radiofrequency fistulotomy: a better alternative for treating low anal fistula. São Paulo medical journal = Revista paulista de medicina. 2004;122(4):172-4.	-	15543373	primary-study	e36947826276f0a9052a87931b47779624002a8c	-	{'publication_type': {'year': 2004, 'cited_medium': None, 'issue': '4', 'issn': '1516-3180', 'volume': '122', 'title': 'Sao Paulo Med. J.', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.875, 'authors': 0.9}, 'authors': [{'given': 'Pravin Jaiprakash', 'family': 'Gupta'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1590/s1516-31802004000400008'}, 'title': 'Radiofrequency fistulotomy: a better alternative for treating low anal fistula', 'source': 'CrossRef'}
Gupta PJ. Radiofrequency fistulotomy: a better alternative for treating low anal fistula. São Paulo medical journal = Revista paulista de medicina. 2004;122(4):172-4.	-	15543373	primary-study	e36947826276f0a9052a87931b47779624002a8c	-	{'publication_type': {'year': 2004, 'cited_medium': None, 'issue': None, 'issn': '15163180', 'volume': None, 'title': 'Sao Paulo Medical Journal', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 1.0, 'total': 0.875, 'authors': 0.9}, 'authors': [{'given': 'Pravin Jaiprakash', 'family': 'Gupta'}], 'abstract': 'Wide varieties of approaches are employed in dealing with low anal fistula. However, the simple method of laying open the fistula tract (fistulotomy) is still considered to be the favored one.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '15543373', 'scopus': '2-s2.0-9144238857', 'doi': '/S1516-31802004000400008'}, 'title': 'Radiofrequency fistulotomy: A better alternative for treating low anal fistula', 'source': 'Mendeley'}
Filingeri V, Gravante G, Baldessari E, Casciani CU. Radiofrequency fistulectomy vs. diathermic fistulotomy for submucosal fistulas: a randomized trial. European review for medical and pharmacological sciences. 2004;8(3):111-6.	-	15368794	primary-study	2e8ef0ba020f4527180f5ccc5dfa322c7368f40a	-	{'publication_type': {'year': 2004, 'cited_medium': None, 'issue': '1', 'issn': '1123-6337', 'volume': '8', 'title': 'Techniques in Coloproctology', 'pagination': '31-36'}, 'language': None, 'rating': {'year': 0, 'title': 0.46153846153846156, 'total': 0.48000000000000004, 'authors': 0.72}, 'authors': [{'given': 'V.', 'family': 'Filingeri'}, {'given': 'G.', 'family': 'Gravante'}, {'given': 'E.', 'family': 'Baldessari'}, {'given': 'M.', 'family': 'Grimaldi'}, {'given': 'C. U.', 'family': 'Casciani'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '15057587', 'scopus': None, 'doi': '10.1007/s10151-004-0048-6'}, 'title': 'Prospective randomized trial of submucosal hemorrhoidectomy with radiofrequency bistoury vs. conventional Parks? operation', 'source': 'CrossRef'}
Filingeri V, Gravante G, Baldessari E, Casciani CU. Radiofrequency fistulectomy vs. diathermic fistulotomy for submucosal fistulas: a randomized trial. European review for medical and pharmacological sciences. 2004;8(3):111-6.	-	15368794	primary-study	2e8ef0ba020f4527180f5ccc5dfa322c7368f40a	-	{'publication_type': {'year': 2004, 'cited_medium': None, 'issue': None, 'issn': '11283602', 'volume': None, 'title': 'European Review for Medical and Pharmacological Sciences', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 1.0, 'total': 0.875, 'authors': 0.9}, 'authors': [{'given': 'V.', 'family': 'Filingeri'}, {'given': 'G.', 'family': 'Gravante'}, {'given': 'E.', 'family': 'Baldessari'}, {'given': 'C. U.', 'family': 'Casciani'}], 'abstract': 'Anal fistula represents one of the most frequent anorectal disease. Fistulotomy is considered the gold standard treatment but related problems are numerous (postoperative pain, bleeding, delayed or impaired wound healing). Fistulectomy lowers the recurrences but is less feasible with longer operating time and healing process. We applied the radiofrequencies to fistulectomy and compared the early and late results with those obtained from traditional fistulotomy.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '15368794', 'scopus': '2-s2.0-4344702737', 'doi': None}, 'title': 'Radiofrequency fistulectomy vs. diathermic fistulotomy for submucosal fistulas: A randomized trial', 'source': 'Mendeley'}
Zbar AP, Ramesh J, Beer-Gabel M, Salazar R, Pescatori M. Conventional cutting vs. internal anal sphincter-preserving seton for high trans-sphincteric fistula: a prospective randomized manometric and clinical trial. Techniques in coloproctology. 2003;7(2):89-94.	10.1007/s10151-003-0016-6	14605927	primary-study	310dd27afb563bf4cb37cc96c9cbaf1f7bbe04a8	-	{'publication_type': {'year': 2003, 'cited_medium': None, 'issue': '2', 'issn': '1123-6337', 'volume': '7', 'title': 'Techniques in Coloproctology', 'pagination': '89-94'}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.86, 'authors': 0.8399999999999999}, 'authors': [{'given': 'A. P.', 'family': 'Zbar'}, {'given': 'J.', 'family': 'Ramesh'}, {'given': 'M.', 'family': 'Beer-Gabel'}, {'given': 'R.', 'family': 'Salazar'}, {'given': 'M.', 'family': 'Pescatori'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '14605927', 'scopus': None, 'doi': '10.1007/s10151-003-0016-6'}, 'title': 'Conventional cutting vs. internal anal sphincter-preserving seton for high trans-sphincteric fistula: a prospective randomized manometric and clinical trial', 'source': 'CrossRef'}
Zbar AP, Ramesh J, Beer-Gabel M, Salazar R, Pescatori M. Conventional cutting vs. internal anal sphincter-preserving seton for high trans-sphincteric fistula: a prospective randomized manometric and clinical trial. Techniques in coloproctology. 2003;7(2):89-94.	10.1007/s10151-003-0016-6	14605927	primary-study	310dd27afb563bf4cb37cc96c9cbaf1f7bbe04a8	-	{'publication_type': {'year': 2003, 'cited_medium': None, 'issue': None, 'issn': '11236337', 'volume': None, 'title': 'Techniques in Coloproctology', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 1.0, 'total': 0.86, 'authors': 0.8399999999999999}, 'authors': [{'given': 'A. P.', 'family': 'Zbar'}, {'given': 'J.', 'family': 'Ramesh'}, {'given': 'M.', 'family': 'Beer-Gabel'}, {'given': 'R.', 'family': 'Salazar'}, {'given': 'M.', 'family': 'Pescatori'}], 'abstract': 'BACKGROUND: Cutting setons have been used in complicated perirectal sepsis with good effect, although there is a moderately high incidence of fecal leakage after their use. The aim of this study was to compare a modified cutting seton, which repaired the internal anal sphincter muscle and re-routed the seton through the intersphincteric space, with a conventional cutting seton. METHODS: A total of 34 patients were randomized between 1998 and 2002. They were prospectively assessed by continence score and anorectal manometry, and for anal function, clinical sepsis and fistula recurrence. RESULTS: There was no difference in postoperative continence score, incidence of recurrent fistula or healing time between groups after a mean follow-up of 12 months. Resting anal manometric pressures and vector volumes were consistently higher with the modified seton (although not statistically significant), as was the area under the inhibitory curve during elicitation of the rectoanal inhibitory reflex across the full sphincter length. ( p<0.05). CONCLUSION: A larger prospective study of internal anal sphincter-preserving seton use in cryptogenic high transshincteric fistula-in-ano appears justified.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '14605927', 'scopus': '2-s2.0-0041878911', 'doi': '10.1007/s10151-003-0016-6'}, 'title': 'Conventional cutting vs. internal anal sphincter-preserving seton for high trans-sphincteric fistula: A prospective randomized manometric and clinical trial', 'source': 'Mendeley'}
Buchanan GN, Bartram CI, Phillips RK, Gould SW, Halligan S, Rockall TA, Sibbons P, Cohen RG. Efficacy of fibrin sealant in the management of complex anal fistula: a prospective trial. Diseases of the colon and rectum. 2003;46(9):1167-74.	10.1097/01.DCR.0000084408.85802.A2	12972959	primary-study	7b24f1da8eb95f331473f5e9153709776046b1fd	-	{'publication_type': {'year': 2003, 'cited_medium': None, 'issue': '9', 'issn': '0012-3706', 'volume': '46', 'title': 'Diseases of the Colon & Rectum', 'pagination': '1167-1174'}, 'language': None, 'rating': {'year': 0, 'title': 1.0, 'total': 0.875, 'authors': 0.9000000000000001}, 'authors': [{'given': 'Gordon N.', 'family': 'Buchanan'}, {'given': 'Clive I.', 'family': 'Bartram'}, {'given': 'Robin K. S.', 'family': 'Phillips'}, {'given': 'Stuart W. T.', 'family': 'Gould'}, {'given': 'Steve', 'family': 'Halligan'}, {'given': 'Tim A.', 'family': 'Rockall'}, {'given': 'Paul', 'family': 'Sibbons'}, {'given': 'Richard G.', 'family': 'Cohen'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1007/s10350-004-6708-9'}, 'title': 'Efficacy of Fibrin Sealant in the Management of Complex Anal Fistula', 'source': 'CrossRef'}
Buchanan GN, Bartram CI, Phillips RK, Gould SW, Halligan S, Rockall TA, Sibbons P, Cohen RG. Efficacy of fibrin sealant in the management of complex anal fistula: a prospective trial. Diseases of the colon and rectum. 2003;46(9):1167-74.	10.1097/01.DCR.0000084408.85802.A2	12972959	primary-study	7b24f1da8eb95f331473f5e9153709776046b1fd	-	{'publication_type': {'year': 1993, 'cited_medium': None, 'issue': None, 'issn': None, 'volume': None, 'title': 'Hepatology. 1993 Nov; 18(5): 1167-74', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.2727272727272727, 'total': 0.18863636363636363, 'authors': 0.045454545454545456}, 'authors': [{'given': 'W Y', 'family': 'Lui'}, {'given': 'F K', 'family': "P'Eng"}, {'given': 'Y F', 'family': 'Chang'}, {'given': 'T J', 'family': 'Chang'}, {'given': 'T F', 'family': 'Tsai'}, {'given': 'M L', 'family': 'Hsu'}, {'given': 'T S', 'family': 'Su'}, {'given': 'S H', 'family': 'Tsay'}, {'given': 'C W', 'family': 'Wu'}, {'given': 'T Y', 'family': 'Liu'}, {'given': 'Al', 'family': 'Et'}], 'abstract': 'Hepatocellular carcinoma is the leading cause of male cancer death in Taiwan. We have found that the level of glucocorticoid receptor in hepatocellular carcinoma is significantly higher than that in the peritumoral tissue. In this study, we used a rat liver glucocorticoid receptor complementary DNA probe to examine the expression of glucocorticoid receptor gene in 15 paired samples of hepatocellular carcinoma and their peritumoral tissues. No differences in genomic DNA patterns of the glucocorticoid receptor gene were found between the tumor and peritumoral tissues. The amount of glucocorticoid receptor was found to be significantly higher in hepatoma samples than in peritumoral liver samples. The levels of glucocorticoid receptor messenger RNAs were increased in most tumors compared with their peritumoral samples. To examine the function of glucocorticoid receptors in hepatoma, we examined the expression of glucocorticoid receptor and its relation to cell-cycle progression in human HepG2 cells. Using specific monoclonal antibodies and flow cytometric study, we found glucocorticoid receptor to be expressed constitutively in all cell-cycle phases. In addition, hydrocortisone treatment of HepG2 cells resulted in increased expression of glucocorticoid receptors and increased secretion of alpha-fetoprotein. RU-486, a glucocorticoid antagonist, blocked the hydrocortisone effect, indicating that glucocorticoid receptors are functional in HepG2 cells. Taken together, our data suggest that glucocorticoids and their receptors play an important role in the growth of hepatoma.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': None}, 'title': 'Analysis of glucocorticoid receptors in human hepatocellular carcinoma and HepG2 cells.', 'source': 'Mendeley'}
Lindsey I, Smilgin-Humphreys MM, Cunningham C, Mortensen NJ, George BD. A randomized, controlled trial of fibrin glue vs. conventional treatment for anal fistula. Diseases of the colon and rectum. 2002;45(12):1608-15.	10.1097/01.DCR.0000034622.59957.55	12473883	primary-study	489c8d817b3768f497d3d24e60662b656b43050b	-	{'publication_type': {'year': 2002, 'cited_medium': None, 'issue': '12', 'issn': '0012-3706', 'volume': '45', 'title': 'Diseases of the Colon & Rectum', 'pagination': '1608-1615'}, 'language': None, 'rating': {'year': 0, 'title': 1.0, 'total': 0.875, 'authors': 0.9}, 'authors': [{'given': 'Ian', 'family': 'Lindsey'}, {'given': 'M. M.', 'family': 'Smilgin-Humphreys'}, {'given': 'Chris', 'family': 'Cunningham'}, {'given': 'Neil J. M.', 'family': 'Mortensen'}, {'given': 'Bruce D.', 'family': 'George'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1007/s10350-004-7247-0'}, 'title': 'A Randomized, Controlled Trial of Fibrin Glue vs. Conventional Treatment for Anal Fistula', 'source': 'CrossRef'}
Lindsey I, Smilgin-Humphreys MM, Cunningham C, Mortensen NJ, George BD. A randomized, controlled trial of fibrin glue vs. conventional treatment for anal fistula. Diseases of the colon and rectum. 2002;45(12):1608-15.	10.1097/01.DCR.0000034622.59957.55	12473883	primary-study	489c8d817b3768f497d3d24e60662b656b43050b	-	{'publication_type': {'year': 2002, 'cited_medium': None, 'issue': None, 'issn': '0012-3706', 'volume': None, 'title': 'Diseases of the Colon and Rectum', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.775, 'authors': 0.5}, 'authors': [{'given': 'Lindsey', 'family': 'I.'}, {'given': 'Smilgin-Humphreys', 'family': 'M.M.'}, {'given': 'Cunningham', 'family': 'C.'}, {'given': 'Mortensen', 'family': 'N.J.M.'}, {'given': 'George', 'family': 'B.D.'}], 'abstract': "PURPOSE: Fibrin glue is a novel treatment for anal fistulas and possesses many advantages in the treatment of difficult high fistulas. Fibrin glue treatment is simple and repeatable; failure does not compromise further treatment options; and sphincter function is preserved. We aimed to compare the outcomes of patients with low and high anal fistulas randomly assigned to either fibrin glue or conventional treatment. METHODS: Patients with simple fistulas (low fistulas) and complex fistulas (high, Crohn's, and low fistulas with compromised sphincters) were randomly assigned to either fibrin glue or conventional treatment (fistulotomy or loose seton insertion with or without subsequent advancement flap). Patients with rectovaginal fistulas and anal fistulas associated with chronic cavities, acute sepsis, and side branches were excluded. The primary end point was fistula healing. Secondary end points were complications, changes in preoperative continence score, changes in maximum resting and squeeze pressure, satisfaction scores, and pain scores and time off work (simple fistulas only). RESULTS: Patients in the fibrin glue and conventional treatment arms were well matched for gender, median age, duration of fistula symptoms, and follow-up. Fibrin glue healed three (50 percent) of six and fistulotomy seven (100 percent) of seven simple fistulas (difference, 50 percent; confidence interval, 10 to 90 percent; P = 0.06, Fisher's exact probability test). There was no change in baseline incontinence score, maximum resting pressures, or squeeze pressures between the study arms. Return to work was quicker in the glue arm, but pain scores were similar and satisfaction scores higher in the fistulotomy group. Fibrin glue healed 9 (69 percent) of 13 and conventional treatment 2 (13 percent) of 16 complex fistulas (difference, 56 percent; 95 percent confidence interval, 25.9 to 86.1 percent; P = 0.003, Fisher's exact probability test). There was no change in baseline incontinence score, maximum resting pressures, or squeeze pressures in either study arm. Satisfaction scores were higher in the fibrin glue group. CONCLUSIONS: No advantage was found for fibrin glue over fistulotomy for simple fistulas, but fibrin glue healed more complex fistulas than conventional treatment and with higher patient satisfaction.", 'type': 'journal', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': None}, 'title': 'A randomized, controlled trial of fibrin glue vs. conventional treatment for anal fistula', 'source': 'Mendeley'}
Theerapol A, So BY, Ngoi SS. Routine use of setons for the treatment of anal fistulae. Singapore medical journal. 2002;43(6):305-7.	-	12380728	primary-study	59d2f2c3980d0ba1a7d02385756832aabfbd4e70	-	{'publication_type': {'year': 2014, 'cited_medium': None, 'issue': '01', 'issn': '0037-5675', 'volume': '55', 'title': 'Singapore Medical Journal', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.38461538461538464, 'total': 0.3333333333333333, 'authors': 0.3333333333333333}, 'authors': [{'given': 'SS', 'family': 'Karanth'}, {'given': 'A', 'family': 'Gupta'}, {'given': 'MM', 'family': 'Prabhu'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.11622/smedj.2013187'}, 'title': 'Melanonychia and mucocutaneous hyperpigmentation from hydroxyurea use for the treatment of essential thrombocytosis', 'source': 'CrossRef'}
Theerapol A, So BY, Ngoi SS. Routine use of setons for the treatment of anal fistulae. Singapore medical journal. 2002;43(6):305-7.	-	12380728	primary-study	59d2f2c3980d0ba1a7d02385756832aabfbd4e70	-	{'publication_type': {'year': 2002, 'cited_medium': None, 'issue': None, 'issn': '00375675', 'volume': None, 'title': 'Singapore Medical Journal', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.875, 'authors': 0.9}, 'authors': [{'given': 'A.', 'family': 'Theerapol'}, {'given': 'B. Y.', 'family': 'So'}, {'given': 'S. S.', 'family': 'Ngoi'}], 'abstract': 'AIM: Anal fistula is usually treated by either fistulotomy or fistulectomy. We described the routine use of setons to treat anal fistula without any surgery. METHOD: Forty-seven consecutive patients with diagnosed anal fistulae were treated using setons alone. RESULTS: The median age of the patients was 41 (range: 18-70). Of the 47 patients, 15 had surgery previously for fistula and perianal abscess. At least two setons were inserted through each fistula. One was tied tightly to function as a cutting seton and this was sequentially tightened by the patient and another was tied loosely for drainage. Of the 47 patients, 33 (70%) had the placement of setons in the clinic without any anaesthesia. The remaining 14 patients had the setons inserted in the operating room, with one patient having a complex anal fistula and 13 patients having perianal abscess requiring drainage at the same time. There were no post procedure complications in the series. Forty-one patients had completed follow up at clinic within a median duration of 15 weeks (range: two to 67 weeks). The fistula was completely healed by this method in 37 patients (78%). The median healing time was nine weeks (range: four to 62 weeks). One patient developed recurrent fistula and was healed after another seton placement. No patient developed any faecal incontinence and all patients were satisfied with this treatment. CONCLUSION: The routine seton method is safe, cheap and effective in the treatment of anal fistula regardless of type. It does not leave an open wound and most patients are satisfied with the treatment.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '12380728', 'scopus': '2-s2.0-0036594007', 'doi': None}, 'title': 'Routine use of setons for the treatment of anal fistulae.', 'source': 'Mendeley'}
Chan KM, Lau CW, Lai KK, Auyeung MC, Ho LS, Luk HT, Lo KH. Preliminary results of using a commercial fibrin sealant in the treatment of fistula-in-ano. Journal of the Royal College of Surgeons of Edinburgh. 2002;47(1):407-10.	-	11878300	primary-study	580d178e19d3ef8b1e50770491f49112f092f952	-	{'publication_type': {'year': 2014, 'cited_medium': None, 'issue': '1', 'issn': '0035-8843', 'volume': '96', 'title': 'The Annals of The Royal College of Surgeons of England', 'pagination': '80-80'}, 'language': None, 'rating': {'year': 0, 'title': 0.42857142857142855, 'total': 0.3410714285714286, 'authors': 0.25}, 'authors': [{'given': 'NC', 'family': 'Tanner'}, {'given': 'A', 'family': 'Maw'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '24417843', 'scopus': None, 'doi': '10.1308/rcsann.2014.96.1.80'}, 'title': 'A novel technique for negotiation of a complex fistula-in-ano using a flexible ureteral catheter', 'source': 'CrossRef'}
Chan KM, Lau CW, Lai KK, Auyeung MC, Ho LS, Luk HT, Lo KH. Preliminary results of using a commercial fibrin sealant in the treatment of fistula-in-ano. Journal of the Royal College of Surgeons of Edinburgh. 2002;47(1):407-10.	-	11878300	primary-study	580d178e19d3ef8b1e50770491f49112f092f952	-	{'publication_type': {'year': 2002, 'cited_medium': None, 'issue': None, 'issn': '0035-8835 (Print)', 'volume': None, 'title': 'Journal of the Royal College of Surgeons of Edinburgh', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 0.9607142857142857, 'authors': 0.8428571428571429}, 'authors': [{'given': 'K M', 'family': 'Chan'}, {'given': 'C W', 'family': 'Lau'}, {'given': 'K K T', 'family': 'Lai'}, {'given': 'M C', 'family': 'Auyeung'}, {'given': 'L S', 'family': 'Ho'}, {'given': 'H T', 'family': 'Luk'}, {'given': 'K H', 'family': 'Lo'}], 'abstract': 'A prospective non-randomised study fibrin sealant injection to manage patients with fistula-in-ano, with magnetic resonance imaging (MRI) monitoring, was performed during the period 5/6/1999 to 28/2/2000. The aim was to determine whether a fibrin sealant could be used as a treatment modality for anorectal fistula and the usefulness of MRI perineum to monitor the disease activity. Ten patients were included in the study. Mean age was 47 years (range 7 months to 70 years). Male: female ratio was 9:1. Mean follow-up duration was 26.4 weeks. The overall success rate was 60%. The success rate of different fistula types were different (60%, 0%, 100% for intersphincteric, transphincteric, subcutaneous, respectively). Variable decrease in signal on STIR images and contrast enhancement was noted in the patients with successful and failure of fibrin sealant injection. In conclusion, fibrin sealant injection is a useful alternative treatment in the management of fistula-in-ano. MRI is helpful in delineating the anatomy of fistula-in-ano but not a useful tool to follow-up disease activity.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '11878300', 'scopus': '2-s2.0-0036177294', 'doi': None}, 'title': 'Preliminary results of using a commercial fibrin sealant in the treatment of fistula-in-ano.', 'source': 'Mendeley'}
Ho KS, Tsang C, Seow-Choen F, Ho YH, Tang CL, Heah SM, Eu KW. Prospective randomised trial comparing ayurvedic cutting seton and fistulotomy for low fistula-in-ano. Techniques in coloproctology. 2001;5(3):137-41.	10.1007/s101510100015	11875680	primary-study	f9597cb9fd1d26aaf5b0b7906eabd876468bbb47	-	{'publication_type': {'year': 2001, 'cited_medium': None, 'issue': '3', 'issn': '1123-6337', 'volume': '5', 'title': 'Techniques in Coloproctology', 'pagination': '137-141'}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.875, 'authors': 0.9000000000000001}, 'authors': [{'given': 'K. S.', 'family': 'Ho'}, {'given': 'C.', 'family': 'Tsang'}, {'given': 'F.', 'family': 'Seow-Choen'}, {'given': 'Y. H.', 'family': 'Ho'}, {'given': 'C. L.', 'family': 'Tang'}, {'given': 'S. M.', 'family': 'Heah'}, {'given': 'K. W.', 'family': 'Eu'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '11875680', 'scopus': None, 'doi': '10.1007/s101510100015'}, 'title': 'Prospective randomised trial comparing ayurvedic cutting seton and fistulotomy for low fistula-in-ano', 'source': 'CrossRef'}
Ho KS, Tsang C, Seow-Choen F, Ho YH, Tang CL, Heah SM, Eu KW. Prospective randomised trial comparing ayurvedic cutting seton and fistulotomy for low fistula-in-ano. Techniques in coloproctology. 2001;5(3):137-41.	10.1007/s101510100015	11875680	primary-study	f9597cb9fd1d26aaf5b0b7906eabd876468bbb47	-	{'publication_type': {'year': 2001, 'cited_medium': None, 'issue': None, 'issn': '11236337', 'volume': None, 'title': 'Techniques in Coloproctology', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.875, 'authors': 0.9000000000000001}, 'authors': [{'given': 'K. S.', 'family': 'Ho'}, {'given': 'C.', 'family': 'Tsang'}, {'given': 'F.', 'family': 'Seow-Choen'}, {'given': 'Y. H.', 'family': 'Ho'}, {'given': 'C. L.', 'family': 'Tang'}, {'given': 'S. M.', 'family': 'Heah'}, {'given': 'K. W.', 'family': 'Eu'}], 'abstract': 'The aim of this study was to evaluate the role of ayurvedic setons in the treatment of low fistula-in-ano. One hundred and eight patients were randomised into either conventional fistulotomy (F) or ayurvedic cutting seton insertion (C). Endpoints investigated included time to wound healing and complications of surgery. Post-operative pain scores were measured daily using a visual analog scale. Anal function was compared using a continence score. Pre- and postoperative manometry and ultrasound were also performed. After exclusions, there were 54 patients in group F and 46 in group C. There were no differences in age, sex or follow-up duration between the two groups. Healing time was similar between the groups. Group C reported more pain following operation and on the first 2-4 postoperative days, but both groups experienced the same amount of pain subsequently. In conclusion, chemical seton was more painful than conventional fistulotomy in the first few days following surgery. However, there was no difference in time to wound healing, complications or functional outcome.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '11875680', 'scopus': '2-s2.0-0035718176', 'doi': '10.1007/s101510100015'}, 'title': 'Prospective randomised trial comparing ayurvedic cutting seton and fistulotomy for low fistula-in-ano', 'source': 'Mendeley'}
Salim AS, Ahmed TM. KTP-Laser and fibrin glue for treatment of fistulae in ano. Saudi medical journal. 2001;22(11):1022-4.	-	11744979	primary-study	7ac6fd3d0188dd67f74ba6ab11a22fe0984793c8	-	{'publication_type': {'year': 2001, 'cited_medium': None, 'issue': '1', 'issn': '0174-2442', 'volume': '23', 'title': 'coloproctology', 'pagination': '17-21'}, 'language': None, 'rating': {'year': 0, 'title': 0.8888888888888888, 'total': 0.6027777777777777, 'authors': 0.1}, 'authors': [{'given': 'Wael', 'family': 'Khafagy'}, {'given': 'Samir', 'family': 'Zedan'}, {'given': 'Ahmed', 'family': 'Setiet'}, {'given': 'Saleh', 'family': 'El-Awady'}, {'given': 'Mohammed T.', 'family': 'El-Shobaky'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1007/pl00001875'}, 'title': 'Autologous Fibrin Glue in Treatment of Fistula in Ano', 'source': 'CrossRef'}
Salim AS, Ahmed TM. KTP-Laser and fibrin glue for treatment of fistulae in ano. Saudi medical journal. 2001;22(11):1022-4.	-	11744979	primary-study	7ac6fd3d0188dd67f74ba6ab11a22fe0984793c8	-	{'publication_type': {'year': 2001, 'cited_medium': None, 'issue': None, 'issn': '03795284', 'volume': None, 'title': 'Saudi Medical Journal', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.875, 'authors': 0.9}, 'authors': [{'given': 'Aws S.', 'family': 'Salim'}, {'given': 'Talal M.', 'family': 'Ahmed'}], 'abstract': 'Fistulae-in-ano remains a significant surgical problem due to the limitations pertinent to accurate assessment and the magnitude, shortcomings and side effects of the various procedures currently employed for their management. Six consecutive fistulae-in-ano patients (males, age range 30 to 58 years) were successfully treated by KTP laser (20-watt continuous aim for 20 to 30 seconds delivering a total energy of 400 to 600 joules) with rapid solidification fibrin glue then followed up for 3 months without recurrence. This approach offers a simple, expeditious and effective treatment for fistulae-in-ano thereby overcoming many of the restrictions associated with other methods.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '11744979', 'scopus': '2-s2.0-0035213089', 'doi': None}, 'title': 'KTP-Laser and fibrin glue for treatment of fistulae in ano', 'source': 'Mendeley'}
Park JJ, Cintron JR, Orsay CP, Pearl RK, Nelson RL, Sone J, Song R, Abcarian H. Repair of chronic anorectal fistulae using commercial fibrin sealant. Archives of surgery (Chicago, Ill. : 1960). 2000;135(2):166-9.	-	10668875	primary-study	1f9eb4a666e07b32699f4ee2f5a6699d18499efc	-	{'publication_type': {'year': 2000, 'cited_medium': None, 'issue': '2', 'issn': '0004-0010', 'volume': '135', 'title': 'Archives of Surgery', 'pagination': '166'}, 'language': None, 'rating': {'year': 0, 'title': 1.0, 'total': 0.875, 'authors': 0.9}, 'authors': [{'given': 'John J.', 'family': 'Park'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1001/archsurg.135.2.166'}, 'title': 'Repair of Chronic Anorectal Fistulae Using Commercial Fibrin Sealant', 'source': 'CrossRef'}
Park JJ, Cintron JR, Orsay CP, Pearl RK, Nelson RL, Sone J, Song R, Abcarian H. Repair of chronic anorectal fistulae using commercial fibrin sealant. Archives of surgery (Chicago, Ill. : 1960). 2000;135(2):166-9.	-	10668875	primary-study	1f9eb4a666e07b32699f4ee2f5a6699d18499efc	-	{'publication_type': {'year': 1997, 'cited_medium': None, 'issue': None, 'issn': '0003-9950', 'volume': None, 'title': 'Archives of ophthalmology (Chicago, Ill.: 1960)', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.2, 'total': 0.13, 'authors': 0.0}, 'authors': [{'given': 'P P', 'family': 'Chen'}, {'given': 'S J', 'family': 'Gedde'}, {'given': 'D L', 'family': 'Budenz'}, {'given': 'R K 2.', 'family': 'Parrish'}], 'abstract': 'OBJECTIVE: To determine the outcome of outpatient treatment of bleb infection after trabeculectomy., DESIGN: Retrospective review., SETTING: University referral center., PATIENTS: Twelve eyes with bleb infection and without clinical vitreous involvement of 11 patients treated as out-patients from January 1994 to May 1996., INTERVENTIONS: After culture of the bleb surface, treatment consisted of intensive topical antibiotics alone (9 eyes), combined with subconjunctival antibiotic injection (1 eye), oral antibiotics (1 eye), or both (1 eye). Five eyes received topical corticosteroids., MAIN OUTCOME MEASURES: Visual acuity, intraocular pressure, and bleb characteristics., RESULTS: All eyes responded to treatment within 24 to 48 hours, and recovered visual acuity to within 1 line of the preinfection level. Intraocular pressure continued to be controlled after resolution of infection in 11 eyes (92%); 1 bleb failed and medical therapy was resumed. Bleb leaks were noted during treatment of infection in 11 eyes, and 5 eyes (42%) underwent bleb revision. Organisms cultured from the bleb surface included Staphylococcus aureus (8 eyes), Haemophilus influenzae (2 eyes), and Streptococcus (1 eye). Outpatient treatment costs were estimated to be 78% less than inpatient treatment costs, per 24 hours., CONCLUSION: Outpatient treatment of bleb infection was efficacious in this group of patients.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': None}, 'title': 'Outpatient treatment of bleb infection', 'source': 'Mendeley'}
Cintron JR, Park JJ, Orsay CP, Pearl RK, Nelson RL, Abcarian H. Repair of fistulas-in-ano using autologous fibrin tissue adhesive. Diseases of the colon and rectum. 1999;42(5):607-13.	-	10344682	primary-study	57472f788d62686d0915f12cb21e587dffb6d095	-	{'publication_type': {'year': 1999, 'cited_medium': None, 'issue': '5', 'issn': '0012-3706', 'volume': '42', 'title': 'Diseases of the Colon & Rectum', 'pagination': '607-613'}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.8791666666666667, 'authors': 0.9166666666666666}, 'authors': [{'given': 'Jose R.', 'family': 'Cintron'}, {'given': 'John J.', 'family': 'Park'}, {'given': 'Charles P.', 'family': 'Orsay'}, {'given': 'Russell K.', 'family': 'Pearl'}, {'given': 'Richard L.', 'family': 'Nelson'}, {'given': 'Herand', 'family': 'Abcarian'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1007/bf02234135'}, 'title': 'Repair of fistulas-in-ano using autologous fibrin tissue adhesive', 'source': 'CrossRef'}
Cintron JR, Park JJ, Orsay CP, Pearl RK, Nelson RL, Abcarian H. Repair of fistulas-in-ano using autologous fibrin tissue adhesive. Diseases of the colon and rectum. 1999;42(5):607-13.	-	10344682	primary-study	57472f788d62686d0915f12cb21e587dffb6d095	-	{'publication_type': {'year': 1999, 'cited_medium': None, 'issue': None, 'issn': '00123706', 'volume': None, 'title': 'Diseases of the Colon and Rectum', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.8791666666666667, 'authors': 0.9166666666666666}, 'authors': [{'given': 'Jose R.', 'family': 'Cintron'}, {'given': 'John J.', 'family': 'Park'}, {'given': 'Charles P.', 'family': 'Orsay'}, {'given': 'Russell K.', 'family': 'Pearl'}, {'given': 'Richard L.', 'family': 'Nelson'}, {'given': 'Herand', 'family': 'Abcarian'}], 'abstract': "PURPOSE: Our goal was to determine if autologous fibrin tissue adhesive derived from the precipitation of fibrinogen using a combination of ethanol and freezing, could be used to completely close both simple and complex fistulas-in-ano. METHODS: A 26-patient pilot study was performed in which 100 ml of a patient's blood was drawn 90 minutes before surgery. Autologous fibrin tissue adhesive was prepared. In the operating room the patient underwent an examination under anesthesia, and the primary and secondary fistula tract openings were attempted to be identified. The fistula tract was curetted, and autologous fibrin tissue adhesive was injected into the secondary fistula tract opening until fibrin glue was seen coming from the primary opening. A petroleum jelly gauze was then applied over the secondary opening, and the patient was sent home. Follow-up visits were scheduled for one week, one month, three months, and one year later. RESULTS: Twenty-six patients received autologous fibrin tissue adhesive fistula injections, with a mean follow-up of 3.5 months. Initial results were encouraging. Twenty-one of 26 patients (81 percent) had successful initial closure of their fistulas. Two of five failures were injected a second time, and one closed, giving an overall successful closure rate of 85 percent (22/26 patients). Of five patients who failed, mean time to failure was 3.8 weeks. In addition, there was no evidence of infection or complications related to the procedure. CONCLUSION: Our initial results are optimistic and require further support through longer follow-up data. Fibrin glue treatment of anorectal fistulas offers a unique mode of management that is safe, simple, and easy for the surgeon to perform. By using autologous fibrin tissue adhesive the patient avoids the risk of anal incontinence and the discomfort of prolonged wound healing which may be associated with fistulotomy.", 'type': 'journal', 'ids': {'embase': None, 'pubmed': '10344682', 'scopus': '2-s2.0-0032965331', 'doi': '10.1007/BF02234135'}, 'title': 'Repair of fistulas-in-ano using autologous fibrin tissue adhesive', 'source': 'Mendeley'}
Ho YH, Tan M, Leong AF, Seow-Choen F. Marsupialization of fistulotomy wounds improves healing: a randomized controlled trial. The British journal of surgery. 1998;85(1):105-7.	10.1046/j.1365-2168.1998.00529.x	9462396	primary-study	4ffa70dfa8dbd7cc63e0fc0a9e53e6bcfc5c49aa	-	{'publication_type': {'year': 1998, 'cited_medium': None, 'issue': '1', 'issn': '0007-1323', 'volume': '85', 'title': 'British Journal of Surgery', 'pagination': '105-107'}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.875, 'authors': 0.9}, 'authors': [{'given': None, 'family': 'HO'}, {'given': None, 'family': 'Tan'}, {'given': None, 'family': 'Leong'}, {'given': None, 'family': 'Seow-Choen'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '9462396', 'scopus': None, 'doi': '10.1046/j.1365-2168.1998.00529.x'}, 'title': 'Marsupialization of fistulotomy wounds improves healing: a randomized controlled trial', 'source': 'CrossRef'}
Ho YH, Tan M, Leong AF, Seow-Choen F. Marsupialization of fistulotomy wounds improves healing: a randomized controlled trial. The British journal of surgery. 1998;85(1):105-7.	10.1046/j.1365-2168.1998.00529.x	9462396	primary-study	4ffa70dfa8dbd7cc63e0fc0a9e53e6bcfc5c49aa	-	{'publication_type': {'year': 1998, 'cited_medium': None, 'issue': None, 'issn': '00071323', 'volume': None, 'title': 'British Journal of Surgery', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 1.0, 'total': 0.8812500000000001, 'authors': 0.925}, 'authors': [{'given': 'Y. H.', 'family': 'Ho'}, {'given': 'M.', 'family': 'Tan'}, {'given': 'A. F P K', 'family': 'Leong'}, {'given': 'F.', 'family': 'Seow-Choen'}], 'abstract': 'BACKGROUND: Marsupialization of anal fistulotomy wounds leaves less raw unepithelialized tissue to granulate and may improve wound healing. METHODS: Some 103 consecutive patients with uncomplicated intersphincteric or trans-sphincteric fistula in ano were recruited into a randomized controlled trial. Fistula tracts were identified and laid open under general anaesthesia. The patients were randomized to have either the wounds left open (LO group) or wound edges marsupialized to the fistula tract with interrupted absorbable sutures (MS group). Anal manometry was performed before operation, and 6 weeks and 3 months after surgery. RESULTS: Some 52 patients were randomized to the LO group and 51 to the MS group. There were no differences in the age, sex, fistula type and fistula length distribution between the groups. Mean follow-up times were 9 and 10.2 months respectively. Wounds in the MS group healed faster (mean(s.e.m.) 6.0 (0.4) weeks) than those in the LO group (10.0(0.5) weeks) (P < 0.001). Only one patient (2 per cent) in the MS group was incontinent of liquids after operation compared with six (12 per cent) in the LO group. There was less impairment in maximum anal squeeze pressure at 3 months after marsupialization compared with leaving fistulotomy wounds open (P < 0.05). Apart from a slightly longer operative time required for marsupialization, the hospitalization and complication rates were the same. CONCLUSION: Anal fistulotomy wounds healed faster after marsupialization. Anal squeeze pressures were better preserved and this may improve anal continence.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '9462396', 'scopus': '2-s2.0-0031962753', 'doi': '10.1046/j.1365-2168.1998.00529.x'}, 'title': 'Marsupialization of fistulotomy wounds improves healing: A randomized controlled trial', 'source': 'Mendeley'}
Kronborg O. To lay open or excise a fistula-in-ano: a randomized trial. The British journal of surgery. 1985;72(12):970.	10.1002/bjs.1800721211	3910159	primary-study	464ca996a8c55e543279b928d72b4d2eba1ab31c	-	{'publication_type': {'year': 1985, 'cited_medium': None, 'issue': '12', 'issn': '0007-1323', 'volume': '72', 'title': 'British Journal of Surgery', 'pagination': '970-970'}, 'language': None, 'rating': {'year': 0, 'title': 0.9, 'total': 0.8350000000000001, 'authors': 1.0}, 'authors': [{'given': 'O.', 'family': 'Kronborg'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1002/bjs.1800721211'}, 'title': 'To lay open or excise a fistula-inano: a randomized trial', 'source': 'CrossRef'}
Kronborg O. To lay open or excise a fistula-in-ano: a randomized trial. The British journal of surgery. 1985;72(12):970.	10.1002/bjs.1800721211	3910159	primary-study	464ca996a8c55e543279b928d72b4d2eba1ab31c	-	{'publication_type': {'year': 1985, 'cited_medium': None, 'issue': None, 'issn': '13652168', 'volume': None, 'title': 'British Journal of Surgery', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.9, 'total': 0.8350000000000001, 'authors': 1.0}, 'authors': [{'given': 'O.', 'family': 'Kronborg'}], 'abstract': 'Two treatments for fistula-in-ano were compared in a randomized trial. Times of healing were significantly shorter when the fistula was laid open (median 34 days, n = 26) than after excision (41 days, n = 21) (P less than 0.02). Revisional surgery was necessary before healing could be obtained in 3 of 26 patients after lay open operations and 2 of 21 after excision. Recurrence rates within 1 year were similar (3/24 and 2/21).', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '3910159', 'scopus': '2-s2.0-0022399432', 'doi': '10.1002/bjs.1800721211'}, 'title': 'To lay open or excise a fistula???inano: a randomized trial', 'source': 'Mendeley'}
Berthold F, Boos J, Burdach S, Erttmann R, Henze G, Hermann J, Klingebiel T, Kremens B, Schilling FH, Schrappe M, Simon T, Hero B. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. The lancet oncology. 2005;6(9):649-58.	10.1016/S1470-2045(05)70291-6	16129365	primary-study	186c1613abb045573949d866bef260e1afd3b57c	-	{'publication_type': {'year': 2005, 'cited_medium': None, 'issue': '9', 'issn': '1470-2045', 'volume': '6', 'title': 'The Lancet Oncology', 'pagination': '649-658'}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.8770833333333334, 'authors': 0.9083333333333335}, 'authors': [{'given': 'Frank', 'family': 'Berthold'}, {'given': 'Joachim', 'family': 'Boos'}, {'given': 'Stefan', 'family': 'Burdach'}, {'given': 'Rudolf', 'family': 'Erttmann'}, {'given': 'Günter', 'family': 'Henze'}, {'given': 'Johann', 'family': 'Hermann'}, {'given': 'Thomas', 'family': 'Klingebiel'}, {'given': 'Bernhard', 'family': 'Kremens'}, {'given': 'Freimut H', 'family': 'Schilling'}, {'given': 'Martin', 'family': 'Schrappe'}, {'given': 'Thorsten', 'family': 'Simon'}, {'given': 'Barbara', 'family': 'Hero'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1016/s1470-2045(05)70291-6'}, 'title': 'Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial', 'source': 'CrossRef'}
Berthold F, Boos J, Burdach S, Erttmann R, Henze G, Hermann J, Klingebiel T, Kremens B, Schilling FH, Schrappe M, Simon T, Hero B. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. The lancet oncology. 2005;6(9):649-58.	10.1016/S1470-2045(05)70291-6	16129365	primary-study	186c1613abb045573949d866bef260e1afd3b57c	-	{'publication_type': {'year': 2005, 'cited_medium': None, 'issue': None, 'issn': '14702045', 'volume': None, 'title': 'Lancet Oncology', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 1.0, 'total': 0.8770833333333334, 'authors': 0.9083333333333335}, 'authors': [{'given': 'Frank', 'family': 'Berthold'}, {'given': 'Joachim', 'family': 'Boos'}, {'given': 'Stefan', 'family': 'Burdach'}, {'given': 'Rudolf', 'family': 'Erttmann'}, {'given': 'Günter', 'family': 'Henze'}, {'given': 'Johann', 'family': 'Hermann'}, {'given': 'Thomas', 'family': 'Klingebiel'}, {'given': 'Bernhard', 'family': 'Kremens'}, {'given': 'Freimut H.', 'family': 'Schilling'}, {'given': 'Martin', 'family': 'Schrappe'}, {'given': 'Thorsten', 'family': 'Simon'}, {'given': 'Barbara', 'family': 'Hero'}], 'abstract': 'Background: Myeloablative megatherapy is commonly used to improve the poor outlook of children with high-risk neuroblastoma, yet its role is poorly defined. We aimed to assess whether megatherapy with autologous stem-cell transplantation could increase event-free survival and overall survival compared with maintenance chemotherapy. Methods: 295 patients with high-risk neuroblastoma (ie, patients with stage 4 disease aged older than 1 year or those with MYCN-amplified tumours and stage 1, 2, 3, or 4S disease or stage 4 disease and <1 year old) were randomly assigned to myeloablative megatherapy (melphalan, etoposide, and carboplatin) with autologous stem-cell transplantation (n=149) or to oral maintenance chemotherapy with cyclophosphamide (n=146). The primary endpoint was event-free survival. Secondary endpoints were overall survival and the number of treatment-related deaths. Analyses were done by intent to treat, as treated, and treated as randomised. Findings: Intention-to-treat analysis showed that patients allocated megatherapy had increased 3-year event-free survival compared with those allocated maintenance therapy (47% [95% CI 38-55] vs 31% [95% CI 23-39]; hazard ratio 1·404 [95% CI 1·048-1·881], p=0·0221), but did not have significantly increased 3-year overall survival (62% [95% CI 54-70] vs 53% [95% CI 45-62]; 1·329 [0·958-1·843], p=0·0875). Improved 3-year event-free survival and 3-year overall survival were also recorded for patients given megatherapy in the as-treated group (n=212) and in the treated-as-randomised group (n=145). Two patients died from therapy-related complications during induction treatment. No patients given maintenance therapy died from acute treatment-related toxic effects. Five patients given megatherapy died from acute complications related to megatherapy. Interpretation: Myeloablative chemotherapy with autologous stem-cell transplantation improves the outcome for children with high-risk neuroblastoma despite the raised risk of treatment-associated death.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '16129365', 'scopus': '2-s2.0-24044487906', 'doi': '10.1016/S1470-2045(05)70291-6'}, 'title': 'Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: A randomised controlled trial', 'source': 'Mendeley'}
Pritchard J, Cotterill SJ, Germond SM, Imeson J, de Kraker J, Jones DR. High dose melphalan in the treatment of advanced neuroblastoma: results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group. Pediatric blood & cancer. 2005;44(4):348-57.	10.1002/pbc.20219	15546135	primary-study	bc747cabd435ee777bb9fd398b03274b2d2d6dd5	-	{'publication_type': {'year': 2005, 'cited_medium': None, 'issue': '4', 'issn': '1545-5009', 'volume': '44', 'title': 'Pediatric Blood & Cancer', 'pagination': '348-357'}, 'language': None, 'rating': {'year': 0, 'title': 1.0, 'total': 0.8583333333333334, 'authors': 0.8333333333333334}, 'authors': [{'given': 'Jon', 'family': 'Pritchard'}, {'given': 'Simon J.', 'family': 'Cotterill'}, {'given': 'Shirley M.', 'family': 'Germond'}, {'given': 'John', 'family': 'Imeson'}, {'given': 'Jan', 'family': 'de Kraker'}, {'given': 'David R.', 'family': 'Jones'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '15546135', 'scopus': None, 'doi': '10.1002/pbc.20219'}, 'title': 'High dose melphalan in the treatment of advanced neuroblastoma: Results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group', 'source': 'CrossRef'}
Pritchard J, Cotterill SJ, Germond SM, Imeson J, de Kraker J, Jones DR. High dose melphalan in the treatment of advanced neuroblastoma: results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group. Pediatric blood & cancer. 2005;44(4):348-57.	10.1002/pbc.20219	15546135	primary-study	bc747cabd435ee777bb9fd398b03274b2d2d6dd5	-	{'publication_type': {'year': 2005, 'cited_medium': None, 'issue': None, 'issn': '15455009', 'volume': None, 'title': 'Pediatric Blood and Cancer', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 1.0, 'total': 0.8583333333333334, 'authors': 0.8333333333333334}, 'authors': [{'given': 'Jon', 'family': 'Pritchard'}, {'given': 'Simon J.', 'family': 'Cotterill'}, {'given': 'Shirley M.', 'family': 'Germond'}, {'given': 'John', 'family': 'Imeson'}, {'given': 'Jan', 'family': 'De Kraker'}, {'given': 'David R.', 'family': 'Jones'}], 'abstract': 'BACKGROUND: High dose myeloablative chemotherapy ("megatherapy"), with haematopoietic stem cell support, is now widely used to consolidate response to induction chemotherapy in patients with advanced neuroblastoma. PROCEDURE: In this study (European Neuroblastoma Study Group, ENSG1), the value of melphalan myeloablative "megatherapy" was evaluated in a randomised, multi-centre trial. Between 1982 and 1985, 167 children with stages IV and III neuroblastoma (123 stage IV > 1 year old at diagnosis and 44 stage III and stage IV from 6 to 12 months old at diagnosis) were treated with oncovin, cisplatin, epipodophyllotoxin, and cyclophosphamide (OPEC) induction chemotherapy every 3 weeks. After surgical excision of primary tumour, the 90 patients (69% of the total) who achieved complete response (CR) or good partial response (GPR) were eligible for randomisation either to high dose melphalan (180 mg per square meter) with autologous bone marrow support or to no further treatment. RESULTS: Sixty-five (72%) of eligible children were actually randomised and 21 of these patients were surviving at time of this analysis, with median follow-up from randomisation of 14.3 years. Five year event-free survival (EFS) was 38% (95% confidence interval (CI) 21-54%) in the melphalan-treated group and 27% (95% CI 12-42%) in the "no-melphalan" group. This difference was not statistically significant (P = 0.08, log rank test) but for the 48 randomised stage IV patients aged >1 year at diagnosis outcome was significantly better in the melphalan-treated group-5 year EFS 33% versus 17% (P = 0.01, log rank test). CONCLUSIONS: In this trial, high dose melphalan improved the length of EFS and overall survival of children with stage IV neuroblastoma >1 year of age who achieved CR or GPR after OPEC induction therapy and surgery. Multi-agent myeloablative regimens are now widely used as consolidation therapy for children with stage IV disease and in those with other disease stages when the MYCN gene copy number in tumour cells is amplified. Because they are more toxic, complex, and costly these combination megatherapy regimens should be compared with single agent melphalan in randomised clinical trials.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '15546135', 'scopus': '2-s2.0-14644397910', 'doi': '10.1002/pbc.20219'}, 'title': 'High dose melphalan in the treatment of advanced neuroblastoma: Results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group', 'source': 'Mendeley'}
Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, Gerbing RB, Reynolds CP. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. The New England journal of medicine. 1999;341(16):1165-73.	10.1056/NEJM199910143411601	10519894	primary-study	fb2948507ad68db43e551fc444fb786f31830862	-	{'publication_type': {'year': 1999, 'cited_medium': None, 'issue': '16', 'issn': '0028-4793', 'volume': '341', 'title': 'New England Journal of Medicine', 'pagination': '1165-1173'}, 'language': None, 'rating': {'year': 0, 'title': 1.0, 'total': 0.8750000000000001, 'authors': 0.9000000000000002}, 'authors': [{'given': 'Katherine K.', 'family': 'Matthay'}, {'given': 'Judith G.', 'family': 'Villablanca'}, {'given': 'Robert C.', 'family': 'Seeger'}, {'given': 'Daniel O.', 'family': 'Stram'}, {'given': 'Richard E.', 'family': 'Harris'}, {'given': 'Norma K.', 'family': 'Ramsay'}, {'given': 'Patrick', 'family': 'Swift'}, {'given': 'Hiroyuki', 'family': 'Shimada'}, {'given': 'C. Thomas', 'family': 'Black'}, {'given': 'Garrett M.', 'family': 'Brodeur'}, {'given': 'Robert B.', 'family': 'Gerbing'}, {'given': 'C. Patrick', 'family': 'Reynolds'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1056/nejm199910143411601'}, 'title': ' Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13- cis -Retinoic Acid ', 'source': 'CrossRef'}
Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, Gerbing RB, Reynolds CP. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. The New England journal of medicine. 1999;341(16):1165-73.	10.1056/NEJM199910143411601	10519894	primary-study	fb2948507ad68db43e551fc444fb786f31830862	-	{'publication_type': {'year': 1999, 'cited_medium': None, 'issue': None, 'issn': None, 'volume': None, 'title': 'New England journal of medicine', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 0.75, 'authors': 0.0}, 'authors': [{'given': 'Villablanca J G', 'family': 'Matthay KK  Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, Gerbing RB, Reynolds CP'}], 'abstract': 'BACKGROUND: Children with high-risk neuroblastoma have a poor outcome. In this study, we assessed whether myeloablative therapy in conjunction with transplantation of autologous bone marrow improved event-free survival as compared with chemotherapy alone, and whether subsequent treatment with 13-cis-retinoic acid (isotretinoin) further improves event-free survival.,  METHODS: All patients were treated with the same initial regimen of chemotherapy, and those without disease progression were then randomly assigned to receive continued treatment with myeloablative chemotherapy, total-body irradiation, and transplantation of autologous bone marrow purged of neuroblastoma cells or to receive three cycles of intensive chemotherapy alone. All patients who completed cytotoxic therapy without disease progression were then randomly assigned to receive no further therapy or treatment with 13-cis-retinoic acid for six months.,  RESULTS: The mean (+/-SE) event-free survival rate three years after the first randomization was significantly better among the 189 patients who were assigned to undergo transplantation than among the 190 patients assigned to receive continuation chemotherapy (34+/-4 percent vs. 22+/-4 percent, P=0.034). The event-free survival rate three years after the second randomization was significantly better among the 130 patients who were assigned to receive 13-cis-retinoic acid than among the 128 patients assigned to receive no further therapy (46+/-6 percent vs. 29+/-5 percent, P=0.027).,  CONCLUSIONS: Treatment with myeloablative therapy and autologous bone marrow transplantation improved event-free survival among children with high-risk neuroblastoma. In addition, treatment with 13-cis-retinoic acid was beneficial for patients without progressive disease when it was administered after chemotherapy or transplantation.', 'type': 'generic', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': None}, 'title': "Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group.", 'source': 'Mendeley'}
Bailey W, Castro M, Matz J, White M, Dransfield M, Yancey S, Ortega H. Asthma exacerbations in African Americans treated for 1 year with combination fluticasone propionate and salmeterol or fluticasone propionate alone. Current medical research and opinion. 2008;24(6):1669-82.	10.1185/03007990802119111	18462564	primary-study	f6f193f5c87eff74f0691d619daca4c52dc8d3e9	-	{'publication_type': {'year': 2008, 'cited_medium': None, 'issue': '6', 'issn': '0300-7995', 'volume': '24', 'title': 'Current Medical Research and Opinion', 'pagination': '1669-1682'}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.8785714285714286, 'authors': 0.9142857142857144}, 'authors': [{'given': 'William', 'family': 'Bailey'}, {'given': 'Mario', 'family': 'Castro'}, {'given': 'Jonathan', 'family': 'Matz'}, {'given': 'Martha', 'family': 'White'}, {'given': 'Mark', 'family': 'Dransfield'}, {'given': 'Steve', 'family': 'Yancey'}, {'given': 'Hector', 'family': 'Ortega'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '18462564', 'scopus': None, 'doi': '10.1185/03007990802119111'}, 'title': 'Asthma exacerbations in African Americans treated for 1 year with combination fluticasone propionate and salmeterol or fluticasone propionate alone', 'source': 'CrossRef'}
Bailey W, Castro M, Matz J, White M, Dransfield M, Yancey S, Ortega H. Asthma exacerbations in African Americans treated for 1 year with combination fluticasone propionate and salmeterol or fluticasone propionate alone. Current medical research and opinion. 2008;24(6):1669-82.	10.1185/03007990802119111	18462564	primary-study	f6f193f5c87eff74f0691d619daca4c52dc8d3e9	-	{'publication_type': {'year': 2008, 'cited_medium': None, 'issue': None, 'issn': '1473-4877', 'volume': None, 'title': 'Current medical research and opinion', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 0.9785714285714285, 'authors': 0.9142857142857144}, 'authors': [{'given': 'William', 'family': 'Bailey'}, {'given': 'Mario', 'family': 'Castro'}, {'given': 'Jonathan', 'family': 'Matz'}, {'given': 'Martha', 'family': 'White'}, {'given': 'Mark', 'family': 'Dransfield'}, {'given': 'Steve', 'family': 'Yancey'}, {'given': 'Hector', 'family': 'Ortega'}], 'abstract': 'OBJECTIVE: This long-term prospective study was conducted in African Americans with persistent asthma to examine the safety and effectiveness of the combination of the inhaled corticosteroid, fluticasone propionate (FP), and the long-acting beta-agonist, salmeterol, compared with FP alone.\\n\\nRESEARCH AND DESIGN METHODS: This was a randomized, double-blind, parallel group, multi-center trial in adolescent and adult subjects >/=12 years of age symptomatic on a low dose of an inhaled corticosteroid (ICS). The study consisted of a 2-week screening period on low dose ICS; a 4-week open-label FP 250 mcg twice daily (BID) run-in; a 52-week double-blind period (FP/salmeterol [FSC] 100/50 mcg [n=239] or FP 100 mcg [n=236] BID), and a 4-week FP 250 mcg BID run-out period. Annualized exacerbation rate was the primary outcome for comparing the two treatments. Other measures of asthma control included peak expiratory flow, asthma symptoms, and albuterol use. Safety was assessed through adverse events.\\n\\nRESULTS: Exacerbation rates were not significantly different in those treated with FSC 100/50 mcg (0.449 per year) compared with FP 100 mcg (0.529 per year, p=0.169). When the per-protocol analysis was applied, the rates were 0.465 and 0.769 per year for FSC 100/50 mcg and FP 100 mcg, respectively. Treatment with FSC 100/50 mcg provided statistically greater improvements in lung function measures and nighttime awakenings (p</=0.050) and demonstrated numerically lower daily symptoms (p=0.216) and albuterol use (p=0.122). Two subjects treated with FSC 100/50 mcg were hospitalized for an asthma exacerbation compared to three treated with FP 100 mcg. The overall incidence of adverse effects during double-blind treatment was similar between the FSC 100/50 mcg and FP 100 mcg treatment groups (61% and 68%, respectively). Frequent study visits were required of subjects during this long-term study, and it remains unknown whether this intervention may affect generalizability.\\n\\nCONCLUSION: In this large, prospective study among African Americans with asthma, the addition of salmeterol to FP resulted in a similar low rate of exacerbations and improved other markers of asthma control. Both FSC 100/50 mcg and FP 100 mcg were well-tolerated, and the overall safety-profiles were similar over 1 year of treatment.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '18462564', 'scopus': '2-s2.0-46449109674', 'doi': '10.1185/03007990802119111'}, 'title': 'Asthma exacerbations in African Americans treated for 1 year with combination fluticasone propionate and salmeterol or fluticasone propionate alone.', 'source': 'Mendeley'}
Houghton CM, Lawson N, Borrill ZL, Wixon CL, Yoxall S, Langley SJ, Woodcock A, Singh D. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory research. 2007;8:52.	10.1186/1465-9921-8-52	17629923	primary-study	384c9b0054d952532c6878fac156a5ddf279e8c2	-	{'publication_type': {'year': 2007, 'cited_medium': None, 'issue': '1', 'issn': '1465-993X', 'volume': '8', 'title': 'Respiratory Research', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.878125, 'authors': 0.9125000000000001}, 'authors': [{'given': 'Catherine M', 'family': 'Houghton'}, {'given': 'Naomi', 'family': 'Lawson'}, {'given': 'Zoe L', 'family': 'Borrill'}, {'given': 'Claire L', 'family': 'Wixon'}, {'given': 'Sally', 'family': 'Yoxall'}, {'given': 'Stephen J', 'family': 'Langley'}, {'given': 'Ashley', 'family': 'Woodcock'}, {'given': 'Dave', 'family': 'Singh'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '17629923', 'scopus': None, 'doi': '10.1186/1465-9921-8-52'}, 'title': 'Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma', 'source': 'CrossRef'}
Houghton CM, Lawson N, Borrill ZL, Wixon CL, Yoxall S, Langley SJ, Woodcock A, Singh D. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory research. 2007;8:52.	10.1186/1465-9921-8-52	17629923	primary-study	384c9b0054d952532c6878fac156a5ddf279e8c2	-	{'publication_type': {'year': 2007, 'cited_medium': None, 'issue': None, 'issn': '1465-993X', 'volume': None, 'title': 'Respiratory research', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 0.978125, 'authors': 0.9125000000000001}, 'authors': [{'given': 'Catherine M', 'family': 'Houghton'}, {'given': 'Naomi', 'family': 'Lawson'}, {'given': 'Zoe L', 'family': 'Borrill'}, {'given': 'Claire L', 'family': 'Wixon'}, {'given': 'Sally', 'family': 'Yoxall'}, {'given': 'Stephen J', 'family': 'Langley'}, {'given': 'Ashley', 'family': 'Woodcock'}, {'given': 'Dave', 'family': 'Singh'}], 'abstract': 'BACKGROUND: This study compared the effect of inhaled fluticasone propionate (FP) with the combination of salmeterol/fluticasone propionate (SFC) on lung function parameters in patients with mild asthma.\\n\\nMETHODS: Adult patients with mild persistent asthma (> or = 80% predicted FEV1) receiving 200-500 mug of BDP or equivalent were randomised to receive either FP 100 mug or SFC 50/100 mug twice daily from a Diskus inhaler for four weeks. The primary outcome was the change from baseline in airway resistance (sRaw) at 12 hrs post dose measured by whole body plethysmography. Impulse oscillometry and spirometry were also performed.\\n\\nRESULTS: A comparison of the geometric mean sRaw at 12 hrs post dose in the SFC group to the FP group gave a ratio of 0.76 (0.66 - 0.89, p < 0.001) at week 2 and 0.81 (0.71 - 0.94, p = 0.006) at week 4. Similarly, significant results in favour of SFC for oscillometry measurements of resistance and reactance were observed. FEV1 was also significantly superior at week 2 in the SFC group (mean difference 0.16L, 95% CI; 0.03 - 0.28, p = 0.015), but not at week 4 (mean difference 0.17L, 95% CI -0.01 - 0.34, p = 0.060).\\n\\nCONCLUSION: SFC is superior to FP in reducing airway resistance in mild asthmatics with near normal FEV1 values. This study provides evidence that changes in pulmonary function in patients with mild asthma are detected more sensitively by plethysmography compared to spirometry\\n\\nTRIAL REGISTRATION NUMBER: NCT00370591.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '17629923', 'scopus': '2-s2.0-34848901107', 'doi': '10.1186/1465-9921-8-52'}, 'title': 'Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma.', 'source': 'Mendeley'}
Morice AH, Peterson S, Beckman O, Kukova Z. Efficacy and safety of a new pressurised metered-dose inhaler formulation of budesonide/formoterol in children with asthma: a superiority and therapeutic equivalence study. Pulmonary pharmacology & therapeutics. 2008;21(1):152-9.	10.1016/j.pupt.2007.01.006	17376722	primary-study	13061c48d02ce694a4520bbbf069fdea55d0ae89	-	{'publication_type': {'year': 2008, 'cited_medium': None, 'issue': '1', 'issn': '1094-5539', 'volume': '21', 'title': 'Pulmonary Pharmacology & Therapeutics', 'pagination': '152-159'}, 'language': None, 'rating': {'year': 0, 'title': 1.0, 'total': 0.8812500000000001, 'authors': 0.925}, 'authors': [{'given': 'Alyn H.', 'family': 'Morice'}, {'given': 'Stefan', 'family': 'Peterson'}, {'given': 'Ola', 'family': 'Beckman'}, {'given': 'Zuzana', 'family': 'Kukova'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '17376722', 'scopus': None, 'doi': '10.1016/j.pupt.2007.01.006'}, 'title': 'Efficacy and safety of a new pressurised metered-dose inhaler formulation of budesonide/formoterol in children with asthma: A superiority and therapeutic equivalence study', 'source': 'CrossRef'}
Morice AH, Peterson S, Beckman O, Kukova Z. Efficacy and safety of a new pressurised metered-dose inhaler formulation of budesonide/formoterol in children with asthma: a superiority and therapeutic equivalence study. Pulmonary pharmacology & therapeutics. 2008;21(1):152-9.	10.1016/j.pupt.2007.01.006	17376722	primary-study	13061c48d02ce694a4520bbbf069fdea55d0ae89	-	{'publication_type': {'year': 2008, 'cited_medium': None, 'issue': None, 'issn': '10945539', 'volume': None, 'title': 'Pulmonary Pharmacology and Therapeutics', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 1.0, 'total': 0.8812500000000001, 'authors': 0.925}, 'authors': [{'given': 'Alyn H.', 'family': 'Morice'}, {'given': 'Stefan', 'family': 'Peterson'}, {'given': 'Ola', 'family': 'Beckman'}, {'given': 'Zuzana', 'family': 'Kukova'}], 'abstract': 'Aim: This paediatric asthma study evaluated the efficacy and safety of a novel hydrofluoroalkane pressurised metered-dose inhaler (pMDI) formulation of budesonide/formoterol versus budesonide pMDI and budesonide/formoterol dry-powder inhaler (DPI). Methods: The study was a 12-week, multinational, double-blind trial involving children (aged 6-11 years) with symptomatic asthma on inhaled corticosteroids (375 - 1000 ?? g / day), with a history of exercise-induced bronchoconstriction and peak expiratory flow (PEF) ??? 50 % of predicted. Patients were randomised (two inhalations twice daily) to budesonide pMDI 100 ?? g, budesonide/formoterol DPI 80 / 4.5 ?? g or budesonide/formoterol pMDI 80 / 4.5 ?? g. The primary endpoint was change from baseline in morning PEF. Results: Overall, 622 patients were randomised. Increases in morning PEF with budesonide/formoterol pMDI and budesonide/formoterol DPI were therapeutically equivalent (29.5 versus 30.2 l/min, respectively; 95% confidence interval: - 6.0 to 4.6; P = 0.78, also confirmed by per-protocol analysis). Improvements in secondary efficacy endpoints with both budesonide/formoterol formulations were not significantly different. Significantly greater improvement was achieved with budesonide/formoterol pMDI versus budesonide pMDI for morning PEF (+ 9.6 l/min; P < 0.001) and other lung function parameters. The safety profile of budesonide/formoterol pMDI was favourable and similar to that of budesonide/formoterol DPI and budesonide pMDI. Conclusion: Budesonide/formoterol, administered via the therapeutically equivalent hydrofluoroalkane pMDI or DPI, is an effective and well-tolerated treatment for children with asthma. ?? 2007 Elsevier Ltd. All rights reserved.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '17376722', 'scopus': '2-s2.0-38049048580', 'doi': '10.1016/j.pupt.2007.01.006'}, 'title': 'Efficacy and safety of a new pressurised metered-dose inhaler formulation of budesonide/formoterol in children with asthma: A superiority and therapeutic equivalence study', 'source': 'Mendeley'}
Noonan M, Rosenwasser LJ, Martin P, O'Brien CD, O'Dowd L. Efficacy and safety of budesonide and formoterol in one pressurised metered-dose inhaler in adults and adolescents with moderate to severe asthma: a randomised clinical trial. Drugs. 2006;66(17):2235-54.	-	17137405	primary-study	df285bbe670ebfa1b16f1927bc3450dbebf4b574	-	{'publication_type': {'year': 2006, 'cited_medium': None, 'issue': '17', 'issn': '0012-6667', 'volume': '66', 'title': 'Drugs', 'pagination': '2235-2254'}, 'language': None, 'rating': {'year': 1, 'title': 1.0, 'total': 0.885, 'authors': 0.54}, 'authors': [{'given': 'Michael', 'family': 'Noonan'}, {'given': 'Lanny J', 'family': 'Rosenwasser'}, {'given': 'Paula', 'family': 'Martin'}, {'given': 'Christopher D', 'family': 'O???Brien'}, {'given': 'Liza', 'family': 'O???Dowd'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.2165/00003495-200666170-00006'}, 'title': 'Efficacy and Safety of Budesonide and Formoterol in One Pressurised Metered-Dose Inhaler in Adults and Adolescents with Moderate to Severe Asthma', 'source': 'CrossRef'}
Noonan M, Rosenwasser LJ, Martin P, O'Brien CD, O'Dowd L. Efficacy and safety of budesonide and formoterol in one pressurised metered-dose inhaler in adults and adolescents with moderate to severe asthma: a randomised clinical trial. Drugs. 2006;66(17):2235-54.	-	17137405	primary-study	df285bbe670ebfa1b16f1927bc3450dbebf4b574	-	{'publication_type': {'year': 2006, 'cited_medium': None, 'issue': None, 'issn': '00126667', 'volume': None, 'title': 'Drugs', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 1.0, 'total': 0.98, 'authors': 0.9199999999999999}, 'authors': [{'given': 'Michael', 'family': 'Noonan'}, {'given': 'Lanny J.', 'family': 'Rosenwasser'}, {'given': 'Paula', 'family': 'Martin'}, {'given': 'Christopher D.', 'family': "O'Brien"}, {'given': 'Liza', 'family': "O'Dowd"}], 'abstract': 'BACKGROUND: Inhaled corticosteroids (ICSs) are the preferred maintenance therapy for adults and children with mild, moderate and severe persistent asthma, with the addition of a long-acting beta(2)-adrenoceptor agonist to ICS therapy recommended for patients with moderate or severe persistent asthma. The efficacy and safety of the combination of budesonide and formoterol delivered via dry powder inhaler (DPI) is well documented. OBJECTIVE: To compare the efficacy and safety of budesonide/formoterol pressurised metered-dose inhaler (budesonide/formoterol pMDI; Symbicort pMDI, AstraZeneca LP, Wilmington, DE, USA) with budesonide pMDI (Pulmicort pMDI, Astra [corrected] Zeneca, Lund, Sweden), formoterol DPI (Oxis Turbuhaler, AstraZeneca, Lund, Sweden), budesonide plus formoterol in separate inhalers (budesonide pMDI + formoterol DPI) and placebo. STUDY DESIGN: This was a 12-week randomised, double-blind, double-dummy, placebo-controlled study. SETTING: This multicentre study was conducted in the respiratory specialty clinical practice setting. PATIENTS: The study included 596 patients > or =12 years of age with moderate to severe persistent asthma previously receiving ICSs. INTERVENTIONS: After 2 weeks on budesonide pMDI 80 microg x two inhalations (160 microg) twice daily, patients received budesonide/formoterol pMDI 160 microg/4.5 microg x two inhalations (320 microg/9 microg); budesonide pMDI 160 microg x two inhalations (320 microg) + formoterol DPI 4.5 microg x two inhalations (9 microg); budesonide pMDI 160 microg x two inhalations (320 microg); formoterol DPI 4.5 microg x two inhalations (9 microg); or placebo twice daily. MAIN OUTCOME MEASURES: There were two prespecified primary efficacy variables: mean change from baseline in morning predose forced expiratory volume in 1 second (FEV(1)), obtained approximately 12 hours after the most recent administration of study medication at home and immediately before the next administration of study medication at the clinic; and mean change from baseline in 12-hour FEV(1), assessed as the average change in FEV(1) from serial spirometry over the 12-hour period after administration of the morning dose of study medication at the clinic. RESULTS: Mean changes from baseline in morning predose FEV(1) at end of treatment were greater (p < or = 0.049) with budesonide/formoterol pMDI (0.19L) versus budesonide pMDI (0.10L), formoterol DPI (-0.12L) and placebo (-0.17L). Mean changes from baseline in 12-hour FEV(1) were greater (p < or = 0.001) with budesonide/formoterol pMDI after 1 day (0.37L), 2 weeks (0.34L) and at end of treatment (0.37L) versus budesonide pMDI (0.11, 0.15 and 0.15L) and placebo (0.09, -0.03 and -0.03L), and after 2 weeks and at end of treatment versus formoterol DPI (0.19 and 0.17L). Fewer (p < or = 0.025) patients receiving budesonide/formoterol pMDI versus monoproducts or placebo met worsening asthma criteria. Results were similar in the budesonide/formoterol pMDI group and the budesonide pMDI + formoterol DPI group on all measures. All treatments were well tolerated with similar safety profiles. CONCLUSIONS: In this population, twice-daily budesonide/formoterol pMDI provides asthma control significantly greater than the monocomponents or placebo and comparable with budesonide pMDI + formoterol DPI. Safety profiles were similar for all treatments.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '17137405', 'scopus': '2-s2.0-33845327497', 'doi': '10.2165/00003495-200666170-00006'}, 'title': 'Efficacy and safety of budesonide and formoterol in one pressurised metered-dose inhaler in adults and adolescents with moderate to severe asthma: A randomised clinical trial', 'source': 'Mendeley'}
Bateman ED, Bousquet J, Keech ML, Busse WW, Clark TJ, Pedersen SE. The correlation between asthma control and health status: the GOAL study. The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology. 2007;29(1):56-62.	10.1183/09031936.00128505	17050557	primary-study	fdd4e576ddaa28a41371c03ac4075026e8ecd6ea	-	{'publication_type': {'year': 2006, 'cited_medium': None, 'issue': '1', 'issn': '0903-1936', 'volume': '29', 'title': 'European Respiratory Journal', 'pagination': '56-62'}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.875, 'authors': 0.9}, 'authors': [{'given': 'E. D.', 'family': 'Bateman'}, {'given': 'J.', 'family': 'Bousquet'}, {'given': 'M. L.', 'family': 'Keech'}, {'given': 'W. W.', 'family': 'Busse'}, {'given': 'T. J. H.', 'family': 'Clark'}, {'given': 'S. E.', 'family': 'Pedersen'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '17050557', 'scopus': None, 'doi': '10.1183/09031936.00128505'}, 'title': 'The correlation between asthma control and health status: the GOAL study', 'source': 'CrossRef'}
Bateman ED, Bousquet J, Keech ML, Busse WW, Clark TJ, Pedersen SE. The correlation between asthma control and health status: the GOAL study. The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology. 2007;29(1):56-62.	10.1183/09031936.00128505	17050557	primary-study	fdd4e576ddaa28a41371c03ac4075026e8ecd6ea	-	{'publication_type': {'year': 2011, 'cited_medium': None, 'issue': None, 'issn': None, 'volume': None, 'title': 'Agronom�a Colombiana; Vol. 13, n�m. 1 (1996); 56-62 Agronom�a Colombiana; Vol. 13, n�m. 1 (1996); 56-62 2357-3732 0120-9965', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.5, 'total': 0.325, 'authors': 0.0}, 'authors': [{'given': 'Luis Felipe', 'family': 'Rodr�guez C.'}, {'given': 'Lilia Teresa', 'family': 'Berm�dez'}], 'abstract': 'Por su posici�n geogr�fica, Colombia presenta grandes ventajas comparativas para la producci�n frut�cola. En Boyac� en los �ltimos a�os se ha notado un importante incremento en la producci�n de frutas especialmente de especies caducifolias y de otras como la feijoa, que han logrado alcanzar una gran aceptaci�n en los mercados regional y nacional. De la feijoa, se han efectuado algunos estudios sobre producci�n y comercializaci�n, no as� sobre consumo, lo cual ha llevado acasi un total desconocimiento del perfil de su consumidor. Por �sto es, que, mediante el presente ensayo, se pretende focalizar los aspectos relevantes de la comercializaci�n y consumo de esta importante especie frut�cola.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': None}, 'title': 'Perfil y caracterizaci�n de la comercializaci�n y consumo de feijoa en boyac�', 'source': 'Mendeley'}
Stelmach I, Grzelewski T, Bobrowska-Korzeniowska M, Stelmach P, Kuna P. A randomized, double-blind trial of the effect of anti-asthma treatment on lung function in children with asthma. Pulmonary pharmacology & therapeutics. 2007;20(6):691-700.	10.1016/j.pupt.2006.08.003	17046300	primary-study	a3ad32196780af1193079b87104f3649eeca2845	-	{'publication_type': {'year': 2007, 'cited_medium': None, 'issue': '6', 'issn': '1094-5539', 'volume': '20', 'title': 'Pulmonary Pharmacology & Therapeutics', 'pagination': '691-700'}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.88, 'authors': 0.9199999999999999}, 'authors': [{'given': 'Iwona', 'family': 'Stelmach'}, {'given': 'Tomasz', 'family': 'Grzelewski'}, {'given': 'Monika', 'family': 'Bobrowska-Korzeniowska'}, {'given': 'Piotr', 'family': 'Stelmach'}, {'given': 'Piotr', 'family': 'Kuna'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '17046300', 'scopus': None, 'doi': '10.1016/j.pupt.2006.08.003'}, 'title': 'A randomized, double-blind trial of the effect of anti-asthma treatment on lung function in children with asthma', 'source': 'CrossRef'}
Stelmach I, Grzelewski T, Bobrowska-Korzeniowska M, Stelmach P, Kuna P. A randomized, double-blind trial of the effect of anti-asthma treatment on lung function in children with asthma. Pulmonary pharmacology & therapeutics. 2007;20(6):691-700.	10.1016/j.pupt.2006.08.003	17046300	primary-study	a3ad32196780af1193079b87104f3649eeca2845	-	{'publication_type': {'year': 2007, 'cited_medium': None, 'issue': None, 'issn': '10945539', 'volume': None, 'title': 'Pulmonology Pharmacology & Therapeutics', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.8791666666666667, 'authors': 0.9166666666666666}, 'authors': [{'given': 'I', 'family': 'Stelmach'}, {'given': 'T', 'family': 'Grzelewski'}, {'given': 'M', 'family': 'Bobrowska-Korzeniowska'}, {'given': 'P', 'family': 'Stelmach'}, {'given': 'P', 'family': 'Kuna'}, {'given': 'T', 'family': 'Grzelewskia'}], 'abstract': 'Background: Pulmonary function tests (PFTs) and especially spirometry measures are useful tools in evaluating early response to treatment of asthma in children mainly due to their worldwide availability. The aim of our study was to determine the effects of anti-asthma treatment in children, equally on FEV<sub>1</sub>, FEF25-75%, R<sub>int</sub> and SR<sub>aw</sub> values. Methods: Children 6-18 years of age with moderate atopic asthma were randomized to 4-week, placebo-controlled, double-blind trial. Patients were randomly allocated to receive 200 mug budesonide (B) (n=29), 5 or 10 mg (according to age) montelukast (M) (n=29), 200 mug B+5 or 10 mg M (n=29), 200 mug B+9 mug formoterol (F) (n=29) or placebo (n=27). FEV<sub>1,</sub> FEF25-75%, R<sub>int</sub>, SR<sub>aw</sub> were measured before and after treatment. Results: R<sub>int</sub>, SR<sub>aw</sub>, FEV<sub>1</sub> improved significantly in all active treatment groups while FEF25-75% improved significantly only in BM group and M group. Combination therapy, showed significantly greater effects on R<sub>int</sub> than monotherapy: BM group compared to B group (P=0.01) and M group (P=0.03) and BF group compared to B group (P=0.01) and M group (P=0.04). Conclusion: This study shows that using single parameter for monitoring asthma can be misleading. Using combination of lung function techniques provides better assessment of treatment. Results of our study confirm this hypothesis. The best effect on large and small airways was achieved with combined anti-inflammatory therapy. copyright 2006 Elsevier Ltd. All rights reserved. Drug Trade Names and Manufacturers Astra Zeneca [United Kingdom] Glaxo SmithKline [United States] Merck Sharp and Dohme [United States] oxis: Astra Zeneca [United Kingdom] pulmicort: Astra Zeneca [United Kingdom] singulair: Merck Sharp and Dohme [United States] ventolin: Glaxo SmithKline [United States]', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '17046300', 'scopus': None, 'doi': '10.1016/j.pupt.2006.08.003'}, 'title': 'A randomized, double-blind trial of the effect of anti-asthma treatment on lung function in children with asthma', 'source': 'Mendeley'}
Pohunek P, Kuna P, Jorup C, De Boeck K. Budesonide/formoterol improves lung function compared with budesonide alone in children with asthma. Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology. 2006;17(6):458-65.	10.1111/j.1399-3038.2006.00425.x	16925692	primary-study	85f9d60650d5db9b13fdada0badee2d48464c945	-	{'publication_type': {'year': 2006, 'cited_medium': None, 'issue': '6', 'issn': '0905-6157', 'volume': '17', 'title': 'Pediatric Allergy and Immunology', 'pagination': '458-465'}, 'language': None, 'rating': {'year': 1, 'title': 0.9166666666666666, 'total': 0.9270833333333334, 'authors': 0.925}, 'authors': [{'given': 'Petr', 'family': 'Pohunek'}, {'given': 'Piotr', 'family': 'Kuna'}, {'given': 'Carin', 'family': 'Jorup'}, {'given': 'Kris', 'family': 'De Boeck'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '16925692', 'scopus': None, 'doi': '10.1111/j.1399-3038.2006.00425.x'}, 'title': 'Budesonide/formoterol improves lung function compared with budesonide alone in children with asthma1', 'source': 'CrossRef'}
Pohunek P, Kuna P, Jorup C, De Boeck K. Budesonide/formoterol improves lung function compared with budesonide alone in children with asthma. Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology. 2006;17(6):458-65.	10.1111/j.1399-3038.2006.00425.x	16925692	primary-study	85f9d60650d5db9b13fdada0badee2d48464c945	-	{'publication_type': {'year': 2013, 'cited_medium': None, 'issue': None, 'issn': '09056157', 'volume': None, 'title': 'Pediatric Allergy and Immunology', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 0.8333333333333334, 'total': 0.6416666666666667, 'authors': 0.0}, 'authors': [{'given': 'Motohiro', 'family': 'Ebisawa'}, {'given': 'Sankei', 'family': 'Nishima'}, {'given': 'Hidenori', 'family': 'Ohnishi'}, {'given': 'Naomi', 'family': 'Kondo'}], 'abstract': 'The Japanese Society of Pediatric Allergy and Clinical Immunology (JSPACI) was started in 1966 and currently has 3613 members as of August 1, 2012. The number of pediatricians specializing in allergies who have been certified by the Japanese Society of Allergology is 817. Among these, there are 125 training directors and training facilities for allergy and clinical immunology. The JSPACI first published an asthma guideline specific for children in 2000, and this has been revised every 3\xa0yrs, contributing to better control of pediatric asthma. Food allergy management guidelines were first developed in 2005, which have helped to improve the care of food allergy patients. Among 514 pediatric training programs by the Japanese Society of Pediatrics, there are 312 facilities routinely performing oral food challenges. Among these, there were already 53 facilities performing oral immunotherapy at the end of 2011, treating 1400 cases of food allergy. The prevalence of pediatric allergic diseases has increased in Japan over the past 50\xa0yrs. A number of International Study of Asthma and Allergies in Childhood surveys have been conducted in the past at specific times. The prevalence of wheezing among children aged 13-14\xa0yrs in 2002 was 13.0%. Multi-year surveys found a 1.5- to 2-fold increase every 10\xa0yrs until 2002. However, according to the latest data in 2012, asthma prevalence seems to have slightly decreased in Japan. Food allergy mainly associated with infantile atopic eczema among infants younger than 1\xa0yr of age is the most common form as with other developed countries. The estimated food allergy prevalence based on data from several surveys is 5-10% among infants (0-6\xa0yrs) and 1-2% among schoolchildren (6-15\xa0yrs). A variety of patients suffering from primary deficiency syndrome have been actively analyzed. Previously, antibody defects and well-defined syndromes with immunodeficiency were analyzed, but recent research is focusing on not only acquired immune disorders but also on innate immune disorders. In contrast to the widespread use of oral immunotherapy, one immediate issue is to develop and reassess subcutaneous and sublingual immunotherapies for mite and Japanese cedar pollen antigens that have been disused in Japan since the 1990s.', 'type': 'generic', 'ids': {'embase': None, 'pubmed': '24112430', 'scopus': '2-s2.0-84885813530', 'doi': '10.1111/pai.12117'}, 'title': 'Pediatric allergy and immunology in Japan', 'source': 'Mendeley'}
Kuna P, Creemers JP, Vondra V, Black PN, Lindqvist A, Nihlen U, Vogelmeier C. Once-daily dosing with budesonide/formoterol compared with twice-daily budesonide/formoterol and once-daily budesonide in adults with mild to moderate asthma. Respiratory medicine. 2006;100(12):2151-9.	10.1016/j.rmed.2006.03.016	16701989	primary-study	603640f1b2e1ec8906b83aeef96cf71b4ab4f54d	-	{'publication_type': {'year': 2006, 'cited_medium': None, 'issue': '12', 'issn': '0954-6111', 'volume': '100', 'title': 'Respiratory Medicine', 'pagination': '2151-2159'}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.8642857142857143, 'authors': 0.8571428571428571}, 'authors': [{'given': 'P.', 'family': 'Kuna'}, {'given': 'J.P.H.M.', 'family': 'Creemers'}, {'given': 'V.', 'family': 'Vondra'}, {'given': 'P.N.', 'family': 'Black'}, {'given': 'A.', 'family': 'Lindqvist'}, {'given': 'U.', 'family': 'Nihlen'}, {'given': 'C.', 'family': 'Vogelmeier'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '16701989', 'scopus': None, 'doi': '10.1016/j.rmed.2006.03.016'}, 'title': 'Once-daily dosing with budesonide/formoterol compared with twice-daily budesonide/formoterol and once-daily budesonide in adults with mild to moderate asthma', 'source': 'CrossRef'}
Kuna P, Creemers JP, Vondra V, Black PN, Lindqvist A, Nihlen U, Vogelmeier C. Once-daily dosing with budesonide/formoterol compared with twice-daily budesonide/formoterol and once-daily budesonide in adults with mild to moderate asthma. Respiratory medicine. 2006;100(12):2151-9.	10.1016/j.rmed.2006.03.016	16701989	primary-study	603640f1b2e1ec8906b83aeef96cf71b4ab4f54d	-	{'publication_type': {'year': 2006, 'cited_medium': None, 'issue': None, 'issn': '09546111', 'volume': None, 'title': 'Respiratory Medicine', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.8642857142857143, 'authors': 0.8571428571428571}, 'authors': [{'given': 'P.', 'family': 'Kuna'}, {'given': 'J. P H M', 'family': 'Creemers'}, {'given': 'V.', 'family': 'Vondra'}, {'given': 'P. N.', 'family': 'Black'}, {'given': 'A.', 'family': 'Lindqvist'}, {'given': 'U.', 'family': 'Nihlen'}, {'given': 'C.', 'family': 'Vogelmeier'}], 'abstract': 'Adherence to maintenance therapy is often poor in patients with asthma. Simplifying dosing regimens has the potential to improve both adherence and asthma-related morbidity. In this 12-week, randomized, double-blind, double-dummy, parallel-group study, 617 patients with mild to moderate persistent asthma (mean forced expiratory volume in 1 s [FEV1] 78.5% predicted) who were not optimally controlled on inhaled corticosteroids (200-500 ??g/day) were randomized to once-daily budesonide/formoterol (80/4.5 ??g, 2 inhalations in the evening), twice-daily budesonide/formoterol (80/4.5 ??g, 1 inhalation), or a corresponding dose of budesonide once-daily (200 ??g, 1 inhalation in the evening). All patients received budesonide (100 ??g twice daily) during a 2-week run-in. Changes in mean morning peak expiratory flow (PEF) were similar for od budesonide/formoterol (23.4 l/min) and twice-daily budesonide/formoterol (24.1 l/min), and both were greater than with budesonide (5.5 l/min; both P<0.001). Evening PEF, symptom-free days, reliever-free days, and asthma control days were improved with budesonide/formoterol therapy vs. budesonide (P<0.05 vs. budesonide for all variables). All treatments were well tolerated. Budesonide/formoterol administered once daily in the evening is a convenient treatment regimen that is as effective in improving asthma control as twice-daily dosing in patients with mild to moderate persistent asthma. ?? 2006 Elsevier Ltd. All rights reserved.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '16701989', 'scopus': '2-s2.0-33750893156', 'doi': '10.1016/j.rmed.2006.03.016'}, 'title': 'Once-daily dosing with budesonide/formoterol compared with twice-daily budesonide/formoterol and once-daily budesonide in adults with mild to moderate asthma', 'source': 'Mendeley'}
Jenkins C, Kolarikova R, Kuna P, Caillaud D, Sanchis J, Popp W, Pettersson E. Efficacy and safety of high-dose budesonide/formoterol (Symbicort) compared with budesonide administered either concomitantly with formoterol or alone in patients with persistent symptomatic asthma. Respirology (Carlton, Vic.). 2006;11(3):276-86.	10.1111/j.1440-1843.2006.00856.x	16635085	primary-study	6fd658cc09b1c20ec9ad9dfbe1a11f5534f75624	-	{'publication_type': {'year': 2006, 'cited_medium': None, 'issue': '3', 'issn': '1323-7799', 'volume': '11', 'title': 'Respirology', 'pagination': '276-286'}, 'language': None, 'rating': {'year': 1, 'title': 0.9565217391304348, 'total': 0.9503105590062112, 'authors': 0.9142857142857144}, 'authors': [{'given': 'Christine', 'family': 'JENKINS'}, {'given': 'Renata', 'family': 'KOLARIKOVA'}, {'given': 'Piotr', 'family': 'KUNA'}, {'given': 'Denis', 'family': 'CAILLAUD'}, {'given': 'Joaquin', 'family': 'SANCHIS'}, {'given': 'Wolfgang', 'family': 'POPP'}, {'given': 'Eva', 'family': 'PETTERSSON'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '16635085', 'scopus': None, 'doi': '10.1111/j.1440-1843.2006.00856.x'}, 'title': 'Efficacy and safety of high-dose budesonide/formoterol (SymbicortR) compared with budesonide administered either concomitantly with formoterol or alone in patients with persistent symptomatic asthma', 'source': 'CrossRef'}
Jenkins C, Kolarikova R, Kuna P, Caillaud D, Sanchis J, Popp W, Pettersson E. Efficacy and safety of high-dose budesonide/formoterol (Symbicort) compared with budesonide administered either concomitantly with formoterol or alone in patients with persistent symptomatic asthma. Respirology (Carlton, Vic.). 2006;11(3):276-86.	10.1111/j.1440-1843.2006.00856.x	16635085	primary-study	6fd658cc09b1c20ec9ad9dfbe1a11f5534f75624	-	{'publication_type': {'year': 2006, 'cited_medium': None, 'issue': None, 'issn': '13237799', 'volume': None, 'title': 'Respirology', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 0.9565217391304348, 'total': 0.9503105590062112, 'authors': 0.9142857142857144}, 'authors': [{'given': 'Christine', 'family': 'Jenkins'}, {'given': 'Renata', 'family': 'Kolarikova'}, {'given': 'Piotr', 'family': 'Kuna'}, {'given': 'Denis', 'family': 'Caillaud'}, {'given': 'Joaquin', 'family': 'Sanchis'}, {'given': 'Wolfgang', 'family': 'Popp'}, {'given': 'Eva', 'family': 'Pettersson'}], 'abstract': 'OBJECTIVE AND BACKGROUND: Budesonide/formoterol 160/4.5 microg, two inhalations bd, is an effective and well-tolerated maintenance therapy for patients not controlled on inhaled corticosteroids alone. The authors assessed the efficacy and safety of a higher dose of budesonide/formoterol in patients with persistent symptomatic asthma.\\n\\nMETHODS: This was a 24-week, double-blind, double-dummy randomized study. Budesonide/formoterol 320/9 microg, two inhalations bd (1280/36 microg/day), was compared with corresponding doses of budesonide during weeks 1-12 and budesonide plus formoterol via separate inhalers during weeks 1-24. Efficacy was assessed during weeks 1-12; the primary variable was morning PEF. Safety was assessed over weeks 1-24.\\n\\nRESULTS: Patients (n=456; aged 12-79 years) had a mean reversibility in FEV1 of 28% and mean pre-study inhaled corticosteroid dose of 1038 microg/day. Mean morning PEF increased by 37 L/min and 36 L/min with budesonide/formoterol and budesonide plus formoterol, respectively, versus an increase of 5 L/min with budesonide (P<0.001 for both vs. budesonide). Budesonide/formoterol increased time to first mild exacerbation (P<0.005) versus budesonide. Budesonide/formoterol and budesonide plus formoterol had similar efficacy. All treatments were well tolerated and the incidence of class-related adverse events was similarly low in all groups. Changes in serum potassium and plasma cortisol were comparable across treatments.\\n\\nCONCLUSIONS: High-dose budesonide/formoterol (320/9 microg, two inhalations bd) is effective and well tolerated in patients with persistent symptomatic asthma. The findings also support the safety of regular high-dose formoterol (36 microg/day).', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '16635085', 'scopus': '2-s2.0-33646012954', 'doi': '10.1111/j.1440-1843.2006.00856.x'}, 'title': 'Efficacy and safety of high-dose budesonide/formoterol (Symbicort??) compared with budesonide administered either concomitantly with formoterol or alone in patients with persistent symptomatic asthma', 'source': 'Mendeley'}
Briggs AH, Bousquet J, Wallace MV, Busse WW, Clark TJ, Pedersen SE, Bateman ED. Cost-effectiveness of asthma control: an economic appraisal of the GOAL study. Allergy. 2006;61(5):531-6.	10.1111/j.1398-9995.2006.01038.x	16629780	primary-study	19ec93a4807b3f6d61e7161cab5fd99a2b7b1db9	-	{'publication_type': {'year': 2006, 'cited_medium': None, 'issue': '5', 'issn': '0105-4538', 'volume': '61', 'title': 'Allergy', 'pagination': '531-536'}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 0.975, 'authors': 0.9000000000000001}, 'authors': [{'given': 'A. H.', 'family': 'Briggs'}, {'given': 'J.', 'family': 'Bousquet'}, {'given': 'M. V.', 'family': 'Wallace'}, {'given': 'W. W.', 'family': 'Busse'}, {'given': 'T. J. H.', 'family': 'Clark'}, {'given': 'S. E.', 'family': 'Pedersen'}, {'given': 'E. D.', 'family': 'Bateman'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '16629780', 'scopus': None, 'doi': '10.1111/j.1398-9995.2006.01038.x'}, 'title': 'Cost-effectiveness of asthma control: an economic appraisal of the GOAL study', 'source': 'CrossRef'}
Briggs AH, Bousquet J, Wallace MV, Busse WW, Clark TJ, Pedersen SE, Bateman ED. Cost-effectiveness of asthma control: an economic appraisal of the GOAL study. Allergy. 2006;61(5):531-6.	10.1111/j.1398-9995.2006.01038.x	16629780	primary-study	19ec93a4807b3f6d61e7161cab5fd99a2b7b1db9	-	{'publication_type': {'year': 2007, 'cited_medium': None, 'issue': None, 'issn': None, 'volume': None, 'title': '5', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.2, 'total': 0.355, 'authors': 0.9}, 'authors': [{'given': None, 'family': '5'}], 'abstract': 'In this and the following chapter we examine the sources of energy to lotic food webs. Autotrophs or primary producers are organisms that acquire their energy from sunlight and materials from nonliving sources. Algae, higher plants, and some bacteria and protists are important autotrophs in running waters. Heterotrophs obtain energy and materials by consuming living or dead organic matter. All animals of course are heterotrophic, but so also are fungi and many protists and bacteria that gain nourishment through the processing of dead organic matter and often make that organic matter more nutrient rich and more accessible to other consumers. Together, these autotrophs and microbial heterotrophs constitute the basal energy resources that support higher trophic levels in lotic food webs. The major autotrophs of running waters include large plants, referred to as macrophytes, and various small producers including individual cells, colonies, and filamentous growth forms. Algae suspended in the water column are referred to as phytoplankton; those attached to substrates are referred to as benthic algae or periphyton.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1002/9781444313512.ch8'}, 'title': '5. Chpt. 6 Primary Producers', 'source': 'Mendeley'}
Nathan RA, Rooklin A, Schoaf L, Scott C, Ellsworth A, House K, Dorinsky P. Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study. Clinical therapeutics. 2006;28(1):73-85.	10.1016/j.clinthera.2006.01.008	16490581	primary-study	8fefd6ebdcfc505e278634409367362deebea7e7	-	{'publication_type': {'year': 2006, 'cited_medium': None, 'issue': '1', 'issn': '0149-2918', 'volume': '28', 'title': 'Clinical Therapeutics', 'pagination': '73-85'}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.8785714285714286, 'authors': 0.9142857142857144}, 'authors': [{'given': 'Robert A.', 'family': 'Nathan'}, {'given': 'Anthony', 'family': 'Rooklin'}, {'given': 'Lynne', 'family': 'Schoaf'}, {'given': 'Catherine', 'family': 'Scott'}, {'given': 'Anna', 'family': 'Ellsworth'}, {'given': 'Karen', 'family': 'House'}, {'given': 'Paul', 'family': 'Dorinsky'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '16490581', 'scopus': None, 'doi': '10.1016/j.clinthera.2006.01.008'}, 'title': 'Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study', 'source': 'CrossRef'}
Nathan RA, Rooklin A, Schoaf L, Scott C, Ellsworth A, House K, Dorinsky P. Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study. Clinical therapeutics. 2006;28(1):73-85.	10.1016/j.clinthera.2006.01.008	16490581	primary-study	8fefd6ebdcfc505e278634409367362deebea7e7	-	{'publication_type': {'year': 2006, 'cited_medium': None, 'issue': None, 'issn': '01492918', 'volume': None, 'title': 'Clinical Therapeutics', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 1.0, 'total': 0.8785714285714286, 'authors': 0.9142857142857144}, 'authors': [{'given': 'Robert A.', 'family': 'Nathan'}, {'given': 'Anthony', 'family': 'Rooklin'}, {'given': 'Lynne', 'family': 'Schoaf'}, {'given': 'Catherine', 'family': 'Scott'}, {'given': 'Anna', 'family': 'Ellsworth'}, {'given': 'Karen', 'family': 'House'}, {'given': 'Paul', 'family': 'Dorinsky'}], 'abstract': 'Objective: This study compared the efficacy andtolerability of the combination of fluticasone propionate (FP) and salmeterol (SAL) delivered via a single hydrofluoroalkane (HFA) 134a metered-dose inhaler (MDI) with those of its 2 components alone delivered via a chlorofluorocarbon (CFC) MDI and placebo (PLA) delivered via HFA MDI in adolescent and adult patients with persistent asthma that was not controlled by medium doses (equivalent to FP 440-660 ??g/d) of inhaled corticosteroids (ICSs). Methods: This was a randomized, double-blind,placebo-controlled, parallel-group study consisting of a 2-week, single-blind, placebo run-in period followed by a 12-week, double-blind treatment period. Participants had to be ???12 years of age and have a diagnosis of asthma requiring pharmacotherapy for at least 6 months before the study. Patients had to have used ICS therapy for ???3 months before the study and at a consistent dose for the previous month. Lack of asthma control was defined as a forced expiratory volume in 1 second (FEV1) that was 40% to 85% of the predicted value. Patients could not enter the double-blind treatment period if they had 3 days when they required >12 puffs of rescue albuterol per day or >3 nighttime awakenings due to asthma that required treatment with albuterol during the 7 days before the randomization visit. Patients were randomized to receive one of the following treatments delivered via MDI twice daily for 12 weeks: FSC 220/42 ??g HFA (2 inhalations of FSC 110/21 ??g; 125 ??g/21 ??g ex-valve); FP 220 ??g CFC (2 inhalations of FP 110 ??g); SAL 42 ??g CFC (2 inhalations of 21 ??g); or 2 inhalations of PLA HFA. The primary efficacy end point for FSC versus FP was the mean area under the 12-hour serial FEV1 curve relative to the prerandomization baseline (FEV1 AUCbl). The primary efficacy end points for FSC versus SAL were the mean change from baseline in morning predose FEV 1 at end point and the probability of not being withdrawn from the study due to worsening asthma. Tolerability assessments included electrocardiograms, routine clinical laboratory tests, vital signs, oropharyngeal examinations, and physical examinations. Adverse events were assessed at each clinic visit. Results: Thirty-two adolescent and 333 adult patientswere randomly assigned to receive double-blind treatment. The treatment groups were comparable at baseline with respect to demographic characteristics (mean age, 38-41 years; white race, 78%-88%) and pulmonary function (mean percent predicted FEV1, 68%-69%; mean asthma symptom score, 1.6 [scale 0-5]; and mean daily albuterol use, 3.1 puffs). After 12 weeks of treatment, the mean FEV1 AUCbl was significantly greater in patients who received FSC compared with those who received FP, SAL, or PLA (7.0, 3.6, 5.3, and 1.4 L-h, respectively; all comparisons, P ??? 0.020). At end point, the mean change from baseline in morning predose FEV1 for FSC was significantly greater than that for FP, SAL, and PLA (0.41, 0.19, 0.15, and -0.12 L; all comparisons, P ??? 0.001). During 12 weeks of treatment, 7% of patients receiving FSC were withdrawn due to worsening asthma, compared with 24% of patients receiving SAL and 54% of patients receiving PLA (P < 0.001); 11% of patients receiving FP were withdrawn due to worsening asthma. Treatment with FSC resulted in significant improvements in morning and evening peak expiratory flow compared with FP, SAL, and PLA (both, P < 0.001); need for rescue albuterol compared with FP and PLA (P ??? 0.005); and asthma symptom scores compared with PLA (P < 0.001). The tolerability of FSC was similar to that of FP or SAL alone. The incidence of possibly drug-related adverse events was generally similar across treatment groups, and the most common (occurring in ??? 2% of patients) were headache (1%-4%), throat irritation (1%-2%), candidiasis of the mouth/throat (0%-2%), unspecified oropharyngeal plaques (0%-2%), and palpitations (0%-2%). Conclusions: In these adolescent and adult patientswhose asthma was not controlled by medium doses of an ICS, FSC delivered via HFA 134a MDI (2 inhalations of 110/21-??g strength administered BID) was more effective in improving lung function than FP or SAL monotherapy or PLA. All treatments were well tolerated. Copyright ?? 2006 Excerpta Medica, Inc.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '16490581', 'scopus': '2-s2.0-32844457856', 'doi': '10.1016/j.clinthera.2006.01.008'}, 'title': 'Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: A randomized, double-blind, placebo-controlled, 12-week study', 'source': 'Mendeley'}
Green RH, Brightling CE, McKenna S, Hargadon B, Neale N, Parker D, Ruse C, Hall IP, Pavord ID. Comparison of asthma treatment given in addition to inhaled corticosteroids on airway inflammation and responsiveness. The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology. 2006;27(6):1144-51.	10.1183/09031936.06.00102605	16455831	primary-study	3772fb4e853a6cd0f94b57b2400db41c2349965d	-	{'publication_type': {'year': 2006, 'cited_medium': None, 'issue': '6', 'issn': '0903-1936', 'volume': '27', 'title': 'European Respiratory Journal', 'pagination': '1144-1151'}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.875, 'authors': 0.9}, 'authors': [{'given': 'R. H.', 'family': 'Green'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '16455831', 'scopus': None, 'doi': '10.1183/09031936.06.00102605'}, 'title': 'Comparison of asthma treatment given in addition to inhaled corticosteroids on airway inflammation and responsiveness', 'source': 'CrossRef'}
Green RH, Brightling CE, McKenna S, Hargadon B, Neale N, Parker D, Ruse C, Hall IP, Pavord ID. Comparison of asthma treatment given in addition to inhaled corticosteroids on airway inflammation and responsiveness. The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology. 2006;27(6):1144-51.	10.1183/09031936.06.00102605	16455831	primary-study	3772fb4e853a6cd0f94b57b2400db41c2349965d	-	{'publication_type': {'year': 2012, 'cited_medium': None, 'issue': None, 'issn': '1399-3003', 'volume': None, 'title': 'The European respiratory journal', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 0.1, 'total': 0.165, 'authors': 0.0}, 'authors': [{'given': 'Pp.667–689.', 'family': 'AASM Task Force, A., 1999. Sleep – Related Breathing Disorders in Adults : Recommendations for Syndrome Definition and Measurement Techniques in Clinical Research. SLEEP, 22(5)'}, {'given': 'titration and side effects of oral appliances in snoring and obstructive sleep apnea patients.', 'family': 'Almeida, F.R., 2005. Compliance'}, {'given': 'Pp.198–204.', 'family': 'Almeida, F.R. et al., 2009. Effect of a Titration Polysomnogram on Treatment Success with a Mandibular Repositioning Appliance. Journal of Clinical Sleep Medicine, 5(3)'}, {'given': 'Pp.659–66.', 'family': 'Almeida, F.R. et al., 2013. Patient preferences and experiences of CPAP and oral appliances for the treatment of obstructive sleep apnea: a qualitative analysis. Sleep & breathing = Schlaf & Atmung, 17(2)'}, {'given': 'Pp.205–13.', 'family': 'Almeida, F.R. De et al., 2006. Long-term sequellae of oral appliance therapy in obstructive sleep apnea patients: Part 2. Study-model analysis. American journal of orthodontics and dentofacial orthopedics : official publication of the American Association'}, {'given': 'Pp.911–23.', 'family': 'Alsufyani, N., Al-Saleh, M. & Major, P., 2013. CBCT assessment of upper airway changes and treatment outcomes of obstructive sleep apnoea: a systematic review. Sleep & breathing, 17(3)'}, {'given': 'Pp.227–34.', 'family': 'Anandam, A. et al., 2013. Effects of dietary weight loss on obstructive sleep apnea: a meta-analysis. Sleep & breathing, 17(1)'}, {'given': 'Pp.1946–9.', 'family': 'Ancoli-Israel, S. et al., 1995. Sleep-disordered breathing in African-American elderly. American journal of respiratory and critical care medicine, 152(6 Pt 1)'}, {'given': 'Pp.90–96.', 'family': 'Ang, P.K., Sandham, A. & Tan, W.C., 2004. Craniofacial Morphology and Head Posture in. Seminars in Orthodontics, 10(1)'}, {'given': 'Cistulli (5 20 10)_PC revisions 24May2010 (2).', 'family': 'Anon'}, {'given': 'symps & conditions of OSA in adults.', 'family': 'Anon, Risk factors'}, {'given': '80(1).', 'family': 'Article, O., 2010. Five Years of Sleep Apnea Treatment with a Mandibular Advancement Device.'}, {'given': 'Pp.737–747.', 'family': 'Article, S., 2007. Clinical Guidelines for the Use of Unattended Portable Monitors in the Diagnosis of Obstructive Sleep Apnea in Adult Patients. Journal of Clinical Sleep Medicine, 3(7)'}, {'given': 'Pp.1408–1413.', 'family': 'Aurora, R.N. et al., 2010. Practice Parameters for the Surgical Modifications of the Upper Airway for Obstructive Sleep Apnea in Adults. SLEEP, 33(10)'}, {'given': 'Pp.17–40.', 'family': 'Aurora, R.N. et al., 2012. The Treatment of Central Sleep Apnea Syndromes in Adults : Practice Parameters with an Evidence-Based Literature Review and Meta-Analyses. SLEEP, 35(1)'}, {'given': 'Pp.485–490.', 'family': 'Awad, K.M. et al., 2012. Exercise Is Associated with a Reduced Incidence of Sleep-disordered Breathing. American Journal of Medicine, 125'}, {'given': 'Pp.982–990.', 'family': 'Bader, G.G. et al., 1997. Descriptive Physiological Data on a Sleep Bruxism Population. SLEEP, 20(11)'}, {'given': 'Pp.124–134.', 'family': 'Baik, U.B., Suzuki, M. & Ikeda, K., 2002. Relationship Between Cephalometric Characteristics and Obstructive Sites in Obstructive Sleep Apnea Syndrome. Angle Orthodontist, 72'}, {'given': 'Pp.495–501.', 'family': 'Ballester, E. et al., 1999. Evidence of the Effectiveness of Continuous Positive Airway Pressure in the Treatment of Sleep Apnea / Hypopnea Syndrome. American journal of respiratory and critical care medicine, 159'}, {'given': 'Pp.583–596.', 'family': 'Bardwell, W.A. et al., 1999. PSYCHOLOGICAL CORRELATES OF SLEEP APNEA. Journal of Psychosomatic Research, 47(6)'}, {'given': 'Pp.656–64.', 'family': 'Barnes, M. et al., 2004. Efficacy of positive airway pressure and oral appliance in mild to moderate obstructive sleep apnea. American journal of respiratory and critical care medicine, 170(6)'}, {'given': 'Pp.299–305.', 'family': 'Barthlen, G.M. et al., 2000. Comparison of three oral appliances for treatment of severe obstructive sleep apnea syndrome q. Sleep Medicine, 1'}, {'given': 'Pp.363–376.', 'family': 'Battagel, J.M. et al., 1999. Changes in airway and hyoid position in response to mandibular protrusion in subjects with obstructive sleep apnoea ( OSA ). European journal of orthodontics, 21'}, {'given': 'Pp.263–276.', 'family': 'Battagel, J.M. et al., 2002. Postural variation in oropharyngeal dimensions in subjects with sleep disordered breathing : a cephalometric study. European journal of orthodontics, 24'}, {'given': 'Pp.121–132.', 'family': 'Battagel, J.M. et al., 1998. The role of lateral cephalometric radiography and fluoroscopy in assessing mandibular advancement in sleep-related disorders. European journal of orthodontics, 20'}, {'given': 'Pp.557–569.', 'family': 'Battagel, J.M. & Estrange, P.R.L., 1996. The cephalometric morphology of patients with obstructive sleep apnoea ( OSA ). European journal of orthodontics, 18'}, {'given': 'Pp.353–365.', 'family': 'Battagel, J.M., Johal, A. & Kotecha, B., 2000. A cephalometric comparison of subjects with snoring and obstructive sleep apnoea. European journal of orthodontics, 22'}, {'given': 'Pp.298–307.', 'family': 'Beebe, D.W. et al., 2003. The Neuropsychological Effects of Obstructive Sleep Apnea : A Meta-Analysis of Norm-Referenced and Case-Controlled Data. SLEEP, 26(3)'}, {'given': 'Pp.558–564.', 'family': 'Bennett, L.S. et al., 1998. Oral appliances for the management of snoring and obstructive sleep apnoea. Thorax, 53(Suppl 2)'}, {'given': 'Pp.529–531.', 'family': 'Berry, D.T., Webb, W.B. & Block, A.J., 1984. Sleep apnea syndrome. A critical review of the apnea index as a diagnostic criterion. Chest, 86'}, {'given': 'Pp.245–50.', 'family': 'Berry, R.B. et al., 1991. Effect of theophylline on sleep and sleep-disordered breathing in patients with chronic obstructive pulmonary disease. The American review of respiratory disease, 143(2)'}, {'given': 'Pp.1423–1431.', 'family': 'Berry, R.B. et al., 2008. Portable Monitoring and Autotitration versus Polysomnography for the Diagnosis and Treatment of Sleep Apnea. SLEEP, 31(1)'}, {'given': 'Pp.641–649.', 'family': 'Bettega, G. et al., 2000. Obstructive Sleep Apnea Syndrome Fifty-one Consecutive Patients Treated by Maxillofacial Surgery. American journal of respiratory and critical care medicine, 162'}, {'given': 'Pp.245–251.', 'family': 'Bittencourt, L.R.A. et al., 2001. The variability of the apnoea ± hypopnoea index. J Prosthet Dent, 10'}, {'given': 'Pp.144–148.', 'family': 'Bixler, E.O. et al., 1998. Effects of Age on Sleep Apnea in Men. Am J Respir Crit Care Med, 157'}, {'given': 'Pp.621–8.', 'family': 'Bondemark, L., 1999. Does 2 years’ nocturnal treatment with a mandibular advancement splint in adult patients with snoring and OSAS cause a change in the posture of the mandible? American journal of orthodontics and dentofacial orthopedics : official publ'}, {'given': 'Pp.53–60.', 'family': 'Bondemark, L. & Lindman, R., 2000. Craniomandibular status and function in patients with habitual snoring and obstructive sleep apnoea after nocturnal treatment with a mandibular advancement splint : a 2-year follow-up. European journal of orthodontics, 2'}, {'given': 'Pp.917–23.', 'family': 'Brevi, B.C. et al., 2011. Counterclockwise rotation of the occlusal plane in the treatment of obstructive sleep apnea syndrome. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 69'}, {'given': 'Pp.1724–1737.', 'family': 'Buchwald, H., Avidor, Y. & Braunwald, E., 2004. Bariatric Surgery: A Systematic Review and Meta-analysis. JAMA, 292(14)'}, {'given': 'Pp.1396–1407.', 'family': 'Caples, S.M. et al., 2010. Surgical Modifications of the Upper Airway for Obstructive Sleep Apnea in Adults : A Systematic Review and Meta-Analysis. SLEEP, 33(10)'}, {'given': 'Pp.187–197.', 'family': 'Caples, S.M., Gami, A.S. & Somers, V.K., 2005. Obstructive Sleep Apnea. Annals of Internal Medicine, 142'}, {'given': 'Pp.163–168.', 'family': 'Carneiro, G. et al., 2012. Is mandatory screening for obstructive sleep apnea with polysomnography in all severely obese patients indicated ? Sleep Breath, 16'}, {'given': 'Pp.546–552.', 'family': 'Cartwright, R. et al., 1991. Clinical Corner A Comparative Study of Treatments for Positional Sleep Apnea. SLEEP, 14(6)'}, {'given': '2005. Sleep nasendoscopy as a predictor of treatment success in snorers using mandibular advancement sp ...', 'family': 'Central, P.'}, {'given': 'Pp.102–6.', 'family': 'Chan, a S.L., Phillips, C.L. & Cistulli, P. a, 2010. Obstructive sleep apnoea--an update. Internal medicine journal, 40(2)'}, {'given': 'Pp.836–842.', 'family': 'Chan, A.S.L., Lee, R.W.W., et al., 2010. Nasopharyngoscopic evaluation of oral appliance therapy for obstructive sleep apnoea. European Respiratory Journal, 35(4)'}, {'given': 'Pp.836–42.', 'family': 'Chan, A.S.L., Lee, R.W.W., et al., 2010. Nasopharyngoscopic evaluation of oral appliance therapy for obstructive sleep apnoea. The European respiratory journal, 35(4)'}, {'given': 'Pp.726–732.', 'family': 'Chan, A.S.L. et al., 2010. The effect of mandibular advancement on upper airway structure in obstructive sleep apnoea. Thorax, 65(8)'}, {'given': 'Pp.693–9.', 'family': 'Chan, A.S.L., Lee, R.W.W. & Cistulli, P. a, 2007. Dental appliance treatment for obstructive sleep apnea. Chest, 132(2)'}, {'given': 'Pp.179–84.', 'family': 'Chan, A.S.L., Lee, R.W.W. & Cistulli, P. a, 2008. Non-positive airway pressure modalities: mandibular advancement devices/positional therapy. Proceedings of the American Thoracic Society, 5(2)'}, {'given': 'Pp.157–162.', 'family': 'Chan, A.S.L., Lee, R.W.W. & Cistulli, P.A., 2011. Use of flow – volume curves to predict oral appliance treatment outcome in obstructive sleep apnea : a prospective validation study. Sleep Breath, 15'}, {'given': 'Pp.102–106.', 'family': 'Chan, A.S.L., Phillips, C.L. & Cistulli, P.A., 2010. Obstructive sleep apnoea – an update. Internal Medicine Journal, 40'}, {'given': 'Pp.39–45.', 'family': 'Chaudhary, B. & Speir, W., 1982. Sleep Apnoea Syndromes. Southern Medical Journal, 75(1)'}, {'given': 'Pp.473–86.', 'family': 'Chen, H. & Lowe, A. a, 2013. Updates in oral appliance therapy for snoring and obstructive sleep apnea. Sleep & breathing = Schlaf & Atmung, 17(2)'}, {'given': 'Pp.907–913.', 'family': 'Chesson, A.L., Berry, R.B. & Pack, A., 2003. Practice Parameters for the Use of Portable Monitoring Devices in the Investigation of Suspected Obstructive Sleep Apnea in Adults. SLEEP, 26(7)'}, {'given': 'Pp.443–57.', 'family': 'Cistulli, P. a et al., 2004. Treatment of snoring and obstructive sleep apnea with mandibular repositioning appliances. Sleep medicine reviews, 8(6)'}, {'given': 'Pp.1–5.', 'family': 'Cistulli, P.A., Palmisano, R.G. & Poole, M.D., 1998. Treatment of Obstructive Sleep Apnea Syndrome by Rapid Maxillary Expansion. SLEEP, 21(8)'}, {'given': 'Pp.624–9.', 'family': 'Clark, G.T. et al., 1993. Effect of anterior mandibular positioning on obstructive sleep apnea. The American review of respiratory disease, 147(3)'}, {'given': 'Pp.146–159.', 'family': 'Dalmasso, F. & Prota, R., 1996. Snoring: analysis, measurement, clinical implications and applications. European Respiratory Journal, 9(1)'}, {'given': 'Pp.1544–1550.', 'family': 'Dancey, D. et al., 2003. Gender Differences in Sleep Apnea: The role of neck circumference. Chest, 123'}, {'given': 'Pp.101–105.', 'family': 'Davies, R.J., Ali, N.J. & Stradling, J.R., 1992. Neck circumference and other clinical features in the diagnosis of the obstructive sleep apnoea syndrome. Thorax, 47'}, {'given': 'Pp.648–653.', 'family': 'Deane, S.A. et al., 2009. Comparison of Mandibular Advancement Splint and Tongue Stabilizing Device in Obstructive Sleep Apnea : A Randomized Controlled Trial. SLEEP, 32(5)'}, {'given': 'Pp.86–87.', 'family': 'Deatherage, J.R., Roden, R.D. & Zouhary, K., 2009. Normal Sleep Architecture. Seminars in Orthodontics, 15'}, {'given': 'Pp.1161–1178.', 'family': 'Deegan, P.C. & McNicholas, W.T., 1995. Pathophysiology of obstructive sleep apnoea. European Respiratory Journal, 8(7)'}, {'given': 'Pp.47–112.', 'family': 'Dempsey, J.A. et al., 2010. Pathophysiology of Sleep Apnea. Physiol Rev, 90'}, {'given': 'Pp.1010–8.', 'family': 'Doff, M.H.J. et al., 2010. Long-term oral-appliance therapy in obstructive sleep apnea: a cephalometric study of craniofacial changes. Journal of dentistry, 38(12)'}, {'given': 'Pp.2076–2084.', 'family': 'Doherty, L.S. et al., 2005. Long-term Effects of Nasal Continuous Positive Airway Pressure Therapy on Cardiovascular Outcomes in Sleep Apnea Syndrome * Long-term Effects of Nasal Continuous Positive Airway Pressure Therapy on Cardiovascular Outcomes in Sl'}, {'given': 'Pp.1003–9.', 'family': 'Dort, L.C., Hadjuk, E. & Remmers, J.E., 2006. Mandibular advancement and obstructive sleep apnoea: a method for determining effective mandibular protrusion. The European respiratory journal, 27(5)'}, {'given': 'Pp.525–531.', 'family': 'Du, X. & Hagg, U., 2003. Muscular Adaptation to Gradual Advancement of the Mandible. Angle Orthodontist, 73(5)'}, {'given': 'Pp.685–689.', 'family': 'Durán, J. et al., 2001. Obstructive Sleep Apnea – Hypopnea and Related Clinical Features in a Population-based Sample of Subjects Aged 30 to 70 Yr. Am J Respir Crit Care Med, 163'}, {'given': 'Pp.144–153.', 'family': 'Eckert, D.J. & Malhotra, A., 2008. Pathophysiology of Adult Obstructive Sleep Apnea. Proc Am Thorac Soc, 5'}, {'given': 'Pp.313–323.', 'family': 'Eckert, D.J., Malhotra, A. & Jordan, A.S., 2009. Mechanisms of Apnea. Progress in Cardiovascular Diseases, 51(4)'}, {'given': 'Pp.858–859.', 'family': 'Editorial, 2009. On the Plausibility of Upper Airway Remodeling as an Outcome of Orofacial Exercise. American journal of respiratory and critical care medicine, 179'}, {'given': 'Pp.1702–1709.', 'family': 'Eikermann, M. et al., 2007. The Influence of Aging on Pharyngeal Collapsibility During Sleep. Chest, 131(6)'}, {'given': 'Pp.305–10.', 'family': 'Ekici, A. et al., 2013. Personality profiles in patients with obstructive sleep apnea. Sleep & breathing = Schlaf & Atmung, 17(1)'}, {'given': 'Pp.e511–e521.', 'family': 'El, H. & Palomo, J.M., 2011. Airway volume for different dentofacial skeletal patterns. American Journal of Orthodontics and Dentofacial Orthopedics, 139'}, {'given': 'Pp.193–200.', 'family': 'Ellen, R. et al., 2006. Systematic Review of Motor Vehicle Crash Risk in Persons With Sleep Apnea. Journal of Clinical Sleep Medicine, 2(2)'}, {'given': 'Pp.263–266.', 'family': 'Ellis, E. & Anderson-Cermin, C., 1998. Occlusal Changes After Hyoid Advancement for Obstructive Sleep Apnea : Case Report. Journal of Oral and Maxillofacial Surgery, 56'}, {'given': 'Pp.855–859.', 'family': 'Engleman, H.M. et al., 2002. Randomized Crossover Trial of Two Treatments for Sleep Apnea / Hypopnea Syndrome Continuous Positive Airway Pressure and Mandibular Repositioning Splint. American journal of respiratory and critical care medicine, 166'}, {'given': 'Pp.263–266.', 'family': 'Engleman, H.M., Martin, S.E. & Douglas, N.J., 1994. Compliance with CPAP therapy in patients with the sleep apnoea / hypopnoea syndrome. Thorax, 49'}, {'given': 'pp.263– 276.', 'family': 'Epstein, L.J. et al., 2009. Clinical Guideline for the Evaluation, Management and Long-term Care of Obstructive Sleep Apnea in Adults. Journal of Clinical Sleep Medicine, 5(3)'}, {'given': 'Pp.905–909.', 'family': 'Eveloff, S.E. et al., 1994. Efficacy of a Herbst Mandibular Advancement Device in Obstructive Sleep Apnea. American journal of respiratory and critical care medicine, 149'}, {'given': 'P.674.', 'family': 'Eveloff, S.E., 2002. Treatment of Obstructive Sleep Apnea. CHEST Journal, 121(3)'}, {'given': 'Pp.77–86.', 'family': 'Faber, C.E. & Grymer, L., 2002. Available Techniques for Objective Assessment of Upper Airway Narrowing in Snoring and Sleep Apnea. Sleep & breathing, 7(2)'}, {'given': '2012. Volumetric analysis of the pharynx in patients with obstructive sleep apnea ( OSA ) treated with maxillomandibular advancement ( MMA ). Sleep Breath.', 'family': 'Faria, A.C. et al.'}, {'given': 'Pp.355–364.', 'family': 'Ferguson, K. a, 2003. The role of oral appliance therapy in the treatment of obstructive sleep apnea. Clinics in Chest Medicine, 24(2)'}, {'given': 'Pp.998–1004.', 'family': 'Ferguson, K. a & Fleetham, J. a, 1995. Sleep-related breathing disorders. 4. Consequences of sleep disordered breathing. Thorax, 50(9)'}, {'given': 'P.1269.', 'family': 'Ferguson, K. a., 1996. A Randomized Crossover Study of an Oral Appliance vs Nasal-Continuous Positive Airway Pressure in the Treatment of Mild-Moderate Obstructive Sleep Apnea. CHEST Journal, 109(5)'}, {'given': 'Pp.1269–1275.', 'family': 'Ferguson, K.A. et al., 1996. A Randomized Crossover Study of an Oral Appliance vs Nasal-Continuous Positive Airway Pressure in the Treatment of Mild-Moderate Obstructive Sleep Apnea *. CHEST Journal, 109'}, {'given': 'Pp.362–368.', 'family': 'Ferguson, K.A., Ono, T., et al., 1997. A short-term controlled trial of an adjustable oral appliance for the treatment of mild to moderate obstructive sleep apnoea. Thorax, 52(4)'}, {'given': 'Pp.244–262.', 'family': 'Ferguson, K.A., Cartwright, R., Rogers, R. & Schmidt-nowara, W., 2006. Oral Appliances for Snoring and Obstructive Sleep Apnea : A Review. SLEEP, 29(2)'}, {'given': 'Pp.244–62.', 'family': 'Ferguson, K.A., Cartwright, R., Rogers, R. & Schmidt-Nowara, W., 2006. Oral appliances for snoring and obstructive sleep apnea: a review. Sleep, 29(2)'}, {'given': 'Pp.375–381.', 'family': 'Ferguson, K.A. et al., 1995. The Relationship Between Obesity and Craniofacial Structure in Obstructive Sleep Apnea *. Chest, 108'}, {'given': 'Pp.1748–1754.', 'family': 'Ferguson, K.A., Love, L.L. & Ryan, C.F., 1997. Effect of Mandibular and Tongue Protrusion on Upper Airway Size During Wakefulness. Am J Respir Crit Care Med, 155'}, {'given': 'Pp.668–72.', 'family': 'Flemons, W.W. et al., 2004. Access to diagnosis and treatment of patients with suspected sleep apnea. American journal of respiratory and critical care medicine, 169(6)'}, {'given': 'Pp.498–504.', 'family': 'Flemons, W.W., 2002. Clinical Practice. The New England Journal of Medicine, 347(7)'}, {'given': 'Pp.1543–1579.', 'family': 'Flemons, W.W. et al., 2003. Home Diagnosis of Sleep Apnea : A Systematic Review of the Literature * : An Evidence Review Cosponsored by the American Academy of Sleep Medicine , the American College of Chest Physicians , and the American Thoracic Society H'}, {'given': 'Pp.618–621.', 'family': 'Flemons, W.W., Remmers, J.E. & Gillis, A.M., 1993. Sleep Apnea and Cardiac Arrhythmias Is There a Relationship ? Am Rev Respir Dis, 148'}, {'given': 'P.1761.', 'family': 'Fleury, B., 2004. Mandibular Advancement Titration for Obstructive Sleep Apnea *. CHEST Journal, 125(5)'}, {'given': 'Pp.2356–2359.', 'family': 'Fleury, B. et al., 1996. Objective patient compliance in long-term use of nCPAP. European Respiratory Journal, 9'}, {'given': 'Pp.150–5.', 'family': 'Fogel, R.B. et al., 2003. Anatomic and physiologic predictors of apnea severity in morbidly obese subjects. Sleep, 26(2)'}, {'given': 'Pp.27–36.', 'family': 'Franklin, K.A. et al., 2009. Effects and Side-Effects of Surgery for Snoring and Obstructive Sleep Apnea – A Systematic Review. Sleep, 32(1)'}, {'given': 'Pp.687–693.', 'family': 'Fransson, A.M.C. et al., 2004. Influence on the masticatory system in treatment of obstructive sleep apnea and snoring with a mandibular protruding device: A 2-year follow-up. American journal of orthodontics and dentofacial orthopedics, 126'}, {'given': 'Pp.813–818.', 'family': 'Fritsch, K.M. et al., 2001. Side Effects of Mandibular Advancement Devices for Sleep Apnea Treatment. , 164'}, {'given': 'Pp.256–61.', 'family': 'Ghoneima, A. & Kula, K., 2013. Accuracy and reliability of cone-beam computed tomography for airway volume analysis. European journal of orthodontics, 35(2)'}, {'given': 'Pp.173–180.', 'family': 'Giannakopoulos, H. & Costello, B.J., 2001. Mortised Genioplasty in the Treatment of Obstructive Sleep Apnea : An Historical Perspective and Modification of Design. Sleep & breathing, 5(4)'}, {'given': 'Pp.375–81.', 'family': 'Giannasi, L.C. et al., 2009. Systematic assessment of the impact of oral appliance therapy on the temporomandibular joint during treatment of obstructive sleep apnea: long-term evaluation. Sleep & breathing = Schlaf & Atmung, 13(4)'}, {'given': 'Pp.336–341.', 'family': 'Giannasi, L.C. et al., 2008. The impact of the Adjustable PM Positioner appliance in the treatment of obstructive sleep apnoea. Arch Med Sci, 4(3)'}, {'given': '(3).', 'family': 'Giles, T. et al., 2006. Continuous positive airways pressure for obstructive sleep apnoea in adults. Cochrane Database of Systematic Reviews'}, {'given': 'Pp.743–748.', 'family': 'Gotsopoulos, H., Chen, C., Qian, J. & Cistulli, P.A., 2002. Oral Appliance Therapy Improves Symptoms in Obstructive Sleep Apnea A Randomized, Controlled Trial. Am J Respir Crit Care Med, 166'}, {'given': 'Pp.743–8.', 'family': 'Gotsopoulos, H., Chen, C., Qian, J. & Cistulli, P. a, 2002. Oral appliance therapy improves symptoms in obstructive sleep apnea: a randomized, controlled trial. American journal of respiratory and critical care medicine, 166(5)'}, {'given': 'Pp.934–941.', 'family': 'Gotsopoulos, H., Kelly, J.J. & Cistulli, P.A., 2004. Oral Appliance Therapy Reduces Blood Pressure in Obstructive Sleep Apnea : a Randomized, Controlled Trial. SLEEP, 27(5)'}, {'given': 'Pp.893–896.', 'family': 'Guilleminault, C. & Li, K.K., 2004. Maxillomandibular Expansion for the Treatment of Sleep-Disordered Breathing : Preliminary Result. Laryngoscope, 114'}, {'given': 'Pp.465–484.', 'family': 'Guilleminault, C., Tilkian, A. & Dement, W., 1976. The Sleep Apnea Syndromes. Annu Rev Med, 27'}, {'given': 'Pp.962–966.', 'family': 'Guimaraes, K. ́tia C. et al., 2009. Effects of Oropharyngeal Exercises on Patients with Moderate Obstructive Sleep Apnea Syndrome. American journal of respiratory and critical care medicine, 179'}, {'given': 'Pp.267–270.', 'family': 'Hakan, E. & Palamo, J.M., 2013. An airway study of different maxillary and mandibular sagital positions. European journal of orthodontics, 35'}, {'given': 'Pp.415–425.', 'family': 'Hamada, T. et al., 2007. Mandibular distraction osteogenesis in a skeletal Class II patient with obstructive sleep apnea. American journal of orthodontics and dentofacial orthopedics, 131'}, {'given': 'Pp.806–14.', 'family': 'Hammond, R.J. et al., 2007. A follow-up study of dental and skeletal changes associated with mandibular advancement splint use in obstructive sleep apnea. American journal of orthodontics and dentofacial orthopedics : official publication of the American'}, {'given': 'Pp.562–570.', 'family': 'Hans, M.G. et al., 1997. Comparison of two dental devices for treatment of obstructive sleep apnea syndrome ( OSAS ). Am J Orthod Dentofac Orthop, 111'}, {'given': 'Pp.132–158.', 'family': 'Haskell, J. a. et al., 2009. Effects of Mandibular Advancement Device (MAD) on Airway Dimensions Assessed With Cone-Beam Computed Tomography. Seminars in Orthodontics, 15(2)'}, {'given': 'Pp.132–158.', 'family': 'Haskell, J.A. et al., 2009. Effects of Mandibular Advancement Device (MAD) on Airway Dimensions Assessed With Cone-Beam Computed Tomography. Seminars in Orthodontics, 15(2)'}, {'given': 'Pp.38–44.', 'family': 'Hassan, B. et al., 2013. Precision of identifying cephalometric landmarks with cone beam computed tomography in vivo. European journal of orthodontics, 35(1)'}, {'given': 'Pp.420–425.', 'family': 'Henke, K., Frantz, D. & Kuna, S., 2000. An Oral Elastic Mandibular Advancement Device for Obstructive Sleep Apnea. Am J Respir Crit Care Med, 161'}, {'given': 'Pp.240–243.', 'family': 'Hirshkowitz, M. et al., 2006. Practice Parameters for the Treatment of Snoring and Obstructive Sleep Apnea with Oral Appliances : An Update for 2005. SLEEP, 29(2)'}, {'given': 'Pp.440–445.', 'family': 'Hiyama, S. et al., 2003. Effects of Mandibular Advancement on Supine Airway Size in Normal Subjects During Sleep. SLEEP, 26(4)'}, {'given': 'Pp.48–54.', 'family': 'Hiyama, S., Kuribayashi, G. & Ono, T., 2002. Nocturnal Masseter and Suprahyoid Muscle Activity Induced by Wearing a Bionator. Angle Orthodontist, 72(1)'}, {'given': 'Pp.1181–1186.', 'family': 'Hoekema, A. et al., 2007. Predictors of Obstructive Sleep Apnea-Hypopnea Treatment Outcome. Journal of Dental Research, 86(12)'}, {'given': 'Pp.129–38.', 'family': 'Hoekema, A. et al., 2007. Simulated driving in obstructive sleep apnoea-hypopnoea; effects of oral appliances and continuous positive airway pressure. Sleep & breathing = Schlaf & Atmung, 11(3)'}, {'given': 'Pp.137–155.', 'family': 'Hoekema, A., Stegenga, B. & de Bont, L.G.M., 2004. Efficacy and Co-Morbidity of Oral Appliances in the Treatment of Obstructive Sleep Apnea-Hypopnea: a Systematic Review. Critical Reviews in Oral Biology & Medicine, 15(3)'}, {'given': 'P.466.', 'family': 'Hoffstein, V., 1994. Cardiac Arrhythmias, Snoring, and Sleep Apnea. CHEST Journal, 106(2)'}, {'given': 'Pp.1–22.', 'family': 'Hoffstein, V., 2007. Review of oral appliances for treatment of sleep-disordered breathing. Sleep & breathing = Schlaf & Atmung, 11(1)'}, {'given': 'Pp.162–170.', 'family': 'Holty, J.C. & Guilleminault, C., 2012. Maxillomandibular Expansion and Advancement for the Treatment of Sleep-Disordered Breathing in Children and Adults. Seminars in Orthodontics, 18'}, {'given': 'Pp.e161–9.', 'family': 'Hong, J.-S. et al., 2011. Three-dimensional analysis of pharyngeal airway volume in adults with anterior position of the mandible. American journal of orthodontics and dentofacial orthopedics : official publication of the American Association of Orthodont'}, {'given': 'Pp.541–549.', 'family': 'Hudgel, W., 1992. Mechanisms of obstructive sleep apnea. Chest, 101'}, {'given': 'Pp.62–69.', 'family': 'Ip, M. et al., 2001. A Community Study of Sleep-Disordered Breathing in Middle-aged Chinese Men in Hong Kong. Chest, 119(1)'}, {'given': 'Pp.323–325.', 'family': 'Ishida, M., Inoue, Y. & Okamoto, K., 1999. Clinical efficacy of prosthetic mandibular advancement on obstructive sleep apnea syndrome.'}, {'given': 'Pp.1319–1326.', 'family': 'Isono, S. et al., 1997. Anatomy of pharynx in patients with obstructive sleep apnea and in normal subjects. J Appl Physiol, 92'}, {'given': 'Pp.908–21.', 'family': 'Isono, S., 2009. Obstructive sleep apnea of obese adults: pathophysiology and perioperative airway management. Anesthesiology, 110(4)'}, {'given': 'Pp.435–441.', 'family': 'Jacobson, R.L. & Schendel, S.A., 2012. Treating Obstructive Sleep Apnea: The case for surgery. Am J Orthod Dentofacial Orthop, 142(4)'}, {'given': 'Pp.314–321.', 'family': 'Jauhar, S. et al., 2008. Ten-year follow-up of mandibular advancement devices for the management of snoring and sleep apnea. J Prosthet Dent, 99'}, {'given': 'Pp.47–53.', 'family': 'Johal, A. et al., 2007. The effect of mandibular advancement appliances on awake upper airway and masticatory muscle activity in patients with obstructive sleep apnoea. Clinical Physiology and Functional Imaging, 27'}, {'given': 'Pp.532–536.', 'family': 'Johal, A. & Battagel, J.M., 2001. Current principles in the management of obstructive sleep apnoea with mandibular advancement appliances. British Dental Journal, 190(10)'}, {'given': 'Pp.607–614.', 'family': 'Johal, A., Battagel, J.M. & Kotecha, B.T., 2005. Sleep nasendoscopy : a diagnostic tool for predicting treatment success with mandibular advancement splints in obstructive sleep apnoea. European journal of orthodontics, 27'}, {'given': 'Pp.251–262.', 'family': 'Johnston, C.D. et al., 2002. Mandibular advancement appliances and obstructive sleep apnoea : a randomized clinical trial. European journal of orthodontics, 24'}, {'given': 'Pp.361–368.', 'family': 'Jordan, A.S. et al., 2009. Airway Dilator Muscle Activity and Lung Volume During Stable Breathing in Obstructive Sleep Apnea. Sleep, 32(3)'}, {'given': 'Pp.63–72.', 'family': 'Jureyda, S. & Shucard, D.W., 2004. Obstructive sleep apnea—an overview of the disorder and its consequences. Seminars in Orthodontics, 10(1)'}, {'given': 'Pp.409–416.', 'family': 'Kapsimalis, F. & Kryger, M.H., 2002. Gender and Obstructive Sleep Apnea Syndrome , Part 1 : Clinical Features. SLEEP, 25(4)'}, {'given': 'Pp.1065–1072.', 'family': 'Kato, J. et al., 2000. Dose-Dependent Effects of Mandibular Advancement on Pharyngeal Mechanics and Nocturnal Oxygenation in Patients With Sleep-Disordered Breath. Chest, 117'}, {'given': 'Pp.647–653.', 'family': 'Katsavrias, E.G., 2003. The Effect of Mandibular Protrusive ( Activator ) Appliances on Articular Eminence Morphology. Angle Orthodontist, 73'}, {'given': 'Physical Examination and Identifying the Sites of Obstruction in OSA.', 'family': 'Kezirian, E.J.'}, {'given': 'Pp.128–33.', 'family': 'Kiely, J.L. & McNicholas, W.T., 2000. Cardiovascular risk factors in patients with obstructive sleep apnoea syndrome. The European respiratory journal, 16(1)'}, {'given': 'Pp.1108–13.', 'family': 'Kim, J. et al., 2004. Prevalence of sleep-disordered breathing in middle-aged Korean men and women. American journal of respiratory and critical care medicine, 170(10)'}, {'given': 'Pp.567–569.', 'family': 'Kimoff, R.J., 2007. Upper Airway Myopathy is Important in the Pathophysiology of Obstructive Sleep Apnea. Journal of Clinical Sleep Medicine, 3(6)'}, {'given': 'Pp.333–344.', 'family': 'Kollias, I. & Krogstad, O., 1999a. Adult craniocervical and pharyngeal changes — a longitudinal cephalometric study between 22 and 42 years of age . Part I : morphological craniocervical and hyoid bone changes. European journal of orthodontics, 21'}, {'given': 'Pp.345–355.', 'family': 'Kollias, I. & Krogstad, O., 1999b. Adult craniocervical and pharyngeal changes — a longitudinal cephalometric study between 22 and 42 years of age . Part II : morphological uvulo-glossopharyngeal changes. European journal of orthodontics, 21'}, {'given': 'Pp.16–19.', 'family': 'KOSKENVUO, M. et al., 1987. Snoring as a risk factor for ischaemic heart disease and stroke in men. Brittish Medical Journal, 294'}, {'given': 'Pp.887–895.', 'family': 'Kribbs, N. et al., 1993. Objective Measurement of Patterns of Nasal CPAP use by Patients with Obstructive Sleep Apnea. American journal of respiratory and critical care medicine, 147'}, {'given': 'Pp.499–521.', 'family': 'Kushida, C.A. et al., 2005. Practice Parameters for the Indications for Polysomnography and Related Procedures : An Update for 2005. SLEEP, 28(4)'}, {'given': 'Pp.240–243.', 'family': 'Kushida, C.A. et al., 2006. Practice Parameters for the Treatment of Snoring and Obstructive Sleep Apnea with Oral Appliances : An Update for 2005. Sleep, 29(2)'}, {'given': 'Pp.15–22.', 'family': 'Kyung, S.H. & Park, Y., 2004. Obstructive Sleep Apnea Patients with the Oral Appliance Experience Pharyngeal Size and Shape Changes in Three Dimensions. Angle Orthodontist, 75'}, {'given': 'Pp.699–711.', 'family': 'L’estrange, P. et al., 1996. A method of studying adaptive changes to the oropharynx to the variation in mandibular position in patients with obstructive sleep apnea. Journal of Oral Rehabilitation, 23'}, {'given': 'Pp.195–201.', 'family': 'Lam, B. et al., 2011. The efficacy of oral appliances in the treatment of severe obstructive sleep apnea. Sleep Breath, 15'}, {'given': 'Pp.39–44.', 'family': 'Lampasso, J.D. & Lampasso, J.G., 2004. Allergy, Nasal Obstruction, and Occlusion. Seminars in Orthodontics, 10'}, {'given': 'Pp.1362–1368.', 'family': 'Larsson, L., Carlson-Nordlander, B. & Svanborg, E., 1994. Four-year Follow-up After Uvulopalatopharyngoplasty In 50 Unselected Patients with Obstructive Sleep Apnea Syndrome. Laryngoscope, 104'}, {'given': 'Pp.2–6.', 'family': 'Lavigne, G.J. et al., 1999. Sleep disorders and the dental patient. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 88(3)'}, {'given': 'Inc.', 'family': 'Lavigne, G.J., Cistulli, P.A. & Smith, M.T., 2009. Sleep Medicine for Dentists: A practical overview, Quintessence Publishing Co'}, {'given': 'Pp.37–45.', 'family': 'Lee, R.W.W., Chan, A.S.L., Grunstein, R.R. & Cistulli, P.A., 2009. Craniofacial Phenotyping in Obstructive Sleep Apnea – A Novel Quantitative Photographic Approach. SLEEP, 32(1)'}, {'given': 'Pp.37–45.', 'family': 'Lee, R.W.W., Chan, A.S.L., Grunstein, R.R. & Cistulli, P. a, 2009. Craniofacial phenotyping in obstructive sleep apnea--a novel quantitative photographic approach. Sleep, 32(1)'}, {'given': 'Pp.46–52.', 'family': 'Lee, R.W.W., Petocz, P., et al., 2009. Prediction of Obstructive Sleep Apnea with Craniofacial Photographic Analysis. SLEEP, 32(1)'}, {'given': 'Pp.96–105.', 'family': 'Lenza, M. et al., 2010. An analysis of different approaches to the assessment of upper airway morphology : a CBCT study. Orthodontics & Craniofacial Research, 13(2)'}, {'given': 'Pp.139–47.', 'family': 'Levendowski, D.J. et al., 2007. In-home evaluation of efficacy and titration of a mandibular advancement device for obstructive sleep apnea. Sleep & breathing = Schlaf & Atmung, 11(3)'}, {'given': 'Pp.201–209.', 'family': 'Li, K.K., 2005. Surgical therapy for adult obstructive sleep apnea. Sleep Medicine Reviews, 9'}, {'given': 'Pp.1751–1755.', 'family': 'Liistro, G., Aubert, G. & Rodenstein, D.O., 1995. Management of sleep apnoea syndrome. European Respiratory Journal, 8(10)'}, {'given': '(1).', 'family': 'Lim, J. et al., 2006. Oral appliances for obstructive sleep apnoea (Review). Cochrane Database of Systematic Reviews'}, {'given': 'Pp.639–647.', 'family': 'Liu, Y. et al., 2001. Cephalometric and physiologic predictors of the efficacy of an adjustable oral appliance for treating obstructive sleep apnea. American Journal of Orthodontics and Dentofacial Orthopedics, 120(6)'}, {'given': 'Pp.248–56.', 'family': 'Liu, Y. et al., 2000. Effects of a mandibular repositioner on obstructive sleep apnea. American journal of orthodontics and dentofacial orthopedics : official publication of the American Association of Orthodontists, its constituent societies, and the Ame'}, {'given': 'Pp.15–23.', 'family': 'Liu, Y. & Lowe, A., 2000. Factors Related to the Efficacy of an Adjustable Oral Appliance for the Treatment of Obstructive Sleep Apnea. CJDR, 3'}, {'given': 'Pp.S93–95.', 'family': 'Lowe, A., 1993. Can We Predict the Success of Dental Appliance Therapy for the Treatment of Obstructive Sleep Apnea Based on Anatomical Considerations? SLEEP, 16(8)'}, {'given': 'Pp.172–178.', 'family': 'Lowe, A. et al., 2000. Treatment, Airway and Compliance Effects of a Titratable Oral Appliance. SLEEP, 23(4)'}, {'given': 'Pp.589–595.', 'family': 'Lowe, A.A. et al., 1995. Cephalometric and computed tomographic predictors of obstructive sleep apnea severity. Am J Orthod Dentofac Orthop, 107'}, {'given': 'Pp.653–664.', 'family': 'Lowe, A.A. et al., 1996. Cephalometric comparisons of craniofacial and upper airway structure by skeletal subtype and gender in patients with obstructive sleep apnea. Am J Orthod Dentofac Orthop, 110'}, {'given': 'Pp.484–491.', 'family': 'Lowe, A.A. et al., 1986. Facial morphology and obstructive sleep apnea. Am J Orthod Dentofac Orthop, 90'}, {'given': 'Pp.434–440.', 'family': 'Lowe, A.A., 2012. Treating Obstructive Sleep Apnea: The case for oral appliances. Am J Orthod Dentofacial Orthop, 142(4)'}, {'given': 'Pp.59–64.', 'family': 'Lugaresi, E. et al., 1975. Snoring. Electroencephalography and Clinical Neurophysiology, 39'}, {'given': 'Pp.99–104.', 'family': 'Lye, K.W. & Deatherage, J.R., 2009a. Surgical Maxillomandibular Advancement Technique. Seminars in Orthodontics, 15(2)'}, {'given': 'Pp.94–98.', 'family': 'Lye, K.W. & Deatherage, J.R., 2009b. Surgical Procedures for the Treatment of Obstructive Sleep Apnea. Seminars in Orthodontics, 15(2)'}, {'given': '2012. Postoperative complications in obstructive sleep apnea. Sleep Breath.', 'family': 'Mador, M.J., Goplani, S. & Abo-khamis, M.'}, {'given': 'Pp.700–8.', 'family': 'Major, M.P., Flores-Mir, C. & Major, P.W., 2006. Assessment of lateral cephalometric diagnosis of adenoid hypertrophy and posterior upper airway obstruction: a systematic review. American journal of orthodontics and dentofacial orthopedics : official publ'}, {'given': 'Pp.513–516.', 'family': 'Malkoc, S. et al., 2005. Reproducibility of airway dimensions and tongue and hyoid positions on lateral cephalograms. Am J Orthod Dentofac Orthop, 128'}, {'given': 'P.707.', 'family': 'Marklund, M., 1998a. The Effect of a Mandibular Advancement Device on Apneas and Sleep in Patients With Obstructive Sleep Apnea. CHEST Journal, 113(3)'}, {'given': 'P.1630.', 'family': 'Marklund, M., 1998b. Treatment Success With a Mandibular Advancement Device Is Related to Supine-Dependent Sleep Apnea. CHEST Journal, 114(6)'}, {'given': 'Pp.135–144.', 'family': 'Marklund, M., Franklin, K.A. & Persson, M., 2001. Orthodontic side-effects of mandibular advancement devices during treatment of snoring and sleep apnoea. , 23'}, {'given': 'Pp.1630–1635.', 'family': 'Marklund, M., Persson, M. & Franklin, K.A., 1998. Treatment Success With a Mandibular Advancement Device Is Related to Supine-Dependent Sleep Apnea1. Chest, 114'}, {'given': 'Pp.1270–1278.', 'family': 'Marklund, M., Stenlund, H. & Franklin, K.A., 2004. Mandibular Advancement Devices in 630 Men and Women With Obstructive Sleep Apnea and Snoring * : Tolerability and Predictors of Treatment Success. Chest, 125'}, {'given': 'Pp.1241–7.', 'family': 'Marklund, M., Verbraecken, J. & Randerath, W., 2012. Non-CPAP therapies in obstructive sleep apnoea: mandibular advancement device therapy. The European respiratory journal, 39(5)'}, {'given': 'Pp.188–97.', 'family': 'Mattos, C.T. et al., 2014. Reliability of upper airway linear, area, and volumetric measurements in cone-beam computed tomography. American journal of orthodontics and dentofacial orthopedics : official publication of the American Association of Orthodont'}, {'given': 'Pp.35–43.', 'family': 'Mayer, G. & Meier-Ewert, K., 1995. Cephalometric predictors for orthopaedic mandibular advancement in obstructive sleep apnoea. European journal of orthodontics, 17(1)'}, {'given': 'Pp.63–69.', 'family': 'McCrillis, J.M. et al., 2009. Obstructive Sleep Apnea and the Use of Cone Beam Computed Tomography in Airway Imaging: A Review. Seminars in Orthodontics, 15(1)'}, {'given': 'Pp.197–205.', 'family': 'McGinley, B.M. et al., 2008. Upper airway neuromuscular compensation during sleep is defective in obstructive sleep apnea. Journal of applied physiology (Bethesda, Md. : 1985), 105(1)'}, {'given': 'Pp.462–6.', 'family': 'McGown, A.D. et al., 2001. Long-term use of mandibular advancement splints for snoring and obstructive sleep apnoea: a questionnaire survey. The European respiratory journal, 17(3)'}, {'given': 'Ontario.', 'family': 'Medical Advisory Secretariat, 2009. Oral Appliances for Obstructive Sleep Apnea: an evidence-based analysis'}, {'given': 'Pp.1457–1461.', 'family': 'Mehta, A. et al., 2001. A Randomized , Controlled Study of a Mandibular Advancement Splint for Obstructive Sleep Apnea. Am J Respir Crit Care Med, 163'}, {'given': 'Pp.320–324.', 'family': 'Meyer, B. & Knudson, C., 1990. The sleep apnea syndrome . Part II : Treatment. Journal of Prosthetic Dentistry, 63(3)'}, {'given': 'Pp.675–679.', 'family': 'Meyer, J.B. & Knudson, R.C., 1989. The sleep apnea syndrome . Part I : Diagnosis. J Prosthet Dent, 62'}, {'given': 'Pp.163–172.', 'family': 'Miles, P.G., Vig, P.S. & Dorth, F.D.S., 1996. Craniofacial structure and obstructive sleep apnea syndrome-a qualitative analysis and meta-analysis of the literature. Am J Orthod Dentofac Orthop, 109'}, {'given': 'Pp.1025–1030.', 'family': 'Millman, R.P. et al., 2000. Simple Predictors of Uvulopalatopharyngoplasty Outcome in the Treatment of Obstructive Sleep Apnea * Simple Predictors of Uvulopalatopharyngoplasty Outcome in the Treatment of Obstructive Sleep Apnea *. CHEST Journal, 118'}, {'given': 'Pp.545–549.', 'family': 'Mokhlesi, B. & Gozal, D., 2010. Pulmonary and Critical Care Updates Update in Sleep Medicine 2009. Am J Respir Crit Care Med, 181'}, {'given': 'Pp.1031–1035.', 'family': 'Morgenthaler, T.I. et al., 2006. Practice Parameters for the Medical Therapy of Obstructive Sleep Apnea. Sleep, 29(8)'}, {'given': 'Pp.606–611.', 'family': 'MORRISON, D.L. et al., 1993. Pharyngeal Narrowing and Closing Pressures in Patients with Obstructive Sleep Apnea. Am J Respir Crit Care Med, 148'}, {'given': 'Pp.280–3.', 'family': 'Mortimore, I.L. et al., 1998. Neck and total body fat deposition in nonobese and obese patients with sleep apnea compared with that in control subjects. American journal of respiratory and critical care medicine, 157(1)'}, {'given': 'Pp.1331–1339.', 'family': 'Mostafiz, W. et al., 2011. Influence of Oral and Craniofacial Dimensions on Mandibular Advancement Splint Treatment Outcome in Obstructive Sleep Apnea. Chest, 139(6)'}, {'given': 'Pp.43–54.', 'family': 'Naismith, S. et al., 2004. Neurobehavioral Functioning in Obstructive Sleep Apnea : Differential Effects of Sleep Quality, Hypoxemia and Subjective Sleepiness. Journal of Psychosomatic Research, 26(1)'}, {'given': 'Pp.47–58.', 'family': 'Ng, A. et al., 2012. Cephalometry and prediction of oral appliance treatment outcome. Sleep Breath, 16'}, {'given': 'Pp.238–41.', 'family': 'Ng, A.T. et al., 2003. Effect of oral appliance therapy on upper airway collapsibility in obstructive sleep apnea. American journal of respiratory and critical care medicine, 168(2)'}, {'given': 'Pp.666–671.', 'family': 'Ng, A.T., Qian, J. & Cistulli, P.A., 2006. Oropharyngeal Collapse Predicts Treatment Response With Oral Appliance Therapy in Obstructive Sleep Apnea. SLEEP, 29(5)'}, {'given': 'Pp.47–58.', 'family': 'Ng, A.T.M., Darendeliler, M.A., Petocz, P. & Cistulli, P. a, 2012. Cephalometry and prediction of oral appliance treatment outcome. Sleep & breathing = Schlaf & Atmung, 16(1)'}, {'given': 'Pp.47–58.', 'family': 'Ng, A.T.M., Darendeliler, M.A., Petocz, P. & Cistulli, P.A., 2012. Cephalometry and prediction of oral appliance treatment outcome. Sleep & breathing = Schlaf & Atmung, 16(1)'}, {'given': 'Pp.408–19.', 'family': 'Ngiam, J. et al., 2013. Clinical guidelines for oral appliance therapy in the treatment of snoring and obstructive sleep apnoea. Australian dental journal, 58(4)'}, {'given': 'Pp.53–61.', 'family': 'Ohayon, M.M., Li, K.K. & Guilleminault, C., 2001. Risk Factors for Sleep Bruxism in the General Population. CHEST Journal, 119'}, {'given': 'Pp.620–622.', 'family': 'Okawara, Y. et al., 2004. Oral appliance titration and nasal resistance in nonapneic subjects. American Journal of Orthodontics and Dentofacial Orthopedics, 126(5)'}, {'given': 'Pp.513–515.', 'family': 'Oksenberg, A. & Arons, E., 2002. Sleep bruxism related to obstructive sleep apnea : the effect of continuous positive airway pressure. Sleep Medicine, 3'}, {'given': 'Pp.1879–1884.', 'family': 'Ono, T. et al., 2000. Effects of Head and Body Position on Two- and Three-dimensional Configurations of the Upper Airway. Journal of Dental Research, 79(11)'}, {'given': 'Pp.222–229.', 'family': 'Otsuka, R., Almeida, R. De, et al., 2006. A comparison of responders and nonresponders to oral appliance therapy for the treatment of obstructive sleep apnea. Am J Orthod Dentofacial Orthop, 129'}, {'given': 'Pp.222–229.', 'family': 'Otsuka, R., Ribeiro De Almeida, F., et al., 2006. obstructive sleep apnea. Am J Orthod Dentofacial Orthop, 129(2)'}, {'given': 'Pp.113–143.', 'family': 'Özbek, M.M. et al., 1998. Natural head posture , upper airway morphology and obstructive sleep apnoea severity in adults. European journal of orthodontics, 20'}, {'given': 'Pp.792–797.', 'family': 'Pae, E. et al., 2008. Can facial type be used to predict changes in hyoid bone position with age? A perspective based on longitudinal data. American journal of orthodontics and dentofacial orthopedics, 134'}, {'given': 'Pp.52–9.', 'family': 'Pae, E.K. et al., 1994. A cephalometric and electromyographic study of upper airway structures in the upright and supine positions. American journal of orthodontics and dentofacial orthopedics : official publication of the American Association of Orthodon'}, {'given': 'Pp.178–84.', 'family': 'Pae, E.K., Lowe, a a & Fleetham, J. a, 1997. A thin-plate spline analysis of the face and tongue in obstructive sleep apnea patients. Clinical oral investigations, 1(4)'}, {'given': 'Pp.1511–1518.', 'family': 'Pancer, J., 1999. Evaluation of Variable Mandibular Advancement Appliance for Treatment of Snoring and Sleep Apnea*. Chest, 116(6)'}, {'given': 'Pp.237–240.', 'family': 'Pantin, C.C., Hillman, D.R. & Tennant, M., 1999. Dental Side Effects of an Oral Device to Treat Snoring and Obstructive Sleep Apnea. SLEEP, 22(2)'}, {'given': 'Pp.R1671–R1683.', 'family': 'Parati, G., Lombardi, C. & Narkiewicz, K., 2007. Sleep apnea : epidemiology , pathophysiology , and relation to cardiovascular risk. Am J Physiol Regul Integr Comp Physiol'}, {'given': 'Pp.549–555.', 'family': 'Park, J.G., Ramar, K. & Olson, E.J., 2011. Updates on Definition , Consequences , and Management of Obstructive Sleep Apnea. Mayo Clinic Proceedings, 86(6)'}, {'given': 'Pp.156–159.', 'family': 'Partinen, M., 1995. Ischaemic stroke, snoring and obstructive sleep apnea. J Sleep Res, 4(1)'}, {'given': 'P.1200.', 'family': 'Partinen, M., 1988. Long-term outcome for obstructive sleep apnea syndrome patients. Mortality. CHEST Journal, 94(6)'}, {'given': 'Pp.375–381.', 'family': 'Pépin, J.L. et al., 1995. Side Effects of Nasal Continuous Positive Airway Pressure in Sleep Apnea Syndrome : Study of 193 Patients in Two French Sleep Centers. CHEST Journal, 107'}, {'given': 'Pp.3015–21.', 'family': 'Peppard, P.E., Young, T., Palta, M., Dempsey, J., et al., 2000. Longitudinal study of moderate weight change and sleep-disordered breathing. JAMA : the journal of the American Medical Association, 284(23)'}, {'given': 'Pp.1378–1384.', 'family': 'Peppard, P.E., Young, T., Palta, M. & Skatrud, J., 2000. Prospective Study of the Association between Sleep-Disordered Breathing and Hypertension. The New England Journal of Medicine, 342(19)'}, {'given': 'Pp.1–10.', 'family': 'Perez, C. V et al., 2012. The incidence and prevalence of temporomandibular disorders and posterior open bite in patients receiving mandibular advancement device therapy for obstructive sleep apnea. Sleep Breath'}, {'given': 'Pp.1150–1153.', 'family': 'Pételle, B. et al., 2002. One-Night Mandibular Advancement Titration for Obstructive Sleep Apnea Syndrome A Pilot Study. Am J Respir Crit Care Med, 165'}, {'given': '2013. Health Outcomes of CPAP versus Oral Appliance Treatment for Obstructive Sleep Apnea: A Randomised Controlled Trial (For Review Only). American journal of respiratory and critical care medicine.', 'family': 'Phillips, C.L. et al.'}, {'given': 'Pp.761–6.', 'family': 'Pirelli, P., Saponara, M. & Guilleminault, C., 2004. Rapid maxillary expansion in children with obstructive sleep apnea syndrome. Sleep, 27(4)'}, {'given': 'Pp.860–4.', 'family': 'Pitsis, A.J. et al., 2002. Effect of vertical dimension on efficacy of oral appliance therapy in obstructive sleep apnea. American journal of respiratory and critical care medicine, 166(6)'}, {'given': 'Pp.362–369.', 'family': 'Powell, N., Riley, R. & Guilleminault, C., 1988. Obstructive Sleep Apnea, Continuous Positive Airway Pressure, and Surgery. Otolaryngol Head Neck Surg, 99'}, {'given': 'Pp.410–419.', 'family': 'Pracharktam, N. et al., 1996. Cephalometric assessment in obstructive sleep apnea. Am J Orthod Dentofac Orthop, 109'}, {'given': 'Pp.3–15.', 'family': 'Preston, C.B., Lampasso, J.D. & Tobias, P. V, 2004. Cephalometric evaluation and measurement of the upper airway. Seminars in Orthodontics, 10(1)'}, {'given': 'Pp.175–186.', 'family': 'Proffit, W., 1978. Equilibrium Theory Revisited: Factors Influecing Position of Teeth. The Angle Orthodontist, 48(3)'}, {'given': 'Pp.1–5.', 'family': 'Puhan, M.A. et al., 2005. Didgeridoo playing as alternative treatment for obstructive sleep apnoea syndrome: randomised controlled trial. BMJ, (Dec)'}, {'given': 'P.e1000132.', 'family': 'Punjabi, N.M. et al., 2009. Sleep-disordered breathing and mortality: a prospective cohort study. PLoS medicine, 6(8)'}, {'given': 'Pp.244–246.', 'family': 'Rahbar, R., 2004. Adenotonsillar Hypertrophy : The Presentation and Management of Upper Airway Obstruction. Seminars in Orthodontics, 10'}, {'given': 'Pp.569–575.', 'family': 'Randerath, W.J. et al., 2002. An Individually Adjustable Oral Appliance vs Continuous Positive Airway Pressure in Mild-to-Moderate Obstructive Sleep Apnea Syndrome. CHEST Journal, 122'}, {'given': 'Pp.1–7.', 'family': 'Raphaelson, M. et al., 1998. Oral Appliance Therapy for Obstructive Sleep Apnea Syndrome: Progressive Mandibular Advancement During Polysomnography. Journal of Craniomandibular Practice, 16(1)'}, {'given': 'Pp.39–49.', 'family': 'Ravesloot, M.J.L. et al., 2013. The undervalued potential of positional therapy in position-dependent snoring and obstructive sleep apnea-a review of the literature. Sleep & breathing = Schlaf & Atmung, 17(1)'}, {'given': 'Pp.105–110.', 'family': 'Ravesloot, M.J.L. & Vries, N. De, 2011. Reliable Calculation of the Efficacy of Non-Surgical and Surgical Treatment of Obstructive Sleep Apnea Revisited. Sleep, 34(1)'}, {'given': 'Pp.186–92.', 'family': 'Redline, S. et al., 1997. Racial differences in sleep-disordered breathing in African-Americans and Caucasians. American journal of respiratory and critical care medicine, 155(1)'}, {'given': 'Pp.583–602.', 'family': 'Redline, S. & Tishler, P. V., 2000. The genetics of sleep apnea. Sleep medicine reviews, 4(6)'}, {'given': 'Pp.505–511.', 'family': 'Ribeiro De Almeida, F. et al., 2002. Effects of Mandibular Posture on Obstructive Sleep Apnea Severity and the Temporomandibular Joint in Patients Fitted with an Oral Appliance. , 25(5)'}, {'given': 'Pp.303–11.', 'family': 'Riley, R. et al., 1983. Cephalometric analyses and flow-volume loops in obstructive sleep apnea patients. Sleep, 6(4)'}, {'given': 'Pp.415–421.', 'family': 'Riley, R. et al., 2000. Surgery and Obstructive Sleep Apnea: Long-term clinical outcomes. Otolaryngol Head Neck Surg, 122'}, {'given': 'Pp.117–125.', 'family': 'Riley, R., Powell, N. & Guilleminault, C., 1993. Obstructive Sleep Apnea Syndrome: A review of 306 consecutively treated surgical patients. Otolaryngol Head Neck Surg, 108'}, {'given': 'Pp.742–747.', 'family': 'Riley, R.W., Powell, N.B. & Guilleminault, C., 1993. Obstructive Sleep Apnea Syndrome : A Surgical Protocol for Dynamic Airway Reconstruction. Journal of Oral and Maxillofacial Surgery, 51'}, {'given': 'Pp.53–60.', 'family': 'Ringqvist, M. et al., 2003. Dental and skeletal changes after 4 years of obstructive sleep apnea treatment with a mandibular advancement device: A prospective, randomized study. Am J Orthod Dentofac Orthop, 124'}, {'given': 'Pp.371–376.', 'family': 'Robertson, C., Herbison, P. & Harkness, M., 2003. Dental and occlusal changes during mandibular advancement splint therapy in sleep disordered patients. European journal of orthodontics, 25'}, {'given': 'Pp.34–45.', 'family': 'Rondeau, B., 2010. The Dentist’s Involvement in Snoring and Sleep Apnea. Chairside'}, {'given': 'Pp.1–14.', 'family': 'Ross, S.D. et al., 2000. Systematic Review and Meta-analysis of the Literature Regarding the Diagnosis of Sleep Apnea. SLEEP, 23(4)'}, {'given': 'Pp.271–273.', 'family': 'Ruoff, C.M. & Guilleminault, C., 2012. Orthodontics and sleep-disordered breathing. Sleep Breath, 16'}, {'given': 'Pp.972–977.', 'family': 'Ryan, C.F. et al., 1999. Mandibular advancement oral appliance therapy for obstructive sleep apnoea : effect on awake calibre of the velopharynx. Thorax, 54'}, {'given': 'Pp.824–30.', 'family': 'Ryan, S., Taylor, C.T. & McNicholas, W.T., 2006. Predictors of elevated nuclear factor-kappaB-dependent genes in obstructive sleep apnea syndrome. American journal of respiratory and critical care medicine, 174(7)'}, {'given': 'Pp.485–489.', 'family': 'Sadaoka, T. et al., 1996. The value of sleep nasendoscopy in the evaluation of patiets with suspected sleep-related breathing disorders. Clin. Otolaryngol, 21'}, {'given': 'Pp.885–90.', 'family': 'Saigusa, H. et al., 2009. Three-dimensional morphological analyses of positional dependence in patients with obstructive sleep apnea syndrome. Anesthesiology, 110(4)'}, {'given': 'Pp.54–62.', 'family': 'Salem, O.H., Briss, B.S. & Annino, D.J., 2004a. Nasorespiratory Function and Craniofacial Morphology — A Review of the Surgical Management of the Upper Airway. Seminars in Orthodontics, 10'}, {'given': 'Pp.54–62.', 'family': 'Salem, O.H., Briss, B.S. & Annino, D.J., 2004b. Nasorespiratory function and craniofacial morphology—a review of the surgical management of the upper airway. Seminars in Orthodontics, 10(1)'}, {'given': 'Pp.143–150.', 'family': 'Sanner, B.M. et al., 2002. MRI of the pharynx and treatment efficacy of a mandibular advancement device in obstructive sleep apnoea syndrome. European Respiratory Journal, 20(1)'}, {'given': 'Pp.629–636.', 'family': 'Santos-Silva, R. et al., 2009. Validation of a Portable Monitoring System for the Diagnosis of Obstructive Sleep Apnea Syndrome. SLEEP, 32(5)'}, {'given': 'Pp.829–39.', 'family': 'Schäfer, H. et al., 2002. Body fat distribution, serum leptin, and cardiovascular risk factors in men with obstructive sleep apnea. Chest, 122(3)'}, {'given': 'Pp.501–510.', 'family': 'Schmidt-Nowara, W. et al., 1995. An American Sleep Disorders Association Review Oral Appliances for the Treatment of Snoring and Obstructive Sleep Apnea : A Review. SLEEP, 18(6)'}, {'given': 'Pp.1673–1689.', 'family': 'Schwab, R.J. et al., 1995. Upper Airway and Soft Tissue Anatomy in Normal Subjects and Patients with Sleep-Disordered Breathing Significance of the lateral Pharyngeal Walls. Am J Physiol Regul Integr Comp Physiol, 152'}, {'given': 'Pp.125–6.', 'family': 'Schwarting, S. et al., 2007. Position paper on the use of mandibular advancement devices in adults with sleep-related breathing disorders. A position paper of the German Society of Dental Sleep Medicine (Deutsche Gesellschaft Zahnaerztliche Schlafmedizin,'}, {'given': 'Pp.185–92.', 'family': 'Schwartz, A.R. et al., 2008. Obesity and obstructive sleep apnea: pathogenic mechanisms and therapeutic approaches. Proceedings of the American Thoracic Society, 5(2)'}, {'given': 'Pp.49–56.', 'family': 'Sengul, Y.S., Ozalevli, S. & Oztura, I., 2011. The effect of exercise on obstructive sleep apnea : a randomized and controlled trial. Sleep Breath, 15'}, {'given': 'Pp.703–714.', 'family': 'Seto, B.H. et al., 2001. Maxillary morphology in obstructive sleep apnoea syndrome. European journal of orthodontics, 23'}, {'given': 'Pp.19–25.', 'family': 'Shahar, E. et al., 2001. Sleep-disordered Breathing and Cardiovascular Disease Cross-sectional Results of the Sleep Heart Health Study. Am J Respir Crit Care Med, 163'}, {'given': 'Pp.1209–1217.', 'family': 'Shen, H.-L. et al., 2012. Craniofacial morphologic predictors of oral appliance outcomes in patients with obstructive sleep apnea. Journal of American Dental Association, 143(11)'}, {'given': 'Pp.156–177.', 'family': 'Sher, A.E., Schechtman, B. & Piccirillo, J.R., 1996. The Efficacy of Surgical Modifications of the Upper Airway in Adults With Obstructive Sleep Apnea Syndrome. SLEEP, 19(2)'}, {'given': 'Pp.347–52.', 'family': 'Shigeta, Y. et al., 2008. Correlation between retroglossal airway size and body mass index in OSA and non-OSA patients using cone beam CT imaging. Sleep & breathing = Schlaf & Atmung, 12(4)'}, {'given': '(1).', 'family': 'Shneerson, J. & Wright, J., 2001. Lifestyle modification for obstructive sleep apnoea (Review). Cochrane Database of Systematic Reviews'}, {'given': '2012. Does physical exercise reduce excessive daytime sleepiness by improving inflammatory profiles in obstructive sleep apnea patients ? Sleep Breath.', 'family': 'Da Silva Alves, E. et al.'}, {'given': 'Pp.105–131.', 'family': 'Sittitavornwong, S. et al., 2009. Evaluation of Obstructive Sleep Apnea Syndrome by Computational Fluid Dynamics. Seminars in Orthodontics, 15(2)'}, {'given': '(2).', 'family': 'Smith, I., Lasserson, T. & Wright, J., 2006. Drug therapy for obstructive sleep apnoea in adults ( Review ). Cochrane Database of Systematic Reviews'}, {'given': 'Pp.618–626.', 'family': 'Smith, T. et al., 2012. Three-dimensional computed tomography analysis of airway volume changes after rapid maxillary expansion. American Journal of Orthodontics and Dentofacial Orthopedics, 141'}, {'given': 'Customer brochure.', 'family': 'Somnomed'}, {'given': 'Pp.1–14.', 'family': 'Somnomed, Key research findings.'}, {'given': 'Pp.1–2.', 'family': 'Somnomed, Offer your OSA patients an alternative to CPAP therapy.'}, {'given': 'Pp.118–125.', 'family': 'Sonnesen, L., 2012. Cervical Vertebral Column Morphology Associated with Head Posture and Craniofacial Morphology. Seminars in Orthodontics, 18(2)'}, {'given': 'Pp.836–842.', 'family': 'Srinivasan, V.K. et al., 2010. Nasopharyngoscopic evaluation of oral appliance therapy for obstructive sleep apnoea. , 35(4)'}, {'given': 'Pp.85–90.', 'family': 'Stradling, R. & Crosby, J.H., 1991. Predictors and prevalence of obstructive sleep apnoea and snoring in 1001 middle aged men. Thorax, 46'}, {'given': 'Pp.555–558.', 'family': 'Strohl, K.P. & Redline, S., 1986. Nasal CPAP Therapy, Upper Airway Muscle Activation, and Obstructive Sleep Apnea. Am Rev Respir Dis, 134'}, {'given': 'Pp.862–865.', 'family': 'Sullivan, C. et al., 1981. Reversal of Obstructive Sleep Apnea By Continuous Positive Airway Pressure Applied Through the Nares. The Lancet'}, {'given': 'Pp.194–198.', 'family': 'Sullivan, R.A.O. et al., 1995. Mandibular Advancement Splint : An Appliance to Treat Snoring and Obstrudive Sleep Apnea. Am J Respir Crit Care Med, 151'}, {'given': '(4).', 'family': 'Sundaram, S., Lim, J. & Tj, L., 2005. Surgery for obstructive sleep apnoea in adults ( Review ). Cochrane Database of Systematic Reviews'}, {'given': 'Pp.469–477.', 'family': 'Sutherland, K. et al., 2011. Comparative Effects of Two Oral Appliances on Upper Airway Structure in Obstructive Sleep Apnea. SLEEP, 34(4)'}, {'given': 'P.w13276.', 'family': 'Sutherland, K. & Cistulli, P., 2011. Mandibular advancement splints for the treatment of sleep apnea syndrome. Swiss medical weekly, 141(September)'}, {'given': 'Pp.1–10.', 'family': 'Sutherland, K. & Cistulli, P.A., 2011. Mandibular advancement splints for the treatment of sleep apnoea syndrome. Swiss Medical Weekly, 114(September)'}, {'given': 'Pp.213–22.', 'family': 'Sutherland, K., Lee, R.W.W. & Cistulli, P. a, 2012. Obesity and craniofacial structure as risk factors for obstructive sleep apnoea: impact of ethnicity. Respirology (Carlton, Vic.), 17(2)'}, {'given': 'Pp.213–222.', 'family': 'SUTHERLAND, K., LEE, R.W.W. & CISTULLI, P.A., 2012. Obesity and craniofacial structure as risk factors for obstructive sleep apnoea: Impact of ethnicityresp_2082. Respirology, 17'}, {'given': 'Pp.239–249.', 'family': 'Tan, Y.K. et al., 2002. Mandibular advancement splints and continuous positive airway pressure in patients with obstructive sleep apnoea : a randomized cross-over trial. European journal of orthodontics, 24'}, {'given': 'Pp.23–35.', 'family': 'Tangugsorn, V. et al., 2001. Obstructive Sleep Apnea : A Canonical Correlation of Cephalometric and Selected Demographic Variables in Obese and Nonobese Patients. Angle Orthodontist, 71(1)'}, {'given': 'Pp.1103–1108.', 'family': 'Thornton, W.K. & Roberts, D.H., 1996. Nonsurgical Obstructive Management Sleep Apnea of the Patient. J Oral Maxillofac Surg, 54'}, {'given': 'Pp.121–126.', 'family': 'Tomfohr, L.M. et al., 2011. Effects of Continuous Positive Airway Pressure on Fatigue and Sleepiness in Patients with Obstructive Sleep Apnea : Data from a Randomized Controlled Trial. SLEEP, 34(1)'}, {'given': 'Pp.573–581.', 'family': 'Tregear, S. et al., 2009. Obstructive Sleep Apnea and Risk of Motor Vehicle Crash: Systematic Review and Meta-Analysis. Journal of Clinical Sleep Medicine, 5(6)'}, {'given': 'Pp.366–370.', 'family': 'Tsai, W.H. et al., 2004. Remotely Controlled Mandibular Positioner Predicts Efficacy of Oral Appliances in Sleep Apnea. Am J Respir Crit Care Med, 170'}, {'given': 'Pp.1009–1015.', 'family': 'Tsuiki, S., Isono, S., Ishikawa, T. & Yamashiro, Y., 2008. Anatomical Balance of the Upper Airway and Obstructive Sleep Apnea. Anesthesiology, 108'}, {'given': 'Pp.1009–15.', 'family': 'Tsuiki, S., Isono, S., Ishikawa, T., Yamashiro, Y., et al., 2008. Anatomical balance of the upper airway and obstructive sleep apnea. Anesthesiology, 108(6)'}, {'given': 'Pp.554–560.', 'family': 'Tsuiki, S. et al., 2001. Effects of a Titratable Oral Appliance on Supine Airway Size in Awake Non-Apneic Individuals. Am J Respir Crit Care Med, 24(5)'}, {'given': 'Pp.263–268.', 'family': 'Tsuiki, S. et al., 2004. Effects of mandibular advancement on airway curvature and obstructive sleep apnoea severity. European Respiratory Journal, 23(2)'}, {'given': 'Pp.1098–1105.', 'family': 'Tsuiki, S. et al., 2010. Optimal positive airway pressure predicts oral appliance response to sleep apnoea. European Respiratory Journal, 35(5)'}, {'given': 'Pp.43–50.', 'family': 'Tsuiki, S. et al., 2003. Supine-Dependent Changes in Upper Airway Size in Awake Obstructive Sleep Apnea Patients. Sleep & breathing, 7(1)'}, {'given': 'Pp.504–12.', 'family': 'Tsuiki, S. et al., 2005. The interaction between changes in upright mandibular position and supine airway size in patients with obstructive sleep apnea. American journal of orthodontics and dentofacial orthopedics : official publication of the American As'}, {'given': '2011. Tongue position controller as an alternative treatment for obstructive sleep apnea. Sleep Breath.', 'family': 'Tsuiki, S. et al.'}, {'given': 'Pp.168–73.', 'family': 'Udwadia, Z.F. et al., 2004. Prevalence of sleep-disordered breathing and sleep apnea in middle-aged urban Indian men. American journal of respiratory and critical care medicine, 169(2)'}, {'given': 'Pp.197–202.', 'family': 'Vanderveken, O.M. et al., 2008. Comparison of a custom-made and a thermoplastic oral appliance for the treatment of mild sleep apnea. American journal of respiratory and critical care medicine, 178(2)'}, {'given': 'Pp.1036–1044.', 'family': 'Veasey, S.C. et al., 2006. Medical Therapy for Obstructive Sleep Apnea : A Review by the Medical Therapy for Obstructive Sleep Apnea Task Force of the Standards of Practice Committee of the American Academy of Sleep Medicine. Sleep, 29(8)'}, {'given': 'Pp.603–611.', 'family': 'Vig, K.W.L., 1998. Nasal obstruction and facial growth: The strength of evidence for clinical assumptions. American journal of orthodontics and dentofacial orthopedics, 113'}, {'given': 'Pp.128–34.', 'family': 'Villa, M.P. et al., 2007. Rapid maxillary expansion in children with obstructive sleep apnea syndrome: 12-month follow-up. Sleep medicine, 8(2)'}, {'given': 'Pp.129–150.', 'family': 'Viviano, J.S., 2002. Acoustic Reflection : Review and Clinical Applications for Sleep- Disordered Breathing. Sleep & breathing, 6(3)'}, {'given': 'Pp.739–746.', 'family': 'Walker-Engström, M.-L. et al., 2002. 4-Year Follow-up of Treatment With Dental Appliance or Uvulopalatopharyngoplasty in Patients With Obstructive Sleep Apnea *. CHEST Journal, 121'}, {'given': 'Pp.119–130.', 'family': 'Walker-Engström, M.-L. et al., 2003. A Prospective Randomized Study Comparing Two Different Degrees of Mandibular Advancement with a Dental Appliance in Treatment of Severe Obstructive Sleep Apnea. Sleep & breathing, 7(3)'}, {'given': 'Pp.73–89.', 'family': 'Warunek, S.P., 2004. Oral appliance therapy in sleep apnea syndromes: a review. Seminars in Orthodontics, 10(1)'}, {'given': 'Pp.2219–2224.', 'family': 'Wetter, D.W. et al., 1994. Smoking as a Risk Factor for Sleep-Disordered Breathing. Arch Intern Med, 154(9)'}, {'given': 'Pp.1363–1370.', 'family': 'White, D.P., 2005. Pathogenesis of Obstructive and Central Sleep Apnea. Am J Respir Crit Care Med, 172'}, {'given': 'Pp.797–804.', 'family': 'White, D.P., 1995. Pathophysiology of obstructive sleep apnea. Thorax, 50'}, {'given': 'Pp.323–328.', 'family': 'Whittle, A.T. et al., 1999. Neck soft tissue and fat distribution : comparison between normal men and women by magnetic resonance imaging. Thorax, 54'}, {'given': '2000. Obesity: Preventing and Managing the Global Epidemic', 'family': 'WHO'}, {'given': 'Pp.304–16.', 'family': 'Wolford, L.M., Chemello, P.D. & Hilliard, F., 1994. Occlusal plane alteration in orthognathic surgery--Part I: Effects on function and esthetics. American journal of orthodontics and dentofacial orthopedics : official publication of the American Associati'}, {'given': 'Pp.193–199.', 'family': 'Won, C.H.J., Li, K.K. & Guilleminault, C., 2008. Surgical Treatment of Obstructive Sleep Apnea Upper Airway and Maxillomandibular Surgery. Proc Am Thorac Soc, 5'}, {'given': 'Pp.845–847.', 'family': 'Yildiri, N. et al., 1991. The Effect of Posture on Upper Airway Dimensions in Normal Subjects and in Patients with the Sleep Apnea/Hypopnea Syndrome. Am Rev Respir Dis, 144'}, {'given': 'Pp.1230–1235.', 'family': 'Young, T. et al., 1993. The Occurrence of Sleep-Disordered Breathing Among Middle-Aged Adults. The New England Journal of Medicine, 328'}, {'given': 'Pp.1217–1239.', 'family': 'Young, T., Peppard, P.E. & Gottlieb, D.J., 2002. Epidemiology of Obstructive Sleep Apnea. American Journal of Respiratory and Critical Care Medicine, 165(9)'}, {'given': 'Pp.2013–2016.', 'family': 'Young, T., Skatrud, J. & Peppard, P.E., 2004. Risk Factors for Obstructive Sleep Apnea. JAMA, 291(16)'}, {'given': 'Pp.88–93.', 'family': 'Yow, M., 2009. An Overview of Oral Appliances and Managing the Airway in Obstructive Sleep Apnea. Seminars in Orthodontics, 15(2)'}, {'given': 'Pp.226–36.', 'family': 'Yumino, D. & Bradley, T.D., 2008. Central sleep apnea and Cheyne-Stokes respiration. Proceedings of the American Thoracic Society, 5(2)'}, {'given': 'Pp.543–7.', 'family': 'Zeng, B. et al., 2008. Influence of nasal resistance on oral appliance treatment outcome in obstructive sleep apnea. Sleep, 31(4)'}, {'given': 'pp.726–730.', 'family': 'Zeng, B. et al., 2007. Use of Flow – Volume Curves to Predict Oral Appliance Treatment Outcome in Obstructive Sleep Apnea. American journal of respiratory and critical care medicine, 175'}], 'abstract': 'Mandibular advancement devices (MADs) represent the main non-continuous positive airway pressure (non-CPAP) therapy for patients with obstructive sleep apnoea (OSA). The aim of the European Respiratory Society Task Force was to review the evidence in favour of MAD therapy. Effects of tongue-retaining devices are not included in this report. Custom-made MADs reduce apnoea/hypopnoea index (AHI) and daytime sleepiness compared with placebo devices. CPAP more effectively diminishes AHI, while increasing data suggest fairly similar outcomes in relation to symptoms and cardiovascular health from these treatments. Patients often prefer MADs to CPAP. Milder cases and patients with a proven increase in upper airway size as a result of mandibular advancement are most likely to experience treatment success with MADs. A custom-made device titrated from an initial 50% of maximum mandibular advancement has been recommended. More research is needed to define the patients who will benefit from MAD treatment compared with CPAP, in terms of the effects on sleep-disordered breathing and on other diseases related to OSA. In conclusion, MADs are recommended for patients with mild to moderate OSA (Recommendation Level A) and for those who do not tolerate CPAP. The treatment must be followed up and the device adjusted or exchanged in relation to the outcome.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '22075487', 'scopus': None, 'doi': '10.1183/09031936.00144711'}, 'title': 'Non-CPAP therapies in obstructive sleep apnoea: mandibular advancement device therapy.', 'source': 'Mendeley'}
Koopmans JG, Lutter R, Jansen HM, van der Zee JS. Adding salmeterol to an inhaled corticosteroid: long term effects on bronchial inflammation in asthma. Thorax. 2006;61(4):306-12.	10.1136/thx.2005.051292	16449264	primary-study	b8f53e13e66bb082bfd6ddbdae067eaafc6b7211	-	{'publication_type': {'year': 2006, 'cited_medium': None, 'issue': '4', 'issn': '0040-6376', 'volume': '61', 'title': 'Thorax', 'pagination': '306-313'}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 0.975, 'authors': 0.9}, 'authors': [{'given': 'J G', 'family': 'Koopmans'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '16449264', 'scopus': None, 'doi': '10.1136/thx.2005.051292'}, 'title': 'Adding salmeterol to an inhaled corticosteroid: long term effects on bronchial inflammation in asthma', 'source': 'CrossRef'}
Koopmans JG, Lutter R, Jansen HM, van der Zee JS. Adding salmeterol to an inhaled corticosteroid: long term effects on bronchial inflammation in asthma. Thorax. 2006;61(4):306-12.	10.1136/thx.2005.051292	16449264	primary-study	b8f53e13e66bb082bfd6ddbdae067eaafc6b7211	-	{'publication_type': {'year': 2006, 'cited_medium': None, 'issue': None, 'issn': '0040-6376', 'volume': None, 'title': 'Thorax', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 0.98125, 'authors': 0.9249999999999999}, 'authors': [{'given': 'J G', 'family': 'Koopmans'}, {'given': 'R', 'family': 'Lutter'}, {'given': 'H M', 'family': 'Jansen'}, {'given': 'J S', 'family': 'van der Zee'}], 'abstract': 'BACKGROUND: Addition of the long acting beta2 agonist salmeterol to inhaled corticosteroids leads to better symptomatic asthma control than increasing the dose of inhaled corticosteroids. However, little is known about the long term effects of adding salmeterol on the asthmatic inflammatory process, control of which is considered important for the long term outcome of asthma. METHODS: After a 4 week fluticasone run-in period, 54 patients with allergic asthma were randomised to receive twice daily treatment with fluticasone 250 microg with or without salmeterol 50 microg for 1 year in a double blind, parallel group design (total daily dose of fluticasone 500 microg in both treatment groups). Primary outcomes were sputum eosinophil numbers and eosinophil cationic protein concentrations. Secondary outcomes were neutrophil associated sputum parameters and a respiratory membrane permeability marker. The effects on allergen induced changes were determined before and at the end of the treatment period. RESULTS: Adding salmeterol to fluticasone resulted in improved peak expiratory flow, symptom scores, rescue medication usage, and bronchial hyperresponsiveness (p < 0.05 for all). There was no sustained effect on sputum cell differential counts and cytokine concentrations during the treatment period or on changes induced by allergen challenge at the end of treatment (p > 0.05). However, adding salmeterol significantly reduced sputum ratios of alpha2-macroglobulin and albumin during the treatment period (p = 0.001). CONCLUSIONS: The addition of salmeterol to fluticasone produces no sustained effect on allergen induced cellular bronchial inflammation but leads to a significant improvement in size selectivity of plasma protein permeation across the respiratory membrane. This may contribute to the improved clinical outcome seen in patients with allergic asthma when a long acting beta2 agonist is combined with inhaled corticosteroids.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '16449264', 'scopus': '2-s2.0-33645564704', 'doi': '10.1136/thx.2005.051292'}, 'title': 'Adding salmeterol to an inhaled corticosteroid: long term effects on bronchial inflammation in asthma.', 'source': 'Mendeley'}
Pedersen SE. [Is guideline-defined asthma control achievable?--secondary publication. The Gaining Optimal Asthma ControL (GOAL) Study]. Ugeskrift for laeger. 2005;167(38):3595-7.	-	16219190	primary-study	840f16b356deadaf85abfdb5e71acc1e62295744	-	{'publication_type': {'year': 2004, 'cited_medium': None, 'issue': '8', 'issn': '1073-449X', 'volume': '170', 'title': 'American Journal of Respiratory and Critical Care Medicine', 'pagination': '830-831'}, 'language': None, 'rating': {'year': 0, 'title': 0.5, 'total': 0.325, 'authors': 0.0}, 'authors': [{'given': 'Neil C.', 'family': 'Barnes'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '15475405', 'scopus': None, 'doi': '10.1164/rccm.2408006'}, 'title': 'Can Guideline-defined Asthma Control Be Achieved?', 'source': 'CrossRef'}
Pedersen SE. [Is guideline-defined asthma control achievable?--secondary publication. The Gaining Optimal Asthma ControL (GOAL) Study]. Ugeskrift for laeger. 2005;167(38):3595-7.	-	16219190	primary-study	840f16b356deadaf85abfdb5e71acc1e62295744	-	{'publication_type': {'year': 2005, 'cited_medium': None, 'issue': None, 'issn': '0041-5782', 'volume': None, 'title': 'Ugeskrift for Laeger', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 1.0, 'total': 0.875, 'authors': 0.9}, 'authors': [{'given': 'S E', 'family': 'Pedersen'}], 'abstract': 'In this study, the percentage of patients with uncontrolled asthma who can achieve guideline-defined asthma control was assessed in 3,421 patients. Significantly more patients (71%) treated with salmeterol-fluticasone achieved asthma control than did patients receiving fluticasone alone (59%). The patients treated with salmeterol-fluticasone achieved asthma control more rapidly and at a lower dose of inhaled corticosteroid than did patients treated with fluticasone alone. Achievement of asthma control was associated with marked improvements in exacerbation rates and quality of life. Thus guideline-defined asthma control can be achieved in the majority of patients and should be the goal of asthma treatment.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '16219190', 'scopus': None, 'doi': 'VP47370 [pii]'}, 'title': 'Is guideline-defined asthma control achievable? The Gaining Optimal Asthma ControL (GOAL) Study', 'source': 'Mendeley'}
Malone R, LaForce C, Nimmagadda S, Schoaf L, House K, Ellsworth A, Dorinsky P. The safety of twice-daily treatment with fluticasone propionate and salmeterol in pediatric patients with persistent asthma. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology. 2005;95(1):66-71.	10.1016/S1081-1206(10)61190-8	16095144	primary-study	ebc9e2840aeed09ad919064f9ab33d73973c37ea	-	{'publication_type': {'year': 2005, 'cited_medium': None, 'issue': '1', 'issn': '1081-1206', 'volume': '95', 'title': 'Annals of Allergy, Asthma & Immunology', 'pagination': '66-71'}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.8642857142857143, 'authors': 0.8571428571428571}, 'authors': [{'given': 'Randolph', 'family': 'Malone'}, {'given': 'Craig', 'family': 'LaForce'}, {'given': 'Sai', 'family': 'Nimmagadda'}, {'given': 'Lynne', 'family': 'Schoaf'}, {'given': 'Karen', 'family': 'House'}, {'given': 'Anna', 'family': 'Ellsworth'}, {'given': 'Paul', 'family': 'Dorinsky'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1016/s1081-1206(10)61190-8'}, 'title': 'The safety of twice-daily treatment with fluticasone propionate and salmeterol in pediatric patients with persistent asthma', 'source': 'CrossRef'}
Malone R, LaForce C, Nimmagadda S, Schoaf L, House K, Ellsworth A, Dorinsky P. The safety of twice-daily treatment with fluticasone propionate and salmeterol in pediatric patients with persistent asthma. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology. 2005;95(1):66-71.	10.1016/S1081-1206(10)61190-8	16095144	primary-study	ebc9e2840aeed09ad919064f9ab33d73973c37ea	-	{'publication_type': {'year': 2004, 'cited_medium': None, 'issue': None, 'issn': '1081-1206 (Print)', 'volume': None, 'title': 'Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 0.5714285714285714, 'total': 0.4714285714285714, 'authors': 0.0}, 'authors': [{'given': 'Stanford R', 'family': "O'Connor RD  Crim C, Yancey SW, Edwards L, Rickard KA, Dorinsky P"}], 'abstract': 'Inhaled corticosteroids are the most effective class of anti-inflammatory agents and are recommended for patients with persistent asthma. To compare the effectiveness of (1) fluticasone propionate, 100 microg, and salmeterol, 50 microg; (2) fluticasone propionate, 100 microg; and (3) montelukast, 10 mg, as first-line maintenance treatment for persistent asthma. Combined analysis of 4 clinical trials, 2 that compared fluticasone propionate-salmeterol with montelukast and 2 that compared fluticasone propionate with montelukast as initial asthma therapy. The 4 studies had a total of 1,910 patients 15 years or older with symptomatic asthma previously treated with inhaled short-acting beta2-agonists alone. At the end point, there were significantly greater increases in forced expiratory volume in 1 second with fluticasone propionate-salmeterol (0.57 L; P < or = .004) vs fluticasone propionate (0.48 L) and montelukast (0.31 L) and significantly greater increases in morning peak expiratory flow rate (84.9 L/min; P < .001) vs fluticasone propionate (56.0 L/min) and montelukast (36.1 L/min). Fluticasone propionate-salmeterol significantly increased the percentage of symptom- and rescue-free days and significantly reduced albuterol use vs fluticasone propionate and montelukast (P < or = .04 for both). Patients treated with fluticasone propionate and montelukast had 2.6 and 3.6 greater risk, respectively, of having an asthma-related exacerbation vs fluticasone propionate-salmeterol users. In addition, mean daily exacerbation costs per treated patient were dollars 0.41 for fluticasone propionate-salmeterol, dollars 4.60 for fluticasone propionate, and dollars 7.57 for montelukast, whereas mean daily costs per patient exacerbation for fluticasone propionate-salmeterol, fluticasone propionate, and montelukast were dollars 29, dollars 128, and dollars 154, respectively. Patients with symptomatic asthma previously treated with short-acting beta2-agonists only who require maintenance therapy are likely to have greater clinical benefits, lower risk of an asthma exacerbation, and reduced exacerbation-related costs when initiating therapy with fluticasone propionate-salmeterol vs fluticasone propionate or montelukast.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '15609769', 'scopus': '2-s2.0-10344234208', 'doi': '10.1016/S1081-1206(10)61267-7'}, 'title': 'Effect of fluticasone propionate and salmeterol in a single device, fluticasone propionate, and montelukast on overall asthma control, exacerbations, and costs.', 'source': 'Mendeley'}
Weiler JM, Nathan RA, Rupp NT, Kalberg CJ, Emmett A, Dorinsky PM. Effect of fluticasone/salmeterol administered via a single device on exercise-induced bronchospasm in patients with persistent asthma. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology. 2005;94(1):65-72.	10.1016/S1081-1206(10)61288-4	15702819	primary-study	e79b60eabc3181f82220c1c44a5e57ad8f204f11	-	{'publication_type': {'year': 2005, 'cited_medium': None, 'issue': '1', 'issn': '1081-1206', 'volume': '94', 'title': 'Annals of Allergy, Asthma & Immunology', 'pagination': '65-72'}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.875, 'authors': 0.9}, 'authors': [{'given': 'John M.', 'family': 'Weiler'}, {'given': 'Robert A.', 'family': 'Nathan'}, {'given': 'Ned T.', 'family': 'Rupp'}, {'given': 'Christopher J.', 'family': 'Kalberg'}, {'given': 'Amanda', 'family': 'Emmett'}, {'given': 'Paul M.', 'family': 'Dorinsky'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1016/s1081-1206(10)61288-4'}, 'title': 'Effect of fluticasone/salmeterol administered via a single device on exercise-induced bronchospasm in patients with persistent asthma', 'source': 'CrossRef'}
Weiler JM, Nathan RA, Rupp NT, Kalberg CJ, Emmett A, Dorinsky PM. Effect of fluticasone/salmeterol administered via a single device on exercise-induced bronchospasm in patients with persistent asthma. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology. 2005;94(1):65-72.	10.1016/S1081-1206(10)61288-4	15702819	primary-study	e79b60eabc3181f82220c1c44a5e57ad8f204f11	-	{'publication_type': {'year': 2005, 'cited_medium': None, 'issue': None, 'issn': '1081-1206 (Print)', 'volume': None, 'title': 'Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 0.975, 'authors': 0.9}, 'authors': [{'given': 'John M', 'family': 'Weiler'}, {'given': 'Robert A', 'family': 'Nathan'}, {'given': 'Ned T', 'family': 'Rupp'}, {'given': 'Christopher J', 'family': 'Kalberg'}, {'given': 'Amanda', 'family': 'Emmett'}, {'given': 'Paul M', 'family': 'Dorinsky'}], 'abstract': 'BACKGROUND: Exercise is a common trigger of asthma symptoms in patients with persistent asthma. OBJECTIVE: To evaluate the protective effect of fluticasone/salmeterol against exercise-induced bronchospasm. METHODS: Multicenter, randomized, double-blind, parallel-group trial of 192 asthma patients who used moderate-dose inhaled corticosteroids. Patients (aged 12-50 years; mean forced expiratory volume in 1 second [FEV1], 78% of predicted at baseline) were randomized to receive fluticasone/salmeterol (250/50 microg twice daily) or fluticasone alone (250 microg twice daily) via Diskus for 4 weeks. Exercise challenge tests were performed 1 and 8.5 hours after administration of the first (day 1) and last (week 4) doses of blinded study medication. RESULTS: On day 1 and at week 4, mean +/- SEM values for the maximal percentage decline in FEV1 1 hour after drug administration were 11.4% +/- 1.5% and 10.9% +/- 1.5% for fluticasone/salmeterol compared with 20.0% +/- 1.7% and 18.4% +/- 1.8% for fluticasone (P < .001). At 8.5 hours, mean +/- SEM values on day 1 and at week 4 were 11.6% +/- 1.4% and 8.9% +/1.1%, respectively, for fluticasone/salmeterol and 12.6% +/- 1.6% and 12.9% +/- 1.4%, respectively, for fluticasone (P = .01 at week 4). More fluticasone-treated patients did not complete the 8.5-hour exercise challenges (36% on day 1 and 33% at week 4) compared with the fluticasone/salmeterol group (18% each) (P < or = .01). Improvements in peak expiratory flow rate and albuterol rescue-free days were significantly greater with fluticasone/salmeterol vs fluticasone over weeks 1 to 4 (P < or = .03). CONCLUSIONS: Consistent with the improvements in other measures of asthma control, long-term fluticasone/salmeterol therapy also provided protection against exercise-induced bronchospasm in patients with persistent asthma.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '15702819', 'scopus': '2-s2.0-12344327379', 'doi': '10.1016/S1081-1206(10)61288-4'}, 'title': 'Effect of fluticasone/salmeterol administered via a single device on exercise-induced bronchospasm in patients with persistent asthma.', 'source': 'Mendeley'}
Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, Pedersen SE. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. American journal of respiratory and critical care medicine. 2004;170(8):836-44.	10.1164/rccm.200401-033OC	15256389	primary-study	5be644334255b010e93228fcb5de8f29aafc6c05	-	{'publication_type': {'year': 2004, 'cited_medium': None, 'issue': '8', 'issn': '1073-449X', 'volume': '170', 'title': 'American Journal of Respiratory and Critical Care Medicine', 'pagination': '836-844'}, 'language': None, 'rating': {'year': 0, 'title': 1.0, 'total': 0.875, 'authors': 0.9000000000000001}, 'authors': [{'given': 'Eric D.', 'family': 'Bateman'}, {'given': 'Homer A.', 'family': 'Boushey'}, {'given': 'Jean', 'family': 'Bousquet'}, {'given': 'William W.', 'family': 'Busse'}, {'given': 'Tim J. H.', 'family': 'Clark'}, {'given': 'Romain A.', 'family': 'Pauwels'}, {'given': 'Søren E.', 'family': 'Pedersen'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1164/rccm.200401-033oc'}, 'title': 'Can Guideline-defined Asthma Control Be Achieved?', 'source': 'CrossRef'}
Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, Pedersen SE. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. American journal of respiratory and critical care medicine. 2004;170(8):836-44.	10.1164/rccm.200401-033OC	15256389	primary-study	5be644334255b010e93228fcb5de8f29aafc6c05	-	{'publication_type': {'year': 2004, 'cited_medium': None, 'issue': None, 'issn': '1073449X', 'volume': None, 'title': 'American Journal of Respiratory and Critical Care Medicine', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 1.0, 'total': 0.875, 'authors': 0.9000000000000001}, 'authors': [{'given': 'Eric D.', 'family': 'Bateman'}, {'given': 'Homer A.', 'family': 'Boushey'}, {'given': 'Jean', 'family': 'Bousquet'}, {'given': 'William W.', 'family': 'Busse'}, {'given': 'Tim J H', 'family': 'Clark'}, {'given': 'Romain A.', 'family': 'Pauwels'}, {'given': 'Søren E.', 'family': 'Pedersen'}], 'abstract': 'For most patients, asthma is not controlled as defined by guidelines; whether this is achievable has not been prospectively studied. A 1-year, randomized, stratified, double-blind, parallel-group study of 3,421 patients with uncontrolled asthma compared fluticasone propionate and salmeterol/fluticasone in achieving two rigorous, composite, guideline-based measures of control: totally and well-controlled asthma. Treatment was stepped-up until total control was achieved (or maximum 500 microg corticosteroid twice a day). Significantly more patients in each stratum (previously corticosteroid-free, low- and moderate-dose corticosteroid users) achieved control with salmeterol/fluticasone than fluticasone. Total control was achieved across all strata: 520 (31%) versus 326 (19%) patients after dose escalation (p < 0.001) and 690 (41%) versus 468 (28%) at 1 year for salmeterol/fluticasone and fluticasone, respectively. Asthma became well controlled in 1,071 (63%) versus 846 (50%) after dose escalation (p < 0.001) and 1,204 (71%) versus 988 (59%) at 1 year. Control was achieved more rapidly and at a lower corticosteroid dose with salmeterol/fluticasone versus fluticasone. Across all strata, 68% and 76% of the patients receiving salmeterol/fluticasone and fluticasone, respectively, were on the highest dose at the end of treatment. Exacerbation rates (0.07-0.27 per patient per year) and improvement in health status were significantly better with salmeterol/fluticasone. This study confirms that the goal of guideline-derived asthma control was achieved in a majority of the patients.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '15256389', 'scopus': '2-s2.0-5144221336', 'doi': '10.1164/rccm.200401-033OC'}, 'title': 'Can guideline-defined asthma control be achieved? The gaining optimal asthma control study', 'source': 'Mendeley'}
Pohunek P, Matulka M, Rybnícek O, Kopriva F, Honomichlová H, Svobodová T. Dose-related efficacy and safety of formoterol (Oxis) Turbuhaler compared with salmeterol Diskhaler in children with asthma. Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology. 2004;15(1):32-9.	-	14998380	primary-study	102818756dc5bda51005be843c07fe87bd7485da	-	{'publication_type': {'year': 2004, 'cited_medium': None, 'issue': '1', 'issn': '0905-6157', 'volume': '15', 'title': 'Pediatric Allergy and Immunology', 'pagination': '32-39'}, 'language': None, 'rating': {'year': 1, 'title': 0.8125, 'total': 0.8572916666666667, 'authors': 0.9166666666666666}, 'authors': [{'given': 'Petr', 'family': 'Pohunek'}, {'given': 'Milan', 'family': 'Matulka'}, {'given': 'Ondrej', 'family': 'Rybnicek'}, {'given': 'Frantisek', 'family': 'Kopriva'}, {'given': 'Helena', 'family': 'Honomichlova'}, {'given': 'Tamara', 'family': 'Svobodova'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1046/j.0905-6157.2003.00096.x'}, 'title': 'Dose-related efficacy and safety of formoterol (OxisR) TurbuhalerR compared with salmeterol DiskhalerR in children with asthma', 'source': 'CrossRef'}
Pohunek P, Matulka M, Rybnícek O, Kopriva F, Honomichlová H, Svobodová T. Dose-related efficacy and safety of formoterol (Oxis) Turbuhaler compared with salmeterol Diskhaler in children with asthma. Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology. 2004;15(1):32-9.	-	14998380	primary-study	102818756dc5bda51005be843c07fe87bd7485da	-	{'publication_type': {'year': 2004, 'cited_medium': None, 'issue': None, 'issn': '09056157', 'volume': None, 'title': 'Pediatric Allergy and Immunology', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 0.8125, 'total': 0.8572916666666667, 'authors': 0.9166666666666666}, 'authors': [{'given': 'Petr', 'family': 'Pohunek'}, {'given': 'Milan', 'family': 'Matulka'}, {'given': 'Ondřej', 'family': 'Rybníček'}, {'given': 'František', 'family': 'Kopřiva'}, {'given': 'Helena', 'family': 'Honomichlová'}, {'given': 'Tamara', 'family': 'Svobodová'}], 'abstract': 'To compare the dose-related bronchodilator efficacy and tolerability of formoterol (Oxis) Turbuhaler with salmeterol Diskhaler and placebo in children with asthma. A single-dose, randomized, double-blind, incomplete crossover study of 68 children (7-17 years), with moderate-to-severe asthma, 82% receiving inhaled corticosteroids. Patients received four of six treatments [4.5, 9, 18, or 36 microg formoterol (6, 12, 24 or 48 microg metered doses), 50 microg salmeterol (metered dose) or placebo] at 12-h visits, separated by > or =3 days. Forced expiratory volume in 1 s (FEV1), pulse, blood pressure, electrocardiogram, adverse events and urine formoterol were assessed. The therapeutic ratio of formoterol vs. salmeterol was estimated from the efficacy and systemic effects results. All active treatments significantly improved FEV1 compared with placebo. Formoterol 9-36 microg provided dose-related increases over salmeterol in lung function: average 12-h FEV1 (increases of 4.9-8.7%, p < 0.001) and FEV1 at 12 h post-dose (7.0-12.2%, p < 0.001). The onset of effect of formoterol was also significantly faster than salmeterol for doses > or =9 microg. Salmeterol 50 microg was estimated to be equieffective to 3.3 microg formoterol for 12-h average FEV1 and the estimated equieffective dose for a variety of systemic effects was 7.8-13.5 microg formoterol. All treatments were well tolerated. Formoterol (Oxis) Turbuhaler 4.5-36 microg provided dose-related improvements in bronchodilator efficacy in children with asthma. Formoterol > or =9 microg provided superior bronchodilator efficacy over 12 h compared with salmeterol Diskhaler 50 microg with no increase in systemic effects.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '14998380', 'scopus': '2-s2.0-1542298201', 'doi': '10.1046/j.0905-6157.2003.00096.x'}, 'title': 'Dose-related efficacy and safety of formoterol (Oxis®) Turbuhaler® compared with salmeterol Diskhaler® in children with asthma', 'source': 'Mendeley'}
Nathan RA, Dorinsky P, Rosenzweig JR, Shah T, Edin H, Prillaman B. Improved ability to perform strenuous activities after treatment with fluticasone propionate/salmeterol combination in patients with persistent asthma. The Journal of asthma : official journal of the Association for the Care of Asthma. 2003;40(7):815-22.	-	14626338	primary-study	f627b6ff72e7a42453033fec5981a9de98c105df	-	{'publication_type': {'year': 2003, 'cited_medium': None, 'issue': '7', 'issn': '0277-0903', 'volume': '40', 'title': 'Journal of Asthma', 'pagination': '815-822'}, 'language': None, 'rating': {'year': 0, 'title': 1.0, 'total': 0.8416666666666667, 'authors': 0.7666666666666666}, 'authors': [{'given': 'Robert A.', 'family': 'Nathan'}, {'given': 'Paul', 'family': 'Dorinsky'}, {'given': 'Jacqueline R.', 'family': 'Carranza Rosenzweig'}, {'given': 'Tushar', 'family': 'Shah'}, {'given': 'Heather', 'family': 'Edin'}, {'given': 'Barbara', 'family': 'Prillaman'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1081/jas-120023573'}, 'title': 'Improved Ability to Perform Strenuous Activities After Treatment with Fluticasone Propionate/Salmeterol Combination in Patients with Persistent Asthma', 'source': 'CrossRef'}
Nathan RA, Dorinsky P, Rosenzweig JR, Shah T, Edin H, Prillaman B. Improved ability to perform strenuous activities after treatment with fluticasone propionate/salmeterol combination in patients with persistent asthma. The Journal of asthma : official journal of the Association for the Care of Asthma. 2003;40(7):815-22.	-	14626338	primary-study	f627b6ff72e7a42453033fec5981a9de98c105df	-	{'publication_type': {'year': 2003, 'cited_medium': None, 'issue': None, 'issn': '0277-0903', 'volume': None, 'title': 'The Journal of asthma : official journal of the Association for the Care of Asthma', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 0.9791666666666666, 'authors': 0.9166666666666666}, 'authors': [{'given': 'Robert A', 'family': 'Nathan'}, {'given': 'Paul', 'family': 'Dorinsky'}, {'given': 'Jacqueline R Carranza', 'family': 'Rosenzweig'}, {'given': 'Tushar', 'family': 'Shah'}, {'given': 'Heather', 'family': 'Edin'}, {'given': 'Barbara', 'family': 'Prillaman'}], 'abstract': 'Patients with asthma experience disruptions in usual activities that can impair their quality of life, and in patients whose daily routine involves an active lifestyle, these disruptions can be severe. We assessed the patient-perceived effect of treatment with fluticasone propionate/salmeterol combination (FSC), compared with fluticasone propionate (FP) or salmeterol (SAL) alone, on activity limitations, particularly strenuous physical activities. The Asthma Quality of Life Questionnaire (AQLQ) was administered in two 12-week, randomized, double-blind, placebo-controlled trials comparing FSC 100/50 or 250/50 microg twice daily vs. the individual components alone in 686 adults and adolescents with asthma. In one study, patients were stratified by prior treatment [low to medium doses of inhaled corticosteroids (ICS) or SAL], and in the other study, all patients were previously treated with medium to high doses of ICS. Patients prospectively identified five activities they performed regularly and were asked how these activities were limited by their asthma. The effect of randomized treatment on strenuous activities (e.g., aerobics, cycling, hiking, and basketball) was assessed. In both studies, treatment with FSC resulted in clinically meaningful improvements (i.e., change in AQLQ of > or = 0.5) and was statistically significantly better than SAL in both studies and FP in one study. Treatment of the two main components of asthma--inflammation and bronchoconstriction--with FSC results in clinically meaningful improvements in the ability of patients with persistent asthma to perform not only their usual activities but also strenuous activities.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '14626338', 'scopus': '2-s2.0-0242664786', 'doi': '10.1081/JAS-120023573'}, 'title': 'Improved ability to perform strenuous activities after treatment with fluticasone propionate/salmeterol combination in patients with persistent asthma.', 'source': 'Mendeley'}
Wallin A, Sue-Chu M, Bjermer L, Ward J, Sandström T, Lindberg A, Lundbäck B, Djukanović R, Holgate S, Wilson S. Effect of inhaled fluticasone with and without salmeterol on airway inflammation in asthma. The Journal of allergy and clinical immunology. 2003;112(1):72-8.	-	12847482	primary-study	0f82426196a5cb6c768825a36d1837bb9c55d631	-	{'publication_type': {'year': 2003, 'cited_medium': None, 'issue': '1', 'issn': '0091-6749', 'volume': '112', 'title': 'Journal of Allergy and Clinical Immunology', 'pagination': '72-78'}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.8775000000000001, 'authors': 0.9100000000000001}, 'authors': [{'given': 'Annika', 'family': 'Wallin'}, {'given': 'Malcolm', 'family': 'Sue-Chu'}, {'given': 'Leif', 'family': 'Bjermer'}, {'given': 'Jonathan', 'family': 'Ward'}, {'given': 'Thomas', 'family': 'Sandström'}, {'given': 'Anne', 'family': 'Lindberg'}, {'given': 'Bo', 'family': 'Lundbäck'}, {'given': 'Ratko', 'family': 'Djukanovic\xa0́'}, {'given': 'Stephen', 'family': 'Holgate'}, {'given': 'Susan', 'family': 'Wilson'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1067/mai.2003.1518'}, 'title': 'Effect of inhaled fluticasone with and without salmeterol on airway inflammation in asthma', 'source': 'CrossRef'}
Wallin A, Sue-Chu M, Bjermer L, Ward J, Sandström T, Lindberg A, Lundbäck B, Djukanović R, Holgate S, Wilson S. Effect of inhaled fluticasone with and without salmeterol on airway inflammation in asthma. The Journal of allergy and clinical immunology. 2003;112(1):72-8.	-	12847482	primary-study	0f82426196a5cb6c768825a36d1837bb9c55d631	-	{'publication_type': {'year': 2003, 'cited_medium': None, 'issue': None, 'issn': '0091-6749', 'volume': None, 'title': 'J Allergy Clin Immunol', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.9, 'authors': 1.0}, 'authors': [{'given': 'A', 'family': 'Wallin'}, {'given': 'M', 'family': 'Sue-Chu'}, {'given': 'L', 'family': 'Bjermer'}, {'given': 'J', 'family': 'Ward'}, {'given': 'T', 'family': 'Sandström'}, {'given': 'A', 'family': 'Lindberg'}, {'given': 'B', 'family': 'Lundbäck'}, {'given': 'R', 'family': 'Djukanović'}, {'given': 'S', 'family': 'Holgate'}, {'given': 'S', 'family': 'Wilson'}], 'abstract': 'The clinical benefit of combining long-acting beta(2)-agonists with inhaled corticosteroids rather than doubling the dose of corticosteroid has been well-documented. However, there are concerns that this might result in a masking of underlying airway inflammation.|The aim of this study was to test the hypothesis that the addition of the long-acting beta(2)-agonist salmeterol (SALM) to a low dose of the inhaled corticosteroid fluticasone propionate (FP) has a steroid-sparing effect and does not result in a worsening of bronchial inflammation compared to doubling the dose of inhaled corticosteroid.|Fifty-six asthmatic subjects, previously not well-controlled on inhaled corticosteroids, were randomized to receive 3 months of treatment with inhaled FP 500 microg twice a day (FP 1000) or FP 200 microg twice a day plus SALM 50 microg twice a day (FP 400 + SALM). Fluticasone propionate 200 microg twice a day served as the control (FP400). Bronchial mucosal biopsy specimens, bronchial washings (BW), and bronchoalveolar lavage were obtained before and after treatment. The primary end points for the study were submucosal mast cell and eosinophil counts.|There was a significant improvement in FEV(1) in the FP400 + SALM group compared to both the FP400 and FP1000 groups. This was accompanied by a significant improvement in peak expiratory flow in the FP400 + SALM group in both the morning and evening compared to the FP1000 group. There were no significant between treatment differences in the change in the number of submucosal mast cells or eosinophils. However, in the FP400 + SALM group there was a significant decrease in submucosal mast cells after 12 weeks of treatment. The addition of SALM to FP was not associated with any increases in airway inflammation in the biopsy specimens, bronchoalveolar lavage, or bronchial washings.|These findings confirm that addition of SALM to FP has clinical benefits but does not mask or exacerbate airway inflammation and suggest that long-acting beta(2)-adrenoceptor agonists might influence mast cell numbers.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '12847482', 'scopus': None, 'doi': 'S0091674903012521 [pii]'}, 'title': 'Effect of inhaled fluticasone with and without salmeterol on airway inflammation in asthma', 'source': 'Mendeley'}
Reid DW, Ward C, Wang N, Zheng L, Bish R, Orsida B, Walters EH. Possible anti-inflammatory effect of salmeterol against interleukin-8 and neutrophil activation in asthma in vivo. The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology. 2003;21(6):994-9.	-	12797494	primary-study	d854ba9519b9356ca1bb727a98c90a4432a38de0	-	{'publication_type': {'year': 2003, 'cited_medium': None, 'issue': '6', 'issn': '0903-1936', 'volume': '21', 'title': 'Eur Respir J', 'pagination': '994-999'}, 'language': None, 'rating': {'year': 0, 'title': 1.0, 'total': 0.875, 'authors': 0.9000000000000001}, 'authors': [{'given': 'D.W.', 'family': 'Reid'}, {'given': 'C.', 'family': 'Ward'}, {'given': 'N.', 'family': 'Wang'}, {'given': 'L.', 'family': 'Zheng'}, {'given': 'R.', 'family': 'Bish'}, {'given': 'B.', 'family': 'Orsida'}, {'given': 'E.H.', 'family': 'Walters'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1183/09031936.03.00109702'}, 'title': ' Possible anti-inflammatory effect of salmeterol against interleukin-8 and neutrophil activation in asthma in vivo ', 'source': 'CrossRef'}
Reid DW, Ward C, Wang N, Zheng L, Bish R, Orsida B, Walters EH. Possible anti-inflammatory effect of salmeterol against interleukin-8 and neutrophil activation in asthma in vivo. The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology. 2003;21(6):994-9.	-	12797494	primary-study	d854ba9519b9356ca1bb727a98c90a4432a38de0	-	{'publication_type': {'year': 2012, 'cited_medium': None, 'issue': None, 'issn': '1399-3003', 'volume': None, 'title': 'The European respiratory journal', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 0.1, 'total': 0.165, 'authors': 0.0}, 'authors': [{'given': 'Pp.667–689.', 'family': 'AASM Task Force, A., 1999. Sleep – Related Breathing Disorders in Adults : Recommendations for Syndrome Definition and Measurement Techniques in Clinical Research. SLEEP, 22(5)'}, {'given': 'titration and side effects of oral appliances in snoring and obstructive sleep apnea patients.', 'family': 'Almeida, F.R., 2005. Compliance'}, {'given': 'Pp.198–204.', 'family': 'Almeida, F.R. et al., 2009. Effect of a Titration Polysomnogram on Treatment Success with a Mandibular Repositioning Appliance. Journal of Clinical Sleep Medicine, 5(3)'}, {'given': 'Pp.659–66.', 'family': 'Almeida, F.R. et al., 2013. Patient preferences and experiences of CPAP and oral appliances for the treatment of obstructive sleep apnea: a qualitative analysis. Sleep & breathing = Schlaf & Atmung, 17(2)'}, {'given': 'Pp.205–13.', 'family': 'Almeida, F.R. De et al., 2006. Long-term sequellae of oral appliance therapy in obstructive sleep apnea patients: Part 2. Study-model analysis. American journal of orthodontics and dentofacial orthopedics : official publication of the American Association'}, {'given': 'Pp.911–23.', 'family': 'Alsufyani, N., Al-Saleh, M. & Major, P., 2013. CBCT assessment of upper airway changes and treatment outcomes of obstructive sleep apnoea: a systematic review. Sleep & breathing, 17(3)'}, {'given': 'Pp.227–34.', 'family': 'Anandam, A. et al., 2013. Effects of dietary weight loss on obstructive sleep apnea: a meta-analysis. Sleep & breathing, 17(1)'}, {'given': 'Pp.1946–9.', 'family': 'Ancoli-Israel, S. et al., 1995. Sleep-disordered breathing in African-American elderly. American journal of respiratory and critical care medicine, 152(6 Pt 1)'}, {'given': 'Pp.90–96.', 'family': 'Ang, P.K., Sandham, A. & Tan, W.C., 2004. Craniofacial Morphology and Head Posture in. Seminars in Orthodontics, 10(1)'}, {'given': 'Cistulli (5 20 10)_PC revisions 24May2010 (2).', 'family': 'Anon'}, {'given': 'symps & conditions of OSA in adults.', 'family': 'Anon, Risk factors'}, {'given': '80(1).', 'family': 'Article, O., 2010. Five Years of Sleep Apnea Treatment with a Mandibular Advancement Device.'}, {'given': 'Pp.737–747.', 'family': 'Article, S., 2007. Clinical Guidelines for the Use of Unattended Portable Monitors in the Diagnosis of Obstructive Sleep Apnea in Adult Patients. Journal of Clinical Sleep Medicine, 3(7)'}, {'given': 'Pp.1408–1413.', 'family': 'Aurora, R.N. et al., 2010. Practice Parameters for the Surgical Modifications of the Upper Airway for Obstructive Sleep Apnea in Adults. SLEEP, 33(10)'}, {'given': 'Pp.17–40.', 'family': 'Aurora, R.N. et al., 2012. The Treatment of Central Sleep Apnea Syndromes in Adults : Practice Parameters with an Evidence-Based Literature Review and Meta-Analyses. SLEEP, 35(1)'}, {'given': 'Pp.485–490.', 'family': 'Awad, K.M. et al., 2012. Exercise Is Associated with a Reduced Incidence of Sleep-disordered Breathing. American Journal of Medicine, 125'}, {'given': 'Pp.982–990.', 'family': 'Bader, G.G. et al., 1997. Descriptive Physiological Data on a Sleep Bruxism Population. SLEEP, 20(11)'}, {'given': 'Pp.124–134.', 'family': 'Baik, U.B., Suzuki, M. & Ikeda, K., 2002. Relationship Between Cephalometric Characteristics and Obstructive Sites in Obstructive Sleep Apnea Syndrome. Angle Orthodontist, 72'}, {'given': 'Pp.495–501.', 'family': 'Ballester, E. et al., 1999. Evidence of the Effectiveness of Continuous Positive Airway Pressure in the Treatment of Sleep Apnea / Hypopnea Syndrome. American journal of respiratory and critical care medicine, 159'}, {'given': 'Pp.583–596.', 'family': 'Bardwell, W.A. et al., 1999. PSYCHOLOGICAL CORRELATES OF SLEEP APNEA. Journal of Psychosomatic Research, 47(6)'}, {'given': 'Pp.656–64.', 'family': 'Barnes, M. et al., 2004. Efficacy of positive airway pressure and oral appliance in mild to moderate obstructive sleep apnea. American journal of respiratory and critical care medicine, 170(6)'}, {'given': 'Pp.299–305.', 'family': 'Barthlen, G.M. et al., 2000. Comparison of three oral appliances for treatment of severe obstructive sleep apnea syndrome q. Sleep Medicine, 1'}, {'given': 'Pp.363–376.', 'family': 'Battagel, J.M. et al., 1999. Changes in airway and hyoid position in response to mandibular protrusion in subjects with obstructive sleep apnoea ( OSA ). European journal of orthodontics, 21'}, {'given': 'Pp.263–276.', 'family': 'Battagel, J.M. et al., 2002. Postural variation in oropharyngeal dimensions in subjects with sleep disordered breathing : a cephalometric study. European journal of orthodontics, 24'}, {'given': 'Pp.121–132.', 'family': 'Battagel, J.M. et al., 1998. The role of lateral cephalometric radiography and fluoroscopy in assessing mandibular advancement in sleep-related disorders. European journal of orthodontics, 20'}, {'given': 'Pp.557–569.', 'family': 'Battagel, J.M. & Estrange, P.R.L., 1996. The cephalometric morphology of patients with obstructive sleep apnoea ( OSA ). European journal of orthodontics, 18'}, {'given': 'Pp.353–365.', 'family': 'Battagel, J.M., Johal, A. & Kotecha, B., 2000. A cephalometric comparison of subjects with snoring and obstructive sleep apnoea. European journal of orthodontics, 22'}, {'given': 'Pp.298–307.', 'family': 'Beebe, D.W. et al., 2003. The Neuropsychological Effects of Obstructive Sleep Apnea : A Meta-Analysis of Norm-Referenced and Case-Controlled Data. SLEEP, 26(3)'}, {'given': 'Pp.558–564.', 'family': 'Bennett, L.S. et al., 1998. Oral appliances for the management of snoring and obstructive sleep apnoea. Thorax, 53(Suppl 2)'}, {'given': 'Pp.529–531.', 'family': 'Berry, D.T., Webb, W.B. & Block, A.J., 1984. Sleep apnea syndrome. A critical review of the apnea index as a diagnostic criterion. Chest, 86'}, {'given': 'Pp.245–50.', 'family': 'Berry, R.B. et al., 1991. Effect of theophylline on sleep and sleep-disordered breathing in patients with chronic obstructive pulmonary disease. The American review of respiratory disease, 143(2)'}, {'given': 'Pp.1423–1431.', 'family': 'Berry, R.B. et al., 2008. Portable Monitoring and Autotitration versus Polysomnography for the Diagnosis and Treatment of Sleep Apnea. SLEEP, 31(1)'}, {'given': 'Pp.641–649.', 'family': 'Bettega, G. et al., 2000. Obstructive Sleep Apnea Syndrome Fifty-one Consecutive Patients Treated by Maxillofacial Surgery. American journal of respiratory and critical care medicine, 162'}, {'given': 'Pp.245–251.', 'family': 'Bittencourt, L.R.A. et al., 2001. The variability of the apnoea ± hypopnoea index. J Prosthet Dent, 10'}, {'given': 'Pp.144–148.', 'family': 'Bixler, E.O. et al., 1998. Effects of Age on Sleep Apnea in Men. Am J Respir Crit Care Med, 157'}, {'given': 'Pp.621–8.', 'family': 'Bondemark, L., 1999. Does 2 years’ nocturnal treatment with a mandibular advancement splint in adult patients with snoring and OSAS cause a change in the posture of the mandible? American journal of orthodontics and dentofacial orthopedics : official publ'}, {'given': 'Pp.53–60.', 'family': 'Bondemark, L. & Lindman, R., 2000. Craniomandibular status and function in patients with habitual snoring and obstructive sleep apnoea after nocturnal treatment with a mandibular advancement splint : a 2-year follow-up. European journal of orthodontics, 2'}, {'given': 'Pp.917–23.', 'family': 'Brevi, B.C. et al., 2011. Counterclockwise rotation of the occlusal plane in the treatment of obstructive sleep apnea syndrome. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 69'}, {'given': 'Pp.1724–1737.', 'family': 'Buchwald, H., Avidor, Y. & Braunwald, E., 2004. Bariatric Surgery: A Systematic Review and Meta-analysis. JAMA, 292(14)'}, {'given': 'Pp.1396–1407.', 'family': 'Caples, S.M. et al., 2010. Surgical Modifications of the Upper Airway for Obstructive Sleep Apnea in Adults : A Systematic Review and Meta-Analysis. SLEEP, 33(10)'}, {'given': 'Pp.187–197.', 'family': 'Caples, S.M., Gami, A.S. & Somers, V.K., 2005. Obstructive Sleep Apnea. Annals of Internal Medicine, 142'}, {'given': 'Pp.163–168.', 'family': 'Carneiro, G. et al., 2012. Is mandatory screening for obstructive sleep apnea with polysomnography in all severely obese patients indicated ? Sleep Breath, 16'}, {'given': 'Pp.546–552.', 'family': 'Cartwright, R. et al., 1991. Clinical Corner A Comparative Study of Treatments for Positional Sleep Apnea. SLEEP, 14(6)'}, {'given': '2005. Sleep nasendoscopy as a predictor of treatment success in snorers using mandibular advancement sp ...', 'family': 'Central, P.'}, {'given': 'Pp.102–6.', 'family': 'Chan, a S.L., Phillips, C.L. & Cistulli, P. a, 2010. Obstructive sleep apnoea--an update. Internal medicine journal, 40(2)'}, {'given': 'Pp.836–842.', 'family': 'Chan, A.S.L., Lee, R.W.W., et al., 2010. Nasopharyngoscopic evaluation of oral appliance therapy for obstructive sleep apnoea. European Respiratory Journal, 35(4)'}, {'given': 'Pp.836–42.', 'family': 'Chan, A.S.L., Lee, R.W.W., et al., 2010. Nasopharyngoscopic evaluation of oral appliance therapy for obstructive sleep apnoea. The European respiratory journal, 35(4)'}, {'given': 'Pp.726–732.', 'family': 'Chan, A.S.L. et al., 2010. The effect of mandibular advancement on upper airway structure in obstructive sleep apnoea. Thorax, 65(8)'}, {'given': 'Pp.693–9.', 'family': 'Chan, A.S.L., Lee, R.W.W. & Cistulli, P. a, 2007. Dental appliance treatment for obstructive sleep apnea. Chest, 132(2)'}, {'given': 'Pp.179–84.', 'family': 'Chan, A.S.L., Lee, R.W.W. & Cistulli, P. a, 2008. Non-positive airway pressure modalities: mandibular advancement devices/positional therapy. Proceedings of the American Thoracic Society, 5(2)'}, {'given': 'Pp.157–162.', 'family': 'Chan, A.S.L., Lee, R.W.W. & Cistulli, P.A., 2011. Use of flow – volume curves to predict oral appliance treatment outcome in obstructive sleep apnea : a prospective validation study. Sleep Breath, 15'}, {'given': 'Pp.102–106.', 'family': 'Chan, A.S.L., Phillips, C.L. & Cistulli, P.A., 2010. Obstructive sleep apnoea – an update. Internal Medicine Journal, 40'}, {'given': 'Pp.39–45.', 'family': 'Chaudhary, B. & Speir, W., 1982. Sleep Apnoea Syndromes. Southern Medical Journal, 75(1)'}, {'given': 'Pp.473–86.', 'family': 'Chen, H. & Lowe, A. a, 2013. Updates in oral appliance therapy for snoring and obstructive sleep apnea. Sleep & breathing = Schlaf & Atmung, 17(2)'}, {'given': 'Pp.907–913.', 'family': 'Chesson, A.L., Berry, R.B. & Pack, A., 2003. Practice Parameters for the Use of Portable Monitoring Devices in the Investigation of Suspected Obstructive Sleep Apnea in Adults. SLEEP, 26(7)'}, {'given': 'Pp.443–57.', 'family': 'Cistulli, P. a et al., 2004. Treatment of snoring and obstructive sleep apnea with mandibular repositioning appliances. Sleep medicine reviews, 8(6)'}, {'given': 'Pp.1–5.', 'family': 'Cistulli, P.A., Palmisano, R.G. & Poole, M.D., 1998. Treatment of Obstructive Sleep Apnea Syndrome by Rapid Maxillary Expansion. SLEEP, 21(8)'}, {'given': 'Pp.624–9.', 'family': 'Clark, G.T. et al., 1993. Effect of anterior mandibular positioning on obstructive sleep apnea. The American review of respiratory disease, 147(3)'}, {'given': 'Pp.146–159.', 'family': 'Dalmasso, F. & Prota, R., 1996. Snoring: analysis, measurement, clinical implications and applications. European Respiratory Journal, 9(1)'}, {'given': 'Pp.1544–1550.', 'family': 'Dancey, D. et al., 2003. Gender Differences in Sleep Apnea: The role of neck circumference. Chest, 123'}, {'given': 'Pp.101–105.', 'family': 'Davies, R.J., Ali, N.J. & Stradling, J.R., 1992. Neck circumference and other clinical features in the diagnosis of the obstructive sleep apnoea syndrome. Thorax, 47'}, {'given': 'Pp.648–653.', 'family': 'Deane, S.A. et al., 2009. Comparison of Mandibular Advancement Splint and Tongue Stabilizing Device in Obstructive Sleep Apnea : A Randomized Controlled Trial. SLEEP, 32(5)'}, {'given': 'Pp.86–87.', 'family': 'Deatherage, J.R., Roden, R.D. & Zouhary, K., 2009. Normal Sleep Architecture. Seminars in Orthodontics, 15'}, {'given': 'Pp.1161–1178.', 'family': 'Deegan, P.C. & McNicholas, W.T., 1995. Pathophysiology of obstructive sleep apnoea. European Respiratory Journal, 8(7)'}, {'given': 'Pp.47–112.', 'family': 'Dempsey, J.A. et al., 2010. Pathophysiology of Sleep Apnea. Physiol Rev, 90'}, {'given': 'Pp.1010–8.', 'family': 'Doff, M.H.J. et al., 2010. Long-term oral-appliance therapy in obstructive sleep apnea: a cephalometric study of craniofacial changes. Journal of dentistry, 38(12)'}, {'given': 'Pp.2076–2084.', 'family': 'Doherty, L.S. et al., 2005. Long-term Effects of Nasal Continuous Positive Airway Pressure Therapy on Cardiovascular Outcomes in Sleep Apnea Syndrome * Long-term Effects of Nasal Continuous Positive Airway Pressure Therapy on Cardiovascular Outcomes in Sl'}, {'given': 'Pp.1003–9.', 'family': 'Dort, L.C., Hadjuk, E. & Remmers, J.E., 2006. Mandibular advancement and obstructive sleep apnoea: a method for determining effective mandibular protrusion. The European respiratory journal, 27(5)'}, {'given': 'Pp.525–531.', 'family': 'Du, X. & Hagg, U., 2003. Muscular Adaptation to Gradual Advancement of the Mandible. Angle Orthodontist, 73(5)'}, {'given': 'Pp.685–689.', 'family': 'Durán, J. et al., 2001. Obstructive Sleep Apnea – Hypopnea and Related Clinical Features in a Population-based Sample of Subjects Aged 30 to 70 Yr. Am J Respir Crit Care Med, 163'}, {'given': 'Pp.144–153.', 'family': 'Eckert, D.J. & Malhotra, A., 2008. Pathophysiology of Adult Obstructive Sleep Apnea. Proc Am Thorac Soc, 5'}, {'given': 'Pp.313–323.', 'family': 'Eckert, D.J., Malhotra, A. & Jordan, A.S., 2009. Mechanisms of Apnea. Progress in Cardiovascular Diseases, 51(4)'}, {'given': 'Pp.858–859.', 'family': 'Editorial, 2009. On the Plausibility of Upper Airway Remodeling as an Outcome of Orofacial Exercise. American journal of respiratory and critical care medicine, 179'}, {'given': 'Pp.1702–1709.', 'family': 'Eikermann, M. et al., 2007. The Influence of Aging on Pharyngeal Collapsibility During Sleep. Chest, 131(6)'}, {'given': 'Pp.305–10.', 'family': 'Ekici, A. et al., 2013. Personality profiles in patients with obstructive sleep apnea. Sleep & breathing = Schlaf & Atmung, 17(1)'}, {'given': 'Pp.e511–e521.', 'family': 'El, H. & Palomo, J.M., 2011. Airway volume for different dentofacial skeletal patterns. American Journal of Orthodontics and Dentofacial Orthopedics, 139'}, {'given': 'Pp.193–200.', 'family': 'Ellen, R. et al., 2006. Systematic Review of Motor Vehicle Crash Risk in Persons With Sleep Apnea. Journal of Clinical Sleep Medicine, 2(2)'}, {'given': 'Pp.263–266.', 'family': 'Ellis, E. & Anderson-Cermin, C., 1998. Occlusal Changes After Hyoid Advancement for Obstructive Sleep Apnea : Case Report. Journal of Oral and Maxillofacial Surgery, 56'}, {'given': 'Pp.855–859.', 'family': 'Engleman, H.M. et al., 2002. Randomized Crossover Trial of Two Treatments for Sleep Apnea / Hypopnea Syndrome Continuous Positive Airway Pressure and Mandibular Repositioning Splint. American journal of respiratory and critical care medicine, 166'}, {'given': 'Pp.263–266.', 'family': 'Engleman, H.M., Martin, S.E. & Douglas, N.J., 1994. Compliance with CPAP therapy in patients with the sleep apnoea / hypopnoea syndrome. Thorax, 49'}, {'given': 'pp.263– 276.', 'family': 'Epstein, L.J. et al., 2009. Clinical Guideline for the Evaluation, Management and Long-term Care of Obstructive Sleep Apnea in Adults. Journal of Clinical Sleep Medicine, 5(3)'}, {'given': 'Pp.905–909.', 'family': 'Eveloff, S.E. et al., 1994. Efficacy of a Herbst Mandibular Advancement Device in Obstructive Sleep Apnea. American journal of respiratory and critical care medicine, 149'}, {'given': 'P.674.', 'family': 'Eveloff, S.E., 2002. Treatment of Obstructive Sleep Apnea. CHEST Journal, 121(3)'}, {'given': 'Pp.77–86.', 'family': 'Faber, C.E. & Grymer, L., 2002. Available Techniques for Objective Assessment of Upper Airway Narrowing in Snoring and Sleep Apnea. Sleep & breathing, 7(2)'}, {'given': '2012. Volumetric analysis of the pharynx in patients with obstructive sleep apnea ( OSA ) treated with maxillomandibular advancement ( MMA ). Sleep Breath.', 'family': 'Faria, A.C. et al.'}, {'given': 'Pp.355–364.', 'family': 'Ferguson, K. a, 2003. The role of oral appliance therapy in the treatment of obstructive sleep apnea. Clinics in Chest Medicine, 24(2)'}, {'given': 'Pp.998–1004.', 'family': 'Ferguson, K. a & Fleetham, J. a, 1995. Sleep-related breathing disorders. 4. Consequences of sleep disordered breathing. Thorax, 50(9)'}, {'given': 'P.1269.', 'family': 'Ferguson, K. a., 1996. A Randomized Crossover Study of an Oral Appliance vs Nasal-Continuous Positive Airway Pressure in the Treatment of Mild-Moderate Obstructive Sleep Apnea. CHEST Journal, 109(5)'}, {'given': 'Pp.1269–1275.', 'family': 'Ferguson, K.A. et al., 1996. A Randomized Crossover Study of an Oral Appliance vs Nasal-Continuous Positive Airway Pressure in the Treatment of Mild-Moderate Obstructive Sleep Apnea *. CHEST Journal, 109'}, {'given': 'Pp.362–368.', 'family': 'Ferguson, K.A., Ono, T., et al., 1997. A short-term controlled trial of an adjustable oral appliance for the treatment of mild to moderate obstructive sleep apnoea. Thorax, 52(4)'}, {'given': 'Pp.244–262.', 'family': 'Ferguson, K.A., Cartwright, R., Rogers, R. & Schmidt-nowara, W., 2006. Oral Appliances for Snoring and Obstructive Sleep Apnea : A Review. SLEEP, 29(2)'}, {'given': 'Pp.244–62.', 'family': 'Ferguson, K.A., Cartwright, R., Rogers, R. & Schmidt-Nowara, W., 2006. Oral appliances for snoring and obstructive sleep apnea: a review. Sleep, 29(2)'}, {'given': 'Pp.375–381.', 'family': 'Ferguson, K.A. et al., 1995. The Relationship Between Obesity and Craniofacial Structure in Obstructive Sleep Apnea *. Chest, 108'}, {'given': 'Pp.1748–1754.', 'family': 'Ferguson, K.A., Love, L.L. & Ryan, C.F., 1997. Effect of Mandibular and Tongue Protrusion on Upper Airway Size During Wakefulness. Am J Respir Crit Care Med, 155'}, {'given': 'Pp.668–72.', 'family': 'Flemons, W.W. et al., 2004. Access to diagnosis and treatment of patients with suspected sleep apnea. American journal of respiratory and critical care medicine, 169(6)'}, {'given': 'Pp.498–504.', 'family': 'Flemons, W.W., 2002. Clinical Practice. The New England Journal of Medicine, 347(7)'}, {'given': 'Pp.1543–1579.', 'family': 'Flemons, W.W. et al., 2003. Home Diagnosis of Sleep Apnea : A Systematic Review of the Literature * : An Evidence Review Cosponsored by the American Academy of Sleep Medicine , the American College of Chest Physicians , and the American Thoracic Society H'}, {'given': 'Pp.618–621.', 'family': 'Flemons, W.W., Remmers, J.E. & Gillis, A.M., 1993. Sleep Apnea and Cardiac Arrhythmias Is There a Relationship ? Am Rev Respir Dis, 148'}, {'given': 'P.1761.', 'family': 'Fleury, B., 2004. Mandibular Advancement Titration for Obstructive Sleep Apnea *. CHEST Journal, 125(5)'}, {'given': 'Pp.2356–2359.', 'family': 'Fleury, B. et al., 1996. Objective patient compliance in long-term use of nCPAP. European Respiratory Journal, 9'}, {'given': 'Pp.150–5.', 'family': 'Fogel, R.B. et al., 2003. Anatomic and physiologic predictors of apnea severity in morbidly obese subjects. Sleep, 26(2)'}, {'given': 'Pp.27–36.', 'family': 'Franklin, K.A. et al., 2009. Effects and Side-Effects of Surgery for Snoring and Obstructive Sleep Apnea – A Systematic Review. Sleep, 32(1)'}, {'given': 'Pp.687–693.', 'family': 'Fransson, A.M.C. et al., 2004. Influence on the masticatory system in treatment of obstructive sleep apnea and snoring with a mandibular protruding device: A 2-year follow-up. American journal of orthodontics and dentofacial orthopedics, 126'}, {'given': 'Pp.813–818.', 'family': 'Fritsch, K.M. et al., 2001. Side Effects of Mandibular Advancement Devices for Sleep Apnea Treatment. , 164'}, {'given': 'Pp.256–61.', 'family': 'Ghoneima, A. & Kula, K., 2013. Accuracy and reliability of cone-beam computed tomography for airway volume analysis. European journal of orthodontics, 35(2)'}, {'given': 'Pp.173–180.', 'family': 'Giannakopoulos, H. & Costello, B.J., 2001. Mortised Genioplasty in the Treatment of Obstructive Sleep Apnea : An Historical Perspective and Modification of Design. Sleep & breathing, 5(4)'}, {'given': 'Pp.375–81.', 'family': 'Giannasi, L.C. et al., 2009. Systematic assessment of the impact of oral appliance therapy on the temporomandibular joint during treatment of obstructive sleep apnea: long-term evaluation. Sleep & breathing = Schlaf & Atmung, 13(4)'}, {'given': 'Pp.336–341.', 'family': 'Giannasi, L.C. et al., 2008. The impact of the Adjustable PM Positioner appliance in the treatment of obstructive sleep apnoea. Arch Med Sci, 4(3)'}, {'given': '(3).', 'family': 'Giles, T. et al., 2006. Continuous positive airways pressure for obstructive sleep apnoea in adults. Cochrane Database of Systematic Reviews'}, {'given': 'Pp.743–748.', 'family': 'Gotsopoulos, H., Chen, C., Qian, J. & Cistulli, P.A., 2002. Oral Appliance Therapy Improves Symptoms in Obstructive Sleep Apnea A Randomized, Controlled Trial. Am J Respir Crit Care Med, 166'}, {'given': 'Pp.743–8.', 'family': 'Gotsopoulos, H., Chen, C., Qian, J. & Cistulli, P. a, 2002. Oral appliance therapy improves symptoms in obstructive sleep apnea: a randomized, controlled trial. American journal of respiratory and critical care medicine, 166(5)'}, {'given': 'Pp.934–941.', 'family': 'Gotsopoulos, H., Kelly, J.J. & Cistulli, P.A., 2004. Oral Appliance Therapy Reduces Blood Pressure in Obstructive Sleep Apnea : a Randomized, Controlled Trial. SLEEP, 27(5)'}, {'given': 'Pp.893–896.', 'family': 'Guilleminault, C. & Li, K.K., 2004. Maxillomandibular Expansion for the Treatment of Sleep-Disordered Breathing : Preliminary Result. Laryngoscope, 114'}, {'given': 'Pp.465–484.', 'family': 'Guilleminault, C., Tilkian, A. & Dement, W., 1976. The Sleep Apnea Syndromes. Annu Rev Med, 27'}, {'given': 'Pp.962–966.', 'family': 'Guimaraes, K. ́tia C. et al., 2009. Effects of Oropharyngeal Exercises on Patients with Moderate Obstructive Sleep Apnea Syndrome. American journal of respiratory and critical care medicine, 179'}, {'given': 'Pp.267–270.', 'family': 'Hakan, E. & Palamo, J.M., 2013. An airway study of different maxillary and mandibular sagital positions. European journal of orthodontics, 35'}, {'given': 'Pp.415–425.', 'family': 'Hamada, T. et al., 2007. Mandibular distraction osteogenesis in a skeletal Class II patient with obstructive sleep apnea. American journal of orthodontics and dentofacial orthopedics, 131'}, {'given': 'Pp.806–14.', 'family': 'Hammond, R.J. et al., 2007. A follow-up study of dental and skeletal changes associated with mandibular advancement splint use in obstructive sleep apnea. American journal of orthodontics and dentofacial orthopedics : official publication of the American'}, {'given': 'Pp.562–570.', 'family': 'Hans, M.G. et al., 1997. Comparison of two dental devices for treatment of obstructive sleep apnea syndrome ( OSAS ). Am J Orthod Dentofac Orthop, 111'}, {'given': 'Pp.132–158.', 'family': 'Haskell, J. a. et al., 2009. Effects of Mandibular Advancement Device (MAD) on Airway Dimensions Assessed With Cone-Beam Computed Tomography. Seminars in Orthodontics, 15(2)'}, {'given': 'Pp.132–158.', 'family': 'Haskell, J.A. et al., 2009. Effects of Mandibular Advancement Device (MAD) on Airway Dimensions Assessed With Cone-Beam Computed Tomography. Seminars in Orthodontics, 15(2)'}, {'given': 'Pp.38–44.', 'family': 'Hassan, B. et al., 2013. Precision of identifying cephalometric landmarks with cone beam computed tomography in vivo. European journal of orthodontics, 35(1)'}, {'given': 'Pp.420–425.', 'family': 'Henke, K., Frantz, D. & Kuna, S., 2000. An Oral Elastic Mandibular Advancement Device for Obstructive Sleep Apnea. Am J Respir Crit Care Med, 161'}, {'given': 'Pp.240–243.', 'family': 'Hirshkowitz, M. et al., 2006. Practice Parameters for the Treatment of Snoring and Obstructive Sleep Apnea with Oral Appliances : An Update for 2005. SLEEP, 29(2)'}, {'given': 'Pp.440–445.', 'family': 'Hiyama, S. et al., 2003. Effects of Mandibular Advancement on Supine Airway Size in Normal Subjects During Sleep. SLEEP, 26(4)'}, {'given': 'Pp.48–54.', 'family': 'Hiyama, S., Kuribayashi, G. & Ono, T., 2002. Nocturnal Masseter and Suprahyoid Muscle Activity Induced by Wearing a Bionator. Angle Orthodontist, 72(1)'}, {'given': 'Pp.1181–1186.', 'family': 'Hoekema, A. et al., 2007. Predictors of Obstructive Sleep Apnea-Hypopnea Treatment Outcome. Journal of Dental Research, 86(12)'}, {'given': 'Pp.129–38.', 'family': 'Hoekema, A. et al., 2007. Simulated driving in obstructive sleep apnoea-hypopnoea; effects of oral appliances and continuous positive airway pressure. Sleep & breathing = Schlaf & Atmung, 11(3)'}, {'given': 'Pp.137–155.', 'family': 'Hoekema, A., Stegenga, B. & de Bont, L.G.M., 2004. Efficacy and Co-Morbidity of Oral Appliances in the Treatment of Obstructive Sleep Apnea-Hypopnea: a Systematic Review. Critical Reviews in Oral Biology & Medicine, 15(3)'}, {'given': 'P.466.', 'family': 'Hoffstein, V., 1994. Cardiac Arrhythmias, Snoring, and Sleep Apnea. CHEST Journal, 106(2)'}, {'given': 'Pp.1–22.', 'family': 'Hoffstein, V., 2007. Review of oral appliances for treatment of sleep-disordered breathing. Sleep & breathing = Schlaf & Atmung, 11(1)'}, {'given': 'Pp.162–170.', 'family': 'Holty, J.C. & Guilleminault, C., 2012. Maxillomandibular Expansion and Advancement for the Treatment of Sleep-Disordered Breathing in Children and Adults. Seminars in Orthodontics, 18'}, {'given': 'Pp.e161–9.', 'family': 'Hong, J.-S. et al., 2011. Three-dimensional analysis of pharyngeal airway volume in adults with anterior position of the mandible. American journal of orthodontics and dentofacial orthopedics : official publication of the American Association of Orthodont'}, {'given': 'Pp.541–549.', 'family': 'Hudgel, W., 1992. Mechanisms of obstructive sleep apnea. Chest, 101'}, {'given': 'Pp.62–69.', 'family': 'Ip, M. et al., 2001. A Community Study of Sleep-Disordered Breathing in Middle-aged Chinese Men in Hong Kong. Chest, 119(1)'}, {'given': 'Pp.323–325.', 'family': 'Ishida, M., Inoue, Y. & Okamoto, K., 1999. Clinical efficacy of prosthetic mandibular advancement on obstructive sleep apnea syndrome.'}, {'given': 'Pp.1319–1326.', 'family': 'Isono, S. et al., 1997. Anatomy of pharynx in patients with obstructive sleep apnea and in normal subjects. J Appl Physiol, 92'}, {'given': 'Pp.908–21.', 'family': 'Isono, S., 2009. Obstructive sleep apnea of obese adults: pathophysiology and perioperative airway management. Anesthesiology, 110(4)'}, {'given': 'Pp.435–441.', 'family': 'Jacobson, R.L. & Schendel, S.A., 2012. Treating Obstructive Sleep Apnea: The case for surgery. Am J Orthod Dentofacial Orthop, 142(4)'}, {'given': 'Pp.314–321.', 'family': 'Jauhar, S. et al., 2008. Ten-year follow-up of mandibular advancement devices for the management of snoring and sleep apnea. J Prosthet Dent, 99'}, {'given': 'Pp.47–53.', 'family': 'Johal, A. et al., 2007. The effect of mandibular advancement appliances on awake upper airway and masticatory muscle activity in patients with obstructive sleep apnoea. Clinical Physiology and Functional Imaging, 27'}, {'given': 'Pp.532–536.', 'family': 'Johal, A. & Battagel, J.M., 2001. Current principles in the management of obstructive sleep apnoea with mandibular advancement appliances. British Dental Journal, 190(10)'}, {'given': 'Pp.607–614.', 'family': 'Johal, A., Battagel, J.M. & Kotecha, B.T., 2005. Sleep nasendoscopy : a diagnostic tool for predicting treatment success with mandibular advancement splints in obstructive sleep apnoea. European journal of orthodontics, 27'}, {'given': 'Pp.251–262.', 'family': 'Johnston, C.D. et al., 2002. Mandibular advancement appliances and obstructive sleep apnoea : a randomized clinical trial. European journal of orthodontics, 24'}, {'given': 'Pp.361–368.', 'family': 'Jordan, A.S. et al., 2009. Airway Dilator Muscle Activity and Lung Volume During Stable Breathing in Obstructive Sleep Apnea. Sleep, 32(3)'}, {'given': 'Pp.63–72.', 'family': 'Jureyda, S. & Shucard, D.W., 2004. Obstructive sleep apnea—an overview of the disorder and its consequences. Seminars in Orthodontics, 10(1)'}, {'given': 'Pp.409–416.', 'family': 'Kapsimalis, F. & Kryger, M.H., 2002. Gender and Obstructive Sleep Apnea Syndrome , Part 1 : Clinical Features. SLEEP, 25(4)'}, {'given': 'Pp.1065–1072.', 'family': 'Kato, J. et al., 2000. Dose-Dependent Effects of Mandibular Advancement on Pharyngeal Mechanics and Nocturnal Oxygenation in Patients With Sleep-Disordered Breath. Chest, 117'}, {'given': 'Pp.647–653.', 'family': 'Katsavrias, E.G., 2003. The Effect of Mandibular Protrusive ( Activator ) Appliances on Articular Eminence Morphology. Angle Orthodontist, 73'}, {'given': 'Physical Examination and Identifying the Sites of Obstruction in OSA.', 'family': 'Kezirian, E.J.'}, {'given': 'Pp.128–33.', 'family': 'Kiely, J.L. & McNicholas, W.T., 2000. Cardiovascular risk factors in patients with obstructive sleep apnoea syndrome. The European respiratory journal, 16(1)'}, {'given': 'Pp.1108–13.', 'family': 'Kim, J. et al., 2004. Prevalence of sleep-disordered breathing in middle-aged Korean men and women. American journal of respiratory and critical care medicine, 170(10)'}, {'given': 'Pp.567–569.', 'family': 'Kimoff, R.J., 2007. Upper Airway Myopathy is Important in the Pathophysiology of Obstructive Sleep Apnea. Journal of Clinical Sleep Medicine, 3(6)'}, {'given': 'Pp.333–344.', 'family': 'Kollias, I. & Krogstad, O., 1999a. Adult craniocervical and pharyngeal changes — a longitudinal cephalometric study between 22 and 42 years of age . Part I : morphological craniocervical and hyoid bone changes. European journal of orthodontics, 21'}, {'given': 'Pp.345–355.', 'family': 'Kollias, I. & Krogstad, O., 1999b. Adult craniocervical and pharyngeal changes — a longitudinal cephalometric study between 22 and 42 years of age . Part II : morphological uvulo-glossopharyngeal changes. European journal of orthodontics, 21'}, {'given': 'Pp.16–19.', 'family': 'KOSKENVUO, M. et al., 1987. Snoring as a risk factor for ischaemic heart disease and stroke in men. Brittish Medical Journal, 294'}, {'given': 'Pp.887–895.', 'family': 'Kribbs, N. et al., 1993. Objective Measurement of Patterns of Nasal CPAP use by Patients with Obstructive Sleep Apnea. American journal of respiratory and critical care medicine, 147'}, {'given': 'Pp.499–521.', 'family': 'Kushida, C.A. et al., 2005. Practice Parameters for the Indications for Polysomnography and Related Procedures : An Update for 2005. SLEEP, 28(4)'}, {'given': 'Pp.240–243.', 'family': 'Kushida, C.A. et al., 2006. Practice Parameters for the Treatment of Snoring and Obstructive Sleep Apnea with Oral Appliances : An Update for 2005. Sleep, 29(2)'}, {'given': 'Pp.15–22.', 'family': 'Kyung, S.H. & Park, Y., 2004. Obstructive Sleep Apnea Patients with the Oral Appliance Experience Pharyngeal Size and Shape Changes in Three Dimensions. Angle Orthodontist, 75'}, {'given': 'Pp.699–711.', 'family': 'L’estrange, P. et al., 1996. A method of studying adaptive changes to the oropharynx to the variation in mandibular position in patients with obstructive sleep apnea. Journal of Oral Rehabilitation, 23'}, {'given': 'Pp.195–201.', 'family': 'Lam, B. et al., 2011. The efficacy of oral appliances in the treatment of severe obstructive sleep apnea. Sleep Breath, 15'}, {'given': 'Pp.39–44.', 'family': 'Lampasso, J.D. & Lampasso, J.G., 2004. Allergy, Nasal Obstruction, and Occlusion. Seminars in Orthodontics, 10'}, {'given': 'Pp.1362–1368.', 'family': 'Larsson, L., Carlson-Nordlander, B. & Svanborg, E., 1994. Four-year Follow-up After Uvulopalatopharyngoplasty In 50 Unselected Patients with Obstructive Sleep Apnea Syndrome. Laryngoscope, 104'}, {'given': 'Pp.2–6.', 'family': 'Lavigne, G.J. et al., 1999. Sleep disorders and the dental patient. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 88(3)'}, {'given': 'Inc.', 'family': 'Lavigne, G.J., Cistulli, P.A. & Smith, M.T., 2009. Sleep Medicine for Dentists: A practical overview, Quintessence Publishing Co'}, {'given': 'Pp.37–45.', 'family': 'Lee, R.W.W., Chan, A.S.L., Grunstein, R.R. & Cistulli, P.A., 2009. Craniofacial Phenotyping in Obstructive Sleep Apnea – A Novel Quantitative Photographic Approach. SLEEP, 32(1)'}, {'given': 'Pp.37–45.', 'family': 'Lee, R.W.W., Chan, A.S.L., Grunstein, R.R. & Cistulli, P. a, 2009. Craniofacial phenotyping in obstructive sleep apnea--a novel quantitative photographic approach. Sleep, 32(1)'}, {'given': 'Pp.46–52.', 'family': 'Lee, R.W.W., Petocz, P., et al., 2009. Prediction of Obstructive Sleep Apnea with Craniofacial Photographic Analysis. SLEEP, 32(1)'}, {'given': 'Pp.96–105.', 'family': 'Lenza, M. et al., 2010. An analysis of different approaches to the assessment of upper airway morphology : a CBCT study. Orthodontics & Craniofacial Research, 13(2)'}, {'given': 'Pp.139–47.', 'family': 'Levendowski, D.J. et al., 2007. In-home evaluation of efficacy and titration of a mandibular advancement device for obstructive sleep apnea. Sleep & breathing = Schlaf & Atmung, 11(3)'}, {'given': 'Pp.201–209.', 'family': 'Li, K.K., 2005. Surgical therapy for adult obstructive sleep apnea. Sleep Medicine Reviews, 9'}, {'given': 'Pp.1751–1755.', 'family': 'Liistro, G., Aubert, G. & Rodenstein, D.O., 1995. Management of sleep apnoea syndrome. European Respiratory Journal, 8(10)'}, {'given': '(1).', 'family': 'Lim, J. et al., 2006. Oral appliances for obstructive sleep apnoea (Review). Cochrane Database of Systematic Reviews'}, {'given': 'Pp.639–647.', 'family': 'Liu, Y. et al., 2001. Cephalometric and physiologic predictors of the efficacy of an adjustable oral appliance for treating obstructive sleep apnea. American Journal of Orthodontics and Dentofacial Orthopedics, 120(6)'}, {'given': 'Pp.248–56.', 'family': 'Liu, Y. et al., 2000. Effects of a mandibular repositioner on obstructive sleep apnea. American journal of orthodontics and dentofacial orthopedics : official publication of the American Association of Orthodontists, its constituent societies, and the Ame'}, {'given': 'Pp.15–23.', 'family': 'Liu, Y. & Lowe, A., 2000. Factors Related to the Efficacy of an Adjustable Oral Appliance for the Treatment of Obstructive Sleep Apnea. CJDR, 3'}, {'given': 'Pp.S93–95.', 'family': 'Lowe, A., 1993. Can We Predict the Success of Dental Appliance Therapy for the Treatment of Obstructive Sleep Apnea Based on Anatomical Considerations? SLEEP, 16(8)'}, {'given': 'Pp.172–178.', 'family': 'Lowe, A. et al., 2000. Treatment, Airway and Compliance Effects of a Titratable Oral Appliance. SLEEP, 23(4)'}, {'given': 'Pp.589–595.', 'family': 'Lowe, A.A. et al., 1995. Cephalometric and computed tomographic predictors of obstructive sleep apnea severity. Am J Orthod Dentofac Orthop, 107'}, {'given': 'Pp.653–664.', 'family': 'Lowe, A.A. et al., 1996. Cephalometric comparisons of craniofacial and upper airway structure by skeletal subtype and gender in patients with obstructive sleep apnea. Am J Orthod Dentofac Orthop, 110'}, {'given': 'Pp.484–491.', 'family': 'Lowe, A.A. et al., 1986. Facial morphology and obstructive sleep apnea. Am J Orthod Dentofac Orthop, 90'}, {'given': 'Pp.434–440.', 'family': 'Lowe, A.A., 2012. Treating Obstructive Sleep Apnea: The case for oral appliances. Am J Orthod Dentofacial Orthop, 142(4)'}, {'given': 'Pp.59–64.', 'family': 'Lugaresi, E. et al., 1975. Snoring. Electroencephalography and Clinical Neurophysiology, 39'}, {'given': 'Pp.99–104.', 'family': 'Lye, K.W. & Deatherage, J.R., 2009a. Surgical Maxillomandibular Advancement Technique. Seminars in Orthodontics, 15(2)'}, {'given': 'Pp.94–98.', 'family': 'Lye, K.W. & Deatherage, J.R., 2009b. Surgical Procedures for the Treatment of Obstructive Sleep Apnea. Seminars in Orthodontics, 15(2)'}, {'given': '2012. Postoperative complications in obstructive sleep apnea. Sleep Breath.', 'family': 'Mador, M.J., Goplani, S. & Abo-khamis, M.'}, {'given': 'Pp.700–8.', 'family': 'Major, M.P., Flores-Mir, C. & Major, P.W., 2006. Assessment of lateral cephalometric diagnosis of adenoid hypertrophy and posterior upper airway obstruction: a systematic review. American journal of orthodontics and dentofacial orthopedics : official publ'}, {'given': 'Pp.513–516.', 'family': 'Malkoc, S. et al., 2005. Reproducibility of airway dimensions and tongue and hyoid positions on lateral cephalograms. Am J Orthod Dentofac Orthop, 128'}, {'given': 'P.707.', 'family': 'Marklund, M., 1998a. The Effect of a Mandibular Advancement Device on Apneas and Sleep in Patients With Obstructive Sleep Apnea. CHEST Journal, 113(3)'}, {'given': 'P.1630.', 'family': 'Marklund, M., 1998b. Treatment Success With a Mandibular Advancement Device Is Related to Supine-Dependent Sleep Apnea. CHEST Journal, 114(6)'}, {'given': 'Pp.135–144.', 'family': 'Marklund, M., Franklin, K.A. & Persson, M., 2001. Orthodontic side-effects of mandibular advancement devices during treatment of snoring and sleep apnoea. , 23'}, {'given': 'Pp.1630–1635.', 'family': 'Marklund, M., Persson, M. & Franklin, K.A., 1998. Treatment Success With a Mandibular Advancement Device Is Related to Supine-Dependent Sleep Apnea1. Chest, 114'}, {'given': 'Pp.1270–1278.', 'family': 'Marklund, M., Stenlund, H. & Franklin, K.A., 2004. Mandibular Advancement Devices in 630 Men and Women With Obstructive Sleep Apnea and Snoring * : Tolerability and Predictors of Treatment Success. Chest, 125'}, {'given': 'Pp.1241–7.', 'family': 'Marklund, M., Verbraecken, J. & Randerath, W., 2012. Non-CPAP therapies in obstructive sleep apnoea: mandibular advancement device therapy. The European respiratory journal, 39(5)'}, {'given': 'Pp.188–97.', 'family': 'Mattos, C.T. et al., 2014. Reliability of upper airway linear, area, and volumetric measurements in cone-beam computed tomography. American journal of orthodontics and dentofacial orthopedics : official publication of the American Association of Orthodont'}, {'given': 'Pp.35–43.', 'family': 'Mayer, G. & Meier-Ewert, K., 1995. Cephalometric predictors for orthopaedic mandibular advancement in obstructive sleep apnoea. European journal of orthodontics, 17(1)'}, {'given': 'Pp.63–69.', 'family': 'McCrillis, J.M. et al., 2009. Obstructive Sleep Apnea and the Use of Cone Beam Computed Tomography in Airway Imaging: A Review. Seminars in Orthodontics, 15(1)'}, {'given': 'Pp.197–205.', 'family': 'McGinley, B.M. et al., 2008. Upper airway neuromuscular compensation during sleep is defective in obstructive sleep apnea. Journal of applied physiology (Bethesda, Md. : 1985), 105(1)'}, {'given': 'Pp.462–6.', 'family': 'McGown, A.D. et al., 2001. Long-term use of mandibular advancement splints for snoring and obstructive sleep apnoea: a questionnaire survey. The European respiratory journal, 17(3)'}, {'given': 'Ontario.', 'family': 'Medical Advisory Secretariat, 2009. Oral Appliances for Obstructive Sleep Apnea: an evidence-based analysis'}, {'given': 'Pp.1457–1461.', 'family': 'Mehta, A. et al., 2001. A Randomized , Controlled Study of a Mandibular Advancement Splint for Obstructive Sleep Apnea. Am J Respir Crit Care Med, 163'}, {'given': 'Pp.320–324.', 'family': 'Meyer, B. & Knudson, C., 1990. The sleep apnea syndrome . Part II : Treatment. Journal of Prosthetic Dentistry, 63(3)'}, {'given': 'Pp.675–679.', 'family': 'Meyer, J.B. & Knudson, R.C., 1989. The sleep apnea syndrome . Part I : Diagnosis. J Prosthet Dent, 62'}, {'given': 'Pp.163–172.', 'family': 'Miles, P.G., Vig, P.S. & Dorth, F.D.S., 1996. Craniofacial structure and obstructive sleep apnea syndrome-a qualitative analysis and meta-analysis of the literature. Am J Orthod Dentofac Orthop, 109'}, {'given': 'Pp.1025–1030.', 'family': 'Millman, R.P. et al., 2000. Simple Predictors of Uvulopalatopharyngoplasty Outcome in the Treatment of Obstructive Sleep Apnea * Simple Predictors of Uvulopalatopharyngoplasty Outcome in the Treatment of Obstructive Sleep Apnea *. CHEST Journal, 118'}, {'given': 'Pp.545–549.', 'family': 'Mokhlesi, B. & Gozal, D., 2010. Pulmonary and Critical Care Updates Update in Sleep Medicine 2009. Am J Respir Crit Care Med, 181'}, {'given': 'Pp.1031–1035.', 'family': 'Morgenthaler, T.I. et al., 2006. Practice Parameters for the Medical Therapy of Obstructive Sleep Apnea. Sleep, 29(8)'}, {'given': 'Pp.606–611.', 'family': 'MORRISON, D.L. et al., 1993. Pharyngeal Narrowing and Closing Pressures in Patients with Obstructive Sleep Apnea. Am J Respir Crit Care Med, 148'}, {'given': 'Pp.280–3.', 'family': 'Mortimore, I.L. et al., 1998. Neck and total body fat deposition in nonobese and obese patients with sleep apnea compared with that in control subjects. American journal of respiratory and critical care medicine, 157(1)'}, {'given': 'Pp.1331–1339.', 'family': 'Mostafiz, W. et al., 2011. Influence of Oral and Craniofacial Dimensions on Mandibular Advancement Splint Treatment Outcome in Obstructive Sleep Apnea. Chest, 139(6)'}, {'given': 'Pp.43–54.', 'family': 'Naismith, S. et al., 2004. Neurobehavioral Functioning in Obstructive Sleep Apnea : Differential Effects of Sleep Quality, Hypoxemia and Subjective Sleepiness. Journal of Psychosomatic Research, 26(1)'}, {'given': 'Pp.47–58.', 'family': 'Ng, A. et al., 2012. Cephalometry and prediction of oral appliance treatment outcome. Sleep Breath, 16'}, {'given': 'Pp.238–41.', 'family': 'Ng, A.T. et al., 2003. Effect of oral appliance therapy on upper airway collapsibility in obstructive sleep apnea. American journal of respiratory and critical care medicine, 168(2)'}, {'given': 'Pp.666–671.', 'family': 'Ng, A.T., Qian, J. & Cistulli, P.A., 2006. Oropharyngeal Collapse Predicts Treatment Response With Oral Appliance Therapy in Obstructive Sleep Apnea. SLEEP, 29(5)'}, {'given': 'Pp.47–58.', 'family': 'Ng, A.T.M., Darendeliler, M.A., Petocz, P. & Cistulli, P. a, 2012. Cephalometry and prediction of oral appliance treatment outcome. Sleep & breathing = Schlaf & Atmung, 16(1)'}, {'given': 'Pp.47–58.', 'family': 'Ng, A.T.M., Darendeliler, M.A., Petocz, P. & Cistulli, P.A., 2012. Cephalometry and prediction of oral appliance treatment outcome. Sleep & breathing = Schlaf & Atmung, 16(1)'}, {'given': 'Pp.408–19.', 'family': 'Ngiam, J. et al., 2013. Clinical guidelines for oral appliance therapy in the treatment of snoring and obstructive sleep apnoea. Australian dental journal, 58(4)'}, {'given': 'Pp.53–61.', 'family': 'Ohayon, M.M., Li, K.K. & Guilleminault, C., 2001. Risk Factors for Sleep Bruxism in the General Population. CHEST Journal, 119'}, {'given': 'Pp.620–622.', 'family': 'Okawara, Y. et al., 2004. Oral appliance titration and nasal resistance in nonapneic subjects. American Journal of Orthodontics and Dentofacial Orthopedics, 126(5)'}, {'given': 'Pp.513–515.', 'family': 'Oksenberg, A. & Arons, E., 2002. Sleep bruxism related to obstructive sleep apnea : the effect of continuous positive airway pressure. Sleep Medicine, 3'}, {'given': 'Pp.1879–1884.', 'family': 'Ono, T. et al., 2000. Effects of Head and Body Position on Two- and Three-dimensional Configurations of the Upper Airway. Journal of Dental Research, 79(11)'}, {'given': 'Pp.222–229.', 'family': 'Otsuka, R., Almeida, R. De, et al., 2006. A comparison of responders and nonresponders to oral appliance therapy for the treatment of obstructive sleep apnea. Am J Orthod Dentofacial Orthop, 129'}, {'given': 'Pp.222–229.', 'family': 'Otsuka, R., Ribeiro De Almeida, F., et al., 2006. obstructive sleep apnea. Am J Orthod Dentofacial Orthop, 129(2)'}, {'given': 'Pp.113–143.', 'family': 'Özbek, M.M. et al., 1998. Natural head posture , upper airway morphology and obstructive sleep apnoea severity in adults. European journal of orthodontics, 20'}, {'given': 'Pp.792–797.', 'family': 'Pae, E. et al., 2008. Can facial type be used to predict changes in hyoid bone position with age? A perspective based on longitudinal data. American journal of orthodontics and dentofacial orthopedics, 134'}, {'given': 'Pp.52–9.', 'family': 'Pae, E.K. et al., 1994. A cephalometric and electromyographic study of upper airway structures in the upright and supine positions. American journal of orthodontics and dentofacial orthopedics : official publication of the American Association of Orthodon'}, {'given': 'Pp.178–84.', 'family': 'Pae, E.K., Lowe, a a & Fleetham, J. a, 1997. A thin-plate spline analysis of the face and tongue in obstructive sleep apnea patients. Clinical oral investigations, 1(4)'}, {'given': 'Pp.1511–1518.', 'family': 'Pancer, J., 1999. Evaluation of Variable Mandibular Advancement Appliance for Treatment of Snoring and Sleep Apnea*. Chest, 116(6)'}, {'given': 'Pp.237–240.', 'family': 'Pantin, C.C., Hillman, D.R. & Tennant, M., 1999. Dental Side Effects of an Oral Device to Treat Snoring and Obstructive Sleep Apnea. SLEEP, 22(2)'}, {'given': 'Pp.R1671–R1683.', 'family': 'Parati, G., Lombardi, C. & Narkiewicz, K., 2007. Sleep apnea : epidemiology , pathophysiology , and relation to cardiovascular risk. Am J Physiol Regul Integr Comp Physiol'}, {'given': 'Pp.549–555.', 'family': 'Park, J.G., Ramar, K. & Olson, E.J., 2011. Updates on Definition , Consequences , and Management of Obstructive Sleep Apnea. Mayo Clinic Proceedings, 86(6)'}, {'given': 'Pp.156–159.', 'family': 'Partinen, M., 1995. Ischaemic stroke, snoring and obstructive sleep apnea. J Sleep Res, 4(1)'}, {'given': 'P.1200.', 'family': 'Partinen, M., 1988. Long-term outcome for obstructive sleep apnea syndrome patients. Mortality. CHEST Journal, 94(6)'}, {'given': 'Pp.375–381.', 'family': 'Pépin, J.L. et al., 1995. Side Effects of Nasal Continuous Positive Airway Pressure in Sleep Apnea Syndrome : Study of 193 Patients in Two French Sleep Centers. CHEST Journal, 107'}, {'given': 'Pp.3015–21.', 'family': 'Peppard, P.E., Young, T., Palta, M., Dempsey, J., et al., 2000. Longitudinal study of moderate weight change and sleep-disordered breathing. JAMA : the journal of the American Medical Association, 284(23)'}, {'given': 'Pp.1378–1384.', 'family': 'Peppard, P.E., Young, T., Palta, M. & Skatrud, J., 2000. Prospective Study of the Association between Sleep-Disordered Breathing and Hypertension. The New England Journal of Medicine, 342(19)'}, {'given': 'Pp.1–10.', 'family': 'Perez, C. V et al., 2012. The incidence and prevalence of temporomandibular disorders and posterior open bite in patients receiving mandibular advancement device therapy for obstructive sleep apnea. Sleep Breath'}, {'given': 'Pp.1150–1153.', 'family': 'Pételle, B. et al., 2002. One-Night Mandibular Advancement Titration for Obstructive Sleep Apnea Syndrome A Pilot Study. Am J Respir Crit Care Med, 165'}, {'given': '2013. Health Outcomes of CPAP versus Oral Appliance Treatment for Obstructive Sleep Apnea: A Randomised Controlled Trial (For Review Only). American journal of respiratory and critical care medicine.', 'family': 'Phillips, C.L. et al.'}, {'given': 'Pp.761–6.', 'family': 'Pirelli, P., Saponara, M. & Guilleminault, C., 2004. Rapid maxillary expansion in children with obstructive sleep apnea syndrome. Sleep, 27(4)'}, {'given': 'Pp.860–4.', 'family': 'Pitsis, A.J. et al., 2002. Effect of vertical dimension on efficacy of oral appliance therapy in obstructive sleep apnea. American journal of respiratory and critical care medicine, 166(6)'}, {'given': 'Pp.362–369.', 'family': 'Powell, N., Riley, R. & Guilleminault, C., 1988. Obstructive Sleep Apnea, Continuous Positive Airway Pressure, and Surgery. Otolaryngol Head Neck Surg, 99'}, {'given': 'Pp.410–419.', 'family': 'Pracharktam, N. et al., 1996. Cephalometric assessment in obstructive sleep apnea. Am J Orthod Dentofac Orthop, 109'}, {'given': 'Pp.3–15.', 'family': 'Preston, C.B., Lampasso, J.D. & Tobias, P. V, 2004. Cephalometric evaluation and measurement of the upper airway. Seminars in Orthodontics, 10(1)'}, {'given': 'Pp.175–186.', 'family': 'Proffit, W., 1978. Equilibrium Theory Revisited: Factors Influecing Position of Teeth. The Angle Orthodontist, 48(3)'}, {'given': 'Pp.1–5.', 'family': 'Puhan, M.A. et al., 2005. Didgeridoo playing as alternative treatment for obstructive sleep apnoea syndrome: randomised controlled trial. BMJ, (Dec)'}, {'given': 'P.e1000132.', 'family': 'Punjabi, N.M. et al., 2009. Sleep-disordered breathing and mortality: a prospective cohort study. PLoS medicine, 6(8)'}, {'given': 'Pp.244–246.', 'family': 'Rahbar, R., 2004. Adenotonsillar Hypertrophy : The Presentation and Management of Upper Airway Obstruction. Seminars in Orthodontics, 10'}, {'given': 'Pp.569–575.', 'family': 'Randerath, W.J. et al., 2002. An Individually Adjustable Oral Appliance vs Continuous Positive Airway Pressure in Mild-to-Moderate Obstructive Sleep Apnea Syndrome. CHEST Journal, 122'}, {'given': 'Pp.1–7.', 'family': 'Raphaelson, M. et al., 1998. Oral Appliance Therapy for Obstructive Sleep Apnea Syndrome: Progressive Mandibular Advancement During Polysomnography. Journal of Craniomandibular Practice, 16(1)'}, {'given': 'Pp.39–49.', 'family': 'Ravesloot, M.J.L. et al., 2013. The undervalued potential of positional therapy in position-dependent snoring and obstructive sleep apnea-a review of the literature. Sleep & breathing = Schlaf & Atmung, 17(1)'}, {'given': 'Pp.105–110.', 'family': 'Ravesloot, M.J.L. & Vries, N. De, 2011. Reliable Calculation of the Efficacy of Non-Surgical and Surgical Treatment of Obstructive Sleep Apnea Revisited. Sleep, 34(1)'}, {'given': 'Pp.186–92.', 'family': 'Redline, S. et al., 1997. Racial differences in sleep-disordered breathing in African-Americans and Caucasians. American journal of respiratory and critical care medicine, 155(1)'}, {'given': 'Pp.583–602.', 'family': 'Redline, S. & Tishler, P. V., 2000. The genetics of sleep apnea. Sleep medicine reviews, 4(6)'}, {'given': 'Pp.505–511.', 'family': 'Ribeiro De Almeida, F. et al., 2002. Effects of Mandibular Posture on Obstructive Sleep Apnea Severity and the Temporomandibular Joint in Patients Fitted with an Oral Appliance. , 25(5)'}, {'given': 'Pp.303–11.', 'family': 'Riley, R. et al., 1983. Cephalometric analyses and flow-volume loops in obstructive sleep apnea patients. Sleep, 6(4)'}, {'given': 'Pp.415–421.', 'family': 'Riley, R. et al., 2000. Surgery and Obstructive Sleep Apnea: Long-term clinical outcomes. Otolaryngol Head Neck Surg, 122'}, {'given': 'Pp.117–125.', 'family': 'Riley, R., Powell, N. & Guilleminault, C., 1993. Obstructive Sleep Apnea Syndrome: A review of 306 consecutively treated surgical patients. Otolaryngol Head Neck Surg, 108'}, {'given': 'Pp.742–747.', 'family': 'Riley, R.W., Powell, N.B. & Guilleminault, C., 1993. Obstructive Sleep Apnea Syndrome : A Surgical Protocol for Dynamic Airway Reconstruction. Journal of Oral and Maxillofacial Surgery, 51'}, {'given': 'Pp.53–60.', 'family': 'Ringqvist, M. et al., 2003. Dental and skeletal changes after 4 years of obstructive sleep apnea treatment with a mandibular advancement device: A prospective, randomized study. Am J Orthod Dentofac Orthop, 124'}, {'given': 'Pp.371–376.', 'family': 'Robertson, C., Herbison, P. & Harkness, M., 2003. Dental and occlusal changes during mandibular advancement splint therapy in sleep disordered patients. European journal of orthodontics, 25'}, {'given': 'Pp.34–45.', 'family': 'Rondeau, B., 2010. The Dentist’s Involvement in Snoring and Sleep Apnea. Chairside'}, {'given': 'Pp.1–14.', 'family': 'Ross, S.D. et al., 2000. Systematic Review and Meta-analysis of the Literature Regarding the Diagnosis of Sleep Apnea. SLEEP, 23(4)'}, {'given': 'Pp.271–273.', 'family': 'Ruoff, C.M. & Guilleminault, C., 2012. Orthodontics and sleep-disordered breathing. Sleep Breath, 16'}, {'given': 'Pp.972–977.', 'family': 'Ryan, C.F. et al., 1999. Mandibular advancement oral appliance therapy for obstructive sleep apnoea : effect on awake calibre of the velopharynx. Thorax, 54'}, {'given': 'Pp.824–30.', 'family': 'Ryan, S., Taylor, C.T. & McNicholas, W.T., 2006. Predictors of elevated nuclear factor-kappaB-dependent genes in obstructive sleep apnea syndrome. American journal of respiratory and critical care medicine, 174(7)'}, {'given': 'Pp.485–489.', 'family': 'Sadaoka, T. et al., 1996. The value of sleep nasendoscopy in the evaluation of patiets with suspected sleep-related breathing disorders. Clin. Otolaryngol, 21'}, {'given': 'Pp.885–90.', 'family': 'Saigusa, H. et al., 2009. Three-dimensional morphological analyses of positional dependence in patients with obstructive sleep apnea syndrome. Anesthesiology, 110(4)'}, {'given': 'Pp.54–62.', 'family': 'Salem, O.H., Briss, B.S. & Annino, D.J., 2004a. Nasorespiratory Function and Craniofacial Morphology — A Review of the Surgical Management of the Upper Airway. Seminars in Orthodontics, 10'}, {'given': 'Pp.54–62.', 'family': 'Salem, O.H., Briss, B.S. & Annino, D.J., 2004b. Nasorespiratory function and craniofacial morphology—a review of the surgical management of the upper airway. Seminars in Orthodontics, 10(1)'}, {'given': 'Pp.143–150.', 'family': 'Sanner, B.M. et al., 2002. MRI of the pharynx and treatment efficacy of a mandibular advancement device in obstructive sleep apnoea syndrome. European Respiratory Journal, 20(1)'}, {'given': 'Pp.629–636.', 'family': 'Santos-Silva, R. et al., 2009. Validation of a Portable Monitoring System for the Diagnosis of Obstructive Sleep Apnea Syndrome. SLEEP, 32(5)'}, {'given': 'Pp.829–39.', 'family': 'Schäfer, H. et al., 2002. Body fat distribution, serum leptin, and cardiovascular risk factors in men with obstructive sleep apnea. Chest, 122(3)'}, {'given': 'Pp.501–510.', 'family': 'Schmidt-Nowara, W. et al., 1995. An American Sleep Disorders Association Review Oral Appliances for the Treatment of Snoring and Obstructive Sleep Apnea : A Review. SLEEP, 18(6)'}, {'given': 'Pp.1673–1689.', 'family': 'Schwab, R.J. et al., 1995. Upper Airway and Soft Tissue Anatomy in Normal Subjects and Patients with Sleep-Disordered Breathing Significance of the lateral Pharyngeal Walls. Am J Physiol Regul Integr Comp Physiol, 152'}, {'given': 'Pp.125–6.', 'family': 'Schwarting, S. et al., 2007. Position paper on the use of mandibular advancement devices in adults with sleep-related breathing disorders. A position paper of the German Society of Dental Sleep Medicine (Deutsche Gesellschaft Zahnaerztliche Schlafmedizin,'}, {'given': 'Pp.185–92.', 'family': 'Schwartz, A.R. et al., 2008. Obesity and obstructive sleep apnea: pathogenic mechanisms and therapeutic approaches. Proceedings of the American Thoracic Society, 5(2)'}, {'given': 'Pp.49–56.', 'family': 'Sengul, Y.S., Ozalevli, S. & Oztura, I., 2011. The effect of exercise on obstructive sleep apnea : a randomized and controlled trial. Sleep Breath, 15'}, {'given': 'Pp.703–714.', 'family': 'Seto, B.H. et al., 2001. Maxillary morphology in obstructive sleep apnoea syndrome. European journal of orthodontics, 23'}, {'given': 'Pp.19–25.', 'family': 'Shahar, E. et al., 2001. Sleep-disordered Breathing and Cardiovascular Disease Cross-sectional Results of the Sleep Heart Health Study. Am J Respir Crit Care Med, 163'}, {'given': 'Pp.1209–1217.', 'family': 'Shen, H.-L. et al., 2012. Craniofacial morphologic predictors of oral appliance outcomes in patients with obstructive sleep apnea. Journal of American Dental Association, 143(11)'}, {'given': 'Pp.156–177.', 'family': 'Sher, A.E., Schechtman, B. & Piccirillo, J.R., 1996. The Efficacy of Surgical Modifications of the Upper Airway in Adults With Obstructive Sleep Apnea Syndrome. SLEEP, 19(2)'}, {'given': 'Pp.347–52.', 'family': 'Shigeta, Y. et al., 2008. Correlation between retroglossal airway size and body mass index in OSA and non-OSA patients using cone beam CT imaging. Sleep & breathing = Schlaf & Atmung, 12(4)'}, {'given': '(1).', 'family': 'Shneerson, J. & Wright, J., 2001. Lifestyle modification for obstructive sleep apnoea (Review). Cochrane Database of Systematic Reviews'}, {'given': '2012. Does physical exercise reduce excessive daytime sleepiness by improving inflammatory profiles in obstructive sleep apnea patients ? Sleep Breath.', 'family': 'Da Silva Alves, E. et al.'}, {'given': 'Pp.105–131.', 'family': 'Sittitavornwong, S. et al., 2009. Evaluation of Obstructive Sleep Apnea Syndrome by Computational Fluid Dynamics. Seminars in Orthodontics, 15(2)'}, {'given': '(2).', 'family': 'Smith, I., Lasserson, T. & Wright, J., 2006. Drug therapy for obstructive sleep apnoea in adults ( Review ). Cochrane Database of Systematic Reviews'}, {'given': 'Pp.618–626.', 'family': 'Smith, T. et al., 2012. Three-dimensional computed tomography analysis of airway volume changes after rapid maxillary expansion. American Journal of Orthodontics and Dentofacial Orthopedics, 141'}, {'given': 'Customer brochure.', 'family': 'Somnomed'}, {'given': 'Pp.1–14.', 'family': 'Somnomed, Key research findings.'}, {'given': 'Pp.1–2.', 'family': 'Somnomed, Offer your OSA patients an alternative to CPAP therapy.'}, {'given': 'Pp.118–125.', 'family': 'Sonnesen, L., 2012. Cervical Vertebral Column Morphology Associated with Head Posture and Craniofacial Morphology. Seminars in Orthodontics, 18(2)'}, {'given': 'Pp.836–842.', 'family': 'Srinivasan, V.K. et al., 2010. Nasopharyngoscopic evaluation of oral appliance therapy for obstructive sleep apnoea. , 35(4)'}, {'given': 'Pp.85–90.', 'family': 'Stradling, R. & Crosby, J.H., 1991. Predictors and prevalence of obstructive sleep apnoea and snoring in 1001 middle aged men. Thorax, 46'}, {'given': 'Pp.555–558.', 'family': 'Strohl, K.P. & Redline, S., 1986. Nasal CPAP Therapy, Upper Airway Muscle Activation, and Obstructive Sleep Apnea. Am Rev Respir Dis, 134'}, {'given': 'Pp.862–865.', 'family': 'Sullivan, C. et al., 1981. Reversal of Obstructive Sleep Apnea By Continuous Positive Airway Pressure Applied Through the Nares. The Lancet'}, {'given': 'Pp.194–198.', 'family': 'Sullivan, R.A.O. et al., 1995. Mandibular Advancement Splint : An Appliance to Treat Snoring and Obstrudive Sleep Apnea. Am J Respir Crit Care Med, 151'}, {'given': '(4).', 'family': 'Sundaram, S., Lim, J. & Tj, L., 2005. Surgery for obstructive sleep apnoea in adults ( Review ). Cochrane Database of Systematic Reviews'}, {'given': 'Pp.469–477.', 'family': 'Sutherland, K. et al., 2011. Comparative Effects of Two Oral Appliances on Upper Airway Structure in Obstructive Sleep Apnea. SLEEP, 34(4)'}, {'given': 'P.w13276.', 'family': 'Sutherland, K. & Cistulli, P., 2011. Mandibular advancement splints for the treatment of sleep apnea syndrome. Swiss medical weekly, 141(September)'}, {'given': 'Pp.1–10.', 'family': 'Sutherland, K. & Cistulli, P.A., 2011. Mandibular advancement splints for the treatment of sleep apnoea syndrome. Swiss Medical Weekly, 114(September)'}, {'given': 'Pp.213–22.', 'family': 'Sutherland, K., Lee, R.W.W. & Cistulli, P. a, 2012. Obesity and craniofacial structure as risk factors for obstructive sleep apnoea: impact of ethnicity. Respirology (Carlton, Vic.), 17(2)'}, {'given': 'Pp.213–222.', 'family': 'SUTHERLAND, K., LEE, R.W.W. & CISTULLI, P.A., 2012. Obesity and craniofacial structure as risk factors for obstructive sleep apnoea: Impact of ethnicityresp_2082. Respirology, 17'}, {'given': 'Pp.239–249.', 'family': 'Tan, Y.K. et al., 2002. Mandibular advancement splints and continuous positive airway pressure in patients with obstructive sleep apnoea : a randomized cross-over trial. European journal of orthodontics, 24'}, {'given': 'Pp.23–35.', 'family': 'Tangugsorn, V. et al., 2001. Obstructive Sleep Apnea : A Canonical Correlation of Cephalometric and Selected Demographic Variables in Obese and Nonobese Patients. Angle Orthodontist, 71(1)'}, {'given': 'Pp.1103–1108.', 'family': 'Thornton, W.K. & Roberts, D.H., 1996. Nonsurgical Obstructive Management Sleep Apnea of the Patient. J Oral Maxillofac Surg, 54'}, {'given': 'Pp.121–126.', 'family': 'Tomfohr, L.M. et al., 2011. Effects of Continuous Positive Airway Pressure on Fatigue and Sleepiness in Patients with Obstructive Sleep Apnea : Data from a Randomized Controlled Trial. SLEEP, 34(1)'}, {'given': 'Pp.573–581.', 'family': 'Tregear, S. et al., 2009. Obstructive Sleep Apnea and Risk of Motor Vehicle Crash: Systematic Review and Meta-Analysis. Journal of Clinical Sleep Medicine, 5(6)'}, {'given': 'Pp.366–370.', 'family': 'Tsai, W.H. et al., 2004. Remotely Controlled Mandibular Positioner Predicts Efficacy of Oral Appliances in Sleep Apnea. Am J Respir Crit Care Med, 170'}, {'given': 'Pp.1009–1015.', 'family': 'Tsuiki, S., Isono, S., Ishikawa, T. & Yamashiro, Y., 2008. Anatomical Balance of the Upper Airway and Obstructive Sleep Apnea. Anesthesiology, 108'}, {'given': 'Pp.1009–15.', 'family': 'Tsuiki, S., Isono, S., Ishikawa, T., Yamashiro, Y., et al., 2008. Anatomical balance of the upper airway and obstructive sleep apnea. Anesthesiology, 108(6)'}, {'given': 'Pp.554–560.', 'family': 'Tsuiki, S. et al., 2001. Effects of a Titratable Oral Appliance on Supine Airway Size in Awake Non-Apneic Individuals. Am J Respir Crit Care Med, 24(5)'}, {'given': 'Pp.263–268.', 'family': 'Tsuiki, S. et al., 2004. Effects of mandibular advancement on airway curvature and obstructive sleep apnoea severity. European Respiratory Journal, 23(2)'}, {'given': 'Pp.1098–1105.', 'family': 'Tsuiki, S. et al., 2010. Optimal positive airway pressure predicts oral appliance response to sleep apnoea. European Respiratory Journal, 35(5)'}, {'given': 'Pp.43–50.', 'family': 'Tsuiki, S. et al., 2003. Supine-Dependent Changes in Upper Airway Size in Awake Obstructive Sleep Apnea Patients. Sleep & breathing, 7(1)'}, {'given': 'Pp.504–12.', 'family': 'Tsuiki, S. et al., 2005. The interaction between changes in upright mandibular position and supine airway size in patients with obstructive sleep apnea. American journal of orthodontics and dentofacial orthopedics : official publication of the American As'}, {'given': '2011. Tongue position controller as an alternative treatment for obstructive sleep apnea. Sleep Breath.', 'family': 'Tsuiki, S. et al.'}, {'given': 'Pp.168–73.', 'family': 'Udwadia, Z.F. et al., 2004. Prevalence of sleep-disordered breathing and sleep apnea in middle-aged urban Indian men. American journal of respiratory and critical care medicine, 169(2)'}, {'given': 'Pp.197–202.', 'family': 'Vanderveken, O.M. et al., 2008. Comparison of a custom-made and a thermoplastic oral appliance for the treatment of mild sleep apnea. American journal of respiratory and critical care medicine, 178(2)'}, {'given': 'Pp.1036–1044.', 'family': 'Veasey, S.C. et al., 2006. Medical Therapy for Obstructive Sleep Apnea : A Review by the Medical Therapy for Obstructive Sleep Apnea Task Force of the Standards of Practice Committee of the American Academy of Sleep Medicine. Sleep, 29(8)'}, {'given': 'Pp.603–611.', 'family': 'Vig, K.W.L., 1998. Nasal obstruction and facial growth: The strength of evidence for clinical assumptions. American journal of orthodontics and dentofacial orthopedics, 113'}, {'given': 'Pp.128–34.', 'family': 'Villa, M.P. et al., 2007. Rapid maxillary expansion in children with obstructive sleep apnea syndrome: 12-month follow-up. Sleep medicine, 8(2)'}, {'given': 'Pp.129–150.', 'family': 'Viviano, J.S., 2002. Acoustic Reflection : Review and Clinical Applications for Sleep- Disordered Breathing. Sleep & breathing, 6(3)'}, {'given': 'Pp.739–746.', 'family': 'Walker-Engström, M.-L. et al., 2002. 4-Year Follow-up of Treatment With Dental Appliance or Uvulopalatopharyngoplasty in Patients With Obstructive Sleep Apnea *. CHEST Journal, 121'}, {'given': 'Pp.119–130.', 'family': 'Walker-Engström, M.-L. et al., 2003. A Prospective Randomized Study Comparing Two Different Degrees of Mandibular Advancement with a Dental Appliance in Treatment of Severe Obstructive Sleep Apnea. Sleep & breathing, 7(3)'}, {'given': 'Pp.73–89.', 'family': 'Warunek, S.P., 2004. Oral appliance therapy in sleep apnea syndromes: a review. Seminars in Orthodontics, 10(1)'}, {'given': 'Pp.2219–2224.', 'family': 'Wetter, D.W. et al., 1994. Smoking as a Risk Factor for Sleep-Disordered Breathing. Arch Intern Med, 154(9)'}, {'given': 'Pp.1363–1370.', 'family': 'White, D.P., 2005. Pathogenesis of Obstructive and Central Sleep Apnea. Am J Respir Crit Care Med, 172'}, {'given': 'Pp.797–804.', 'family': 'White, D.P., 1995. Pathophysiology of obstructive sleep apnea. Thorax, 50'}, {'given': 'Pp.323–328.', 'family': 'Whittle, A.T. et al., 1999. Neck soft tissue and fat distribution : comparison between normal men and women by magnetic resonance imaging. Thorax, 54'}, {'given': '2000. Obesity: Preventing and Managing the Global Epidemic', 'family': 'WHO'}, {'given': 'Pp.304–16.', 'family': 'Wolford, L.M., Chemello, P.D. & Hilliard, F., 1994. Occlusal plane alteration in orthognathic surgery--Part I: Effects on function and esthetics. American journal of orthodontics and dentofacial orthopedics : official publication of the American Associati'}, {'given': 'Pp.193–199.', 'family': 'Won, C.H.J., Li, K.K. & Guilleminault, C., 2008. Surgical Treatment of Obstructive Sleep Apnea Upper Airway and Maxillomandibular Surgery. Proc Am Thorac Soc, 5'}, {'given': 'Pp.845–847.', 'family': 'Yildiri, N. et al., 1991. The Effect of Posture on Upper Airway Dimensions in Normal Subjects and in Patients with the Sleep Apnea/Hypopnea Syndrome. Am Rev Respir Dis, 144'}, {'given': 'Pp.1230–1235.', 'family': 'Young, T. et al., 1993. The Occurrence of Sleep-Disordered Breathing Among Middle-Aged Adults. The New England Journal of Medicine, 328'}, {'given': 'Pp.1217–1239.', 'family': 'Young, T., Peppard, P.E. & Gottlieb, D.J., 2002. Epidemiology of Obstructive Sleep Apnea. American Journal of Respiratory and Critical Care Medicine, 165(9)'}, {'given': 'Pp.2013–2016.', 'family': 'Young, T., Skatrud, J. & Peppard, P.E., 2004. Risk Factors for Obstructive Sleep Apnea. JAMA, 291(16)'}, {'given': 'Pp.88–93.', 'family': 'Yow, M., 2009. An Overview of Oral Appliances and Managing the Airway in Obstructive Sleep Apnea. Seminars in Orthodontics, 15(2)'}, {'given': 'Pp.226–36.', 'family': 'Yumino, D. & Bradley, T.D., 2008. Central sleep apnea and Cheyne-Stokes respiration. Proceedings of the American Thoracic Society, 5(2)'}, {'given': 'Pp.543–7.', 'family': 'Zeng, B. et al., 2008. Influence of nasal resistance on oral appliance treatment outcome in obstructive sleep apnea. Sleep, 31(4)'}, {'given': 'pp.726–730.', 'family': 'Zeng, B. et al., 2007. Use of Flow – Volume Curves to Predict Oral Appliance Treatment Outcome in Obstructive Sleep Apnea. American journal of respiratory and critical care medicine, 175'}], 'abstract': 'Mandibular advancement devices (MADs) represent the main non-continuous positive airway pressure (non-CPAP) therapy for patients with obstructive sleep apnoea (OSA). The aim of the European Respiratory Society Task Force was to review the evidence in favour of MAD therapy. Effects of tongue-retaining devices are not included in this report. Custom-made MADs reduce apnoea/hypopnoea index (AHI) and daytime sleepiness compared with placebo devices. CPAP more effectively diminishes AHI, while increasing data suggest fairly similar outcomes in relation to symptoms and cardiovascular health from these treatments. Patients often prefer MADs to CPAP. Milder cases and patients with a proven increase in upper airway size as a result of mandibular advancement are most likely to experience treatment success with MADs. A custom-made device titrated from an initial 50% of maximum mandibular advancement has been recommended. More research is needed to define the patients who will benefit from MAD treatment compared with CPAP, in terms of the effects on sleep-disordered breathing and on other diseases related to OSA. In conclusion, MADs are recommended for patients with mild to moderate OSA (Recommendation Level A) and for those who do not tolerate CPAP. The treatment must be followed up and the device adjusted or exchanged in relation to the outcome.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '22075487', 'scopus': None, 'doi': '10.1183/09031936.00144711'}, 'title': 'Non-CPAP therapies in obstructive sleep apnoea: mandibular advancement device therapy.', 'source': 'Mendeley'}
Ind PW, Dal Negro R, Colman NC, Fletcher CP, Browning D, James MH. Addition of salmeterol to fluticasone propionate treatment in moderate-to-severe asthma. Respiratory medicine. 2003;97(5):555-62.	-	12735675	primary-study	8c14ac69d32ce6f8903203d9532a0396094e774a	-	{'publication_type': {'year': 2003, 'cited_medium': None, 'issue': '5', 'issn': '0954-6111', 'volume': '97', 'title': 'Respiratory Medicine', 'pagination': '555-562'}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.875, 'authors': 0.9}, 'authors': [{'given': 'P.W.', 'family': 'IND'}, {'given': 'R.', 'family': 'DAL NEGRO'}, {'given': 'N.C.', 'family': 'COLMAN'}, {'given': 'C.P.', 'family': 'FLETCHER'}, {'given': 'D.', 'family': 'BROWNING'}, {'given': 'M.H.', 'family': 'JAMES'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1053/rmed.2003.1483'}, 'title': 'Addition of salmeterol to fluticasone propionate treatment in moderate-to-severe asthma', 'source': 'CrossRef'}
Ind PW, Dal Negro R, Colman NC, Fletcher CP, Browning D, James MH. Addition of salmeterol to fluticasone propionate treatment in moderate-to-severe asthma. Respiratory medicine. 2003;97(5):555-62.	-	12735675	primary-study	8c14ac69d32ce6f8903203d9532a0396094e774a	-	{'publication_type': {'year': 2002, 'cited_medium': None, 'issue': None, 'issn': None, 'volume': None, 'title': 'Journal of the American Academy of Child & Adolescent Psychiatry.41(5):555-62,', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.0, 'total': 0.015625, 'authors': 0.0625}, 'authors': [{'given': 'J E', 'family': 'Max'}, {'given': 'K', 'family': 'Mathews'}, {'given': 'A E', 'family': 'Lansing'}, {'given': 'B A', 'family': 'Robertson'}, {'given': 'P T', 'family': 'Fox'}, {'given': 'J L', 'family': 'Lancaster'}, {'given': 'F F', 'family': 'Manes'}, {'given': 'J', 'family': 'Smith'}], 'abstract': 'OBJECTIVES: To determine the rate, types, and correlates of psychiatric disorder (PD) following stroke and orthopedic disorders in children and adolescents. METHOD: Children aged 5 to 19 were assessed. The study used a cross-sectional design that compared 29 stroke subjects with 29 congenital clubfoot or scoliosis subjects. Assessments of psychiatric status; cognitive, adaptive, academic, and family functioning; family psychiatric history; neuroimaging; and neurological status were conducted. The main outcome measure was a current PD not present before the stroke or orthopedic disorder. RESULTS: Poststroke PD occurred significantly more often than postorthopedic diagnosis PD (17/29 [59%] versus 4/29 [14%], p < or =.001). Subjects with ongoing poststroke PD had significantly more impaired intellectual and adaptive functioning, higher intensity family psychiatric history scores, and tended toward higher neurological severity index scores, but they were not different regarding lesion volume or family functioning compared with stroke subjects without PD. Regression analyses showed that neurological severity and family psychiatric history independently contributed significantly to predicting PD. CONCLUSIONS: The data suggest that there are significant biopsychosocial correlates of PD in children with focal neurological lesions. These include a relatively abnormal neurological exam, lower IQ, and increased family psychopathology', 'type': 'journal', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': None}, 'title': 'Psychiatric disorders after childhood stroke', 'source': 'Mendeley'}
Buhl R, Creemers JP, Vondra V, Martelli NA, Naya IP, Ekström T. Once-daily budesonide/formoterol in a single inhaler in adults with moderate persistent asthma. Respiratory medicine. 2003;97(4):323-30.	-	12693793	primary-study	5d1bb583a2b1ab9952db6be20da1da3e37357343	-	{'publication_type': {'year': 2003, 'cited_medium': None, 'issue': '4', 'issn': '0954-6111', 'volume': '97', 'title': 'Respiratory Medicine', 'pagination': '323-330'}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.8791666666666667, 'authors': 0.9166666666666666}, 'authors': [{'given': 'R.', 'family': 'BUHL'}, {'given': 'J.P.H.M.', 'family': 'CREEMERS'}, {'given': 'V.', 'family': 'VONDRA'}, {'given': 'N.A.', 'family': 'MARTELLI'}, {'given': 'I.P.', 'family': 'NAYA'}, {'given': 'T.', 'family': 'EKSTRÖm'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1053/rmed.2002.1427'}, 'title': 'Once-daily budesonide/formoterol in a single inhaler in adults with moderate persistent asthma', 'source': 'CrossRef'}
Buhl R, Creemers JP, Vondra V, Martelli NA, Naya IP, Ekström T. Once-daily budesonide/formoterol in a single inhaler in adults with moderate persistent asthma. Respiratory medicine. 2003;97(4):323-30.	-	12693793	primary-study	5d1bb583a2b1ab9952db6be20da1da3e37357343	-	{'publication_type': {'year': 2001, 'cited_medium': None, 'issue': None, 'issn': None, 'volume': None, 'title': 'Arthritis Rheum.2001.Feb.;44.(2):323.-30.', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.21428571428571427, 'total': 0.1392857142857143, 'authors': 0.0}, 'authors': [{'given': 'B J', 'family': 'Harrison'}, {'given': 'A J', 'family': 'Silman'}, {'given': 'N J', 'family': 'Wiles'}, {'given': 'D G', 'family': 'Scott'}, {'given': 'D P', 'family': 'Symmons'}], 'abstract': 'OBJECTIVE: Cigarette smoking is known to increase rheumatoid factor (RF) and nodule formation in patients with rheumatoid arthritis (RA). In this study, we examined the influence of smoking on disease outcome at 3 years among patients newly presenting with inflammatory polyarthritis (IP). METHODS: We studied 486 patients with IP who were referred to the Norfolk Arthritis Register, of whom 323 (67%) satisfied the American College of Rheumatology 1987 criteria for RA. Smoking status was assessed at baseline. Disease outcome was assessed at 3 years, using measures of joint inflammation, functional disability, and radiologic damage. The influence of smoking on disease outcome was explored using logistic regression techniques, with patients who had never smoked as the referent group. Results are expressed as odds ratios (ORs), with their 95% confidence intervals (95% CIs). RESULTS: Current smokers were significantly more likely to be RF positive at baseline (47%) than were ex-smokers (34%) and never smokers (31%). After 3 years, rheumatoid nodules were significantly more common in smokers (13%) compared with ex-smokers/never smokers (4%), a relationship which persisted after adjusting for age and sex (OR 4.07, 95% CI 1.38-12). In contrast, after adjusting for age and sex, current smokers had significantly fewer swollen joints (OR 0.61, 95% CI 0.37-0.98). However, smoking status had no influence on the development of erosions or functional disability. CONCLUSION: Despite smokers being more likely to develop nodules and to be RF positive, current smokers did not have higher levels of radiologic damage, and had fewer swollen joints. We hypothesize that this could be due to either the effect of cigarette smoking on the inflammatory response or other factors (e.g., reduced physical activity in smokers) which may limit joint inflammation and damage', 'type': 'journal', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': None}, 'title': 'The association of cigarette smoking with disease outcome in patients with early inflammatory polyarthritis', 'source': 'Mendeley'}
Wallin A, Sandström T, Cioppa GD, Holgate S, Wilson S. The effects of regular inhaled formoterol and budesonide on preformed Th-2 cytokines in mild asthmatics. Respiratory medicine. 2002;96(12):1021-5.	-	12477218	primary-study	51a45cadb2b1ce512462ac9c658eb801973e54d4	-	{'publication_type': {'year': 2002, 'cited_medium': None, 'issue': '12', 'issn': '0954-6111', 'volume': '96', 'title': 'Respiratory Medicine', 'pagination': '1021-1025'}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.8600000000000001, 'authors': 0.8400000000000001}, 'authors': [{'given': 'A.', 'family': 'WALLIN'}, {'given': 'T.', 'family': 'SANDSTRÖM'}, {'given': 'G.D.', 'family': 'CIOPPA'}, {'given': 'S.', 'family': 'HOLGATE'}, {'given': 'S.', 'family': 'WILSON'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1053/rmed.2002.1388'}, 'title': 'The effects of regular inhaled formoterol and budesonide on preformed Th-2 cytokines in mild asthmatics', 'source': 'CrossRef'}
Wallin A, Sandström T, Cioppa GD, Holgate S, Wilson S. The effects of regular inhaled formoterol and budesonide on preformed Th-2 cytokines in mild asthmatics. Respiratory medicine. 2002;96(12):1021-5.	-	12477218	primary-study	51a45cadb2b1ce512462ac9c658eb801973e54d4	-	{'publication_type': {'year': 2002, 'cited_medium': None, 'issue': None, 'issn': '09546111', 'volume': None, 'title': 'Respiratory Medicine', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.8600000000000001, 'authors': 0.8400000000000001}, 'authors': [{'given': 'A.', 'family': 'Wallin'}, {'given': 'T.', 'family': 'Sandström'}, {'given': 'G. D.', 'family': 'Cioppa'}, {'given': 'S.', 'family': 'Holgate'}, {'given': 'S.', 'family': 'Wilson'}], 'abstract': 'In a recent placebo-controlled study in mild atopic asthmatics, we observed a significant decrease in eosinophils in the bronchial submucosa, after 2 months of treatment with inhaled formoterol and budesonide. Biopsy material from each treatment group; formoterol (24 μg bid), budesonide (400 μg b.i.d.) and placebo has been further assessed to investigate the role of Th-2 cytokines by immunohistochemistry using Mabs to eosinophils as an index of inflammation, IL-4 and IL-5. Treatment with formoterol significantly reduced the number of eosinophils (EG2+) in the submucosa and epithelium, but this was not paralleled by changes in cytokine immunoreactivity. In contrast, treatment with budesonide significantly reduced both the number of eosinophils (EG2+) and immunoreactivity for IL-4 and IL-5 in the submucosa. Thus, while budesonide has effects on cytokines involved in eosinophil recruitment this explanation does not apply to the eosinopaenia observed with the long-acting β2 adrenoreceptor agonist formoterol. © 2002 Elsevier Science Ltd. All rights reserved.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '12477218', 'scopus': '2-s2.0-0036893330', 'doi': '10.1053/rmed.2002.1388'}, 'title': 'The effects of regular inhaled formoterol and budesonide on preformed Th-2 cytokines in mild asthmatics', 'source': 'Mendeley'}
Tal A, Simon G, Vermeulen JH, Petru V, Cobos N, Everard ML, de Boeck K. Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma. Pediatric pulmonology. 2002;34(5):342-50.	10.1002/ppul.10173	12357478	primary-study	c233cd8c819111f8c77f8bb8d27db9c10b659428	-	{'publication_type': {'year': 2002, 'cited_medium': None, 'issue': '5', 'issn': '8755-6863', 'volume': '34', 'title': 'Pediatric Pulmonology', 'pagination': '342-350'}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.8642857142857143, 'authors': 0.8571428571428571}, 'authors': [{'given': 'A.', 'family': 'Tal'}, {'given': 'G.', 'family': 'Simon'}, {'given': 'J.H.', 'family': 'Vermeulen'}, {'given': 'V.', 'family': 'Petru'}, {'given': 'N.', 'family': 'Cobos'}, {'given': 'M.L.', 'family': 'Everard'}, {'given': 'K.', 'family': 'de Boeck'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '12357478', 'scopus': None, 'doi': '10.1002/ppul.10173'}, 'title': 'Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma', 'source': 'CrossRef'}
Tal A, Simon G, Vermeulen JH, Petru V, Cobos N, Everard ML, de Boeck K. Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma. Pediatric pulmonology. 2002;34(5):342-50.	10.1002/ppul.10173	12357478	primary-study	c233cd8c819111f8c77f8bb8d27db9c10b659428	-	{'publication_type': {'year': 2002, 'cited_medium': None, 'issue': None, 'issn': '87556863', 'volume': None, 'title': 'Pediatric Pulmonology', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.8642857142857143, 'authors': 0.8571428571428571}, 'authors': [{'given': 'A.', 'family': 'Tal'}, {'given': 'G.', 'family': 'Simon'}, {'given': 'J. H.', 'family': 'Vermeulen'}, {'given': 'V.', 'family': 'Petru'}, {'given': 'N.', 'family': 'Cobos'}, {'given': 'M. L.', 'family': 'Everard'}, {'given': 'K.', 'family': 'De Boeck'}], 'abstract': "The aim of this study was to evaluate the efficacy (expressed as effect on lung function) and tolerability of Symbicort (budesonide/formoterol in a single inhaler) in children with asthma. This was a double-blind, double-dummy, randomized, parallel-group, multicenter trial. After a 2-4-week run-in period, 286 asthmatic children (177 boys, 109 girls; mean age, 11 years; mean forced expiratory volume in 1 sec (FEV(1)), 75% predicted normal), previously treated with inhaled corticosteroids (average dose 548 microg/day), were randomized to 12 weeks' treatment with either budesonide/formoterol 80/4.5 microg, two inhalations twice daily (n = 148), or an equivalent dose of budesonide 100 microg, two inhalations twice daily (n = 138). Efficacy variables included morning and evening peak expiratory flow (PEF), spirometery, asthma symptoms, and use of rescue medication (beta(2)-agonists). Serial FEV(1) assessments were carried out on a subgroup of children (budesonide/formoterol, n = 41; budesonide, n = 40) at randomization and at week 12. Relative to baseline, morning PEF (primary variable) increased to a significantly greater extent with budesonide/formoterol than with budesonide alone (7.22% predicted normal vs 3.45% predicted normal; P < 0.001). Evening PEF also increased significantly with budesonide/formoterol (6.13% predicted normal vs. 2.73% predicted normal; P < 0.001), as did mean FEV(1) and serial FEV(1) measured over 12 hr (both P < 0.05). Similar improvements in asthma symptoms and rescue medication use were observed in both groups. The two treatment groups were similar in terms of their adverse-event profile and rates of discontinuation. Budesonide/formoterol in a single inhaler provided rapid improvements in PEF and FEV(1) compared to inhaled budesonide alone. These improvements were sustained throughout the study period. Budesonide/formoterol was well-tolerated in children with moderate persistent asthma.", 'type': 'journal', 'ids': {'embase': None, 'pubmed': '12357478', 'scopus': '2-s2.0-0036841323', 'doi': '10.1002/ppul.10173'}, 'title': 'Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma', 'source': 'Mendeley'}
Price D, Dutchman D, Mawson A, Bodalia B, Duggan S, Todd P. Early asthma control and maintenance with eformoterol following reduction of inhaled corticosteroid dose. Thorax. 2002;57(9):791-8.	-	12200524	primary-study	7652353c02402ade0547b7db544fa55e50c141c9	-	{'publication_type': {'year': 2002, 'cited_medium': None, 'issue': '9', 'issn': '0040-6376', 'volume': '57', 'title': 'Thorax', 'pagination': '791-798'}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 1.0, 'authors': 1.0}, 'authors': [{'given': 'D', 'family': 'Price'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1136/thorax.57.9.791'}, 'title': 'Early asthma control and maintenance with eformoterol following reduction of inhaled corticosteroid dose', 'source': 'CrossRef'}
Price D, Dutchman D, Mawson A, Bodalia B, Duggan S, Todd P. Early asthma control and maintenance with eformoterol following reduction of inhaled corticosteroid dose. Thorax. 2002;57(9):791-8.	-	12200524	primary-study	7652353c02402ade0547b7db544fa55e50c141c9	-	{'publication_type': {'year': 2002, 'cited_medium': None, 'issue': None, 'issn': '0040-6376 (Print)', 'volume': None, 'title': 'Thorax', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 1.0, 'authors': 1.0}, 'authors': [{'given': 'D', 'family': 'Price'}, {'given': 'D', 'family': 'Dutchman'}, {'given': 'A', 'family': 'Mawson'}, {'given': 'B', 'family': 'Bodalia'}, {'given': 'S', 'family': 'Duggan'}, {'given': 'P', 'family': 'Todd'}], 'abstract': 'BACKGROUND: Previous studies have indicated the benefits of adding long acting beta(2) agonists to inhaled corticosteroids in the maintenance treatment of moderate to severe asthma. The effects of adding eformoterol to corticosteroids on asthma control and exacerbations in patients with mild to moderate asthma were studied. METHODS: After a run in period of 7-14 days on existing medication, 663 symptomatic patients were randomised to receive budesonide Turbohaler 400 microg twice daily together with either eformoterol Turbohaler 9 micro g (delivered dose) or placebo twice daily. After 4 weeks patients whose asthma was well controlled (n=505) were re-randomised to receive budesonide 400 microg daily and either eformoterol 9 micro g or placebo twice daily for a further 6 months. RESULTS: Patients receiving eformoterol achieved asthma control 10 days sooner than those receiving budesonide alone, and improvements in lung function, symptoms, quality of life, and relief beta(2) agonist use were significantly greater with eformoterol. During the 6 month follow up the frequency of mild exacerbations was significantly lower in the eformoterol group than in those receiving budesonide alone (7.2 versus 10.5 per patient, 95% confidence interval for ratio 0.49 to 0.96, p=0.03). The time to first day of poorly controlled asthma was 97 days in the eformoterol group compared with 42 days in the placebo group (p=0.003). CONCLUSIONS: Adding eformoterol to a low or moderate dose of budesonide in mild asthma resulted in faster and more effective control than treatment with budesonide alone. Eformoterol allowed the corticosteroid dose to be reduced while also decreasing the rate of mild exacerbations compared with budesonide alone. These data suggest a therapeutic advantage of adding eformoterol to inhaled corticosteroids in patients with mild to moderate asthma.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '12200524', 'scopus': '2-s2.0-0036727059', 'doi': '10.1136/thorax.57.9.791'}, 'title': 'Early asthma control and maintenance with eformoterol following reduction of inhaled corticosteroid dose.', 'source': 'Mendeley'}
Price MJ, Briggs AH. Development of an economic model to assess the cost effectiveness of asthma management strategies. PharmacoEconomics. 2002;20(3):183-94.	-	11929348	primary-study	fd1daf14e382544413b2400b6bbd5d65dce55eef	-	{'publication_type': {'year': 2002, 'cited_medium': None, 'issue': '3', 'issn': '1170-7690', 'volume': '20', 'title': 'PharmacoEconomics', 'pagination': '183-194'}, 'language': None, 'rating': {'year': 1, 'title': 1.0, 'total': 0.975, 'authors': 0.9}, 'authors': [{'given': 'Martin J.', 'family': 'Price'}, {'given': 'Andrew H.', 'family': 'Briggs'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.2165/00019053-200220030-00004'}, 'title': 'Development of an Economic Model to Assess the Cost Effectiveness of Asthma Management Strategies', 'source': 'CrossRef'}
Price MJ, Briggs AH. Development of an economic model to assess the cost effectiveness of asthma management strategies. PharmacoEconomics. 2002;20(3):183-94.	-	11929348	primary-study	fd1daf14e382544413b2400b6bbd5d65dce55eef	-	{'publication_type': {'year': 2002, 'cited_medium': None, 'issue': None, 'issn': '1170-7690', 'volume': None, 'title': 'Pharmacoeconomics', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.875, 'authors': 0.9}, 'authors': [{'given': 'M J', 'family': 'Price'}, {'given': 'A H', 'family': 'Briggs'}], 'abstract': "BACKGROUND AND OBJECTIVE: Asthma is a chronic-episodic disease characterised by acute, symptomatic episodes of varying severity. We developed a Markov model that can be used to estimate the cost effectiveness of alternative asthma treatments. Because of the costs they incur, asthma exacerbations ('attacks') requiring intervention by a healthcare professional were a central consideration in the development of the model. METHODS: Treatment success was assessed as asthma control, a composite measure based on goals defined in world-wide asthma management guidelines and in terms of quality-adjusted life-years (QALYs). The data from which the transition probabilities were derived came from patients with asthma who received either salmeterol/fluticasone propionate combination (SFC) 50/100microg or fluticasone propionate (FP) 100microg, administered twice daily via an inhaler, in a 12-week, randomised, double-blind, clinical trial. Costs were estimated from resource profiles defined for each of the model states. A key aspect of the model was the use of probabilistic sensitivity analysis techniques to examine the uncertainty in the cost-effectiveness results. Distributions were fitted to transition probabilities and to cost input parameters and values were sampled at random from these distributions using a second order Monte Carlo simulation technique. This produced a distribution for incremental cost effectiveness that was employed to construct 95% uncertainty intervals and to construct cost effectiveness acceptability curves. RESULTS: In this analysis, the model was run over a 12-week period using transition probabilities derived from the trial data. The results showed that treatment with SFC resulted in a higher proportion of successfully controlled weeks per patient than treatment with FP (66 vs 47%), and higher mean weekly direct asthma management costs (pound sterling 15.77 vs pound sterling 11.83; 2000 values). The average incremental cost per successfully controlled week with SFC was pound sterling 20.83. Probabilistic sensitivity analysis showed that the 95% uncertainty intervals for the incremental cost-effectiveness ratio was - pound sterling 64.94 to pound sterling 112.66. In approximately 25% of cases, SFC was dominant (more effective and less costly), but in the remaining cases, it was both more effective and more costly. It was shown that if decision makers are willing to pay approximately pound sterling 45 for an additional successfully controlled week, SFC will be the more cost-effective strategy in this patient population for 80% of the time. CONCLUSIONS: This is one of the first decision-analytic models of asthma to incorporate probabilistic sensitivity analysis techniques to explore uncertainty. The model's flexible yet standardised framework permits the cost effectiveness of alternative asthma management strategies in different healthcare settings to be established.", 'type': 'journal', 'ids': {'embase': None, 'pubmed': '11929348', 'scopus': '2-s2.0-0036235385', 'doi': '200304 [pii]'}, 'title': 'Development of an economic model to assess the cost effectiveness of asthma management strategies', 'source': 'Mendeley'}
O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, Runnerstrom E, Sandstrom T, Svensson K, Tattersfield A. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. American journal of respiratory and critical care medicine. 2001;164(8 Pt 1):1392-7.	10.1164/ajrccm.164.8.2104102	11704584	primary-study	f1c24e24d71e4820fe80ff31ecc4c2fea907c952	-	{'publication_type': {'year': 2001, 'cited_medium': None, 'issue': '8', 'issn': '1073-449X', 'volume': '164', 'title': 'American Journal of Respiratory and Critical Care Medicine', 'pagination': '1392-1397'}, 'language': None, 'rating': {'year': 0, 'title': 1.0, 'total': 0.8785714285714286, 'authors': 0.9142857142857144}, 'authors': [{'given': 'PAUL M.', 'family': "O'BYRNE"}, {'given': 'PETER J.', 'family': 'BARNES'}, {'given': 'ROBERTO', 'family': 'RODRIGUEZ-ROISIN'}, {'given': 'EVA', 'family': 'RUNNERSTROM'}, {'given': 'THOMAS', 'family': 'SANDSTROM'}, {'given': 'KLAS', 'family': 'SVENSSON'}, {'given': 'ANNE', 'family': 'TATTERSFIELD'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '11704584', 'scopus': None, 'doi': '10.1164/ajrccm.164.8.2104102'}, 'title': 'Low Dose Inhaled Budesonide and Formoterol in Mild Persistent Asthma', 'source': 'CrossRef'}
O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, Runnerstrom E, Sandstrom T, Svensson K, Tattersfield A. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. American journal of respiratory and critical care medicine. 2001;164(8 Pt 1):1392-7.	10.1164/ajrccm.164.8.2104102	11704584	primary-study	f1c24e24d71e4820fe80ff31ecc4c2fea907c952	-	{'publication_type': {'year': 2001, 'cited_medium': None, 'issue': None, 'issn': '1073449X', 'volume': None, 'title': 'American Journal of Respiratory and Critical Care Medicine', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 1.0, 'total': 0.8785714285714286, 'authors': 0.9142857142857144}, 'authors': [{'given': 'Paul M.', 'family': "O'Byrne"}, {'given': 'Peter J.', 'family': 'Barnes'}, {'given': 'Roberto', 'family': 'Rodriguez-Roisin'}, {'given': 'Eva', 'family': 'Runnerstrom'}, {'given': 'Thomas', 'family': 'Sandstrom'}, {'given': 'Klas', 'family': 'Svensson'}, {'given': 'Anne', 'family': 'Tattersfield'}], 'abstract': 'The optimal treatment for mild asthma is uncertain. We assessed the effects of adding a long-acting inhaled beta-agonist, formoterol, to low doses of an inhaled corticosteroid, budesonide, for 1 yr in subjects with mild asthma, receiving no or only a small dose of inhaled corticosteroid. The 698 corticosteroid free patients (Group A) were assigned to twice daily treatment with 100 microg budesonide, 100 microg budesonide plus 4.5 microg formoterol, or placebo. The 1,272 corticosteroid-treated patients (Group B) were assigned to twice daily treatment with 100 microg budesonide, 100 microg budesonide plus 4.5 microg formoterol, 200 microg budesonide, or 200 microg budesonide plus 4.5 microg formoterol. The main outcome variables were time to the first severe asthma exacerbation and poorly controlled asthma days. In Group A, budesonide alone reduced the risk for severe exacerbations by 60% and poorly controlled days by 48%; adding formoterol increased lung function with no change in other end points. By contrast, in Group B, adding formoterol reduced the risk for the first severe exacerbation and for poorly controlled days by 43 and 30%, respectively. Thus, in corticosteroid-free patients, low dose inhaled budesonide alone reduced severe exacerbations and improved asthma control, and in patients already receiving inhaled corticosteroid, adding formoterol was more effective than doubling the corticosteroid dose.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '11704584', 'scopus': '2-s2.0-0035888721', 'doi': '10.1164/ajrccm.164.8.2104102'}, 'title': 'Low dose inhaled budesonide and formoterol in mild persistent asthma: The OPTIMA randomized trial', 'source': 'Mendeley'}
Zetterström O, Buhl R, Mellem H, Perpiñá M, Hedman J, O'Neill S, Ekström T. Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology. 2001;18(2):262-8.	-	11529282	primary-study	ecddf9b5481f0287713b0a219a1e23e4812e4fd8	-	{'publication_type': {'year': 2001, 'cited_medium': None, 'issue': '2', 'issn': '0000-0000', 'volume': '18', 'title': 'European Respiratory Journal', 'pagination': '262-268'}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.8785714285714286, 'authors': 0.9142857142857144}, 'authors': [{'given': 'O.', 'family': 'Zetterström'}, {'given': 'R.', 'family': 'Buhl'}, {'given': 'H.', 'family': 'Mellem'}, {'given': 'M.', 'family': 'Perpiñá'}, {'given': 'J.', 'family': 'Hedman'}, {'given': 'S.', 'family': "O'Neill"}, {'given': 'T.', 'family': 'Ekström'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1183/09031936.01.00065801'}, 'title': 'Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone', 'source': 'CrossRef'}
Zetterström O, Buhl R, Mellem H, Perpiñá M, Hedman J, O'Neill S, Ekström T. Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology. 2001;18(2):262-8.	-	11529282	primary-study	ecddf9b5481f0287713b0a219a1e23e4812e4fd8	-	{'publication_type': {'year': 2001, 'cited_medium': None, 'issue': None, 'issn': '09031936', 'volume': None, 'title': 'European Respiratory Journal', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.9230769230769231, 'total': 0.8285714285714287, 'authors': 0.9142857142857144}, 'authors': [{'given': 'O.', 'family': 'Zetterström'}, {'given': 'R.', 'family': 'Buhl'}, {'given': 'H.', 'family': 'Mellem'}, {'given': 'M.', 'family': 'Perpiña'}, {'given': 'J.', 'family': 'Hedman'}, {'given': 'S.', 'family': "O'Neill"}, {'given': 'T.', 'family': 'Ekström'}], 'abstract': 'Budesonide/formoterol in a single inhaler was compared with budesonide alone, and with concurrent administration of budesonide and formoterol from separate inhalers, in patients with asthma, not controlled with inhaled glucocorticosteroids alone. In this 12-week, double-blind, randomized, double-dummy study, 362 adult asthmatics (forced expiratory volume in one second 73.8% of predicted, inhaled glucocorticosteroid dose 960 microg x day(-1)) received single inhaler budesonide/formoterol (Symbicort Turbuhaler) 160/4.5 microg, two inhalations b.i.d., or corresponding treatment with budesonide, or budesonide plus formoterol via separate inhalers. There was a greater increase in morning peak expiratory flow (PEF) with single-inhaler (35.7 L x min(-1)) and separate-inhaler (32.0 L x min(-1)) budesonide and formoterol, compared with budesonide alone (0.2 L x min(-1); p<0.001, both comparisons); the effect was apparent after 1 day (p<0.001 versus budesonide, both comparisons). Similarly, evening PEF, use of rescue medication, total asthma symptom scores and percentage of symptom-free days improved more with both single inhaler and separate inhaler therapy than with budesonide alone, as did asthma control days (approximately 15% more, p<0.001 versus budesonide, both comparisons, with a marked increase in the first week). All treatments were well tolerated and the adverse event profile was similar in all three treatment groups. It is concluded that single inhaler therapy with budesonide and formoterol is a clinically effective and well-tolerated treatment for patients with asthma that is not fully controlled by inhaled glucocorticosteroids alone.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '11529282', 'scopus': '2-s2.0-0034887370', 'doi': '10.1183/09031936.01.00065801'}, 'title': 'Improved asthma control with budesonide/formeterol in a single inhaler, compared with budesonide alone', 'source': 'Mendeley'}
D'Urzo AD, Chapman KR, Cartier A, Hargreave FE, Fitzgerald M, Tesarowski D. Effectiveness and safety of salmeterol in nonspecialist practice settings. Chest. 2001;119(3):714-9.	-	11243947	primary-study	0ada9c72f673396d67ad449f98e678cfa4e9b7dd	-	{'publication_type': {'year': 2001, 'cited_medium': None, 'issue': '3', 'issn': '0012-3692', 'volume': '119', 'title': 'Chest', 'pagination': '714-719'}, 'language': None, 'rating': {'year': 1, 'title': 1.0, 'total': 0.9791666666666666, 'authors': 0.9166666666666666}, 'authors': [{'given': 'Anthony D.', 'family': "D'Urzo"}, {'given': 'Kenneth R.', 'family': 'Chapman'}, {'given': 'André', 'family': 'Cartier'}, {'given': 'Frederick E.', 'family': 'Hargreave'}, {'given': 'Mark', 'family': 'Fitzgerald'}, {'given': 'David', 'family': 'Tesarowski'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1378/chest.119.3.714'}, 'title': 'Effectiveness and Safety of Salmeterol in Nonspecialist Practice Settings', 'source': 'CrossRef'}
D'Urzo AD, Chapman KR, Cartier A, Hargreave FE, Fitzgerald M, Tesarowski D. Effectiveness and safety of salmeterol in nonspecialist practice settings. Chest. 2001;119(3):714-9.	-	11243947	primary-study	0ada9c72f673396d67ad449f98e678cfa4e9b7dd	-	{'publication_type': {'year': 2001, 'cited_medium': None, 'issue': None, 'issn': '00123692', 'volume': None, 'title': 'Chest', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 0.9791666666666666, 'authors': 0.9166666666666666}, 'authors': [{'given': 'A. D.', 'family': "D'Urzo"}, {'given': 'K. R.', 'family': 'Chapman'}, {'given': 'A.', 'family': 'Cartier'}, {'given': 'F. E.', 'family': 'Hargreave'}, {'given': 'M.', 'family': 'Fitzgerald'}, {'given': 'D.', 'family': 'Tesarowski'}], 'abstract': 'STUDY OBJECTIVES: To evaluate the effectiveness and safety of inhaled salmeterol in patients managed in nonspecialist practice settings.\\n\\nDESIGN: A randomized, double-blind, 6-month, parallel-group study involving 253 centers.\\n\\nSETTING: Primarily nonspecialist practices (n = 232).\\n\\nPATIENTS: A total of 911 subjects (417 men; 494 women) who met American Thoracic Society asthma criteria were enrolled and randomized to treatment with either twice-daily salmeterol aerosol (50 microg; n = 455) or matching placebo twice daily (n = 456). Both groups were allowed to take salbutamol as needed. All subjects were previously treated with anti-inflammatory maintenance therapy that was continued throughout the study.\\n\\nMEASUREMENTS AND RESULTS: The primary outcome variable was the proportion of subjects with serious asthma exacerbations defined as an exacerbation requiring hospitalization, emergency department visit, or use of prednisone during the treatment period. A total of 712 subjects competed the study. There was no significant difference in the proportion of subjects experiencing serious exacerbations between the salmeterol and placebo groups (20.8% vs 20.9%, respectively; p = 0.935; power > 88%). Peak expiratory flow was significantly higher in the salmeterol group (398 L/min vs 386 L/min for placebo; p < 0.01). Median daily use of salbutamol was two inhalations for the salmeterol group and three inhalations for placebo (p < 0.001). The proportion of subjects sleeping through the night was significantly higher in the salmeterol group (74%) as compared to placebo (68%; p = 0.028).\\n\\nCONCLUSIONS: Salmeterol treatment is effective in subjects typically cared for in the primary-care setting and does not increase the frequency of severe exacerbations.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '11243947', 'scopus': '2-s2.0-0035091885', 'doi': '10.1378/chest.119.3.714'}, 'title': 'Effectiveness and safety of salmeterol in nonspecialist practice settings', 'source': 'Mendeley'}
Molimard M, Bourcereau J, Le Gros V, Bourdeix I, Leynadier F, Duroux P. Comparison between formoterol 12 microg b.i.d. and on-demand salbutamol in moderate persistent asthma. Respiratory medicine. 2001;95(1):64-70.	-	11207020	primary-study	1143ccbc7929eb33b19f900a6e139183511a8609	-	{'publication_type': {'year': 2001, 'cited_medium': None, 'issue': '1', 'issn': '0954-6111', 'volume': '95', 'title': 'Respiratory Medicine', 'pagination': '64-70'}, 'language': None, 'rating': {'year': 0, 'title': 0.9285714285714286, 'total': 0.8160714285714287, 'authors': 0.8500000000000001}, 'authors': [{'given': 'M.', 'family': 'MOLIMARD'}, {'given': 'J.', 'family': 'BOURCEREAU'}, {'given': 'V.', 'family': 'LE GROS'}, {'given': 'I.', 'family': 'BOURDEIX'}, {'given': 'F.', 'family': 'LEYNADIER'}, {'given': 'P.', 'family': 'DUROUX'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1053/rmed.2000.0972'}, 'title': 'Comparison between formoterol 12 μ g b.i.d. and on-demand salbutamol in moderate persistent asthma', 'source': 'CrossRef'}
Molimard M, Bourcereau J, Le Gros V, Bourdeix I, Leynadier F, Duroux P. Comparison between formoterol 12 microg b.i.d. and on-demand salbutamol in moderate persistent asthma. Respiratory medicine. 2001;95(1):64-70.	-	11207020	primary-study	1143ccbc7929eb33b19f900a6e139183511a8609	-	{'publication_type': {'year': 2001, 'cited_medium': None, 'issue': None, 'issn': '09546111', 'volume': None, 'title': 'Respiratory Medicine', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.9230769230769231, 'total': 0.8125000000000001, 'authors': 0.8500000000000001}, 'authors': [{'given': 'M.', 'family': 'Molimard'}, {'given': 'J.', 'family': 'Bourcereau'}, {'given': 'V.', 'family': 'Le Gros'}, {'given': 'I.', 'family': 'Bourdeix'}, {'given': 'F.', 'family': 'Leynadier'}, {'given': 'P.', 'family': 'Duroux'}], 'abstract': "Inhalation of on-demand salbutamol (ODS) several times daily is sometimes the only β 2-agonist prescribed in moderate persistent asthma, whereas a long-acting β 2-agonist should be added. This trial aimed to compare the efficacy of formoterol dry-powder capsule 12μg b.i.d. (Foradil®) and ODS in patients with moderate persistent asthma treated with inhaled corticosteroids, in the conditions of real practice. Two hundred and fifty-nine patients were randomized (formoterol; 130; ODS: 129) in this open parallel-group trial. The mean increases in morning peak expiratory flow (PEF primary variable) and evening PEF over the 3-month treatment period were statistically significantly higher with formoterol: +25.7 and +24.11 min -1, respectively vs. +4.5 and +0.51 min -1 respectively with ODS. The increase in FEV 1 was statistically significantly higher with formoterol at months 1 and 3. Formoterol reduced the use of salbutamol as rescue medication by two-thirds. The percentages of symptom-free days and nights statistically significantly increased with formoterol (+20% and + 33% respectively), but did not significantly change with ODS. Clinically relevant and statistically significant improvement in the mean total score of the St George's Hospital Respiratory Questionnaire was observed in the formoterol group. Adverse events were similar in the two groups. The results show that treatment with formoterol has significant advantages over ODS in patients with moderate persistent asthma. © 2001 Harcourt Publishers Ltd.", 'type': 'journal', 'ids': {'embase': None, 'pubmed': '11207020', 'scopus': '2-s2.0-0034937536', 'doi': '10.1053/rmed.2000.0972'}, 'title': 'Comparison between formoterol 12 μg b.i.d. and on-demand salbutamol in moderate persistent asthma', 'source': 'Mendeley'}
Shapiro G, Lumry W, Wolfe J, Given J, White MV, Woodring A, Baitinger L, House K, Prillaman B, Shah T. Combined salmeterol 50 microg and fluticasone propionate 250 microg in the diskus device for the treatment of asthma. American journal of respiratory and critical care medicine. 2000;161(2 Pt 1):527-34.	10.1164/ajrccm.161.2.9905091	10673196	primary-study	ba86f1e082a22f743c6204513590582f9a454acc	-	{'publication_type': {'year': 2000, 'cited_medium': None, 'issue': '2', 'issn': '1073-449X', 'volume': '161', 'title': 'American Journal of Respiratory and Critical Care Medicine', 'pagination': '527-534'}, 'language': None, 'rating': {'year': 0, 'title': 0.9, 'total': 0.8125000000000001, 'authors': 0.9100000000000001}, 'authors': [{'given': 'GAIL', 'family': 'SHAPIRO'}, {'given': 'WILLIAM', 'family': 'LUMRY'}, {'given': 'JAMES', 'family': 'WOLFE'}, {'given': 'JOHN', 'family': 'GIVEN'}, {'given': 'MARTHA V.', 'family': 'WHITE'}, {'given': 'ANITA', 'family': 'WOODRING'}, {'given': 'LESLIE', 'family': 'BAITINGER'}, {'given': 'KAREN', 'family': 'HOUSE'}, {'given': 'BARBARA', 'family': 'PRILLAMAN'}, {'given': 'TUSHAR', 'family': 'SHAH'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '10673196', 'scopus': None, 'doi': '10.1164/ajrccm.161.2.9905091'}, 'title': 'Combined Salmeterol 50 μ g and Fluticasone Propionate 250 μ g in the Diskus Device for the Treatment of Asthma', 'source': 'CrossRef'}
Shapiro G, Lumry W, Wolfe J, Given J, White MV, Woodring A, Baitinger L, House K, Prillaman B, Shah T. Combined salmeterol 50 microg and fluticasone propionate 250 microg in the diskus device for the treatment of asthma. American journal of respiratory and critical care medicine. 2000;161(2 Pt 1):527-34.	10.1164/ajrccm.161.2.9905091	10673196	primary-study	ba86f1e082a22f743c6204513590582f9a454acc	-	{'publication_type': {'year': 2000, 'cited_medium': None, 'issue': None, 'issn': '1073-449X', 'volume': None, 'title': 'American journal of respiratory and critical care medicine', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 0.9974999999999999, 'authors': 0.99}, 'authors': [{'given': 'G', 'family': 'Shapiro'}, {'given': 'W', 'family': 'Lumry'}, {'given': 'J', 'family': 'Wolfe'}, {'given': 'J', 'family': 'Given'}, {'given': 'M V', 'family': 'White'}, {'given': 'a', 'family': 'Woodring'}, {'given': 'L', 'family': 'Baitinger'}, {'given': 'K', 'family': 'House'}, {'given': 'B', 'family': 'Prillaman'}, {'given': 'T', 'family': 'Shah'}], 'abstract': 'Three hundred forty-nine patients with asthma previously treated with medium doses of inhaled corticosteroids during a 2-wk, single-blind, run-in period were randomized to treatment with salmeterol 50 microg combined with fluticasone propionate (FP) 250 microg, salmeterol 50 microg, FP 250 microg, or placebo, each given twice daily through a Diskus device for 12 wk. Mean change in FEV(1) at endpoint was significantly (p </= 0.001) greater with the salmeterol/FP combination product (0.48 L) than with placebo (-0.11 L), salmeterol (0.05 L), or FP (0.25 L). The combination product significantly increased the area under the 12-h serial FEV(1) curve relative to baseline over that with placebo, salmeterol, or FP at Day 1, Week 1, and Week 12 (p </= 0.025). Patients in the combination-product group had a significantly greater probability of remaining in the study without being withdrawn because of worsening asthma than did patients in the placebo, salmeterol, or FP groups (p </= 0.002). The combination product significantly increased (p < 0. 001) morning PEF at endpoint (53.5 L/min) as compared with placebo (-14 L/min), salmeterol (-11.6 L/min), or FP (15.2 L/min). The combination product significantly (p </= 0.011) reduced asthma symptom scores and supplemental albuterol use, and significantly increased the percentage of nights with no awakenings as compared with placebo, salmeterol, and FP (p </= 0.016). Combination treatment with salmeterol 50 microg and FP 250 microg given twice daily from the Diskus device provided better asthma control and greater improvement in pulmonary function than did the individual agents, and may simplify the management of asthma in patients who need both classes of drugs for optimal control of their disease.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '10673196', 'scopus': None, 'doi': '10.1164/ajrccm.161.2.9905091'}, 'title': 'Combined salmeterol 50 microg and fluticasone propionate 250 microg in the diskus device for the treatment of asthma.', 'source': 'Mendeley'}
Aubier M, Pieters WR, Schlösser NJ, Steinmetz KO. Salmeterol/fluticasone propionate (50/500 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma. Respiratory medicine. 1999;93(12):876-84.	-	10653049	primary-study	e5efed77d45dfa9ff81626863bc3ef4d8e4c13a2	-	{'publication_type': {'year': 1999, 'cited_medium': None, 'issue': '12', 'issn': '0954-6111', 'volume': '93', 'title': 'Respiratory Medicine', 'pagination': '876-884'}, 'language': None, 'rating': {'year': 0, 'title': 0.8095238095238095, 'total': 0.7511904761904762, 'authors': 0.9}, 'authors': [{'given': 'M.', 'family': 'Aubier'}, {'given': 'W.R.', 'family': 'Pieters'}, {'given': 'N.J.J.', 'family': 'Schlösser'}, {'given': 'K-O.', 'family': 'Steinmetz'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1016/s0954-6111(99)90053-7'}, 'title': 'Salmeterol/fluticasone propionate (50500 μg) in combination in a Diskus® inhaler (Seretide®) is effective and safe in the treatment of steroid-dependent asthma', 'source': 'CrossRef'}
Aubier M, Pieters WR, Schlösser NJ, Steinmetz KO. Salmeterol/fluticasone propionate (50/500 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma. Respiratory medicine. 1999;93(12):876-84.	-	10653049	primary-study	e5efed77d45dfa9ff81626863bc3ef4d8e4c13a2	-	{'publication_type': {'year': 1999, 'cited_medium': None, 'issue': None, 'issn': '09546111', 'volume': None, 'title': 'Respiratory Medicine', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.8095238095238095, 'total': 0.7511904761904762, 'authors': 0.9}, 'authors': [{'given': 'M.', 'family': 'Aubier'}, {'given': 'W.R.', 'family': 'Pieters'}, {'given': 'N.J.J.', 'family': 'Schlösser'}, {'given': 'K-O.', 'family': 'Steinmetz'}], 'abstract': "This multicentre double-blind, double-dummy study compared the safety and efficacy of a new combination Diskus® inhaler containing both salmeterol 50 μg and fluticasone propionate 500 μg (Seretide®, GlaxoWellcome, France) with the same doses of the two drugs delivered via separate Diskus® inhalers and with the same dose of fluticasone propionate alone. Patients were eligible for study entry if they had received an inhaled corticosteroid continuously for 12 weeks prior to run-in, and had received treatment with beclomethasone dipropionate or budesonide 1500–2000 μg day−1 or fluticasone propionate 750–1000 μg day−1 for at least 4 weeks prior to run-in. In total, 503 patients receiving inhaled corticosteroids were randomized to 28 weeks' treatment with either salmeterol/fluticasone propionate (50500 μg) via a single Diskus® inhaler (combination) and placebo, or salmeterol 50 μg and fluticasone propionate 500μg administered via separate Diskus® inhalers (concurrent), or fluticasone propionate 500 μg and placebo. All treatments were administered twice daily, mean morning peak expiratory flow rate (PEFR) and asthma symptoms were measured for the first 12 weeks and safety data were collected throughout the 28-week study. Over weeks 1 to 12, improvement in adjusted mean morning PEFR was 35 and 33 l min−1, respectively, in the combination and concurrent therapy treatment groups (12 and 10% increase from baseline, respectively). The mean difference between treatments was −3 l min−1 (90% confidence interval −10·4 l min−1) which was within the criteria for clinical equivalence. However, the combination therapy was statistically significantly superior to fluticasone propionate alone for mean morning PEFR (P<0·001) and other measures of lung function, whilst clinical equivalence of the combination and concurrent therapies was observed. All three treatments were well tolerated. In addition, there were no differences between the three treatments in either the change in serum cortisol or urinary cortisol concentrations, which, for each treatment group, were no significantly different from baseline at the end of the treatment period. Thus, the combination of salmeterol and fluticasone propionate in a single inhaler is as well tolerated and effective in achieving asthma control in steroid-dependent patients as the separate administration of the two drugs, and both combination and concurrent therapy are superior to administration of the same dose of corticosteroid alone.", 'type': 'journal', 'ids': {'embase': None, 'pubmed': '10653049', 'scopus': '2-s2.0-0033403842', 'doi': '10.1016/S0954-6111(99)90053-7'}, 'title': 'Salmeterol/fluticasone propionate (50500 μg) in combination in a Diskus® inhaler (Seretide®) is effective and safe in the treatment of steroid-dependent asthma', 'source': 'Mendeley'}
Li X, Ward C, Thien F, Bish R, Bamford T, Bao X, Bailey M, Wilson JW, Haydn Walters E. An antiinflammatory effect of salmeterol, a long-acting beta(2) agonist, assessed in airway biopsies and bronchoalveolar lavage in asthma. American journal of respiratory and critical care medicine. 1999;160(5 Pt 1):1493-9.	-	10556111	primary-study	588cc151603f15dc2db4f1e47bff9ead77bd6adc	-	{'publication_type': {'year': 1999, 'cited_medium': None, 'issue': '5', 'issn': '1073-449X', 'volume': '160', 'title': 'American Journal of Respiratory and Critical Care Medicine', 'pagination': '1493-1499'}, 'language': None, 'rating': {'year': 0, 'title': 0.9523809523809523, 'total': 0.8468253968253969, 'authors': 0.9111111111111112}, 'authors': [{'given': 'XUN', 'family': 'LI'}, {'given': 'CHRIS', 'family': 'WARD'}, {'given': 'FRANCIS', 'family': 'THIEN'}, {'given': 'ROS', 'family': 'BISH'}, {'given': 'TIFFANY', 'family': 'BAMFORD'}, {'given': 'XIANGHUA', 'family': 'BAO'}, {'given': 'MICHAEL', 'family': 'BAILEY'}, {'given': 'JOHN W.', 'family': 'WILSON'}, {'given': 'E.', 'family': 'HAYDN WALTERS'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '10556111', 'scopus': None, 'doi': '10.1164/ajrccm.160.5.9811052'}, 'title': ' An Antiinflammatory Effect of Salmeterol, a Long-acting β 2 Agonist, Assessed in Airway Biopsies and Bronchoalveolar Lavage in Asthma ', 'source': 'CrossRef'}
Li X, Ward C, Thien F, Bish R, Bamford T, Bao X, Bailey M, Wilson JW, Haydn Walters E. An antiinflammatory effect of salmeterol, a long-acting beta(2) agonist, assessed in airway biopsies and bronchoalveolar lavage in asthma. American journal of respiratory and critical care medicine. 1999;160(5 Pt 1):1493-9.	-	10556111	primary-study	588cc151603f15dc2db4f1e47bff9ead77bd6adc	-	{'publication_type': {'year': 1999, 'cited_medium': None, 'issue': None, 'issn': '1073449X', 'volume': None, 'title': 'American Journal of Respiratory and Critical Care Medicine', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.9444444444444444, 'total': 0.8416666666666668, 'authors': 0.9111111111111112}, 'authors': [{'given': 'Xun', 'family': 'Li'}, {'given': 'Chris', 'family': 'Ward'}, {'given': 'Francis', 'family': 'Thien'}, {'given': 'Ros', 'family': 'Bish'}, {'given': 'Tiffany', 'family': 'Bamford'}, {'given': 'Xianghua', 'family': 'Bao'}, {'given': 'Michael', 'family': 'Bailey'}, {'given': 'John W.', 'family': 'Wilson'}, {'given': 'E. Haydn', 'family': 'Walters'}], 'abstract': 'The addition of long-acting beta(2) agonists to inhaled corticosteroid (ICS) therapy in symptomatic patients with asthma improves clinical status more than increasing the dose of ICS. It has been suggested that these benefits could be at the cost of an increase in airway inflammation, but few histopathological studies have been performed in the relevant group. In a double-blind, parallel-group, placebo-controlled study, we randomly assigned 50 symptomatic patients with asthma who were receiving ICS (range, 100 -500 microgram/d) to 12 wk of supplementary treatment with salmeterol (50 microgram twice daily) or fluticasone (100 microgram twice daily) or placebo. Bronchial biopsies and BAL were obtained from 45 patients before and after treatment and analyzed. After treatment with salmeterol there was no deterioration of airway inflammation as assessed by mast cells, lymphocytes, or macrophages in BAL or biopsies, but rather a significant fall in EG1-positive eosinophils in the lamina propria (from a median 18.3 to 7.6 cells/mm, p = 0.01), which was not seen after treatment with fluticasone. The only cellular effect of added fluticasone was a decrease in BAL lymphocyte activation. There was a concurrent improvement in clinical status, more marked with salmeterol than with increased ICS. Thus, adding salmeterol to ICS is not associated with increased "allergic" airway inflammation, but conversely with a complementary antieosinophil effect.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '10556111', 'scopus': '2-s2.0-0032724631', 'doi': '10.1164/ajrccm.160.5.9811052'}, 'title': 'An antiinflammatory effect of salmeterol, a long-acting β2 agonist, assessed in airway biopsies and bronchoalveolar lavage in asthma', 'source': 'Mendeley'}
Akpinarli A, Tuncer A, Saraçlar Y, Sekerel BE, Kalayci O. Effect of formoterol on clinical parameters and lung functions in patients with bronchial asthma: a randomised controlled trial. Archives of disease in childhood. 1999;81(1):45-8.	-	10373134	primary-study	22837edddb4f971cab1f971cd631d7836732c295	-	{'publication_type': {'year': 1999, 'cited_medium': None, 'issue': '1', 'issn': '0003-9888', 'volume': '81', 'title': 'Archives of Disease in Childhood', 'pagination': '45-48'}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.88, 'authors': 0.9199999999999999}, 'authors': [{'given': 'A.', 'family': 'Akpinarli'}, {'given': 'A.', 'family': 'Tuncer'}, {'given': 'Y.', 'family': 'Saraclar'}, {'given': 'B. E', 'family': 'Sekerel'}, {'given': 'O.', 'family': 'Kalayci'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1136/adc.81.1.45'}, 'title': 'Effect of formoterol on clinical parameters and lung functions in patients with bronchial asthma: a randomised controlled trial', 'source': 'CrossRef'}
Akpinarli A, Tuncer A, Saraçlar Y, Sekerel BE, Kalayci O. Effect of formoterol on clinical parameters and lung functions in patients with bronchial asthma: a randomised controlled trial. Archives of disease in childhood. 1999;81(1):45-8.	-	10373134	primary-study	22837edddb4f971cab1f971cd631d7836732c295	-	{'publication_type': {'year': 2005, 'cited_medium': None, 'issue': None, 'issn': None, 'volume': None, 'title': 'Current Opinion in Urology.15(1):45-8,', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.23076923076923078, 'total': 0.23333333333333334, 'authors': 0.3333333333333333}, 'authors': [{'given': 'Y K', 'family': 'Fong'}, {'given': 'S', 'family': 'Milani'}, {'given': 'B', 'family': 'Djavan'}], 'abstract': 'PURPOSE OF REVIEW: Serenoa repens extract is a popular phytotherapeutic agent in men with lower urinary tract symptoms. Although the exact mechanism of action is unknown, the agent is generally well accepted for its easy availability and good tolerability. This paper reviews the evidence of its efficacy in comparison with placebo, 5-alpha reductase inhibitor and alpha-1 adrenoreceptor antagonist. RECENT FINDINGS: Serenoa repens extract is comparable with 5-alpha reductase (finasteride) and alpha-1 antagonist in the treatment of benign prostatic hyperplasia in terms of symptom score and peak urinary flow rate improvement, but has a lower incidence of associated sexual dysfunction. Furthermore, long-term usage (36 months) of Serenoa repens decreases the progression rate of the condition as compared with watchful waiting. In addition, the efficacies of Serenoa repens are proven in several placebo-controlled trials. SUMMARY: Serenoa repens has proven its role in the management of benign prostatic hyperplasia and will remain as a viable first-line treatment option. [References: 23]', 'type': 'journal', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': None}, 'title': 'Role of phytotherapy in men with lower urinary tract symptoms. [Review] [23 refs]', 'source': 'Mendeley'}
Norhaya MR, Yap TM, Zainudin BM. Addition of inhaled salmeterol to inhaled corticosteroids in patients with poorly controlled nocturnal asthma. Respirology (Carlton, Vic.). 1999;4(1):77-81.	-	10339734	primary-study	05010e0c959420afce8fa1f8c93f9adb0675bfe1	-	{'publication_type': {'year': 1999, 'cited_medium': None, 'issue': '1', 'issn': '1323-7799', 'volume': '4', 'title': 'Respirology', 'pagination': '77-81'}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 0.9916666666666667, 'authors': 0.9666666666666667}, 'authors': [{'given': 'MR', 'family': 'Norhaya'}, {'given': 'TM', 'family': 'Yap'}, {'given': 'BMZ', 'family': 'Zainudin'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1046/j.1440-1843.1999.00153.x'}, 'title': 'Addition of inhaled salmeterol to inhaled corticosteroids in patients with poorly controlled nocturnal asthma', 'source': 'CrossRef'}
Norhaya MR, Yap TM, Zainudin BM. Addition of inhaled salmeterol to inhaled corticosteroids in patients with poorly controlled nocturnal asthma. Respirology (Carlton, Vic.). 1999;4(1):77-81.	-	10339734	primary-study	05010e0c959420afce8fa1f8c93f9adb0675bfe1	-	{'publication_type': {'year': 1999, 'cited_medium': None, 'issue': None, 'issn': '13237799', 'volume': None, 'title': 'Respirology', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 0.975, 'authors': 0.9}, 'authors': [{'given': 'M. R.', 'family': 'Norhaya'}], 'abstract': "The effect of adding inhaled salmeterol to inhaled corticosteroids was studied in patients with poorly controlled nocturnal asthma. In a double-blind, cross-over study, 20 patients were randomized to receive either salmeterol 50 micrograms twice daily or placebo via a Diskhaler after a 1-week run-in period. After 4 weeks of treatment, patients were subsequently crossed over to receive the other treatment for a further 4 weeks with a 2-week wash-out period in between. The response to treatment was assessed by peak expiratory flow rates (PEF) measured in the morning and evening, symptom scores of asthma, number of bronchodilators used, forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) at regular intervals. Patients' preference for the Diskhaler or metered-dose inhaler was assessed at the last visit. The results showed that morning PEF was significantly higher while on salmeterol than on placebo (296.9 +/- 70.2 vs 274.6 +/- 77.4 L/min). Evening PEF showed a trend towards a higher value while on salmeterol than on placebo (321.1 +/- 73.4 vs 288.7 +/- 79.4 L/min), but the difference was not significant. There was no statistically significant improvement in symptom scores, number of rescue bronchodilators used and FEV1 or FVC between the two treatment groups. The occurrence of side effects in terms of tremors and palpitations between treatment and placebo were similar. There were more patients who preferred Diskhaler to metered-dose inhaler (70% vs 30%). We conclude that salmeterol 50 micrograms twice daily produces significant improvement in morning PEF and is well tolerated in patients with nocturnal asthma. Diskhaler is a device which is easy to use and preferred to a metered-dose inhaler.", 'type': 'journal', 'ids': {'embase': None, 'pubmed': '10339734', 'scopus': '2-s2.0-0032956156', 'doi': '10.1046/j.1440-1843.1999.00153.x'}, 'title': 'Addition of inhaled salmeterol to inhaled corticosteroids in patients with poorly controlled nocturnal asthma', 'source': 'Mendeley'}
FitzGerald JM, Chapman KR, Della Cioppa G, Stubbing D, Fairbarn MS, Till MD, Brambilla R. Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity. The Canadian FO/OD1 Study Group. The Journal of allergy and clinical immunology. 1999;103(3 Pt 1):427-35.	-	10069876	primary-study	915b3d6fec9192eccfb29a3cd4a4646f10fd55ed	-	{'publication_type': {'year': 1999, 'cited_medium': None, 'issue': '3', 'issn': '0091-6749', 'volume': '103', 'title': 'Journal of Allergy and Clinical Immunology', 'pagination': '427-435'}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.8785714285714286, 'authors': 0.9142857142857144}, 'authors': [{'given': 'J.Mark', 'family': 'FitzGerald'}, {'given': 'Kenneth R.', 'family': 'Chapman'}, {'given': 'Giovanni Della', 'family': 'Cioppa'}, {'given': 'David', 'family': 'Stubbing'}, {'given': 'Mary Sue', 'family': 'Fairbarn'}, {'given': 'M.Denise', 'family': 'Till'}, {'given': 'Reto', 'family': 'Brambilla'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1016/s0091-6749(99)70467-7'}, 'title': 'Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity', 'source': 'CrossRef'}
FitzGerald JM, Chapman KR, Della Cioppa G, Stubbing D, Fairbarn MS, Till MD, Brambilla R. Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity. The Canadian FO/OD1 Study Group. The Journal of allergy and clinical immunology. 1999;103(3 Pt 1):427-35.	-	10069876	primary-study	915b3d6fec9192eccfb29a3cd4a4646f10fd55ed	-	{'publication_type': {'year': 1999, 'cited_medium': None, 'issue': None, 'issn': '0091-6749', 'volume': None, 'title': 'J Allergy Clin Immunol', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.8857142857142858, 'authors': 0.942857142857143}, 'authors': [{'given': 'J M', 'family': 'FitzGerald'}, {'given': 'K R', 'family': 'Chapman'}, {'given': 'G', 'family': 'Della Cioppa'}, {'given': 'D', 'family': 'Stubbing'}, {'given': 'M S', 'family': 'Fairbarn'}, {'given': 'M D', 'family': 'Till'}, {'given': 'R', 'family': 'Brambilla'}], 'abstract': 'Recent studies have raised concern that regular inhalation of beta2 -agonists may cause a worsening of asthma control compared with on-demand dosing regimens.|The objective of this study was to compare the effect of twice daily formoterol (Foradil), 4 times daily albuterol, and on-demand albuterol on bronchial hyperresponsiveness (BHR), lung function measurements, symptoms, and other indicators of disease control over 6 months inpatients with asthma of moderate or greater severity receiving concomitant inhaled corticosteroids. We also looked for occurrence of rebound BHR on discontinuation of treatment.|This was a multicenter, parallel-group, double-blind, clinical trial. Methacholine PC20 was the primary outcome variable. Other outcome variables included symptom scores, use of rescue medication, morning peak expiratory flow (PEF), serial FEV1 measurements, and asthma exacerbations.|Of the 271 randomized patients, 217 completed the study. Formoterol was significantly superior to on-demand albuterol with regard to methacholine PC20, FEV1, PEF, symptom scores, and use of rescue medication at each measured time point/interval. Regular albuterol was superior to on-demand albuterol with regard to PC20 and FEV1, but not PEF or various clinical scores. After a small drop in the magnitude of bronchoprotection and bronchodilatation occurring shortly after randomization, there was no evidence of progressive tolerance to either regular treatment for any of the measured variables or of rebound increase in BHR 2 days after the end of treatment. The formoterol group had the lowest number of exacerbation days, as defined by high intake of rescue bronchodilator and/or symptom scores, whereas the number of exacerbations requiring increased corticosteroid coverage was similar in the 3 groups.|In patients with asthma of moderate or greater severity receiving inhaled corticosteroids, formoterol taken twice daily resulted in superior bronchoprotection, bronchodilatation, and clinical control compared with on-demand albuterol over 6 months. Four times daily albuterol was superior to on-demand albuterol for only some of the end points. Progressive tolerance and a rebound increase in BHR on discontinuation of beta-agonists were not found', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '10069876', 'scopus': '2-s2.0-0033013813', 'doi': None}, 'title': 'Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity. The Canadian FO/OD1 Study Group', 'source': 'Mendeley'}
van der Molen T, Sears MR, de Graaff CS, Postma DS, Meyboom-de Jong B. Quality of life during formoterol treatment: comparison between asthma-specific and generic questionnaires. Canadian and the Dutch Formoterol Investigators. The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology. 1998;12(1):30-4.	-	9701410	primary-study	c2f881ab2a9e90f024db63a29576e446284bc573	-	{'publication_type': {'year': 1998, 'cited_medium': None, 'issue': '1', 'issn': '0000-0000', 'volume': '12', 'title': 'European Respiratory Journal', 'pagination': '30-34'}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.88, 'authors': 0.9199999999999999}, 'authors': [{'given': 'T.', 'family': 'van der Molen'}, {'given': 'M.R.', 'family': 'Sears'}, {'given': 'C.S.', 'family': 'De Graaff'}, {'given': 'D.S.', 'family': 'Postma'}, {'given': 'B.', 'family': 'Meyboom-de Jong'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1183/09031936.98.12010030'}, 'title': 'Quality of life during formoterol treatment: comparison between asthma-specific and generic questionnaires', 'source': 'CrossRef'}
van der Molen T, Sears MR, de Graaff CS, Postma DS, Meyboom-de Jong B. Quality of life during formoterol treatment: comparison between asthma-specific and generic questionnaires. Canadian and the Dutch Formoterol Investigators. The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology. 1998;12(1):30-4.	-	9701410	primary-study	c2f881ab2a9e90f024db63a29576e446284bc573	-	{'publication_type': {'year': 1998, 'cited_medium': None, 'issue': None, 'issn': '09031936', 'volume': None, 'title': 'European Respiratory Journal', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 1.0, 'total': 0.835, 'authors': 0.74}, 'authors': [{'given': 'T.', 'family': 'Van Der Molen'}, {'given': 'M. R.', 'family': 'Sears'}, {'given': 'C. S.', 'family': 'De Graafft'}, {'given': 'D. S.', 'family': 'Postma'}, {'given': 'B.', 'family': 'Meyboom-de Jong'}], 'abstract': 'This study aimed to investigate the effect of treating patients with moderate asthma with formoterol on quality of life (QoL) and to compare several questionnaires in their ability to detect changes in QoL. In an eight month multicentre, randomized, placebo-controlled trial, patients with asthma using daily inhaled corticosteroids and beta2-agonists (> or = 5 inhalations x week(-1)) were randomized to 6 months treatment with formoterol 24 microg b.i.d. (by Turbuhaler) or a matching placebo. Patients recorded symptoms (maximal score 21) and peak expiratory flow (PEF) twice daily. QoL was measured with two asthma-specific questionnaires, the Asthma Quality of Life Questionnaire (AQLQ) and the Living with Asthma Questionnaire (LWAQ), and with two generic QoL forms, i.e. the Short Form 36 (SF36) and the Psychological and General Well-Being scale (PGWB) at randomization and after 6 months of treatment. Out of 110 patients studied, 56 received formoterol and 54 placebo. Mean baseline forced expiratory volume in one second was 65% predicted. Mean morning PEF was 369 L x min(-1). Mean total symptom score was 3.6. Morning PEF increased (26.8 L x min(-1), p=0.0001) and symptoms decreased (-1.23, p=0.012) in the formoterol group in contrast to placebo. QoL improvements were measured in the LWAQ total score (baseline 0.61, change -0.05, p=0.048) and the physical construct of the LWAQ (baseline 0.71, change 0.07, p=0.044). The AQLQ and the generic QoL instruments showed no significant changes. In conclusion, the improvement in quality of life reported after 6 months was very small and only reflected by the Living with Asthma Questionnaire.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '9701410', 'scopus': '2-s2.0-0031816646', 'doi': '10.1183/09031936.98.12010030'}, 'title': 'Quality of life during formoterol treatment: Comparison between asthma-specific and generic questionnaires', 'source': 'Mendeley'}
Verberne AA, Frost C, Duiverman EJ, Grol MH, Kerrebijn KF. Addition of salmeterol versus doubling the dose of beclomethasone in children with asthma. The Dutch Asthma Study Group. American journal of respiratory and critical care medicine. 1998;158(1):213-9.	10.1164/ajrccm.158.1.9706048	9655732	primary-study	08be5278cd0fb69bbd0de13d9d5b3cff12f5a162	-	{'publication_type': {'year': 1998, 'cited_medium': None, 'issue': '1', 'issn': '1073-449X', 'volume': '158', 'title': 'American Journal of Respiratory and Critical Care Medicine', 'pagination': '213-219'}, 'language': None, 'rating': {'year': 0, 'title': 1.0, 'total': 0.875, 'authors': 0.9}, 'authors': [{'given': 'ANJA A. P. H.', 'family': 'VERBERNE'}, {'given': 'CHRIS', 'family': 'FROST'}, {'given': 'ERIC J.', 'family': 'DUIVERMAN'}, {'given': 'MARION H.', 'family': 'GROL'}, {'given': 'KAREL F.', 'family': 'KERREBIJN'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '9655732', 'scopus': None, 'doi': '10.1164/ajrccm.158.1.9706048'}, 'title': 'Addition of Salmeterol versus Doubling the Dose of Beclomethasone in Children with Asthma', 'source': 'CrossRef'}
Verberne AA, Frost C, Duiverman EJ, Grol MH, Kerrebijn KF. Addition of salmeterol versus doubling the dose of beclomethasone in children with asthma. The Dutch Asthma Study Group. American journal of respiratory and critical care medicine. 1998;158(1):213-9.	10.1164/ajrccm.158.1.9706048	9655732	primary-study	08be5278cd0fb69bbd0de13d9d5b3cff12f5a162	-	{'publication_type': {'year': 1998, 'cited_medium': None, 'issue': None, 'issn': '1073449X', 'volume': None, 'title': 'American Journal of Respiratory and Critical Care Medicine', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.7336956521739131, 'authors': 0.33478260869565224}, 'authors': [{'given': 'A. A P H', 'family': 'Verberne'}, {'given': 'C.', 'family': 'Frost'}, {'given': 'E. J.', 'family': 'Duiverman'}, {'given': 'M. H.', 'family': 'Grol'}, {'given': 'K. F.', 'family': 'Kerrebijn'}, {'given': 'J. A M', 'family': 'Raaymakers'}, {'given': 'S. J.', 'family': 'Pocock'}, {'given': 'J. M.', 'family': 'Bogaard'}, {'given': 'J. C.', 'family': 'Van Nierop'}, {'given': 'A. F.', 'family': 'Nagelkerke'}, {'given': 'B.', 'family': 'Thio'}, {'given': 'T. J.', 'family': 'Schouten'}, {'given': 'E. E M', 'family': 'Van Esseri-Zandvliet'}, {'given': 'A.', 'family': 'Denteneer'}, {'given': 'J.', 'family': 'Gerritsen'}, {'given': 'M. J.', 'family': 'Grol'}, {'given': 'R. J.', 'family': 'Roorda'}, {'given': 'J. J E', 'family': 'Hendriks'}, {'given': 'E. J.', 'family': 'Duiverman'}, {'given': 'J. M.', 'family': 'Kouwenberg'}, {'given': 'J.', 'family': 'van der Laag'}, {'given': 'H. J L', 'family': 'Brackel'}, {'given': 'A. A P H', 'family': 'Verberne'}], 'abstract': 'Studies in adults revealed that addition of salmeterol to a moderate dose of inhaled corticosteroid resulted in better symptom control and higher PEF compared with doubling the dose of inhaled corticosteroid. The aim of this three group study was to compare the effects of a moderate dose of beclomethasone, the same dose of beclomethasone with salmeterol, and a doubling dose of beclomethasone on lung function and symptoms in children with moderate asthma. A total of 177 children already treated with inhaled corticosteroids, were randomized in a double-blind parallel study either to salmeterol 50 microg twice daily (BDP400+salm), beclomethasone 200 microg twice daily (BDP800), or placebo (BDP400) in addition to beclomethasone 200 microg twice daily. No significant differences between groups were found in FEV1, PD20 methacholine, symptom scores, and exacerbation rates after 1 yr. Salmeterol resulted in slightly better PEF in the first months of treatment. FEV1, and PD20 methacholine significantly improved in all groups. After 1 yr mean changes in FEV1, percent predicted were 4.3% (95% CI 1.3; 7.2), 5.8% (95% CI 2.9; 8.7), and 4.3% (95% CI 2.1; 6.5) for BDP400+salm, BDP800, and BDP400, respectively. Changes in airway responsiveness were 0.60 (95% CI 0.05; 1.14), 1.30 (95% CI 0.73; 1. 87), and 0.80 (95% CI 0.33; 1.27) doubling doses. Growth was significantly slower in the BDP800 group. We conclude that no additional benefit was found of adding either salmeterol or more beclomethasone to a daily dose of 400 microg beclomethasone in this group of children with excellent compliance of medication.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '9655732', 'scopus': '2-s2.0-7344248007', 'doi': '10.1164/ajrccm.158.1.9706048'}, 'title': 'Addition of salmeterol versus doubling the dose of beclomethasone in children with asthma', 'source': 'Mendeley'}
Pauwels R. Additive effects of inhaled formoterol and budesonide in reducing asthma exacerbations. Allergy. 1998;53(42 Suppl):20-3.	-	9615842	primary-study	1aef79749cbb69ec38a365998e995444e3c3d883	-	{'publication_type': {'year': 1998, 'cited_medium': None, 'issue': None, 'issn': '0105-4538', 'volume': '53', 'title': 'Allergy', 'pagination': '20-23'}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 1.0, 'authors': 1.0}, 'authors': [{'given': 'R.', 'family': 'Pauwels'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1111/j.1398-9995.1998.tb04889.x'}, 'title': 'Additive effects of inhaled formoterol and budesonide in reducing asthma exacerbations', 'source': 'CrossRef'}
Pauwels R. Additive effects of inhaled formoterol and budesonide in reducing asthma exacerbations. Allergy. 1998;53(42 Suppl):20-3.	-	9615842	primary-study	1aef79749cbb69ec38a365998e995444e3c3d883	-	{'publication_type': {'year': 2013, 'cited_medium': None, 'issue': None, 'issn': None, 'volume': None, 'title': 'Vasa - Jnl Vasc Dis', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.0, 'total': 0.125, 'authors': 0.5}, 'authors': [{'given': 'A', 'family': 'Neufang'}], 'abstract': 'The proceedings contain 142 papers. The special focus in this conference is on Angiology. The topics include: Serum angiogenin which influences vascular repair is related to macrovascular complications of diabetes, but not to diabetes per SE; longterm evaluation on the impact of thrombus formation on the course of abdominal aortic diameter expansion; preserved thrombin inducible platelet activation in thienopyridine-treated patients; prasugrel reduces agonists´ inducible platelet activation and leukocyteplatelet interaction more efficiently than clopidogrel; recent trends in morbidity and in-hospital outcomes of inpatients with peripheral arterial disease – a nationwide population-based analysis; infrapopliteal arterial lesion morphology in patients with critical limb ischemia; proton pump inhibitor intake and outcome after percutaneous intervention for symptomatic iliac artery occlusive disease; percutaneous transluminal angioplasty (PTA) versus primary stenting in patients with severe claudication and critical limb ischemia with infrapopliteal vasular lesions– EXPAND study; treatment of in-stent-restenosis with silverhawk atherctomy; care of patients with aortic abdominal aneurysmas within an interdisciplinary vascular center improves patients’ outcome and is economically effective; pulse wave velocity predicts lifetime survival – a 50-year longitudinal study; outcome of patients with reduced ankle brachial index (ABI) undergoing open heart surgery with cardiopulmonary bypass; prognostic value of neutrophils in patients with asymptomatic carotid artery disease; influence of the inflammatorical burden and plaque stability on the 11-year mortality after carotid endarterectomy; differentiation of superficial femoral artery restenosis by optical coherence tomography (OCT); assessment of disease activity in extracranial giant cell arteritis with positron emission tomography; endovenous laser ablation of the great saphenous vein using the new radial fiber slim – 1 month follow-up; endovenous laser ablation of varicose veins with the 1470 diode laser using a radial fibre – 1 year follow-up; hemodynamic prerequisites triggering venous reflux as well as reflux recurrence; pharmacomechanical thrombectomy of pulmonary embolism - a case series; longterm mortality after percutanous transluminal angioplasty in PAD patients with chronic kidney disease; cardiovascular risk in peripheral arterial disease; an unusual cause for the usual case of intermittent claudication; derived neutrophil-to-lymphocyte ratio and its association with critical limb ischemia in PAOD patients; the interdisciplinary challenge; successful infrarenal aortic replacement with superficial femoral vein; transapical endovascular aortic repair to treat complex aortic pathologies; lightweight personal protection devices for superior radiation protection in fluoroscopy-guided interventions; sensitivity and specificity of fluorescence microlymphography for detecting lymphedema of the lower extremity; imaging characterization of central conducting lymphatic anomalies; the interaction between circadian rhythms of endothelial function; gender related disparity in hospitalization and in-hospital outcome of patients with peripheral arterial disease; vascular malformations in particular syndromes with regional overgrowth; D-dimer levels over time and the risk of recurrent venous thromboembolism; cardiovascular risk profile of individuals with pulmonary embolism with and without history of deep vein thrombosis; D-dimer; prevalence of established risk factors for venous thromboembolism according to age; impact of the interventionalist on success and outcome of carotid artery stenting in a real life scenario; retrograde recanalization technique after failed antegrade angioplasty in chronic femoral artery occlusions; clinical evaluation of a unique stent with 3D helical geometry – 12-month data from the mimics study; optic coherence tomography of tack optimized balloon angioplasty; ultrasound-accelerated vs standard catheter-directed thrombolysis for treatm nt of iliofemoral deep vein thrombosis; 6 month outcomes for a below the knee use of a novel balloon catheter first in man clinical study; twelve-month results of the BIOLUX P-I first-in-man study comparing a paclitaxel-releasing balloon catheter versus an uncoated catheter in femoropopliteal lesions; vaspin in patients with peripheral arterial disease; injection of vascular resident progenitor cells enhances collateral growth; vascular progenitor cells following massive weight loss induced by bariatric surgery; catestatin for the treatment of myocardial ischemia; transmembraneous activation of the proteasome in vascular resident endothelial progenitor cells reduces collateral growth; secretoneurin gene therapy improves hindlimb and cardiac ischemia in apo E -/- mice without influencing systemic atherosclerosis; management of NOAC bleeding complications - findings from the dresden NOAC registry; peri-interventional management of NOAC patients - results from the Dresden NOAC registry; incidence and causes of heparin-induced skin lesions in postmenopausal women; recurrent cerebral ischaemia in a pregnant woman with PFO and thrombophilia under therapy with LMWH; evaluation of assay performance monitoring new oral anticoagulants; response to antiplatelet therapy and platelet reactivity to thrombin receptor activating peptide-6 in cardiovascular interventions; clinically driven need for secondary interventions after endovascular revascularization of tibial arteries in patients with critical limb ischemia; early recoil after plain balloon angioplasty of tibial arterial obstructions in patients with critical limb ischemia; lymphocyte-to-monocyte ratio; correlation between intima-media thickness (IMT) and flow-mediated dilation (FMD); gene therapy in peripheral arterial disease; fibromuscular dysplasia of the superior mesenteric artery - a rare cause of angina abdominalis; the impact of red cell distribution width on outcome in patients with atherosclerosis; phosphorus-rich diet specifically induces media calcification in the abdominal aorta; wall shear stress in the stented superficial femoral artery in patients with peripheral arterial disease; short term effectiveness of paclitaxel-eluting stents in femoropopliteal lesions; two years follow-up after endovascular repair of a symptomatic aneurysm of the posterior circumflex humeral artery; short- and longterm success of thrombin occluded aneurysm spuria in 632 patients; complications and mortality; standard radial approach for coronary catheterization and access site complications - an observational registry; monocyte vaccination for therapeutic collateralization; a case of successful critical limb ischaemia treatment by pharmacomechanical thrombectomy; soluble P-selectin, D-dimer and high-sensitivity C-reactive protein after acute deep vein thrombosis of the lower limb; D-dimer for risk stratification in hemodynamic stable patients with acute pulmonary embolism; ethiodol in sclerotherapy of venous malformations; nucleoside triphosphates inhibit ADP, collagen, and epinephrine-induced platelet aggregation; essential thrombocythemia and abdominal angina; post-interventional evaluation of stent-perfusion with vascular ultrasonography; late structural damage of the thoracic aorta in patients with giant cell arteritis; pictorial review of fibro-adipose vascular anomaly (FAVA); risk factors for puncture site complications after endovascular procedures in peripheral arterial disease patients; foreign body pulmonary embolism; endovascular therapy for a huge subclavian aneurysm in the elderly; PTA registry for diabetic foot syndrome; stenting of the popliteal artery - a single center experience with 5 year follow up; monolateral intermittent claudication revealing renal graft ischemia; acute wiiitis representing as thrombosis of the inferior vena cava and left pelvic veins; statin medication and incidence of recurrent deep venous thrombosis; the complex DVT-case; intraprocedural complications for sclerotherapy in venous malformations; insights to prostanoid therapy in CLI by indocyanine fluorescent angiography; acute effects of dark chocolate on vascular function in patients with peripheral artery disease; contribution of non invasive diagnostic in dialysis associated steal syndrome; microvascular reactivity as function of sex and age; impact of cytochrome 2c9 allelic variants on clopidogrel-mediated platelet inhibition; the efficacy of antiplatelet therapy with aspirin in patients after ischemic stroke; indirect local fibrinolysis as therapy for subacute digital ischemia; blue toe syndrome - a description of positive evolutions through patient adapted therapy; tinnitus and hypercoagulable state; use of radial approach for stenting of left carotid artery stenosis in patients with bovine aortic arch; ambulatory negative pressure wound therapy with a miniaturized sytem shortens in-hospital stay; from ollier to maffucci; aortic aneurysm im giant cell arteritis; functional stenosis of the right iliac artery in a young healthy road cyclist; accidental injection of epinephrine in the thumb and AGXT2 plays important role in regulation of urine ADMA levels after acute ADMA loading in mice.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1024/0301-1526.a000276'}, 'title': 'Vasa 2013; 42: Suppl. 84', 'source': 'Mendeley'}
Kemp JP, Cook DA, Incaudo GA, Corren J, Kalberg C, Emmett A, Cox FM, Rickard K. Salmeterol improves quality of life in patients with asthma requiring inhaled corticosteroids. Salmeterol Quality of Life Study Group. The Journal of allergy and clinical immunology. 1998;101(2 Pt 1):188-95.	-	9500751	primary-study	a7b6819177e703d5d86a88b292cd88abb067c63c	-	{'publication_type': {'year': 1998, 'cited_medium': None, 'issue': '2', 'issn': '0091-6749', 'volume': '101', 'title': 'Journal of Allergy and Clinical Immunology', 'pagination': '188-195'}, 'language': None, 'rating': {'year': 0, 'title': 0.9166666666666666, 'total': 0.8239583333333333, 'authors': 0.9125000000000001}, 'authors': [{'given': 'James P.', 'family': 'Kemp'}, {'given': 'David A.', 'family': 'Cook'}, {'given': 'Gary A.', 'family': 'Incaudo'}, {'given': 'Jonathan', 'family': 'Corren'}, {'given': 'Chris', 'family': 'Kalberg'}, {'given': 'Amanda', 'family': 'Emmett'}, {'given': 'Fred M.', 'family': 'Cox'}, {'given': 'Kathleen', 'family': 'Rickard'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1016/s0091-6749(98)70383-5'}, 'title': 'Salmeterol improves quality of life in patients with asthma requiring inhaled corticosteroids☆☆☆★★★♢', 'source': 'CrossRef'}
Kemp JP, Cook DA, Incaudo GA, Corren J, Kalberg C, Emmett A, Cox FM, Rickard K. Salmeterol improves quality of life in patients with asthma requiring inhaled corticosteroids. Salmeterol Quality of Life Study Group. The Journal of allergy and clinical immunology. 1998;101(2 Pt 1):188-95.	-	9500751	primary-study	a7b6819177e703d5d86a88b292cd88abb067c63c	-	{'publication_type': {'year': 1998, 'cited_medium': None, 'issue': None, 'issn': '0091-6749 (Print)', 'volume': None, 'title': 'The Journal of allergy and clinical immunology', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 0.9875, 'authors': 0.9500000000000001}, 'authors': [{'given': 'J P', 'family': 'Kemp'}, {'given': 'D A', 'family': 'Cook'}, {'given': 'G A', 'family': 'Incaudo'}, {'given': 'J', 'family': 'Corren'}, {'given': 'C', 'family': 'Kalberg'}, {'given': 'A', 'family': 'Emmett'}, {'given': 'F M', 'family': 'Cox'}, {'given': 'K', 'family': 'Rickard'}], 'abstract': 'BACKGROUND: Traditional clinical outcomes have demonstrated that salmeterol improves pulmonary function and reduces asthma symptoms. However, they do not evaluate how patients perceive the effect of therapeutic intervention on day-to-day functioning and well-being. OBJECTIVE: We sought to evaluate the impact of salmeterol on disease-specific quality of life with the Asthma Quality-of-Life Questionnaire, as well as the efficacy and safety of salmeterol in patients with stable asthma who were symptomatic despite daily use of inhaled corticosteroids. METHODS: This was a randomized, double-blind, placebo-controlled, parallel-group study of 506 patients. Patients were treated with 42 microg salmeterol or placebo twice daily for 12 weeks delivered through a metered dose inhaler. RESULTS: Mean change from baseline in asthma quality-of-life scores was significantly greater (p < or = 0.006) after 12 weeks of treatment with salmeterol compared with placebo ("as-needed" albuterol) in global scores (1.08 vs 0.61) and individual domains (activity limitations, 0.91 vs 0.54; asthma symptoms, 1.28 vs 0.71; emotional function, 1.17 vs 0.65; and environmental exposure, 0.84 vs 0.47). Patients treated with salmeterol experienced significantly greater improvements from baseline to week 12 compared with placebo in FEV1 (0.42 L vs 0.15 L, p < 0.001), morning peak expiratory flow (47 L/min vs 14 L/min, p < 0.001), evening peak expiratory flow (29 L/min vs 11 L/min, p < 0.001), and asthma symptom scores (daytime scores reduced by 0.55 vs 0.30, p < 0.001). Patients treated with salmeterol used significantly less supplemental albuterol (reduced by 3 puffs/day vs 1 puff/day, p < 0.001). CONCLUSION: Salmeterol provided significantly greater improvement in quality-of-life outcomes in patients whose asthma symptoms are not well controlled with inhaled corticosteroids. These results demonstrate that the benefits of salmeterol are not limited to conventional clinical measures of efficacy.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '9500751', 'scopus': None, 'doi': None}, 'title': 'Salmeterol improves quality of life in patients with asthma requiring inhaled corticosteroids. Salmeterol Quality of Life Study Group.', 'source': 'Mendeley'}
Pauwels RA, Löfdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, Ullman A. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. The New England journal of medicine. 1997;337(20):1405-11.	10.1056/NEJM199711133372001	9358137	primary-study	539f0ceb0642805a9adaae62ceddbef31f4b7ba4	-	{'publication_type': {'year': 1999, 'cited_medium': None, 'issue': '4', 'issn': '0277-0903', 'volume': '36', 'title': 'Journal of Asthma', 'pagination': '389-390'}, 'language': None, 'rating': {'year': 0, 'title': 0.8787878787878788, 'total': 0.5712121212121213, 'authors': 0.0}, 'authors': [{'given': 'Christopher', 'family': 'Randolph'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.3109/02770909909068232'}, 'title': " Effect of Inhaled Formoterol and Budesonide on Exacerbations of Asthma Pauwells RA, Lofdahs CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, Ullman A New Engl J Med 337 (20):1405-1411 (1997) ", 'source': 'CrossRef'}
Pauwels RA, Löfdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, Ullman A. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. The New England journal of medicine. 1997;337(20):1405-11.	10.1056/NEJM199711133372001	9358137	primary-study	539f0ceb0642805a9adaae62ceddbef31f4b7ba4	-	{'publication_type': {'year': 1997, 'cited_medium': None, 'issue': None, 'issn': '0028-4793', 'volume': None, 'title': 'N Engl J Med', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.8821428571428571, 'authors': 0.9285714285714286}, 'authors': [{'given': 'R A', 'family': 'Pauwels'}, {'given': 'C G', 'family': 'Lofdahl'}, {'given': 'D S', 'family': 'Postma'}, {'given': 'A E', 'family': 'Tattersfield'}, {'given': 'P', 'family': "O'Byrne"}, {'given': 'P J', 'family': 'Barnes'}, {'given': 'A', 'family': 'Ullman'}], 'abstract': 'BACKGROUND: The role of long-acting, inhaled beta2-agonists in treating asthma is uncertain. In a double-blind study, we evaluated the effects of adding inhaled formoterol to both lower and higher doses of the inhaled glucocorticoid budesonide. METHODS: After a four-week run-in period of treatment with budesonide (800 microg twice daily), 852 patients being treated with glucocorticoids were randomly assigned to one of four treatments given twice daily by means of a dry-powder inhaler (Turbuhaler): 100 microg of budesonide plus placebo, 100 microg of budesonide plus 12 microg of formoterol, 400 microg of budesonide plus placebo, or 400 microg of budesonide plus 12 microg of formoterol. Terbutaline was permitted as needed. Treatment continued for one year; we compared the frequency of exacerbations of asthma, symptoms, and lung function in the four groups. A severe exacerbation was defined by the need for oral glucocorticoids or a decrease in the peak flow to more than 30 percent below the base-line value on two consecutive days. RESULTS: The rates of severe and mild exacerbations were reduced by 26 percent and 40 percent, respectively, when formoterol was added to the lower dose of budesonide. The higher dose of budesonide alone reduced the rates of severe and mild exacerbations by 49 percent and 37 percent, respectively. Patients treated with formoterol and the higher dose of budesonide had the greatest reductions -- 63 percent and 62 percent, respectively. Symptoms of asthma and lung function improved with both formoterol and the higher dose of budesonide, but the improvements with formoterol were greater. CONCLUSIONS: In patients who have persistent symptoms of asthma despite treatment with inhaled glucocorticoids, the addition of formoterol to budesonide therapy or the use of a higher dose of budesonide may be beneficial. The addition of formoterol to budesonide therapy improves symptoms and lung function without lessening the control of asthma.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '9358137', 'scopus': None, 'doi': '10.1056/NEJM199711133372001'}, 'title': 'Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group', 'source': 'Mendeley'}
van der Molen T, Postma DS, Turner MO, Jong BM, Malo JL, Chapman K, Grossman R, de Graaff CS, Riemersma RA, Sears MR. Effects of the long acting beta agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids. The Netherlands and Canadian Formoterol Study Investigators. Thorax. 1997;52(6):535-9.	-	9227720	primary-study	6a2e09da71539e57f5c084abf40f1835b6315b0d	-	{'publication_type': {'year': 1997, 'cited_medium': None, 'issue': '6', 'issn': '0040-6376', 'volume': '52', 'title': 'Thorax', 'pagination': '535-539'}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 0.965, 'authors': 0.8600000000000001}, 'authors': [{'given': 'T.', 'family': 'van der Molen'}, {'given': 'D. S.', 'family': 'Postma'}, {'given': 'M. O.', 'family': 'Turner'}, {'given': 'B. M.', 'family': 'Jong'}, {'given': 'J. L.', 'family': 'Malo'}, {'given': 'K.', 'family': 'Chapman'}, {'given': 'R.', 'family': 'Grossman'}, {'given': 'C. S.', 'family': 'de Graaff'}, {'given': 'R. A.', 'family': 'Riemersma'}, {'given': 'M. R.', 'family': 'Sears'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1136/thx.52.6.535'}, 'title': 'Effects of the long acting beta agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids. The Netherlands and Canadian Formoterol Study Investigators', 'source': 'CrossRef'}
van der Molen T, Postma DS, Turner MO, Jong BM, Malo JL, Chapman K, Grossman R, de Graaff CS, Riemersma RA, Sears MR. Effects of the long acting beta agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids. The Netherlands and Canadian Formoterol Study Investigators. Thorax. 1997;52(6):535-9.	-	9227720	primary-study	6a2e09da71539e57f5c084abf40f1835b6315b0d	-	{'publication_type': {'year': 1997, 'cited_medium': None, 'issue': None, 'issn': '0040-6376', 'volume': None, 'title': 'Thorax', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 1, 'total': 0.9825, 'authors': 0.93}, 'authors': [{'given': 'T', 'family': 'van der Molen'}, {'given': 'D S', 'family': 'Postma'}, {'given': 'M O', 'family': 'Turner'}, {'given': 'B M', 'family': 'Jong'}, {'given': 'J L', 'family': 'Malo'}, {'given': 'K', 'family': 'Chapman'}, {'given': 'R', 'family': 'Grossman'}, {'given': 'C S', 'family': 'de Graaff'}, {'given': 'R A', 'family': 'Riemersma'}, {'given': 'M R', 'family': 'Sears'}], 'abstract': 'BACKGROUND: The long acting beta 2 agonist formoterol has proved to be an effective bronchodilator with a prolonged action of 12-14 hours. However, the precise role of formoterol in the maintenance treatment of asthma is still under debate. A study was performed to investigate the efficacy and safety of treatment with formoterol for six months in subjects with asthma. METHODS: In a multicentre double blind, placebo controlled, parallel group study 239 subjects with mild to moderate asthma were randomly assigned to treatment with either inhaled formoterol 24 micrograms twice daily (n = 125) or placebo (n = 114) during eight months. The study consisted of a four week run in period, a 24 week treatment period, and a four week washout period. All subjects were using regular inhaled corticosteroids (100-3200 micrograms daily) but were still needing at least five inhalations of short acting beta 2 agonist per week for symptom relief. The study was performed in 10 outpatient clinics in Canada, and five outpatient clinics and one coordinating centre for 44 Dutch general practitioners in The Netherlands. Twice daily self-reported peak expiratory flow (PEF) measurements, symptom scores, and rescue beta 2 agonist use during the last 28 treatment days compared with baseline values were used as main outcome measures. Spirometric values were measured at entry, at the start of treatment, after four, 12 and 24 weeks of treatment, and after four weeks washout. RESULTS: One hundred and twenty five subjects received formoterol 24 micrograms twice daily via Turbohaler and 114 received placebo. Baseline FEV1 was 67.1% predicted and mean bronchodilator reversibility was 26%. The mean total asthma symptom score was 3.6 (maximum possible 21). A significant decrease in symptoms in favour of formoterol (difference from placebo -0.64, 95% CI -0.04 to -1.23, p = 0.04) was observed. Compared with placebo, morning PEF increased (difference from placebo 28 l/min, 95% CI 18.3 to 37.7, p = 0.0001) and the use of short acting beta 1 agonists decreased (daytime difference from placebo -1.1 inhalation, 95% CI -1.4 to -0.7, p = 0.0001) in the formoterol group. PEF returned to baseline following discontinuation of formoterol, as did asthma symptom scores. Thirty three patients treated with formoterol and 32 treated with placebo required treatment with prednisolone during the study (58 and 55 courses, respectively). CONCLUSIONS: Adding formoterol 24 micrograms twice daily by Turbohaler to inhaled corticosteroids was effective in improving symptom scores and morning PEF, and decreasing the use of rescue beta 2 agonists. There was no apparent loss of asthma control during 24 weeks of treatment with formoterol.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '9227720', 'scopus': None, 'doi': None}, 'title': 'Effects of the long acting beta agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids. The Netherlands and Canadian Formoterol Study Investigators', 'source': 'Mendeley'}
Simons FE, Gerstner TV, Cheang MS. Tolerance to the bronchoprotective effect of salmeterol in adolescents with exercise-induced asthma using concurrent inhaled glucocorticoid treatment. Pediatrics. 1997;99(5):655-9.	-	9113940	primary-study	346f78889e9e56df912ee5256ac2ec53283d162e	-	{'publication_type': {'year': 1997, 'cited_medium': None, 'issue': '5', 'issn': '0031-4005', 'volume': '99', 'title': 'PEDIATRICS', 'pagination': '655-659'}, 'language': None, 'rating': {'year': 0, 'title': 1.0, 'total': 0.875, 'authors': 0.9}, 'authors': [{'given': 'F. E. R.', 'family': 'Simons'}, {'given': 'T. V.', 'family': 'Gerstner'}, {'given': 'M. S.', 'family': 'Cheang'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1542/peds.99.5.655'}, 'title': 'Tolerance to the Bronchoprotective Effect of Salmeterol in Adolescents With Exercise-induced Asthma Using Concurrent Inhaled Glucocorticoid Treatment', 'source': 'CrossRef'}
Simons FE, Gerstner TV, Cheang MS. Tolerance to the bronchoprotective effect of salmeterol in adolescents with exercise-induced asthma using concurrent inhaled glucocorticoid treatment. Pediatrics. 1997;99(5):655-9.	-	9113940	primary-study	346f78889e9e56df912ee5256ac2ec53283d162e	-	{'publication_type': {'year': 1997, 'cited_medium': None, 'issue': None, 'issn': '1098-4275 (Electronic)', 'volume': None, 'title': 'Pediatrics', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 1.0, 'total': 0.975, 'authors': 0.9}, 'authors': [{'given': 'F Estelle R', 'family': 'Simons'}, {'given': 'Thomas V', 'family': 'Gerstner'}, {'given': 'Mary S', 'family': 'Cheang'}], 'abstract': 'Objectives. The long-acting β2-adrenergic agonist salmeterol prevents exercise-induced asthma, but tolerance may develop to its bronchoprotective effect. We wanted to ascertain if the development of tolerance could be prevented by using a low-dose treatment regimen of 50 μg once daily, instead of the usual dose of 50 μg twice daily, in adolescents receiving regular glucocorticoid inhalations.Methods. In a randomized, double-blind, 2x28-day crossover study, we administered salmeterol (50 μg) or placebo once daily via a metered-dose inhaler and Nebulizer Chronolog device to monitor compliance. Exercise challenge tests were performed 1 and 9 hours after salmeterol or placebo inhalation on the 1st and 28th day of each treatment period. The primary outcome variable was the maximum decrease in percent predicted FEV1 postexercise.Results. Fourteen subjects with a mean age of 13.1 years completed the study. The first dose of salmeterol had an excellent bronchoprotective effect against exercise-induced asthma at 1 and 9 hours. After the 28th consecutive daily dose of salmeterol, the bronchoprotective effect was significantly greater than that of placebo at 1 hour, but not at 9 hours.Conclusions. We conclude that a single 50-μg dose of salmeterol has an excellent protective effect against exercise-induced asthma for at least 9 hours, but that this effect may wane during regular once-daily salmeterol treatment, despite the reduced frequency of dosing and despite concomitant use of inhaled glucocorticoids.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '9113940', 'scopus': '2-s2.0-0030895074', 'doi': '10.1542/peds.99.5.655'}, 'title': 'Tolerance to the Bronchoprotective Effect of Salmeterol in Adolescents With Exercise-induced Asthma Using Concurrent Inhaled Glucocorticoid Treatment', 'source': 'Mendeley'}
Leblanc P, Knight A, Kreisman H, Borkhoff CM, Johnston PR. A placebo-controlled, crossover comparison of salmeterol and salbutamol in patients with asthma. American journal of respiratory and critical care medicine. 1996;154(2 Pt 1):324-8.	-	8756801	primary-study	1e7d8a996fb26c5dfa615f985b527b427549638f	-	{'publication_type': {'year': 1996, 'cited_medium': None, 'issue': '2', 'issn': '1073-449X', 'volume': '154', 'title': 'American Journal of Respiratory and Critical Care Medicine', 'pagination': '324-328'}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.89, 'authors': 0.96}, 'authors': [{'given': 'P', 'family': 'Leblanc'}, {'given': 'A', 'family': 'Knight'}, {'given': 'H', 'family': 'Kreisman'}, {'given': 'C M', 'family': 'Borkhoff'}, {'given': 'P R', 'family': 'Johnston'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '8756801', 'scopus': None, 'doi': '10.1164/ajrccm.154.2.8756801'}, 'title': 'A placebo-controlled, crossover comparison of salmeterol and salbutamol in patients with asthma.', 'source': 'CrossRef'}
Leblanc P, Knight A, Kreisman H, Borkhoff CM, Johnston PR. A placebo-controlled, crossover comparison of salmeterol and salbutamol in patients with asthma. American journal of respiratory and critical care medicine. 1996;154(2 Pt 1):324-8.	-	8756801	primary-study	1e7d8a996fb26c5dfa615f985b527b427549638f	-	{'publication_type': {'year': 1993, 'cited_medium': None, 'issue': None, 'issn': None, 'volume': None, 'title': 'Am J Physiol. 1993 Feb;264(2 Pt 1):E197-202.', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.23076923076923078, 'total': 0.15000000000000002, 'authors': 0.0}, 'authors': [{'given': 'Dunaif A.', 'family': 'Rosenbaum D, Haber RS'}], 'abstract': 'We have found that women with polycystic ovary syndrome (PCOS) have decreased sensitivity and responsiveness to insulin. The present study was performed to determine whether this impaired insulin responsiveness was associated with diminished GLUT-4 glucose transporter content in adipocytes. Insulin-stimulated glucose transport and GLUT-4 abundance were measured in abdominal adipocytes from obese (n = 9) and lean (n = 7) PCOS as well as obese (n = 8) and lean (n = 8) control women matched for age and weight. No woman had impaired glucose tolerance. The maximal insulin-stimulated increment in adipocyte glucose transport was independently decreased by obesity and by PCOS. As expected, GLUT-4 content in adipocyte membranes was decreased in obesity (by 40%, P < or = 0.01). GLUT-4 content was also significantly decreased in PCOS (by 36%, P < or = 0.01), independent of obesity. There was a highly significant correlation (R = 0.66, P < = 0.001) between GLUT-4 content and insulin-stimulated glucose transport in adipocytes from individual women across the study population. We conclude that the diminished adipocyte insulin responsiveness in PCOS is associated with decreased GLUT-4 abundance. This represents a newly recognized phenotypic feature of the insulin resistance of PCOS. Moreover, in human adipocytes, GLUT-4 abundance is highly correlated with insulin responsiveness.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': None}, 'title': 'Insulin resistance in polycystic ovary _decreased expression of GLUT-4 glucose transporters in adipocytes', 'source': 'Mendeley'}
Meijer GG, Postma DS, Mulder PG, van Aalderen WM. Long-term circadian effects of salmeterol in asthmatic children treated with inhaled corticosteroids. American journal of respiratory and critical care medicine. 1996;152(6 Pt 1):1887-92.	-	8520751	primary-study	76db99ec1201c9fdf96264d998101ed80ad2bd3b	-	{'publication_type': {'year': 1995, 'cited_medium': None, 'issue': '6', 'issn': '1073-449X', 'volume': '152', 'title': 'American Journal of Respiratory and Critical Care Medicine', 'pagination': '1887-1892'}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.875, 'authors': 0.9}, 'authors': [{'given': 'G G', 'family': 'Meijer'}, {'given': 'D S', 'family': 'Postma'}, {'given': 'P G', 'family': 'Mulder'}, {'given': 'W M', 'family': 'van Aalderen'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '8520751', 'scopus': None, 'doi': '10.1164/ajrccm.152.6.8520751'}, 'title': 'Long-term circadian effects of salmeterol in asthmatic children treated with inhaled corticosteroids.', 'source': 'CrossRef'}
Meijer GG, Postma DS, Mulder PG, van Aalderen WM. Long-term circadian effects of salmeterol in asthmatic children treated with inhaled corticosteroids. American journal of respiratory and critical care medicine. 1996;152(6 Pt 1):1887-92.	-	8520751	primary-study	76db99ec1201c9fdf96264d998101ed80ad2bd3b	-	{'publication_type': {'year': 1995, 'cited_medium': None, 'issue': None, 'issn': '1073449X', 'volume': None, 'title': 'American Journal of Respiratory and Critical Care Medicine', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.875, 'authors': 0.9}, 'authors': [{'given': 'Gerda C.', 'family': 'Meijer'}, {'given': 'Dirkje S.', 'family': 'Postma'}, {'given': 'Paul G H', 'family': 'Mulder'}, {'given': 'Wim M C', 'family': 'Van Aalderen'}], 'abstract': 'The present study was set up to investigate whether salmeterol in children with asthma already treated with inhaled corticosteroids (ICS) leads to a sustained bronchodilator effect and decreased bronchial responsiveness, both during the day and night. Furthermore, we investigated whether cessation of salmeterol leads to a rebound increase in bronchial responsiveness. Forty children with asthma (aged 7-15 yrs) using ICS participated in a randomized, double-blind, parallel study. They received either twice daily 50 micrograms salmeterol or placebo. FEV1 and provocative concentration of methacholine that caused a 20% fall in FEV1 (PC20) were measured at 4:00 P.M. and 4:00 A.M. at baseline and after 16 wk. The same measurements were performed at 4:00 P.M. at 8 h after the first dose, and after 1 and 8 wk. After cessation of the study drug, FEV1 and PC20 were measured at 12 and 20 h and after 1 wk. Overall mean FEV1 from 1 to 16 wk of treatment was significantly higher in the salmeterol group than in the placebo group (difference, 4.9 +/- 2.0%, p = 0.01). Evolution in time of FEV1 did not differ significantly between the two groups (p = 0.09). Overall mean PC20 from 1 to 16 wk of treatment was not significantly higher with salmeterol than with placebo (difference, 0.7 +/- 0.4 doubling dose [DD] p = 0.07); evolution in time of PC20 did not differ significantly between the two groups (p = 0.58).(ABSTRACT TRUNCATED AT 250 WORDS)', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '8520751', 'scopus': '2-s2.0-0028786417', 'doi': '10.1164/ajrccm.152.6.8520751'}, 'title': 'Long-term circadian effects of salmeterol in asthmatic children treated with inhaled corticosteroids', 'source': 'Mendeley'}
Russell G, Williams DA, Weller P, Price JF. Salmeterol xinafoate in children on high dose inhaled steroids. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology. 1995;75(5):423-8.	-	7583864	primary-study	a6095aad57616d5908c703db0f2dbe7260003402	-	{'publication_type': {'year': 1999, 'cited_medium': None, 'issue': '2', 'issn': '1081-1206', 'volume': '83', 'title': 'Annals of Allergy, Asthma & Immunology', 'pagination': '121-126'}, 'language': None, 'rating': {'year': 0, 'title': 0.4444444444444444, 'total': 0.28888888888888886, 'authors': 0.0}, 'authors': [{'given': 'Richard J.', 'family': 'Martin'}, {'given': 'Monica', 'family': 'Kraft'}, {'given': 'Wilfred N.', 'family': 'Beaucher'}, {'given': 'Frederic', 'family': 'Kiechel'}, {'given': 'James L.', 'family': 'Sublett'}, {'given': 'Nicole', 'family': 'LaVallee'}, {'given': 'Jonathan', 'family': 'Shilstone'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1016/s1081-1206(10)62622-1'}, 'title': 'Comparative study of extended release albuterol sulfate and long-acting inhaled salmeterol xinafoate in the treatment of nocturnal asthma', 'source': 'CrossRef'}
Russell G, Williams DA, Weller P, Price JF. Salmeterol xinafoate in children on high dose inhaled steroids. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology. 1995;75(5):423-8.	-	7583864	primary-study	a6095aad57616d5908c703db0f2dbe7260003402	-	{'publication_type': {'year': 2008, 'cited_medium': None, 'issue': None, 'issn': '1081-1206', 'volume': None, 'title': 'Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 0.3125, 'total': 0.303125, 'authors': 0.0}, 'authors': [{'given': 'Joelle', 'family': "O'Neil"}, {'given': 'Susan', 'family': 'Hughes'}, {'given': 'Andrea', 'family': 'Lourie'}, {'given': '384–8. http://doi.org/10.1016/S1081-1206(10)60603-5', 'family': 'Zweifler, JohnO’Neil, J., Hughes, S., Lourie, A., & Zweifler, J. (2008). Effects of echinacea on the frequency of upper respiratory tract symptoms: a randomized, double-blind, placebo-controlled trial. Annals of Allergy, Asthma & Immunology : Official Pub'}], 'abstract': 'BACKGROUND: Upper respiratory tract infection symptoms are a common cause of morbidity. Herbal preparations of the plant Echinacea purpurea have immune-enhancing properties. OBJECTIVE: To compare the frequency of upper respiratory tract symptoms in individuals receiving E. purpurea capsules and those receiving placebo to evaluate the preventive efficacy of echinacea. METHODS: In a randomized, double-blind clinical trial, 90 volunteers recruited from hospital personnel were randomly assigned to receive 3 capsules twice daily of either placebo (parsley) or E. purpurea for 8 weeks during the winter months. Upper respiratory tract symptoms were reported weekly during this period. RESULTS: Fifty-eight individuals were included in the final data analysis: 28 in the echinacea group and 30 in the placebo group. Individuals in the echinacea group reported 9 sick days per person during the 8-week period, whereas the placebo group reported 14 sick days (z = -0.42; P = .67). Mild adverse effects were noted by 8% of the echinacea group and 7% of the placebo group (P = .24). CONCLUSION: Prophylactic treatment with commercially available E. purpurea capsules did not significantly alter the frequency of upper respiratory tract symptoms compared with placebo use.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '18450126', 'scopus': None, 'doi': '10.1016/S1081-1206(10)60603-5'}, 'title': 'Effects of echinacea on the frequency of upper respiratory tract symptoms: a randomized, double-blind, placebo-controlled trial.', 'source': 'Mendeley'}
Boyd G. Salmeterol xinafoate in asthmatic patients under consideration for maintenance oral corticosteroid therapy. UK Study Group. The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology. 1996;8(9):1494-8.	-	8575574	primary-study	92ab83e4dae560dde5cfecccfdc0ccc23007fdb5	-	{'publication_type': {'year': 1996, 'cited_medium': None, 'issue': '8', 'issn': '0000-0000', 'volume': '9', 'title': 'European Respiratory Journal', 'pagination': '1678-1683'}, 'language': None, 'rating': {'year': 0, 'title': 0.6666666666666666, 'total': 0.43333333333333335, 'authors': 0.0}, 'authors': [{'given': 'A.J.M.', 'family': 'Schreurs'}, {'given': 'H.E.J.', 'family': 'Sinninghe Damsté'}, {'given': 'C.S.', 'family': 'de Graaff'}, {'given': 'A.P.M.', 'family': 'Greefhorst'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1183/09031936.96.09081678'}, 'title': 'A dose-response study with formoterol Turbuhaler® as maintenance therapy in asthmatic patients', 'source': 'CrossRef'}
Boyd G. Salmeterol xinafoate in asthmatic patients under consideration for maintenance oral corticosteroid therapy. UK Study Group. The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology. 1996;8(9):1494-8.	-	8575574	primary-study	92ab83e4dae560dde5cfecccfdc0ccc23007fdb5	-	{'publication_type': {'year': 2012, 'cited_medium': None, 'issue': None, 'issn': '1399-3003', 'volume': None, 'title': 'The European respiratory journal', 'pagination': None}, 'language': None, 'rating': {'year': 1, 'title': 0.2, 'total': 0.23, 'authors': 0.0}, 'authors': [{'given': 'Pp.667–689.', 'family': 'AASM Task Force, A., 1999. Sleep – Related Breathing Disorders in Adults : Recommendations for Syndrome Definition and Measurement Techniques in Clinical Research. SLEEP, 22(5)'}, {'given': 'titration and side effects of oral appliances in snoring and obstructive sleep apnea patients.', 'family': 'Almeida, F.R., 2005. Compliance'}, {'given': 'Pp.198–204.', 'family': 'Almeida, F.R. et al., 2009. Effect of a Titration Polysomnogram on Treatment Success with a Mandibular Repositioning Appliance. Journal of Clinical Sleep Medicine, 5(3)'}, {'given': 'Pp.659–66.', 'family': 'Almeida, F.R. et al., 2013. Patient preferences and experiences of CPAP and oral appliances for the treatment of obstructive sleep apnea: a qualitative analysis. Sleep & breathing = Schlaf & Atmung, 17(2)'}, {'given': 'Pp.205–13.', 'family': 'Almeida, F.R. De et al., 2006. Long-term sequellae of oral appliance therapy in obstructive sleep apnea patients: Part 2. Study-model analysis. American journal of orthodontics and dentofacial orthopedics : official publication of the American Association'}, {'given': 'Pp.911–23.', 'family': 'Alsufyani, N., Al-Saleh, M. & Major, P., 2013. CBCT assessment of upper airway changes and treatment outcomes of obstructive sleep apnoea: a systematic review. Sleep & breathing, 17(3)'}, {'given': 'Pp.227–34.', 'family': 'Anandam, A. et al., 2013. Effects of dietary weight loss on obstructive sleep apnea: a meta-analysis. Sleep & breathing, 17(1)'}, {'given': 'Pp.1946–9.', 'family': 'Ancoli-Israel, S. et al., 1995. Sleep-disordered breathing in African-American elderly. American journal of respiratory and critical care medicine, 152(6 Pt 1)'}, {'given': 'Pp.90–96.', 'family': 'Ang, P.K., Sandham, A. & Tan, W.C., 2004. Craniofacial Morphology and Head Posture in. Seminars in Orthodontics, 10(1)'}, {'given': 'Cistulli (5 20 10)_PC revisions 24May2010 (2).', 'family': 'Anon'}, {'given': 'symps & conditions of OSA in adults.', 'family': 'Anon, Risk factors'}, {'given': '80(1).', 'family': 'Article, O., 2010. Five Years of Sleep Apnea Treatment with a Mandibular Advancement Device.'}, {'given': 'Pp.737–747.', 'family': 'Article, S., 2007. Clinical Guidelines for the Use of Unattended Portable Monitors in the Diagnosis of Obstructive Sleep Apnea in Adult Patients. Journal of Clinical Sleep Medicine, 3(7)'}, {'given': 'Pp.1408–1413.', 'family': 'Aurora, R.N. et al., 2010. Practice Parameters for the Surgical Modifications of the Upper Airway for Obstructive Sleep Apnea in Adults. SLEEP, 33(10)'}, {'given': 'Pp.17–40.', 'family': 'Aurora, R.N. et al., 2012. The Treatment of Central Sleep Apnea Syndromes in Adults : Practice Parameters with an Evidence-Based Literature Review and Meta-Analyses. SLEEP, 35(1)'}, {'given': 'Pp.485–490.', 'family': 'Awad, K.M. et al., 2012. Exercise Is Associated with a Reduced Incidence of Sleep-disordered Breathing. American Journal of Medicine, 125'}, {'given': 'Pp.982–990.', 'family': 'Bader, G.G. et al., 1997. Descriptive Physiological Data on a Sleep Bruxism Population. SLEEP, 20(11)'}, {'given': 'Pp.124–134.', 'family': 'Baik, U.B., Suzuki, M. & Ikeda, K., 2002. Relationship Between Cephalometric Characteristics and Obstructive Sites in Obstructive Sleep Apnea Syndrome. Angle Orthodontist, 72'}, {'given': 'Pp.495–501.', 'family': 'Ballester, E. et al., 1999. Evidence of the Effectiveness of Continuous Positive Airway Pressure in the Treatment of Sleep Apnea / Hypopnea Syndrome. American journal of respiratory and critical care medicine, 159'}, {'given': 'Pp.583–596.', 'family': 'Bardwell, W.A. et al., 1999. PSYCHOLOGICAL CORRELATES OF SLEEP APNEA. Journal of Psychosomatic Research, 47(6)'}, {'given': 'Pp.656–64.', 'family': 'Barnes, M. et al., 2004. Efficacy of positive airway pressure and oral appliance in mild to moderate obstructive sleep apnea. American journal of respiratory and critical care medicine, 170(6)'}, {'given': 'Pp.299–305.', 'family': 'Barthlen, G.M. et al., 2000. Comparison of three oral appliances for treatment of severe obstructive sleep apnea syndrome q. Sleep Medicine, 1'}, {'given': 'Pp.363–376.', 'family': 'Battagel, J.M. et al., 1999. Changes in airway and hyoid position in response to mandibular protrusion in subjects with obstructive sleep apnoea ( OSA ). European journal of orthodontics, 21'}, {'given': 'Pp.263–276.', 'family': 'Battagel, J.M. et al., 2002. Postural variation in oropharyngeal dimensions in subjects with sleep disordered breathing : a cephalometric study. European journal of orthodontics, 24'}, {'given': 'Pp.121–132.', 'family': 'Battagel, J.M. et al., 1998. The role of lateral cephalometric radiography and fluoroscopy in assessing mandibular advancement in sleep-related disorders. European journal of orthodontics, 20'}, {'given': 'Pp.557–569.', 'family': 'Battagel, J.M. & Estrange, P.R.L., 1996. The cephalometric morphology of patients with obstructive sleep apnoea ( OSA ). European journal of orthodontics, 18'}, {'given': 'Pp.353–365.', 'family': 'Battagel, J.M., Johal, A. & Kotecha, B., 2000. A cephalometric comparison of subjects with snoring and obstructive sleep apnoea. European journal of orthodontics, 22'}, {'given': 'Pp.298–307.', 'family': 'Beebe, D.W. et al., 2003. The Neuropsychological Effects of Obstructive Sleep Apnea : A Meta-Analysis of Norm-Referenced and Case-Controlled Data. SLEEP, 26(3)'}, {'given': 'Pp.558–564.', 'family': 'Bennett, L.S. et al., 1998. Oral appliances for the management of snoring and obstructive sleep apnoea. Thorax, 53(Suppl 2)'}, {'given': 'Pp.529–531.', 'family': 'Berry, D.T., Webb, W.B. & Block, A.J., 1984. Sleep apnea syndrome. A critical review of the apnea index as a diagnostic criterion. Chest, 86'}, {'given': 'Pp.245–50.', 'family': 'Berry, R.B. et al., 1991. Effect of theophylline on sleep and sleep-disordered breathing in patients with chronic obstructive pulmonary disease. The American review of respiratory disease, 143(2)'}, {'given': 'Pp.1423–1431.', 'family': 'Berry, R.B. et al., 2008. Portable Monitoring and Autotitration versus Polysomnography for the Diagnosis and Treatment of Sleep Apnea. SLEEP, 31(1)'}, {'given': 'Pp.641–649.', 'family': 'Bettega, G. et al., 2000. Obstructive Sleep Apnea Syndrome Fifty-one Consecutive Patients Treated by Maxillofacial Surgery. American journal of respiratory and critical care medicine, 162'}, {'given': 'Pp.245–251.', 'family': 'Bittencourt, L.R.A. et al., 2001. The variability of the apnoea ± hypopnoea index. J Prosthet Dent, 10'}, {'given': 'Pp.144–148.', 'family': 'Bixler, E.O. et al., 1998. Effects of Age on Sleep Apnea in Men. Am J Respir Crit Care Med, 157'}, {'given': 'Pp.621–8.', 'family': 'Bondemark, L., 1999. Does 2 years’ nocturnal treatment with a mandibular advancement splint in adult patients with snoring and OSAS cause a change in the posture of the mandible? American journal of orthodontics and dentofacial orthopedics : official publ'}, {'given': 'Pp.53–60.', 'family': 'Bondemark, L. & Lindman, R., 2000. Craniomandibular status and function in patients with habitual snoring and obstructive sleep apnoea after nocturnal treatment with a mandibular advancement splint : a 2-year follow-up. European journal of orthodontics, 2'}, {'given': 'Pp.917–23.', 'family': 'Brevi, B.C. et al., 2011. Counterclockwise rotation of the occlusal plane in the treatment of obstructive sleep apnea syndrome. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 69'}, {'given': 'Pp.1724–1737.', 'family': 'Buchwald, H., Avidor, Y. & Braunwald, E., 2004. Bariatric Surgery: A Systematic Review and Meta-analysis. JAMA, 292(14)'}, {'given': 'Pp.1396–1407.', 'family': 'Caples, S.M. et al., 2010. Surgical Modifications of the Upper Airway for Obstructive Sleep Apnea in Adults : A Systematic Review and Meta-Analysis. SLEEP, 33(10)'}, {'given': 'Pp.187–197.', 'family': 'Caples, S.M., Gami, A.S. & Somers, V.K., 2005. Obstructive Sleep Apnea. Annals of Internal Medicine, 142'}, {'given': 'Pp.163–168.', 'family': 'Carneiro, G. et al., 2012. Is mandatory screening for obstructive sleep apnea with polysomnography in all severely obese patients indicated ? Sleep Breath, 16'}, {'given': 'Pp.546–552.', 'family': 'Cartwright, R. et al., 1991. Clinical Corner A Comparative Study of Treatments for Positional Sleep Apnea. SLEEP, 14(6)'}, {'given': '2005. Sleep nasendoscopy as a predictor of treatment success in snorers using mandibular advancement sp ...', 'family': 'Central, P.'}, {'given': 'Pp.102–6.', 'family': 'Chan, a S.L., Phillips, C.L. & Cistulli, P. a, 2010. Obstructive sleep apnoea--an update. Internal medicine journal, 40(2)'}, {'given': 'Pp.836–842.', 'family': 'Chan, A.S.L., Lee, R.W.W., et al., 2010. Nasopharyngoscopic evaluation of oral appliance therapy for obstructive sleep apnoea. European Respiratory Journal, 35(4)'}, {'given': 'Pp.836–42.', 'family': 'Chan, A.S.L., Lee, R.W.W., et al., 2010. Nasopharyngoscopic evaluation of oral appliance therapy for obstructive sleep apnoea. The European respiratory journal, 35(4)'}, {'given': 'Pp.726–732.', 'family': 'Chan, A.S.L. et al., 2010. The effect of mandibular advancement on upper airway structure in obstructive sleep apnoea. Thorax, 65(8)'}, {'given': 'Pp.693–9.', 'family': 'Chan, A.S.L., Lee, R.W.W. & Cistulli, P. a, 2007. Dental appliance treatment for obstructive sleep apnea. Chest, 132(2)'}, {'given': 'Pp.179–84.', 'family': 'Chan, A.S.L., Lee, R.W.W. & Cistulli, P. a, 2008. Non-positive airway pressure modalities: mandibular advancement devices/positional therapy. Proceedings of the American Thoracic Society, 5(2)'}, {'given': 'Pp.157–162.', 'family': 'Chan, A.S.L., Lee, R.W.W. & Cistulli, P.A., 2011. Use of flow – volume curves to predict oral appliance treatment outcome in obstructive sleep apnea : a prospective validation study. Sleep Breath, 15'}, {'given': 'Pp.102–106.', 'family': 'Chan, A.S.L., Phillips, C.L. & Cistulli, P.A., 2010. Obstructive sleep apnoea – an update. Internal Medicine Journal, 40'}, {'given': 'Pp.39–45.', 'family': 'Chaudhary, B. & Speir, W., 1982. Sleep Apnoea Syndromes. Southern Medical Journal, 75(1)'}, {'given': 'Pp.473–86.', 'family': 'Chen, H. & Lowe, A. a, 2013. Updates in oral appliance therapy for snoring and obstructive sleep apnea. Sleep & breathing = Schlaf & Atmung, 17(2)'}, {'given': 'Pp.907–913.', 'family': 'Chesson, A.L., Berry, R.B. & Pack, A., 2003. Practice Parameters for the Use of Portable Monitoring Devices in the Investigation of Suspected Obstructive Sleep Apnea in Adults. SLEEP, 26(7)'}, {'given': 'Pp.443–57.', 'family': 'Cistulli, P. a et al., 2004. Treatment of snoring and obstructive sleep apnea with mandibular repositioning appliances. Sleep medicine reviews, 8(6)'}, {'given': 'Pp.1–5.', 'family': 'Cistulli, P.A., Palmisano, R.G. & Poole, M.D., 1998. Treatment of Obstructive Sleep Apnea Syndrome by Rapid Maxillary Expansion. SLEEP, 21(8)'}, {'given': 'Pp.624–9.', 'family': 'Clark, G.T. et al., 1993. Effect of anterior mandibular positioning on obstructive sleep apnea. The American review of respiratory disease, 147(3)'}, {'given': 'Pp.146–159.', 'family': 'Dalmasso, F. & Prota, R., 1996. Snoring: analysis, measurement, clinical implications and applications. European Respiratory Journal, 9(1)'}, {'given': 'Pp.1544–1550.', 'family': 'Dancey, D. et al., 2003. Gender Differences in Sleep Apnea: The role of neck circumference. Chest, 123'}, {'given': 'Pp.101–105.', 'family': 'Davies, R.J., Ali, N.J. & Stradling, J.R., 1992. Neck circumference and other clinical features in the diagnosis of the obstructive sleep apnoea syndrome. Thorax, 47'}, {'given': 'Pp.648–653.', 'family': 'Deane, S.A. et al., 2009. Comparison of Mandibular Advancement Splint and Tongue Stabilizing Device in Obstructive Sleep Apnea : A Randomized Controlled Trial. SLEEP, 32(5)'}, {'given': 'Pp.86–87.', 'family': 'Deatherage, J.R., Roden, R.D. & Zouhary, K., 2009. Normal Sleep Architecture. Seminars in Orthodontics, 15'}, {'given': 'Pp.1161–1178.', 'family': 'Deegan, P.C. & McNicholas, W.T., 1995. Pathophysiology of obstructive sleep apnoea. European Respiratory Journal, 8(7)'}, {'given': 'Pp.47–112.', 'family': 'Dempsey, J.A. et al., 2010. Pathophysiology of Sleep Apnea. Physiol Rev, 90'}, {'given': 'Pp.1010–8.', 'family': 'Doff, M.H.J. et al., 2010. Long-term oral-appliance therapy in obstructive sleep apnea: a cephalometric study of craniofacial changes. Journal of dentistry, 38(12)'}, {'given': 'Pp.2076–2084.', 'family': 'Doherty, L.S. et al., 2005. Long-term Effects of Nasal Continuous Positive Airway Pressure Therapy on Cardiovascular Outcomes in Sleep Apnea Syndrome * Long-term Effects of Nasal Continuous Positive Airway Pressure Therapy on Cardiovascular Outcomes in Sl'}, {'given': 'Pp.1003–9.', 'family': 'Dort, L.C., Hadjuk, E. & Remmers, J.E., 2006. Mandibular advancement and obstructive sleep apnoea: a method for determining effective mandibular protrusion. The European respiratory journal, 27(5)'}, {'given': 'Pp.525–531.', 'family': 'Du, X. & Hagg, U., 2003. Muscular Adaptation to Gradual Advancement of the Mandible. Angle Orthodontist, 73(5)'}, {'given': 'Pp.685–689.', 'family': 'Durán, J. et al., 2001. Obstructive Sleep Apnea – Hypopnea and Related Clinical Features in a Population-based Sample of Subjects Aged 30 to 70 Yr. Am J Respir Crit Care Med, 163'}, {'given': 'Pp.144–153.', 'family': 'Eckert, D.J. & Malhotra, A., 2008. Pathophysiology of Adult Obstructive Sleep Apnea. Proc Am Thorac Soc, 5'}, {'given': 'Pp.313–323.', 'family': 'Eckert, D.J., Malhotra, A. & Jordan, A.S., 2009. Mechanisms of Apnea. Progress in Cardiovascular Diseases, 51(4)'}, {'given': 'Pp.858–859.', 'family': 'Editorial, 2009. On the Plausibility of Upper Airway Remodeling as an Outcome of Orofacial Exercise. American journal of respiratory and critical care medicine, 179'}, {'given': 'Pp.1702–1709.', 'family': 'Eikermann, M. et al., 2007. The Influence of Aging on Pharyngeal Collapsibility During Sleep. Chest, 131(6)'}, {'given': 'Pp.305–10.', 'family': 'Ekici, A. et al., 2013. Personality profiles in patients with obstructive sleep apnea. Sleep & breathing = Schlaf & Atmung, 17(1)'}, {'given': 'Pp.e511–e521.', 'family': 'El, H. & Palomo, J.M., 2011. Airway volume for different dentofacial skeletal patterns. American Journal of Orthodontics and Dentofacial Orthopedics, 139'}, {'given': 'Pp.193–200.', 'family': 'Ellen, R. et al., 2006. Systematic Review of Motor Vehicle Crash Risk in Persons With Sleep Apnea. Journal of Clinical Sleep Medicine, 2(2)'}, {'given': 'Pp.263–266.', 'family': 'Ellis, E. & Anderson-Cermin, C., 1998. Occlusal Changes After Hyoid Advancement for Obstructive Sleep Apnea : Case Report. Journal of Oral and Maxillofacial Surgery, 56'}, {'given': 'Pp.855–859.', 'family': 'Engleman, H.M. et al., 2002. Randomized Crossover Trial of Two Treatments for Sleep Apnea / Hypopnea Syndrome Continuous Positive Airway Pressure and Mandibular Repositioning Splint. American journal of respiratory and critical care medicine, 166'}, {'given': 'Pp.263–266.', 'family': 'Engleman, H.M., Martin, S.E. & Douglas, N.J., 1994. Compliance with CPAP therapy in patients with the sleep apnoea / hypopnoea syndrome. Thorax, 49'}, {'given': 'pp.263– 276.', 'family': 'Epstein, L.J. et al., 2009. Clinical Guideline for the Evaluation, Management and Long-term Care of Obstructive Sleep Apnea in Adults. Journal of Clinical Sleep Medicine, 5(3)'}, {'given': 'Pp.905–909.', 'family': 'Eveloff, S.E. et al., 1994. Efficacy of a Herbst Mandibular Advancement Device in Obstructive Sleep Apnea. American journal of respiratory and critical care medicine, 149'}, {'given': 'P.674.', 'family': 'Eveloff, S.E., 2002. Treatment of Obstructive Sleep Apnea. CHEST Journal, 121(3)'}, {'given': 'Pp.77–86.', 'family': 'Faber, C.E. & Grymer, L., 2002. Available Techniques for Objective Assessment of Upper Airway Narrowing in Snoring and Sleep Apnea. Sleep & breathing, 7(2)'}, {'given': '2012. Volumetric analysis of the pharynx in patients with obstructive sleep apnea ( OSA ) treated with maxillomandibular advancement ( MMA ). Sleep Breath.', 'family': 'Faria, A.C. et al.'}, {'given': 'Pp.355–364.', 'family': 'Ferguson, K. a, 2003. The role of oral appliance therapy in the treatment of obstructive sleep apnea. Clinics in Chest Medicine, 24(2)'}, {'given': 'Pp.998–1004.', 'family': 'Ferguson, K. a & Fleetham, J. a, 1995. Sleep-related breathing disorders. 4. Consequences of sleep disordered breathing. Thorax, 50(9)'}, {'given': 'P.1269.', 'family': 'Ferguson, K. a., 1996. A Randomized Crossover Study of an Oral Appliance vs Nasal-Continuous Positive Airway Pressure in the Treatment of Mild-Moderate Obstructive Sleep Apnea. CHEST Journal, 109(5)'}, {'given': 'Pp.1269–1275.', 'family': 'Ferguson, K.A. et al., 1996. A Randomized Crossover Study of an Oral Appliance vs Nasal-Continuous Positive Airway Pressure in the Treatment of Mild-Moderate Obstructive Sleep Apnea *. CHEST Journal, 109'}, {'given': 'Pp.362–368.', 'family': 'Ferguson, K.A., Ono, T., et al., 1997. A short-term controlled trial of an adjustable oral appliance for the treatment of mild to moderate obstructive sleep apnoea. Thorax, 52(4)'}, {'given': 'Pp.244–262.', 'family': 'Ferguson, K.A., Cartwright, R., Rogers, R. & Schmidt-nowara, W., 2006. Oral Appliances for Snoring and Obstructive Sleep Apnea : A Review. SLEEP, 29(2)'}, {'given': 'Pp.244–62.', 'family': 'Ferguson, K.A., Cartwright, R., Rogers, R. & Schmidt-Nowara, W., 2006. Oral appliances for snoring and obstructive sleep apnea: a review. Sleep, 29(2)'}, {'given': 'Pp.375–381.', 'family': 'Ferguson, K.A. et al., 1995. The Relationship Between Obesity and Craniofacial Structure in Obstructive Sleep Apnea *. Chest, 108'}, {'given': 'Pp.1748–1754.', 'family': 'Ferguson, K.A., Love, L.L. & Ryan, C.F., 1997. Effect of Mandibular and Tongue Protrusion on Upper Airway Size During Wakefulness. Am J Respir Crit Care Med, 155'}, {'given': 'Pp.668–72.', 'family': 'Flemons, W.W. et al., 2004. Access to diagnosis and treatment of patients with suspected sleep apnea. American journal of respiratory and critical care medicine, 169(6)'}, {'given': 'Pp.498–504.', 'family': 'Flemons, W.W., 2002. Clinical Practice. The New England Journal of Medicine, 347(7)'}, {'given': 'Pp.1543–1579.', 'family': 'Flemons, W.W. et al., 2003. Home Diagnosis of Sleep Apnea : A Systematic Review of the Literature * : An Evidence Review Cosponsored by the American Academy of Sleep Medicine , the American College of Chest Physicians , and the American Thoracic Society H'}, {'given': 'Pp.618–621.', 'family': 'Flemons, W.W., Remmers, J.E. & Gillis, A.M., 1993. Sleep Apnea and Cardiac Arrhythmias Is There a Relationship ? Am Rev Respir Dis, 148'}, {'given': 'P.1761.', 'family': 'Fleury, B., 2004. Mandibular Advancement Titration for Obstructive Sleep Apnea *. CHEST Journal, 125(5)'}, {'given': 'Pp.2356–2359.', 'family': 'Fleury, B. et al., 1996. Objective patient compliance in long-term use of nCPAP. European Respiratory Journal, 9'}, {'given': 'Pp.150–5.', 'family': 'Fogel, R.B. et al., 2003. Anatomic and physiologic predictors of apnea severity in morbidly obese subjects. Sleep, 26(2)'}, {'given': 'Pp.27–36.', 'family': 'Franklin, K.A. et al., 2009. Effects and Side-Effects of Surgery for Snoring and Obstructive Sleep Apnea – A Systematic Review. Sleep, 32(1)'}, {'given': 'Pp.687–693.', 'family': 'Fransson, A.M.C. et al., 2004. Influence on the masticatory system in treatment of obstructive sleep apnea and snoring with a mandibular protruding device: A 2-year follow-up. American journal of orthodontics and dentofacial orthopedics, 126'}, {'given': 'Pp.813–818.', 'family': 'Fritsch, K.M. et al., 2001. Side Effects of Mandibular Advancement Devices for Sleep Apnea Treatment. , 164'}, {'given': 'Pp.256–61.', 'family': 'Ghoneima, A. & Kula, K., 2013. Accuracy and reliability of cone-beam computed tomography for airway volume analysis. European journal of orthodontics, 35(2)'}, {'given': 'Pp.173–180.', 'family': 'Giannakopoulos, H. & Costello, B.J., 2001. Mortised Genioplasty in the Treatment of Obstructive Sleep Apnea : An Historical Perspective and Modification of Design. Sleep & breathing, 5(4)'}, {'given': 'Pp.375–81.', 'family': 'Giannasi, L.C. et al., 2009. Systematic assessment of the impact of oral appliance therapy on the temporomandibular joint during treatment of obstructive sleep apnea: long-term evaluation. Sleep & breathing = Schlaf & Atmung, 13(4)'}, {'given': 'Pp.336–341.', 'family': 'Giannasi, L.C. et al., 2008. The impact of the Adjustable PM Positioner appliance in the treatment of obstructive sleep apnoea. Arch Med Sci, 4(3)'}, {'given': '(3).', 'family': 'Giles, T. et al., 2006. Continuous positive airways pressure for obstructive sleep apnoea in adults. Cochrane Database of Systematic Reviews'}, {'given': 'Pp.743–748.', 'family': 'Gotsopoulos, H., Chen, C., Qian, J. & Cistulli, P.A., 2002. Oral Appliance Therapy Improves Symptoms in Obstructive Sleep Apnea A Randomized, Controlled Trial. Am J Respir Crit Care Med, 166'}, {'given': 'Pp.743–8.', 'family': 'Gotsopoulos, H., Chen, C., Qian, J. & Cistulli, P. a, 2002. Oral appliance therapy improves symptoms in obstructive sleep apnea: a randomized, controlled trial. American journal of respiratory and critical care medicine, 166(5)'}, {'given': 'Pp.934–941.', 'family': 'Gotsopoulos, H., Kelly, J.J. & Cistulli, P.A., 2004. Oral Appliance Therapy Reduces Blood Pressure in Obstructive Sleep Apnea : a Randomized, Controlled Trial. SLEEP, 27(5)'}, {'given': 'Pp.893–896.', 'family': 'Guilleminault, C. & Li, K.K., 2004. Maxillomandibular Expansion for the Treatment of Sleep-Disordered Breathing : Preliminary Result. Laryngoscope, 114'}, {'given': 'Pp.465–484.', 'family': 'Guilleminault, C., Tilkian, A. & Dement, W., 1976. The Sleep Apnea Syndromes. Annu Rev Med, 27'}, {'given': 'Pp.962–966.', 'family': 'Guimaraes, K. ́tia C. et al., 2009. Effects of Oropharyngeal Exercises on Patients with Moderate Obstructive Sleep Apnea Syndrome. American journal of respiratory and critical care medicine, 179'}, {'given': 'Pp.267–270.', 'family': 'Hakan, E. & Palamo, J.M., 2013. An airway study of different maxillary and mandibular sagital positions. European journal of orthodontics, 35'}, {'given': 'Pp.415–425.', 'family': 'Hamada, T. et al., 2007. Mandibular distraction osteogenesis in a skeletal Class II patient with obstructive sleep apnea. American journal of orthodontics and dentofacial orthopedics, 131'}, {'given': 'Pp.806–14.', 'family': 'Hammond, R.J. et al., 2007. A follow-up study of dental and skeletal changes associated with mandibular advancement splint use in obstructive sleep apnea. American journal of orthodontics and dentofacial orthopedics : official publication of the American'}, {'given': 'Pp.562–570.', 'family': 'Hans, M.G. et al., 1997. Comparison of two dental devices for treatment of obstructive sleep apnea syndrome ( OSAS ). Am J Orthod Dentofac Orthop, 111'}, {'given': 'Pp.132–158.', 'family': 'Haskell, J. a. et al., 2009. Effects of Mandibular Advancement Device (MAD) on Airway Dimensions Assessed With Cone-Beam Computed Tomography. Seminars in Orthodontics, 15(2)'}, {'given': 'Pp.132–158.', 'family': 'Haskell, J.A. et al., 2009. Effects of Mandibular Advancement Device (MAD) on Airway Dimensions Assessed With Cone-Beam Computed Tomography. Seminars in Orthodontics, 15(2)'}, {'given': 'Pp.38–44.', 'family': 'Hassan, B. et al., 2013. Precision of identifying cephalometric landmarks with cone beam computed tomography in vivo. European journal of orthodontics, 35(1)'}, {'given': 'Pp.420–425.', 'family': 'Henke, K., Frantz, D. & Kuna, S., 2000. An Oral Elastic Mandibular Advancement Device for Obstructive Sleep Apnea. Am J Respir Crit Care Med, 161'}, {'given': 'Pp.240–243.', 'family': 'Hirshkowitz, M. et al., 2006. Practice Parameters for the Treatment of Snoring and Obstructive Sleep Apnea with Oral Appliances : An Update for 2005. SLEEP, 29(2)'}, {'given': 'Pp.440–445.', 'family': 'Hiyama, S. et al., 2003. Effects of Mandibular Advancement on Supine Airway Size in Normal Subjects During Sleep. SLEEP, 26(4)'}, {'given': 'Pp.48–54.', 'family': 'Hiyama, S., Kuribayashi, G. & Ono, T., 2002. Nocturnal Masseter and Suprahyoid Muscle Activity Induced by Wearing a Bionator. Angle Orthodontist, 72(1)'}, {'given': 'Pp.1181–1186.', 'family': 'Hoekema, A. et al., 2007. Predictors of Obstructive Sleep Apnea-Hypopnea Treatment Outcome. Journal of Dental Research, 86(12)'}, {'given': 'Pp.129–38.', 'family': 'Hoekema, A. et al., 2007. Simulated driving in obstructive sleep apnoea-hypopnoea; effects of oral appliances and continuous positive airway pressure. Sleep & breathing = Schlaf & Atmung, 11(3)'}, {'given': 'Pp.137–155.', 'family': 'Hoekema, A., Stegenga, B. & de Bont, L.G.M., 2004. Efficacy and Co-Morbidity of Oral Appliances in the Treatment of Obstructive Sleep Apnea-Hypopnea: a Systematic Review. Critical Reviews in Oral Biology & Medicine, 15(3)'}, {'given': 'P.466.', 'family': 'Hoffstein, V., 1994. Cardiac Arrhythmias, Snoring, and Sleep Apnea. CHEST Journal, 106(2)'}, {'given': 'Pp.1–22.', 'family': 'Hoffstein, V., 2007. Review of oral appliances for treatment of sleep-disordered breathing. Sleep & breathing = Schlaf & Atmung, 11(1)'}, {'given': 'Pp.162–170.', 'family': 'Holty, J.C. & Guilleminault, C., 2012. Maxillomandibular Expansion and Advancement for the Treatment of Sleep-Disordered Breathing in Children and Adults. Seminars in Orthodontics, 18'}, {'given': 'Pp.e161–9.', 'family': 'Hong, J.-S. et al., 2011. Three-dimensional analysis of pharyngeal airway volume in adults with anterior position of the mandible. American journal of orthodontics and dentofacial orthopedics : official publication of the American Association of Orthodont'}, {'given': 'Pp.541–549.', 'family': 'Hudgel, W., 1992. Mechanisms of obstructive sleep apnea. Chest, 101'}, {'given': 'Pp.62–69.', 'family': 'Ip, M. et al., 2001. A Community Study of Sleep-Disordered Breathing in Middle-aged Chinese Men in Hong Kong. Chest, 119(1)'}, {'given': 'Pp.323–325.', 'family': 'Ishida, M., Inoue, Y. & Okamoto, K., 1999. Clinical efficacy of prosthetic mandibular advancement on obstructive sleep apnea syndrome.'}, {'given': 'Pp.1319–1326.', 'family': 'Isono, S. et al., 1997. Anatomy of pharynx in patients with obstructive sleep apnea and in normal subjects. J Appl Physiol, 92'}, {'given': 'Pp.908–21.', 'family': 'Isono, S., 2009. Obstructive sleep apnea of obese adults: pathophysiology and perioperative airway management. Anesthesiology, 110(4)'}, {'given': 'Pp.435–441.', 'family': 'Jacobson, R.L. & Schendel, S.A., 2012. Treating Obstructive Sleep Apnea: The case for surgery. Am J Orthod Dentofacial Orthop, 142(4)'}, {'given': 'Pp.314–321.', 'family': 'Jauhar, S. et al., 2008. Ten-year follow-up of mandibular advancement devices for the management of snoring and sleep apnea. J Prosthet Dent, 99'}, {'given': 'Pp.47–53.', 'family': 'Johal, A. et al., 2007. The effect of mandibular advancement appliances on awake upper airway and masticatory muscle activity in patients with obstructive sleep apnoea. Clinical Physiology and Functional Imaging, 27'}, {'given': 'Pp.532–536.', 'family': 'Johal, A. & Battagel, J.M., 2001. Current principles in the management of obstructive sleep apnoea with mandibular advancement appliances. British Dental Journal, 190(10)'}, {'given': 'Pp.607–614.', 'family': 'Johal, A., Battagel, J.M. & Kotecha, B.T., 2005. Sleep nasendoscopy : a diagnostic tool for predicting treatment success with mandibular advancement splints in obstructive sleep apnoea. European journal of orthodontics, 27'}, {'given': 'Pp.251–262.', 'family': 'Johnston, C.D. et al., 2002. Mandibular advancement appliances and obstructive sleep apnoea : a randomized clinical trial. European journal of orthodontics, 24'}, {'given': 'Pp.361–368.', 'family': 'Jordan, A.S. et al., 2009. Airway Dilator Muscle Activity and Lung Volume During Stable Breathing in Obstructive Sleep Apnea. Sleep, 32(3)'}, {'given': 'Pp.63–72.', 'family': 'Jureyda, S. & Shucard, D.W., 2004. Obstructive sleep apnea—an overview of the disorder and its consequences. Seminars in Orthodontics, 10(1)'}, {'given': 'Pp.409–416.', 'family': 'Kapsimalis, F. & Kryger, M.H., 2002. Gender and Obstructive Sleep Apnea Syndrome , Part 1 : Clinical Features. SLEEP, 25(4)'}, {'given': 'Pp.1065–1072.', 'family': 'Kato, J. et al., 2000. Dose-Dependent Effects of Mandibular Advancement on Pharyngeal Mechanics and Nocturnal Oxygenation in Patients With Sleep-Disordered Breath. Chest, 117'}, {'given': 'Pp.647–653.', 'family': 'Katsavrias, E.G., 2003. The Effect of Mandibular Protrusive ( Activator ) Appliances on Articular Eminence Morphology. Angle Orthodontist, 73'}, {'given': 'Physical Examination and Identifying the Sites of Obstruction in OSA.', 'family': 'Kezirian, E.J.'}, {'given': 'Pp.128–33.', 'family': 'Kiely, J.L. & McNicholas, W.T., 2000. Cardiovascular risk factors in patients with obstructive sleep apnoea syndrome. The European respiratory journal, 16(1)'}, {'given': 'Pp.1108–13.', 'family': 'Kim, J. et al., 2004. Prevalence of sleep-disordered breathing in middle-aged Korean men and women. American journal of respiratory and critical care medicine, 170(10)'}, {'given': 'Pp.567–569.', 'family': 'Kimoff, R.J., 2007. Upper Airway Myopathy is Important in the Pathophysiology of Obstructive Sleep Apnea. Journal of Clinical Sleep Medicine, 3(6)'}, {'given': 'Pp.333–344.', 'family': 'Kollias, I. & Krogstad, O., 1999a. Adult craniocervical and pharyngeal changes — a longitudinal cephalometric study between 22 and 42 years of age . Part I : morphological craniocervical and hyoid bone changes. European journal of orthodontics, 21'}, {'given': 'Pp.345–355.', 'family': 'Kollias, I. & Krogstad, O., 1999b. Adult craniocervical and pharyngeal changes — a longitudinal cephalometric study between 22 and 42 years of age . Part II : morphological uvulo-glossopharyngeal changes. European journal of orthodontics, 21'}, {'given': 'Pp.16–19.', 'family': 'KOSKENVUO, M. et al., 1987. Snoring as a risk factor for ischaemic heart disease and stroke in men. Brittish Medical Journal, 294'}, {'given': 'Pp.887–895.', 'family': 'Kribbs, N. et al., 1993. Objective Measurement of Patterns of Nasal CPAP use by Patients with Obstructive Sleep Apnea. American journal of respiratory and critical care medicine, 147'}, {'given': 'Pp.499–521.', 'family': 'Kushida, C.A. et al., 2005. Practice Parameters for the Indications for Polysomnography and Related Procedures : An Update for 2005. SLEEP, 28(4)'}, {'given': 'Pp.240–243.', 'family': 'Kushida, C.A. et al., 2006. Practice Parameters for the Treatment of Snoring and Obstructive Sleep Apnea with Oral Appliances : An Update for 2005. Sleep, 29(2)'}, {'given': 'Pp.15–22.', 'family': 'Kyung, S.H. & Park, Y., 2004. Obstructive Sleep Apnea Patients with the Oral Appliance Experience Pharyngeal Size and Shape Changes in Three Dimensions. Angle Orthodontist, 75'}, {'given': 'Pp.699–711.', 'family': 'L’estrange, P. et al., 1996. A method of studying adaptive changes to the oropharynx to the variation in mandibular position in patients with obstructive sleep apnea. Journal of Oral Rehabilitation, 23'}, {'given': 'Pp.195–201.', 'family': 'Lam, B. et al., 2011. The efficacy of oral appliances in the treatment of severe obstructive sleep apnea. Sleep Breath, 15'}, {'given': 'Pp.39–44.', 'family': 'Lampasso, J.D. & Lampasso, J.G., 2004. Allergy, Nasal Obstruction, and Occlusion. Seminars in Orthodontics, 10'}, {'given': 'Pp.1362–1368.', 'family': 'Larsson, L., Carlson-Nordlander, B. & Svanborg, E., 1994. Four-year Follow-up After Uvulopalatopharyngoplasty In 50 Unselected Patients with Obstructive Sleep Apnea Syndrome. Laryngoscope, 104'}, {'given': 'Pp.2–6.', 'family': 'Lavigne, G.J. et al., 1999. Sleep disorders and the dental patient. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 88(3)'}, {'given': 'Inc.', 'family': 'Lavigne, G.J., Cistulli, P.A. & Smith, M.T., 2009. Sleep Medicine for Dentists: A practical overview, Quintessence Publishing Co'}, {'given': 'Pp.37–45.', 'family': 'Lee, R.W.W., Chan, A.S.L., Grunstein, R.R. & Cistulli, P.A., 2009. Craniofacial Phenotyping in Obstructive Sleep Apnea – A Novel Quantitative Photographic Approach. SLEEP, 32(1)'}, {'given': 'Pp.37–45.', 'family': 'Lee, R.W.W., Chan, A.S.L., Grunstein, R.R. & Cistulli, P. a, 2009. Craniofacial phenotyping in obstructive sleep apnea--a novel quantitative photographic approach. Sleep, 32(1)'}, {'given': 'Pp.46–52.', 'family': 'Lee, R.W.W., Petocz, P., et al., 2009. Prediction of Obstructive Sleep Apnea with Craniofacial Photographic Analysis. SLEEP, 32(1)'}, {'given': 'Pp.96–105.', 'family': 'Lenza, M. et al., 2010. An analysis of different approaches to the assessment of upper airway morphology : a CBCT study. Orthodontics & Craniofacial Research, 13(2)'}, {'given': 'Pp.139–47.', 'family': 'Levendowski, D.J. et al., 2007. In-home evaluation of efficacy and titration of a mandibular advancement device for obstructive sleep apnea. Sleep & breathing = Schlaf & Atmung, 11(3)'}, {'given': 'Pp.201–209.', 'family': 'Li, K.K., 2005. Surgical therapy for adult obstructive sleep apnea. Sleep Medicine Reviews, 9'}, {'given': 'Pp.1751–1755.', 'family': 'Liistro, G., Aubert, G. & Rodenstein, D.O., 1995. Management of sleep apnoea syndrome. European Respiratory Journal, 8(10)'}, {'given': '(1).', 'family': 'Lim, J. et al., 2006. Oral appliances for obstructive sleep apnoea (Review). Cochrane Database of Systematic Reviews'}, {'given': 'Pp.639–647.', 'family': 'Liu, Y. et al., 2001. Cephalometric and physiologic predictors of the efficacy of an adjustable oral appliance for treating obstructive sleep apnea. American Journal of Orthodontics and Dentofacial Orthopedics, 120(6)'}, {'given': 'Pp.248–56.', 'family': 'Liu, Y. et al., 2000. Effects of a mandibular repositioner on obstructive sleep apnea. American journal of orthodontics and dentofacial orthopedics : official publication of the American Association of Orthodontists, its constituent societies, and the Ame'}, {'given': 'Pp.15–23.', 'family': 'Liu, Y. & Lowe, A., 2000. Factors Related to the Efficacy of an Adjustable Oral Appliance for the Treatment of Obstructive Sleep Apnea. CJDR, 3'}, {'given': 'Pp.S93–95.', 'family': 'Lowe, A., 1993. Can We Predict the Success of Dental Appliance Therapy for the Treatment of Obstructive Sleep Apnea Based on Anatomical Considerations? SLEEP, 16(8)'}, {'given': 'Pp.172–178.', 'family': 'Lowe, A. et al., 2000. Treatment, Airway and Compliance Effects of a Titratable Oral Appliance. SLEEP, 23(4)'}, {'given': 'Pp.589–595.', 'family': 'Lowe, A.A. et al., 1995. Cephalometric and computed tomographic predictors of obstructive sleep apnea severity. Am J Orthod Dentofac Orthop, 107'}, {'given': 'Pp.653–664.', 'family': 'Lowe, A.A. et al., 1996. Cephalometric comparisons of craniofacial and upper airway structure by skeletal subtype and gender in patients with obstructive sleep apnea. Am J Orthod Dentofac Orthop, 110'}, {'given': 'Pp.484–491.', 'family': 'Lowe, A.A. et al., 1986. Facial morphology and obstructive sleep apnea. Am J Orthod Dentofac Orthop, 90'}, {'given': 'Pp.434–440.', 'family': 'Lowe, A.A., 2012. Treating Obstructive Sleep Apnea: The case for oral appliances. Am J Orthod Dentofacial Orthop, 142(4)'}, {'given': 'Pp.59–64.', 'family': 'Lugaresi, E. et al., 1975. Snoring. Electroencephalography and Clinical Neurophysiology, 39'}, {'given': 'Pp.99–104.', 'family': 'Lye, K.W. & Deatherage, J.R., 2009a. Surgical Maxillomandibular Advancement Technique. Seminars in Orthodontics, 15(2)'}, {'given': 'Pp.94–98.', 'family': 'Lye, K.W. & Deatherage, J.R., 2009b. Surgical Procedures for the Treatment of Obstructive Sleep Apnea. Seminars in Orthodontics, 15(2)'}, {'given': '2012. Postoperative complications in obstructive sleep apnea. Sleep Breath.', 'family': 'Mador, M.J., Goplani, S. & Abo-khamis, M.'}, {'given': 'Pp.700–8.', 'family': 'Major, M.P., Flores-Mir, C. & Major, P.W., 2006. Assessment of lateral cephalometric diagnosis of adenoid hypertrophy and posterior upper airway obstruction: a systematic review. American journal of orthodontics and dentofacial orthopedics : official publ'}, {'given': 'Pp.513–516.', 'family': 'Malkoc, S. et al., 2005. Reproducibility of airway dimensions and tongue and hyoid positions on lateral cephalograms. Am J Orthod Dentofac Orthop, 128'}, {'given': 'P.707.', 'family': 'Marklund, M., 1998a. The Effect of a Mandibular Advancement Device on Apneas and Sleep in Patients With Obstructive Sleep Apnea. CHEST Journal, 113(3)'}, {'given': 'P.1630.', 'family': 'Marklund, M., 1998b. Treatment Success With a Mandibular Advancement Device Is Related to Supine-Dependent Sleep Apnea. CHEST Journal, 114(6)'}, {'given': 'Pp.135–144.', 'family': 'Marklund, M., Franklin, K.A. & Persson, M., 2001. Orthodontic side-effects of mandibular advancement devices during treatment of snoring and sleep apnoea. , 23'}, {'given': 'Pp.1630–1635.', 'family': 'Marklund, M., Persson, M. & Franklin, K.A., 1998. Treatment Success With a Mandibular Advancement Device Is Related to Supine-Dependent Sleep Apnea1. Chest, 114'}, {'given': 'Pp.1270–1278.', 'family': 'Marklund, M., Stenlund, H. & Franklin, K.A., 2004. Mandibular Advancement Devices in 630 Men and Women With Obstructive Sleep Apnea and Snoring * : Tolerability and Predictors of Treatment Success. Chest, 125'}, {'given': 'Pp.1241–7.', 'family': 'Marklund, M., Verbraecken, J. & Randerath, W., 2012. Non-CPAP therapies in obstructive sleep apnoea: mandibular advancement device therapy. The European respiratory journal, 39(5)'}, {'given': 'Pp.188–97.', 'family': 'Mattos, C.T. et al., 2014. Reliability of upper airway linear, area, and volumetric measurements in cone-beam computed tomography. American journal of orthodontics and dentofacial orthopedics : official publication of the American Association of Orthodont'}, {'given': 'Pp.35–43.', 'family': 'Mayer, G. & Meier-Ewert, K., 1995. Cephalometric predictors for orthopaedic mandibular advancement in obstructive sleep apnoea. European journal of orthodontics, 17(1)'}, {'given': 'Pp.63–69.', 'family': 'McCrillis, J.M. et al., 2009. Obstructive Sleep Apnea and the Use of Cone Beam Computed Tomography in Airway Imaging: A Review. Seminars in Orthodontics, 15(1)'}, {'given': 'Pp.197–205.', 'family': 'McGinley, B.M. et al., 2008. Upper airway neuromuscular compensation during sleep is defective in obstructive sleep apnea. Journal of applied physiology (Bethesda, Md. : 1985), 105(1)'}, {'given': 'Pp.462–6.', 'family': 'McGown, A.D. et al., 2001. Long-term use of mandibular advancement splints for snoring and obstructive sleep apnoea: a questionnaire survey. The European respiratory journal, 17(3)'}, {'given': 'Ontario.', 'family': 'Medical Advisory Secretariat, 2009. Oral Appliances for Obstructive Sleep Apnea: an evidence-based analysis'}, {'given': 'Pp.1457–1461.', 'family': 'Mehta, A. et al., 2001. A Randomized , Controlled Study of a Mandibular Advancement Splint for Obstructive Sleep Apnea. Am J Respir Crit Care Med, 163'}, {'given': 'Pp.320–324.', 'family': 'Meyer, B. & Knudson, C., 1990. The sleep apnea syndrome . Part II : Treatment. Journal of Prosthetic Dentistry, 63(3)'}, {'given': 'Pp.675–679.', 'family': 'Meyer, J.B. & Knudson, R.C., 1989. The sleep apnea syndrome . Part I : Diagnosis. J Prosthet Dent, 62'}, {'given': 'Pp.163–172.', 'family': 'Miles, P.G., Vig, P.S. & Dorth, F.D.S., 1996. Craniofacial structure and obstructive sleep apnea syndrome-a qualitative analysis and meta-analysis of the literature. Am J Orthod Dentofac Orthop, 109'}, {'given': 'Pp.1025–1030.', 'family': 'Millman, R.P. et al., 2000. Simple Predictors of Uvulopalatopharyngoplasty Outcome in the Treatment of Obstructive Sleep Apnea * Simple Predictors of Uvulopalatopharyngoplasty Outcome in the Treatment of Obstructive Sleep Apnea *. CHEST Journal, 118'}, {'given': 'Pp.545–549.', 'family': 'Mokhlesi, B. & Gozal, D., 2010. Pulmonary and Critical Care Updates Update in Sleep Medicine 2009. Am J Respir Crit Care Med, 181'}, {'given': 'Pp.1031–1035.', 'family': 'Morgenthaler, T.I. et al., 2006. Practice Parameters for the Medical Therapy of Obstructive Sleep Apnea. Sleep, 29(8)'}, {'given': 'Pp.606–611.', 'family': 'MORRISON, D.L. et al., 1993. Pharyngeal Narrowing and Closing Pressures in Patients with Obstructive Sleep Apnea. Am J Respir Crit Care Med, 148'}, {'given': 'Pp.280–3.', 'family': 'Mortimore, I.L. et al., 1998. Neck and total body fat deposition in nonobese and obese patients with sleep apnea compared with that in control subjects. American journal of respiratory and critical care medicine, 157(1)'}, {'given': 'Pp.1331–1339.', 'family': 'Mostafiz, W. et al., 2011. Influence of Oral and Craniofacial Dimensions on Mandibular Advancement Splint Treatment Outcome in Obstructive Sleep Apnea. Chest, 139(6)'}, {'given': 'Pp.43–54.', 'family': 'Naismith, S. et al., 2004. Neurobehavioral Functioning in Obstructive Sleep Apnea : Differential Effects of Sleep Quality, Hypoxemia and Subjective Sleepiness. Journal of Psychosomatic Research, 26(1)'}, {'given': 'Pp.47–58.', 'family': 'Ng, A. et al., 2012. Cephalometry and prediction of oral appliance treatment outcome. Sleep Breath, 16'}, {'given': 'Pp.238–41.', 'family': 'Ng, A.T. et al., 2003. Effect of oral appliance therapy on upper airway collapsibility in obstructive sleep apnea. American journal of respiratory and critical care medicine, 168(2)'}, {'given': 'Pp.666–671.', 'family': 'Ng, A.T., Qian, J. & Cistulli, P.A., 2006. Oropharyngeal Collapse Predicts Treatment Response With Oral Appliance Therapy in Obstructive Sleep Apnea. SLEEP, 29(5)'}, {'given': 'Pp.47–58.', 'family': 'Ng, A.T.M., Darendeliler, M.A., Petocz, P. & Cistulli, P. a, 2012. Cephalometry and prediction of oral appliance treatment outcome. Sleep & breathing = Schlaf & Atmung, 16(1)'}, {'given': 'Pp.47–58.', 'family': 'Ng, A.T.M., Darendeliler, M.A., Petocz, P. & Cistulli, P.A., 2012. Cephalometry and prediction of oral appliance treatment outcome. Sleep & breathing = Schlaf & Atmung, 16(1)'}, {'given': 'Pp.408–19.', 'family': 'Ngiam, J. et al., 2013. Clinical guidelines for oral appliance therapy in the treatment of snoring and obstructive sleep apnoea. Australian dental journal, 58(4)'}, {'given': 'Pp.53–61.', 'family': 'Ohayon, M.M., Li, K.K. & Guilleminault, C., 2001. Risk Factors for Sleep Bruxism in the General Population. CHEST Journal, 119'}, {'given': 'Pp.620–622.', 'family': 'Okawara, Y. et al., 2004. Oral appliance titration and nasal resistance in nonapneic subjects. American Journal of Orthodontics and Dentofacial Orthopedics, 126(5)'}, {'given': 'Pp.513–515.', 'family': 'Oksenberg, A. & Arons, E., 2002. Sleep bruxism related to obstructive sleep apnea : the effect of continuous positive airway pressure. Sleep Medicine, 3'}, {'given': 'Pp.1879–1884.', 'family': 'Ono, T. et al., 2000. Effects of Head and Body Position on Two- and Three-dimensional Configurations of the Upper Airway. Journal of Dental Research, 79(11)'}, {'given': 'Pp.222–229.', 'family': 'Otsuka, R., Almeida, R. De, et al., 2006. A comparison of responders and nonresponders to oral appliance therapy for the treatment of obstructive sleep apnea. Am J Orthod Dentofacial Orthop, 129'}, {'given': 'Pp.222–229.', 'family': 'Otsuka, R., Ribeiro De Almeida, F., et al., 2006. obstructive sleep apnea. Am J Orthod Dentofacial Orthop, 129(2)'}, {'given': 'Pp.113–143.', 'family': 'Özbek, M.M. et al., 1998. Natural head posture , upper airway morphology and obstructive sleep apnoea severity in adults. European journal of orthodontics, 20'}, {'given': 'Pp.792–797.', 'family': 'Pae, E. et al., 2008. Can facial type be used to predict changes in hyoid bone position with age? A perspective based on longitudinal data. American journal of orthodontics and dentofacial orthopedics, 134'}, {'given': 'Pp.52–9.', 'family': 'Pae, E.K. et al., 1994. A cephalometric and electromyographic study of upper airway structures in the upright and supine positions. American journal of orthodontics and dentofacial orthopedics : official publication of the American Association of Orthodon'}, {'given': 'Pp.178–84.', 'family': 'Pae, E.K., Lowe, a a & Fleetham, J. a, 1997. A thin-plate spline analysis of the face and tongue in obstructive sleep apnea patients. Clinical oral investigations, 1(4)'}, {'given': 'Pp.1511–1518.', 'family': 'Pancer, J., 1999. Evaluation of Variable Mandibular Advancement Appliance for Treatment of Snoring and Sleep Apnea*. Chest, 116(6)'}, {'given': 'Pp.237–240.', 'family': 'Pantin, C.C., Hillman, D.R. & Tennant, M., 1999. Dental Side Effects of an Oral Device to Treat Snoring and Obstructive Sleep Apnea. SLEEP, 22(2)'}, {'given': 'Pp.R1671–R1683.', 'family': 'Parati, G., Lombardi, C. & Narkiewicz, K., 2007. Sleep apnea : epidemiology , pathophysiology , and relation to cardiovascular risk. Am J Physiol Regul Integr Comp Physiol'}, {'given': 'Pp.549–555.', 'family': 'Park, J.G., Ramar, K. & Olson, E.J., 2011. Updates on Definition , Consequences , and Management of Obstructive Sleep Apnea. Mayo Clinic Proceedings, 86(6)'}, {'given': 'Pp.156–159.', 'family': 'Partinen, M., 1995. Ischaemic stroke, snoring and obstructive sleep apnea. J Sleep Res, 4(1)'}, {'given': 'P.1200.', 'family': 'Partinen, M., 1988. Long-term outcome for obstructive sleep apnea syndrome patients. Mortality. CHEST Journal, 94(6)'}, {'given': 'Pp.375–381.', 'family': 'Pépin, J.L. et al., 1995. Side Effects of Nasal Continuous Positive Airway Pressure in Sleep Apnea Syndrome : Study of 193 Patients in Two French Sleep Centers. CHEST Journal, 107'}, {'given': 'Pp.3015–21.', 'family': 'Peppard, P.E., Young, T., Palta, M., Dempsey, J., et al., 2000. Longitudinal study of moderate weight change and sleep-disordered breathing. JAMA : the journal of the American Medical Association, 284(23)'}, {'given': 'Pp.1378–1384.', 'family': 'Peppard, P.E., Young, T., Palta, M. & Skatrud, J., 2000. Prospective Study of the Association between Sleep-Disordered Breathing and Hypertension. The New England Journal of Medicine, 342(19)'}, {'given': 'Pp.1–10.', 'family': 'Perez, C. V et al., 2012. The incidence and prevalence of temporomandibular disorders and posterior open bite in patients receiving mandibular advancement device therapy for obstructive sleep apnea. Sleep Breath'}, {'given': 'Pp.1150–1153.', 'family': 'Pételle, B. et al., 2002. One-Night Mandibular Advancement Titration for Obstructive Sleep Apnea Syndrome A Pilot Study. Am J Respir Crit Care Med, 165'}, {'given': '2013. Health Outcomes of CPAP versus Oral Appliance Treatment for Obstructive Sleep Apnea: A Randomised Controlled Trial (For Review Only). American journal of respiratory and critical care medicine.', 'family': 'Phillips, C.L. et al.'}, {'given': 'Pp.761–6.', 'family': 'Pirelli, P., Saponara, M. & Guilleminault, C., 2004. Rapid maxillary expansion in children with obstructive sleep apnea syndrome. Sleep, 27(4)'}, {'given': 'Pp.860–4.', 'family': 'Pitsis, A.J. et al., 2002. Effect of vertical dimension on efficacy of oral appliance therapy in obstructive sleep apnea. American journal of respiratory and critical care medicine, 166(6)'}, {'given': 'Pp.362–369.', 'family': 'Powell, N., Riley, R. & Guilleminault, C., 1988. Obstructive Sleep Apnea, Continuous Positive Airway Pressure, and Surgery. Otolaryngol Head Neck Surg, 99'}, {'given': 'Pp.410–419.', 'family': 'Pracharktam, N. et al., 1996. Cephalometric assessment in obstructive sleep apnea. Am J Orthod Dentofac Orthop, 109'}, {'given': 'Pp.3–15.', 'family': 'Preston, C.B., Lampasso, J.D. & Tobias, P. V, 2004. Cephalometric evaluation and measurement of the upper airway. Seminars in Orthodontics, 10(1)'}, {'given': 'Pp.175–186.', 'family': 'Proffit, W., 1978. Equilibrium Theory Revisited: Factors Influecing Position of Teeth. The Angle Orthodontist, 48(3)'}, {'given': 'Pp.1–5.', 'family': 'Puhan, M.A. et al., 2005. Didgeridoo playing as alternative treatment for obstructive sleep apnoea syndrome: randomised controlled trial. BMJ, (Dec)'}, {'given': 'P.e1000132.', 'family': 'Punjabi, N.M. et al., 2009. Sleep-disordered breathing and mortality: a prospective cohort study. PLoS medicine, 6(8)'}, {'given': 'Pp.244–246.', 'family': 'Rahbar, R., 2004. Adenotonsillar Hypertrophy : The Presentation and Management of Upper Airway Obstruction. Seminars in Orthodontics, 10'}, {'given': 'Pp.569–575.', 'family': 'Randerath, W.J. et al., 2002. An Individually Adjustable Oral Appliance vs Continuous Positive Airway Pressure in Mild-to-Moderate Obstructive Sleep Apnea Syndrome. CHEST Journal, 122'}, {'given': 'Pp.1–7.', 'family': 'Raphaelson, M. et al., 1998. Oral Appliance Therapy for Obstructive Sleep Apnea Syndrome: Progressive Mandibular Advancement During Polysomnography. Journal of Craniomandibular Practice, 16(1)'}, {'given': 'Pp.39–49.', 'family': 'Ravesloot, M.J.L. et al., 2013. The undervalued potential of positional therapy in position-dependent snoring and obstructive sleep apnea-a review of the literature. Sleep & breathing = Schlaf & Atmung, 17(1)'}, {'given': 'Pp.105–110.', 'family': 'Ravesloot, M.J.L. & Vries, N. De, 2011. Reliable Calculation of the Efficacy of Non-Surgical and Surgical Treatment of Obstructive Sleep Apnea Revisited. Sleep, 34(1)'}, {'given': 'Pp.186–92.', 'family': 'Redline, S. et al., 1997. Racial differences in sleep-disordered breathing in African-Americans and Caucasians. American journal of respiratory and critical care medicine, 155(1)'}, {'given': 'Pp.583–602.', 'family': 'Redline, S. & Tishler, P. V., 2000. The genetics of sleep apnea. Sleep medicine reviews, 4(6)'}, {'given': 'Pp.505–511.', 'family': 'Ribeiro De Almeida, F. et al., 2002. Effects of Mandibular Posture on Obstructive Sleep Apnea Severity and the Temporomandibular Joint in Patients Fitted with an Oral Appliance. , 25(5)'}, {'given': 'Pp.303–11.', 'family': 'Riley, R. et al., 1983. Cephalometric analyses and flow-volume loops in obstructive sleep apnea patients. Sleep, 6(4)'}, {'given': 'Pp.415–421.', 'family': 'Riley, R. et al., 2000. Surgery and Obstructive Sleep Apnea: Long-term clinical outcomes. Otolaryngol Head Neck Surg, 122'}, {'given': 'Pp.117–125.', 'family': 'Riley, R., Powell, N. & Guilleminault, C., 1993. Obstructive Sleep Apnea Syndrome: A review of 306 consecutively treated surgical patients. Otolaryngol Head Neck Surg, 108'}, {'given': 'Pp.742–747.', 'family': 'Riley, R.W., Powell, N.B. & Guilleminault, C., 1993. Obstructive Sleep Apnea Syndrome : A Surgical Protocol for Dynamic Airway Reconstruction. Journal of Oral and Maxillofacial Surgery, 51'}, {'given': 'Pp.53–60.', 'family': 'Ringqvist, M. et al., 2003. Dental and skeletal changes after 4 years of obstructive sleep apnea treatment with a mandibular advancement device: A prospective, randomized study. Am J Orthod Dentofac Orthop, 124'}, {'given': 'Pp.371–376.', 'family': 'Robertson, C., Herbison, P. & Harkness, M., 2003. Dental and occlusal changes during mandibular advancement splint therapy in sleep disordered patients. European journal of orthodontics, 25'}, {'given': 'Pp.34–45.', 'family': 'Rondeau, B., 2010. The Dentist’s Involvement in Snoring and Sleep Apnea. Chairside'}, {'given': 'Pp.1–14.', 'family': 'Ross, S.D. et al., 2000. Systematic Review and Meta-analysis of the Literature Regarding the Diagnosis of Sleep Apnea. SLEEP, 23(4)'}, {'given': 'Pp.271–273.', 'family': 'Ruoff, C.M. & Guilleminault, C., 2012. Orthodontics and sleep-disordered breathing. Sleep Breath, 16'}, {'given': 'Pp.972–977.', 'family': 'Ryan, C.F. et al., 1999. Mandibular advancement oral appliance therapy for obstructive sleep apnoea : effect on awake calibre of the velopharynx. Thorax, 54'}, {'given': 'Pp.824–30.', 'family': 'Ryan, S., Taylor, C.T. & McNicholas, W.T., 2006. Predictors of elevated nuclear factor-kappaB-dependent genes in obstructive sleep apnea syndrome. American journal of respiratory and critical care medicine, 174(7)'}, {'given': 'Pp.485–489.', 'family': 'Sadaoka, T. et al., 1996. The value of sleep nasendoscopy in the evaluation of patiets with suspected sleep-related breathing disorders. Clin. Otolaryngol, 21'}, {'given': 'Pp.885–90.', 'family': 'Saigusa, H. et al., 2009. Three-dimensional morphological analyses of positional dependence in patients with obstructive sleep apnea syndrome. Anesthesiology, 110(4)'}, {'given': 'Pp.54–62.', 'family': 'Salem, O.H., Briss, B.S. & Annino, D.J., 2004a. Nasorespiratory Function and Craniofacial Morphology — A Review of the Surgical Management of the Upper Airway. Seminars in Orthodontics, 10'}, {'given': 'Pp.54–62.', 'family': 'Salem, O.H., Briss, B.S. & Annino, D.J., 2004b. Nasorespiratory function and craniofacial morphology—a review of the surgical management of the upper airway. Seminars in Orthodontics, 10(1)'}, {'given': 'Pp.143–150.', 'family': 'Sanner, B.M. et al., 2002. MRI of the pharynx and treatment efficacy of a mandibular advancement device in obstructive sleep apnoea syndrome. European Respiratory Journal, 20(1)'}, {'given': 'Pp.629–636.', 'family': 'Santos-Silva, R. et al., 2009. Validation of a Portable Monitoring System for the Diagnosis of Obstructive Sleep Apnea Syndrome. SLEEP, 32(5)'}, {'given': 'Pp.829–39.', 'family': 'Schäfer, H. et al., 2002. Body fat distribution, serum leptin, and cardiovascular risk factors in men with obstructive sleep apnea. Chest, 122(3)'}, {'given': 'Pp.501–510.', 'family': 'Schmidt-Nowara, W. et al., 1995. An American Sleep Disorders Association Review Oral Appliances for the Treatment of Snoring and Obstructive Sleep Apnea : A Review. SLEEP, 18(6)'}, {'given': 'Pp.1673–1689.', 'family': 'Schwab, R.J. et al., 1995. Upper Airway and Soft Tissue Anatomy in Normal Subjects and Patients with Sleep-Disordered Breathing Significance of the lateral Pharyngeal Walls. Am J Physiol Regul Integr Comp Physiol, 152'}, {'given': 'Pp.125–6.', 'family': 'Schwarting, S. et al., 2007. Position paper on the use of mandibular advancement devices in adults with sleep-related breathing disorders. A position paper of the German Society of Dental Sleep Medicine (Deutsche Gesellschaft Zahnaerztliche Schlafmedizin,'}, {'given': 'Pp.185–92.', 'family': 'Schwartz, A.R. et al., 2008. Obesity and obstructive sleep apnea: pathogenic mechanisms and therapeutic approaches. Proceedings of the American Thoracic Society, 5(2)'}, {'given': 'Pp.49–56.', 'family': 'Sengul, Y.S., Ozalevli, S. & Oztura, I., 2011. The effect of exercise on obstructive sleep apnea : a randomized and controlled trial. Sleep Breath, 15'}, {'given': 'Pp.703–714.', 'family': 'Seto, B.H. et al., 2001. Maxillary morphology in obstructive sleep apnoea syndrome. European journal of orthodontics, 23'}, {'given': 'Pp.19–25.', 'family': 'Shahar, E. et al., 2001. Sleep-disordered Breathing and Cardiovascular Disease Cross-sectional Results of the Sleep Heart Health Study. Am J Respir Crit Care Med, 163'}, {'given': 'Pp.1209–1217.', 'family': 'Shen, H.-L. et al., 2012. Craniofacial morphologic predictors of oral appliance outcomes in patients with obstructive sleep apnea. Journal of American Dental Association, 143(11)'}, {'given': 'Pp.156–177.', 'family': 'Sher, A.E., Schechtman, B. & Piccirillo, J.R., 1996. The Efficacy of Surgical Modifications of the Upper Airway in Adults With Obstructive Sleep Apnea Syndrome. SLEEP, 19(2)'}, {'given': 'Pp.347–52.', 'family': 'Shigeta, Y. et al., 2008. Correlation between retroglossal airway size and body mass index in OSA and non-OSA patients using cone beam CT imaging. Sleep & breathing = Schlaf & Atmung, 12(4)'}, {'given': '(1).', 'family': 'Shneerson, J. & Wright, J., 2001. Lifestyle modification for obstructive sleep apnoea (Review). Cochrane Database of Systematic Reviews'}, {'given': '2012. Does physical exercise reduce excessive daytime sleepiness by improving inflammatory profiles in obstructive sleep apnea patients ? Sleep Breath.', 'family': 'Da Silva Alves, E. et al.'}, {'given': 'Pp.105–131.', 'family': 'Sittitavornwong, S. et al., 2009. Evaluation of Obstructive Sleep Apnea Syndrome by Computational Fluid Dynamics. Seminars in Orthodontics, 15(2)'}, {'given': '(2).', 'family': 'Smith, I., Lasserson, T. & Wright, J., 2006. Drug therapy for obstructive sleep apnoea in adults ( Review ). Cochrane Database of Systematic Reviews'}, {'given': 'Pp.618–626.', 'family': 'Smith, T. et al., 2012. Three-dimensional computed tomography analysis of airway volume changes after rapid maxillary expansion. American Journal of Orthodontics and Dentofacial Orthopedics, 141'}, {'given': 'Customer brochure.', 'family': 'Somnomed'}, {'given': 'Pp.1–14.', 'family': 'Somnomed, Key research findings.'}, {'given': 'Pp.1–2.', 'family': 'Somnomed, Offer your OSA patients an alternative to CPAP therapy.'}, {'given': 'Pp.118–125.', 'family': 'Sonnesen, L., 2012. Cervical Vertebral Column Morphology Associated with Head Posture and Craniofacial Morphology. Seminars in Orthodontics, 18(2)'}, {'given': 'Pp.836–842.', 'family': 'Srinivasan, V.K. et al., 2010. Nasopharyngoscopic evaluation of oral appliance therapy for obstructive sleep apnoea. , 35(4)'}, {'given': 'Pp.85–90.', 'family': 'Stradling, R. & Crosby, J.H., 1991. Predictors and prevalence of obstructive sleep apnoea and snoring in 1001 middle aged men. Thorax, 46'}, {'given': 'Pp.555–558.', 'family': 'Strohl, K.P. & Redline, S., 1986. Nasal CPAP Therapy, Upper Airway Muscle Activation, and Obstructive Sleep Apnea. Am Rev Respir Dis, 134'}, {'given': 'Pp.862–865.', 'family': 'Sullivan, C. et al., 1981. Reversal of Obstructive Sleep Apnea By Continuous Positive Airway Pressure Applied Through the Nares. The Lancet'}, {'given': 'Pp.194–198.', 'family': 'Sullivan, R.A.O. et al., 1995. Mandibular Advancement Splint : An Appliance to Treat Snoring and Obstrudive Sleep Apnea. Am J Respir Crit Care Med, 151'}, {'given': '(4).', 'family': 'Sundaram, S., Lim, J. & Tj, L., 2005. Surgery for obstructive sleep apnoea in adults ( Review ). Cochrane Database of Systematic Reviews'}, {'given': 'Pp.469–477.', 'family': 'Sutherland, K. et al., 2011. Comparative Effects of Two Oral Appliances on Upper Airway Structure in Obstructive Sleep Apnea. SLEEP, 34(4)'}, {'given': 'P.w13276.', 'family': 'Sutherland, K. & Cistulli, P., 2011. Mandibular advancement splints for the treatment of sleep apnea syndrome. Swiss medical weekly, 141(September)'}, {'given': 'Pp.1–10.', 'family': 'Sutherland, K. & Cistulli, P.A., 2011. Mandibular advancement splints for the treatment of sleep apnoea syndrome. Swiss Medical Weekly, 114(September)'}, {'given': 'Pp.213–22.', 'family': 'Sutherland, K., Lee, R.W.W. & Cistulli, P. a, 2012. Obesity and craniofacial structure as risk factors for obstructive sleep apnoea: impact of ethnicity. Respirology (Carlton, Vic.), 17(2)'}, {'given': 'Pp.213–222.', 'family': 'SUTHERLAND, K., LEE, R.W.W. & CISTULLI, P.A., 2012. Obesity and craniofacial structure as risk factors for obstructive sleep apnoea: Impact of ethnicityresp_2082. Respirology, 17'}, {'given': 'Pp.239–249.', 'family': 'Tan, Y.K. et al., 2002. Mandibular advancement splints and continuous positive airway pressure in patients with obstructive sleep apnoea : a randomized cross-over trial. European journal of orthodontics, 24'}, {'given': 'Pp.23–35.', 'family': 'Tangugsorn, V. et al., 2001. Obstructive Sleep Apnea : A Canonical Correlation of Cephalometric and Selected Demographic Variables in Obese and Nonobese Patients. Angle Orthodontist, 71(1)'}, {'given': 'Pp.1103–1108.', 'family': 'Thornton, W.K. & Roberts, D.H., 1996. Nonsurgical Obstructive Management Sleep Apnea of the Patient. J Oral Maxillofac Surg, 54'}, {'given': 'Pp.121–126.', 'family': 'Tomfohr, L.M. et al., 2011. Effects of Continuous Positive Airway Pressure on Fatigue and Sleepiness in Patients with Obstructive Sleep Apnea : Data from a Randomized Controlled Trial. SLEEP, 34(1)'}, {'given': 'Pp.573–581.', 'family': 'Tregear, S. et al., 2009. Obstructive Sleep Apnea and Risk of Motor Vehicle Crash: Systematic Review and Meta-Analysis. Journal of Clinical Sleep Medicine, 5(6)'}, {'given': 'Pp.366–370.', 'family': 'Tsai, W.H. et al., 2004. Remotely Controlled Mandibular Positioner Predicts Efficacy of Oral Appliances in Sleep Apnea. Am J Respir Crit Care Med, 170'}, {'given': 'Pp.1009–1015.', 'family': 'Tsuiki, S., Isono, S., Ishikawa, T. & Yamashiro, Y., 2008. Anatomical Balance of the Upper Airway and Obstructive Sleep Apnea. Anesthesiology, 108'}, {'given': 'Pp.1009–15.', 'family': 'Tsuiki, S., Isono, S., Ishikawa, T., Yamashiro, Y., et al., 2008. Anatomical balance of the upper airway and obstructive sleep apnea. Anesthesiology, 108(6)'}, {'given': 'Pp.554–560.', 'family': 'Tsuiki, S. et al., 2001. Effects of a Titratable Oral Appliance on Supine Airway Size in Awake Non-Apneic Individuals. Am J Respir Crit Care Med, 24(5)'}, {'given': 'Pp.263–268.', 'family': 'Tsuiki, S. et al., 2004. Effects of mandibular advancement on airway curvature and obstructive sleep apnoea severity. European Respiratory Journal, 23(2)'}, {'given': 'Pp.1098–1105.', 'family': 'Tsuiki, S. et al., 2010. Optimal positive airway pressure predicts oral appliance response to sleep apnoea. European Respiratory Journal, 35(5)'}, {'given': 'Pp.43–50.', 'family': 'Tsuiki, S. et al., 2003. Supine-Dependent Changes in Upper Airway Size in Awake Obstructive Sleep Apnea Patients. Sleep & breathing, 7(1)'}, {'given': 'Pp.504–12.', 'family': 'Tsuiki, S. et al., 2005. The interaction between changes in upright mandibular position and supine airway size in patients with obstructive sleep apnea. American journal of orthodontics and dentofacial orthopedics : official publication of the American As'}, {'given': '2011. Tongue position controller as an alternative treatment for obstructive sleep apnea. Sleep Breath.', 'family': 'Tsuiki, S. et al.'}, {'given': 'Pp.168–73.', 'family': 'Udwadia, Z.F. et al., 2004. Prevalence of sleep-disordered breathing and sleep apnea in middle-aged urban Indian men. American journal of respiratory and critical care medicine, 169(2)'}, {'given': 'Pp.197–202.', 'family': 'Vanderveken, O.M. et al., 2008. Comparison of a custom-made and a thermoplastic oral appliance for the treatment of mild sleep apnea. American journal of respiratory and critical care medicine, 178(2)'}, {'given': 'Pp.1036–1044.', 'family': 'Veasey, S.C. et al., 2006. Medical Therapy for Obstructive Sleep Apnea : A Review by the Medical Therapy for Obstructive Sleep Apnea Task Force of the Standards of Practice Committee of the American Academy of Sleep Medicine. Sleep, 29(8)'}, {'given': 'Pp.603–611.', 'family': 'Vig, K.W.L., 1998. Nasal obstruction and facial growth: The strength of evidence for clinical assumptions. American journal of orthodontics and dentofacial orthopedics, 113'}, {'given': 'Pp.128–34.', 'family': 'Villa, M.P. et al., 2007. Rapid maxillary expansion in children with obstructive sleep apnea syndrome: 12-month follow-up. Sleep medicine, 8(2)'}, {'given': 'Pp.129–150.', 'family': 'Viviano, J.S., 2002. Acoustic Reflection : Review and Clinical Applications for Sleep- Disordered Breathing. Sleep & breathing, 6(3)'}, {'given': 'Pp.739–746.', 'family': 'Walker-Engström, M.-L. et al., 2002. 4-Year Follow-up of Treatment With Dental Appliance or Uvulopalatopharyngoplasty in Patients With Obstructive Sleep Apnea *. CHEST Journal, 121'}, {'given': 'Pp.119–130.', 'family': 'Walker-Engström, M.-L. et al., 2003. A Prospective Randomized Study Comparing Two Different Degrees of Mandibular Advancement with a Dental Appliance in Treatment of Severe Obstructive Sleep Apnea. Sleep & breathing, 7(3)'}, {'given': 'Pp.73–89.', 'family': 'Warunek, S.P., 2004. Oral appliance therapy in sleep apnea syndromes: a review. Seminars in Orthodontics, 10(1)'}, {'given': 'Pp.2219–2224.', 'family': 'Wetter, D.W. et al., 1994. Smoking as a Risk Factor for Sleep-Disordered Breathing. Arch Intern Med, 154(9)'}, {'given': 'Pp.1363–1370.', 'family': 'White, D.P., 2005. Pathogenesis of Obstructive and Central Sleep Apnea. Am J Respir Crit Care Med, 172'}, {'given': 'Pp.797–804.', 'family': 'White, D.P., 1995. Pathophysiology of obstructive sleep apnea. Thorax, 50'}, {'given': 'Pp.323–328.', 'family': 'Whittle, A.T. et al., 1999. Neck soft tissue and fat distribution : comparison between normal men and women by magnetic resonance imaging. Thorax, 54'}, {'given': '2000. Obesity: Preventing and Managing the Global Epidemic', 'family': 'WHO'}, {'given': 'Pp.304–16.', 'family': 'Wolford, L.M., Chemello, P.D. & Hilliard, F., 1994. Occlusal plane alteration in orthognathic surgery--Part I: Effects on function and esthetics. American journal of orthodontics and dentofacial orthopedics : official publication of the American Associati'}, {'given': 'Pp.193–199.', 'family': 'Won, C.H.J., Li, K.K. & Guilleminault, C., 2008. Surgical Treatment of Obstructive Sleep Apnea Upper Airway and Maxillomandibular Surgery. Proc Am Thorac Soc, 5'}, {'given': 'Pp.845–847.', 'family': 'Yildiri, N. et al., 1991. The Effect of Posture on Upper Airway Dimensions in Normal Subjects and in Patients with the Sleep Apnea/Hypopnea Syndrome. Am Rev Respir Dis, 144'}, {'given': 'Pp.1230–1235.', 'family': 'Young, T. et al., 1993. The Occurrence of Sleep-Disordered Breathing Among Middle-Aged Adults. The New England Journal of Medicine, 328'}, {'given': 'Pp.1217–1239.', 'family': 'Young, T., Peppard, P.E. & Gottlieb, D.J., 2002. Epidemiology of Obstructive Sleep Apnea. American Journal of Respiratory and Critical Care Medicine, 165(9)'}, {'given': 'Pp.2013–2016.', 'family': 'Young, T., Skatrud, J. & Peppard, P.E., 2004. Risk Factors for Obstructive Sleep Apnea. JAMA, 291(16)'}, {'given': 'Pp.88–93.', 'family': 'Yow, M., 2009. An Overview of Oral Appliances and Managing the Airway in Obstructive Sleep Apnea. Seminars in Orthodontics, 15(2)'}, {'given': 'Pp.226–36.', 'family': 'Yumino, D. & Bradley, T.D., 2008. Central sleep apnea and Cheyne-Stokes respiration. Proceedings of the American Thoracic Society, 5(2)'}, {'given': 'Pp.543–7.', 'family': 'Zeng, B. et al., 2008. Influence of nasal resistance on oral appliance treatment outcome in obstructive sleep apnea. Sleep, 31(4)'}, {'given': 'pp.726–730.', 'family': 'Zeng, B. et al., 2007. Use of Flow – Volume Curves to Predict Oral Appliance Treatment Outcome in Obstructive Sleep Apnea. American journal of respiratory and critical care medicine, 175'}], 'abstract': 'Mandibular advancement devices (MADs) represent the main non-continuous positive airway pressure (non-CPAP) therapy for patients with obstructive sleep apnoea (OSA). The aim of the European Respiratory Society Task Force was to review the evidence in favour of MAD therapy. Effects of tongue-retaining devices are not included in this report. Custom-made MADs reduce apnoea/hypopnoea index (AHI) and daytime sleepiness compared with placebo devices. CPAP more effectively diminishes AHI, while increasing data suggest fairly similar outcomes in relation to symptoms and cardiovascular health from these treatments. Patients often prefer MADs to CPAP. Milder cases and patients with a proven increase in upper airway size as a result of mandibular advancement are most likely to experience treatment success with MADs. A custom-made device titrated from an initial 50% of maximum mandibular advancement has been recommended. More research is needed to define the patients who will benefit from MAD treatment compared with CPAP, in terms of the effects on sleep-disordered breathing and on other diseases related to OSA. In conclusion, MADs are recommended for patients with mild to moderate OSA (Recommendation Level A) and for those who do not tolerate CPAP. The treatment must be followed up and the device adjusted or exchanged in relation to the outcome.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '22075487', 'scopus': None, 'doi': '10.1183/09031936.00144711'}, 'title': 'Non-CPAP therapies in obstructive sleep apnoea: mandibular advancement device therapy.', 'source': 'Mendeley'}
Langton Hewer S, Hobbs J, French D, Lenney W. Pilgrim's progress: the effect of salmeterol in older children with chronic severe asthma. Respiratory medicine. 1995;89(6):435-40.	-	7644775	primary-study	001668db19b2b70d1fedb3ad88d0eafdcc876770	-	{'publication_type': {'year': 1995, 'cited_medium': None, 'issue': '6', 'issn': '0954-6111', 'volume': '89', 'title': 'Respiratory Medicine', 'pagination': '435-440'}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.8812500000000001, 'authors': 0.925}, 'authors': [{'given': 'S.Langton', 'family': 'Hewer'}, {'given': 'J.', 'family': 'Hobbs'}, {'given': 'D.', 'family': 'French'}, {'given': 'W.', 'family': 'Lenney'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1016/0954-6111(95)90213-9'}, 'title': "Pilgrim's progress: the effect of salmeterol in older children with chronic severe asthma", 'source': 'CrossRef'}
Langton Hewer S, Hobbs J, French D, Lenney W. Pilgrim's progress: the effect of salmeterol in older children with chronic severe asthma. Respiratory medicine. 1995;89(6):435-40.	-	7644775	primary-study	001668db19b2b70d1fedb3ad88d0eafdcc876770	-	{'publication_type': {'year': 1995, 'cited_medium': None, 'issue': None, 'issn': '09546111', 'volume': None, 'title': 'Respiratory Medicine', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.8812500000000001, 'authors': 0.925}, 'authors': [{'given': 'S. Langton', 'family': 'Hewer'}, {'given': 'J.', 'family': 'Hobbs'}, {'given': 'D.', 'family': 'French'}, {'given': 'W.', 'family': 'Lenney'}], 'abstract': 'Twenty-four children aged 12-17 years entered a randomized, double-blind placebo-controlled study investigating the use of salmeterol in chronic severe asthma. In addition to their usual medication, the children were given either placebo or 100 ??g salmeterol b.d. by dry powder inhalation. Treatment was continued throughout one term at a residential school for asthma. Symptom scores, peak expiratory flow rates, spirometry and quality-of-life scores were compared between the two treatment groups. One child withdrew during the run-in period. Twelve pupils received placebo and 11 pupils received salmeterol. There were consistent improvements in favour of salmeterol, reaching statistical significance for morning and evening peak flow rates and spirometry when measured on four occasions during the study period. There were no medication-related adverse events recorded and no pulse rate changes. Salmeterol (100 ??g b.d.) is well tolerated and efficacious in older children with chronic severe asthma. ?? 1995.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '7644775', 'scopus': '2-s2.0-0029011694', 'doi': '10.1016/0954-6111(95)90213-9'}, 'title': "Pilgrim's progress: the effect of salmeterol in older children with chronic severe asthma", 'source': 'Mendeley'}
Gardiner PV, Ward C, Booth H, Allison A, Hendrick DJ, Walters EH. Effect of eight weeks of treatment with salmeterol on bronchoalveolar lavage inflammatory indices in asthmatics. American journal of respiratory and critical care medicine. 1994;150(4):1006-11.	-	7921429	primary-study	486b6dcf33b297cf8f288873785e1068f77ded0b	-	{'publication_type': {'year': 1994, 'cited_medium': None, 'issue': '4', 'issn': '1073-449X', 'volume': '150', 'title': 'American Journal of Respiratory and Critical Care Medicine', 'pagination': '1006-1011'}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.8875000000000001, 'authors': 0.9500000000000001}, 'authors': [{'given': 'P V', 'family': 'Gardiner'}, {'given': 'C', 'family': 'Ward'}, {'given': 'H', 'family': 'Booth'}, {'given': 'A', 'family': 'Allison'}, {'given': 'D J', 'family': 'Hendrick'}, {'given': 'E H', 'family': 'Walters'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '7921429', 'scopus': None, 'doi': '10.1164/ajrccm.150.4.7921429'}, 'title': 'Effect of eight weeks of treatment with salmeterol on bronchoalveolar lavage inflammatory indices in asthmatics.', 'source': 'CrossRef'}
Gardiner PV, Ward C, Booth H, Allison A, Hendrick DJ, Walters EH. Effect of eight weeks of treatment with salmeterol on bronchoalveolar lavage inflammatory indices in asthmatics. American journal of respiratory and critical care medicine. 1994;150(4):1006-11.	-	7921429	primary-study	486b6dcf33b297cf8f288873785e1068f77ded0b	-	{'publication_type': {'year': 1994, 'cited_medium': None, 'issue': None, 'issn': '1073449X', 'volume': None, 'title': 'American Journal of Respiratory and Critical Care Medicine', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.875, 'authors': 0.9}, 'authors': [{'given': 'Phillip V.', 'family': 'Gardiner'}, {'given': 'Christopher', 'family': 'Ward'}, {'given': 'Helen', 'family': 'Booth'}, {'given': 'Anne', 'family': 'Allison'}, {'given': 'David J.', 'family': 'Hendrick'}, {'given': 'E. Haydn', 'family': 'Walters'}], 'abstract': 'Using BAL, we studied the effects of 8 wk of treatment with salmeterol on airway inflammation in nine asth- matic subjects in a double-blind crossover placebo-controlled protocol. The study patients were all receiv- ing regular inhaled corticosteroid therapy (400 to 1,000 IJ.g beclomethasone dipropionate per day) and in- haled albuterol for symptomatic relief, i.e., subjects who might be considered suitable for treatment with salmeterol. The asthmatic group had significant differences in numbers of epithelial cells and eosinophils in BAL compared with a group of 15 normal control subjects (p <0.01). During salmeterol treatment mean morning and evening peak flow rates were increased (p <0.05). There was no significant change in BAL cell profile and no change in percentages of CD4 and CD8 lymphocytes or proportion of lymphocytes ex- pressing HLA-DR after salmeterol. In conclusion, we were unable to demonstrate any significant anti- inflammatory effect of regular salmeterol therapy on airway inflammation using BAL in these asthmatic patients. At the same time, there was equally no evidence of a deterioration in the underlying inflammatory disease process.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '7921429', 'scopus': '2-s2.0-0027945321', 'doi': '10.1164/ajrccm.150.4.7921429'}, 'title': 'Effect of eight weeks of treatment with salmeterol on bronchoalveolar lavage inflammatory indices in asthmatics', 'source': 'Mendeley'}
Carmeli E, Kessel S, Coleman R, Ayalon M. Effects of a treadmill walking program on muscle strength and balance in elderly people with Down syndrome. The journals of gerontology. Series A, Biological sciences and medical sciences. 2002;57(2):M106-10.	-	11818429	primary-study	35aea84d5f886c19add7ea83666cd3cde9e472e3	-	{'publication_type': {'year': 2002, 'cited_medium': None, 'issue': '2', 'issn': '1079-5006', 'volume': '57', 'title': 'The Journals of Gerontology Series A: Biological Sciences and Medical Sciences', 'pagination': 'M106-M110'}, 'language': None, 'rating': {'year': 0, 'title': 1.0, 'total': 0.83125, 'authors': 0.725}, 'authors': [{'given': 'E.', 'family': 'Carmeli'}, {'given': 'S.', 'family': 'Kessel'}, {'given': 'R.', 'family': 'Coleman'}, {'given': 'M.', 'family': 'Ayalon'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1093/gerona/57.2.m106'}, 'title': 'Effects of a Treadmill Walking Program on Muscle Strength and Balance in Elderly People With Down Syndrome', 'source': 'CrossRef'}
Carmeli E, Kessel S, Coleman R, Ayalon M. Effects of a treadmill walking program on muscle strength and balance in elderly people with Down syndrome. The journals of gerontology. Series A, Biological sciences and medical sciences. 2002;57(2):M106-10.	-	11818429	primary-study	35aea84d5f886c19add7ea83666cd3cde9e472e3	-	{'publication_type': {'year': 2002, 'cited_medium': None, 'issue': None, 'issn': '1079-5006', 'volume': None, 'title': 'The Journals of Gerontology Series A: Biological Sciences and Medical Sciences', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 1.0, 'total': 0.83125, 'authors': 0.725}, 'authors': [{'given': 'E.', 'family': 'Carmeli'}, {'given': 'S.', 'family': 'Kessel'}, {'given': 'R.', 'family': 'Coleman'}, {'given': 'M.', 'family': 'Ayalon'}], 'abstract': 'Background. Longer life expectancy is resulting in increasing numbers of elderly adults with mental retardation. In elderly adults with Down syndrome (DS), the maintenance of muscle strength, endurance, and dynamic balance are important to ensure quality of life and functional independence. The objective of this study was to compare isokinetic leg strength and dynamic balance of aged mentally retarded individuals with DS (n = 16, mean age 63) before and after a treadmill walking program lasting 6 months in comparison with a nonwalking control group (n = 10) with similar physical characteristics.  Methods. Participants in the study undertook leg strength testing on a dynamometer. Parameters measured included peak torque, peak torque % body weight, and average power % body weight. A "timed get-up and go" functional test for dynamic balance was also analyzed and compared prior to and after the treadmill program.  Results. Knee extension and flexion isokinetic strength in elderly individuals with DS showed significant improvement after 6 months of treadmill training. Dynamic balance performance was also significantly improved (p < .05).  Conclusions. Aged adults with DS can significantly improve muscle strength and balance by adopting suitable programs of treadmill walking.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1093/gerona/57.2.M106'}, 'title': 'Effects of a Treadmill Walking Program on Muscle Strength and Balance in Elderly People With Down Syndrome', 'source': 'Mendeley'}
Varela AM, Sardinha LB, Pitetti KH. Effects of an aerobic rowing training regimen in young adults with Down syndrome. American journal of mental retardation : AJMR. 2001;106(2):135-44.	10.1352/0895-8017(2001)106<0135:EOAART>2.0.CO;2	11321604	primary-study	894e328fd8dad29a1140b23f039f9db63c51f9de	-	{'publication_type': {'year': 2001, 'cited_medium': None, 'issue': '2', 'issn': '0895-8017', 'volume': '106', 'title': 'American Journal on Mental Retardation', 'pagination': '135'}, 'language': None, 'rating': {'year': 0, 'title': 1.0, 'total': 0.8, 'authors': 0.6}, 'authors': [{'given': 'Ana Maria', 'family': 'Varela'}, {'given': 'Luis', 'family': 'Bettencount Sardinha'}, {'given': 'Kenneth H.', 'family': 'Pitetti'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1352/0895-8017(2001)106<0135:eoaart>2.0.co;2'}, 'title': 'Effects of an Aerobic Rowing Training Regimen in Young Adults With Down Syndrome', 'source': 'CrossRef'}
Varela AM, Sardinha LB, Pitetti KH. Effects of an aerobic rowing training regimen in young adults with Down syndrome. American journal of mental retardation : AJMR. 2001;106(2):135-44.	10.1352/0895-8017(2001)106<0135:EOAART>2.0.CO;2	11321604	primary-study	894e328fd8dad29a1140b23f039f9db63c51f9de	-	{'publication_type': {'year': 1999, 'cited_medium': None, 'issue': None, 'issn': None, 'volume': None, 'title': 'Alimentary pharmacology & therapeutics, 1999 Feb, 13(2):135-44', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.15384615384615385, 'total': 0.225, 'authors': 0.5}, 'authors': [{'given': 'A', 'family': 'Perner'}, {'given': 'J', 'family': 'Rask-Madsen'}], 'abstract': "The aetiology of the chronic inflammatory bowel diseases-ulcerative colitis and Crohn's disease-as well as 'microscopic colitis'-both collagenous (COC) and lymphocytic colitis (LC)-remains unknown. Autoimmune mechanisms, cytokine polymorphism, commensal bacteria, infectious agents and vascular impairment have all been proposed as playing important roles in the pathogenesis of this spectrum of diseases. A variety of proinflammatory mediators, including tumour necrosis factor alpha, interleukin-1beta, interferon gamma, leukotriene B4 and platelet activating factor, promote the adherence of phagocytes to the venular endothelium and extravasation of these cells into the colonic mucosa. In addition to large amounts of nitric oxide (NO), injurious peroxynitrite may be formed in the epithelium by the inducible nitric oxide synthase (iNOS), which is considered to elicit cytotoxicity by the generation of superoxide with reduced L-arginine availability. In active ulcerative colitis, and to a lesser extent in Crohn's disease, a greatly increased production of NO has been demonstrated by indirect and direct measurements. Surprisingly, even higher rates of production have been observed in COC-a condition which is never associated with injurious inflammation. The latter observation favours the notion that NO promotes mucosal integrity. Further evidence for a protective role of NO in chronic inflammatory bowel disorders is provided by the observation of increased susceptibility to the induction of experi mental colitis in 'knock-out' mice deficient in iNOS. Selective inhibitors of iNOS activity, as well as topical L-arginine, may therefore prove beneficial in inflammatory bowel disease by reducing the production of superoxide by iNOS, while only the former option may be expected to reduce diarrhoea in chronic inflammatory bowel disorders. Clearly, further experimental work needs to be done before testing topical L-arginine in human inflammatory bowel disease.", 'type': 'journal', 'ids': {'embase': None, 'pubmed': '10102942', 'scopus': None, 'doi': None}, 'title': 'Review article: the potential role of nitric oxide in chronic inflammatory bowel disorders', 'source': 'Mendeley'}
Monteiro CP, Varela A, Pinto M, Neves J, Felisberto GM, Vaz C, Bicho MP, Laires MJ. Effect of an aerobic training on magnesium, trace elements and antioxidant systems in a Down syndrome population. Magnesium research : official organ of the International Society for the Development of Research on Magnesium. 1997;10(1):65-71.	-	9339840	primary-study	12611ad69ddf683bcdbebc9893289d6194b90d81	-	{'publication_type': {'year': 1994, 'cited_medium': None, 'issue': 's1', 'issn': '0143-5221', 'volume': '87', 'title': 'Clin. Sci.', 'pagination': '78-79'}, 'language': None, 'rating': {'year': 0, 'title': 0.3793103448275862, 'total': 0.4397335423197492, 'authors': 0.7727272727272727}, 'authors': [{'given': 'MJ', 'family': 'Laires'}, {'given': 'CP', 'family': 'Monteiro'}, {'given': 'A', 'family': 'Varela'}, {'given': 'J', 'family': 'Sérgio'}, {'given': 'GM', 'family': 'Felisberto'}, {'given': 'I', 'family': 'Neto'}, {'given': 'L', 'family': 'Breitenfeld'}, {'given': 'E', 'family': 'Rola'}, {'given': 'C', 'family': 'Vaz'}, {'given': 'M', 'family': 'Bicho'}, {'given': 'C', 'family': 'Manso'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1042/cs087s078'}, 'title': 'A Preliminary Study of the Relationship between Plasma and Erythrocyte Magnesium, Copper, Zinc and Selenium Variations and some Circulating Pro- and Anti- Oxidant Parameters in a Standardized Physical Effort', 'source': 'CrossRef'}
Monteiro CP, Varela A, Pinto M, Neves J, Felisberto GM, Vaz C, Bicho MP, Laires MJ. Effect of an aerobic training on magnesium, trace elements and antioxidant systems in a Down syndrome population. Magnesium research : official organ of the International Society for the Development of Research on Magnesium. 1997;10(1):65-71.	-	9339840	primary-study	12611ad69ddf683bcdbebc9893289d6194b90d81	-	{'publication_type': {'year': 1987, 'cited_medium': None, 'issue': None, 'issn': None, 'volume': None, 'title': "Corrections in the People's Republic of China (From International Corrections - An Overview, P 65-71, 1987 - See NCJ-106200)", 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.42105263157894735, 'total': 0.3986842105263158, 'authors': 0.5}, 'authors': [{'given': 'E', 'family': 'Miller'}], 'abstract': 'There are jails for pretrial prisoners and for sentenced offenders. Sentences may include (1) supervision in the community by a committee or (2) incarceration. Inmates are eligible for parole after having served half their sentences, showing repentence, and performing meritoriously. The Beijing Municipal Prison houses up to 2,300 inmates and has a staff of 300. Inmates are classified on the basis of education, physical condition, and technical skills. This classification is the basis for housing and job assignments, and all inmates are expected to work. Discipline is maintained through a system of rewards and punishments. Inmates are allowed supervised visits. Political study is considered a primary rehabilitative tool, and staff have one-to-one talks and group discussions with inmates. The Beijing Labor Reformatory for juvenile delinquents has a highly regimented program of study and work. Work-study schools provide programs for juveniles who have committed offenses not punishable under criminal law.', 'type': 'generic', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': None}, 'title': "Corrections in the People's Republic of China (From International Corrections - An Overview, P 65-71, 1987 - See NCJ-106200)", 'source': 'Mendeley'}
Millar AL, Fernhall B, Burkett LN. Effects of aerobic training in adolescents with Down syndrome. Medicine and science in sports and exercise. 1993;25(2):270-4.	-	8450732	primary-study	7fd4973a4730a9416a31018621539f9617fc10ef	-	{'publication_type': {'year': 1993, 'cited_medium': None, 'issue': '2', 'issn': '0195-9131', 'volume': '25', 'title': 'Medicine & Science in Sports & Exercise', 'pagination': '270???274'}, 'language': None, 'rating': {'year': 0, 'title': 1, 'total': 0.875, 'authors': 0.9}, 'authors': [{'given': 'A. LYNN', 'family': 'MILLAR'}, {'given': 'B O', 'family': 'FERNHALL'}, {'given': 'LEEE N.', 'family': 'BURKETT'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': None, 'scopus': None, 'doi': '10.1249/00005768-199302000-00018'}, 'title': 'Effects of aerobic training in adolescents with Down syndrome', 'source': 'CrossRef'}
Millar AL, Fernhall B, Burkett LN. Effects of aerobic training in adolescents with Down syndrome. Medicine and science in sports and exercise. 1993;25(2):270-4.	-	8450732	primary-study	7fd4973a4730a9416a31018621539f9617fc10ef	-	{'publication_type': {'year': 1990, 'cited_medium': None, 'issue': None, 'issn': None, 'volume': None, 'title': 'Surface Science. April 1990; 228(1 3): 270 4', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.16666666666666666, 'total': 0.10833333333333334, 'authors': 0.0}, 'authors': [{'given': 'R J', 'family': 'Warburton'}, {'given': 'G M', 'family': 'Sundaram'}, {'given': 'R J', 'family': 'Nicholas'}, {'given': 'S K', 'family': 'Haywood'}, {'given': 'G J', 'family': 'Rees'}, {'given': 'N J', 'family': 'Mason'}, {'given': 'P J', 'family': 'Walker'}], 'abstract': 'The authors report measurements of the dispersion relation for holes in the M/sub J/=3/2 strain split valence band in Ga/sub 1-x/In/sub x/Sb/GaSb quantum wells. The strain decoupling of the M/sub J/=3/2 and M/sub J/=1/2 levels gives the M/sub J/=3/2 sub-band a very light mass (as low as ~0.07 m/sub 0/) for in-plane motion. The band is found to be highly nonparabolic, and the change in mass has been modelled directly using a full Luttinger-Kohn Hamiltonian calculation. Good agreement with experiment is achieved. Inter-band magneto-absorption experiments agreed with the low hole masses observed in cyclotron resonance and extended the study to higher energies in both the conduction and valence band.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '3666218', 'scopus': None, 'doi': None}, 'title': 'Strain reconstruction of the valence band in Ga/sub 1-x/In/sub x/Sb/GaSb quantum wells', 'source': 'Mendeley'}
Brochet B. [Long-term effects of glatiramer acetate in multiple sclerosis]. Revue neurologique. 2008;164(11):917-26.	10.1016/j.neurol.2008.02.045	18790510	primary-study	cceda8a7c5f47df3610f85ea0d36f1f5d62d8a0c	-	{'publication_type': {'year': 2008, 'cited_medium': None, 'issue': '11', 'issn': '0035-3787', 'volume': '164', 'title': 'Revue Neurologique', 'pagination': '917-926'}, 'language': None, 'rating': {'year': 0, 'title': 0.15789473684210525, 'total': 0.3526315789473684, 'authors': 1.0}, 'authors': [{'given': 'B.', 'family': 'Brochet'}], 'abstract': None, 'type': 'journal-article', 'ids': {'embase': None, 'pubmed': '18790510', 'scopus': None, 'doi': '10.1016/j.neurol.2008.02.045'}, 'title': 'Activité à long terme de l’acétate de glatiramère dans le traitement de la sclérose en plaques\xa0: état des connaissances', 'source': 'CrossRef'}
Brochet B. [Long-term effects of glatiramer acetate in multiple sclerosis]. Revue neurologique. 2008;164(11):917-26.	10.1016/j.neurol.2008.02.045	18790510	primary-study	cceda8a7c5f47df3610f85ea0d36f1f5d62d8a0c	-	{'publication_type': {'year': 2010, 'cited_medium': None, 'issue': None, 'issn': '11727047', 'volume': None, 'title': 'CNS Drugs', 'pagination': None}, 'language': None, 'rating': {'year': 0, 'title': 0.4117647058823529, 'total': 0.2676470588235294, 'authors': 0.0}, 'authors': [{'given': 'Yára D.', 'family': 'Fragoso'}, {'given': 'Alessandro', 'family': 'Finkelsztejn'}, {'given': 'Damacio R.', 'family': 'Kaimen-Maciel'}, {'given': 'Anderson K.', 'family': 'Grzesiuk'}, {'given': 'Andre S.', 'family': 'Gallina'}, {'given': 'Josiane', 'family': 'Lopes'}, {'given': 'Nivea M O', 'family': 'Morales'}, {'given': 'Soniza V.', 'family': 'Alves-Leon'}, {'given': 'Sandra M G', 'family': 'De Almeida'}], 'abstract': 'Glatiramer acetate is a US FDA category B drug with regard to use by pregnant women with multiple sclerosis (MS). There are no data currently available for the continuous use of glatiramer acetate during pregnancy.', 'type': 'journal', 'ids': {'embase': None, 'pubmed': '20806993', 'scopus': '2-s2.0-77957850617', 'doi': '10.2165/11538960-000000000-00000'}, 'title': 'Long-term use of glatiramer acetate by 11 pregnant women with multiple sclerosis: A retrospective, multicentre case series', 'source': 'Mendeley'}
